

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request: cder_mpl1r_wp077, Report 2 of 3

Request ID: cder_mpl1p_wp077

Request Description: In this report, we describe the incidence rate of hospitalized tachyarrhythmia, defined as tachyarrhythmia, overall and by subtype, that occurred from May 13, 2022 (the approval date of Mounjaro (tirzepatide) in the U.S.) to June 30, 2023, in adult type 2 diabetes mellitus (T2DM) patients who newly initiated Mounjaro (tirzepatide) or other long-acting glucagon-like peptide-1 (LA GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

This is report 2 of 3 and contains the results from the first sensitivity analysis. For Report 1 of 3, the primary analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on index date (i.e., the blackout period is set to 1 day). Two sensitivity analyses were conducted. For the first sensitivity analysis, the lookback period was 183 days in length. For Report 3 of 3, the second sensitivity analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and events were allowed to occur on index date.

<u>Sentinel Routine Querying Module:</u> Cohort Identification and Descriptive Analysis (CIDA) module, version 12.1.2 with custom programming

<u>Data Source:</u> We distributed this query to seven Sentinel Data Partners (DPs) on September 28, 2023. Six of these Data Partners are a subset of the SDD that rapidly refresh to provide freshest feasible data. Data from Medicare patients having both fee-for-service medical coverage and Part D drug coverage are included. The study period included data from May 13, 2022 through June 20,2023. See Appendix A for a list of dates of available data for each DP.

<u>Study Design:</u> We identified all individuals with incident use of Mounjaro (tirzepatide) or other LA GLP-1 RAs and evaluated the occurrence of hospitalized tachyarrhythmia within each LA GLP-1 RA exposure cohorts.

In addition to the overall exposure cohorts, analyses were also conducted by the following subgroups:

- Age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater)
- Sex (male, female)
- Calendar year of index date
- Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)
- Calendar year * race
- Age group * race
- Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

This is a Type 2 analysis with custom programming in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were defined as the first qualifying dispensing of one of the following LA GLP-1 RA brand names, each as its own separate cohort: Mounjaro (tirzepatide), Bydureon or Bydureon BCISE (exenatide synthetic), Ozempic (semaglutide), Rybelsus (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide), Victoza (liraglutide), Trulicity (dulaglutide) or Xultophy (insulin degludec/liraglutide). We defined exposures using National Drug Codes (NDCs). Only the first qualifying (index) dispensings of the exposures of interest were included; cohort re-entry was not allowed. See Appendix B for generic and brand names of medical products used to define exposures of interest.

<u>Stockpiling Rules:</u> Brand names within a single exposure definition were stockpiled together, and dispensing dates were not adjusted in case of early refills. If multiple dispensings occurred on the same day, the maximum value for days supply and amount supply among these dispensings were taken to be days supply and amount supply values on that day.

<u>Outcomes of Interest:</u> The following health outcomes of interest (HOI) were evaluated for each of the exposure definitions:

- Hospitalized tachyarrhythmia (defined as the presence of any of the conditions below)
- Atrial fibrillation and flutter
- Sinus tachycardia
- Supraventricular tachycardia
- Other tachycardia

cder_mpl1p_wp077 Page 1 of 990



Overview for Request: cder_mpl1r_wp077, Report 2 of 3

- Cardiac arrest
- Ventricular fibrillation and flutter
- Ventricular tachycardia

Outcomes were defined in the inpatient care setting in principal position (IPP) and in the emergency department caresetting (ED*).

We defined outcomes using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. See Appendix C for diagnosis codes used to define the outcome.

<u>Cohort Eligibility Criteria:</u> We required eligible members to be aged 18 years or older and to be continuously enrolled in health plans with medical and drug coverage for at least 183 days prior to the index date, during which gaps in coverage of up to 45 days were allowed. We defined new use as no evidence use of the index-defining exposure or any other LA GLP-1 RA in the 183 days prior to index date.

<u>Inclusion criteria</u>: We required exposure episodes to have a T2DM diagnosis and usage of any oral anti-diabetic drug in the 183 days prior to index date.

<u>Exclusion criteria</u>: We excluded exposure episodes with a T1DM diagnosis, gestational diabetes, other secondary diabetes illnesses, use of any short-acting (SA) GLP-1 RAs, pregnancy, or insulin-only use (defined as evidence of insulin use without evidence of use of any other anti-diabetic drug) in the 183 days prior to the index date.

We defined inclusion and exclusion criteria using NDCs, ICD-10-CM diagnosis and procedure codes, Healthcare Common Procedure Coding System (HCPCS), Level II codes, and Current Procedural Terminology, Fourth Edition (CPT-4) codes.

See Appendix D for diagnosis or procedure codes used to define inclusion and exclusion characteristics and Appendix E for generic and brand names of medical products.

<u>Follow-up Time:</u> We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 5 days apart and added 5 days to the end of each episode

Outcome evaluation began on the day after index date and continued until the earliest occurrence of the following:

- Outcome
- Treatment discontinuation
- Disenrollment
- Death (except for when all-cause mortality is the outcome)
- End of DP data
- Pregnancy
- Inpatient (IP*) or ED* encounter (other than the HOI-defining hospitalized tachyarrhythmia)
- Non-index LA GLP-1 RA

<u>Baseline Characteristics</u>: The following demographic and clinical characteristics of our study population were ascertained on index date: continuous age, age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater), sex (male, female), race (American Indian or Alaska native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, Unknown, Multi-racial), calendar year of treatment initiation, tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes.

cder mpl1p wp077 Page 2 of 990



Overview for Request: cder_mpl1r_wp077, Report 2 of 3

The following clinical characteristics were ascertained in the 365 days prior to cohort entry in the primary analysis and second sensitivity analysis or in the 183 days prior to cohort entry in the first sensitivity analysis: alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease or stroke or transient ischemic attack, chronic kidney disease, chronic obstructive pulmonary disease, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease or coronary artery disease or myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular or mitral valve disease, disease of veins and lymphatics and other diseases of the circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac disease (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea or hypertrophic cardiomyopathy), history of serious hypoglycemia (ED* or IP*), antidiabetic drugs [alpha-glucosidase inhibitors, amylin analogs, dipeptidyl peptidase 4 (DPP-4) inhibitors, incretin mimetics, meglitinides, insulin, biguanides, sodium-glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas, and thiazolidinediones], no baseline use of any of the previous antidiabetic drugs, other antidiabetic drugs (bromocriptine, mifepristone), antiarrhythmic agents [sodium channel blockers, beta blockers, potassium channel blockers or openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents], any of the previous antiarrhythmic agents, antihypertensives [angiotensinconverting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), dihydropyridines, diuretic, other antihypertensives], any of the previous antihypertensives, cardiac medications [oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists)], any of previous cardiac medications, lipid lowering therapy, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes, health care services and drug utilization metrics, continuous Charlson/Elixhauser combined comorbidity index1 (CCI), CCI groups (0, 1-2, 3-4, 5 or greater), continuous adapted diabetes complications severity index2 (ADCSI), and ADCSI groups (0, 1-2, 3-4, 5 or greater).

These characteristics were defined using NDCs; ICD-10-CM diagnosis codes; ICD-10-PCS procedure codes; HCPCS, Level II codes; CPT-4, Category I; and CPT-4, Category III codes. See Appendix F for diagnosis or procedure codes used to define baseline characteristics and Appendix G for generic and brand names of medical products.

Please see Appendices H - J for the specifications of parameters used in this request.

Please see Appendix K for a diagram detailing the design of this request.

<u>Limitations:</u> Algorithms to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

¹Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

²Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

cder mpl1p wp077 Page 3 of 990



- Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
 - <u>Table 1a</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1b</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1c</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1d</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1e</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1f</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1g</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1h</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1i</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1j</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1k</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 11</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1m</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1n</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 10</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1p</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1q</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1r</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1s</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1t</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1u</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder mpl1p wp077 Page 4 of 990



- <u>Table 1v</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1w</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1x</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1y</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1z</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1aa</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ab</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ac</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ad</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ae</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1af</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ag</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ah</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ai</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ai</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ak</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1al</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1am</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1an</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ao</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ap</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1aq</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder_mpl1p_wp077 Page 5 of 990



- <u>Table 1ar</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1as</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1at</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1au</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1av</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1aw</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ax</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ay</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1az</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ba</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bb</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bc</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bd</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1be</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bf</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bg</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bh</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bi</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bi</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bk</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bl</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bm</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder_mpl1p_wp077 Page 6 of 990



- <u>Table 1bn</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bo</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bp</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bq</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1br</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bs</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 2</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 3</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex
 - <u>Table 4</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group
 - <u>Table 5</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year
 - <u>Table 6</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race
 - <u>Table 7</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease
 - <u>Table 8</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group
 - <u>Table 9</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year
- <u>Table 10</u> Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 11</u> Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 12</u> Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 13</u> Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 14</u> Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 15</u> Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 16</u> Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 17</u> Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder_mpl1p_wp077 Page 7 of 990



- <u>Table 18</u> Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 19</u> Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 20</u> Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 21</u> Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 22</u> Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 23a</u> Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23b</u> Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23c</u> Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23d</u> Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23e</u> Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23f</u> Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23g</u> Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23h</u> Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23i</u> Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23j</u> Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23k</u> Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 231</u> Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23m</u> Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23n</u> Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23o</u> Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23p</u> Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23q</u> Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23r</u> Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23s</u> Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder mpl1p wp077 Page 8 of 990



- <u>Table 23t</u> Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23u</u> Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23v</u> Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23w</u> Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23x</u> Total Code Counts of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23y</u> Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23z</u> Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23aa</u> Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ab</u> Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ac</u> Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ad</u> Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ae</u> Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23af</u> Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ag</u> Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ah</u> Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ai</u> Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ai</u> Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ak</u> Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23al</u> Total Code Counts of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23am</u> Full Code Distribution of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23an</u> Total Code Counts of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ao</u> Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ap</u> Total Code Counts of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23aq</u> Full Code Distribution of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 9 of 990



- <u>Table 23ar</u> Total Code Counts of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23as</u> Full Code Distribution of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23at</u> Total Code Counts of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23au</u> Full Code Distribution of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23av</u> Total Code Counts of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23aw</u> Full Code Distribution of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel
 Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ax</u> Total Code Counts of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ay</u> Full Code Distribution of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23az</u> Total Code Counts of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ba</u> Full Code Distribution of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bb</u> Total Code Counts of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bc</u> Full Code Distribution of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bd</u> Total Code Counts of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23be</u> Full Code Distribution of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bf</u> Total Code Counts of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bg</u> Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bh</u> Total Code Counts of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bi</u> Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bj</u> Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bk</u> Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bl</u> Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bm</u> Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bn</u> Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bo</u> Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder mpl1p wp077 Page 10 of 990



- <u>Table 23bp</u> Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bq</u> Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23br</u> Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bs</u> Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bt</u> Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bu</u> Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bv</u> Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bw</u> Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bx</u> Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23by</u> Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bz</u> Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ca</u> Full Code Distribution of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cb</u> Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cc</u> Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cd</u> Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ce</u> Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cf</u> Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cg</u> Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ch</u> Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ci</u> Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ci</u> Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ck</u> Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cl</u> Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cm</u> Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 11 of 990



- <u>Table 23cn</u> Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23co</u> Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cp</u> Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cq</u> Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cr</u> Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed
 Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cs</u> Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ct</u> Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cu</u> Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cv</u> Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cw</u> Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cx</u> Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cy</u> Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cz</u> Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23da</u> Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23db</u> Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dc</u> Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dd</u> Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23de</u> Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23df</u> Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dg</u> Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dh</u> Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23di</u> Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23di</u> Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dk</u> Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 12 of 990



- <u>Table 23dl</u> Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dm</u> Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dn</u> Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23do</u> Full Code Distribution of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dp</u> Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dq</u> Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dr</u> Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ds</u> Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dt</u> Total Code Counts of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23du</u> Full Code Distribution of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dv</u> Total Code Counts of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dw</u> Full Code Distribution of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dx</u> Total Code Counts of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dy</u> Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dz</u> Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ea</u> Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23eb</u> Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ec</u> Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ed</u> Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ee</u> Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ef</u> Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23eg</u> Full Code Distribution of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23eh</u> Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ei</u> Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 13 of 990



- <u>Table 23ej</u> Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ek</u> Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23el</u> Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23em</u> Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23en</u> Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
 - <u>Table 24</u> Summary of Patient Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)
- Appendix B Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request
- <u>Appendix C</u> List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes
 Used to Define Tachyarrhythmia in this Request
- Appendix D
 List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes,
 International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare
 Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4),
 Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request
- Appendix E

 Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

 Appendix F

 List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes,

 International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare

 Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4),

 Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request
- Appendix G Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request
- Appendix H Specifications Defining Parameters for this Request (Sensitivity Analysis for 183 Days Lookback)
- <u>Appendix I</u> Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for 183 Days Lookback)
- <u>Appendix J</u> Specifications Defining Combination Code Parameters Used in this Request (Sensitivity Analysius for 183 Days Lookback)
- Appendix K Design Diagrams Detailing this Request

cder mpl1p wp077 Page 14 of 990



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. **Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level)

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

cder mpl1p wp077 Page 15 of 990



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode. **Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest. **Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

cder mpl1p wp077 Page 16 of 990



Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,992	N/A
Demographic Characteristics		
Age (years)	64.4	10.1
Age		
0-40 years	108	5.4%
41-64 years	700	35.1%
65-74 years	874	43.9%
75-84 years	288	14.5%
≥ 85 years	22	1.1%
Sex		
Female	1,038	52.1%
Male	954	47.9%
Race ²		
American Indian or Alaska Native	****	****
Asian	56	2.8%
Black or African American	256	12.9%
Multi-racial	33	1.7%
Native Hawaiian or Other Pacific Islander	****	****
Unknown	397	19.9%
White	1,234	61.9%
Hispanic origin		
Yes	112	5.6%
No	1,417	71.1%
Unknown	463	23.2%
Year		
2022	1,642	82.4%
2023	350	17.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	760	38.2%
1-2	706	35.4%
3-4	351	17.6%
5+	175	8.8%
Combined comorbidity score ⁴	2.0	2.3
Combined comorbidity score categories ⁴	0	
<0	111	5.6%
0	467	23.4%
1-2	788	39.6%
3-4	345	17.3%
5+	281	14.1%
Alcohol use or abuse	40	2.0%
הוכטווטו עזב טו מטעזב	40	2.0/0

cder_mpl1p_wp077 Page 17 of 990



Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Obesity	907	45.5%
Tobacco use	393	19.7%
Arrhythmia	374	18.8%
Cerebrovascular disease/stroke/transient ischemic attack	207	10.4%
Chronic kidney disease	326	16.4%
Chronic obstructive pulmonary disease	194	9.7%
Congenital heart disease	194	9.7%
Heart failure	234	11.7%
Hyperlipidemia	1,459	73.2%
Hypertensive disease	1,567	78.7%
Thyroid disease	377	18.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	439	22.0%
	66	
Left ventricular hypertrophy		3.3%
Peripheral artery disease	66	3.3%
Valvular/mitral valve disease	53	2.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	197	9.9%
Obstructive sleep apnea	423	21.2%
Hypertrophic cardiomyopathy	78	3.9%
Other cardiac disease	812	40.8%
Tachyarrhythmia day 0	21	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide) DPP-4 inhibitors	0 251	0.0% 12.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	22	1.1%
Insulin	722	36.2%
Biguanides (metformin, phenformin, etc.)	1,553	78.0%
SGLT2 inhibitors	648	32.5%
Sulfonylurea	766	38.5%
Thiazolidinedione	219	11.0%
No baseline use of any of the above antidiabetic drugs	0 ****	0.0% ****
Other antidiabetics Sodium channel blockers	****	****
Beta blockers	819	41.1%
Potassium channel blockers/openers	27	1.4%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	17	0.9%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	830	41.7%
Angiotensin-converting-enzyme (ACE) inhibitors	771	38.7%
Angiotensin ii receptor blockers (ARB)	657	33.0%
Dihydropyridines Diverties	474 602	23.8%
Diuretics	693	34.8%

cder_mpl1p_wp077 Page 18 of 990



Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antihypertensives	142	7.1%
Antihypertensives (any of the above antihypertensives)	1,625	81.6%
Oral anticoagulants	188	9.4%
Vitamin K antagonists	38	1.9%
Other cardiac medications not mentioned above	105	5.3%
Other cardiac medications (any of the other cardiac medications)	301	15.1%
Lipid lowering therapy	1,645	82.6%
Baseline known risk of prolonged QT and torsades de pointes	680	34.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,642	82.4%
torsades de pointes	285	14.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.1	9.9
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.5	8.3
Mean number of filled prescriptions	25.0	18.9
Mean number of generics dispensed	10.6	5.2
Mean number of unique drug classes dispensed	9.4	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 19 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	397	N/A
Demographic Characteristics		
Age (years)	62.2	11.5
Age		
0-40 years	****	****
41-64 years	187	47.1%
65-74 years	143	36.0%
75-84 years	44	11.1%
≥ 85 years	****	****
Sex Sex		
Female	197	49.6%
Male	200	50.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	397	100.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	301	75.8%
/ear		
2022	303	76.3%
2023	94	23.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.5	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	168	42.3%
1-2	130	32.7%
3-4	69	17.4%
5+	30	7.6%
Combined comorbidity score ⁴	1.6	2.1
Combined comorbidity score categories ⁴		
<0	29	7.3%
0	117	29.5%
1-2	163	41.1%
3-4	50	12.6%
5+	38	9.6%

cder_mpl1p_wp077 Page 20 of 990



Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown	
	Percent/Stand	
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	177	44.6%
Tobacco use	54	13.6%
Arrhythmia	61	15.4%
Cerebrovascular disease/stroke/transient ischemic attack	41	10.3%
Chronic kidney disease	52	13.1%
Chronic obstructive pulmonary disease	21	5.3%
Congenital heart disease	21	5.3%
Heart failure	34	8.6%
Hyperlipidemia	291	73.3%
	302	76.1%
Hypertensive disease		
Thyroid disease	62	15.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	76	19.1%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	40	10.1%
Obstructive sleep apnea	65	16.4%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	143	36.0%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors Incretin mimetics (albiglutide, dulaglutide, etc.)	45 0	11.3% 0.0%
Meglitinides	****	U.U70 ****
Insulin	134	33.8%
Biguanides (metformin, phenformin, etc.)	317	79.8%
SGLT2 inhibitors	137	34.5%
Sulfonylurea	149	37.5%
Thiazolidinedione	42	10.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers		
Beta blockers Potassium channel blockers (anonors	161 ****	40.6% ****
Potassium channel blockers/openers Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	162	40.8%
Angiotensin-converting-enzyme (ACE) inhibitors	150	37.8%
Angiotensin ii receptor blockers (ARB)	124	31.2%

cder_mpl1p_wp077 Page 21 of 990



Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia,	
	Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Dihydropyridines	83	20.9%
Diuretics	111	28.0%
Other antihypertensives	27	6.8%
Antihypertensives (any of the above antihypertensives)	310	78.1%
Oral anticoagulants	33	8.3%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	13	3.3%
Other cardiac medications (any of the other cardiac medications)	49	12.3%
Lipid lowering therapy	325	81.9%
Baseline known risk of prolonged QT and torsades de pointes	122	30.7%
Baseline possible risk of prolonged QT and torsades de pointes	301	75.8%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	51	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.7	9.9
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.6	4.2
Mean number of filled prescriptions	22.6	16.7
Mean number of generics dispensed	10.1	5.3
Mean number of unique drug classes dispensed	8.9	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 22 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhy	
	Race=American India	
Dations Chanacteristics	Ni	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients Demographic Characteristics	15	N/A
	60.6	8.8
Age (years)	00.0	0.0
Age 0-40 years	0	0.0%
•	****	V.U% ****
41-64 years	****	****
65-74 years 75-84 years	****	****
•	0	0.0%
≥ 85 years	U	0.0%
Gex Female	****	****
	****	****
Male Race ²	vi de de de	. 10.00.00.00
	15	100.00/
American Indian or Alaska Native Asian	15 0	100.0% 0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander		0.0%
	0	0.0%
Unknown	0	
White	0	0.0%
lispanic origin	****	****
Yes	****	****
No Unknown	****	****
'ear 2022	****	****
2022	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.2
Adapted Diabetes Complications Severity Index (aDCSI) Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.1	1.2
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	0	0.0%
Combined comorbidity score ⁴	1.3	1.9
Combined comorbidity score categories ⁴	1.5	1.9
<0	****	****
0	****	****
1-2	****	****
	****	****
3-4	****	****
5+	<i>ተ ጥ ጥ ጥ</i>	77 · T · T · T

cder_mpl1p_wp077 Page 23 of 990



Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

the Rapid Sentinel Distributed Database and Sentinel Distributed Database	Bydureon, Hospitalized Tachyarrhythmia,	
	Race=American Indian or Alaska Native	
Alcohol use or abuse	0	0.0%
Obesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia		
Hypertensive disease	11	73.3%
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0 ****	0.0% ****
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.) Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	12	80.0%
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics Sodium channel blockers	0 0	0.0% 0.0%
Beta blockers	****	U.U70 ****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines Diuretics	****	****
Didictics		

cder_mpl1p_wp077 Page 24 of 990



Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	12	80.0%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	14	93.3%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.3	4.9
Mean number of emergency room encounters	0.5	0.6
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	1.5	1.6
Mean number of filled prescriptions	27.9	26.3
Mean number of generics dispensed	10.4	5.7
Mean number of unique drug classes dispensed	9.3	6.0

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 25 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	56	N/A
Demographic Characteristics		
Age (years)	56.0	10.9
Age		
0-40 years	14	25.0%
41-64 years	23	41.1%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	35	62.5%
Male	21	37.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	56	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	45	80.4%
Unknown	11	19.6%
/ear		
2022	38	67.9%
2023	18	32.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	62.5%
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.4	1.6
Combined comorbidity score categories ⁴		
<0	****	****
0	17	30.4%
1-2	24	42.9%
3-4	****	****
5+	****	****

cder_mpl1p_wp077 Page 26 of 990



Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Number/Mean Deviation¹ Alcohol use or abuse ****** ****** Obesity 15 26.8% Tobacco use ****** ****** Arrhythmia ****** ****** Cerebrovascular disease/stroke/transient ischemic attack ****** ****** Chronic kidney disease ****** ****** Chronic obstructive pulmonary disease ****** ****** Chronic obstructive pulmonary disease ****** ****** Congenital heart disease ****** ******* Heart failure ****** ****** Hyperlipidemia 29 51.8% Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** ****** Ischemic heart disease/coronary artery disease/myocardial infarction ****** ******* Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0%
Patient Characteristics Number/Mean Deviation¹ Alcohol use or abuse ****** ****** Obesity 15 26.8% Tobacco use ****** ****** Arrhythmia ****** ****** Cerebrovascular disease/stroke/transient ischemic attack ****** ****** Chronic kidney disease ****** ****** Chronic obstructive pulmonary disease ****** ****** Chronic obstructive pulmonary disease ****** ****** Congenital heart disease ****** ****** Congenital heart disease ****** ****** Heart failure ****** ****** Hypertensive disease 28 50.0% Thyroid disease 28 50.0% Thyroid disease ****** ******* Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ******
Alcohol use or abuse Obesity 15 26.8% Tobacco use Arrhythmia Cerebrovascular disease/stroke/transient ischemic attack Chronic kidney disease Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Congenital heart disease Heart failure Hyperlipidemia Hyperlipidemia Hyperlipidedia Hypertensive disease 128 50.0% Thyroid disease 28 50.0% Thyroid disease 28 50.0% Thyroid disease 28 50.0% Thyroid disease 28 50.0% Thyroid disease 0 0 0.0% Peripheral artery disease 0 0 0.0% Peripheral artery disease 0 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system Obstructive sleep apnea Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0 0.0% Medical Product Use
Tobacco use ***** Arrhythmia ***** Cerebrovascular disease/stroke/transient ischemic attack ***** Cerebrovascular disease/stroke/transient ischemic attack ***** Chronic kidney disease Chronic obstructive pulmonary disease ***** Congenital heart disease ***** Heart failure ***** Heyperlipidemia 29 51.8% Hyperlensive disease 28 50.0% Thyroid disease ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Obstructive sleep apnea ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) O Medical Product Use
Tobacco use ***** ***** Arrhythmia ***** ***** Cerebrovascular disease/stroke/transient ischemic attack ***** ***** Chronic kidney disease ***** ***** Chronic obstructive pulmonary disease ***** ***** Congenital heart disease ***** ***** Heart failure ***** ***** Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Arrhythmia ***** ***** Cerebrovascular disease/stroke/transient ischemic attack ***** ***** Chronic kidney disease ***** ***** Chronic obstructive pulmonary disease ***** ***** Congenital heart disease ***** ***** Heart failure ***** ***** Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% Medical Product Use
Cerebrovascular disease/stroke/transient ischemic attack Cerebrovascular disease Chronic kidney disease Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Congenital heart disease ***** Heart failure ***** Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system Obstructive sleep apnea ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) O Medical Product Use
Chronic kidney disease Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease ***** Congenital heart disease ***** Heart failure ***** Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system Obstructive sleep apnea ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) Medical Product Use
Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Heart failure Heart failure Hyperlipidemia Hypertensive disease Thyroid disease Ischemic heart disease/coronary artery disease/myocardial infarction Eft ventricular hypertrophy O O O Valvular/mitral valve disease O O O Diseases of veins and lymphatics, and other diseases of circulatory system Obstructive sleep apnea Hypertrophic cardiomyopathy O Hospitalized tachyarrhythmia day O Hospitalized tachyarrhythmia day O Medical Product Use
Congenital heart disease ***** ***** Heart failure ***** ***** Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0 0.0% Valvular/mitral valve disease 0 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** ***** Hypertrophic cardiomyopathy ****** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% Medical Product Use
Heart failure ***** ***** Hyperlipidemia 29 51.8% Hypertensive disease Hypertensive disease 28 50.0% Thyroid disease ***** ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 1 0.0% Medical Product Use
Hyperlipidemia 29 51.8% Hypertensive disease 28 50.0% Thyroid disease ***** ***** Ischemic heart disease/coronary artery disease/myocardial infarction ***** ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** ***** Obstructive sleep apnea ***** ***** Hypertrophic cardiomyopathy ***** ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Hypertensive disease Thyroid disease Ischemic heart disease/coronary artery disease/myocardial infarction ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) Medical Product Use
Thyroid disease Ischemic heart disease/coronary artery disease/myocardial infarction Ieft ventricular hypertrophy O O O O O O O O O O O O O O O O O O O
Ischemic heart disease/coronary artery disease/myocardial infarction ***** Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system Distructive sleep apnea ***** Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 Hospitalized tachyarrhythmia day 0 History of serious hypoglycemia (ED and/or IP) Medical Product Use
Left ventricular hypertrophy Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 Hospitalized tachyarrhythmia day 0 Medical Product Use
Left ventricular hypertrophy Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 Hospitalized tachyarrhythmia day 0 History of serious hypoglycemia (ED and/or IP) Medical Product Use
Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Valvular/mitral valve disease Diseases of veins and lymphatics, and other diseases of circulatory system ***** Obstructive sleep apnea ***** Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 Hospitalized tachyarrhythmia day 0 History of serious hypoglycemia (ED and/or IP) Medical Product Use
Obstructive sleep apnea ***** ***** Hypertrophic cardiomyopathy ***** Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Hypertrophic cardiomyopathy Other cardiac disease 15 26.8% Tachyarrhythmia day 0 Hospitalized tachyarrhythmia day 0 History of serious hypoglycemia (ED and/or IP) Medical Product Use
Other cardiac disease 15 26.8% Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Tachyarrhythmia day 0 0 0.0% Hospitalized tachyarrhythmia day 0 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Hospitalized tachyarrhythmia day 0 0.0% History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
History of serious hypoglycemia (ED and/or IP) 0 0.0% Medical Product Use
Medical Product Use
Alpha-glucosidase inhibitors 0 0.0%
Amylin analogs (pramlintide) 0 0.0%
DPP-4 inhibitors 13 23.2%
Incretin mimetics (albiglutide, dulaglutide, etc.) 0 0.0%
Meglitinides ****
Insulin 25 44.6%
Biguanides (metformin, phenformin, etc.) 52 92.9%
SGLT2 inhibitors 17 30.4%
Sulfonylurea 24 42.9%
Thiazolidinedione ***** *****
No baseline use of any of the above antidiabetic drugs 0 0.0%
Other antidiabetics 0 0.0%
Sodium channel blockers 0 0.0%
Beta blockers 13 23.2%
Potassium channel blockers/openers *****
Non-dihydropyridine calcium channel blockers 0 0.0%
Digoxin 0 0.0% Other antiarrhythmic agents 0 0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents) 13 23.2%

cder_mpl1p_wp077 Page 27 of 990



Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia,	
	Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Angiotensin-converting-enzyme (ACE) inhibitors	12	21.4%
Angiotensin ii receptor blockers (ARB)	21	37.5%
Dihydropyridines	11	19.6%
Diuretics	13	23.2%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	37	66.1%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	41	73.2%
Baseline known risk of prolonged QT and torsades de pointes	12	21.4%
Baseline possible risk of prolonged QT and torsades de pointes	36	64.3%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.4	7.1
Mean number of emergency room encounters	0.1	0.3
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.8	1.9
Mean number of filled prescriptions	20.0	15.8
Mean number of generics dispensed	7.9	3.7
Mean number of unique drug classes dispensed	6.6	3.2

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalize	ed Tachyarrhythmia,
	Race=Black or Af	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	256	N/A
Demographic Characteristics		
Age (years)	60.8	10.6
Age		
0-40 years	****	****
41-64 years	125	48.8%
65-74 years	86	33.6%
75-84 years	25	9.8%
≥ 85 years	****	****
Sex		
Female	162	63.3%
Male	94	36.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	256	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	234	91.4%
Unknown	****	****
Year Year		
2022	191	74.6%
2023	65	25.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	94	36.7%
1-2	96	37.5%
3-4	41	16.0%
5+	25	9.8%
Combined comorbidity score ⁴	2.1	2.3
Combined comorbidity score categories ⁴		
<0	****	****
0	64	25.0%
1-2	103	40.2%
3-4	****	****
5+	46	18.0%

cder_mpl1p_wp077 Page 29 of 990



Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitaliz	ed Tachyarrhythmia,
	Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	128	50.0%
Tobacco use	41	16.0%
Arrhythmia	34	13.3%
Cerebrovascular disease/stroke/transient ischemic attack	32	12.5%
Chronic kidney disease	44	17.2%
Chronic obstructive pulmonary disease	22	8.6%
Congenital heart disease	22	8.6%
Heart failure	35	13.7%
Hyperlipidemia	173	67.6%
Hypertensive disease	211	82.4%
Thyroid disease	27	10.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	46	18.0%
Left ventricular hypertrophy	12	4.7%
Peripheral artery disease	12	4.7%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	20	7.8%
Obstructive sleep apnea	49	19.1%
Hypertrophic cardiomyopathy	15	5.9%
Other cardiac disease	101	39.5%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	37	14.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	103	40.2%
Biguanides (metformin, phenformin, etc.)	192	75.0%
SGLT2 inhibitors	85	33.2%
Sulfonylurea	93	36.3%
Thiazolidinedione	18	7.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	105	41.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0 0	0.0% 0.0%
Digoxin Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	107	41.8%

cder_mpl1p_wp077 Page 30 of 990



Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Angiotensin-converting-enzyme (ACE) inhibitors 87 34.0% 98 Angiotensin ii receptor blockers (ARB) 38.3% Dihydropyridines 94 36.7% **Diuretics** 103 40.2% Other antihypertensives 34 13.3% Antihypertensives (any of the above antihypertensives) 211 82.4% Oral anticoagulants 14 5.5% Vitamin K antagonists Other cardiac medications not mentioned above 19 7.4% Other cardiac medications (any of the other cardiac medications) 34 13.3% Lipid lowering therapy 198 77.3% Baseline known risk of prolonged QT and torsades de pointes 32.0% 82 Baseline possible risk of prolonged QT and torsades de pointes 211 82.4% Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes 29 11.3% **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 12.0 11.0 Mean number of emergency room encounters 0.5 1.3 Mean number of inpatient hospital encounters 0.1 0.3 Mean number of non-acute institutional encounters 0.3 0.1 Mean number of other ambulatory encounters 3.9 7.4 Mean number of filled prescriptions 24.3 19.2 Mean number of generics dispensed 10.7 5.3 Mean number of unique drug classes dispensed 9.6 4.9

N/A: Not applicable

cder mpl1p wp077 Page 31 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalize	
	Race=\	White Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,234	N/A
Demographic Characteristics	1,234	N/A
Age (years)	66.7	9.2
Age (years)	00.7	J. <u>Z</u>
0-40 years	46	3.7%
41-64 years	335	27.1%
65-74 years	626	50.7%
75-84 years	211	17.1%
> 85 years	16	1.3%
Sex	10	1.570
Female	611	49.5%
Male	623	50.5%
Race ²	023	30.370
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	1,234	100.0%
Hispanic origin	1,234	100.0%
Yes	****	****
No	1,100	89.1%
Unknown	****	****
Year		
2022	1,074	87.0%
2023	160	13.0%
Health Characteristics	100	13.0%
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.7	1.5
<0	0	0.0%
0	439	35.6%
1-2	447	36.2%
3-4	229	18.6%
5+	119	9.6%
Combined comorbidity score ⁴	2.2	2.5
Combined comorbidity score categories ⁴	۷.۷	2.5
<0	70	5.7%
0	255	20.7%
1-2	474	38.4%
3-4	244	19.8%
5+	191	15.5%
<u>. </u>	191	13.370

cder_mpl1p_wp077 Page 32 of 990



Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalize	
	Race=\	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	28	2.3%
Obesity	569	46.1%
Tobacco use	285	23.1%
Arrhythmia	271	22.0%
Cerebrovascular disease/stroke/transient ischemic attack	128	10.4%
Chronic kidney disease	224	18.2%
Chronic obstructive pulmonary disease	144	11.7%
Congenital heart disease	144	11.7%
Heart failure	160	13.0%
- Hyperlipidemia	945	76.6%
Hypertensive disease	998	80.9%
Thyroid disease	278	22.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	307	24.9%
Left ventricular hypertrophy	47	3.8%
	47	
Peripheral artery disease		3.8%
/alvular/mitral valve disease	39	3.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	135	10.9%
Obstructive sleep apnea	292	23.7%
Hypertrophic cardiomyopathy	52	4.2%
Other cardiac disease	540	43.8%
Fachyarrhythmia day 0	16	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	149	12.1%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides Insulin	13 439	1.1% 35.6%
Biguanides (metformin, phenformin, etc.)	947	76.7%
SGLT2 inhibitors	395	32.0%
Sulfonylurea	483	39.1%
Fhiazolidinedione	155	12.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	****	****
Beta blockers	530	42.9%
Potassium channel blockers/openers	18	1.5%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	13	1.1%
Other antiarrhythmic agents Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	538	43.6%
Angiotensin-converting-enzyme (ACE) inhibitors	505 403	40.9% 32.7%
Angiotensin ii receptor blockers (ARB)	403	32.1%

cder_mpl1p_wp077 Page 33 of 990



Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitaliz	zed Tachyarrhythmia,
	Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Dihydropyridines	279	22.6%
Diuretics	458	37.1%
Other antihypertensives	77	6.2%
Antihypertensives (any of the above antihypertensives)	1,038	84.1%
Oral anticoagulants	139	11.3%
Vitamin K antagonists	27	2.2%
Other cardiac medications not mentioned above	72	5.8%
Other cardiac medications (any of the other cardiac medications)	215	17.4%
Lipid lowering therapy	1,050	85.1%
Baseline known risk of prolonged QT and torsades de pointes	450	36.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,054	85.4%
torsades de pointes	199	16.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.5	9.7
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	3.9	9.7
Mean number of filled prescriptions	26.2	19.5
Mean number of generics dispensed	10.9	5.1
Mean number of unique drug classes dispensed	9.7	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 34 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalize Race=Mu	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	33	N/A
Demographic Characteristics		
Age (years)	47.7	12.3
Age		
0-40 years	****	****
41-64 years	22	66.7%
65-74 years	****	****
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	21	63.6%
Male	12	36.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	33	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	****
No	18	54.5%
Unknown	****	****
'ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	16	48.5%
1-2	****	****
3-4	****	****
5+	0	0.0%
Combined comorbidity score ⁴	1.5	1.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	****	****
1-2	19	57.6%
3-4	****	****
5+	0	0.0%
	J	3.0,0

cder_mpl1p_wp077 Page 35 of 990



Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia	
	Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	13	39.4%
obacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	0	0.0%
Hyperlipidemia	15	45.5%
Hypertensive disease	16	48.5%
Thyroid disease	****	****
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
	0	0.0%
/alvular/mitral valve disease	****	0.0% ****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea		
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0 ****	0.0% ****
PPP-4 inhibitors		
ncretin mimetics (albiglutide, dulaglutide, etc.) Meglitinides	0 0	0.0% 0.0%
nsulin	12	36.4%
Biguanides (metformin, phenformin, etc.)	32	97.0%
GGLT2 inhibitors	****	****
Sulfonylurea	****	****
hiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
deta blockers	****	****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers Digoxin	0 0	0.0% 0.0%
Digoxin Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	0.0% ****
Angiotensin-converting-enzyme (ACE) inhibitors	11	33.3%
Angiotensin ii receptor blockers (ARB)	****	****

cder_mpl1p_wp077 Page 36 of 990



Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitaliz	ed Tachyarrhythmia,
	Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	16	48.5%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	22	66.7%
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	26	78.8%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.9	14.2
Mean number of emergency room encounters	0.6	0.8
Mean number of inpatient hospital encounters	0.1	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.0	2.6
Mean number of filled prescriptions	22.2	16.7
Mean number of generics dispensed	9.7	5.7
Mean number of unique drug classes dispensed	8.5	5.0

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1h. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhyth	
		Percent/Standa
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	22,618	N/A
Demographic Characteristics		
Age (years)	61.3	10.0
Age		
0-40 years	1,301	5.8%
41-64 years	11,248	49.7%
65-74 years	7,876	34.8%
75-84 years	2,091	9.2%
≥ 85 years	102	0.5%
Sex		
Female	12,975	57.4%
Male	9,643	42.6%
Race ²	, -	
American Indian or Alaska Native	44	0.2%
Asian	145	0.6%
Black or African American	2,004	8.9%
Multi-racial	71	0.3%
Native Hawaiian or Other Pacific Islander	76	0.3%
Unknown	9,777	43.2%
White	10,501	46.4%
Hispanic origin	10,301	40.470
Yes	426	1.9%
No	12,103	53.5%
Unknown	10,089	44.6%
	10,069	44.070
Year 2022	11 647	51.5%
	11,647	
2023 Health Characteristics	10,971	48.5%
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.6
Adapted Diabetes Complications Severity Index (aDCSI) Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.3	1.6
<0 < 0	0	0.00/
	0	0.0%
0	10,390	45.9%
1-2	7,990	35.3%
3-4	3,008	13.3%
5+	1,230	5.4%
Combined comorbidity score ⁴	1.6	2.1
Combined comorbidity score categories ⁴		
<0	2,223	9.8%
0	5,804	25.7%
1-2	8,683	38.4%
3-4	3,539	15.6%
5+	2,369	10.5%

cder_mpl1p_wp077 Page 38 of 990



Table 1h. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitaliz	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	265	1.2%
Obesity	13,239	58.5%
Tobacco use	3,826	16.9%
Arrhythmia	3,857	17.1%
Cerebrovascular disease/stroke/transient ischemic attack	1,682	7.4%
Chronic kidney disease	3,108	13.7%
Chronic obstructive pulmonary disease	2,059	9.1%
Congenital heart disease	2,059	9.1%
Heart failure	2,151	9.5%
Hyperlipidemia	17,029	75.3%
Hypertensive disease	18,166	80.3%
Thyroid disease	4,892	21.6%
schemic heart disease/coronary artery disease/myocardial infarction	4,127	18.2%
Left ventricular hypertrophy	716	3.2%
Peripheral artery disease	716	3.2%
Valvular/mitral valve disease	506	2.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,825	8.1%
Dbstructive sleep apnea	5,854	25.9%
Hypertrophic cardiomyopathy	741	3.3%
Other cardiac disease	9,117	40.3%
Fachyarrhythmia day 0	293	1.3%
	295	0.0%
Hospitalized tachyarrhythmia day 0	-	
History of serious hypoglycemia (ED and/or IP)	79	0.3%
Medical Product Use		0.20/
Alpha-glucosidase inhibitors	68 ****	0.3% ****
Amylin analogs (pramlintide)		
DPP-4 inhibitors	2,435	10.8%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	134	0.6%
nsulin	5,682	25.1%
Biguanides (metformin, phenformin, etc.)	18,097	80.0%
GLT2 inhibitors	5,959	26.3%
Gulfonylurea Thiazolidinedione	6,286 2,057	27.8% 9.1%
No baseline use of any of the above antidiabetic drugs	2,037	0.0%
Other antidiabetics	****	****
Sodium channel blockers	154	0.7%
Beta blockers	8,455	37.4%
Potassium channel blockers/openers	243	1.1%
Non-dihydropyridine calcium channel blockers	24	0.1%
Digoxin	103	0.5%
Other antiarrhythmic agents Antiarrhythmic agents (any of the above antiarrhythmic agents)	0 8,559	0.0% 37.8%
Antiarrhytimic agents (any of the above antiarrhytimic agents) Angiotensin-converting-enzyme (ACE) inhibitors	8,009	35.4%

cder_mpl1p_wp077 Page 39 of 990



Table 1h. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mouniaro Hosnitali	zed Tachyarrhythmia
	Wiodrijaro, Hospitari	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Angiotensin ii receptor blockers (ARB)	8,207	36.3%
Dihydropyridines	5,279	23.3%
Diuretics	7,688	34.0%
Other antihypertensives	1,756	7.8%
Antihypertensives (any of the above antihypertensives)	18,482	81.7%
Oral anticoagulants	1,570	6.9%
Vitamin K antagonists	315	1.4%
Other cardiac medications not mentioned above	1,109	4.9%
Other cardiac medications (any of the other cardiac medications)	2,776	12.3%
Lipid lowering therapy	17,722	78.4%
Baseline known risk of prolonged QT and torsades de pointes	8,945	39.5%
Baseline possible risk of prolonged QT and torsades de pointes	18,621	82.3%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	3,728	16.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.6	9.2
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.4	5.1
Mean number of filled prescriptions	24.0	16.7
Mean number of generics dispensed	10.7	5.3
Mean number of unique drug classes dispensed	9.7	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 40 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythm	
	Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	9,777	N/A
Demographic Characteristics		
Age (years)	54.1	10.4
Age		
0-40 years	1,093	11.2%
41-64 years	7,367	75.4%
65-74 years	1,120	11.5%
75-84 years	186	1.9%
≥ 85 years	11	0.1%
Sex		
Female	5,326	54.5%
Male	4,451	45.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	9,777	100.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	9,373	95.9%
Year	-,	
2022	5,131	52.5%
2023	4,646	47.5%
Health Characteristics	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	•	
<0	0	0.0%
0	6,201	63.4%
1-2	2,749	28.1%
3-4	635	6.5%
5+	192	2.0%
Combined comorbidity score ⁴	0.9	1.6
Combined comorbidity score categories ⁴	0.5	1.0
<0	1,361	13.9%
0	3,257	33.3%
1-2	3,875	39.6%
3-4	918	9.4%
5+	366	3.7%

cder_mpl1p_wp077 Page 41 of 990



Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown	
	Percent/Stand	
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	96	1.0%
Obesity	5,406	55.3%
Tobacco use	1,059	10.8%
Arrhythmia	1,061	10.9%
Cerebrovascular disease/stroke/transient ischemic attack	349	3.6%
Chronic kidney disease	623	6.4%
Chronic obstructive pulmonary disease	318	3.3%
Congenital heart disease	318	3.3%
Heart failure	364	3.7%
Hyperlipidemia	6,742	69.0%
Hypertensive disease	7,036	72.0%
Thyroid disease	1,710	17.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	999	10.2%
Left ventricular hypertrophy	189	1.9%
Peripheral artery disease	189	1.9%
Valvular/mitral valve disease	106	1.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	501	5.1%
Obstructive sleep apnea	2,181	22.3%
Hypertrophic cardiomyopathy	176	1.8%
Other cardiac disease	2,976	30.4%
Tachyarrhythmia day 0	46	0.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	16	0.2%
Medical Product Use		
Alpha-glucosidase inhibitors	22	0.2%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	952	9.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	33	0.3%
Insulin	2,026	20.7%
Biguanides (metformin, phenformin, etc.)	8,238	84.3%
SGLT2 inhibitors	2,713	27.7%
Sulfonylurea	2,171	22.2%
Thiazolidinedione	707	7.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics Sodium channel blockers	****	****
Beta blockers	43 2,663	0.4% 27.2%
Potassium channel blockers/openers	53	0.5%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	15	0.2%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,686	27.5%
Angiotensin-converting-enzyme (ACE) inhibitors	3,393	34.7%

cder_mpl1p_wp077 Page 42 of 990



Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia,	
	Race=U	nknown
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Angiotensin ii receptor blockers (ARB)	3,083	31.5%
Dihydropyridines	1,720	17.6%
Diuretics	2,395	24.5%
Other antihypertensives	480	4.9%
Antihypertensives (any of the above antihypertensives)	7,280	74.5%
Oral anticoagulants	385	3.9%
Vitamin K antagonists	63	0.6%
Other cardiac medications not mentioned above	243	2.5%
Other cardiac medications (any of the other cardiac medications)	658	6.7%
Lipid lowering therapy	6,872	70.3%
Baseline known risk of prolonged QT and torsades de pointes	3,468	35.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	7,339	75.1%
torsades de pointes	1,276	13.1%
Health Service Utilization Intensity Metrics	·	
Mean number of ambulatory encounters	8.4	7.8
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.2	3.7
Mean number of filled prescriptions	20.3	15.3
Mean number of generics dispensed	9.1	5.0
Mean number of unique drug classes dispensed	8.1	4.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 43 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythr	
	Race=American India	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	44	N/A
Demographic Characteristics		
Age (years)	62.5	12.3
Age		
0-40 years	****	****
41-64 years	20	45.5%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	27	61.4%
Male	17	38.6%
Race ²		
American Indian or Alaska Native	44	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
Year		
2022	28	63.6%
2023	16	36.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	19	43.2%
1-2	11	25.0%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	3.0	2.9
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	14	31.8%
3-4	****	****
5+	12	27.3%

cder_mpl1p_wp077 Page 44 of 990



Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia,	
	Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	30	68.2%
Tobacco use	12	27.3%
Arrhythmia	11	25.0%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	11	25.0%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	34	77.3%
Hypertensive disease	38	86.4%
Thyroid disease	12	27.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy		
Other cardiac disease	15 ****	34.1% ****
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0	0 ****	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	13	29.5%
Biguanides (metformin, phenformin, etc.)	35	79.5%
SGLT2 inhibitors	****	****
Sulfonylurea This religional	16 ****	36.4% ****
Thiazolidinedione No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	19	43.2%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin Other entire shuthmin agents	0	0.0%
Other antiarrhythmic agents Antiarrhythmic agents (any of the above antiarrhythmic agents)	0 19	0.0% 43.2%
Angiotensin-converting-enzyme (ACE) inhibitors	14	31.8%

cder_mpl1p_wp077 Page 45 of 990



Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Angiotensin ii receptor blockers (ARB)	17	38.6%
Dihydropyridines	****	****
Diuretics	20	45.5%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	35	79.5%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	35	79.5%
Baseline known risk of prolonged QT and torsades de pointes	21	47.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	42	95.5%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.4	11.4
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.8
Mean number of other ambulatory encounters	4.9	12.4
Mean number of filled prescriptions	29.5	19.4
Mean number of generics dispensed	13.0	6.3
Mean number of unique drug classes dispensed	11.8	5.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 46 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	145	N/A
Demographic Characteristics		
Age (years)	65.0	10.0
Age		
0-40 years	****	****
41-64 years	41	28.3%
65-74 years	72	49.7%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	80	55.2%
Male	65	44.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	145	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	120	82.8%
Unknown	25	17.2%
/ear		
2022	97	66.9%
2023	48	33.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.4	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	58	40.0%
1-2	53	36.6%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	2.0	2.3
Combined comorbidity score categories ⁴		
<0	****	****
0	33	22.8%
1-2	61	42.1%
3-4	28	19.3%
5+	****	****

cder_mpl1p_wp077 Page 47 of 990



Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	61	42.1%
Tobacco use	14	9.7%
Arrhythmia	19	13.1%
Cerebrovascular disease/stroke/transient ischemic attack	16	11.0%
Chronic kidney disease	22	15.2%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	12	8.3%
Hyperlipidemia	121	83.4%
Hypertensive disease	116	80.0%
Thyroid disease	42	29.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	32	22.1%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	16	11.0%
Obstructive sleep apnea	24	16.6%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	52	35.9%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
	****	U.U% ****
History of serious hypoglycemia (ED and/or IP) Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	38	26.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0 ****	0.0% ****
Meglitinides		
Insulin	47	32.4%
Biguanides (metformin, phenformin, etc.) SGLT2 inhibitors	102 51	70.3% 35.2%
Sulfonylurea	51	35.2%
Thiazolidinedione	23	15.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers Potassium channel blockers (anonors)	50 ****	34.5% ****
Potassium channel blockers/openers Non-dihydropyridine calcium channel blockers	****	****
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	51	35.2%
Angiotensin-converting-enzyme (ACE) inhibitors	43	29.7%

cder_mpl1p_wp077 Page 48 of 990



Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Angiotensin ii receptor blockers (ARB)	71	49.0%
Dihydropyridines	37	25.5%
Diuretics	39	26.9%
Other antihypertensives	11	7.6%
Antihypertensives (any of the above antihypertensives)	131	90.3%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	12	8.3%
Other cardiac medications (any of the other cardiac medications)	19	13.1%
Lipid lowering therapy	127	87.6%
Baseline known risk of prolonged QT and torsades de pointes	49	33.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	110	75.9%
torsades de pointes	14	9.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.8	10.1
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.9	5.3
Mean number of filled prescriptions	24.4	18.8
Mean number of generics dispensed	11.1	5.9
Mean number of unique drug classes dispensed	9.7	5.3

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 49 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1l. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythi	
	Race=Black or Af	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	2,004	N/A
Demographic Characteristics		
Age (years)	64.6	9.4
Age		
0-40 years	****	****
41-64 years	839	41.9%
65-74 years	919	45.9%
75-84 years	187	9.3%
≥ 85 years	****	****
Sex		
Female	1,464	73.1%
Male	540	26.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	2,004	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	1,906	95.1%
Unknown	98	4.9%
Year Year		
2022	794	39.6%
2023	1,210	60.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	610	30.4%
1-2	806	40.2%
3-4	395	19.7%
5+	193	9.6%
Combined comorbidity score ⁴	2.3	2.5
Combined comorbidity score categories ⁴		
<0	126	6.3%
0	396	19.8%
1-2	709	35.4%
3-4	401	20.0%
5+	372	18.6%

cder_mpl1p_wp077 Page 50 of 990



Table 1l. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia	
	Race=Black or A	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	27	1.3%
Obesity	1,372	68.5%
Tobacco use	402	20.1%
Arrhythmia	371	18.5%
Cerebrovascular disease/stroke/transient ischemic attack	221	11.0%
Chronic kidney disease	465	23.2%
Chronic obstructive pulmonary disease	239	11.9%
Congenital heart disease	239	11.9%
Heart failure	353	17.6%
Hyperlipidemia	1,556	77.6%
Hypertensive disease	1,868	93.2%
Γhyroid disease	296	14.8%
schemic heart disease/coronary artery disease/myocardial infarction	392	19.6%
Left ventricular hypertrophy	120	6.0%
Peripheral artery disease	120	6.0%
/alvular/mitral valve disease	41	2.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	200	10.0%
Dbstructive sleep apnea	502	25.0%
Hypertrophic cardiomyopathy	105	5.2%
Other cardiac disease	881	44.0%
Fachyarrhythmia day 0	23	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	14	0.7%
Medical Product Use	14	0.770
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	232	11.6%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	13	0.6%
nsulin	599	29.9%
Biguanides (metformin, phenformin, etc.)	1,489	74.3%
GLT2 inhibitors	497	24.8%
Sulfonylurea	557	27.8%
Thiazolidinedione	150	7.5%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	***** 4E 90/
Beta blockers Potassium channel blockers/openers	918 16	45.8% 0.8%
Non-dihydropyridine calcium channel blockers	****	V.O/0 ****
Digoxin	11	0.5%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	926	46.2%

cder_mpl1p_wp077 Page 51 of 990



Table 1l. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Angiotensin-converting-enzyme (ACE) inhibitors 571 28.5% Angiotensin ii receptor blockers (ARB) 985 49.2% Dihydropyridines 873 43.6% **Diuretics** 1,024 51.1% Other antihypertensives 308 15.4% Antihypertensives (any of the above antihypertensives) 92.6% 1,855 Oral anticoagulants 142 7.1% Vitamin K antagonists 21 1.0% Other cardiac medications not mentioned above 131 6.5% Other cardiac medications (any of the other cardiac medications) 268 13.4% Lipid lowering therapy 1,648 82.2% Baseline known risk of prolonged QT and torsades de pointes 743 37.1% Baseline possible risk of prolonged QT and torsades de pointes 1,769 88.3% Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes 288 14.4% **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 12.4 10.7 Mean number of emergency room encounters 0.6 1.5 Mean number of inpatient hospital encounters 0.1 0.3 Mean number of non-acute institutional encounters 0.0 0.1 Mean number of other ambulatory encounters 2.5 5.9 Mean number of filled prescriptions 26.0 16.9 Mean number of generics dispensed 12.0 5.6 Mean number of unique drug classes dispensed 11.0 4.9

N/A: Not applicable

cder_mpl1p_wp077 Page 52 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	76	N/A
Demographic Characteristics		
nge (years)	70.3	6.2
nge .		
0-40 years	0	0.0%
41-64 years	12	15.8%
65-74 years	53	69.7%
75-84 years	****	****
≥ 85 years	****	****
ex		
Female	36	47.4%
Male	40	52.6%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	76	100.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	76	100.0%
Unknown	0	0.0%
'ear		
2022	28	36.8%
2023	48	63.2%
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	24	31.6%
1-2	31	40.8%
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	2.3	2.7
Combined comorbidity score categories ⁴		
<0	****	****
0	17	22.4%
1-2	28	36.8%
3-4	****	****

cder_mpl1p_wp077 Page 53 of 990



Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
5+	15	19.7%
Alcohol use or abuse	****	****
Desity	39	51.3%
obacco use	****	****
nrhythmia	16	21.1%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	24	31.6%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
lyperlipidemia	65	85.5%
Typertensive disease	67	88.2%
Thyroid disease	14	18.4%
schemic heart disease/coronary artery disease/myocardial infarction	17	22.4%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	17	22.4%
lypertrophic cardiomyopathy	****	****
Other cardiac disease	29	38.2%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
alpha-glucosidase inhibitors	0	0.0%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	11	14.5%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Лeglitinides	0	0.0%
nsulin	27	35.5%
liguanides (metformin, phenformin, etc.)	55	72.4%
GLT2 inhibitors	17	22.4%
ulfonylurea	29	38.2%
hiazolidinedione	15	19.7%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	34	44.7%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%

cder_mpl1p_wp077 Page 54 of 990



Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	13101	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	34	44.7%
Angiotensin-converting-enzyme (ACE) inhibitors	28	36.8%
Angiotensin ii receptor blockers (ARB)	32	42.1%
Dihydropyridines	24	31.6%
Diuretics	24	31.6%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	70	92.1%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	11	14.5%
Lipid lowering therapy	70	92.1%
Baseline known risk of prolonged QT and torsades de pointes	26	34.2%
Baseline possible risk of prolonged QT and torsades de pointes	63	82.9%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	11	14.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.1	9.5
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.3	4.4
Mean number of filled prescriptions	21.3	12.4
Mean number of generics dispensed	10.5	4.2
Mean number of unique drug classes dispensed	9.3	3.7

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 55 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	10,501	N/A
Demographic Characteristics		
Age (years)	67.2	8.8
Age		
0-40 years	136	1.3%
41-64 years	2,914	27.7%
65-74 years	5,693	54.2%
75-84 years	1,679	16.0%
≥ 85 years	79	0.8%
Sex		
Female	6,002	57.2%
Male	4,499	42.8%
Race ²	·	
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	10,501	100.0%
Hispanic origin	-,	
Yes	****	****
No	9,956	94.8%
Unknown	****	****
/ear		
2022	5,530	52.7%
2023	4,971	47.3%
Health Characteristics	1,37.1	17.370
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		,
<0	0	0.0%
0	3,428	32.6%
1-2	4,322	41.2%
3-4	1,927	18.4%
5+	824	7.8%
Combined comorbidity score ⁴	2.1	2.4
Combined comorbidity score categories ⁴	۷.1	۷.٦
<0	712	6.8%
0	2,070	19.7%
1-2	3,972	37.8%
3-4	2,163	20.6%

cder_mpl1p_wp077 Page 56 of 990



Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	1,584	15.1%
Alcohol use or abuse	135	1.3%
Obesity	6,290	59.9%
Tobacco use	2,321	22.1%
Arrhythmia	2,368	22.6%
Cerebrovascular disease/stroke/transient ischemic attack	1,086	10.3%
Chronic kidney disease	1,959	18.7%
Chronic obstructive pulmonary disease	1,479	14.1%
Congenital heart disease	1,479	14.1%
Heart failure	1,404	13.4%
Hyperlipidemia	8,461	80.6%
Hypertensive disease	8,987	85.6%
Thyroid disease	2,803	26.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,677	25.5%
Left ventricular hypertrophy	388	3.7%
Peripheral artery disease	388	3.7%
Valvular/mitral valve disease	351	3.3%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,090	10.4%
Obstructive sleep apnea	3,102	29.5%
Hypertrophic cardiomyopathy	449	4.3%
Other cardiac disease	5,142	49.0%
Tachyarrhythmia day 0	219	2.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	44	0.4%
Medical Product Use	44	0.470
Alpha-glucosidase inhibitors	39	0.4%
Amylin analogs (pramlintide)	****	V.470 ****
DPP-4 inhibitors	1,187	11.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
	83	0.8%
Meglitinides Insulin		28.2%
	2,959	
Biguanides (metformin, phenformin, etc.)	8,120	77.3%
SGLT2 inhibitors	2,652	25.3%
Sulfonylurea	3,450	32.9%
Thiazolidinedione	1,151	11.0%
No baseline use of any of the above antidiabetic drugs	0 ****	0.0% ****
Other antidiabetics		
Sodium channel blockers	103	1.0%
Beta blockers Potassium channel blockers/openers	4,755 169	45.3% 1.6%
Non-dihydropyridine calcium channel blockers	17	0.2%
Digoxin	77	0.7%

cder_mpl1p_wp077 Page 57 of 990



Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,827	46.0%
Angiotensin-converting-enzyme (ACE) inhibitors	3,936	37.5%
Angiotensin ii receptor blockers (ARB)	3,997	38.1%
Dihydropyridines	2,609	24.8%
Diuretics	4,176	39.8%
Other antihypertensives	939	8.9%
Antihypertensives (any of the above antihypertensives)	9,060	86.3%
Oral anticoagulants	1,029	9.8%
Vitamin K antagonists	227	2.2%
Other cardiac medications not mentioned above	716	6.8%
Other cardiac medications (any of the other cardiac medications)	1,814	17.3%
Lipid lowering therapy	8,924	85.0%
Baseline known risk of prolonged QT and torsades de pointes	4,620	44.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	9,253	88.1%
torsades de pointes	2,124	20.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.2	9.9
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.6	5.9
Mean number of filled prescriptions	27.1	17.6
Mean number of generics dispensed	12.1	5.4
Mean number of unique drug classes dispensed	11.0	4.9

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	71	N/A
Demographic Characteristics		
Age (years)	53.2	10.5
Age		
0-40 years	****	****
41-64 years	55	77.5%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	40	56.3%
Male	31	43.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	71	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	****
No	****	****
Unknown	48	67.6%
'ear		
2022	39	54.9%
2023	32	45.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	0.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	50	70.4%
1-2	****	****
3-4	****	****
5+	0	0.0%
Combined comorbidity score ⁴	1.0	1.6
Combined comorbidity score categories ⁴	3	5
<0	****	****
0	24	33.8%
1-2	24	33.8%
3-4	****	****

cder_mpl1p_wp077 Page 59 of 990



Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean ****	Deviation ¹ ****
5+	****	****
Alcohol use or abuse		
Obesity	41 ****	57.7% ****
Tobacco use		
Arrhythmia	11	15.5%
Cerebrovascular disease/stroke/transient ischemic attack	****	
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	50	70.4%
Hypertensive disease	54	76.1%
Thyroid disease	15	21.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	18	25.4%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	22	31.0%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	11	15.5%
Biguanides (metformin, phenformin, etc.)	58	81.7%
SGLT2 inhibitors	21	29.6%
Sulfonylurea	12	16.9%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	16	22.5%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin		0.0%

cder_mpl1p_wp077 Page 60 of 990



Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Mounjaro, Hospitalizo Race=Mu	• •
	Nucc-Ivia	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	16	22.5%
Angiotensin-converting-enzyme (ACE) inhibitors	24	33.8%
Angiotensin ii receptor blockers (ARB)	22	31.0%
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	51	71.8%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	46	64.8%
Baseline known risk of prolonged QT and torsades de pointes	18	25.4%
Baseline possible risk of prolonged QT and torsades de pointes	45	63.4%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.4	5.7
Mean number of emergency room encounters	0.3	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.5	2.8
Mean number of filled prescriptions	17.6	12.5
Mean number of generics dispensed	7.9	3.8
Mean number of unique drug classes dispensed	7.1	3.6

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1p. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhyt	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	139,413	N/A
Demographic Characteristics		
Age (years)	63.1	10.2
Age		
0-40 years	6,619	4.7%
41-64 years	59,783	42.9%
65-74 years	54,245	38.9%
75-84 years	17,331	12.4%
≥ 85 years	1,435	1.0%
Sex		
Female	77,670	55.7%
Male	61,743	44.3%
Race ²		
American Indian or Alaska Native	901	0.6%
Asian	1,746	1.3%
Black or African American	12,374	8.9%
Multi-racial	919	0.7%
Native Hawaiian or Other Pacific Islander	429	0.3%
Unknown	53,485	38.4%
White	69,559	49.9%
Hispanic origin		
Yes	4,070	2.9%
No	73,856	53.0%
Unknown	61,487	44.1%
'ear		
2022	94,901	68.1%
2023	44,512	31.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.4	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	60,250	43.2%
1-2	49,202	35.3%
3-4	20,442	14.7%
5+	9,519	6.8%
ombined comorbidity score ⁴	1.8	2.2
Combined comorbidity score categories ⁴		
<0	13,116	9.4%
0	34,333	24.6%
1-2	51,869	37.2%
3-4	23,118	16.6%

cder_mpl1p_wp077 Page 62 of 990



Table 1p. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalize	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	16,977	12.2%
Alcohol use or abuse	1,761	1.3%
Dbesity	73,139	52.5%
Tobacco use	24,720	17.7%
Arrhythmia	26,760	19.2%
Cerebrovascular disease/stroke/transient ischemic attack	12,432	8.9%
Chronic kidney disease	21,502	15.4%
Chronic obstructive pulmonary disease	12,706	9.1%
Congenital heart disease	12,706	9.1%
Heart failure	14,617	10.5%
Hyperlipidemia	104,796	75.2%
Hypertensive disease	112,418	80.6%
Thyroid disease	27,761	19.9%
schemic heart disease/coronary artery disease/myocardial infarction	29,059	20.8%
eft ventricular hypertrophy	4,942	3.5%
Peripheral artery disease	4,942	3.5%
/alvular/mitral valve disease	3,639	2.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	12,389	8.9%
Dbstructive sleep apnea	33,215	23.8%
Hypertrophic cardiomyopathy	5,605	4.0%
Other cardiac disease	57,346	41.1%
achyarrhythmia day 0	2,171	1.6%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	665	0.5%
Medical Product Use		0.370
Alpha-glucosidase inhibitors	460	0.3%
Amylin analogs (pramlintide)	****	****
DPP-4 inhibitors	17,959	12.9%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	1,167	0.8%
nsulin	35,933	25.8%
Biguanides (metformin, phenformin, etc.)	112,827	80.9%
GGLT2 inhibitors	35,713	25.6%
Sulfonylurea	42,460	30.5%
'hiazolidinedione	10,892	7.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	30	0.0%
Sodium channel blockers Beta blockers	863 55,746	0.6% 40.0%
Potassium channel blockers/openers	1,811	1.3%
Non-dihydropyridine calcium channel blockers	166	0.1%
Digoxin	929	0.7%

cder_mpl1p_wp077 Page 63 of 990



Table 1p. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozemnic, Hosnitaliz	ed Tachyarrhythmia
	Ozempie, mospitanz	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	56,409	40.5%
Angiotensin-converting-enzyme (ACE) inhibitors	50,154	36.0%
Angiotensin ii receptor blockers (ARB)	49,792	35.7%
Dihydropyridines	34,326	24.6%
Diuretics	47,769	34.3%
Other antihypertensives	10,486	7.5%
Antihypertensives (any of the above antihypertensives)	113,870	81.7%
Oral anticoagulants	11,125	8.0%
Vitamin K antagonists	2,377	1.7%
Other cardiac medications not mentioned above	7,982	5.7%
Other cardiac medications (any of the other cardiac medications)	19,705	14.1%
Lipid lowering therapy	111,023	79.6%
Baseline known risk of prolonged QT and torsades de pointes	50,274	36.1%
Baseline possible risk of prolonged QT and torsades de pointes	112,203	80.5%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	21,212	15.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.0	10.2
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.9	5.9
Mean number of filled prescriptions	23.7	17.8
Mean number of generics dispensed	10.4	5.1
Mean number of unique drug classes dispensed	9.4	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmi Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	53,485	N/A
Demographic Characteristics		
Age (years)	56.5	10.9
Age		
0-40 years	4,863	9.1%
41-64 years	36,779	68.8%
65-74 years	9,509	17.8%
75-84 years	2,167	4.1%
≥ 85 years	167	0.3%
Sex		
Female	28,603	53.5%
Male	24,882	46.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	53,485	100.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	49,717	93.0%
/ear	-,	
2022	33,470	62.6%
2023	20,015	37.4%
Health Characteristics		<u> </u>
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	31,526	58.9%
1-2	15,788	29.5%
3-4	4,483	8.4%
5+	1,688	3.2%
Combined comorbidity score ⁴	1.1	1.8
Combined comorbidity score categories ⁴	1.1	1.0
<0	7,056	13.2%
0	16,893	31.6%
1-2	20,555	38.4%
3-4	6,033	11.3%

cder_mpl1p_wp077 Page 65 of 990



Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	2,948	5.5%
Alcohol use or abuse	541	1.0%
Obesity	27,100	50.7%
Tobacco use	6,512	12.2%
Arrhythmia	7,037	13.2%
Cerebrovascular disease/stroke/transient ischemic attack	2,587	4.8%
Chronic kidney disease	4,497	8.4%
Chronic obstructive pulmonary disease	2,393	4.5%
Congenital heart disease	2,393	4.5%
Heart failure	2,963	5.5%
Hyperlipidemia	37,138	69.4%
Hypertensive disease	39,210	73.3%
Thyroid disease	8,479	15.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	6,729	12.6%
Left ventricular hypertrophy	1,306	2.4%
Peripheral artery disease	1,306	2.4%
Valvular/mitral valve disease	783	1.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	3,110	5.8%
Obstructive sleep apnea	11,354	21.2%
Hypertrophic cardiomyopathy	1,316	2.5%
Other cardiac disease	17,118	32.0%
Tachyarrhythmia day 0	472	0.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	145	0.3%
Medical Product Use	143	0.370
Alpha-glucosidase inhibitors	147	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,395	12.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0,333	0.0%
Meglitinides	312	0.6%
Insulin	11,004	20.6%
Biguanides (metformin, phenformin, etc.)	45,639	85.3%
SGLT2 inhibitors	13,954	26.1%
Sulfonylurea	13,454	25.2%
Thiazolidinedione	3,315	6.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	14	0.0%
Sodium channel blockers	226	0.4%
Beta blockers	16,221	30.3%
Potassium channel blockers/openers	354	0.7%
Non-dihydropyridine calcium channel blockers	48	0.1%
Digoxin	182	0.3%

cder_mpl1p_wp077 Page 66 of 990



Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	• • •	ed Tachyarrhythmia, nknown
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	16,360	30.6%
Angiotensin-converting-enzyme (ACE) inhibitors	18,775	35.1%
Angiotensin ii receptor blockers (ARB)	17,104	32.0%
Dihydropyridines	10,737	20.1%
Diuretics	14,127	26.4%
Other antihypertensives	2,811	5.3%
Antihypertensives (any of the above antihypertensives)	40,326	75.4%
Oral anticoagulants	2,561	4.8%
Vitamin K antagonists	472	0.9%
Other cardiac medications not mentioned above	1,851	3.5%
Other cardiac medications (any of the other cardiac medications)	4,573	8.6%
Lipid lowering therapy	38,784	72.5%
Baseline known risk of prolonged QT and torsades de pointes	17,728	33.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	39,618	74.1%
torsades de pointes	6,829	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.8	9.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.4	3.9
Mean number of filled prescriptions	20.4	15.8
Mean number of generics dispensed	9.1	5.0
Mean number of unique drug classes dispensed	8.2	4.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Number/Mean Deviation³ Deviation³ Unique patients 901 N/A Demographic Characteristics		Ozempic, Hospitalized Tachyarrhythmia Race=American Indian or Alaska Native	
Unique patients 901 N/A Demographic Characteristics N/A Age (years) 66.7 10.9 Age Colovers 30 3.3% 41-64 years 403 44.7% 55-74 years 403 44.7% 75-84 years 169 18.8% ≥ 85 years 16 1.8% Sex Female 515 57.2% Male 386 42.8% Race² American Indian or Alaska Native 901 100.0% Asian 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% White 0 0.0% Multi-racial 0 0.0% White 0 0.0% 0.0% 0.0% 0.0 0.0% <tr< th=""><th></th><th></th><th></th></tr<>			
Demographic Characteristics Age (years) 66.7 10.9 Age (years) 10.9 Age (years) 10.9 Age (years) 30 3.3% 41.4% 42.8% 31.4% 65.74 years 28.3 31.4% 65.74 years 403 44.7% 75.84 years 16.9 18.8% 28.55 years 16.9 18.8% 28.55 years 16.5 1.8% 28.55 years 16.5 15.72% 2.7% 2.2%	Patient Characteristics	Number/Mean	Deviation ¹
Age (years) 66.7 10.9 Age 30 3.3% 0-40 years 30 3.3% 41-64 years 283 31.4% 65-74 years 403 44.7% 75-84 years 169 18.8% 2 85 years 16 1.8% Sex Female 515 57.2% Male 386 42.8% Race² 4.8% 42.8% Race² 4.8% 42.8% American Indian or Alaska Native 901 100.0% Asian 0 0.0% Multi-racial 0 0.0% Matice Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ********* Year 2022 27 747 82.9% 2023 154 17.1% 4**** Health Characteristics ***** ******* 40	Unique patients	901	N/A
Age 0-40 years 30 3.3% 41-64 years 6283 31.4% 65-74 years 403 44.7% 75-84 years 169 18.8% ≥ 85 years 16 1.8% Sex Female 515 57.2% Male 386 42.8% Race² American Indian or Alaska Native 901 100.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% White 0 0.0% Unknown 0 0.0% White 0 0.0% White 0 0.0% Whome 10 0.0% Whome 10 0.0% White 10 0.0% White 10 0.0% Mative Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 10 0.0%	Demographic Characteristics		
0-40 years	Age (years)	66.7	10.9
41-64 years 283 31.4% 65-74 years 403 44.7% 75-84 years 169 18.8% 2 85 years 16 1.8% Sex Temale 515 57.2% Male 386 42.8% Race² Temale 901 100.0% Asian 0 0.0% Asian 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ************************************	Age		
65-74 years 403 44.7% 75-84 years 169 18.8% ≥ 85 years 16 1.8% Sex Female 515 57.2% Male 386 42.8% Race² American Indian or Alaska Native 991 100.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% White 10 0.0% White 10 0.0% Whous 10 0.0% White 10 0.	0-40 years	30	3.3%
75-84 years 169 18.8% ≥ 85 years 16 16 1.8% Sex Female 515 57.2% Male 386 42.8% Race² American Indian or Alaska Native 901 100.0% Asian 0 0 0.0% Black or African American 0 0 0.0% Multi-racial 0 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 10 0 0.0% Hispanic origin Yes 100 830 92.1% Unknown 100	41-64 years	283	31.4%
≥ 85 years Sex Female 515 57.2% Male 386 42.8% Race² American Indian or Alaska Native 901 100.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 1 0 0.0% Hispanic origin Yes ***** No 830 92.1% Unknown ***** Year 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) at egories³ <0 0 0.0% 0 0.0% 1 1-2 318 318 35.3% 1 -2 3.3 4 168 18.6% 5 + 68 7.5% Combined comorbidity score 4 2.0 2.3 Combined comorbidity score 4 2.0 2.3 Combined comorbidity score 4 78 8.7% Combined comorbidity score 4	65-74 years	403	44.7%
Sex Female 515 57.2% Male 386 42.8% Race² ************************************	75-84 years	169	18.8%
Female Male 515 57.2% Male Race² 386 42.8% Race² American Indian or Alaska Native 901 100.0% Asian 0 0.0% Down and a signature and asian or of the Asian of African American 0 0.0% Down and asian or of African American 0 0.0% Down and asian or of African American of O.0% Down and asian or Other Pacific Islander 0 0.0% Down and asian or of O.0% Down and	≥ 85 years	16	1.8%
Male 386 42.8% Race²	Sex		
Race² 901 100.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes ***** ****** No 830 92.1% Unknown ****** ****** Year 2022 747 82.9% 2023 747 82.9% 2023 747 82.9% 2023 747 82.9% 2023 747 82.9% 2023 747 82.9% 40 1.5 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ <td>Female</td> <td>515</td> <td>57.2%</td>	Female	515	57.2%
American Indian or Alaska Native 901 100.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes ***** ****** No 830 92.1% Unknown ****** ****** Year ****** ****** 2022 747 82.9% 2023 154 17.1% Health Characteristics ******* Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI)* 0 0.0% 0 0 0.0% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combi	Male	386	42.8%
Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes ***** ****** No 830 92.1% Unknown ****** ****** Year 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) at eagories 3 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories 3 0 0 0.0% 0 0 0.0% 0 0 0.0% 0 0 0.0% 0 0 0 0.0% 0 0 0.0% 0 0 0 0 0 0 0 0 0.0% 0 0	Race ²		
Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes ***** ****** No 830 92.1% Unknown ***** ****** Year 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 0 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ 78 8.7% 0 194 21.5% </td <td></td> <td>901</td> <td>100.0%</td>		901	100.0%
Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes ****** ****** No 830 92.1% Unknown ****** ****** Year 747 82.9% 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score decembers 2.0 2.3 Combined comorbidity score categories decembers 78 8.7% 0 194 21.5% 1-2 346 <td>Asian</td> <td>0</td> <td>0.0%</td>	Asian	0	0.0%
Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin Yes ****** ****** No 830 92.1% Unknown ****** Year 2022 747 82.9% 2023 154 17.1% Health Characteristics ***********************************	Black or African American	0	0.0%
Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes ***** ****** No 830 92.1% Unknown ****** ****** Year ****** ****** 2022 747 82.9% 203 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	Multi-racial	0	0.0%
White 0 0.0% Hispanic origin Yes ****** ****** No 830 92.1% Unknown ****** ****** Year Year ****** ****** 2022 747 82.9% 20.0 ***** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	Native Hawaiian or Other Pacific Islander	0	0.0%
Hispanic origin Yes	Unknown	0	0.0%
Yes ****** ****** No 830 92.1% Unknown ****** ****** Year ****** ****** 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 0 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 2.0 2.3 Combined comorbidity score categories⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	White	0	0.0%
Yes ****** ****** No 830 92.1% Unknown ****** ****** Year ****** ****** 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 0 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 2.0 2.3 Combined comorbidity score categories⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	Hispanic origin		
Unknown ****** ****** Year 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ <0		****	****
Year 2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) ³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ <0 78 8.7% 0 194 21.5% 1-2 346 38.4%	No	830	92.1%
2022 747 82.9% 2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ <0	Unknown	****	****
2023 154 17.1% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) categories³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 2.0 2.3 <0	Year		
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	2022	747	82.9%
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 1.6 1.7 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score⁴ 2.0 2.3 Combined comorbidity score categories⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	2023	154	17.1%
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ <0 78 8.7% 0 194 21.5% 1-2 346 38.4%	Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ <0 78 8.7% 0 194 21.5% 1-2 346 38.4%	Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.7
0 347 38.5% 1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%	Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ -78 8.7% 0 194 21.5% 1-2 346 38.4%	<0	0	0.0%
1-2 318 35.3% 3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ -78 8.7% 0 78 8.7% 0 194 21.5% 1-2 346 38.4%	0	347	38.5%
3-4 168 18.6% 5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ 78 8.7% 0 78 8.7% 1-2 346 38.4%	1-2	318	
5+ 68 7.5% Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴ -78 8.7% 0 194 21.5% 1-2 346 38.4%			
Combined comorbidity score ⁴ 2.0 2.3 Combined comorbidity score categories ⁴			
Combined comorbidity score categories ⁴ 78 8.7% 0 194 21.5% 1-2 346 38.4%			
<0			
019421.5%1-234638.4%		78	8.7%
1-2 346 38.4%			
1/2 13.1/0	3-4	172	19.1%

cder_mpl1p_wp077 Page 68 of 990



Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
	Race=American Ind	ian or Alaska Native Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	111	12.3%
Alcohol use or abuse	18	2.0%
Obesity	326	36.2%
Tobacco use	217	24.1%
Arrhythmia	168	18.6%
Cerebrovascular disease/stroke/transient ischemic attack	97	10.8%
Chronic kidney disease	174	19.3%
Chronic obstructive pulmonary disease	105	11.7%
Congenital heart disease	105	11.7%
Heart failure	111	12.3%
Hyperlipidemia	526	58.4%
Hypertensive disease	696	77.2%
Thyroid disease	163	18.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	199	22.1%
Left ventricular hypertrophy	30	3.3%
Peripheral artery disease	30	3.3%
Valvular/mitral valve disease	28	3.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	28 85	9.4%
	166	18.4%
Obstructive sleep apnea		4.2%
Hypertrophic cardiomyopathy Other cardiac disease	38 342	4.2% 38.0%
	_	
Tachyarrhythmia day 0	22	2.4%
Hospitalized tachyarrhythmia day 0	0 ****	0.0% ****
History of serious hypoglycemia (ED and/or IP) Medical Product Use	4, 4, 4, 4,	4.4.4.4.4.
	****	****
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide) DPP-4 inhibitors	_	18.9%
	170	
Incretin mimetics (albiglutide, dulaglutide, etc.)	0 ****	0.0%
Meglitinides		
Insulin Disconides (metformin phenformin etc.)	406 695	45.1% 77.1%
Biguanides (metformin, phenformin, etc.)		
SGLT2 inhibitors	233	25.9%
Sulfonylurea	273	30.3%
Thiazolidinedione No baseline was of any of the above antidiabetic drugs	84	9.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0 ****	0.0%
Sodium channel blockers Beta blockers	342	38.0%
Potassium channel blockers/openers	13	1.4%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****

cder_mpl1p_wp077 Page 69 of 990



Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% Antiarrhythmic agents (any of the above antiarrhythmic agents) 345 38.3% Angiotensin-converting-enzyme (ACE) inhibitors 379 42.1% Angiotensin ii receptor blockers (ARB) 321 35.6% Dihydropyridines 221 24.5% **Diuretics** 340 37.7% 77 Other antihypertensives 8.5% Antihypertensives (any of the above antihypertensives) 773 85.8% Oral anticoagulants 97 10.8% Vitamin K antagonists 14 1.6% Other cardiac medications not mentioned above 6.9% 62 Other cardiac medications (any of the other cardiac medications) 159 17.6% Lipid lowering therapy 718 79.7% Baseline known risk of prolonged QT and torsades de pointes 318 35.3% Baseline possible risk of prolonged QT and torsades de pointes 727 80.7% Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes 101 11.2% **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 10.6 9.2 Mean number of emergency room encounters 0.4 1.1 Mean number of inpatient hospital encounters 0.1 0.5 Mean number of non-acute institutional encounters 0.0 0.2 2.8 6.2 Mean number of other ambulatory encounters Mean number of filled prescriptions 35.6 23.8 Mean number of generics dispensed 11.1 5.0 Mean number of unique drug classes dispensed 10.1 4.5

N/A: Not applicable

cder mpl1p wp077 Page 70 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalize Race=/	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,746	N/A
Demographic Characteristics		
Age (years)	65.8	10.4
Age		
0-40 years	106	6.1%
41-64 years	440	25.2%
65-74 years	825	47.3%
75-84 years	318	18.2%
≥ 85 years	57	3.3%
Sex		
Female	945	54.1%
Male	801	45.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,746	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	·	0.075
Yes	****	****
No	1,313	75.2%
Unknown	****	****
Year		
2022	1,279	73.3%
2023	467	26.7%
Health Characteristics	407	20.770
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.5	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.5	1.7
<0	0	0.0%
0	680	38.9%
1-2	643	36.8%
3-4	290	16.6%
5+	133	7.6%
Combined comorbidity score categories ⁴	2.0	2.3
Combined comorbidity score categories ⁴	120	0.00/
<0	139	8.0%
0	418	23.9%
1-2	642	36.8%
3-4	301	17.2%

cder_mpl1p_wp077 Page 71 of 990



Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Asian Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
5+	246	14.1%
Alcohol use or abuse	****	****
Obesity	514	29.4%
Tobacco use	167	9.6%
Arrhythmia	285	16.3%
Cerebrovascular disease/stroke/transient ischemic attack	176	10.1%
Chronic kidney disease	375	21.5%
Chronic obstructive pulmonary disease	95	5.4%
Congenital heart disease	95	5.4%
Heart failure	177	10.1%
Hyperlipidemia	1,393	79.8%
Hypertensive disease	1,398	80.1%
Thyroid disease	344	19.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	417	23.9%
Left ventricular hypertrophy	63	3.6%
Peripheral artery disease	63	3.6%
Valvular/mitral valve disease	36	2.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	134	7.7%
Obstructive sleep apnea	197	11.3%
Hypertrophic cardiomyopathy	62	3.6%
Other cardiac disease	612	35.1%
Tachyarrhythmia day 0	16	0.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	24	1.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	322	18.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	33	1.9%
Insulin	574	32.9%
Biguanides (metformin, phenformin, etc.)	1,445	82.8%
SGLT2 inhibitors	572	32.8%
Sulfonylurea	618	35.4%
Thiazolidinedione	178	10.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	****	****
Beta blockers	711	40.7%
Potassium channel blockers/openers	21	1.2%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	14	0.8%

cder_mpl1p_wp077 Page 72 of 990



Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	717	41.1%
Angiotensin-converting-enzyme (ACE) inhibitors	466	26.7%
Angiotensin ii receptor blockers (ARB)	865	49.5%
Dihydropyridines	540	30.9%
Diuretics	437	25.0%
Other antihypertensives	149	8.5%
Antihypertensives (any of the above antihypertensives)	1,430	81.9%
Oral anticoagulants	88	5.0%
Vitamin K antagonists	12	0.7%
Other cardiac medications not mentioned above	118	6.8%
Other cardiac medications (any of the other cardiac medications)	203	11.6%
Lipid lowering therapy	1,491	85.4%
Baseline known risk of prolonged QT and torsades de pointes	488	27.9%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,217	69.7%
torsades de pointes	180	10.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.5	11.7
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.9	6.1
Mean number of filled prescriptions	21.9	17.1
Mean number of generics dispensed	10.0	5.1
Mean number of unique drug classes dispensed	8.7	4.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 73 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	12,374	N/A
Demographic Characteristics		
Age (years)	64.4	10.2
Age		
0-40 years	404	3.3%
41-64 years	4,747	38.4%
65-74 years	5,789	46.8%
75-84 years	1,318	10.7%
≥ 85 years	116	0.9%
Sex		
Female	8,766	70.8%
Male	3,608	29.2%
Race ²	•	
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	12,374	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	-	
Yes	0	0.0%
No	10,723	86.7%
Unknown	1,651	13.3%
Year	_,-,	
2022	7,567	61.2%
2023	4,807	38.8%
Health Characteristics	.,,	33.3.7
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	3,812	30.8%
1-2	4,739	38.3%
3-4	2,523	20.4%
5+	1,300	10.5%
Combined comorbidity score ⁴	2.4	2.5
Combined comorbidity score categories ⁴	2	5
<0	875	7.1%
0	2,424	19.6%
1-2	4,165	33.7%
3-4	2,616	21.1%

cder_mpl1p_wp077 Page 74 of 990



Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American	
Dations Characteristics	N	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	2,294	18.5%
Alcohol use or abuse	186	1.5%
Obesity	7,712	62.3%
Tobacco use	2,506	20.3%
Arrhythmia	2,411	19.5%
Cerebrovascular disease/stroke/transient ischemic attack	1,490	12.0%
Chronic kidney disease	3,006	24.3%
Chronic obstructive pulmonary disease	1,289	10.4%
Congenital heart disease	1,289	10.4%
Heart failure	2,151	17.4%
Hyperlipidemia	9,550	77.2%
Hypertensive disease	11,306	91.4%
Thyroid disease	1,631	13.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,454	19.8%
Left ventricular hypertrophy	608	4.9%
Peripheral artery disease	608	4.9%
Valvular/mitral valve disease	308	2.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,218	9.8%
Obstructive sleep apnea	3,019	24.4%
Hypertrophic cardiomyopathy	774	6.3%
Other cardiac disease	5,440	44.0%
Tachyarrhythmia day 0	156	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	108	0.9%
Medical Product Use		
Alpha-glucosidase inhibitors	55	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,723	13.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	100	0.8%
Insulin	4,017	32.5%
Biguanides (metformin, phenformin, etc.)	9,130	73.8%
SGLT2 inhibitors	3,148	25.4%
Sulfonylurea	3,984	32.2%
Thiazolidinedione	855	6.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	52	0.4%
Beta blockers	5,812	47.0%
Potassium channel blockers/openers	144	1.2%
Non-dihydropyridine calcium channel blockers	17	0.1%
Digoxin	76	0.6%

cder_mpl1p_wp077 Page 75 of 990



Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% Antiarrhythmic agents (any of the above antiarrhythmic agents) 5,853 47.3% Angiotensin-converting-enzyme (ACE) inhibitors 3,742 30.2% Angiotensin ii receptor blockers (ARB) 5.644 45.6% Dihydropyridines 5,403 43.7% **Diuretics** 5,919 47.8% Other antihypertensives 1,763 14.2% Antihypertensives (any of the above antihypertensives) 11,241 90.8% Oral anticoagulants 897 7.2% Vitamin K antagonists 173 1.4% Other cardiac medications not mentioned above 776 6.3% Other cardiac medications (any of the other cardiac medications) 1,684 13.6% Lipid lowering therapy 10,176 82.2% Baseline known risk of prolonged QT and torsades de pointes 34.3% 4,240 Baseline possible risk of prolonged QT and torsades de pointes 10,667 86.2% Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes 1,617 13.1% **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 12.2 11.2 Mean number of emergency room encounters 0.5 1.4 Mean number of inpatient hospital encounters 0.1 0.4 Mean number of non-acute institutional encounters 0.0 0.2 7.4 Mean number of other ambulatory encounters 3.1 Mean number of filled prescriptions 25.1 17.9 Mean number of generics dispensed 11.3 5.3 Mean number of unique drug classes dispensed 10.3 4.8

N/A: Not applicable

cder mpl1p wp077 Page 76 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	429	N/A
Demographic Characteristics		
Age (years)	68.9	8.2
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	245	57.1%
75-84 years	97	22.6%
≥ 85 years	****	****
Sex		
Female	206	48.0%
Male	223	52.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	429	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	409	95.3%
Unknown	20	4.7%
Year		
2022	195	45.5%
2023	234	54.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	132	30.8%
1-2	162	37.8%
3-4	95	22.1%
5+	40	9.3%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴		
<0	21	4.9%
0	96	22.4%
1-2	159	37.1%
	84	19.6%

cder_mpl1p_wp077 Page 77 of 990



Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Islander	
	A. 1. /a.a	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	69	16.1%
Alcohol use or abuse	****	****
Obesity	186	43.4%
Tobacco use	61	14.2%
Arrhythmia	78	18.2%
Cerebrovascular disease/stroke/transient ischemic attack	45	10.5%
Chronic kidney disease	101	23.5%
Chronic obstructive pulmonary disease	27	6.3%
Congenital heart disease	27	6.3%
Heart failure	61	14.2%
Hyperlipidemia	363	84.6%
Hypertensive disease	364	84.8%
Thyroid disease	77	17.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	99	23.1%
Left ventricular hypertrophy	13	3.0%
Peripheral artery disease	13	3.0%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	34	7.9%
Obstructive sleep apnea	74	17.2%
Hypertrophic cardiomyopathy	20	4.7%
Other cardiac disease	170	39.6%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	48	11.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	139	32.4%
Biguanides (metformin, phenformin, etc.)	354	82.5%
SGLT2 inhibitors	103	24.0%
Sulfonylurea	163	38.0%
Thiazolidinedione	54	12.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	176	41.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%

cder_mpl1p_wp077 Page 78 of 990



Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	176	41.0%
Angiotensin-converting-enzyme (ACE) inhibitors	167	38.9%
Angiotensin ii receptor blockers (ARB)	182	42.4%
Dihydropyridines	126	29.4%
Diuretics	137	31.9%
Other antihypertensives	33	7.7%
Antihypertensives (any of the above antihypertensives)	371	86.5%
Oral anticoagulants	29	6.8%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	25	5.8%
Other cardiac medications (any of the other cardiac medications)	56	13.1%
Lipid lowering therapy	385	89.7%
Baseline known risk of prolonged QT and torsades de pointes	118	27.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	328	76.5%
torsades de pointes	46	10.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.8	8.5
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.3	3.7
Mean number of filled prescriptions	21.7	15.4
Mean number of generics dispensed	10.3	4.8
Mean number of unique drug classes dispensed	9.1	4.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 79 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	69,559	N/A
Demographic Characteristics		
Age (years)	68.0	9.1
Age		
0-40 years	1,070	1.5%
41-64 years	16,757	24.1%
65-74 years	37,400	53.8%
75-84 years	13,254	19.1%
≥ 85 years	1,078	1.5%
Sex		
Female	38,132	54.8%
Male	31,427	45.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	69,559	100.0%
Hispanic origin	·	
Yes	28	0.0%
No	60,513	87.0%
Unknown	9,018	13.0%
Year	·	
2022	51,170	73.6%
2023	18,389	26.4%
Health Characteristics	,	
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	23,125	33.2%
1-2	27,328	39.3%
3-4	12,829	18.4%
5+	6,277	9.0%
Combined comorbidity score ⁴	2.2	2.5
Combined comorbidity score categories ⁴		-
<0	4,826	6.9%
0	14,006	20.1%
1-2	25,616	36.8%
3-4	13,829	19.9%

cder_mpl1p_wp077 Page 80 of 990



Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	11,282	16.2%
Alcohol use or abuse	993	1.4%
Obesity	36,818	52.9%
Tobacco use	15,168	21.8%
Arrhythmia	16,677	24.0%
Cerebrovascular disease/stroke/transient ischemic attack	8,006	11.5%
Chronic kidney disease	13,298	19.1%
Chronic obstructive pulmonary disease	8,785	12.6%
Congenital heart disease	8,785	12.6%
Heart failure	9,127	13.1%
Hyperlipidemia	55,189	79.3%
Hypertensive disease	58,841	84.6%
Thyroid disease	16,934	24.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	19,078	27.4%
Left ventricular hypertrophy	2,908	4.2%
Peripheral artery disease	2,908	4.2%
Valvular/mitral valve disease	2,467	3.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	7,772	11.2%
Obstructive sleep apnea	18,207	26.2%
Hypertrophic cardiomyopathy	3,379	4.9%
Other cardiac disease	33,409	48.0%
Tachyarrhythmia day 0	1,488	2.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	389	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	225	0.3%
Amylin analogs (pramlintide)	****	****
DPP-4 inhibitors	9,218	13.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	710	1.0%
Insulin	19,603	28.2%
Biguanides (metformin, phenformin, etc.)	54,773	78.7%
SGLT2 inhibitors	17,460	25.1%
Sulfonylurea	23,787	34.2%
Thiazolidinedione	6,355	9.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	14	0.0%
Sodium channel blockers	570	0.8%
Beta blockers	32,264	46.4%
Potassium channel blockers/openers	1,272	1.8%
Non-dihydropyridine calcium channel blockers	100	0.1%
Digoxin	646	0.9%

cder_mpl1p_wp077 Page 81 of 990



Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	32,738	47.1%
Angiotensin-converting-enzyme (ACE) inhibitors	26,322	37.8%
Angiotensin ii receptor blockers (ARB)	25,377	36.5%
Dihydropyridines	17,141	24.6%
Diuretics	26,615	38.3%
Other antihypertensives	5,610	8.1%
Antihypertensives (any of the above antihypertensives)	59,081	84.9%
Oral anticoagulants	7,419	10.7%
Vitamin K antagonists	1,695	2.4%
Other cardiac medications not mentioned above	5,128	7.4%
Other cardiac medications (any of the other cardiac medications)	12,975	18.7%
Lipid lowering therapy	58,851	84.6%
Baseline known risk of prolonged QT and torsades de pointes	27,105	39.0%
Baseline possible risk of prolonged QT and torsades de pointes	59,034	84.9%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	12,351	17.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.4	10.9
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.2	6.9
Mean number of filled prescriptions	25.9	19.1
Mean number of generics dispensed	11.2	5.2
Mean number of unique drug classes dispensed	10.2	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	919	N/A
Demographic Characteristics		
Age (years)	52.3	10.2
Age		
0-40 years	138	15.0%
41-64 years	699	76.1%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	503	54.7%
Male	416	45.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	919	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	277	30.1%
No	63	6.9%
Unknown	579	63.0%
Year		
2022	473	51.5%
2023	446	48.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	628	68.3%
1-2	224	24.4%
3-4	54	5.9%
5+	13	1.4%
Combined comorbidity score ⁴	0.9	1.5
Combined comorbidity score categories ⁴		
<0	121	13.2%
0	302	32.9%
1-2	386	42.0%
3-4	83	9.0%

cder_mpl1p_wp077 Page 83 of 990



Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	27	2.9%
Alcohol use or abuse	****	****
Obesity	483	52.6%
Tobacco use	89	9.7%
Arrhythmia	104	11.3%
Cerebrovascular disease/stroke/transient ischemic attack	31	3.4%
Chronic kidney disease	51	5.5%
Chronic obstructive pulmonary disease	12	1.3%
Congenital heart disease	12	1.3%
Heart failure	27	2.9%
Hyperlipidemia	637	69.3%
Hypertensive disease	603	65.6%
Thyroid disease	133	14.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	83	9.0%
Left ventricular hypertrophy	14	1.5%
Peripheral artery disease	14	1.5%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	36	3.9%
Obstructive sleep apnea	198	21.5%
Hypertrophic cardiomyopathy	16	1.7%
Other cardiac disease	255	27.7%
Tachyarrhythmia day 0	11	1.2%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	83	9.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	190	20.7%
Biguanides (metformin, phenformin, etc.)	791	86.1%
SGLT2 inhibitors	243	
	181	26.4% 19.7%
Sulfonylurea Thiazolidinedione		
	51	5.5%
No baseline use of any of the above antidiabetic drugs Other antidiabetics	0	0.0%
Other antidiabetics	0 ****	0.0% ****
Sodium channel blockers Beta blockers	220	23.9%
Potassium channel blockers/openers	*****	23.970 ****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****

cder_mpl1p_wp077 Page 84 of 990



Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	220	23.9%
Angiotensin-converting-enzyme (ACE) inhibitors	303	33.0%
Angiotensin ii receptor blockers (ARB)	299	32.5%
Dihydropyridines	158	17.2%
Diuretics	194	21.1%
Other antihypertensives	43	4.7%
Antihypertensives (any of the above antihypertensives)	648	70.5%
Oral anticoagulants	34	3.7%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	22	2.4%
Other cardiac medications (any of the other cardiac medications)	55	6.0%
Lipid lowering therapy	618	67.2%
Baseline known risk of prolonged QT and torsades de pointes	277	30.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	612	66.6%
torsades de pointes	88	9.6%
Health Service Utilization Intensity Metrics		5.57.
Mean number of ambulatory encounters	8.6	8.3
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.7	4.0
Mean number of filled prescriptions	18.4	13.4
Mean number of generics dispensed	8.1	4.4
Mean number of unique drug classes dispensed	7.3	4.0

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1x. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Rybelsus, Hospital		d Tachyarrhythmia
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	39,924	N/A
Demographic Characteristics		
Age (years)	65.5	10.2
Age	4 202	2.50/
0-40 years	1,393	3.5%
41-64 years	14,438	36.2%
65-74 years	16,358	41.0%
75-84 years	6,766	16.9%
≥ 85 years	969	2.4%
Sex	20.445	54.40 /
Female	20,415	51.1%
Male	19,509	48.9%
Race ²		
American Indian or Alaska Native	83	0.2%
Asian	1,278	3.2%
Black or African American	4,150	10.4%
Multi-racial	220	0.6%
Native Hawaiian or Other Pacific Islander	177	0.4%
Unknown	15,015	37.6%
White	19,001	47.6%
Hispanic origin		
Yes	1,576	3.9%
No	21,655	54.2%
Unknown	16,693	41.8%
/ear		
2022	29,615	74.2%
2023	10,309	25.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	18,050	45.2%
1-2	14,033	35.1%
3-4	5,528	13.8%
5+	2,313	5.8%
Combined comorbidity score ⁴	1.6	2.2
Combined comorbidity score categories ⁴		
<0	4,106	10.3%
0	10,715	26.8%
1-2	14,537	36.4%
3-4	6,287	15.7%

cder_mpl1p_wp077 Page 86 of 990



Table 1x. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	4,279	10.7%
Alcohol use or abuse	442	1.1%
Desity	16,594	41.6%
obacco use	6,055	15.2%
Arrhythmia	6,772	17.0%
Gerebrovascular disease/stroke/transient ischemic attack	3,467	8.7%
Chronic kidney disease	6,323	15.8%
Chronic obstructive pulmonary disease	2,971	7.4%
Congenital heart disease	2,971	7.4%
leart failure	3,445	8.6%
lyperlipidemia	30,402	76.1%
lypertensive disease	32,055	80.3%
hyroid disease	7,066	17.7%
schemic heart disease/coronary artery disease/myocardial infarction	7,370	18.5%
eft ventricular hypertrophy	1,167	2.9%
eripheral artery disease	1,167	2.9%
/alvular/mitral valve disease	921	2.3%
siseases of veins and lymphatics, and other diseases of circulatory system	3,037	7.6%
Obstructive sleep apnea	6,579	16.5%
lypertrophic cardiomyopathy	1,344	3.4%
other cardiac disease	13,529	33.9%
achyarrhythmia day 0	558	1.4%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	154	0.4%
Nedical Product Use		
lpha-glucosidase inhibitors	201	0.5%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	7,132	17.9%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
/leglitinides	517	1.3%
nsulin	5,280	13.2%
iguanides (metformin, phenformin, etc.)	32,107	80.4%
GLT2 inhibitors	12,632	31.6%
ulfonylurea	15,229	38.1%
hiazolidinedione	3,772	9.4%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
odium channel blockers	189	0.5%
Beta blockers	14,901	37.3%
Potassium channel blockers/openers	429	1.1%
Non-dihydropyridine calcium channel blockers	51	0.1%
Digoxin	278	0.7%

cder_mpl1p_wp077 Page 87 of 990



Table 1x. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus. Hospitaliz	ed Tachyarrhythmia
	пушения, пеориана	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	15,072	37.8%
Angiotensin-converting-enzyme (ACE) inhibitors	14,885	37.3%
Angiotensin ii receptor blockers (ARB)	13,973	35.0%
Dihydropyridines	10,111	25.3%
Diuretics	11,816	29.6%
Other antihypertensives	2,803	7.0%
Antihypertensives (any of the above antihypertensives)	32,529	81.5%
Oral anticoagulants	2,891	7.2%
Vitamin K antagonists	555	1.4%
Other cardiac medications not mentioned above	1,819	4.6%
Other cardiac medications (any of the other cardiac medications)	4,888	12.2%
Lipid lowering therapy	32,656	81.8%
Baseline known risk of prolonged QT and torsades de pointes	12,118	30.4%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	29,742	74.5%
torsades de pointes	4,741	11.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.8	9.5
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.4	5.0
Mean number of filled prescriptions	21.1	16.0
Mean number of generics dispensed	9.4	4.6
Mean number of unique drug classes dispensed	8.3	4.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	15,015	N/A
Demographic Characteristics		
Age (years)	59.2	10.9
Age		
0-40 years	967	6.4%
41-64 years	9,300	61.9%
65-74 years	3,584	23.9%
75-84 years	1,000	6.7%
≥ 85 years	164	1.1%
Sex		
Female	7,056	47.0%
Male	7,959	53.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	15,015	100.0%
White	0	0.0%
Hispanic origin		
Yes	1,510	10.1%
No	****	****
Unknown	13,504	89.9%
Year		
2022	10,665	71.0%
2023	4,350	29.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	8,828	58.8%
1-2	4,485	29.9%
3-4	1,291	8.6%
5+	411	2.7%
Combined comorbidity score ⁴	1.0	1.8
Combined comorbidity score categories ⁴		
<0	2,067	13.8%
0	4,999	33.3%
1-2	5,613	37.4%
3-4	1,525	10.2%

cder_mpl1p_wp077 Page 89 of 990



Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	811	5.4%
Alcohol use or abuse	135	0.9%
Obesity	6,069	40.4%
Tobacco use	1,581	10.5%
Arrhythmia	1,720	11.5%
Cerebrovascular disease/stroke/transient ischemic attack	766	5.1%
Chronic kidney disease	1,381	9.2%
Chronic obstructive pulmonary disease	568	3.8%
Congenital heart disease	568	3.8%
Heart failure	687	4.6%
Hyperlipidemia	10,846	72.2%
Hypertensive disease	11,064	73.7%
Thyroid disease	2,137	14.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,804	12.0%
Left ventricular hypertrophy	293	2.0%
Peripheral artery disease	293	2.0%
Valvular/mitral valve disease	209	1.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	805	5.4%
Obstructive sleep apnea	2,304	15.3%
Hypertrophic cardiomyopathy	311	2.1%
Other cardiac disease	4,016	26.7%
Tachyarrhythmia day 0	117	0.8%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	39	0.3%
Medical Product Use	33	0.370
Alpha-glucosidase inhibitors	61	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	2,478	16.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	134	0.9%
Insulin	1,670	11.1%
Biguanides (metformin, phenformin, etc.)	12,718	84.7%
SGLT2 inhibitors	4,902	32.6%
Sulfonylurea	4,902	32.7%
Thiazolidinedione	·	8.4%
	1,258 0	0.0%
No baseline use of any of the above antidiabetic drugs	****	U.U% ****
Other antidiabetics		
Sodium channel blockers Beta blockers	49 4,221	0.3% 28.1%
Potassium channel blockers/openers	4,221 89	0.6%
Non-dihydropyridine calcium channel blockers	14	0.1%
Digoxin	59	0.4%

cder_mpl1p_wp077 Page 90 of 990



Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,249	28.3%
Angiotensin-converting-enzyme (ACE) inhibitors	5,520	36.8%
Angiotensin ii receptor blockers (ARB)	4,830	32.2%
Dihydropyridines	3,138	20.9%
Diuretics	3,393	22.6%
Other antihypertensives	694	4.6%
Antihypertensives (any of the above antihypertensives)	11,399	75.9%
Oral anticoagulants	683	4.5%
Vitamin K antagonists	106	0.7%
Other cardiac medications not mentioned above	433	2.9%
Other cardiac medications (any of the other cardiac medications)	1,152	7.7%
Lipid lowering therapy	11,574	77.1%
Baseline known risk of prolonged QT and torsades de pointes	4,128	27.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	10,062	67.0%
torsades de pointes	1,442	9.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.9	8.2
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.1	3.6
Mean number of filled prescriptions	18.4	14.2
Mean number of generics dispensed	8.3	4.5
Mean number of unique drug classes dispensed	7.3	4.0

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	83	N/A
Demographic Characteristics		
Age (years)	62.0	12.6
Age		
0-40 years	****	****
41-64 years	33	39.8%
65-74 years	29	34.9%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	51	61.4%
Male	32	38.6%
Race ²		
American Indian or Alaska Native	83	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	71	85.5%
Unknown	****	****
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	39	47.0%
1-2	29	34.9%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.7	2.0
Combined comorbidity score categories ⁴	<u></u>	•
<0	****	****
0	17	20.5%
1-2	36	43.4%
3-4	16	19.3%

cder_mpl1p_wp077 Page 92 of 990



Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia,	
	Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	40	48.2%
Tobacco use	16	19.3%
Arrhythmia	12	14.5%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	11	13.3%
Chronic obstructive pulmonary disease	11	13.3%
Congenital heart disease	11	13.3%
Heart failure	****	****
Hyperlipidemia	51	61.4%
Hypertensive disease	63	75.9%
Thyroid disease	13	15.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	13	15.7%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	20	24.1%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	20	24.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	16	19.3%
Biguanides (metformin, phenformin, etc.)	68	81.9%
SGLT2 inhibitors	26	31.3%
Sulfonylurea	29	34.9%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	24	28.9%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 93 of 990



Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% Antiarrhythmic agents (any of the above antiarrhythmic agents) 24 28.9% Angiotensin-converting-enzyme (ACE) inhibitors 37 44.6% Angiotensin ii receptor blockers (ARB) 20 24.1% Dihydropyridines 17 20.5% **Diuretics** 21 25.3% **** **** Other antihypertensives Antihypertensives (any of the above antihypertensives) 65 78.3% Oral anticoagulants **** **** **** Vitamin K antagonists Other cardiac medications not mentioned above **** Other cardiac medications (any of the other cardiac medications) **** Lipid lowering therapy 66 79.5% Baseline known risk of prolonged QT and torsades de pointes 34 41.0% Baseline possible risk of prolonged QT and torsades de pointes 69 83.1% Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes 11 13.3% **Health Service Utilization Intensity Metrics** 7.9 Mean number of ambulatory encounters 6.8 Mean number of emergency room encounters 0.4 1.0 Mean number of inpatient hospital encounters 0.1 0.3 Mean number of non-acute institutional encounters 0.0 0.1 3.2 7.3 Mean number of other ambulatory encounters Mean number of filled prescriptions 30.3 22.1 Mean number of generics dispensed 10.7 4.6 Mean number of unique drug classes dispensed 9.5 4.2

N/A: Not applicable

cder mpl1p wp077 Page 94 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,278	N/A
Demographic Characteristics		
Age (years)	70.2	9.8
Age		
0-40 years	30	2.3%
41-64 years	205	16.0%
65-74 years	641	50.2%
75-84 years	327	25.6%
≥ 85 years	75	5.9%
Sex		
Female	713	55.8%
Male	565	44.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,278	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	G	0.070
Yes	****	****
No	1,083	84.7%
Unknown	****	****
Year		
2022	1,069	83.6%
2023	209	16.4%
Health Characteristics	203	10.470
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.4	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.4	1.7
<0	0	0.0%
0	535	41.9%
1-2	461	36.1%
3-4	199	15.6%
5+ Combined comorbidity score ⁴	83	6.5%
Combined comorbidity score Combined comorbidity score categories ⁴	1.8	2.3
· · · · · · · · · · · · · · · · · · ·	116	0.10/
<0	116	9.1%
0	307	24.0%
1-2	474	37.1%
3-4	223	17.4%

cder_mpl1p_wp077 Page 95 of 990



Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia,	
	Race=Asian	
Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
5+	158	12.4%
Alcohol use or abuse	****	****
Obesity	229	17.9%
Tobacco use	97	7.6%
Arrhythmia	177	13.8%
Cerebrovascular disease/stroke/transient ischemic attack	142	11.1%
Chronic kidney disease	303	23.7%
Chronic obstructive pulmonary disease	78	6.1%
Congenital heart disease	78	6.1%
Heart failure	113	8.8%
Hyperlipidemia	1,043	81.6%
Hypertensive disease	1,042	81.5%
Thyroid disease	201	15.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	261	20.4%
Left ventricular hypertrophy	33	2.6%
Peripheral artery disease	33	2.6%
Valvular/mitral valve disease	29	2.3%
Diseases of veins and lymphatics, and other diseases of circulatory system	68	5.3%
Obstructive sleep apnea	84	6.6%
Hypertrophic cardiomyopathy	36	2.8%
Other cardiac disease	372	29.1%
Tachyarrhythmia day 0	20	1.6%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	26	2.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	356	27.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	36	2.8%
Insulin	184	14.4%
Biguanides (metformin, phenformin, etc.)	1,047	81.9%
SGLT2 inhibitors	533	41.7%
Sulfonylurea	584	45.7%
Thiazolidinedione	192	15.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
	V ****	U.U% ****
Sodium channel blockers Beta blockers	507	39.7%
Potassium channel blockers/openers	11	0.9%
Non-dihydropyridine calcium channel blockers Digoxin	 0 ****	0.0%

cder_mpl1p_wp077 Page 96 of 990



Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	511	40.0%
Angiotensin-converting-enzyme (ACE) inhibitors	329	25.7%
Angiotensin ii receptor blockers (ARB)	662	51.8%
Dihydropyridines	445	34.8%
Diuretics	270	21.1%
Other antihypertensives	110	8.6%
Antihypertensives (any of the above antihypertensives)	1,073	84.0%
Oral anticoagulants	71	5.6%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	105	8.2%
Other cardiac medications (any of the other cardiac medications)	175	13.7%
Lipid lowering therapy	1,139	89.1%
Baseline known risk of prolonged QT and torsades de pointes	300	23.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	837	65.5%
torsades de pointes	94	7.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.2	11.1
Mean number of emergency room encounters	0.1	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.6	4.7
Mean number of filled prescriptions	22.1	17.4
Mean number of generics dispensed	9.8	5.0
Mean number of unique drug classes dispensed	8.4	4.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	4,150	N/A
Demographic Characteristics		
Age (years)	66.9	10.2
Age		
0-40 years	105	2.5%
41-64 years	1,202	29.0%
65-74 years	2,116	51.0%
75-84 years	638	15.4%
≥ 85 years	89	2.1%
Sex		
Female	2,729	65.8%
Male	1,421	34.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	4,150	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	·	0.075
Yes	****	****
No	3,598	86.7%
Unknown	****	****
Year		
2022	2,838	68.4%
2023	1,312	31.6%
Health Characteristics	1,312	31.070
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.7	1.0
<0	0	0.0%
0	1,487	35.8%
1-2	1,593	38.4%
3-4	710	17.1%
5+	360	8.7%
Combined comorbidity score categories ⁴	2.0	2.4
Combined comorbidity score categories ⁴	240	0.40/
<0	348	8.4%
0	967	23.3%
1-2	1,428	34.4%
3-4	804	19.4%

cder_mpl1p_wp077 Page 98 of 990



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia,	
	Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	603	14.5%
Alcohol use or abuse	58	1.4%
Obesity	2,103	50.7%
Tobacco use	754	18.2%
Arrhythmia	644	15.5%
Cerebrovascular disease/stroke/transient ischemic attack	421	10.1%
Chronic kidney disease	957	23.1%
Chronic obstructive pulmonary disease	385	9.3%
Congenital heart disease	385	9.3%
Heart failure	542	13.1%
Hyperlipidemia	3,166	76.3%
Hypertensive disease	3,751	90.4%
Thyroid disease	477	11.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	666	16.0%
Left ventricular hypertrophy	170	4.1%
Peripheral artery disease	170	4.1%
Valvular/mitral valve disease	78	1.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	391	9.4%
Obstructive sleep apnea	653	15.7%
Hypertrophic cardiomyopathy	204	4.9%
Other cardiac disease	1,391	33.5%
Tachyarrhythmia day 0	41	1.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	37	0.9%
Medical Product Use		
Alpha-glucosidase inhibitors	18	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	726	17.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	46	1.1%
Insulin	665	16.0%
Biguanides (metformin, phenformin, etc.)	3,087	74.4%
SGLT2 inhibitors	1,196	28.8%
Sulfonylurea	1,667	40.2%
Thiazolidinedione	338	8.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	V.U/0 ****
Beta blockers	1,696	40.9%
Potassium channel blockers/openers	38	0.9%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	15	0.4%

cder_mpl1p_wp077 Page 99 of 990



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% Antiarrhythmic agents (any of the above antiarrhythmic agents) 1,714 41.3% Angiotensin-converting-enzyme (ACE) inhibitors 1,350 32.5% Angiotensin ii receptor blockers (ARB) 1,778 42.8% Dihydropyridines 1,744 42.0% **Diuretics** 1,736 41.8% Other antihypertensives 534 12.9% Antihypertensives (any of the above antihypertensives) 3,740 90.1% Oral anticoagulants 251 6.0% Vitamin K antagonists 49 1.2% Other cardiac medications not mentioned above 190 4.6% Other cardiac medications (any of the other cardiac medications) 457 11.0% Lipid lowering therapy 3,385 81.6% Baseline known risk of prolonged QT and torsades de pointes 28.3% 1,173 Baseline possible risk of prolonged QT and torsades de pointes 3,359 80.9% Concomitant use of medical products with a known risk of prolonged QT and 9.9% torsades de pointes 411 **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 10.6 10.0 Mean number of emergency room encounters 0.4 1.2 Mean number of inpatient hospital encounters 0.1 0.3 Mean number of non-acute institutional encounters 0.0 0.2 6.0 Mean number of other ambulatory encounters 2.4 Mean number of filled prescriptions 21.7 15.4 Mean number of generics dispensed 9.9 4.7 Mean number of unique drug classes dispensed 8.9 4.3

N/A: Not applicable

cder mpl1p wp077 Page 100 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia,	
	Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹

cder_mpl1p_wp077 Page 101 of 990



Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	177	N/A
Demographic Characteristics		
Age (years)	71.0	7.7
Age		
0-40 years	****	****
41-64 years	26	14.7%
65-74 years	100	56.5%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	68	38.4%
Male	109	61.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	177	100.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
'ear		
2022	100	56.5%
2023	77	43.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	58	32.8%
1-2	72	40.7%
3-4	29	16.4%
5+	18	10.2%
Combined comorbidity score ⁴	2.0	2.3
Combined comorbidity score categories ⁴	-	-
<0	18	10.2%
0	38	21.5%
1-2	53	29.9%
3-4	45	25.4%
3	45	23.7/0

cder_mpl1p_wp077 Page 102 of 990



Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific

	Islan	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	23	13.0%
Alcohol use or abuse	****	****
Dbesity	56	31.6%
obacco use	22	12.4%
Arrhythmia	35	19.8%
Cerebrovascular disease/stroke/transient ischemic attack	17	9.6%
Chronic kidney disease	53	29.9%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
leart failure	22	12.4%
Hyperlipidemia	146	82.5%
Hypertensive disease	154	87.0%
hyroid disease	31	17.5%
schemic heart disease/coronary artery disease/myocardial infarction	37	20.9%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Dbstructive sleep apnea	15	8.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	53	29.9%
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	23	13.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	22	12.4%
Biguanides (metformin, phenformin, etc.)	143	80.8%
GLT2 inhibitors	58	32.8%
ulfonylurea	95	53.7%
, hiazolidinedione	30	16.9%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	69	39.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%

cder_mpl1p_wp077 Page 103 of 990



Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	13101	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	70	39.5%
Angiotensin-converting-enzyme (ACE) inhibitors	64	36.2%
Angiotensin ii receptor blockers (ARB)	77	43.5%
Dihydropyridines	46	26.0%
Diuretics	47	26.6%
Other antihypertensives	12	6.8%
Antihypertensives (any of the above antihypertensives)	154	87.0%
Oral anticoagulants	11	6.2%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	20	11.3%
Lipid lowering therapy	155	87.6%
Baseline known risk of prolonged QT and torsades de pointes	40	22.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	115	65.0%
torsades de pointes	16	9.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.8	7.5
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	0.9	3.5
Mean number of filled prescriptions	17.1	10.3
Mean number of generics dispensed	8.8	3.8
Mean number of unique drug classes dispensed	7.5	3.3

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 104 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmi Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	19,001	N/A
Demographic Characteristics		
Age (years)	70.0	9.3
Age		
0-40 years	245	1.3%
41-64 years	3,517	18.5%
65-74 years	9,861	51.9%
75-84 years	4,749	25.0%
≥ 85 years	629	3.3%
Sex		
Female	9,692	51.0%
Male	9,309	49.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	19,001	100.0%
Hispanic origin		
Yes	****	****
No	16,720	88.0%
Unknown	****	****
Year		
2022	14,730	77.5%
2023	4,271	22.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	6,951	36.6%
1-2	7,339	38.6%
3-4	3,274	17.2%
5+	1,437	7.6%
Combined comorbidity score ⁴	2.0	2.4
Combined comorbidity score categories ⁴		
<0	1,524	8.0%
0	4,312	22.7%
1-2	6,838	36.0%
3-4	3,656	19.2%

cder_mpl1p_wp077 Page 105 of 990



Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	2,671	14.1%
Alcohol use or abuse	231	1.2%
Obesity	7,996	42.1%
Tobacco use	3,563	18.8%
Arrhythmia	4,163	21.9%
Cerebrovascular disease/stroke/transient ischemic attack	2,109	11.1%
Chronic kidney disease	3,605	19.0%
Chronic obstructive pulmonary disease	1,923	10.1%
Congenital heart disease	1,923	10.1%
Heart failure	2,071	10.9%
Hyperlipidemia	15,009	79.0%
Hypertensive disease	15,838	83.4%
Thyroid disease	4,184	22.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	4,567	24.0%
Left ventricular hypertrophy	658	3.5%
Peripheral artery disease	658	3.5%
Valvular/mitral valve disease	599	3.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,751	9.2%
Obstructive sleep apnea	3,489	18.4%
Hypertrophic cardiomyopathy	783	4.1%
Other cardiac disease	7,632	40.2%
Tachyarrhythmia day 0	378	2.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	72	0.4%
Medical Product Use	72	0.470
Alpha-glucosidase inhibitors	95	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	3,510	18.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	297	1.6%
Insulin	2,711	14.3%
Biguanides (metformin, phenformin, etc.)	14,851	78.2%
SGLT2 inhibitors	5,854	30.8%
Sulfonylurea	7,881	41.5%
Thiazolidinedione	1,924	10.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	V.U/0 ****
Sodium channel blockers	128	0.7%
Beta blockers	8,335	43.9%
Potassium channel blockers/openers	289	1.5%
Non-dihydropyridine calcium channel blockers	29	0.2%
Digoxin	194	1.0%

cder_mpl1p_wp077 Page 106 of 990



Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	8,455	44.5%
Angiotensin-converting-enzyme (ACE) inhibitors	7,507	39.5%
Angiotensin ii receptor blockers (ARB)	6,542	34.4%
Dihydropyridines	4,680	24.6%
Diuretics	6,311	33.2%
Other antihypertensives	1,442	7.6%
Antihypertensives (any of the above antihypertensives)	15,940	83.9%
Oral anticoagulants	1,866	9.8%
Vitamin K antagonists	384	2.0%
Other cardiac medications not mentioned above	1,072	5.6%
Other cardiac medications (any of the other cardiac medications)	3,062	16.1%
Lipid lowering therapy	16,185	85.2%
Baseline known risk of prolonged QT and torsades de pointes	6,393	33.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	15,173	79.9%
torsades de pointes	2,761	14.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.1	10.1
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.6	5.7
Mean number of filled prescriptions	23.0	17.3
Mean number of generics dispensed	10.1	4.7
Mean number of unique drug classes dispensed	9.0	4.3

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 107 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	220	N/A
Demographic Characteristics		
Age (years)	52.5	11.1
Age		
0-40 years	36	16.4%
41-64 years	155	70.5%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	106	48.2%
Male	114	51.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	220	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	Ŭ	0.070
Yes	60	27.3%
No	13	5.9%
Unknown	147	66.8%
Year	14/	00.070
2022	140	63.6%
2022		
Health Characteristics	80	36.4%
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	1.0
Adapted Diabetes Complications Severity Index (aDCSI) Adapted Diabetes Complications Severity Index (aDCSI) categories ³	0.5	1.0
<0 < 0	0	0.0%
0	152	69.1%
1-2	54 ****	24.5% ****
3-4	****	****
5+		
Combined comorbidity score ⁴	0.8	1.5
Combined comorbidity score categories ⁴		
<0	27	12.3%
0	75	34.1%
1-2	95	43.2%
3-4	****	****

cder_mpl1p_wp077 Page 108 of 990



Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia,	
	Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	101	45.9%
Tobacco use	22	10.0%
Arrhythmia	21	9.5%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	13	5.9%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	141	64.1%
Hypertensive disease	143	65.0%
Thyroid disease	23	10.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	22	10.0%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	26	11.8%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	45	20.5%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	19	8.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	12	5.5%
Biguanides (metformin, phenformin, etc.)	193	3.3% 87.7%
SGLT2 inhibitors	63	28.6%
Sulfonylurea	65	29.5%
Thiazolidinedione	21	9.5%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers Potassium channel blockers/openers	49 0	22.3% 0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
	•	0.070

cder_mpl1p_wp077 Page 109 of 990



Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	49	22.3%
Angiotensin-converting-enzyme (ACE) inhibitors	78	35.5%
Angiotensin ii receptor blockers (ARB)	64	29.1%
Dihydropyridines	41	18.6%
Diuretics	38	17.3%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	158	71.8%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	15	6.8%
Lipid lowering therapy	152	69.1%
Baseline known risk of prolonged QT and torsades de pointes	50	22.7%
Baseline possible risk of prolonged QT and torsades de pointes	127	57.7%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.2	6.0
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.6	1.2
Mean number of filled prescriptions	15.4	11.1
Mean number of generics dispensed	7.0	3.6
Mean number of unique drug classes dispensed	6.1	3.3

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 110 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1af. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalize	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	385	N/A
Demographic Characteristics		
Age (years)	50.4	10.1
Age		
0-40 years	70	18.2%
41-64 years	295	76.6%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	289	75.1%
Male	96	24.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	****	****
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	344	89.4%
White	30	7.8%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	371	96.4%
Year		
2022	327	84.9%
2023	58	15.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.4	0.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	290	75.3%
1-2	80	20.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	0.8	1.5
Combined comorbidity score categories ⁴		
<0	67	17.4%
0	129	33.5%
1-2	141	36.6%
3-4	36	9.4%

cder_mpl1p_wp077 Page 111 of 990



Table 1af. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	12 ****	3.1% ****
Alcohol use or abuse		
Desity	309	80.3%
obacco use	43	11.2%
Arrhythmia	56	14.5% ****
Cerebrovascular disease/stroke/transient ischemic attack	****	
Chronic kidney disease	12	3.1%
Chronic obstructive pulmonary disease	****	****
ongenital heart disease	****	****
leart failure	11	2.9%
Hyperlipidemia	229	59.5%
lypertensive disease	264	68.6%
hyroid disease	74	19.2%
schemic heart disease/coronary artery disease/myocardial infarction	15	3.9%
eft ventricular hypertrophy	****	****
eripheral artery disease	****	****
'alvular/mitral valve disease	****	****
viseases of veins and lymphatics, and other diseases of circulatory system	21	5.5%
Obstructive sleep apnea	113	29.4%
lypertrophic cardiomyopathy	****	****
other cardiac disease	127	33.0%
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
lpha-glucosidase inhibitors	****	****
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	21	5.5%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	23	6.0%
siguanides (metformin, phenformin, etc.)	353	91.7%
GLT2 inhibitors	49	12.7%
ulfonylurea	46	11.9%
hiazolidinedione	****	****
lo baseline use of any of the above antidiabetic drugs	0	0.0%
obsident disc of any of the above untidiabetic drugs	0	0.0%
odium channel blockers	0	0.0%
eta blockers	119	30.9%
Potassium channel blockers/openers	****	****
Ion-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 112 of 990



Table 1af. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitaliz	ed Tachyarrhythmia
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	119	30.9%
Angiotensin-converting-enzyme (ACE) inhibitors	97	25.2%
Angiotensin ii receptor blockers (ARB)	110	28.6%
Dihydropyridines	79	20.5%
Diuretics	129	33.5%
Other antihypertensives	20	5.2%
Antihypertensives (any of the above antihypertensives)	273	70.9%
Oral anticoagulants	14	3.6%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	18	4.7%
Lipid lowering therapy	208	54.0%
Baseline known risk of prolonged QT and torsades de pointes	170	44.2%
Baseline possible risk of prolonged QT and torsades de pointes	318	82.6%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	70	18.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.5	8.7
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	3.0
Mean number of filled prescriptions	20.7	13.9
Mean number of generics dispensed	9.8	5.0
Mean number of unique drug classes dispensed	9.1	4.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 113 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	344	N/A
Demographic Characteristics		
Age (years)	50.1	10.1
Age		
0-40 years	63	18.3%
41-64 years	270	78.5%
65-74 years	11	3.2%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	259	75.3%
Male	85	24.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	344	100.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	0	0.0%
Unknown	****	****
Year		
2022	295	85.8%
2023	49	14.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.4	0.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	261	75.9%
1-2	69	20.1%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	0.7	1.4
Combined comorbidity score categories ⁴	5	 .
<0	61	17.7%
0	117	34.0%
1-2	129	37.5%
3-4	****	****

cder_mpl1p_wp077 Page 114 of 990



Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	276	80.2%
Tobacco use	35	10.2%
Arrhythmia	45	13.1%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	11	3.2%
Hyperlipidemia	199	57.8%
Hypertensive disease	237	68.9%
Thyroid disease	66	19.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	12	3.5%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	16	4.7%
Obstructive sleep apnea	98	28.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	108	31.4%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	18	5.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	18	5.2%
Biguanides (metformin, phenformin, etc.)	316	91.9%
SGLT2 inhibitors	42	12.2%
Sulfonylurea	36	10.5%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	104	30.2%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 115 of 990



Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	104	30.2%
Angiotensin-converting-enzyme (ACE) inhibitors	90	26.2%
Angiotensin ii receptor blockers (ARB)	96	27.9%
Dihydropyridines	67	19.5%
Diuretics	112	32.6%
Other antihypertensives	18	5.2%
Antihypertensives (any of the above antihypertensives)	243	70.6%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	13	3.8%
Lipid lowering therapy	182	52.9%
Baseline known risk of prolonged QT and torsades de pointes	154	44.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	283	82.3%
torsades de pointes	62	18.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.8	7.9
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	2.8
Mean number of filled prescriptions	20.1	13.7
Mean number of generics dispensed	9.6	5.0
Mean number of unique drug classes dispensed	8.9	4.5

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 116 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

the Rapid Sentiner Distributed Database and Sentiner Distributed Databa	Saxenda, Hospitalized Tachyarrhyth Race=American Indian or Alaska Na	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	-	-
Age	-	-
0-40 years	-	-
41-64 years	-	-
65-74 years	-	-
75-84 years	-	-
≥ 85 years	-	-
Sex	-	-
Female	-	-
Male	-	-
Race ²	-	-
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin	-	-
Yes	-	-
No	-	-
Unknown	-	-
Year	_	-
2022	_	-
2023	_	-
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	-	-
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	_	-
<0	_	-
0	_	-
1-2	_	_
3-4	_	_
5+	_	_
Combined comorbidity score ⁴	- -	_
Combined comorbidity score categories ⁴	- -	_
<0	-	-
	-	-
0	-	-
1-2	-	-
3-4	-	-

cder_mpl1p_wp077 Page 117 of 990



Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	-	-
Alcohol use or abuse	-	-
Obesity	-	-
Tobacco use	-	-
Arrhythmia	-	-
Cerebrovascular disease/stroke/transient ischemic attack	-	-
Chronic kidney disease	-	-
Chronic obstructive pulmonary disease	-	-
Congenital heart disease	-	-
Heart failure	-	-
Hyperlipidemia	-	-
Hypertensive disease	-	-
Thyroid disease	-	-
Ischemic heart disease/coronary artery disease/myocardial infarction	-	-
Left ventricular hypertrophy	-	-
Peripheral artery disease	-	-
Valvular/mitral valve disease	-	-
Diseases of veins and lymphatics, and other diseases of circulatory system	-	-
Obstructive sleep apnea	-	-
Hypertrophic cardiomyopathy	-	-
Other cardiac disease	-	-
Tachyarrhythmia day 0	-	-
Hospitalized tachyarrhythmia day 0	-	-
History of serious hypoglycemia (ED and/or IP)	-	-
Medical Product Use		
Alpha-glucosidase inhibitors	-	-
Amylin analogs (pramlintide)	-	-
DPP-4 inhibitors	-	-
Incretin mimetics (albiglutide, dulaglutide, etc.)	-	-
Meglitinides	-	-
Insulin	-	-
Biguanides (metformin, phenformin, etc.)	-	-
SGLT2 inhibitors	-	-
Sulfonylurea	-	-
Thiazolidinedione	-	-
No baseline use of any of the above antidiabetic drugs	-	-
Other antidiabetics	<u>-</u>	-
Sodium channel blockers	-	-
Beta blockers	-	-
Potassium channel blockers/openers	-	-
Non-dihydropyridine calcium channel blockers	-	-
Digoxin	-	-

cder_mpl1p_wp077 Page 118 of 990



Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	-	-
Antiarrhythmic agents (any of the above antiarrhythmic agents)	-	-
Angiotensin-converting-enzyme (ACE) inhibitors	-	-
Angiotensin ii receptor blockers (ARB)	-	-
Dihydropyridines	-	-
Diuretics	-	-
Other antihypertensives	-	-
Antihypertensives (any of the above antihypertensives)	-	-
Oral anticoagulants	-	-
Vitamin K antagonists	-	-
Other cardiac medications not mentioned above	-	-
Other cardiac medications (any of the other cardiac medications)	-	-
Lipid lowering therapy	-	-
Baseline known risk of prolonged QT and torsades de pointes	-	-
Baseline possible risk of prolonged QT and torsades de pointes	-	-
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 119 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.



Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Number/Mean Deviation of Name (Process) Demographic Characteristics Image: Process of Characteristics Image: Process of Characteristics Age (years) Image: Process of Characteristics Image: Process of Characteristics Image: Process of Characteristics 65-74 years Image: Process of Characteristics Image: Process of Characteristics Image: Process of Characteristics 5-84 years Image: Process of Characteristics Image: Process of Characteristics Image: Process of Characteristics 5-82 Sex Image: Process of Characteristics Image: Process of Charac		Saxenda, Hospitalized Tachyarrhythmia, Race=Asian	
Unique patients 0 N/A Demographic Characteristics . <th></th> <th></th> <th>Percent/Standard</th>			Percent/Standard
Demographic Characteristics	Patient Characteristics	Number/Mean	Deviation ¹
Age (years) . . Age . . O-40 years . . 41-64 years . . 65-74 years . . 75-84 years . . 75-84 years . . Sex . . Female . . Male . . Race² . . American Indian or Alaska Native . . Asian . . Black or African American . . Multi-racial . . Native Hawaiian or Other Pacific Islander . . Unknown . . White . . Hispanic origin . . Yes . . No . . Unknown . . Year . . 2022 . . </th <th>Unique patients</th> <th>0</th> <th>N/A</th>	Unique patients	0	N/A
Age -	Demographic Characteristics		
0-40 years 41-64 years 15-54 years 25-84 years 2	Age (years)	-	-
41-64 years - - 55-74 years - - 75-84 years - - 2 85 years - - Sex - - Female - - Male - - Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - 2022 - - 2023 - - Adapted Diabetes Complications Severity Index (aDCSI) ategories³ - -	Age	-	-
65-74 years - - 75-84 years - - 2 85 years - - Sex - - Female - - Male - - Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Ilsipanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2022 - - 2022 - - 2022 - - 2022 - - Adapted Diabetes Complications Severity Index (aDCSI) ategories³ - - <	0-40 years	-	-
75-84 years Sex Female Male Race² American Indian or Alaska Native Asian Black or African American Multi-racial Native Hawaiian or Other Pacific Islander Unknown White Hispanic origin Yes No Unknown Yes No Unknown Yes No Qualtican American American Native Hawaiian or Other Pacific Islander Unknown White Hispanic origin Yes Yes No Qualtican American American No Qualtican Yes No Qualtican American American American American Multi-racial Native Hawaiian or Other Pacific Islander Unknown Qualtican American	41-64 years	-	-
≥ 85 years - - Sex - - Female - - Male - - Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Var - - 2022 - - 2023 - - Health Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - 40 - - - 5+ - - - 1-2 - - -	65-74 years	-	-
Sex - - Female - - Male - - Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Year - - 2022 - - 2022 - - 2022 - - 2022 - - 2022 - - 2024 - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - 40 - - 40 - -	75-84 years	-	-
Female - - Male - - Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Vear - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories³ - - <0	≥ 85 years	-	-
Male - - Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - White - - Health Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI) ategories³ - - <0	Sex	-	-
Race² - - American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2022 - - 2022 - - 2022 - - 2023 - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories³ - - <0	Female	-	-
American Indian or Alaska Native - - Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Peatht Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI) ³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories ³ - - <0	Male	-	-
Asian - - Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Adapted Diabetes Complications Severity Index (aDCSI) ³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories ³ - - <0	Race ²	-	-
Black or African American - - Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Health Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories³ - - <0	American Indian or Alaska Native	-	-
Multi-racial - - Native Hawaiian or Other Pacific Islander - - Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Health Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI) ³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories ³ - - <0	Asian	-	-
Native Hawaiian or Other Pacific Islander Unknown White Hispanic origin Pes No Unknown Ves No Unknown Vear 2022 2022 2023 2023 2023 2024 2026 2028 2029 2020 2020 2020 2020 2020 2020	Black or African American	-	-
Unknown - - White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Health Characteristics - - Mdapted Diabetes Complications Severity Index (aDCSI)³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories³ - - 40 - - 1-2 - - 3-4 - - 5+ - - Combined comorbidity score⁴ - - Combined comorbidity score categories⁴ - - 40 - - 60 - - 70 - - 80 - - 80 - - 80	Multi-racial	-	-
White - - Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Zo23 - - Meath Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI) ³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories ³ - - - - - 0 - - 1-2 - - 3-4 - - 5+ - - Combined comorbidity score ⁴ - - Combined comorbidity score categories ⁴ - - <0	Native Hawaiian or Other Pacific Islander	-	-
Hispanic origin - - Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ - - <0	Unknown	-	-
Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Health Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - 40 - - 0 - - 1-2 - - 3-4 - - 5+ - - Combined comorbidity score ⁴ - - Combined comorbidity score categories ⁴ - - <0	White	-	-
Yes - - No - - Unknown - - Year - - 2022 - - 2023 - - Health Characteristics - - Adapted Diabetes Complications Severity Index (aDCSI)³ - - 40 - - 0 - - 1-2 - - 3-4 - - 5+ - - Combined comorbidity score ⁴ - - Combined comorbidity score categories ⁴ - - <0	Hispanic origin	-	-
Unknown - - Year - - 2022 - - 2023 - - Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ - - Adapted Diabetes Complications Severity Index (aDCSI) categories³ - - 0 - - - 1-2 - - - 3-4 - - - 5+ - - - Combined comorbidity score⁴ - - - Combined comorbidity score categories⁴ - - - <0		-	-
Year 2022	No	-	-
2022 2023 Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) ³ Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 1-2 3-4 5+ Combined comorbidity score ⁴ Combined comorbidity score categories ⁴ <0 0	Unknown	-	-
2023Health CharacteristicsAdapted Diabetes Complications Severity Index (aDCSI)³Adapted Diabetes Complications Severity Index (aDCSI) categories³<0	Year	-	-
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ Adapted Diabetes Complications Severity Index (aDCSI) categories³ <0	2022	-	-
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ Adapted Diabetes Complications Severity Index (aDCSI) categories³ <0	2023	-	-
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <pre></pre>			
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <pre></pre>	Adapted Diabetes Complications Severity Index (aDCSI) ³	-	-
<0		-	-
1-2 -		-	-
3-4 5+ Combined comorbidity score ⁴ Combined comorbidity score categories ⁴ <0 0 1-2 Combined comorbidity score categories	0	-	-
3-4 5+ Combined comorbidity score Combined comorbidity score categories Combined comorbidity score Com	1-2	-	-
5+ Combined comorbidity score Combined comorbidity score categories Combined comorbidity score Combined comorbidity score categories Combined comorbidity score categori		-	-
Combined comorbidity score ⁴ Combined comorbidity score categories ⁴ <0 0 1-2 - - - - - - - - - - - -		-	-
Combined comorbidity score categories ⁴		-	-
<0		-	-
0 - - 1-2 - -		-	_
1-2		-	-
		-	-
		-	_

cder_mpl1p_wp077 Page 120 of 990



Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia,	
	Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	-	-
Alcohol use or abuse	-	-
Obesity	-	-
Tobacco use	-	-
Arrhythmia	-	-
Cerebrovascular disease/stroke/transient ischemic attack	-	-
Chronic kidney disease	-	-
Chronic obstructive pulmonary disease	-	-
Congenital heart disease	-	-
Heart failure	-	-
Hyperlipidemia	-	-
Hypertensive disease	-	-
Thyroid disease	-	-
Ischemic heart disease/coronary artery disease/myocardial infarction	-	-
Left ventricular hypertrophy	-	-
Peripheral artery disease	-	-
Valvular/mitral valve disease	-	-
Diseases of veins and lymphatics, and other diseases of circulatory system	-	-
Obstructive sleep apnea	-	-
Hypertrophic cardiomyopathy	-	-
Other cardiac disease	-	-
Tachyarrhythmia day 0	-	-
Hospitalized tachyarrhythmia day 0	-	-
History of serious hypoglycemia (ED and/or IP)	-	-
Medical Product Use		
Alpha-glucosidase inhibitors	_	-
Amylin analogs (pramlintide)	-	-
DPP-4 inhibitors	-	-
Incretin mimetics (albiglutide, dulaglutide, etc.)	-	-
Meglitinides	-	-
Insulin	_	_
Biguanides (metformin, phenformin, etc.)	_	_
SGLT2 inhibitors	_	_
Sulfonylurea	_	_
Thiazolidinedione	-	-
No baseline use of any of the above antidiabetic drugs	-	-
Other antidiabetics	-	-
	-	-
Sodium channel blockers Beta blockers	-	- -
Potassium channel blockers/openers	- -	- -
Non-dihydropyridine calcium channel blockers	-	-
Digoxin	-	-

cder_mpl1p_wp077 Page 121 of 990



Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Asian	
	Percent/Stan	
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	-	-
Antiarrhythmic agents (any of the above antiarrhythmic agents)	-	-
Angiotensin-converting-enzyme (ACE) inhibitors	-	-
Angiotensin ii receptor blockers (ARB)	-	-
Dihydropyridines	-	-
Diuretics	-	-
Other antihypertensives	-	-
Antihypertensives (any of the above antihypertensives)	-	-
Oral anticoagulants	-	-
Vitamin K antagonists	-	-
Other cardiac medications not mentioned above	-	-
Other cardiac medications (any of the other cardiac medications)	-	-
Lipid lowering therapy	-	-
Baseline known risk of prolonged QT and torsades de pointes	-	-
Baseline possible risk of prolonged QT and torsades de pointes	-	-
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 122 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.



Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	48.2	11.5
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	****	****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.3	0.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.6	1.6
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	****	****
3-4	****	****

cder_mpl1p_wp077 Page 123 of 990



Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	****	****
Tobacco use	0	0.0%
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	0	0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	0	0.09/
	_	0.0%
Sulfonylurea Thiazolidinedione	0	0.0%
	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers Beta blockers	0 ****	0.0% ****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin		

cder_mpl1p_wp077 Page 124 of 990



Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% 0 **** Antiarrhythmic agents (any of the above antiarrhythmic agents) Angiotensin-converting-enzyme (ACE) inhibitors 0 0.0% Angiotensin ii receptor blockers (ARB) **** Dihydropyridines 0 0.0% **Diuretics** Other antihypertensives 0 0.0% **** **** Antihypertensives (any of the above antihypertensives) Oral anticoagulants 0 0.0% Vitamin K antagonists 0 0.0% Other cardiac medications not mentioned above 0 0.0% Other cardiac medications (any of the other cardiac medications) n 0.0% Lipid lowering therapy Baseline known risk of prolonged QT and torsades de pointes **** Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and **** torsades de pointes **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 15.0 12.3 Mean number of emergency room encounters 1.0 2.1 Mean number of inpatient hospital encounters 0.0 NaN Mean number of non-acute institutional encounters 0.0 NaN 2.9 6.8 Mean number of other ambulatory encounters Mean number of filled prescriptions 18.6 11.9 Mean number of generics dispensed 9.0 4.9 Mean number of unique drug classes dispensed 8.1 4.3

NaN: Not a number N/A: Not applicable

cder mpl1p wp077 Page 125 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹	
Unique patients	0	N/A	
Demographic Characteristics			
Age (years)	-	-	
Age	-	-	
0-40 years	-	-	
41-64 years	-	-	
65-74 years	-	-	
75-84 years	-	-	
≥ 85 years	-	-	
Sex	-	-	
Female	-	-	
Male	-	-	
Race ²	-	-	
American Indian or Alaska Native	-	-	
Asian	-	-	
Black or African American	-	-	
Multi-racial	-	-	
Native Hawaiian or Other Pacific Islander	-	-	
Unknown	-	-	
White	-	-	
Hispanic origin	-	-	
Yes	-	-	
No	-	-	
Unknown	-	-	
Year	-	-	
2022	-	-	
2023	-	-	
Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) ³	-	-	
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	-	-	
<0	-	-	
0	-	-	
1-2	-	-	
3-4	-	-	
5+	-	-	
Combined comorbidity score ⁴	-	-	
Combined comorbidity score categories ⁴	-	-	
<0	-	-	
0	-	-	
1-2	-	-	
3-4	_	_	

cder_mpl1p_wp077 Page 126 of 990



Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Islander Paragraph (Changle	
Dation Characteristics	NIh - /2.4	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	-	-
Alcohol use or abuse	-	-
Obesity	-	-
Tobacco use	-	-
Arrhythmia	-	-
Cerebrovascular disease/stroke/transient ischemic attack	-	-
Chronic kidney disease	-	-
Chronic obstructive pulmonary disease	-	-
Congenital heart disease	-	-
Heart failure	-	-
Hyperlipidemia	-	-
Hypertensive disease	-	-
Thyroid disease	-	-
Ischemic heart disease/coronary artery disease/myocardial infarction	-	-
Left ventricular hypertrophy	-	-
Peripheral artery disease	-	-
Valvular/mitral valve disease	-	-
Diseases of veins and lymphatics, and other diseases of circulatory system	-	-
Obstructive sleep apnea	-	-
Hypertrophic cardiomyopathy	-	-
Other cardiac disease	-	-
Tachyarrhythmia day 0	-	-
Hospitalized tachyarrhythmia day 0	-	-
History of serious hypoglycemia (ED and/or IP)	-	-
Medical Product Use		
Alpha-glucosidase inhibitors	-	-
Amylin analogs (pramlintide)	-	-
DPP-4 inhibitors	<u>-</u>	-
Incretin mimetics (albiglutide, dulaglutide, etc.)	<u>-</u>	<u>-</u>
Meglitinides	_	_
Insulin	_	_
Biguanides (metformin, phenformin, etc.)	_	_
SGLT2 inhibitors	<u>-</u>	_
Sulfonylurea	-	-
Thiazolidinedione	-	-
	-	-
No baseline use of any of the above antidiabetic drugs	-	-
Other antidiabetics	-	-
Sodium channel blockers	-	-
Beta blockers Potassium channel blockers/openers	-	-
Non-dihydropyridine calcium channel blockers	- -	<u>-</u>

cder_mpl1p_wp077 Page 127 of 990



Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	-	-
Other antiarrhythmic agents	-	-
Antiarrhythmic agents (any of the above antiarrhythmic agents)	-	-
Angiotensin-converting-enzyme (ACE) inhibitors	-	-
Angiotensin ii receptor blockers (ARB)	-	-
Dihydropyridines	-	-
Diuretics	-	-
Other antihypertensives	-	-
Antihypertensives (any of the above antihypertensives)	-	-
Oral anticoagulants	-	-
Vitamin K antagonists	-	-
Other cardiac medications not mentioned above	-	-
Other cardiac medications (any of the other cardiac medications)	-	-
Lipid lowering therapy	-	-
Baseline known risk of prolonged QT and torsades de pointes	-	-
Baseline possible risk of prolonged QT and torsades de pointes	-	-
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 128 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable



Table 1al. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	30	N/A
Demographic Characteristics		
Age (years)	54.9	8.2
Age		
0-40 years	****	****
41-64 years	16	53.3%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	30	100.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
/ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	0.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	0	0.0%
Combined comorbidity score ⁴	1.5	2.2
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	****	****
3-4	****	****

cder_mpl1p_wp077 Page 129 of 990



Table 1al. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=White Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	0	0.0%
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	12	40.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	16	53.3%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	14	46.7%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 130 of 990



Table 1al. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	14	46.7%
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	13	43.3%
Dihydropyridines	11	36.7%
Diuretics	15	50.0%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	12	40.0%
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.7	14.3
Mean number of emergency room encounters	0.7	2.4
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	2.4	3.4
Mean number of filled prescriptions	28.4	17.2
Mean number of generics dispensed	12.9	5.2
Mean number of unique drug classes dispensed	11.7	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 131 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	49.5	6.3
Age		
0-40 years	0	0.0%
41-64 years	****	****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	****	****
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	2.0	1.7
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	****	****
1-2	0	0.0%
3-4	****	****

cder_mpl1p_wp077 Page 132 of 990



Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	****	****
Tobacco use	****	****
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 133 of 990



Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	0	0.0%
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.0	17.5
Mean number of emergency room encounters	1.0	0.0
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.3	1.5
Mean number of filled prescriptions	17.3	6.5
Mean number of generics dispensed	9.3	2.1
Mean number of unique drug classes dispensed	8.0	2.6

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 134 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1an. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	83,649	N/A
Demographic Characteristics		10.4
Age (years)	65.4	10.4
Age	2.054	2.60/
0-40 years	3,051	3.6%
41-64 years 65-74 years	29,900	35.7%
•	34,943	41.8% 16.6%
75-84 years	13,927	2.2%
≥ 85 years Sex	1,828	2.2%
Female	43,453	51.9%
Male	43,433 40,196	48.1%
Race ²	40,130	40.1/0
American Indian or Alaska Native	302	0.4%
Asian	1,465	1.8%
Black or African American	8,504	10.2%
Multi-racial	373	0.4%
Native Hawaiian or Other Pacific Islander	321	0.4%
Unknown	27,633	33.0%
White	45,051	53.9%
Hispanic origin	45,031	33.370
Yes	3,251	3.9%
No	50,100	59.9%
Unknown	30,298	36.2%
/ear	5.5,2.5	
2022	65,426	78.2%
2023	18,223	21.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	32,153	38.4%
1-2	29,830	35.7%
3-4	14,060	16.8%
5+	7,606	9.1%
Combined comorbidity score ⁴	2.1	2.5
Combined comorbidity score categories ⁴		
<0	6,476	7.7%
0	19,110	22.8%
1-2	30,244	36.2%
3-4	14,784	17.7%

cder_mpl1p_wp077 Page 135 of 990



Table 1an. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalize	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	13,035	15.6%
Alcohol use or abuse	1,255	1.5%
Dbesity	37,288	44.6%
Tobacco use	16,486	19.7%
Arrhythmia	17,248	20.6%
Cerebrovascular disease/stroke/transient ischemic attack	9,331	11.2%
Chronic kidney disease	15,749	18.8%
Chronic obstructive pulmonary disease	8,439	10.1%
Congenital heart disease	8,439	10.1%
Heart failure	10,154	12.1%
Hyperlipidemia	63,090	75.4%
Hypertensive disease	68,200	81.5%
Thyroid disease	15,771	18.9%
schemic heart disease/coronary artery disease/myocardial infarction	19,124	22.9%
eft ventricular hypertrophy	3,339	4.0%
Peripheral artery disease	3,339	4.0%
/alvular/mitral valve disease	2,466	2.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	8,175	9.8%
Dbstructive sleep apnea	16,629	19.9%
Hypertrophic cardiomyopathy	3,762	4.5%
Other cardiac disease	33,645	40.2%
achyarrhythmia day 0	1,476	1.8%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	708	0.8%
Medical Product Use		
ulpha-glucosidase inhibitors	317	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	13,129	15.7%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	1,030	1.2%
nsulin	25,494	30.5%
Biguanides (metformin, phenformin, etc.)	65,858	78.7%
GCLT2 inhibitors	23,580	28.2%
ulfonylurea	31,604	37.8%
hiazolidinedione	7,312	8.7%
The baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	0.0%
odium channel blockers	389	0.5%
Beta blockers	34,911	41.7%
Potassium channel blockers/openers	1,178	1.4%
Non-dihydropyridine calcium channel blockers	98	0.1%
Digoxin	687	0.8%

cder_mpl1p_wp077 Page 136 of 990



Table 1an. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity Hospitalize	ed Tachyarrhythmia
	Transity, 1103pitanz	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	35,312	42.2%
Angiotensin-converting-enzyme (ACE) inhibitors	32,422	38.8%
Angiotensin ii receptor blockers (ARB)	28,125	33.6%
Dihydropyridines	21,877	26.2%
Diuretics	28,672	34.3%
Other antihypertensives	6,630	7.9%
Antihypertensives (any of the above antihypertensives)	69,133	82.6%
Oral anticoagulants	7,341	8.8%
Vitamin K antagonists	1,629	1.9%
Other cardiac medications not mentioned above	5,182	6.2%
Other cardiac medications (any of the other cardiac medications)	12,876	15.4%
Lipid lowering therapy	68,582	82.0%
Baseline known risk of prolonged QT and torsades de pointes	28,409	34.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	66,648	79.7%
torsades de pointes	12,334	14.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.9	10.6
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	8.6
Mean number of filled prescriptions	24.4	19.7
Mean number of generics dispensed	10.3	5.1
Mean number of unique drug classes dispensed	9.2	4.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 137 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	27,633	N/A
Demographic Characteristics		
Age (years)	58.8	11.3
Age		
0-40 years	2,069	7.5%
41-64 years	17,051	61.7%
65-74 years	6,395	23.1%
75-84 years	1,878	6.8%
≥ 85 years	240	0.9%
Sex		
Female	13,570	49.1%
Male	14,063	50.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	27,633	100.0%
White	0	0.0%
Hispanic origin		
Yes	****	11.3%
No	****	0.0%
Unknown	24,512	88.7%
Year		
2022	19,838	71.8%
2023	7,795	28.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	14,925	54.0%
1-2	8,585	31.1%
3-4	2,811	10.2%
5+	1,312	4.7%
Combined comorbidity score ⁴	1.3	2.0
Combined comorbidity score categories ⁴		
<0	3,079	11.1%
0	8,512	30.8%
1-2	10,570	38.3%
3-4	3,399	12.3%

cder_mpl1p_wp077 Page 138 of 990



Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	2,073	7.5%
Alcohol use or abuse	304	1.1%
Obesity	11,677	42.3%
Tobacco use	3,779	13.7%
Arrhythmia	3,830	13.9%
Cerebrovascular disease/stroke/transient ischemic attack	1,720	6.2%
Chronic kidney disease	2,950	10.7%
Chronic obstructive pulmonary disease	1,460	5.3%
Congenital heart disease	1,460	5.3%
Heart failure	1,853	6.7%
Hyperlipidemia	19,285	69.8%
Hypertensive disease	20,425	73.9%
Thyroid disease	3,955	14.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	3,908	14.1%
Left ventricular hypertrophy	709	2.6%
Peripheral artery disease	709	2.6%
Valvular/mitral valve disease	438	1.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,739	6.3%
Obstructive sleep apnea	4,831	17.5%
Hypertrophic cardiomyopathy	776	2.8%
Other cardiac disease	8,407	30.4%
Tachyarrhythmia day 0	274	1.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	127	0.5%
Medical Product Use	127	0.570
Alpha-glucosidase inhibitors	89	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	4,043	14.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	220	0.8%
Insulin	7,267	26.3%
Biguanides (metformin, phenformin, etc.)	22,982	83.2%
SGLT2 inhibitors	8,041	29.1%
Sulfonylurea Thiazolidinedione	9,175	33.2%
	2,092	7.6%
No baseline use of any of the above antidiabetic drugs	0 ****	0.0%
Other antidiabetics		0.0%
Sodium channel blockers Beta blockers	94 8 666	0.3% 31.4%
Potassium channel blockers/openers	8,666 219	31.4% 0.8%
Non-dihydropyridine calcium channel blockers	27	0.8%
Digoxin	130	0.5%

cder_mpl1p_wp077 Page 139 of 990



Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	8,751	31.7%
Angiotensin-converting-enzyme (ACE) inhibitors	10,662	38.6%
Angiotensin ii receptor blockers (ARB)	8,316	30.1%
Dihydropyridines	5,835	21.1%
Diuretics	7,141	25.8%
Other antihypertensives	1,557	5.6%
Antihypertensives (any of the above antihypertensives)	21,150	76.5%
Oral anticoagulants	1,497	5.4%
Vitamin K antagonists	271	1.0%
Other cardiac medications not mentioned above	1,100	4.0%
Other cardiac medications (any of the other cardiac medications)	2,648	9.6%
Lipid lowering therapy	21,093	76.3%
Baseline known risk of prolonged QT and torsades de pointes	8,310	30.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	19,958	72.2%
torsades de pointes	3,239	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.6	9.7
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.6	5.4
Mean number of filled prescriptions	20.6	16.5
Mean number of generics dispensed	9.0	4.9
Mean number of unique drug classes dispensed	8.0	4.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 140 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	302	N/A
Demographic Characteristics		
Age (years)	64.3	11.4
Age		
0-40 years	****	****
41-64 years	126	41.7%
65-74 years	110	36.4%
75-84 years	47	15.6%
≥ 85 years	****	****
Sex		
Female	180	59.6%
Male	122	40.4%
Race ²		
American Indian or Alaska Native	302	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	283	93.7%
Unknown	19	6.3%
Year		
2022	267	88.4%
2023	35	11.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	111	36.8%
1-2	106	35.1%
3-4	62	20.5%
5+	23	7.6%
Combined comorbidity score ⁴	2.0	2.2
Combined comorbidity score categories ⁴		
<0	24	7.9%
0	51	16.9%
1-2	127	42.1%
3-4	64	21.2%

cder_mpl1p_wp077 Page 141 of 990



Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia,	
	Race=American Indian or Alaska Na	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	36	11.9%
Alcohol use or abuse	15	5.0%
Obesity	113	37.4%
Tobacco use	78	25.8%
Arrhythmia	53	17.5%
Cerebrovascular disease/stroke/transient ischemic attack	33	10.9%
Chronic kidney disease	52	17.2%
Chronic obstructive pulmonary disease	27	8.9%
Congenital heart disease	27	8.9%
Heart failure	28	9.3%
Hyperlipidemia	201	66.6%
Hypertensive disease	236	78.1%
Thyroid disease	50	16.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	62	20.5%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	29	9.6%
Obstructive sleep apnea	63	20.9%
Hypertrophic cardiomyopathy	12	4.0%
Other cardiac disease	114	37.7%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	48	15.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	135	44.7%
Biguanides (metformin, phenformin, etc.)	241	79.8%
SGLT2 inhibitors	81	26.8%
Sulfonylurea	103	34.1%
Thiazolidinedione	33	10.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	103	34.1%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers Digoxin	0 ****	0.0%

cder_mpl1p_wp077 Page 142 of 990



Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	104	34.4%
Angiotensin-converting-enzyme (ACE) inhibitors	149	49.3%
Angiotensin ii receptor blockers (ARB)	79	26.2%
Dihydropyridines	71	23.5%
Diuretics	100	33.1%
Other antihypertensives	31	10.3%
Antihypertensives (any of the above antihypertensives)	255	84.4%
Oral anticoagulants	19	6.3%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	17	5.6%
Other cardiac medications (any of the other cardiac medications)	35	11.6%
Lipid lowering therapy	238	78.8%
Baseline known risk of prolonged QT and torsades de pointes	111	36.8%
Baseline possible risk of prolonged QT and torsades de pointes	251	83.1%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	52	17.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.9	10.6
Mean number of emergency room encounters	0.5	1.5
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	15.4
Mean number of filled prescriptions	32.9	24.7
Mean number of generics dispensed	11.2	5.2
Mean number of unique drug classes dispensed	10.0	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 143 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1aq. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,465	N/A
Demographic Characteristics		
Age (years)	69.2	10.7
Age		
0-40 years	55	3.8%
41-64 years	266	18.2%
65-74 years	703	48.0%
75-84 years	358	24.4%
≥ 85 years	83	5.7%
Sex		
Female	746	50.9%
Male	719	49.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,465	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	· ·	0.070
Yes	****	****
No	1,269	86.6%
Unknown	****	****
Year		
2022	1,253	85.5%
2023	212	14.5%
Health Characteristics	212	14.5/0
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.7	1.0
<0	0	0.0%
0	506	34.5%
1-2	555	37.9%
3-4	265	18.1%
5+ Combined comorbidity score ⁴	139	9.5%
•	2.2	2.4
Combined comorbidity score categories ⁴	72	4.00/
<0	72	4.9%
0	329	22.5%
1-2	537	36.7%
3-4	295	20.1%

cder_mpl1p_wp077 Page 144 of 990



Table 1aq. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Race=	d Tachyarrhythmia, Asian Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	232	15.8%
Alcohol use or abuse	13	0.9%
Dbesity	297	20.3%
obacco use	144	9.8%
ırrhythmia	267	18.2%
Cerebrovascular disease/stroke/transient ischemic attack	183	12.5%
Chronic kidney disease	380	25.9%
Chronic obstructive pulmonary disease	90	6.1%
Congenital heart disease	90	6.1%
leart failure	175	11.9%
lyperlipidemia	1,171	79.9%
Hypertensive disease	1,208	82.5%
hyroid disease	273	18.6%
schemic heart disease/coronary artery disease/myocardial infarction	347	23.7%
eft ventricular hypertrophy	53	3.6%
Peripheral artery disease	53	3.6%
/alvular/mitral valve disease	41	2.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	111	7.6%
Dbstructive sleep apnea	138	9.4%
Typertrophic cardiomyopathy	57	3.9%
Other cardiac disease	506	34.5%
achyarrhythmia day 0	21	1.4%
	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	16	1.1%
Medical Product Use		
Alpha-glucosidase inhibitors	28	1.9%
amylin analogs (pramlintide)	0	0.0%
PPP-4 inhibitors	380	25.9%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	50	3.4%
nsulin	530	36.2%
siguanides (metformin, phenformin, etc.)	1,159	79.1%
GLT2 inhibitors	543	37.1%
ulfonylurea	626	42.7%
, hiazolidinedione	155	10.6%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
) Other antidiabetics	0	0.0%
odium channel blockers	****	****
Beta blockers	621	42.4%
otassium channel blockers/openers	18	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
bigoxin	****	****

cder_mpl1p_wp077 Page 145 of 990



Table 1aq. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	626	42.7%
Angiotensin-converting-enzyme (ACE) inhibitors	420	28.7%
Angiotensin ii receptor blockers (ARB)	701	47.8%
Dihydropyridines	479	32.7%
Diuretics	385	26.3%
Other antihypertensives	137	9.4%
Antihypertensives (any of the above antihypertensives)	1,233	84.2%
Oral anticoagulants	101	6.9%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	103	7.0%
Other cardiac medications (any of the other cardiac medications)	201	13.7%
Lipid lowering therapy	1,299	88.7%
Baseline known risk of prolonged QT and torsades de pointes	387	26.4%
Baseline possible risk of prolonged QT and torsades de pointes	1,059	72.3%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	161	11.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.4	14.2
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.7	8.3
Mean number of filled prescriptions	22.9	17.5
Mean number of generics dispensed	10.0	4.8
Mean number of unique drug classes dispensed	8.6	4.3

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 146 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	8,504	N/A
Demographic Characteristics		
Age (years)	66.1	10.5
Age		
0-40 years	263	3.1%
41-64 years	2,772	32.6%
65-74 years	4,053	47.7%
75-84 years	1,264	14.9%
≥ 85 years	152	1.8%
Sex		
Female	5,535	65.1%
Male	2,969	34.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	8,504	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	7,538	88.6%
Unknown	966	11.4%
Year		
2022	6,242	73.4%
2023	2,262	26.6%
Health Characteristics	·	
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	2,395	28.2%
1-2	3,103	36.5%
3-4	1,876	22.1%
5+	1,130	13.3%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	469	5.5%
0	1,531	18.0%
1-2	2,839	33.4%
3-4	1,803	21.2%

cder_mpl1p_wp077 Page 147 of 990



Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia,	
	Race=Black or African American Percent/Standa	
Patient Characteristics	Number/Mean	Deviation ¹
5+	1,862	21.9%
Alcohol use or abuse	144	1.7%
Obesity	4,379	51.5%
Tobacco use	1,923	22.6%
Arrhythmia	1,754	20.6%
Cerebrovascular disease/stroke/transient ischemic attack	1,268	14.9%
Chronic kidney disease	2,398	28.2%
Chronic obstructive pulmonary disease	907	10.7%
Congenital heart disease	907	10.7%
Heart failure	1,529	18.0%
Hyperlipidemia	6,565	77.2%
Hypertensive disease	7,746	91.1%
Thyroid disease	1,067	12.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,833	21.6%
	1,655 499	5.9%
Left ventricular hypertrophy	499 499	5.9% 5.9%
Peripheral artery disease		
Valvular/mitral valve disease	241	2.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	974	11.5%
Obstructive sleep apnea	1,593	18.7%
Hypertrophic cardiomyopathy	513	6.0%
Other cardiac disease	3,500	41.2%
Tachyarrhythmia day 0	113	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	133	1.6%
Medical Product Use	20	0.20/
Alpha-glucosidase inhibitors	29	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,397	16.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	109	1.3%
Insulin	3,314	39.0%
Biguanides (metformin, phenformin, etc.)	6,054	71.2%
SGLT2 inhibitors	2,300	27.0%
Sulfonylurea	3,150	37.0%
Thiazolidinedione	599	7.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	24	0.3%
Beta blockers Potassium channel blockers/openers	3,968 89	46.7% 1.0%
Non-dihydropyridine calcium channel blockers	×***	1.U70 ****
Digoxin	50	0.6%

cder_mpl1p_wp077 Page 148 of 990



Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% Antiarrhythmic agents (any of the above antiarrhythmic agents) 4,001 47.0% Angiotensin-converting-enzyme (ACE) inhibitors 2,804 33.0% Angiotensin ii receptor blockers (ARB) 3.652 42.9% Dihydropyridines 3,868 45.5% **Diuretics** 3,906 45.9% Other antihypertensives 1,269 14.9% Antihypertensives (any of the above antihypertensives) 91.1% 7,750 Oral anticoagulants 701 8.2% Vitamin K antagonists 135 1.6% Other cardiac medications not mentioned above 577 6.8% Other cardiac medications (any of the other cardiac medications) 1,279 15.0% Lipid lowering therapy 7,084 83.3% Baseline known risk of prolonged QT and torsades de pointes 31.5% 2,682 Baseline possible risk of prolonged QT and torsades de pointes 7,089 83.4% Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes 1,077 12.7% **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 11.7 11.8 Mean number of emergency room encounters 0.6 1.4 Mean number of inpatient hospital encounters 0.1 0.5 Mean number of non-acute institutional encounters 0.0 0.3 4.3 10.5 Mean number of other ambulatory encounters Mean number of filled prescriptions 25.6 20.0 Mean number of generics dispensed 10.9 5.1 Mean number of unique drug classes dispensed 9.8 4.6

N/A: Not applicable

cder mpl1p wp077 Page 149 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

Islander Perc		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	321	N/A
Demographic Characteristics		,
Age (years)	70.6	7.1
Age		
0-40 years	****	****
41-64 years	47	14.6%
65-74 years	188	58.6%
75-84 years	75	23.4%
≥ 85 years	****	****
Sex		
Female	146	45.5%
Male	175	54.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	321	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	310	96.6%
Unknown	****	****
Year		
2022	183	57.0%
2023	138	43.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	101	31.5%
1-2	133	41.4%
3-4	61	19.0%
5+	26	8.1%
Combined comorbidity score ⁴	2.1	2.3
Combined comorbidity score categories ⁴		
<0	22	6.9%
0	68	21.2%
1-2	124	38.6%
3-4	64	19.9%

cder_mpl1p_wp077 Page 150 of 990



Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	13141	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	43	13.4%
Alcohol use or abuse	****	****
Obesity	110	34.3%
Tobacco use	53	16.5%
Arrhythmia	49	15.3%
Cerebrovascular disease/stroke/transient ischemic attack	34	10.6%
Chronic kidney disease	91	28.3%
Chronic obstructive pulmonary disease	26	8.1%
Congenital heart disease	26	8.1%
Heart failure	31	9.7%
Hyperlipidemia	260	81.0%
Hypertensive disease	274	85.4%
Thyroid disease	44	13.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	71	22.1%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	22	6.9%
Obstructive sleep apnea	40	12.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	105	32.7%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	51	15.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	100	31.2%
Biguanides (metformin, phenformin, etc.)	265	82.6%
SGLT2 inhibitors	85	26.5%
Sulfonylurea	147	45.8%
Thiazolidinedione	46	14.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	125	38.9%
Potassium channel blockers/openers Non dibudropyriding calcium channel blockers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%

cder_mpl1p_wp077 Page 151 of 990



Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	126	39.3%
Angiotensin-converting-enzyme (ACE) inhibitors	141	43.9%
Angiotensin ii receptor blockers (ARB)	122	38.0%
Dihydropyridines	112	34.9%
Diuretics	78	24.3%
Other antihypertensives	24	7.5%
Antihypertensives (any of the above antihypertensives)	280	87.2%
Oral anticoagulants	19	5.9%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	17	5.3%
Other cardiac medications (any of the other cardiac medications)	37	11.5%
Lipid lowering therapy	286	89.1%
Baseline known risk of prolonged QT and torsades de pointes	85	26.5%
Baseline possible risk of prolonged QT and torsades de pointes	229	71.3%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	25	7.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.9	10.2
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	1.2	3.4
Mean number of filled prescriptions	18.7	12.4
Mean number of generics dispensed	9.6	4.4
Mean number of unique drug classes dispensed	8.4	4.1

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 152 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Number/Mean Deviation Unique patients 45,051 N/A Demographic Characteristics 89.3 9.4 Age (years) 69.3 9.4 Age 599 1.3% 41-64 years 9,360 20.8% 65-74 years 23,462 55.1% 75-84 years 10,295 22.9% 285 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 3 0.0 Yes 13 0.0 No 40,681 <	Trulicity, Hospitalized Tachyarrhythmia, Race=White	
Unique patients 45,051 N/A Demographic Characteristics 89.3 9.4 Age 69.3 9.4 Age 9.360 20.8% 69-74 years 9,360 20.8% 65-74 years 10,295 22.9% ≥ 85 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² American Indian or Alaska Native 0 0.0% Asian 0 0.0% Asian 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 2 13 0.0% Yes 13 0.0% No 4,367 9.7% <t< th=""><th></th></t<>		
Demographic Characteristics Age (years) 69.3 9.4 Age	n¹	
Age (years) 69.3 9.4 Age 0-40 years 599 1.3% 41-64 years 9,360 20.8% 65-74 years 23,462 52.1% 75-84 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² 48.8% 48.8% Race² 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 13 0.0% Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Age 0-40 years 599 1.3% 41-64 years 9,360 20.8% 65-74 years 23,462 52.1% 75-84 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² 48.8% 48.8% Race² 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Mative Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 40,681 90.3% Ves 13 0.0% No 40,681 90.3% Unknown 43,557 9.7% Year 2022 37,394 83.0%		
0-40 years 599 1.3% 41-64 years 9,360 20.8% 65-74 years 23,462 52.1% 75-84 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Temale 23,086 51.2% Male 21,965 48.8% Race² Temperican Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%		
41-64 years 9,360 20.86 65-74 years 23,462 52.1% 75-84 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.86 Race² American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% White 45,051 100.0% Hispanic origin Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
65-74 years 23,462 52.1% 75-84 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² 8 48.8% American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
75-84 years 10,295 22.9% ≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 1 45,051 100.0% White 1 3 0.0% Hispanic origin Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
≥ 85 years 1,335 3.0% Sex Female 23,086 51.2% Male 21,965 48.8% Race² Trican Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 13 0.0% Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Sex Female 23,086 51.2% Male 21,965 48.8% Race² American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Female 23,086 51.2% Male 21,965 48.8% Race²		
Male 21,965 48.8% Race² 0 0.0% American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 40,681 90.3% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Race² 0 0.0% American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 3 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Asian 0 0.0% Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 3 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 3 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 2022 37,394 83.0%		
Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 45,051 100.0% Hispanic origin 3 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%		
Unknown 0 0.0% White 45,051 100.0% Hispanic origin 3 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%		
White 45,051 100.0% Hispanic origin 3 0.0% Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%		
Hispanic origin Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%		
Hispanic origin Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%	,	
Yes 13 0.0% No 40,681 90.3% Unknown 4,357 9.7% Year 37,394 83.0%		
Unknown 4,357 9.7% Year 37,394 83.0%		
Unknown 4,357 9.7% Year 37,394 83.0%		
Year 2022 37,394 83.0%		
2022 37,394 83.0%		
2023 7,657 17.0%		
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³ 1.9 1.9		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0 0 0.0%		
0 13,873 30.8%		
1-2 17,240 38.3%		
3-4 8,967 19.9%		
5+ 4,971 11.0%		
Combined comorbidity score ⁴ 2.5 2.7		
Combined comorbidity score categories ⁴		
<0 2,770 6.1%		
0 8,497 18.9%		
1-2 15,875 35.2%		
3-4 9,134 20.3%		

cder_mpl1p_wp077 Page 153 of 990



Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=White	
	Percent/Standar	
Patient Characteristics	Number/Mean	Deviation ¹
5+	8,775	19.5%
Alcohol use or abuse	772	1.7%
Obesity	20,547	45.6%
Tobacco use	10,480	23.3%
Arrhythmia	11,245	25.0%
Cerebrovascular disease/stroke/transient ischemic attack	6,080	13.5%
Chronic kidney disease	9,855	21.9%
Chronic obstructive pulmonary disease	5,925	13.2%
Congenital heart disease	5,925	13.2%
Heart failure	6,525	14.5%
Hyperlipidemia	35,374	78.5%
Hypertensive disease	38,070	84.5%
Thyroid disease	10,335	22.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	12,879	28.6%
Left ventricular hypertrophy	2,053	4.6%
Peripheral artery disease	2,053	4.6%
Valvular/mitral valve disease	1,732	3.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	5,288	11.7%
Obstructive sleep apnea	9,911	22.0%
Hypertrophic cardiomyopathy	2,387	5.3%
Other cardiac disease	20,934	46.5%
Tachyarrhythmia day 0	1,062	2.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	426	0.9%
Medical Product Use	420	0.570
Alpha-glucosidase inhibitors	166	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	7,165	15.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	642	1.4%
Insulin	14,070	31.2%
Biguanides (metformin, phenformin, etc.)	34,842	77.3%
SGLT2 inhibitors		
Sulfonylurea	12,423 18,289	27.6%
Thiazolidinedione		40.6%
	4,361 0	9.7% 0.0%
No baseline use of any of the above antidiabetic drugs Other antidiabetics	V ****	U.U% ****
Other antidiabetics		
Sodium channel blockers Beta blockers	267 21,353	0.6% 47.4%
Potassium channel blockers/openers	21,353 843	47.4% 1.9%
Non-dihydropyridine calcium channel blockers	63	0.1%
Digoxin	488	1.1%

cder_mpl1p_wp077 Page 154 of 990



Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	21,628	48.0%
Angiotensin-converting-enzyme (ACE) inhibitors	18,119	40.2%
Angiotensin ii receptor blockers (ARB)	15,132	33.6%
Dihydropyridines	11,457	25.4%
Diuretics	16,986	37.7%
Other antihypertensives	3,594	8.0%
Antihypertensives (any of the above antihypertensives)	38,202	84.8%
Oral anticoagulants	4,989	11.1%
Vitamin K antagonists	1,208	2.7%
Other cardiac medications not mentioned above	3,361	7.5%
Other cardiac medications (any of the other cardiac medications)	8,653	19.2%
Lipid lowering therapy	38,328	85.1%
Baseline known risk of prolonged QT and torsades de pointes	16,729	37.1%
Baseline possible risk of prolonged QT and torsades de pointes	37,818	83.9%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	7,747	17.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.2	10.8
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.1	9.6
Mean number of filled prescriptions	26.5	21.3
Mean number of generics dispensed	11.0	5.1
Mean number of unique drug classes dispensed	9.9	4.7

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 155 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	373	N/A
Demographic Characteristics		
Age (years)	53.5	11.1
Age		
0-40 years	51	13.7%
41-64 years	278	74.5%
65-74 years	32	8.6%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	190	50.9%
Male	183	49.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	373	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	118	31.6%
No	16	4.3%
Unknown	239	64.1%
Year		
2022	249	66.8%
2023	124	33.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	242	64.9%
1-2	108	29.0%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.0	1.7
Combined comorbidity score categories ⁴	-	
<0	40	10.7%
0	122	32.7%
1-2	172	46.1%

cder_mpl1p_wp077 Page 156 of 990



Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	14	3.8%
Alcohol use or abuse	****	****
Obesity	165	44.2%
Tobacco use	29	7.8%
Arrhythmia	50	13.4%
Cerebrovascular disease/stroke/transient ischemic attack	13	3.5%
Chronic kidney disease	23	6.2%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	13	3.5%
Hyperlipidemia	234	62.7%
Hypertensive disease	241	64.6%
Thyroid disease	47	12.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	24	6.4%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	12	3.2%
Obstructive sleep apnea	53	14.2%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	79	21.2%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	45	12.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	78	20.9%
Biguanides (metformin, phenformin, etc.)	315	84.5%
SGLT2 inhibitors	107	28.7%
Sulfonylurea	114	30.6%
Thiazolidinedione	26	7.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	75	20.1%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****

cder_mpl1p_wp077 Page 157 of 990



Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	76	20.4%
Angiotensin-converting-enzyme (ACE) inhibitors	127	34.0%
Angiotensin ii receptor blockers (ARB)	123	33.0%
Dihydropyridines	55	14.7%
Diuretics	76	20.4%
Other antihypertensives	18	4.8%
Antihypertensives (any of the above antihypertensives)	263	70.5%
Oral anticoagulants	15	4.0%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	23	6.2%
Lipid lowering therapy	254	68.1%
Baseline known risk of prolonged QT and torsades de pointes	105	28.2%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	244	65.4%
torsades de pointes	33	8.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.3	8.2
Mean number of emergency room encounters	0.3	1.1
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.5	4.3
Mean number of filled prescriptions	17.4	13.5
Mean number of generics dispensed	7.7	4.3
Mean number of unique drug classes dispensed	6.9	3.9

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 158 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1av. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Victoza, Hospital		d Tachyarrhythmia
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	8,683	N/A
Demographic Characteristics		
Age (years)	64.4	11.0
Age	400	4.50/
0-40 years	400	4.6%
41-64 years	3,316	38.2%
65-74 years	3,492	40.2%
75-84 years	1,326	15.3%
≥ 85 years	149	1.7%
Sex	4.044	F.C. 00/
Female	4,941	56.9%
Male	3,742	43.1%
Race ²		
American Indian or Alaska Native	76	0.9%
Asian	137	1.6%
Black or African American	969	11.2%
Multi-racial	86	1.0%
Native Hawaiian or Other Pacific Islander	23	0.3%
Unknown	2,336	26.9%
White	5,056	58.2%
Hispanic origin		
Yes	347	4.0%
No	5,622	64.7%
Unknown	2,714	31.3%
'ear		
2022	6,702	77.2%
2023	1,981	22.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	3,043	35.0%
1-2	3,240	37.3%
3-4	1,544	17.8%
5+	856	9.9%
Combined comorbidity score ⁴	2.3	2.5
Combined comorbidity score categories ⁴		
<0	540	6.2%
0	1,790	20.6%
1-2	3,235	37.3%
3-4	1,663	19.2%

cder_mpl1p_wp077 Page 159 of 990



Table 1av. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	1,455	16.8%
Alcohol use or abuse	162	1.9%
Obesity	4,251	49.0%
Tobacco use	1,898	21.9%
Arrhythmia	1,900	21.9%
Cerebrovascular disease/stroke/transient ischemic attack	905	10.4%
Chronic kidney disease	1,721	19.8%
Chronic obstructive pulmonary disease	976	11.2%
Congenital heart disease	976	11.2%
Heart failure	1,166	13.4%
Hyperlipidemia	6,137	70.7%
Hypertensive disease	6,935	79.9%
Thyroid disease	1,595	18.4%
schemic heart disease/coronary artery disease/myocardial infarction	1,998	23.0%
eft ventricular hypertrophy	352	4.1%
Peripheral artery disease	352	4.1%
/alvular/mitral valve disease	252	2.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	885	10.2%
Dbstructive sleep apnea	1,931	22.2%
lypertrophic cardiomyopathy	416	4.8%
Other cardiac disease	3,666	42.2%
achyarrhythmia day 0	90	1.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	100	1.2%
Medical Product Use	100	1.270
Alpha-glucosidase inhibitors	38	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	909	10.5%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	101	1.2%
nsulin	3,355	38.6%
Biguanides (metformin, phenformin, etc.)	6,778	78.1%
GGLT2 inhibitors	2,362	27.2%
Gulfonylurea	2,768	31.9%
'hiazolidinedione	705	8.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	62	0.7%
Beta blockers	3,720	42.8%
Potassium channel blockers/openers	113	1.3%
Non-dihydropyridine calcium channel blockers	11	0.1%
Digoxin	74	0.9%

cder_mpl1p_wp077 Page 160 of 990



Table 1av. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victora Hospitaliza	ed Tachyarrhythmia
	victoza, nospitalize	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,764	43.3%
Angiotensin-converting-enzyme (ACE) inhibitors	3,415	39.3%
Angiotensin ii receptor blockers (ARB)	2,879	33.2%
Dihydropyridines	2,247	25.9%
Diuretics	3,268	37.6%
Other antihypertensives	701	8.1%
Antihypertensives (any of the above antihypertensives)	7,218	83.1%
Oral anticoagulants	778	9.0%
Vitamin K antagonists	200	2.3%
Other cardiac medications not mentioned above	616	7.1%
Other cardiac medications (any of the other cardiac medications)	1,448	16.7%
Lipid lowering therapy	7,066	81.4%
Baseline known risk of prolonged QT and torsades de pointes	3,066	35.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	7,138	82.2%
torsades de pointes	1,346	15.5%
Health Service Utilization Intensity Metrics	·	
Mean number of ambulatory encounters	11.6	11.7
Mean number of emergency room encounters	0.4	1.3
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.1	9.1
Mean number of filled prescriptions	25.5	20.2
Mean number of generics dispensed	10.8	5.3
Mean number of unique drug classes dispensed	9.8	4.8

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 161 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	2,336	N/A
Demographic Characteristics		
Age (years)	58.7	12.3
Age		
0-40 years	195	8.3%
41-64 years	1,362	58.3%
65-74 years	605	25.9%
75-84 years	153	6.5%
≥ 85 years	21	0.9%
Sex		
Female	1,322	56.6%
Male	1,014	43.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	2,336	100.0%
White	0	0.0%
Hispanic origin		
Yes	309	13.2%
No	0	0.0%
Unknown	2,027	86.8%
Year	,-	
2022	1,696	72.6%
2023	640	27.4%
Health Characteristics	<u> </u>	
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,157	49.5%
1-2	776	33.2%
3-4	284	12.2%
5+	119	5.1%
Combined comorbidity score ⁴	1.5	2.1
Combined comorbidity score categories ⁴	1.5	۷.1
<0	208	8.9%
0	666	28.5%
1-2	927	39.7%
3-4	336	14.4%

cder_mpl1p_wp077 Page 162 of 990



Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	199	8.5%
Alcohol use or abuse	27	1.2%
Obesity	1,111	47.6%
Tobacco use	361	15.5%
Arrhythmia	368	15.8%
Cerebrovascular disease/stroke/transient ischemic attack	130	5.6%
Chronic kidney disease	270	11.6%
Chronic obstructive pulmonary disease	157	6.7%
Congenital heart disease	157	6.7%
Heart failure	174	7.4%
Hyperlipidemia	1,511	64.7%
Hypertensive disease	1,698	72.7%
Thyroid disease	340	14.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	357	15.3%
Left ventricular hypertrophy	54	2.3%
Peripheral artery disease	54	2.3%
Valvular/mitral valve disease	45	1.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	141	6.0%
Obstructive sleep apnea	442	18.9%
Hypertrophic cardiomyopathy	80	3.4%
Other cardiac disease	748	32.0%
Tachyarrhythmia day 0	17	0.7%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	16	0.7%
Medical Product Use		
Alpha-glucosidase inhibitors	12	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	248	10.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	22	0.9%
Insulin	808	34.6%
Biguanides (metformin, phenformin, etc.)	1,877	80.4%
SGLT2 inhibitors	680	29.1%
Sulfonylurea	675	28.9%
Thiazolidinedione	171	7.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	12	0.5%
Beta blockers	802	34.3%
Potassium channel blockers/openers	17	0.7%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	12	0.5%

cder_mpl1p_wp077 Page 163 of 990



Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	809	34.6%
Angiotensin-converting-enzyme (ACE) inhibitors	929	39.8%
Angiotensin ii receptor blockers (ARB)	709	30.4%
Dihydropyridines	483	20.7%
Diuretics	681	29.2%
Other antihypertensives	137	5.9%
Antihypertensives (any of the above antihypertensives)	1,819	77.9%
Oral anticoagulants	134	5.7%
Vitamin K antagonists	33	1.4%
Other cardiac medications not mentioned above	110	4.7%
Other cardiac medications (any of the other cardiac medications)	257	11.0%
Lipid lowering therapy	1,765	75.6%
Baseline known risk of prolonged QT and torsades de pointes	807	34.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,792	76.7%
torsades de pointes	342	14.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.4	10.7
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.8	4.8
Mean number of filled prescriptions	22.2	17.9
Mean number of generics dispensed	9.8	5.3
Mean number of unique drug classes dispensed	8.8	4.7

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 164 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	-	Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹	
Unique patients	76	N/A	
Demographic Characteristics			
Age (years)	64.7	10.3	
Age			
0-40 years	****	****	
41-64 years	32	42.1%	
65-74 years	30	39.5%	
75-84 years	****	****	
≥ 85 years	0	0.0%	
Sex			
Female	44	57.9%	
Male	32	42.1%	
Race ²			
American Indian or Alaska Native	76	100.0%	
Asian	0	0.0%	
Black or African American	0	0.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	0	0.0%	
White	0	0.0%	
Hispanic origin			
Yes	0	0.0%	
No	****	****	
Unknown	****	****	
Year			
2022	****	****	
2023	****	****	
Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.6	
Adapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	33	43.4%	
1-2	30	39.5%	
3-4	****	****	
5+	****	****	
Combined comorbidity score ⁴	1.6	2.2	
Combined comorbidity score categories ⁴			
<0	****	****	
0	16	21.1%	
1-2	33	43.4%	
3-4	13	17.1%	

cder_mpl1p_wp077 Page 165 of 990



Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia,	
	Race=American Indian or Alaska Nativ	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	23	30.3%
Tobacco use	19	25.0%
Arrhythmia	14	18.4%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	42	55.3%
Hypertensive disease	54	71.1%
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	14	18.4%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	20	26.3%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	<u> </u>	0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	V.U/0 ****
	0	
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	41	53.9%
Biguanides (metformin, phenformin, etc.)	60	78.9%
SGLT2 inhibitors	20	26.3%
Sulfonylurea	18	23.7%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	29	38.2%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers Digoxin	0 0	0.0% 0.0%
DIBOVIII	U	U.U/0

cder_mpl1p_wp077 Page 166 of 990



Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	29	38.2%
Angiotensin-converting-enzyme (ACE) inhibitors	37	48.7%
Angiotensin ii receptor blockers (ARB)	20	26.3%
Dihydropyridines	23	30.3%
Diuretics	25	32.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	64	84.2%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	13	17.1%
Lipid lowering therapy	55	72.4%
Baseline known risk of prolonged QT and torsades de pointes	18	23.7%
Baseline possible risk of prolonged QT and torsades de pointes	54	71.1%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.3	7.8
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.8	6.4
Mean number of filled prescriptions	31.4	28.7
Mean number of generics dispensed	10.4	5.5
Mean number of unique drug classes dispensed	9.4	4.8

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 167 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	137	N/A
Demographic Characteristics		
Age (years)	64.0	11.8
Age		
0-40 years	****	****
41-64 years	42	30.7%
65-74 years	59	43.1%
75-84 years	20	14.6%
≥ 85 years	****	****
Sex		
Female	88	64.2%
Male	49	35.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	137	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	120	87.6%
Unknown	17	12.4%
Year		
2022	110	80.3%
2023	27	19.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	56	40.9%
1-2	39	28.5%
3-4	24	17.5%
5+	18	13.1%
Combined comorbidity score ⁴	2.1	2.6
Combined comorbidity score categories ⁴		
<0	****	****
0	33	24.1%
1-2	41	29.9%
3-4	30	21.9%

cder_mpl1p_wp077 Page 168 of 990



Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	36	26.3%
Tobacco use	12	8.8%
Arrhythmia	26	19.0%
Cerebrovascular disease/stroke/transient ischemic attack	19	13.9%
Chronic kidney disease	29	21.2%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	16	11.7%
Hyperlipidemia	94	68.6%
Hypertensive disease	103	75.2%
Thyroid disease	19	13.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	24	17.5%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	14	10.2%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	45	32.8%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	20	14.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	71	51.8%
Biguanides (metformin, phenformin, etc.)	102	74.5%
SGLT2 inhibitors	34	24.8%
Sulfonylurea	41	29.9%
Thiazolidinedione	16	11.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	55	40.1%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****

cder_mpl1p_wp077 Page 169 of 990



Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	56	40.9%
Angiotensin-converting-enzyme (ACE) inhibitors	48	35.0%
Angiotensin ii receptor blockers (ARB)	52	38.0%
Dihydropyridines	40	29.2%
Diuretics	41	29.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	109	79.6%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	15	10.9%
Lipid lowering therapy	120	87.6%
Baseline known risk of prolonged QT and torsades de pointes	34	24.8%
Baseline possible risk of prolonged QT and torsades de pointes	95	69.3%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	16	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.2	9.7
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.8	5.3
Mean number of filled prescriptions	23.2	19.4
Mean number of generics dispensed	9.6	5.1
Mean number of unique drug classes dispensed	8.7	4.4

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 170 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	969	N/A
Demographic Characteristics		
Age (years)	63.2	10.8
Age		
0-40 years	56	5.8%
41-64 years	403	41.6%
65-74 years	398	41.1%
75-84 years	98	10.1%
≥ 85 years	14	1.4%
Sex		
Female	639	65.9%
Male	330	34.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	969	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	854	88.1%
Unknown	****	****
Year		
2022	704	72.7%
2023	265	27.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	255	26.3%
1-2	362	37.4%
3-4	216	22.3%
5+	136	14.0%
Combined comorbidity score ⁴	2.7	2.6
Combined comorbidity score categories ⁴		
<0	57	5.9%
0	155	16.0%
		34.2%
1-2	331	34.2%

cder_mpl1p_wp077 Page 171 of 990



Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia,	
	Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	209	21.6%
Alcohol use or abuse	22	2.3%
Obesity	536	55.3%
Tobacco use	237	24.5%
Arrhythmia	190	19.6%
Cerebrovascular disease/stroke/transient ischemic attack	126	13.0%
Chronic kidney disease	248	25.6%
Chronic obstructive pulmonary disease	115	11.9%
Congenital heart disease	115	11.9%
Heart failure	181	18.7%
Hyperlipidemia	691	71.3%
Hypertensive disease	853	88.0%
Thyroid disease	113	11.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	211	21.8%
Left ventricular hypertrophy	69	7.1%
Peripheral artery disease	69	7.1%
Valvular/mitral valve disease	30	3.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	96	9.9%
Obstructive sleep apnea	207	21.4%
Hypertrophic cardiomyopathy	62	6.4%
Other cardiac disease	417	43.0%
Tachyarrhythmia day 0	14	1.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	18	1.9%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	106	10.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	414	42.7%
Biguanides (metformin, phenformin, etc.)	734	75.7%
SGLT2 inhibitors	250	25.8%
Sulfonylurea	294	30.3%
Thiazolidinedione	57	5.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	445	45.9%
Potassium channel blockers/openers	12	1.2%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****

cder_mpl1p_wp077 Page 172 of 990



Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia,	
	Race=Black or A	frican American
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	452	46.6%
Angiotensin-converting-enzyme (ACE) inhibitors	334	34.5%
Angiotensin ii receptor blockers (ARB)	400	41.3%
Dihydropyridines	433	44.7%
Diuretics	472	48.7%
Other antihypertensives	135	13.9%
Antihypertensives (any of the above antihypertensives)	872	90.0%
Oral anticoagulants	101	10.4%
Vitamin K antagonists	17	1.8%
Other cardiac medications not mentioned above	74	7.6%
Other cardiac medications (any of the other cardiac medications)	167	17.2%
Lipid lowering therapy	779	80.4%
Baseline known risk of prolonged QT and torsades de pointes	325	33.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	823	84.9%
torsades de pointes	120	12.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.6	12.9
Mean number of emergency room encounters	0.6	2.3
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.1	10.4
Mean number of filled prescriptions	25.8	20.2
Mean number of generics dispensed	11.2	5.1
Mean number of unique drug classes dispensed	10.2	4.7

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 173 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Islan	ger Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	23	N/A
Demographic Characteristics	23	13/75
Age (years)	68.6	9.1
Age	00.0	5.1
0-40 years	0	0.0%
41-64 years	****	****
65-74 years	****	****
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	23	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	· ·	0.070
Yes	0	0.0%
No	23	100.0%
Unknown	0	0.0%
/ear	O .	0.070
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	1.7	1.7
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	2.3	1.7
Combined comorbidity score categories ⁴	2.3	1.7
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****

cder_mpl1p_wp077 Page 174 of 990



Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Islander Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
Patient Characteristics 5+	Number/Mean ****	veriation *****
Alcohol use or abuse	0	0.0%
	V ****	U.U% ****
Obesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease		
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
·	****	****
	0	0.0%
	0	
	****	****
Beta blockers	****	****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Thiazolidinedione No baseline use of any of the above antidiabetic drugs Other antidiabetics Sodium channel blockers Beta blockers Potassium channel blockers/openers	***** 0 0 **** **** 0	***** 0.0% 0.0% **** ****

cder_mpl1p_wp077 Page 175 of 990



Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Islanuei	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.9	7.4
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.5	1.2
Mean number of filled prescriptions	19.9	17.9
Mean number of generics dispensed	9.5	5.3
Mean number of unique drug classes dispensed	8.6	4.8

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 176 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	5,056	N/A
Demographic Characteristics		
Age (years)	67.5	10.0
Age		
0-40 years	112	2.2%
41-64 years	1,414	28.0%
65-74 years	2,380	47.1%
75-84 years	1,040	20.6%
≥ 85 years	110	2.2%
Sex		
Female	2,778	54.9%
Male	2,278	45.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	5,056	100.0%
Hispanic origin		
Yes	19	0.4%
No	4,510	89.2%
Unknown	527	10.4%
Year		
2022	4,057	80.2%
2023	999	19.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,478	29.2%
1-2	2,002	39.6%
3-4	999	19.8%
5+	577	11.4%
Combined comorbidity score ⁴	2.6	2.7
Combined comorbidity score categories ⁴		
<0	252	5.0%
0	894	17.7%
1-2	1,851	36.6%
3-4	1,048	20.7%

cder_mpl1p_wp077 Page 177 of 990



Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=White	
	Percent/Stand	
Patient Characteristics	Number/Mean	Deviation ¹
5+	1,011	20.0%
Alcohol use or abuse	102	2.0%
Obesity	2,490	49.2%
Tobacco use	1,247	24.7%
Arrhythmia	1,287	25.5%
Cerebrovascular disease/stroke/transient ischemic attack	619	12.2%
Chronic kidney disease	1,153	22.8%
Chronic obstructive pulmonary disease	690	13.6%
Congenital heart disease	690	13.6%
Heart failure	779	15.4%
Hyperlipidemia	3,734	73.9%
Hypertensive disease	4,168	82.4%
Thyroid disease	1,099	21.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,380	27.3%
Left ventricular hypertrophy	223	4.4%
Peripheral artery disease	223	4.4%
Valvular/mitral valve disease	174	3.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	634	12.5%
Obstructive sleep apnea	1,240	24.5%
Hypertrophic cardiomyopathy	265	5.2%
Other cardiac disease	2,402	47.5%
Tachyarrhythmia day 0	57	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	64	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	21	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	515	10.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	64	1.3%
Insulin	1,982	39.2%
Biguanides (metformin, phenformin, etc.)	3,912	77.4%
SGLT2 inhibitors	1,351	26.7%
Sulfonylurea	1,716	33.9%
Thiazolidinedione	453	9.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	46	0.9%
Beta blockers	2,359	46.7%
Potassium channel blockers/openers	82	1.6%
Non-dihydropyridine calcium channel blockers	****	*****
Digoxin	52	1.0%

cder_mpl1p_wp077 Page 178 of 990



Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,388	47.2%
Angiotensin-converting-enzyme (ACE) inhibitors	2,035	40.2%
Angiotensin ii receptor blockers (ARB)	1,669	33.0%
Dihydropyridines	1,242	24.6%
Diuretics	2,026	40.1%
Other antihypertensives	406	8.0%
Antihypertensives (any of the above antihypertensives)	4,285	84.8%
Oral anticoagulants	529	10.5%
Vitamin K antagonists	146	2.9%
Other cardiac medications not mentioned above	411	8.1%
Other cardiac medications (any of the other cardiac medications)	990	19.6%
Lipid lowering therapy	4,268	84.4%
Baseline known risk of prolonged QT and torsades de pointes	1,847	36.5%
Baseline possible risk of prolonged QT and torsades de pointes	4,291	84.9%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	848	16.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.4	12.1
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.7	10.4
Mean number of filled prescriptions	27.1	20.9
Mean number of generics dispensed	11.3	5.3
Mean number of unique drug classes dispensed	10.3	4.8

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 179 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmi Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	86	N/A
Demographic Characteristics		
Age (years)	48.5	13.1
Age		
0-40 years	****	****
41-64 years	58	67.4%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	61	70.9%
Male	25	29.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	86	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	18	20.9%
No	43	50.0%
Unknown	25	29.1%
Year		
2022	52	60.5%
2023	34	39.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	-	
<0	0	0.0%
0	58	67.4%
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.4	1.6
Combined comorbidity score categories ⁴	±. ,	1.0
<0	****	****
0	23	26.7%
1-2	39	45.3%
3-4	****	****

cder_mpl1p_wp077 Page 180 of 990



Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	42	48.8%
Tobacco use	19	22.1%
Arrhythmia	11	12.8%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	****	****
Hyperlipidemia	48	55.8%
Hypertensive disease	39	45.3%
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	16	18.6%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	25	29.1%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	0	0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
	****	V.U/0 ****
Meglitinides Insulin	35	40.7%
	73	
Biguanides (metformin, phenformin, etc.)	_	84.9%
SGLT2 inhibitors	22	25.6%
Sulfonylurea	15 ****	17.4% ****
Thiazolidinedione		
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0 22	0.0%
Beta blockers Potassium channel blockers/openers	22 0	25.6% 0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 181 of 990



Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Victoza, Hospitalized Tachyarrhythmia Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	22	25.6%
Angiotensin-converting-enzyme (ACE) inhibitors	25	29.1%
Angiotensin ii receptor blockers (ARB)	19	22.1%
Dihydropyridines	19	22.1%
Diuretics	18	20.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	52	60.5%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	60	69.8%
Baseline known risk of prolonged QT and torsades de pointes	28	32.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	66	76.7%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.6	9.6
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.9	9.1
Mean number of filled prescriptions	22.5	18.2
Mean number of generics dispensed	9.6	4.5
Mean number of unique drug classes dispensed	8.8	4.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 182 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bd. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalize	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	761	N/A
Demographic Characteristics		
Age (years)	52.5	10.2
Age		
0-40 years	113	14.8%
41-64 years	575	75.6%
65-74 years	62	8.1%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	511	67.1%
Male	250	32.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	****	****
Black or African American	40	5.3%
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	604	79.4%
White	95	12.5%
Hispanic origin		
Yes	14	1.8%
No	54	7.1%
Unknown	693	91.1%
Year		
2022	86	11.3%
2023	675	88.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	528	69.4%
1-2	196	25.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	0.8	1.6
Combined comorbidity score categories ⁴		-
<0	138	18.1%
0	245	32.2%
1-2	281	36.9%
3-4	68	8.9%

cder_mpl1p_wp077 Page 183 of 990



Table 1bd. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia	
		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
5+	29	3.8%
Alcohol use or abuse	****	****
Dbesity	588	77.3%
Tobacco use	86	11.3%
Arrhythmia	107	14.1%
Cerebrovascular disease/stroke/transient ischemic attack	20	2.6%
Chronic kidney disease	46	6.0%
Chronic obstructive pulmonary disease	19	2.5%
Congenital heart disease	19	2.5%
leart failure	36	4.7%
lyperlipidemia	456	59.9%
lypertensive disease	526	69.1%
hyroid disease	154	20.2%
schemic heart disease/coronary artery disease/myocardial infarction	71	9.3%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
'alvular/mitral valve disease	11	1.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	37	4.9%
Dbstructive sleep apnea	226	29.7%
lypertrophic cardiomyopathy	20	2.6%
Other cardiac disease	274	36.0%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
Ipha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	33	4.3%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	44	5.8%
siguanides (metformin, phenformin, etc.)	656	86.2%
GLT2 inhibitors	126	16.6%
ulfonylurea	87	11.4%
hiazolidinedione	23	3.0%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	****	****
Beta blockers	212	27.9%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****

cder_mpl1p_wp077 Page 184 of 990



Table 1bd. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia	
	vvegovy, mospitumz	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	215	28.3%
Angiotensin-converting-enzyme (ACE) inhibitors	200	26.3%
Angiotensin ii receptor blockers (ARB)	235	30.9%
Dihydropyridines	140	18.4%
Diuretics	245	32.2%
Other antihypertensives	37	4.9%
Antihypertensives (any of the above antihypertensives)	540	71.0%
Oral anticoagulants	36	4.7%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	24	3.2%
Other cardiac medications (any of the other cardiac medications)	62	8.1%
Lipid lowering therapy	428	56.2%
Baseline known risk of prolonged QT and torsades de pointes	289	38.0%
Baseline possible risk of prolonged QT and torsades de pointes	604	79.4%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	122	16.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.5	9.1
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.6	4.2
Mean number of filled prescriptions	19.7	14.9
Mean number of generics dispensed	9.2	5.1
Mean number of unique drug classes dispensed	8.6	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 185 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythn Race=Unknown	
	nace on	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	604	N/A
Demographic Characteristics		,
Age (years)	51.3	10.2
Age		
0-40 years	94	15.6%
41-64 years	480	79.5%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex	•	2.2,2
Female	417	69.0%
Male	187	31.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	604	100.0%
White	0	0.0%
Hispanic origin		
Yes	11	1.8%
No	0	0.0%
Unknown	593	98.2%
Year		
2022	77	12.7%
2023	527	87.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	0.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	443	73.3%
1-2	141	23.3%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	0.7	1.5
Combined comorbidity score categories ⁴		
<0	117	19.4%
0	206	34.1%
1-2	212	35.1%
3-4	52	8.6%

cder_mpl1p_wp077 Page 186 of 990



Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	17	2.8%
Alcohol use or abuse	****	****
Obesity	460	76.2%
Tobacco use	64	10.6%
Arrhythmia	78	12.9%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	32	5.3%
Chronic obstructive pulmonary disease	11	1.8%
Congenital heart disease	11	1.8%
Heart failure	23	3.8%
Hyperlipidemia	358	59.3%
Hypertensive disease	418	69.2%
Thyroid disease	121	20.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	49	8.1%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	24	4.0%
Obstructive sleep apnea	161	26.7%
Hypertrophic cardiomyopathy	15	2.5%
Other cardiac disease	194	32.1%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	4.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	28	4.6%
Biguanides (metformin, phenformin, etc.)	530	87.7%
SGLT2 inhibitors	99	16.4%
Sulfonylurea	62	10.3%
Thiazolidinedione	17	2.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	V.U/0 ****
Beta blockers	164	27.2%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****

cder_mpl1p_wp077 Page 187 of 990



Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	167	27.6%
Angiotensin-converting-enzyme (ACE) inhibitors	162	26.8%
Angiotensin ii receptor blockers (ARB)	183	30.3%
Dihydropyridines	110	18.2%
Diuretics	186	30.8%
Other antihypertensives	25	4.1%
Antihypertensives (any of the above antihypertensives)	429	71.0%
Oral anticoagulants	26	4.3%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	18	3.0%
Other cardiac medications (any of the other cardiac medications)	45	7.5%
Lipid lowering therapy	328	54.3%
Baseline known risk of prolonged QT and torsades de pointes	242	40.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	481	79.6%
torsades de pointes	102	16.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.9	8.6
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.5	3.6
Mean number of filled prescriptions	19.0	14.1
Mean number of generics dispensed	9.1	4.9
Mean number of unique drug classes dispensed	8.5	4.5

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 188 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	-	-
Age	-	-
0-40 years	-	-
41-64 years	-	-
65-74 years	-	-
75-84 years	-	-
≥ 85 years	-	-
Sex	-	-
Female	-	-
Male	-	-
Race ²	-	-
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	_
Native Hawaiian or Other Pacific Islander	-	_
Unknown	-	_
White	-	_
Hispanic origin	-	_
Yes	-	-
No	_	_
Unknown	-	-
Year	-	-
2022	-	-
2023	-	_
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	-	-
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	-	-
<0	-	-
0	-	-
1-2	-	-
3-4	-	<u>-</u>
5+	-	<u>-</u>
Combined comorbidity score ⁴	-	-
Combined comorbidity score categories ⁴	-	_
<0	-	<u>-</u>
0	-	_
1-2	-	_
3-4	<u>-</u>	_
J- ' 4	-	-

cder_mpl1p_wp077 Page 189 of 990



Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
5+	-	-
Alcohol use or abuse	-	-
Obesity	-	-
Tobacco use	-	-
Arrhythmia	-	-
Cerebrovascular disease/stroke/transient ischemic attack	-	-
Chronic kidney disease	-	-
Chronic obstructive pulmonary disease	-	-
Congenital heart disease	-	-
Heart failure	-	-
Hyperlipidemia	-	-
Hypertensive disease	-	-
Thyroid disease	-	-
Ischemic heart disease/coronary artery disease/myocardial infarction	-	-
Left ventricular hypertrophy	-	-
Peripheral artery disease	-	-
Valvular/mitral valve disease	-	-
Diseases of veins and lymphatics, and other diseases of circulatory system	-	-
Obstructive sleep apnea	-	-
Hypertrophic cardiomyopathy	-	-
Other cardiac disease	-	-
Tachyarrhythmia day 0	-	-
Hospitalized tachyarrhythmia day 0	-	-
History of serious hypoglycemia (ED and/or IP)	-	-
Medical Product Use		
Alpha-glucosidase inhibitors	-	-
Amylin analogs (pramlintide)	-	-
DPP-4 inhibitors	-	-
Incretin mimetics (albiglutide, dulaglutide, etc.)	-	-
Meglitinides	-	-
Insulin	-	-
Biguanides (metformin, phenformin, etc.)	-	-
SGLT2 inhibitors	-	-
Sulfonylurea	-	-
Thiazolidinedione	-	-
No baseline use of any of the above antidiabetic drugs	-	-
Other antidiabetics	_	-
Sodium channel blockers	-	-
Beta blockers	-	-
Potassium channel blockers/openers	-	-
Non-dihydropyridine calcium channel blockers	-	-
Digoxin	-	-

cder_mpl1p_wp077 Page 190 of 990



Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native Percent/Standard <u>Deviation</u>1 **Patient Characteristics** Number/Mean Other antiarrhythmic agents Antiarrhythmic agents (any of the above antiarrhythmic agents) Angiotensin-converting-enzyme (ACE) inhibitors Angiotensin ii receptor blockers (ARB) Dihydropyridines **Diuretics** Other antihypertensives Antihypertensives (any of the above antihypertensives) Oral anticoagulants Vitamin K antagonists Other cardiac medications not mentioned above Other cardiac medications (any of the other cardiac medications) Lipid lowering therapy Baseline known risk of prolonged QT and torsades de pointes Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters Mean number of emergency room encounters Mean number of inpatient hospital encounters Mean number of non-acute institutional encounters Mean number of other ambulatory encounters Mean number of filled prescriptions Mean number of generics dispensed Mean number of unique drug classes dispensed

N/A: Not applicable

cder mpl1p wp077 Page 191 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.



Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Unique patients N/A Demographic Characteristics 1.9 Age (years) 48.9 1.9 Age 0 0.0% 41-64 years 0 0.0% 55-74 years 0 0.0% 75-84 years 0 0.0% 5ex years 0 0.0% Female 0 0.0% Male ************************************		Wegovy, Hospitalized Tachyarrhythmia, Race=Asian		
Unique patients N/A Demographic Characteristics 1.9 Age 48.9 1.9 Age 48.9 1.9 Age 48.9 1.9 Age 48.9 1.9 4.9 48.9 1.9 Age 0 0.0% 41-64 years 0 0.0% 65-74 years 0 0.0% 58 years 0 0.0% 58 years 0 0.0% 58x 8 1.0 0.0% Male ************************************				
Single patents Sin	Patient Characteristics	Number/Mean	Deviation ¹	
Age (years) 48.9 1.9 Age 0 0.0% 0-40 years 0 0.0% 41-64 years 0 0.0% 55-74 years 0 0.0% 5-86 years 0 0.0% Sex Female 0 0.0% Male ************************************	Unique patients	****	N/A	
Age 0 0.0% 41-64 years ************************************	Demographic Characteristics			
0-40 years 0 0.0% 41-64 years 0 0 0.0% 65-74 years 0 0 0.0% 75-84 years 0 0 0.0% 75-84 years 0 0 0.0% 82 85 years 0 0 0.0% 82 85 years 0 0 0.0% 83 83 years 8 0 0 0.0% 83 83 93 83 83 83 83 83 83 83 83 83 83 83 83 83	Age (years)	48.9	1.9	
41-64 years 0 0.0% 65-74 years 0 0.0% 75-84 years 0 0.0% 2 85 years 0 0.0% Sex <td a="" common="" common<="" of="" rows="" td="" the=""><td>Age</td><td></td><td></td></td>	<td>Age</td> <td></td> <td></td>	Age		
15-74 years	0-40 years	0	0.0%	
75-84 years 0 0.00% ≥ 85 years 0 0.00% Sex Female 0 0 0.0% Male ***** Race² American Indian or Alaska Native 0 0 0.0% Asian ***** Black or African American 0 0 0.0% Multi-racial 0 0 0.0% Multi-racial 0 0 0.0% Multi-racial 0 0 0.0% White Hawaiian or Other Pacific Islander 0 0 0.0% White Hawaiian or Other Pacific Islander 0 0 0.0% White 0 0 0.0% White 0 0 0.0% White 0 0 0.0% Unknown 0 0 0.0% Unknown **** Yes 0 0 0.0% Unknown **** Year 2022 0 0 0.0% 2033 **** ***** ***** ***** ***** ***** ****	41-64 years	****	****	
≥ 85 years Sex Female Male Race² American Indian or Alaska Native Asian Black or African American Multi-racial Multi-racial No Native Hawaiian or Other Pacific Islander Unknown White Yes No O O O O No No O O O O O O O O O O O	65-74 years	0	0.0%	
Sex Female 0 0.0% Male Race ² Temper and Indian or Alaska Native 0 0.0% Asian ****** ****** Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ***** ***** Yes 0 0.0% No 0 0.0% Unknown 0 0.0% No 0 0.0% Unknown 0 0.0% Vear 0 0.0% 2022 0 0.0% 2023 ***** ***** Health Characteristics 40 0 0.0% Adapted Diabetes Complications Severity Index (aDCSI) ategories³ 0 0.0% 5 0 0 0.0% 5 0	75-84 years	0	0.0%	
Female 0 0.0% Male ****** ****** Race² ****** ****** American Indian or Alaska Native 0 0.0% Asian ****** ****** Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% White 0 0.0% No 0 0.0% 2022 0 0.0% 2023 ****** ****** Health Characteristics ***** Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 0.0% 0 0 0.0% 0.0% 0 0	≥ 85 years	0	0.0%	
Male ****** ****** Race² ****** ****** Armerican Indian or Alaska Native 0 0.0% Asian ******* ******* Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ***** ******* Yes 0 0.0% No 0 0.0% Unknown ****** ****** Year 2022 0 0.0% 2022 0 0.0% ***** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ***** ****** ****** ***** ****** ****** ***** ****** ****** </td <td>Sex</td> <td></td> <td></td>	Sex			
Race² American Indian or Alaska Native 0 0.0% Asian ****** Black or African American 0 0.0% Multi-racial 0 0.0% Multi-racial 0 0.0% Unknown 0 0.0% White 0 0 0.0% White 0 0 0.0% White 0 0 0.0% Unknown 0 0 0.0% Unknown 0 0 0.0% Unknown 0 0 0.0% White 0 0 0.0% White 0 0 0.0% White 0 0 0.0% Unknown **** Yes 0 0 0.0% Unknown **** Yes 0 0 0.0% Unknown **** Year 2022 0 0 0.0% 2023 0 0 0.0% Unknown **** ***** ***** ***** ***** ***** ****	Female	0	0.0%	
American Indian or Alaska Native 0 0.0% Asian ******* ******* Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ***** ****** Yes 0 0.0% Unknown ***** ***** Year 0 0.0% 2022 0 0.0% 2023 ***** ****** Health Characteristics ***** Adapted Diabetes Complications Severity Index (aDCSI) ³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories ³ 0 0.0% 0 0 0.0% 1-2 0 0.0% 5+ 0 0.0% 5+ 0 0.0% Combined comorbidity score 4 0 0.0%	Male	****	****	
Asian ****** ****** Black or African American 0 0.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ***** ****** Yes 0 0.0% Unknown ***** ****** Year 0 0.0% 2022 0 0.0% 2023 ***** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) actegories³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 3-4 0 0.0% 5+ 0 0.0% Combined comorbidity score 4 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0 0.0% 0 0	Race ²			
Black or African American 0	American Indian or Alaska Native	0	0.0%	
Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes 0 0.0% No 0 0.0% Unknown ****** ****** Year 0 0.0% 2022 0 0.0% 2023 ***** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) ³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories ³ 0 0.0% <0	Asian	****	****	
Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin Tes 0 0.0% No 0 0.0% Unknown ****** ****** Year 0 0.0% 2022 0 0.0% 2023 ***** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ******* 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% 5+ 0 0.0% 5+ 0 0.7 Combined comorbidity score⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% 0.0% 0 0.0% 0.0% <td>Black or African American</td> <td>0</td> <td>0.0%</td>	Black or African American	0	0.0%	
Unknown 0 0.0% White 0 0.0% Hispanic origin	Multi-racial	0	0.0%	
White 0 0.0% Hispanic origin 7es 0 0.0% No 0 0.0% 0.0% Unknown ****** ****** Year 0 0.0% 0.0% 2022 0 0.0% 0.0% 0.0% Beath Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ******* 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% 5+ 0 0.0% 5+ 0 0.0% Combined comorbidity score degories⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% 0.0% 0.0% 0 0.0% 0.0% 0.0% 0 0.0% 0.0% 0.0% 0 0.0% 0.0% 0.0% 0 0.0%	Native Hawaiian or Other Pacific Islander	0	0.0%	
Hispanic origin Yes 0 0.0% No 0 0.0% Unknown ***** ***** Year 0 0.0% 2022 0 0.0% 2023 ***** ***** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ ****** ******* <0	Unknown	0	0.0%	
Yes 0 0.0% No 0 0.0% Unknown ****** ****** Year ***** ****** 2022 0 0.0% 2023 ***** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% 5+ 0 0.0% 5+ 0 0.0% Combined comorbidity score dategories⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** 40 0 0.0% 0 0.0% ****** 40 0 0.0% 0 0.0% ****** 40 0	White	0	0.0%	
Yes 0 0.0% No 0 0.0% Unknown ****** ****** Year ***** ****** 2022 0 0.0% 2023 ***** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% 5+ 0 0.0% 5+ 0 0.0% Combined comorbidity score dategories⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** 40 0 0.0% 0 0.0% ****** 40 0 0.0% 0 0.0% ****** 40 0	Hispanic origin			
Unknown ****** ****** Year 0 0.0% 2022 0 0.0% 2023 ****** ****** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 0.0% 1-2 0 0.0% 0.0% 3-4 0 0.0% 0.0% 5+ 0 0.0% 0.0% Combined comorbidity score⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** ****** 1-2 ****** ******		0	0.0%	
Year 2022	No	0	0.0%	
2022 0 0.0% 2023 ***** ***** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% 5+ 0 0.0% Combined comorbidity score⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** ****** 1-2 ****** *******	Unknown	****	****	
2023 ***** ***** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** ****** 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% Combined comorbidity score⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** ****** 1-2 ****** ****** ******	Year			
2023 ***** ***** Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** ****** 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% Combined comorbidity score⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** ****** 1-2 ****** ****** ******	2022	0	0.0%	
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 0.0 NaN Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** 1-2 0 0.0% 3-4 0 0.0% 5+ 0 0.0% Combined comorbidity score⁴ 0.5 0.7 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% ****** ******* 1-2 ****** ****** *******		****		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 ***** ***** 1-2 0 0 0.0% 3-4 0 0 0.0% 5+ 0 0 0.0% Combined comorbidity score ⁴ 0.5 0.7 Combined comorbidity score categories ⁴ <0 0 0.0% 0 ***** ***** 1-2 ***** ****** 1-2 ***** ******	Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 ***** ***** 1-2 0 0 0.0% 3-4 0 0 0.0% 5+ 0 0 0.0% Combined comorbidity score ⁴ 0.5 0.7 Combined comorbidity score categories ⁴ <0 0 0.0% 0 ***** ***** 1-2 ***** ****** 1-2 ***** ******	Adapted Diabetes Complications Severity Index (aDCSI) ³	0.0	NaN	
<0				
1-2 0 0 0.0% 3-4 0 0 0.0% 5+ 0 0 0.0% Combined comorbidity score ⁴ 0.5 0.7 Combined comorbidity score categories ⁴ 0 0 0.0% 0 0 0.0% 1-2 ***** *****		0	0.0%	
1-2 0 0.0% 3-4 0 0.0% 5+ 0 0 0.0% Combined comorbidity score ⁴ 0.5 0.7 Combined comorbidity score categories ⁴ 0.5 0.7 Combined comorbidity score categories 0 0 0.0% 0 ***** **** 1-2 *****		****		
3-4 0 0.0% 5+ 0 0.0% Combined comorbidity score ⁴ 0.5 0.7 Combined comorbidity score categories ⁴ 0 0 0.0%		0	0.0%	
5+ 0 0.0% Combined comorbidity score ⁴ 0.5 0.7 Combined comorbidity score categories ⁴ 0 0.0% 0 ***** ***** 1-2 ***** ******				
Combined comorbidity score ⁴ Combined comorbidity score categories ⁴ <0 0 0 0.0% 0 ***** 1-2 ***** ***** ****** 1-2		-		
Combined comorbidity score categories ⁴ <0				
<pre><0</pre>				
0 ***** ***** 1-2 ***** *****		0	0.0%	
1-2				
		****	****	
	3-4	0	0.0%	

cder_mpl1p_wp077 Page 192 of 990



Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Race=AsianPatient CharacteristicsNumber/MeanDeviation¹5+00.0%Alcohol use or abuse00.0%Obesity**************Tobacco use00.0%Arrhythmia00.0%Cerebrovascular disease/stroke/transient ischemic attack00.0%Chronic kidney disease00.0%Chronic obstructive pulmonary disease00.0%Congenital heart disease00.0%Heart failure00.0%Hyperlipidemia**************Hypertensive disease*************Thyroid disease00.0%Ischemic heart disease/coronary artery disease/myocardial infarction00.0%Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Other cardiac disease00.0%Other cardiac disease00.0%Other cardiac disease00.0%Tachyarrhythmia day 000.0%
Patient Characteristics Number/Mean Deviation¹ 5+ 0 0.0% Alcohol use or abuse 0 0.0% Obesity ******* ******* Tobacco use 0 0.0% Arrhythmia 0 0.0% Cerebrovascular disease/stroke/transient ischemic attack 0 0.0% Chronic kidney disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Congenital heart disease 0 0.0% Congenital heart disease 0 0.0% Hyperlipidemia ******* ******* Hyperlipidemia ******* ******* Hypertensive disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0%
5+ 0 0.0% Alcohol use or abuse 0 0.0% Obesity ****** ****** Tobacco use 0 0.0% Arrhythmia 0 0.0% Cerebrovascular disease/stroke/transient ischemic attack 0 0.0% Chronic kidney disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Congenital heart disease 0 0.0% Heart failure 0 0.0% Hyperlipidemia ******* ******* Hypertensive disease 0 0.0% Hypertensive disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Valvular/mitral valve disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0%
Alcohol use or abuse 0 0.0% Obesity ****** ****** Tobacco use 0 0.0% Arrhythmia 0 0.0% Cerebrovascular disease/stroke/transient ischemic attack 0 0.0% Chronic kidney disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Congenital heart disease 0 0.0% Heart failure 0 0.0% Hyperlipidemia ******* ****** Hypertensive disease 0 0.0% Hypertensive disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Ieft ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Obstructive sleep apnea 0 0.0%
Obesity ****** ****** Tobacco use 0 0.0% Arrhythmia 0 0.0% Cerebrovascular disease/stroke/transient ischemic attack 0 0.0% Chronic kidney disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Congenital heart disease 0 0.0% Heart failure 0 0.0% Hyperlipidemia ******* ****** Hypertensive disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease 0
Observed 0 0.0% Arrhythmia 0 0.0% Cerebrovascular disease/stroke/transient ischemic attack 0 0.0% Chronic kidney disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Congenital heart disease 0 0.0% Heart failure 0 0.0% Hyperlipidemia ******* ******* Hypertensive disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease 0 0.0%
Arrhythmia 0 0.0% Cerebrovascular disease/stroke/transient ischemic attack 0 0.0% Chronic kidney disease 0 0.0% Chronic obstructive pulmonary disease 0 0.0% Congenital heart disease 0 0.0% Heart failure 0 0.0% Hyperlipidemia ****** Hypertensive disease ****** Thyroid disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Chronic kidney disease 0
Cerebrovascular disease/stroke/transient ischemic attack00.0%Chronic kidney disease00.0%Chronic obstructive pulmonary disease00.0%Congenital heart disease00.0%Heart failure00.0%Hyperlipidemia**************Hypertensive disease************Thyroid disease00.0%Ischemic heart disease/coronary artery disease/myocardial infarction00.0%Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Chronic kidney disease00.0%Chronic obstructive pulmonary disease00.0%Congenital heart disease00.0%Heart failure00.0%Hyperlipidemia**************Hypertensive disease************Thyroid disease00.0%Ischemic heart disease/coronary artery disease/myocardial infarction00.0%Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Chronic obstructive pulmonary disease00.0%Congenital heart disease00.0%Heart failure00.0%Hyperlipidemia************Hypertensive disease************Thyroid disease00.0%Ischemic heart disease/coronary artery disease/myocardial infarction00.0%Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Congenital heart disease00.0%Heart failure00.0%Hyperlipidemia************Hypertensive disease************Thyroid disease00.0%Ischemic heart disease/coronary artery disease/myocardial infarction00.0%Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Heart failure00.0%Hyperlipidemia************Hypertensive disease************Thyroid disease00.0%Ischemic heart disease/coronary artery disease/myocardial infarction00.0%Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Hyperlipidemia ***** **** Hypertensive disease Thyroid disease 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease
Hypertensive disease ***** ***** Thyroid disease 0 0 0.0% Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0 0.0% Valvular/mitral valve disease 0 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease 0 0.0%
Thyroid disease Thyroid disease Ischemic heart disease/coronary artery disease/myocardial infarction Left ventricular hypertrophy Peripheral artery disease O O O Valvular/mitral valve disease O O O O O Valvular/mitral valve disease O O O O O O O O O O O O O
Ischemic heart disease/coronary artery disease/myocardial infarction 0 0.0% Left ventricular hypertrophy 0 0.0% Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease 0 0.0%
Left ventricular hypertrophy00.0%Peripheral artery disease00.0%Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Peripheral artery disease 0 0.0% Valvular/mitral valve disease 0 0.0% Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease 0 0.0%
Valvular/mitral valve disease00.0%Diseases of veins and lymphatics, and other diseases of circulatory system00.0%Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Diseases of veins and lymphatics, and other diseases of circulatory system 0 0.0% Obstructive sleep apnea 0 0.0% Hypertrophic cardiomyopathy 0 0.0% Other cardiac disease 0 0.0%
Obstructive sleep apnea00.0%Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Hypertrophic cardiomyopathy00.0%Other cardiac disease00.0%
Other cardiac disease 0 0.0%
Tachvarrhythmia day 0 0 0.0%
Hospitalized tachyarrhythmia day 0 0 0.0%
History of serious hypoglycemia (ED and/or IP) 0 0.0%
Medical Product Use
Alpha-glucosidase inhibitors 0 0.0%
Amylin analogs (pramlintide) 0 0.0%
DPP-4 inhibitors 0 0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.) 0 0.0%
Meglitinides 0 0.0%
Insulin 0 0.0%
Biguanides (metformin, phenformin, etc.)
SGLT2 inhibitors 0 0.0%
Sulfonylurea ***** *****
Thiazolidinedione 0 0.0%
No baseline use of any of the above antidiabetic drugs 0 0.0% Other antidiabetics 0 0.0%
Sodium channel blockers 0 0.0% Beta blockers *****
Potassium channel blockers/openers 0 0.0%
Non-dihydropyridine calcium channel blockers 0 0.0%
Digoxin 0 0.0%

cder_mpl1p_wp077 Page 193 of 990



Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	3.5	2.1
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.5	0.7
Mean number of filled prescriptions	12.0	1.4
Mean number of generics dispensed	7.0	1.4
Mean number of unique drug classes dispensed	6.5	0.7

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 194 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American	
		Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹	
Unique patients	40	N/A	
Demographic Characteristics			
Age (years)	57.0	8.4	
Age			
0-40 years	****	****	
41-64 years	23	57.5%	
65-74 years	****	****	
75-84 years	****	****	
≥ 85 years	0	0.0%	
Sex			
Female	****	****	
Male	****	****	
Race ²			
American Indian or Alaska Native	0	0.0%	
Asian	0	0.0%	
Black or African American	40	100.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	0	0.0%	
White	0	0.0%	
Hispanic origin			
Yes	0	0.0%	
No	17	42.5%	
Unknown	23	57.5%	
/ear			
2022	****	****	
2023	****	****	
Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.2	
Adapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	21	52.5%	
1-2	****	****	
3-4	****	****	
5+	****	****	
Combined comorbidity score ⁴	1.2	1.8	
Combined comorbidity score categories ⁴	1.2	1.0	
<0	****	****	
0	11	27.5%	
1-2	17	42.5%	
3-4	1 <i>/</i> ****	42.5% ****	

cder_mpl1p_wp077 Page 195 of 990



Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia,	
	Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	****	****
Hyperlipidemia	26	65.0%
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	13	32.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	16	40.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
	_	
Sodium channel blockers Beta blockers	0 ****	0.0% ****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****

cder_mpl1p_wp077 Page 196 of 990



Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% 0 **** Antiarrhythmic agents (any of the above antiarrhythmic agents) **** **** Angiotensin-converting-enzyme (ACE) inhibitors Angiotensin ii receptor blockers (ARB) 18 45.0% Dihydropyridines 12 30.0% **Diuretics** 20 50.0% **** **** Other antihypertensives **** Antihypertensives (any of the above antihypertensives) Oral anticoagulants 0 0.0% **** Vitamin K antagonists Other cardiac medications not mentioned above 0.0% 0 Other cardiac medications (any of the other cardiac medications) **** **** Lipid lowering therapy 22 55.0% Baseline known risk of prolonged QT and torsades de pointes **** **** Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and **** **** torsades de pointes **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 11.3 8.7 Mean number of emergency room encounters 0.9 0.4 Mean number of inpatient hospital encounters 0.0 NaN Mean number of non-acute institutional encounters 0.0 NaN 3.2 Mean number of other ambulatory encounters 1.8 Mean number of filled prescriptions 19.2 19.2 Mean number of generics dispensed 9.1 5.4 Mean number of unique drug classes dispensed 8.3 4.6

NaN: Not a number N/A: Not applicable

cder mpl1p wp077 Page 197 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Wegovy, Hospitalized Tachyarrhythmia,

Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	131411	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	-	-
Age	-	-
0-40 years	-	-
41-64 years	-	-
65-74 years	-	-
75-84 years	-	-
≥ 85 years	-	-
Sex	-	-
Female	-	-
Male	-	-
Race ²	-	-
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin	-	-
Yes	-	-
No	-	-
Unknown	-	-
Year	-	-
2022	-	-
2023	-	-
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	-	-
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	-	-
<0	-	-
0	-	-
1-2	-	-
3-4	-	-
5+	-	-
Combined comorbidity score ⁴	-	-
Combined comorbidity score categories ⁴	-	-
<0	-	-
0	-	-
1-2	-	-
3-4	-	-

cder_mpl1p_wp077 Page 198 of 990



Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Wegovy, Hospitalized Tachyarrhythmia,

Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	151411	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	-	-
Alcohol use or abuse	-	-
Obesity	-	-
Tobacco use	-	-
Arrhythmia	-	-
Cerebrovascular disease/stroke/transient ischemic attack	-	-
Chronic kidney disease	-	-
Chronic obstructive pulmonary disease	-	-
Congenital heart disease	-	-
Heart failure	-	-
Hyperlipidemia	-	-
Hypertensive disease	-	-
Thyroid disease	-	-
Ischemic heart disease/coronary artery disease/myocardial infarction	-	-
Left ventricular hypertrophy	-	-
Peripheral artery disease	-	_
Valvular/mitral valve disease	-	-
Diseases of veins and lymphatics, and other diseases of circulatory system	-	-
Obstructive sleep apnea	-	-
Hypertrophic cardiomyopathy	-	-
Other cardiac disease	-	-
Tachyarrhythmia day 0	-	-
Hospitalized tachyarrhythmia day 0	-	-
History of serious hypoglycemia (ED and/or IP)	-	-
Medical Product Use		
Alpha-glucosidase inhibitors	-	-
Amylin analogs (pramlintide)	-	-
DPP-4 inhibitors	-	-
Incretin mimetics (albiglutide, dulaglutide, etc.)	-	-
Meglitinides	-	-
Insulin	-	-
Biguanides (metformin, phenformin, etc.)	-	-
SGLT2 inhibitors	-	-
Sulfonylurea	-	-
Thiazolidinedione	-	-
No baseline use of any of the above antidiabetic drugs	-	-
Other antidiabetics	-	-
Sodium channel blockers	-	-
Beta blockers	-	-
Potassium channel blockers/openers	-	-
Non-dihydropyridine calcium channel blockers	-	-
Digoxin	-	-

cder_mpl1p_wp077 Page 199 of 990



Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	-	-
Antiarrhythmic agents (any of the above antiarrhythmic agents)	-	-
Angiotensin-converting-enzyme (ACE) inhibitors	-	-
Angiotensin ii receptor blockers (ARB)	-	-
Dihydropyridines	-	-
Diuretics	-	-
Other antihypertensives	-	-
Antihypertensives (any of the above antihypertensives)	-	-
Oral anticoagulants	-	-
Vitamin K antagonists	-	-
Other cardiac medications not mentioned above	-	-
Other cardiac medications (any of the other cardiac medications)	-	-
Lipid lowering therapy	-	-
Baseline known risk of prolonged QT and torsades de pointes	-	-
Baseline possible risk of prolonged QT and torsades de pointes	-	-
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where no % follows the value.

cder_mpl1p_wp077 Page 200 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable



Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	95	N/A
Demographic Characteristics		
Age (years)	58.9	10.4
Age		
0-40 years	****	****
41-64 years	54	56.8%
65-74 years	26	27.4%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	50	52.6%
Male	45	47.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	95	100.0%
Hispanic origin		
Yes	0	0.0%
No	35	36.8%
Unknown	60	63.2%
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	48	50.5%
1-2	34	35.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.3	2.0
Combined comorbidity score categories ⁴		
<0	12	12.6%
0	22	23.2%
1-2	44	46.3%
3-4	****	****

cder_mpl1p_wp077 Page 201 of 990



Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	77	81.1%
Tobacco use	17	17.9%
Arrhythmia	20	21.1%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	60	63.2%
Hypertensive disease	62	65.3%
Thyroid disease	20	21.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	20	21.1%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	46	48.4%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	57	60.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	-	
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	74	77.9%
SGLT2 inhibitors	17	17.9%
Sulfonylurea	15	15.8%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	_	
Beta blockers	0 30	0.0% 31.6%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 202 of 990



Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	30	31.6%
Angiotensin-converting-enzyme (ACE) inhibitors	27	28.4%
Angiotensin ii receptor blockers (ARB)	27	28.4%
Dihydropyridines	14	14.7%
Diuretics	33	34.7%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	61	64.2%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	14	14.7%
Lipid lowering therapy	66	69.5%
Baseline known risk of prolonged QT and torsades de pointes	30	31.6%
Baseline possible risk of prolonged QT and torsades de pointes	75	78.9%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	12	12.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.8	11.1
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.1	6.0
Mean number of filled prescriptions	22.4	14.4
Mean number of generics dispensed	10.1	4.9
Mean number of unique drug classes dispensed	9.4	4.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 203 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythr Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	50.2	9.4
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin	O	0.070
Yes	****	****
No	****	****
Unknown	****	****
Year 2022	****	****
	****	****
2023	*****	4444
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.3
Adapted Diabetes Complications Severity Index (aDCSI) Adapted Diabetes Complications Severity Index (aDCSI) categories ³	0.7	1.3
· · · · · · · · · · · · · · · · · · ·	0	0.00/
<0	0 ****	0.0% ****
0	****	****
1-2		
3-4	0 ****	0.0%
5+		****
Combined comorbidity score ⁴	1.1	1.9
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	****	****
3-4	****	****

cder_mpl1p_wp077 Page 204 of 990



Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia,	
	Race=Mu	
Dations Characteristics	N / N. A	Percent/Standard
Patient Characteristics	Number/Mean ****	Deviation ¹ ****
5+		
Alcohol use or abuse	0 ****	0.0%
Obesity	****	****
Tobacco use	****	****
Arrhythmia		
Cerebrovascular disease/stroke/transient ischemic attack	0 ****	0.0%
Chronic kidney disease		
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0 ****	0.0%
Hyperlipidemia		
Hypertensive disease	****	****
Thyroid disease		****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	****	****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 205 of 990



Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.7	11.8
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.8	9.2
Mean number of filled prescriptions	29.6	27.8
Mean number of generics dispensed	11.4	9.5
Mean number of unique drug classes dispensed	10.3	8.8

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 206 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bl. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	594	N/A
Demographic Characteristics		
Age (years)	68.3	8.8
Age		
0-40 years	12	2.0%
41-64 years	143	24.1%
65-74 years	308	51.9%
75-84 years	116	19.5%
≥ 85 years	15	2.5%
Sex		
Female	283	47.6%
Male	311	52.4%
Race ²		
American Indian or Alaska Native	****	****
Asian	****	****
Black or African American	70	11.8%
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	****	****
Unknown	125	21.0%
White	379	63.8%
Hispanic origin		
Yes	21	3.5%
No	420	70.7%
Unknown	153	25.8%
Year		
2022	381	64.1%
2023	213	35.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	166	27.9%
1-2	215	36.2%
3-4	129	21.7%
5+	84	14.1%
Combined comorbidity score ⁴	2.4	2.5
Combined comorbidity score categories ⁴		
<0	22	3.7%
0	131	22.1%
1-2	215	36.2%
3-4	117	19.7%

cder_mpl1p_wp077 Page 207 of 990



Table 1bl. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalize	ed Tachvarrhvthmia
	, , , , , , , , , , , , , , , , , , ,	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	109	18.4%
Alcohol use or abuse	****	****
Obesity	222	37.4%
Tobacco use	104	17.5%
Arrhythmia	125	21.0%
Cerebrovascular disease/stroke/transient ischemic attack	85	14.3%
Chronic kidney disease	149	25.1%
Chronic obstructive pulmonary disease	55	9.3%
Congenital heart disease	55	9.3%
Heart failure	94	15.8%
Hyperlipidemia	478	80.5%
Hypertensive disease	508	85.5%
Thyroid disease	112	18.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	163	27.4%
Left ventricular hypertrophy	22	3.7%
Peripheral artery disease	22	3.7%
Valvular/mitral valve disease	21	3.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	54	9.1%
Obstructive sleep apnea	107	18.0%
Hypertrophic cardiomyopathy	42	7.1%
Other cardiac disease	241	40.6%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	63	10.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	15	2.5%
Insulin	278	46.8%
Biguanides (metformin, phenformin, etc.)	462	77.8%
SGLT2 inhibitors	166	27.9%
Sulfonylurea	208	35.0%
Thiazolidinedione	76	12.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	265	44.6%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****

cder_mpl1p_wp077 Page 208 of 990



Table 1bl. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitaliz	ed Tachyarrhythmia
	,,	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	266	44.8%
Angiotensin-converting-enzyme (ACE) inhibitors	242	40.7%
Angiotensin ii receptor blockers (ARB)	215	36.2%
Dihydropyridines	146	24.6%
Diuretics	181	30.5%
Other antihypertensives	37	6.2%
Antihypertensives (any of the above antihypertensives)	499	84.0%
Oral anticoagulants	44	7.4%
Vitamin K antagonists	15	2.5%
Other cardiac medications not mentioned above	38	6.4%
Other cardiac medications (any of the other cardiac medications)	88	14.8%
Lipid lowering therapy	516	86.9%
Baseline known risk of prolonged QT and torsades de pointes	172	29.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	447	75.3%
torsades de pointes	78	13.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.1	10.3
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.4	4.3
Mean number of filled prescriptions	20.3	13.6
Mean number of generics dispensed	9.6	4.6
Mean number of unique drug classes dispensed	8.7	4.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 209 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	125	N/A
Demographic Characteristics		
Age (years)	60.7	10.7
Age		
0-40 years	****	****
41-64 years	68	54.4%
65-74 years	39	31.2%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	61	48.8%
Male	64	51.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	125	100.0%
White	0	0.0%
Hispanic origin		
Yes	21	16.8%
No	0	0.0%
Unknown	104	83.2%
Year		
2022	83	66.4%
2023	42	33.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	59	47.2%
1-2	46	36.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.5	2.4
Combined comorbidity score categories ⁴		
<0	****	****
0	43	34.4%
1-2	53	42.4%
3-4	12	9.6%

cder_mpl1p_wp077 Page 210 of 990



Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	****	****
Obesity	45	36.0%
Tobacco use	19	15.2%
Arrhythmia	17	13.6%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	13	10.4%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	99	79.2%
Hypertensive disease	94	75.2%
Thyroid disease	19	15.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	22	17.6%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	21	16.8%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	39	31.2%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	13	10.4%
	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.) Meglitinides	****	****
Insulin		39.2%
Biguanides (metformin, phenformin, etc.)	49 96	76.8%
SGLT2 inhibitors	40	32.0%
Sulfonylurea	33	26.4%
Thiazolidinedione	15	12.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	40	32.0%
Potassium channel blockers/openers Non-dihydropyridine calcium channel blockers	0 ****	0.0% ****
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 211 of 990



Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	41	32.8%
Angiotensin-converting-enzyme (ACE) inhibitors	49	39.2%
Angiotensin ii receptor blockers (ARB)	38	30.4%
Dihydropyridines	23	18.4%
Diuretics	26	20.8%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	90	72.0%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	14	11.2%
Lipid lowering therapy	97	77.6%
Baseline known risk of prolonged QT and torsades de pointes	39	31.2%
Baseline possible risk of prolonged QT and torsades de pointes	90	72.0%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	16	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.6	11.7
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.6	5.2
Mean number of filled prescriptions	18.2	15.6
Mean number of generics dispensed	8.6	5.4
Mean number of unique drug classes dispensed	7.8	5.0

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 212 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	70.8	6.4
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	0	0.0%
Male	****	****
Race ²		
American Indian or Alaska Native	****	****
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	0	0.0%
Year	·	0.075
2022	0	0.0%
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		<u>-</u>
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.0	1.4
Combined comorbidity score categories ⁴	1.0	1.7
<0	0	0.0%
0	****	V.U/0 ****
1-2	****	****
3-4	0	0.0%

cder_mpl1p_wp077 Page 213 of 990



Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia,	
	Race=American Indian or Alaska Nativ	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	0	0.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	0	0.0%
Sulfonylurea	****	****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 214 of 990



Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native Percent/Standard Deviation¹ **Patient Characteristics** Number/Mean Other antiarrhythmic agents 0.0% 0 Antiarrhythmic agents (any of the above antiarrhythmic agents) 0 0.0% **** **** Angiotensin-converting-enzyme (ACE) inhibitors Angiotensin ii receptor blockers (ARB) 0 0.0% Dihydropyridines **** **** **Diuretics** Other antihypertensives 0 0.0% **** **** Antihypertensives (any of the above antihypertensives) Oral anticoagulants 0 0.0% Vitamin K antagonists 0 0.0% Other cardiac medications not mentioned above 0 0.0% Other cardiac medications (any of the other cardiac medications) 0 0.0% **** Lipid lowering therapy Baseline known risk of prolonged QT and torsades de pointes 0 0.0% Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and 0 torsades de pointes 0.0% **Health Service Utilization Intensity Metrics** Mean number of ambulatory encounters 6.0 2.8 Mean number of emergency room encounters 0.0 NaN Mean number of inpatient hospital encounters 0.0 NaN Mean number of non-acute institutional encounters 0.0 NaN 0.0 Mean number of other ambulatory encounters NaN Mean number of filled prescriptions 18.5 13.4 Mean number of generics dispensed 10.0 5.7 Mean number of unique drug classes dispensed 8.5 3.5

NaN: Not a number N/A: Not applicable

cder mpl1p wp077 Page 215 of 990

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	75.7	7.1
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	****	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	2.8	2.6
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	****	****
1-2	****	****
		

cder_mpl1p_wp077 Page 216 of 990



Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	<u> </u>	0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
	****	****
SGLT2 inhibitors	****	****
Sulfonylurea This polition displays	****	****
Thiazolidinedione		
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0 ****	0.0% ****
Beta blockers Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
-		

cder_mpl1p_wp077 Page 217 of 990



Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=Asian	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.3	18.2
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.5	7.0
Mean number of filled prescriptions	15.7	10.8
Mean number of generics dispensed	7.8	3.7
Mean number of unique drug classes dispensed	6.8	2.9

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 218 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Unique patients 70 N/A Demographic Characteristics 867.9 7.7 Age 67.9 7.7 Age		Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American	
Unique patients 70 N/A Demographic Characteristics Rege (years) 67.9 7.7 Age Cod years 67.9 7.7 Age 41-64 years 41-64 years 49 70.0% 55-74 years 49 70.0% 75-84 years 49 70.0% 75-84 years 49 70.0% 75-84 years 80			Percent/Standard
Demographic Characteristics Age (years) 67.9 7.7 Age	Patient Characteristics	Number/Mean	Deviation ¹
Age (years) 67.9 7.7 Age	Unique patients	70	N/A
Age	Demographic Characteristics		
0-40 years 4.1-64 years 7.1-64 years 4.9 4.9 70.0% 75-84 years 7.0-84 years 7.5-84	Age (years)	67.9	7.7
### ### ### ### ### ### ### ### ### ##	Age		
65-74 years 49 70.0% 75-84 years ************************************	0-40 years	****	****
75-84 years ≥ 85 years Sex Female Male A3 61.4% Male 27 38.6% Race² American Indian or Alaska Native Asian Black or African American Multi-racial O0 0.0% Multi-racial O0 0.0% Multi-racial O0 0.0% White Hawaiian or Other Pacific Islander Unknown O0 0.0% White O0 0.0% Hispanic origin Yes O0 0.0% Unknown Ves Unknown Ves Unknown Ves Unknown Ves O0 0.0% Aday 57.1% Ago 223 A0 0.57.1% Ago 233 A0 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ Combined Comorbidity score Combined comorbidity score A 0 0 0 0.0% Combined comorbidity score A 0 0 0.0% A 0 0.0% A 0 0 0 0.0% A 0 0 0 0.0% A 0 0 0 0 0.0% A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	41-64 years	****	****
Sex ***** Female 43 61.4% Male 27 38.6% Race² **** **** American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 70 100.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Isspanic origin ***** ****** Yes 0 0.0% No ***** ****** Year 2022 40 57.1% 2023 40 57.1% 2023 40 57.1% 2024 40 57.1% 4dapted Diabetes Complications Severity Index (aDCSI) actegories³ 2.3 1.9 4dapted Diabetes Complications Severity Index (aDCSI) actegories³ 2.5 2.3 5+ ********* *********** 1-2	65-74 years	49	70.0%
Sex Female 43 61.4% Male 27 38.6% Race² Temerican Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 70 100.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ************************************	75-84 years	****	****
Female 43 61.4% Male 27 38.6% Race² ************************************	≥ 85 years	****	****
Male 27 38.6% Race² ————————————————————————————————————	Sex		
Race² American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 70 100.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 2022 40 57.1% 2023 40 57.1% 2022 40 57.1% 2023 40 57.1% 2023 40 57.1% 2024 40 57.1% 2023 23 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 28 40.0% 3-4 18 25.7%	Female	43	61.4%
American Indian or Alaska Native 0 0.0% Asian 0 0.0% Black or African American 70 100.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Ves 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1% 2022 40 57.1% 2023 40 57.1% 2023 40 57.1% 2024 40 57.1% 2023 40 57.1% Adapted Diabetes Complications Severity Index (aDCSI) 3 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) actegories³ 2 0 0.0% 0 2 28 40.0% 4.0% 4.0% 4.0% 4.0% 4.0%	Male	27	38.6%
Asian 0 0.0% Black or African American 70 100.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1% 2022 40 57.1% 2023 40 40 2024 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) actegories³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) actegories³ 28 40.0% 3-4 18 25.7% 5+ ****** ****** 1-2 28 40.0% 3-4 18 25.7% <	Race ²		
Black or African American 70 100.0% Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ******* Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 0 57.1% 2022 40 57.1% 2023 30 42.9% Health Characteristics ****** Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) at a graph of the second	American Indian or Alaska Native	0	0.0%
Multi-racial 0 0.0% Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1% 2022 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 4.0% 3-4 18 25.7% 5+ ****** ******* Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 0 0.0% 0 0 0.0% 0 0 0.0% 0 0 0.0% 0 0 <	Asian	0	0.0%
Native Hawaiian or Other Pacific Islander 0 0.0% Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1% 2022 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 4.0 40 0 0.0% 5+ 28 40.0% 5+ ****** ******* Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 0 0.0% 0 0 0.0% 0 0 0.0% 0<	Black or African American	70	100.0%
Unknown 0 0.0% White 0 0.0% Hispanic origin ****** ****** Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1%	Multi-racial	0	0.0%
White 0 0.0% Hispanic origin Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1%	Native Hawaiian or Other Pacific Islander	0	0.0%
Hispanic origin Yes 0 0.0% No ****** ****** Unknown ****** ****** Year 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ √ 0 0.0% 0 ****** ****** ****** 1-2 28 40.0% 3-4 18 25.7% 5+ ****** ****** Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 2.5 2.3 Combined comorbidity score categories⁴ 0 0.0% 0 0.0% 0 0 0.0% 0	Unknown	0	0.0%
Yes 0 0.0% No ***** ****** Unknown ****** ****** Year ***** ****** 2022 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** 1-2 28 40.0% 3-4 18 25.7% 5+ ****** ****** Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 2.5 2.3 Combined comorbidity score categories⁴ 0 0.0% 0 0 0.0% 0 0.0% 0 0 0.0% 0 2.2 2.3 2.3 2.3 2.3 2.3 3.4 3.0 3.0 3.0	White	0	0.0%
No ***** ****** Unknown ****** ****** Year 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ <0	Hispanic origin		
No. ****** ******* Year 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 0 1.9 0.0% 0 0.0% 0.0% 3-4 28 40.0% 3-4 18 25.7% 5+ ****** ****** Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 2.5 2.3 <0	Yes	0	0.0%
Year 2022	No	****	****
2022 40 57.1% 2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) categories³ <0	Unknown	****	****
2023 30 42.9% Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI) categories³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 0 0.0% 0 28 40.0% 3-4 18 25.7% 5+ ****** ****** Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 2.5 2.3 <0	Year		
Health Characteristics Adapted Diabetes Complications Severity Index (aDCSI)³ 2.3 1.9 Adapted Diabetes Complications Severity Index (aDCSI) categories³ 0 0.0% 0 ****** ****** 1-2 28 40.0% 3-4 18 25.7% 5+ ****** ****** Combined comorbidity score⁴ 2.5 2.3 Combined comorbidity score categories⁴ 0 0.0% 0 0 0.0% 0 16 22.9% 1-2 27 38.6%	2022	40	57.1%
Adapted Diabetes Complications Severity Index (aDCSI) ³ Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 ***** ***** 1-2 28 40.0% 3-4 18 25.7% 5+ ***** Combined comorbidity score ⁴ 2.5 2.3 Combined comorbidity score categories ⁴ <0 0 0.0% 0 16 22.9% 1-2 27 38.6%	2023	30	42.9%
Adapted Diabetes Complications Severity Index (aDCSI) categories ³ <0 0 0.0% 0 ***** ***** 1-2 28 40.0% 3-4 18 25.7% 5+ ***** Combined comorbidity score ⁴ 2.5 2.3 Combined comorbidity score categories ⁴ <0 0 0.0% 0 0.0% 0 16 22.9% 1-2 27 38.6%	Health Characteristics		
<0	Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	1.9
0 ***** ***** 1-2 28 40.0% 3-4 18 25.7% 5+ ***** ***** Combined comorbidity score ⁴ 2.5 2.3 Combined comorbidity score categories ⁴ 0 0.0% 0 0.0% 0 0 16 22.9% 1-2 27 38.6%	Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
1-2 28 40.0% 3-4 18 25.7% 5+ ***** Combined comorbidity score Combined comorbidity score categories Combined comorbidity score categories Combined comorbidity score categories Combined comorbidity score categories 2.5 2.3 Combined comorbidity score categories Combined comorbidity score categories 20 0 0.0% 0 16 22.9% 1-2 27 38.6%	<0	0	0.0%
3-4 5+ Combined comorbidity score ⁴ Combined comorbidity score categories ⁴ <0 0 0 0 0 0 16 22.9% 1-2 38.6%	0	****	****
3-4 5+	1-2	28	40.0%
Combined comorbidity score ⁴ Combined comorbidity score categories ⁴ <0 0 0 0.0% 0 16 22.9% 1-2 27 38.6%	3-4	18	25.7%
Combined comorbidity score categories ⁴ <0	5+	****	****
Combined comorbidity score categories ⁴ 0 0.0% 0 16 22.9% 1-2 27 38.6%		2.5	2.3
<0			
01622.9%1-22738.6%	,	0	0.0%
1-2 27 38.6%		16	
	3-4	12	17.1%

cder_mpl1p_wp077 Page 219 of 990



Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia,	
	Race=Black or African America	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	15	21.4%
Alcohol use or abuse	0	0.0%
Obesity	26	37.1%
Tobacco use	****	****
Arrhythmia	12	17.1%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	19	27.1%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	13	18.6%
Hyperlipidemia	51	72.9%
Hypertensive disease	62	88.6%
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	15	21.4%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	26	37.1%
	****	37.1/0
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	****	****
Alpha-glucosidase inhibitors		
Amylin analogs (pramlintide)	0 ****	0.0%
DPP-4 inhibitors		
Incretin mimetics (albiglutide, dulaglutide, etc.)	0 ****	0.0% ****
Meglitinides		
Insulin	35	50.0%
Biguanides (metformin, phenformin, etc.)	53	75.7%
SGLT2 inhibitors	21	30.0%
Sulfonylurea	26	37.1%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	35	50.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0 0	0.0% 0.0%
Digoxin	U	U.U%

cder_mpl1p_wp077 Page 220 of 990



Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia,	
	Race=Black or African American	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	35	50.0%
Angiotensin-converting-enzyme (ACE) inhibitors	20	28.6%
Angiotensin ii receptor blockers (ARB)	30	42.9%
Dihydropyridines	27	38.6%
Diuretics	23	32.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	11	15.7%
Lipid lowering therapy	61	87.1%
Baseline known risk of prolonged QT and torsades de pointes	14	20.0%
Baseline possible risk of prolonged QT and torsades de pointes	51	72.9%
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.6	13.0
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.2	4.3
Mean number of filled prescriptions	18.9	15.1
Mean number of generics dispensed	9.4	5.3
Mean number of unique drug classes dispensed	8.5	4.8

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 221 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	59.1	23.5
Age		
0-40 years	****	****
41-64 years	0	0.0%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	****	****
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	0	0.0%
'ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	0	0.0%
Combined comorbidity score ⁴	3.3	2.3
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	****	****
3-4	0	0.0%

cder_mpl1p_wp077 Page 222 of 990



Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

	Islan	<u> </u>
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	****	****
Alcohol use or abuse	0	0.0%
Dbesity	****	****
obacco use	****	****
nrhythmia	****	****
erebrovascular disease/stroke/transient ischemic attack	0	0.0%
hronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
ongenital heart disease	0	0.0%
leart failure	****	****
lyperlipidemia	****	****
ypertensive disease	****	****
hyroid disease	0	0.0%
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	****	****
eripheral artery disease	****	****
alvular/mitral valve disease	0	0.0%
iseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	****
lypertrophic cardiomyopathy	****	****
Other cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Nedical Product Use		
lpha-glucosidase inhibitors	0	0.0%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	0	0.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
∕ leglitinides	0	0.0%
nsulin	****	****
iguanides (metformin, phenformin, etc.)	****	****
GLT2 inhibitors	0	0.0%
ulfonylurea	****	****
, hiazolidinedione	0	0.0%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
eta blockers	****	****
otassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%

cder_mpl1p_wp077 Page 223 of 990



Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitors	0	0.0%
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines	****	****
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.0	5.3
Mean number of emergency room encounters	2.3	4.0
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.3	0.6
Mean number of other ambulatory encounters	6.0	5.6
Mean number of filled prescriptions	29.7	15.0
Mean number of generics dispensed	12.0	2.0
Mean number of unique drug classes dispensed	11.7	2.1

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 224 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	379	N/A
Demographic Characteristics		
Age (years)	70.8	7.8
Age		
0-40 years	****	****
41-64 years	61	16.1%
65-74 years	211	55.7%
75-84 years	95	25.1%
≥ 85 years	****	****
Sex		
Female	169	44.6%
Male	210	55.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	379	100.0%
Hispanic origin		
Yes	0	0.0%
No	344	90.8%
Unknown	35	9.2%
Year		
2022	246	64.9%
2023	133	35.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.4	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	85	22.4%
1-2	133	35.1%
3-4	95	25.1%
5+	66	17.4%
Combined comorbidity score ⁴	2.7	2.6
Combined comorbidity score categories ⁴		
<0	15	4.0%
0	68	17.9%
1-2	124	32.7%
3-4	92	24.3%

cder_mpl1p_wp077 Page 225 of 990



Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	80	21.1%
Alcohol use or abuse	****	****
Obesity	149	39.3%
Tobacco use	73	19.3%
Arrhythmia	93	24.5%
Cerebrovascular disease/stroke/transient ischemic attack	70	18.5%
Chronic kidney disease	112	29.6%
Chronic obstructive pulmonary disease	46	12.1%
Congenital heart disease	46	12.1%
Heart failure	68	17.9%
Hyperlipidemia	311	82.1%
Hypertensive disease	336	88.7%
Thyroid disease	78	20.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	120	31.7%
Left ventricular hypertrophy	18	4.7%
Peripheral artery disease	18	4.7%
Valvular/mitral valve disease	19	5.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	40	10.6%
Obstructive sleep apnea	74	19.5%
Hypertrophic cardiomyopathy	29	7.7%
Other cardiac disease	168	44.3%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	37	9.8%
	0	
Incretin mimetics (albiglutide, dulaglutide, etc.)	12	0.0% 3.2%
Meglitinides Insulin	186	49.1%
Biguanides (metformin, phenformin, etc.)	298	78.6%
SGLT2 inhibitors	99	26.1%
Sulfonylurea	142	37.5%
Thiazolidinedione	52	13.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	**** 40 00/
Beta blockers Potassium channel blockers/openers	185 ****	48.8% ****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****

cder_mpl1p_wp077 Page 226 of 990



Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalized Tachyarrhythmia, Race=White	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	185	48.8%
Angiotensin-converting-enzyme (ACE) inhibitors	169	44.6%
Angiotensin ii receptor blockers (ARB)	138	36.4%
Dihydropyridines	92	24.3%
Diuretics	129	34.0%
Other antihypertensives	21	5.5%
Antihypertensives (any of the above antihypertensives)	334	88.1%
Oral anticoagulants	32	8.4%
Vitamin K antagonists	12	3.2%
Other cardiac medications not mentioned above	26	6.9%
Other cardiac medications (any of the other cardiac medications)	63	16.6%
Lipid lowering therapy	340	89.7%
Baseline known risk of prolonged QT and torsades de pointes	115	30.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	293	77.3%
torsades de pointes	55	14.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.4	8.8
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.4	3.9
Mean number of filled prescriptions	21.4	12.7
Mean number of generics dispensed	10.1	4.1
Mean number of unique drug classes dispensed	9.1	3.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 227 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalize Race=Mu	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	50.1	4.4
Age		
0-40 years	0	0.0%
41-64 years	****	****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	****	****
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	U	
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.3	0.5
Combined comorbidity score categories ⁴	0.3	0.5
<0	0	0.0%
0	****	****
1-2	****	****
3-4		0.0%
J- 11	0	0.0%

cder_mpl1p_wp077 Page 228 of 990



Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalize Race=Mu	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	0	0.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 229 of 990



Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Xultophy, Hospitalize Race=Mu	
		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitors	****	****
Angiotensin ii receptor blockers (ARB)	****	****
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	0	0.0%
Baseline possible risk of prolonged QT and torsades de pointes	****	****
Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	5.7	4.0
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	8.7	5.0
Mean number of generics dispensed	5.0	1.5
Mean number of unique drug classes dispensed	4.3	2.0

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 230 of 990

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients		Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Years
Bydureon, Hospitalized	1,992	1,992	12	0.60 (0.26, 0.94)	276.8	101,086	433.59 (246.24, 763.49)	3,068	3,068	776.5
Tachyarrhythmia Mounjaro, Hospitalized	22,618	22,618	112	0.50 (0.40, 0.59)	2,589.8	945,940	432.46 (359.35, 520.45)	37,152	37,660	6,401.5
Tachyarrhythmia Ozempic, Hospitalized	139,413	139,413	951	0.68 (0.64, 0.73)	19,377.6	7,077,673	490.77 (460.55, 522.98)	205,986	206,584	50,802.5
Tachyarrhythmia Rybelsus, Hospitalized	39,924	39,924	219	0.55 (0.48, 0.62)	5,491.1	2,005,637	398.82 (349.35, 455.30)	58,262	59,504	15,119.3
Tachyarrhythmia Saxenda, Hospitalized	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
Tachyarrhythmia Trulicity, Hospitalized	83,649	83,649	632	0.76 (0.70, 0.81)	12,351.1	4,511,231	511.70 (473.32, 553.19)	144,367	145,254	32,354.0
Tachyarrhythmia Victoza, Hospitalized	8,683	8,683	69	0.79 (0.61, 0.98)	1,242.1	453,659	555.53 (438.77, 703.37)	12,189	12,192	3,348.0
Tachyarrhythmia Wegovy, Hospitalized	761	761	****	****	****	****	150.19 (21.16, 1,066.26)	1,178	1,205	133.2
Tachyarrhythmia Xultophy, Hospitalized	594	594	****	****	****	****	313.11 (100.98, 970.83)	776	776	224.5
Tachyarrhythmia Mounjaro, Atrial Fibrillation	22,618	22,618	68	0.30 (0.23, 0.37)	2,589.8	945,940	262.56 (207.02, 333.01)	37,152	37,660	6,401.5
and Flutter Bydureon, Atrial Fibrillation and	1,992	1,992	****	****	****	****	289.06 (144.56, 578.02)	3,068	3,068	776.5
Flutter Ozempic, Atrial Fibrillation and	139,413	139,413	593	0.43 (0.39, 0.46)	19,377.6	7,077,673	306.02 (282.36, 331.67)	205,986	206,584	50,802.5
Flutter Rybelsus, Atrial Fibrillation and	39,924	39,924	149	0.37 (0.31, 0.43)	5,491.1	2,005,637	271.35 (231.09, 318.61)	58,262	59,504	15,119.3
Flutter Wegovy, Atrial Fibrillation and Flutter	761	761	****	****	****	****	150.19 (21.16, 1,066.26)	1,178	1,205	133.2
Saxenda, Atrial Fibrillation and Flutter	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
Flutter Victoza, Atrial Fibrillation and Flutter	8,683	8,683	44	0.51 (0.36, 0.66)	1,242.1	453,659	354.25 (263.63, 476.04)	12,189	12,192	3,348.0



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Atrial Fibrillation and	83,649	83,649	445	0.53 (0.48, 0.58)	12,351.1	4,511,231	360.29 (328.32, 395.37)	144,367	145,254	32,354.0
Flutter Xultophy, Atrial Fibrillation and Flutter	594	594	****	****	****	****	208.74 (52.20, 834.65)	776	776	224.5
Mounjaro, Sinus Tachycardia	22,618	22,618	34	0.15 (0.10, 0.20)	2,589.8	945,940	131.28 (93.80, 183.73)	37,152	37,660	6,401.5
Bydureon, Sinus Tachycardia	1,992	1,992	****	****	****	****	36.13 (5.09, 256.52)	3,068	3,068	776.5
Ozempic, Sinus Tachycardia	139,413	139,413	241	0.17 (0.15, 0.19)	19,377.6	7,077,673	124.37 (109.62, 141.11)	205,986	206,584	50,802.5
Rybelsus, Sinus Tachycardia	39,924	39,924	57	0.14 (0.11, 0.18)	5,491.1	2,005,637	103.80 (80.07, 134.57)	58,262	59,504	15,119.3
Wegovy, Sinus Tachycardia	761	761	0	0.00 (0.00, 0.00)	66.6	24,319	0.00 (0.00, 0.00)	1,178	1,205	133.2
Saxenda, Sinus Tachycardia	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
Victoza, Sinus Tachycardia	8,683	8,683	20	0.23 (0.13, 0.33)	1,242.1	453,659	161.02 (103.88, 249.59)	12,189	12,192	3,348.0
Trulicity, Sinus Tachycardia	83,649	83,649	128	0.15 (0.13, 0.18)	12,351.1	4,511,231	103.63 (87.15, 123.24)	144,367	145,254	32,354.0
Xultophy, Sinus Tachycardia	594	594	0	0.00 (0.00, 0.00)	95.8	34,996	0.00 (0.00, 0.00)	776	776	224.5
Mounjaro, Supraventricular Tachycardia	22,618	22,618	11	0.05 (0.02, 0.08)	2,589.8	945,940	42.47 (23.52, 76.70)	37,152	37,660	6,401.5
Bydureon, Supraventricular Tachycardia	1,992	1,992	****	****	****	****	36.13 (5.09, 256.52)	3,068	3,068	776.5
Ozempic, Supraventricular Tachycardia	139,413	139,413	87	0.06 (0.05, 0.08)	19,377.6	7,077,673	44.90 (36.39, 55.40)	205,986	206,584	50,802.5
Rybelsus, Supraventricular Tachycardia	39,924	39,924	16	0.04 (0.02, 0.06)	5,491.1	2,005,637	29.14 (17.85, 47.56)	58,262	59,504	15,119.3



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 2. Summary of Exposures	or miceres	t iii tiic itaj	ora serramer	Distributed Database	and Sentin	er Bistributet	Database Holli May 13,	LULL to June 5	, <u> </u>	
			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining-	Number of Exposure Episode Defining-	
				•				_	_	
		Number	Exposure	100 Exposure			Event Rate per 10,000	Dispensings	Dispensings	
	Number	of	Episodes	Episodes (95%	Total		Patient-Years at Risk	(Adjusted for	(Not Adjusted	Total
	of	Exposure	with an	Confidence	Years at	Total Days	(95% Confidence	Same-Day	for Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Wegovy, Supraventricular	761	761	0	0.00 (0.00, 0.00)	66.6	24,319	0.00 (0.00, 0.00)	1,178	1,205	133.2
Tachvcardia										
Saxenda, Supraventricular	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
Tachycardia										
Victoza, Supraventricular	8,683	8,683	****	****	****	****	32.20 (12.09, 85.81)	12,189	12,192	3,348.0
Tachycardia										
Trulicity, Supraventricular	83,649	83,649	51	0.06 (0.04, 0.08)	12,351.1	4,511,231	41.29 (31.38, 54.33)	144,367	145,254	32,354.0
Tachycardia										
Xultophy, Supraventricular	594	594	0	0.00 (0.00, 0.00)	95.8	34,996	0.00 (0.00, 0.00)	776	776	224.5
Tachycardia			ate ale ale ale	****	****	ale ale ale ale ale	(
Mounjaro, Other Tachycardia	22,618	22,618	****	****	****	****	23.17 (10.41, 51.57)	37,152	37,660	6,401.5
Bydureon, Other Tachycardia	1,992	1,992	****	****	****	****	72.27 (18.07, 288.96)	3,068	3,068	776.5
Ozempic, Other Tachycardia	139,413	139,413	59	0.04 (0.03, 0.05)	19,377.6	7,077,673	30.45 (23.59, 39.30)	205,986	206,584	50,802.5
Rybelsus, Other Tachycardia	39,924	39,924	****	****	****	****	16.39 (8.53, 31.50)	58,262	59,504	15,119.3
				,			/			
Wegovy, Other Tachycardia	761	761	0	0.00 (0.00, 0.00)	66.6	24,319	0.00 (0.00, 0.00)	1,178	1,205	133.2
Cayonda Othor Tachyoardia	385	385	0	0.00 (0.00, 0.00)	Г1 С	10 042	0.00 (0.00, 0.00)	590	590	189.6
Saxenda, Other Tachycardia	383	365	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.0
Victoza, Other Tachycardia	8,683	8,683	****	****	****	****	56.36 (26.87, 118.22)	12,189	12,192	3,348.0
Trulicity, Other Tachycardia	83,649	83,649	28	0.03 (0.02, 0.05)	12,351.1	4,511,231	22.67 (15.65, 32.83)	144,367	145,254	32,354.0
Truncity, Other rachycaraia	03,043	05,045	20	0.03 (0.02, 0.03)	12,331.1	4,311,231	22.07 (13.03, 32.03)	144,507	143,234	32,334.0
Xultophy, Other Tachycardia	594	594	****	****	****	****	104.37 (14.70, 740.95)	776	776	224.5
Mauriana Candina Ansat	22.640	22.640	****	****	****	****	2.00/0.54.27.44\	27.452	27.660	C 401 F
Mounjaro, Cardiac Arrest	22,618	22,618	****	****	****	****	3.86 (0.54, 27.41)	37,152	37,660	6,401.5 776.5
Bydureon, Cardiac Arrest	1,992	1,992					36.13 (5.09, 256.52)	3,068	3,068	
Ozempic, Cardiac Arrest Rybelsus, Cardiac Arrest	139,413 39,924	139,413 39,924	21 ****	0.02 (0.01, 0.02) ****	19,377.6 ****	7,077,673 ****	10.84 (7.07, 16.62) 3.64 (0.91, 14.56)	205,986 58,262	206,584 59,504	50,802.5 15,119.3
	39,924 761	39,924 761	0		66.6	24,319		·	·	133.2
Wegovy, Cardiac Arrest	/01	/01	U	0.00 (0.00, 0.00)	0.00	24,319	0.00 (0.00, 0.00)	1,178	1,205	155.2



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Cardiac Arrest	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
Victoza, Cardiac Arrest	8,683	8,683	****	****	****	****	24.15 (7.79, 74.89)	12,189	12,192	3,348.0
Trulicity, Cardiac Arrest	83,649	83,649	14	0.02 (0.01, 0.03)	12,351.1	4,511,231	11.34 (6.71, 19.14)	144,367	145,254	32,354.0
Xultophy, Cardiac Arrest	594	594	0	0.00 (0.00, 0.00)	95.8	34,996	0.00 (0.00, 0.00)	776	776	224.5
Mounjaro, Ventricular	22,618	22,618	0	0.00 (0.00, 0.00)	2,589.8	945,940	0.00 (0.00, 0.00)	37,152	37,660	6,401.5
Tachycardia				, , ,		•			•	
Bydureon, Ventricular	1,992	1,992	0	0.00 (0.00, 0.00)	276.8	101,086	0.00 (0.00, 0.00)	3,068	3,068	776.5
Tachycardia										
Ozempic, Ventricular	139,413	139,413	****	****	****	****	4.13 (2.06, 8.26)	205,986	206,584	50,802.5
Tachycardia										
Rybelsus, Ventricular	39,924	39,924	0	0.00 (0.00, 0.00)	5,491.1	2,005,637	0.00 (0.00, 0.00)	58,262	59,504	15,119.3
Tachycardia										
Wegovy, Ventricular	761	761	0	0.00 (0.00, 0.00)	66.6	24,319	0.00 (0.00, 0.00)	1,178	1,205	133.2
Tachycardia										
Saxenda, Ventricular	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
Tachycardia			4.4.4.4.				(
Victoza, Ventricular	8,683	8,683	****	****	****	****	8.05 (1.13, 57.16)	12,189	12,192	3,348.0
Tachycardia	02.640	02.640	****	****	****	****	2 42 (0 70 7 52)	444.267	4.45.25.4	22.254.0
Trulicity, Ventricular	83,649	83,649	****	<i>ተተተተ</i>	****	****	2.43 (0.78, 7.53)	144,367	145,254	32,354.0
Tachycardia	F04	FO4	0	0.00 (0.00, 0.00)	05.0	24.000	0.00 (0.00, 0.00)	776	77.0	224.5
Xultophy, Ventricular	594	594	0	0.00 (0.00, 0.00)	95.8	34,996	0.00 (0.00, 0.00)	776	776	224.5
Tachycardia Mounjaro, Ventricular	22,618	22,618	****	****	****	****	3.86 (0.54, 27.41)	37,152	37,660	6,401.5
Fibrillation and Flutter	22,010	22,010					3.80 (0.34, 27.41)	37,132	37,000	0,401.5
Bydureon, Ventricular	1,992	1,992	0	0.00 (0.00, 0.00)	276.8	101,086	0.00 (0.00, 0.00)	3,068	3,068	776.5
Fibrillation and Flutter	1,332	1,332	U	0.00 (0.00, 0.00)	270.0	101,000	0.00 (0.00, 0.00)	3,000	3,000	770.5
Ozempic, Ventricular Fibrillation	139,413	139,413	****	****	****	****	2.06 (0.77, 5.50)	205,986	206,584	50,802.5
and Flutter	100,410	100,410					2.00 (0.77, 0.00)	200,000	200,004	30,002.3
Rybelsus, Ventricular	39,924	39,924	0	0.00 (0.00, 0.00)	5,491.1	2,005,637	0.00 (0.00, 0.00)	58,262	59,504	15,119.3
Fibrillation and Flutter	,	,	-	2.22 (2.30) 3.00)	-,	_, , ,	()	/	,	,
Wegovy, Ventricular Fibrillation	761	761	0	0.00 (0.00, 0.00)	66.6	24,319	0.00 (0.00, 0.00)	1,178	1,205	133.2
and Flutter				, ,,		•	, , -,	,	,	



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days	Event Rate per 10,000 Patient-Years at Risk (95% Confidence	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	
	Patients		Event	Interval)	Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Saxenda, Ventricular Fibrillation	385	385	0	0.00 (0.00, 0.00)	51.6	18,842	0.00 (0.00, 0.00)	590	590	189.6
and Flutter			_				,			
Victoza, Ventricular Fibrillation	8,683	8,683	0	0.00 (0.00, 0.00)	1,242.1	453,659	0.00 (0.00, 0.00)	12,189	12,192	3,348.0
and Flutter										
Trulicity, Ventricular Fibrillation	83,649	83,649	****	****	****	****	6.48 (3.24, 12.95)	144,367	145,254	32,354.0
and Flutter										
Xultophy, Ventricular	594	594	0	0.00 (0.00, 0.00)	95.8	34,996	0.00 (0.00, 0.00)	776	776	224.5
Fibrillation and Flutter										

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Bydureon,	Hospitalize	d Tachyarrl	•							
Female	1,038	1,038	****	****	****	****	418.90 (188.19, 932.44)	1,605	1,605	410.6
Male	954	954	****	****	****	****	449.34 (201.87, 1,000.20)	1,463	1,463	365.9
Mounjaro,	Hospitalize	ed Tachyarr								
Female	12,975	12,975	****	****	****	****	344.50 (261.82, 453.30)	21,473	21,773	3,661.9
Male	9,643	9,643	****	****	****	****	549.82 (427.79, 706.65)	15,679	15,887	2,739.6
Ozempic, H	Hospitalized	l Tachyarrh								
Female	77,670	77,670	****	****	****	****	466.61 (427.56, 509.22)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	521.07 (474.98, 571.62)	90,556	90,840	22,330.1
Rybelsus, I	Hospitalized	d Tachyarrh	ythmia							
Female	20,415	20,415	****	****	****	****	372.73 (307.27, 452.13)	29,671	30,252	7,748.7
Male	19,509	19,509	****	****	****	****	425.27 (354.51, 510.14)	28,591	29,252	7,370.6
Saxenda, F	lospitalized	Tachyarrhy	/thmia							
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
Trulicity, H	ospitalized	Tachyarrhy	thmia							
Female	43,453	43,453	****	****	****	****	437.78 (389.31, 492.28)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	590.50 (532.01, 655.43)	69,200	69,642	15,482.1
Victoza, Ho	ospitalized '	Tachyarrhyt	:hmia							
Female	4,941	4,941	****	****	****	****	484.79 (346.40, 678.48)	6,971	6,974	1,924.5
Male	3,742	3,742	****	****	****	****	647.29 (464.75, 901.53)	5,218	5,218	1,423.5
Wegovy, H	ospitalized	Tachyarrhy	thmia							
Female	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Male	250	250	****	****	****	****	445.37 (62.73, 3,161.85)	387	399	43.6
Xultophy,	Hospitalize	d Tachyarrh	ythmia							
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	****	****	****	****	611.19 (197.12, 1,895.09)	400	400	117.1
Mounjaro,	Atrial Fibri	llation and	Flutter							
		12,975	****	****	****	****	175.63 (119.58, 257.95)	21,473	21,773	3,661.9
Female	12,975	12,5/3					173.03 (113.30, 237.33)	21,773	21,773	3,001.3

Page 236 of 990



Table 3. Si	ummary of	Exposures o	of Interest in	n the Rapid Sentinel Distribu	ted Data	base an	d Sentinel Distributed Database	from May 13, 202	2 to June 30, 2023	, by Sex
		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Bydureon	, Atrial Fibri	llation and	Flutter	·			-			
Female	1,038	1,038	****	****	****	****	279.27 (104.81, 744.10)	1,605	1,605	410.6
Male	954	954	****	****	****	****	299.56 (112.43, 798.17)	1,463	1,463	365.9
Ozempic,	Atrial Fibrill	ation and F	lutter							
Female	77,670	77,670	****	****	****	****	266.24 (237.15, 298.89)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	355.91 (318.18, 398.11)	90,556	90,840	22,330.1
Rybelsus,	Atrial Fibrill	lation and F	lutter							
Female	20,415	20,415	****	****	****	****	235.22 (184.45, 299.95)	29,671	30,252	7,748.7
Male	19,509	19,509	****	****	****	****	307.95 (248.66, 381.38)	28,591	29,252	7,370.6
Wegovy, A	Atrial Fibrilla	ation and Fl	utter							
Female	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Male	250	250	****	****	****	****	445.37 (62.73, 3,161.85)	387	399	43.6
Saxenda, A	Atrial Fibrill	ation and F	lutter							
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
Victoza, A	trial Fibrilla	tion and Flu	ıtter							
Female	4,941	4,941	****	****	****	****	270.91 (172.80, 424.73)	6,971	6,974	1,924.5
Male	3,742	3,742	****	****	****	****	462.35 (312.41, 684.25)	5,218	5,218	1,423.5
Trulicity, A	Atrial Fibrilla	ation and Fl	utter							
Female	43,453	43,453	****	****	****	****	298.13 (258.61, 343.68)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	426.57 (377.30, 482.27)	69,200	69,642	15,482.1
Xultophy,	Atrial Fibril	lation and F	lutter							
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	****	****	****	****	407.46 (101.90, 1,629.26)	400	400	117.1
	, Sinus Tach	-								
Female	12,975	12,975	****	****	****	****	121.59 (76.61, 192.99)	21,473	21,773	3,661.9
Male	9,643	9,643	****	****	****	****	144.21 (88.35, 235.40)	15,679	15,887	2,739.6
	, Sinus Tach	ycardia								
Female	1,038	1,038	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,605	1,605	410.6
Male	954	954	****	****	****	****	74.89 (10.55, 531.67)	1,463	1,463	365.9

Page 237 of 990



		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes		Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Ozempic,	Sinus Tachy									
Female	77,670	77,670	****	****	****	****	142.86 (121.99, 167.30)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	101.19 (82.01, 124.85)	90,556	90,840	22,330.1
Rybelsus,	Sinus Tachy	cardia								
Female	20,415	20,415	****	****	****	****	108.56 (75.90, 155.27)	29,671	30,252	7,748.7
Male	19,509	19,509	****	****	****	****	98.98 (67.88, 144.34)	28,591	29,252	7,370.6
Wegovy, S	Sinus Tachyo	cardia								
Female	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Male	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	387	399	43.6
Saxenda, S	Sinus Tachy	cardia								
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
Victoza, Si	inus Tachyc	ardia								
Female	4,941	4,941	****	****	****	****	156.84 (86.86, 283.22)	6,971	6,974	1,924.5
Male	3,742	3,742	****	****	****	****	166.45 (86.60, 319.90)	5,218	5,218	1,423.5
Trulicity, S	Sinus Tachyo	cardia					· · · · · · · · · · · · · · · · · · ·	·	·	
Female	43,453	43,453	****	****	****	****	100.42 (78.60, 128.30)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	107.06 (83.80, 136.78)	69,200	69,642	15,482.1
Xultophy,	Sinus Tachy	/cardia					· · · · · · · · · · · · · · · · · · ·	·	·	
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	117.1
	, Supravent		ycardia	· · ·						
Female	12,975	12,975	****	****	****	****	47.28 (22.54, 99.19)	21,473	21,773	3,661.9
Male	9,643	9,643	****	****	****	****	36.05 (13.53, 96.06)	15,679	15,887	2,739.6
Bydureon	, Supravent	ricular Tach	ycardia							
Female	1,038	1,038	****	****	****	****	69.82 (9.83, 495.66)	1,605	1,605	410.6
Male	954	954	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,463	1,463	365.9
Ozempic,	Supraventri	cular Tachy	cardia	•			· · · · · ·	•	·	
Female	77,670	77,670	****	****	****	****	43.60 (32.76, 58.03)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	46.52 (34.13, 63.43)	90,556	90,840	22,330.1
	- , -	- , -					(//	/	,	,

Page 238 of 990



		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Rybelsus,	Supraventr	icular Tachy								
Female	20,415	20,415	****	****	****	****	28.95 (14.48, 57.89)	29,671	30,252	7,748.7
Male	19,509	19,509	****	****	****	****	29.33 (14.67, 58.65)	28,591	29,252	7,370.6
Wegovy, S	upraventri	cular Tachyo	cardia							
Female	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Male	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	387	399	43.6
Saxenda, S	Supraventri	cular Tachy	cardia							
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
Victoza, Su	upraventric	ular Tachyc	ardia							
Female	4,941	4,941	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,971	6,974	1,924.5
Male	3,742	3,742	****	****	****	****	73.98 (27.76, 197.11)	5,218	5,218	1,423.5
Trulicity, S	upraventri	cular Tachyo	cardia							
Female	43,453	43,453	****	****	****	****	31.38 (20.25, 48.64)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	51.86 (36.47, 73.74)	69,200	69,642	15,482.1
Xultophy,	Supraventr	icular Tachy	/cardia							
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	117.1
Mounjaro	, Other Tacl	hycardia								
Female	12,975	12,975	****	****	****	****	20.26 (6.54, 62.83)	21,473	21,773	3,661.9
Male	9,643	9,643	****	****	****	****	27.04 (8.72, 83.84)	15,679	15,887	2,739.6
Bydureon,	Other Tack	nycardia								
Female	1,038	1,038	****	****	****	****	69.82 (9.83, 495.66)	1,605	1,605	410.6
Male	954	954	****	****	****	****	74.89 (10.55, 531.67)	1,463	1,463	365.9
Ozempic, (Other Tachy	ycardia								
Female	77,670	77,670	****	****	****	****	34.32 (24.87, 47.37)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	25.59 (16.85, 38.86)	90,556	90,840	22,330.1
Rybelsus,	Other Tach									
Female	20,415	20,415	****	****	****	****	10.86 (3.50, 33.66)	29,671	30,252	7,748.7
Male	19,509	19,509	****	****	****	****	22.00 (9.88, 48.96)	28,591	29,252	7,370.6



Female Male Saxenda, C Female Male Victoza, Ot Female Male Trulicity, C Female Male	of	Number of Exposure	Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
Female Male Saxenda, C Female Male Victoza, Ot Female Male Trulicity, C Female Male	Patients	Episodes	Event	(95% Confidence Interval)		•	Interval)	Dispensings)	Dispensings)	Years
Female Male Saxenda, C Female Male Victoza, Ot Female Male Trulicity, C Female Male	Other Tachy	•					,	, ,,	<u> </u>	
Female Male Victoza, Oth Female Male Trulicity, Oth Female Male	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Female Male Victoza, Ot Female Male Trulicity, O Female Male	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	387	399	43.6
Male Victoza, Ot Female Male Trulicity, O Female Male	Other Tachy			•			· , , , , , , , , , , , , , , , , , , ,			
Victoza, Ot Female Male Trulicity, O Female Male	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Female Male Trulicity, O Female Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
Male Trulicity, O Female Male	ther Tachyo	ardia								
Trulicity, O Female Male	4,941	4,941	****	****	****	****	28.52 (7.13, 114.03)	6,971	6,974	1,924.5
Female Male	3,742	3,742	****	****	****	****	92.47 (38.49, 222.16)	5,218	5,218	1,423.5
Male	Other Tachy	cardia								
	43,453	43,453	****	****	****	****	21.97 (13.01, 37.09)	75,167	75,612	16,872.0
Vultanhy	40,196	40,196	****	****	****	****	23.42 (13.87, 39.54)	69,200	69,642	15,482.1
Auitopily,	Other Tach	ycardia								
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	****	****	****	****	203.73 (28.70, 1,446.36)	400	400	117.1
Mounjaro,	, Cardiac Ar	rest								
Female	12,975	12,975	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,473	21,773	3,661.9
Male	9,643	9,643	****	****	****	****	9.01 (1.27, 63.99)	15,679	15,887	2,739.6
Bydureon,	, Cardiac Ar	rest								
Female	1,038	1,038	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,605	1,605	410.6
Male	954	954	****	****	****	****	74.89 (10.55, 531.67)	1,463	1,463	365.9
Ozempic, O	Cardiac Arre	est								
Female	77,670	77,670	****	****	****	****	9.28 (4.99, 17.24)	115,430	115,744	28,472.4
Male	61,743	61,743	11	0.02 (0.01, 0.03)	****	****	12.79 (7.09, 23.10)	90,556	90,840	22,330.1
Rybelsus, (Cardiac Arro	est								
Female	20,415	20,415	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,671	30,252	7,748.7
Male	19,509	19,509	****	****	****	****	7.33 (1.83, 29.32)	28,591	29,252	7,370.6
Wegovy, C	Cardiac Arre									
Female	E11	Г11	^	0.00.(0.00.0.00)	****	****	0.00 (0.00, 0.00)	704	200	00 =
Male	511 250	511 250	0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791 387	806 399	89.5 43.6



		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
	of Datients	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
Savanda (Patients Cardiac Arre	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
	ardiac Arres		<u> </u>	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	140	140	30.2
Female	4,941	4,941	****	****	****	****	42.78 (13.80, 132.63)	6,971	6,974	1,924.5
Male	3,742	3,742	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,218	5,218	1,423.5
	Cardiac Arre	·		0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	3,210	3,210	1,423.3
Female	43,453	43,453	****	****	****	****	9.41 (4.23, 20.96)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	13.38 (6.69, 26.76)	69,200	69,642	15,482.1
	Cardiac Arr						10:00 (0:00) 20:10)	55,255	33,6	20, 10212
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	117.1
Mounjaro	, Ventricula	r Tachycard	lia	, , ,			,			
Female	12,975	12,975	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,473	21,773	3,661.9
Male	9,643	9,643	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15,679	15,887	2,739.6
Bydureon,	Ventricula	r Tachycard	ia							
Female	1,038	1,038	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,605	1,605	410.6
Male	954	954	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,463	1,463	365.9
Ozempic, \	Ventricular	Tachycardia	9							
Female	77,670	77,670	****	****	****	****	3.71 (1.39, 9.89)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	4.65 (1.75, 12.40)	90,556	90,840	22,330.1
Rybelsus, '	Ventricular	Tachycardia	a							
Female	20,415	20,415	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,671	30,252	7,748.7
Male	19,509	19,509	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28,591	29,252	7,370.6
		Tachycardia								
Female	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Male	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	387	399	43.6
		Tachycardia								
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2



		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Victoza, V	entricular T	achycardia								
Female	4,941	4,941	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,971	6,974	1,924.5
Male	3,742	3,742	****	****	****	****	18.49 (2.61, 131.29)	5,218	5,218	1,423.5
Trulicity, V	entricular ⁻	Tachycardia								
Female	43,453	43,453	****	****	****	****	1.57 (0.22, 11.14)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	3.35 (0.84, 13.38)	69,200	69,642	15,482.1
Xultophy,	Ventricular	Tachycardi	a							
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	117.1
Mounjaro,	, Ventricula	r Fibrillation	n and Flutte	er						
Female	12,975	12,975	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,473	21,773	3,661.9
Male	9,643	9,643	****	****	****	****	9.01 (1.27, 63.99)	15,679	15,887	2,739.6
Bydureon,	Ventricula	r Fibrillation	and Flutte	r						
Female	1,038	1,038	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,605	1,605	410.6
Male	954	954	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,463	1,463	365.9
Ozempic, \	Ventricular	Fibrillation	and Flutter							
Female	77,670	77,670	****	****	****	****	1.86 (0.46, 7.42)	115,430	115,744	28,472.4
Male	61,743	61,743	****	****	****	****	2.33 (0.58, 9.30)	90,556	90,840	22,330.1
Rybelsus, '	Ventricular	Fibrillation	and Flutter							
Female	20,415	20,415	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,671	30,252	7,748.7
Male	19,509	19,509	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28,591	29,252	7,370.6
Wegovy, V	entricular l	Fibrillation a	and Flutter							
Female	511	511	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	791	806	89.5
Male	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	387	399	43.6
Saxenda, \	/entricular	Fibrillation a	and Flutter							
Female	289	289	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	444	444	139.4
Male	96	96	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	50.2
Victoza, V	entricular F	ibrillation a	nd Flutter							
Female	4,941	4,941	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,971	6,974	1,924.5
Male	3,742	3,742	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,218	5,218	1,423.5



Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

								Number of	Number of	
			Number					Exposure Episode	Exposure	
			of					Defining-	Episode Defining	
		Number	Exposure	Number of Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Trulicity, V	entricular f	ibrillation a	nd Flutter							
Female	43,453	43,453	****	****	****	****	4.71 (1.52, 14.60)	75,167	75,612	16,872.0
Male	40,196	40,196	****	****	****	****	8.36 (3.48, 20.10)	69,200	69,642	15,482.1
Xultophy,	Ventricular	Fibrillation	and Flutter	•						
Female	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	107.3
Male	311	311	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	117.1

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
			Number of	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings	
		Number	Exposure	Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of		with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Exposure			Risk	Risk	·	•	-	
Bydureon, Hospitalized		Episodes	Event	Interval)	RISK	KISK	Interval)	Dispensings)	Dispensings)	Years
0-40 years	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	156	50.8
•	700	700	****	****		****				288.6
41-64 years	700 874	700 874	****	****		****	441.43 (165.67, 1,176.17) 297.20 (111.54, 791.89)	1,071	1,071	332.0
65-74 years 75-84 years	874 288	874 288	****	****	****	****	779.12 (251.28, 2,415.76)	1,394 418	1,394 418	97.5
75-64 years ≥ 85 years	200	200	****	****	****	****	• • • • • • • • • • • • • • • • • • • •	29	29	
Mounjaro, Hospitalized							5,324.34 (749.98, 37,799.26)	29	29	7.6
0-40 years	1,301	1,301	****	****	****	****	69.11 (9.73, 490.60)	2,178	2,206	362.4
41-64 years	11,248	11,248	****	****	****	****	350.61 (262.62, 468.10)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****	****	****	568.38 (431.96, 747.88)	12,605	12,817	2,164.2
75-84 years	2,091	2,091	****	****	****	****	532.84 (302.60, 938.26)	3,184	3,227	545.5
≥ 85 years	102	102	****	****	****	****	1,876.93 (469.40, 7,504.97)	148	150	22.2
Ozempic, Hospitalized							1,870.33 (403.40, 7,304.37)	140	130	22.2
0-40 years	6,619	6,619	****	****	****	****	288.34 (193.26, 430.19)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****	****	****	357.50 (318.82, 400.87)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****	****	****	516.33 (468.19, 569.43)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****	****	****	876.54 (765.65, 1,003.48)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	****	****	****	****	1,228.09 (816.09, 1,848.08)	2,014	2,017	496.6
Rybelsus, Hospitalized							1,220.03 (010.03, 1,040.00)	2,014	2,017	430.0
0-40 years	1,393	1,393	****	****	****	****	345.08 (155.03, 768.12)	2,002	2,044	528.5
41-64 years	14,438	14,438	****	****	****	****	242.01 (182.38, 321.14)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	****	****	****	****	336.72 (269.32, 420.99)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	****	****	****	****	761.62 (602.55, 962.67)	9,833	10,009	2,414.4
≥ 85 years	969	969	****	****	****	****	1,405.92 (885.78, 2,231.49)	1,457	1,471	340.1
Saxenda, Hospitalized										
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	104	104	34.0
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
75-84 years	Number of Patients ****	Number of Exposure Episodes ****	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) 0.00 (0.00, 0.00)	Total Years at Risk *****	Total Days at Risk ****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval) 0.00 (0.00, 0.00)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings) *****	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings) *****	Total Observable Years 2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Trulicity, Hospitalized	d Tachyarrhythi	mia								
0-40 years 41-64 years	3,051 29,900	3,051 29,900	*****	****		*****	285.57 (162.18, 502.86) 346.84 (296.46, 405.77)	5,294 53,420	5,329 53,797	1,207.6 12,119.9
65-74 years 75-84 years	34,943 13,927	34,943 13,927	***** ****	**** **** ****	****	***** *****	514.36 (456.22, 579.91) 838.97 (721.23, 975.93)	59,342 23,161	59,692 23,275	13,213.7 5,172.5
≥ 85 years	1,828	1,828	****	****	****	****	1,210.16 (840.96, 1,741.44)	3,150	3,161	640.4
Victoza, Hospitalized	400	400	****	****	****	****	186.67 (26.29, 1,325.21)	603	603	167.6
0-40 years 41-64 years 65-74 years 75-84 years	3,316 3,492 1,326	3,316 3,492 1,326	**** ****	***** *****	*****	**** ****	434.32 (280.20, 673.21) 539.69 (372.63, 781.64) 996.60 (635.68, 1,562.45)	4,788 4,824 1,773	4,789 4,826 1,773	1,344.9 1,316.8 467.3
≥ 85 years	149	149	****	****	****	****	539.83 (76.04, 3,832.44)	201	201	51.3
Wegovy, Hospitalized										3 = 13
0-40 years 41-64 years 65-74 years 75-84 years	113 575 62 ****	113 575 62 ****	0 0 *****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00)	***** ***** ****		0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 1,538.54 (216.72, 10,922.62) 0.00 (0.00, 0.00)	157 890 112 ****	164 905 116 ****	17.3 102.3 10.8 1.8
, ≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Xultophy, Hospitalize	d Tachyarrhyth	nmia					, ,			
0-40 years 41-64 years 65-74 years 75-84 years	12 143 308 116 15	12 143 308 116 15	0 0 **** ****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00) ***** *****	*****	**** **** **** ****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 189.40 (26.68, 1,344.58) 1,101.81 (275.55, 4,405.63) 0.00 (0.00, 0.00)	13 179 410 154 20	13 179 410 154 20	5.5 55.1 121.0 36.3 6.5
≥ 85 years Mounjaro, Atrial Fibr			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	20	20	0.5
0-40 years	1,301	1,301	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,178	2,206	362.4



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of Patients	Number of Exposure Episodes	Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	11,248	11,248	****				198.17 (134.93, 291.06)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****		****	334.34 (233.76, 478.19)	12,605	12,817	2,164.2
75-84 years	2,091	2,091	****	****		****	488.44 (270.49, 881.99)	3,184	3,227	545.5
≥ 85 years	102	102	****	****	****	****	938.46 (132.19, 6,662.46)	148	150	22.2
Bydureon, Atrial Fibrilla										
0-40 years	108	108	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	156	156	50.8
41-64 years	700	700	****	****		****	331.07 (106.78, 1,026.53)	1,071	1,071	288.6
65-74 years	874	874	****	****		****	222.90 (71.89, 691.14)	1,394	1,394	332.0
75-84 years	288	288	****	****		****	259.71 (36.58, 1,843.74)	418	418	97.5
≥ 85 years	22	22	****	****	****	****	5,324.34 (749.98, 37,799.26)	29	29	7.6
Ozempic, Atrial Fibrillati										
0-40 years	6,619	6,619	****	****		****	24.03 (6.01, 96.08)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****		****	170.82 (144.74, 201.59)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****		****	345.08 (306.14, 388.97)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****	****	****	684.53 (587.39, 797.74)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	****	****	****	****	1,014.51 (647.10, 1,590.52)	2,014	2,017	496.6
Rybelsus, Atrial Fibrillati										
0-40 years	1,393	1,393	****	****	****		57.51 (8.10, 408.31)	2,002	2,044	528.5
41-64 years	14,438	14,438	****	****	****	****	126.05 (85.17, 186.54)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	****	****	****	****	236.14 (180.86, 308.33)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	****	****		****	598.41 (459.43, 779.43)	9,833	10,009	2,414.4
≥ 85 years	969	969	****	****	****	****	1,093.49 (647.62, 1,846.35)	1,457	1,471	340.1
Wegovy, Atrial Fibrillation	on and Flutte									
0-40 years	113	113	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	157	164	17.3
41-64 years	575	575	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	890	905	102.3
65-74 years	62	62	****	****	****	****	1,538.54 (216.72, 10,922.62)	112	116	10.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Atrial Fibrillat	tion and Flutt	er:					·			
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	104	104	34.0
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial Fibrillati	on and Flutte	r								
0-40 years	400	400	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	603	603	167.6
41-64 years	3,316	3,316	****	****	****	****	217.16 (116.84, 403.61)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	****	****	****	****	346.94 (218.59, 550.67)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	****	****	****	****	839.25 (514.14, 1,369.91)	1,773	1,773	467.3
≥ 85 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	51.3
Trulicity, Atrial Fibrillat										
0-40 years	3,051	3,051	****	****		****	71.39 (23.03, 221.37)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****		****	182.31 (146.83, 226.37)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****	****	379.51 (330.04, 436.38)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	****	****	****	****	679.16 (574.09, 803.46)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	****	****	****	****	1,126.70 (772.66, 1,642.95)	3,150	3,161	640.4
Xultophy, Atrial Fibrilla										
0-40 years	12	12	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	****	****		****	189.40 (26.68, 1,344.58)	410	410	121.0
75-84 years	116	116	****	****		****	550.90 (77.60, 3,911.05)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5
Mounjaro, Sinus Tachy										
0-40 years	1,301	1,301	****	****	****		69.11 (9.73, 490.60)	2,178	2,206	362.4
41-64 years	11,248	11,248	****	****		****	137.20 (86.44, 217.76)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****	****	****	144.88 (84.12, 249.51)	12,605	12,817	2,164.2



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
								Number of	Number of	
				Number of				Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with an				Defining-	Defining-	
			of	Event per 100				Dispensings	Dispensings	
		Number	Exposure	Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	•	Years
75-84 years	2,091	2,091	****	****	****	****	44.40 (6.25, 315.24)	3,184	3,227	545.5
≥ 85 years	102	102	****	****	****	****	938.46 (132.19, 6,662.46)	148	150	22.2
Bydureon, Sinus Tachy	cardia									
0-40 years	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	156	50.8
41-64 years	700	700	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	288.6
65-74 years	874	874	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,394	1,394	332.0
75-84 years	288	288	****	****		****	259.71 (36.58, 1,843.74)	418	418	97.5
≥ 85 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	7.6
Ozempic, Sinus Tachyc										
0-40 years	6,619	6,619	****	****		****	252.30 (164.50, 386.96)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****		****	141.53 (117.99, 169.78)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****		****	99.15 (79.30, 123.96)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****		****	112.70 (77.29, 164.34)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,014	2,017	496.6
Rybelsus, Sinus Tachyo										
0-40 years	1,393	1,393	****	****		****	287.57 (119.69, 690.90)	2,002	2,044	528.5
41-64 years	14,438	14,438	****	****		****	105.88 (69.03, 162.39)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	****	****		****	78.71 (49.59, 124.94)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	****	****		****	130.56 (74.15, 229.90)	9,833	10,009	2,414.4
≥ 85 years	969	969	****	****	****	****	78.11 (11.00, 554.50)	1,457	1,471	340.1
Wegovy, Sinus Tachyca										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	157	164	17.3
41-64 years	575	575	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	890	905	102.3
65-74 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	116	10.8
75-84 years	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	1.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Sinus Tachyc	ardia									



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	104	104	34.0
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus Tachycard	ia									
0-40 years	400	400	****	****	****	****	186.67 (26.29, 1,325.21)	603	603	167.6
41-64 years	3,316	3,316	****	****	****	****	173.73 (86.88, 347.39)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	****	****	****	****	134.92 (64.32, 283.02)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	****	****	****	****	209.81 (78.74, 559.03)	1,773	1,773	467.3
≥ 85 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	51.3
Trulicity, Sinus Tachycard	dia									
0-40 years	3,051	3,051	****	****	****	****	190.38 (95.21, 380.70)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****	****	****	122.28 (93.88, 159.27)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****	****	90.54 (68.03, 120.51)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	****	****	****	****	89.89 (56.63, 142.67)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,150	3,161	640.4
Xultophy, Sinus Tachycar										
0-40 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	121.0
75-84 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5
Mounjaro, Supraventricu										
0-40 years	1,301	1,301	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	2,178	2,206	362.4
41-64 years	11,248	11,248	****	****		****	38.11 (15.86, 91.56)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****	****	****	66.87 (30.04, 148.84)	12,605	12,817	2,164.2



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
				Number of				Number of Exposure	Number of Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with an				Defining-	Defining-	
			of	Event per 100				Dispensings	Dispensings	
		Number		Exposure	Total	Total		(Adjusted	(Not	
	Number	Number of	Exposure	•			Format Bata was 40 000 Batisast	•	•	T-4-1
			Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk ****	Risk ****	Interval)	Dispensings)	Dispensings)	Years
75-84 years	2,091	2,091	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	3,184	3,227	545.5
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	148	150	22.2
Bydureon, Supraventric										
0-40 years	108	108	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	156	156	50.8
41-64 years	700	700	****	****	****		110.36 (15.54, 783.46)	1,071	1,071	288.6
65-74 years	874	874	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,394	1,394	332.0
75-84 years	288	288	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	418	418	97.5
≥ 85 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	7.6
Ozempic, Supraventricu	lar Tachycar									
0-40 years	6,619	6,619	****	****	****		12.01 (1.69, 85.29)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****	****	****	25.62 (16.71, 39.30)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****	****	****	60.52 (45.47, 80.55)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****	****	****	70.96 (44.11, 114.14)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	****	****	****	****	53.40 (7.52, 379.07)	2,014	2,017	496.6
Rybelsus, Supraventricu	lar Tachycar	dia								
0-40 years	1,393	1,393	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,002	2,044	528.5
41-64 years	14,438	14,438	****	****	****	****	20.17 (7.57, 53.74)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	****	****	****	****	26.24 (11.79, 58.40)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	****	****	****	****	43.52 (16.33, 115.96)	9,833	10,009	2,414.4
≥ 85 years	969	969	****	****	****	****	156.21 (39.07, 624.62)	1,457	1,471	340.1
Wegovy, Supraventricul	ar Tachycard	dia								
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	164	17.3
41-64 years	575	575	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	890	905	102.3
65-74 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	116	10.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Supraventricul	ar Tachycar	dia								



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	104	104	34.0
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supraventricular	r Tachycard	ia								
0-40 years	400	400	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	603	603	167.6
41-64 years	3,316	3,316	****	****	****	****	21.72 (3.06, 154.17)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	****	****	****	****	19.27 (2.71, 136.84)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	****	****	****	****	104.91 (26.24, 419.47)	1,773	1,773	467.3
≥ 85 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	51.3
Trulicity, Supraventricula	r Tachycar	dia								
0-40 years	3,051	3,051	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****	****	****	33.35 (20.11, 55.32)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****	****	36.60 (23.35, 57.38)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	****	****	****	****	69.91 (41.41, 118.05)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	****	****	****	****	125.19 (40.38, 388.16)	3,150	3,161	640.4
Xultophy, Supraventricul	lar Tachyca	rdia								
0-40 years	12	12	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	121.0
75-84 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5
Mounjaro, Other Tachyca										
0-40 years	1,301	1,301	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	2,178	2,206	362.4
41-64 years	11,248	11,248	****	****		****	7.62 (1.07, 54.11)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****	****	****	55.72 (23.19, 133.88)	12,605	12,817	2,164.2

cder_mpl1p_wp077 Page 251 of 990



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days at	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	2,091	2,091	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,184	3,227	545.5
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	148	150	22.2
Bydureon, Other Tachyca	ardia									
0-40 years	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	156	50.8
41-64 years	700	700	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	288.6
65-74 years	874	874	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,394	1,394	332.0
75-84 years	288	288	****	****	****	****	519.41 (129.90, 2,076.89)	418	418	97.5
≥ 85 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	7.6
Ozempic, Other Tachyca	rdia									
0-40 years	6,619	6,619	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****	****	****	25.62 (16.71, 39.30)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****	****	****	30.90 (20.71, 46.11)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****	****	****	45.91 (25.43, 82.91)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	****	****	****	****	160.19 (51.66, 496.68)	2,014	2,017	496.6
Rybelsus, Other Tachyca	rdia									
0-40 years	1,393	1,393	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,002	2,044	528.5
41-64 years	14,438	14,438	****	****	****		10.08 (2.52, 40.32)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	****	****	****	****	4.37 (0.62, 31.05)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	****	****	****	****	43.52 (16.33, 115.96)	9,833	10,009	2,414.4
≥ 85 years	969	969	****	****	****	****	156.21 (39.07, 624.62)	1,457	1,471	340.1
Wegovy, Other Tachycar	dia									
0-40 years	113	113	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	157	164	17.3
41-64 years	575	575	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	890	905	102.3
65-74 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	116	10.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	1.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Other Tachycar	rdia									



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	104	104	34.0
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other Tachycard	lia									
0-40 years	400	400	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	603	603	167.6
41-64 years	3,316	3,316	****	****	****	****	21.72 (3.06, 154.17)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	****	****	****	****	38.55 (9.64 <i>,</i> 154.14)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	****	****	****	****	157.36 (50.75, 487.91)	1,773	1,773	467.3
≥ 85 years	149	149	****	****	****	****	539.83 (76.04, 3,832.44)	201	201	51.3
Trulicity, Other Tachycar	dia									
0-40 years	3,051	3,051	****	****	****	****	47.60 (11.90, 190.31)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****	****	****	4.45 (1.11, 17.78)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****	****	36.60 (23.35, 57.38)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	****	****	****	****	24.97 (10.39, 59.99)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,150	3,161	640.4
Xultophy, Other Tachyca	rdia									
0-40 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	121.0
75-84 years	116	116	****	****	****	****	550.90 (77.60, 3,911.05)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5
Mounjaro, Cardiac Arres										
0-40 years	1,301	1,301	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	2,178	2,206	362.4
41-64 years	11,248	11,248	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****	****	****	11.14 (1.57, 79.12)	12,605	12,817	2,164.2

cder_mpl1p_wp077 Page 253 of 990



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
				Number of				Number of Exposure	Number of Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with an				Defining-	Defining-	
			of	Event per 100				Dispensings	Dispensings	
		Number	Exposure	Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	2,091	2,091	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	3,184	3,227	545.5
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	148	150	22.2
Bydureon, Cardiac Arrest	•									
0-40 years	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	156	50.8
41-64 years	700	700	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	288.6
65-74 years	874	874	****	****	****	****	74.30 (10.47, 527.49)	1,394	1,394	332.0
75-84 years	288	288	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	418	418	97.5
≥ 85 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	7.6
Ozempic, Cardiac Arrest										
0-40 years	6,619	6,619	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****	****	****	7.32 (3.29, 16.30)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****	****	****	12.88 (6.93, 23.93)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****	****	****	16.70 (6.27, 44.49)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	****	****	****	****	53.40 (7.52, 379.07)	2,014	2,017	496.6
Rybelsus, Cardiac Arrest										
0-40 years	1,393	1,393	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,002	2,044	528.5
41-64 years	14,438	14,438	****	****		****	5.04 (0.71, 35.79)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	****	****	****		4.37 (0.62, 31.05)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	9,833	10,009	2,414.4
≥ 85 years	969	969	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,457	1,471	340.1
Wegovy, Cardiac Arrest										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	164	17.3
41-64 years	575	575	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	890	905	102.3
65-74 years	62	62	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	112	116	10.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Cardiac Arrest										
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	104	104	34.0



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
			Number of	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings	
		Number	Exposure	Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	-	Years
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardiac Arrest										
0-40 years	400	400	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	603	603	167.6
41-64 years	3,316	3,316	****	****	****	****	21.72 (3.06, 154.17)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	****	****	****	****	38.55 (9.64 <i>,</i> 154.14)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,773	1,773	467.3
≥ 85 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	51.3
Trulicity, Cardiac Arrest										
0-40 years	3,051	3,051	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****	****	****	6.67 (2.15, 20.68)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****	****	9.63 (4.01, 23.14)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	****	****	****	****	29.96 (13.46, 66.70)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,150	3,161	640.4
Xultophy, Cardiac Arrest										
0-40 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	121.0
75-84 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5
Mounjaro, Ventricular T	achycardia									
0-40 years	1,301	1,301	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,178	2,206	362.4
41-64 years	11,248	11,248	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,605	12,817	2,164.2
75-84 years	2,091	2,091	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,184	3,227	545.5
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	148	150	22.2



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
				Number of				Number of Exposure	Number of Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with an				Defining-	Defining-	
			of	Event per 100				Dispensings	Dispensings	
		Number	Exposure	Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	•	Years
Bydureon, Ventricular 1		Lpisoucs	LVCIIC	meervary	Kisk	MISK	interval)	Dispensings	Disperisings	rears
0-40 years	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	156	50.8
41-64 years	700	700	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	288.6
65-74 years	874	874	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,394	1,394	332.0
75-84 years	288	288	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	418	418	97.5
≥ 85 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	7.6
Ozempic, Ventricular Ta	chycardia						·			
0-40 years	6,619	6,619	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,662	9,693	2,399.1
41-64 years	59,783	59,783	****	****	****	****	2.44 (0.61, 9.76)	90,137	90,414	22,461.7
65-74 years	54,245	54,245	****	****	****	****	5.15 (1.93, 13.72)	79,691	79,912	19,325.0
75-84 years	17,331	17,331	****	****	****	****	8.35 (2.09, 33.38)	24,482	24,548	6,120.1
≥ 85 years	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,014	2,017	496.6
Rybelsus, Ventricular Ta	achycardia									
0-40 years	1,393	1,393	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,002	2,044	528.5
41-64 years	14,438	14,438	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,188	21,691	5,773.7
65-74 years	16,358	16,358	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	23,782	24,289	6,062.5
75-84 years	6,766	6,766	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	9,833	10,009	2,414.4
≥ 85 years	969	969	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,457	1,471	340.1
Wegovy, Ventricular Ta	-									
0-40 years	113	113	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	157	164	17.3
41-64 years	575	575	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	890	905	102.3
65-74 years	62	62	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	112	116	10.8
75-84 years	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	1.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Ventricular Ta	-		_		ale ale at at at	ale ale ale ale ale				
0-40 years	70	70	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	104	104	34.0
41-64 years	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5

Page 256 of 990



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Ta	-				at at at at at	district district				
0-40 years	400	400	0 ****	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	603	603	167.6
41-64 years	3,316	3,316			****	****	21.72 (3.06, 154.17)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,773	1,773	467.3
≥ 85 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	51.3
Trulicity, Ventricular Ta					at at at at at	district district				
0-40 years	3,051	3,051	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****		****	2.22 (0.31, 15.78)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****		3.85 (0.96, 15.41)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,150	3,161	640.4
Xultophy, Ventricular T										
0-40 years	12	12	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	121.0
75-84 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5
Mounjaro, Ventricular										
0-40 years	1,301	1,301	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,178	2,206	362.4
41-64 years	11,248	11,248	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,037	19,260	3,307.1
65-74 years	7,876	7,876	****	****	****	****	11.14 (1.57, 79.12)	12,605	12,817	2,164.2
75-84 years	2,091	2,091	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,184	3,227	545.5
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	148	150	22.2

cder_mpl1p_wp077 Page 257 of 990



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
ibrillation ar	nd Flutter								
108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	156	50.8
700	700	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	288.6
874	874	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,394	1,394	332.0
		0	• • • • •	****	****		418	418	97.5
		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	7.6
orillation and	d Flutter								
6,619	6,619	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,662	9,693	2,399.1
				****		• • • •		•	22,461.7
		****		****					19,325.0
•		0	, , ,	****	****	• • •		•	6,120.1
		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,014	2,017	496.6
•	•	0	, , ,			, , ,	•	•	528.5
	-		•			• • •		•	5,773.7
	•		, , ,						6,062.5
•	•		, , ,				-	•	2,414.4
		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,457	1,471	340.1
			• • • •			· · · · · · · · · · · · · · · · · · ·			17.3
			, , ,	****	****	• • •			102.3
			, , ,	****	****	• • •			10.8
				****	****				1.8
		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
					did to to the				
			• • • •			· · · · · · · · · · · · · · · · · · ·		_	34.0
295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	454	454	142.5
	of Patients ibrillation ar 108 700 874 288 22 orillation and 6,619 59,783 54,245 17,331 1,435 orillation and 1,393 14,438 16,358 6,766 969 orillation and 113 575 62 ***** *****	Number of of Exposure Patients Exposure Episodes ibrillation and Flutter 108 108 700 700 874 874 288 28 22 22 crillation and Flutter 6,619 6,619 59,783 59,783 54,245 17,331 17,331 17,331 17,331 1,435 14435 14435 14,438 14,438 16,358 6,766 969 969 1113 113 575 575 62 62 ****** ***** ***** ****** ***** ***** ***** ***** ***** ***** ***** ***** <td> Number of Exposure Episodes with an </td> <td> Number Seposure Seposure </td> <td> Number of Exposure Number of Exposure Exposure Total </td> <td> Number Seposure Number Seposure Se</td> <td> Number Septender Number Septender Septender</td> <td> Number Number Exposure Fisodes with an of positions Exposure Fisodes with an of positions Exposure Fisodes with an of positions Exposure Exposure</td> <td> Number Fire Fire</td>	Number of Exposure Episodes with an	Number Seposure Seposure	Number of Exposure Number of Exposure Exposure Total	Number Seposure Number Seposure Se	Number Septender Number Septender Septender	Number Number Exposure Fisodes with an of positions Exposure Fisodes with an of positions Exposure Fisodes with an of positions Exposure Exposure	Number Fire Fire



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Group										
								Number of	Number of	
				Number of				Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with an				Defining-	Defining-	
			of	Event per 100				Dispensings	Dispensings	
		Number	Exposure	Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Fibr	illation and	Flutter								
0-40 years	400	400	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	603	603	167.6
41-64 years	3,316	3,316	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,788	4,789	1,344.9
65-74 years	3,492	3,492	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,824	4,826	1,316.8
75-84 years	1,326	1,326	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,773	1,773	467.3
≥ 85 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	51.3
Trulicity, Ventricular Fib		l Flutter								
0-40 years	3,051	3,051	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,294	5,329	1,207.6
41-64 years	29,900	29,900	****	****	****	****	8.89 (3.34, 23.70)	53,420	53,797	12,119.9
65-74 years	34,943	34,943	****	****	****	****	5.78 (1.86, 17.92)	59,342	59,692	13,213.7
75-84 years	13,927	13,927	****	****	****	****	4.99 (0.70, 35.45)	23,161	23,275	5,172.5
≥ 85 years	1,828	1,828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,150	3,161	640.4
Xultophy, Ventricular Fi	brillation an									
0-40 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	5.5
41-64 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	179	179	55.1
65-74 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	121.0
75-84 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	154	36.3
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	6.5

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

cder_mpl1p_wp077 Page 259 of 990



		Number	Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
-	, Hospitalize									
2022	1,642	1,642	****	****	****	****	375.37 (195.31, 721.44)	2,587	2,587	711.1
2023	350	350	****	****	****	****	810.89 (261.52, 2,514.26)	481	481	65.4
Mounjaro	, Hospitalize		•							
2022	11,647	11,647	****	****	****	****	382.67 (295.17, 496.10)	19,952	20,185	4,546.2
2023	10,971	10,971	****	****	****	****	499.86 (383.77, 651.07)	17,200	17,475	1,855.3
Ozempic,	Hospitalized	d Tachyarrh	ythmia							
2022	94,901	94,901	****	****	****	****	498.88 (464.11, 536.26)	146,987	147,344	43,770.8
2023	44,512	44,512	****	****	****	****	464.90 (406.73, 531.39)	58,999	59,240	7,031.7
Rybelsus,	Hospitalized	d Tachyarrh	ythmia							
2022	29,615	29,615	****	****	****	****	384.64 (330.81, 447.23)	44,844	45,708	13,315.3
2023	10,309	10,309	****	****	****	****	455.63 (345.33, 601.16)	13,418	13,796	1,804.0
Saxenda, I	Hospitalized	l Tachyarrhy	/thmia							
2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8
Trulicity, F	- lospitalized	Tachyarrhy	rthmia							
2022	65,426	65,426	****	****	****	****	500.79 (459.35, 545.97)	117,013	117,680	29,015.4
2023	18,223	18,223	****	****	****	****	565.95 (472.15, 678.38)	27,354	27,574	3,338.6
Victoza, H	ospitalized '	Tachyarrhyt	hmia							
2022	6,702	6,702	****	****	****	****	535.18 (409.89, 698.78)	9,650	9,652	2,953.8
2023	1,981	1,981	****	****	****	****	643.64 (388.03, 1,067.65)	2,539	2,540	394.1
	lospitalized		rthmia				, , , ,			
2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
2023	675	675	****	****	****	****	172.77 (24.34, 1,226.54)	1,050	1,077	85.6
Xultophy,	Hospitalize	d Tachyarrh	ythmia							
2022	381	381	****	****	****	****	298.37 (74.62, 1,193.05)	501	501	183.4
2023	213	213	****	****	****	****	347.43 (48.94, 2,466.50)	275	275	41.1
		llation and	Flutter				, , , , , =1			
iviouniaro										
2022	11,647	11,647	****	****	****	****	234.97 (168.71, 327.26)	19,952	20,185	4,546.2



Patients Episodes Event Event (95% Confidence Interval) at Risk at Risk Interval) Dispensings) Year			Number	Number of Exposure	Number of Exposure			d Sentinel Distributed Database	Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
Patients Episodes Event (95% Confidence Interval) at Risk at Risk Interval) Dispensings Dispensings Year		Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
Bydureon, Atrial Fibrillation and Flutter 2022 1,642 1			-		•		-	•	•	•	Observable
2022			_		(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
2022 350 350 **** **** ******	_	•									
Compiler Atrial Fibrillation and Flutter Compiler Atrial Fibrill		•						• • • • • • • • • • • • • • • • • • • •	•	•	711.1
2022 94,901 94,901 ***** ***** ***** ***** 325.36 (297.51, 355.81) 146,987 147,344 43,77 2023 44,512 44,512 ***** ***** ***** 244.34 (203.20, 293.82) 58,999 59,240 7,03					****	****	****	810.89 (261.52, 2,514.26)	481	481	65.4
2022 44,512 44,512 ***** **** ***** 244,34 (203.20, 293.82) 58,999 59,240 7,03 Rybelsus, Atrial Fibrillation and Flutter 2022 29,615 29,615 ***** ***** ***** 288.56 (224.23, 321.67) 44,844 45,708 13,33 2023 10,309 10,309 ***** ***** ***** 282.49 (198.66, 401.68) 13,418 13,796 1,80 Wegovy, Atrial Fibrillation and Flutter 2022 86 86 0 0 0.00 (0.00,0.00) ***** ***** 172.77 (24.34, 1,226.54) 1,050 1,077 85 Saxenda, Atrial Fibrillation and Flutter 2022 327 327 0 0.000 (0.00,0.00) ***** ***** 0.00 (0.00,0.00) 74 74 74 8. Victoza, Atrial Fibrillation and Flutter 2023 58 58 0 0.000 (0.00,0.00) ***** ***** 0.00 (0.00,0.00) 74 74 74 8. Victoza, Atrial Fibrillation and Flutter 2022 6,702 6,702 ***** ***** ***** 346.88 (249.05, 483.12) 9,650 9,652 2,955 2023 1,981 1,981 ***** ***** ***** 386.19 (200.94, 742.22) 2,539 2,540 394 Trulicity, Atrial Fibrillation and Flutter 2022 65,426 65,426 ***** ***** ***** ***** 357.85 (323.09, 396.34) 117,013 117,680 29,03 2023 18,223 18,223 ***** ***** ***** ***** 372.46 (297.90, 465.68) 27,354 27,574 3,33 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 ***** ***** ***** ***** 149.19 (21.01, 1,059.11) 501 501 183 2023 19,471 11,647 ***** ***** ****** ****** ****** 149.19 (21.01, 1,059.11) 501 501 183 2023 10,971 10,971 ***** ***** ****** ****** ****** ******											
Rybelsus, Atrial Fibrillation and Flutter 2022	-	•						• • • • • • • • • • • • • • • • • • • •	•	•	43,770.8
2022 29,615 29,615 ***** ***** ***** ***** 268.56 (224.23, 321.67) 44,844 45,708 13,33 2023 10,309 10,309 ***** ***** ***** ***** 282.49 (198.66, 401.68) 13,418 13,796 1,80					****	****	****	244.34 (203.20, 293.82)	58,999	59,240	7,031.7
2022 10,309 10,309 ***** ***** ***** 282.49 (198.66, 401.68) 13,418 13,796 1,80 Wegovy, Atrial Fibrillation and Flutter 2022 86 86 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 128 47 2023 675 675 ***** ***** ***** ***** 172.77 (24.34, 1,226.54) 1,050 1,077 85 Saxenda, Atrial Fibrillation and Flutter 2022 327 327 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 516 516 180 2023 58 58 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 74 74 8. Victoza, Atrial Fibrillation and Flutter 2022 67,702 6,702 ***** ***** ***** 346.88 (249.05, 483.12) 9,650 9,652 2,95 2023 1,981 1,981 ***** ***** ***** 386.19 (200.94, 742.22) 2,539 2,540 394 Trulicity, Atrial Fibrillation and Flutter 2022 65,426 65,426 ***** ***** ***** ***** 357.85 (323.09, 396.34) 117,013 117,680 29,03 2023 18,223 18,223 ***** ***** ***** ***** ***** 372.46 (297.90, 465.68) 27,354 27,574 3,333 Kultophy, Atrial Fibrillation and Flutter 2022 381 381 ***** ***** ***** ***** ***** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 ***** ***** ***** ***** ***** ***** ****	Rybelsus,	Atrial Fibrill	ation and F								
Negovy, Atrial Fibrillation and Flutter		•	29,615	****		****	****	268.56 (224.23, 321.67)	44,844	45,708	13,315.3
2022 86 86 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 47 2023 675 675 ***** **** ***** ***** 172.77 (24.34, 1,226.54) 1,050 1,077 85 Saxenda, Atrial Fibrillation and Flutter 2022 327 327 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 516 516 180 2023 58 58 8 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 74 74 8. Victoza, Atrial Fibrillation and Flutter 2022 6,702 6,702 ***** ***** ***** 346.88 (249.05, 483.12) 9,650 9,652 2,95 2023 1,981 1,981 ***** ***** ***** 386.19 (200.94, 742.22) 2,539 2,540 394 Trulicity, Atrial Fibrillation and Flutter 2022 65,426 65,426 ***** ***** ***** ***** 372.46 (297.90, 465.68) 27,354 27,574 3,33 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 ***** ***** ***** ***** ***** 374.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 ***** ***** ***** ***** ***** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2022 1,642 1,642 ***** ***** ***** ***** ***** 103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia	2023	10,309	10,309	****	****	****	****	282.49 (198.66, 401.68)	13,418	13,796	1,804.0
2023 675 675 ******	Wegovy,	Atrial Fibrilla	ation and Fl	utter							
Saxenda, Atrial Fibrillation and Flutter	2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
2022 327 327 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 516 516 180 2023 58 58 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 74 74 8. Victoza, Atrial Fibrillation and Flutter 2022 67,02 6,702 ***** **** ***** 346.88 (249.05, 483.12) 9,650 9,652 2,95 2023 1,981 1,981 ***** **** ***** ***** 386.19 (200.94, 742.22) 2,539 2,540 394 394 394 394 394 394 394 394 394 394	2023	675	675	****	****	****	****	172.77 (24.34, 1,226.54)	1,050	1,077	85.6
2022 527 527 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 74 74 8. Victoza, Atrial Fibrillation and Flutter 2022 6,702 6,702 ***** ***** ***** 346.88 (249.05, 483.12) 9,650 9,652 2,952 2023 1,981 1,981 ***** ***** ***** 386.19 (200.94, 742.22) 2,539 2,540 394 Trulicity, Atrial Fibrillation and Flutter 2022 65,426 65,426 ***** ***** ***** ***** 357.85 (323.09, 396.34) 117,013 117,680 29,013 18,223 18,223 ***** ***** ***** ***** 372.46 (297.90, 465.68) 27,354 27,574 3,333 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 ***** ***** ***** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 ***** ***** ***** ***** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 ***** ***** ***** ***** 163.59 (103.07, 259.65) 17,200 17,475 1,855 Bydureon, Sinus Tachycardia 2022 1,642 1,642 ***** ***** ***** ***** 41.71 (5.87, 296.10) 2,587 2,587 711	Saxenda,	Atrial Fibrill	ation and Fl	utter							
Victoza, Atrial Fibrillation and Flutter ****** ****** ****** 34.88 (249.05, 483.12) 9,650 9,652 2,952 2022 6,702 6,702 ****** ****** ****** 346.88 (249.05, 483.12) 9,650 9,652 2,955 2023 1,981 1,981 ****** ****** ****** 386.19 (200.94, 742.22) 2,539 2,540 394 Trulicity, Atrial Fibrillation and Flutter 2022 65,426 65,426 ****** ****** ****** 357.85 (323.09, 396.34) 117,013 117,680 29,00 2023 18,223 18,223 ****** ****** ****** 372.46 (297.90, 465.68) 27,354 27,574 3,33 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 ****** ****** ****** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 ***** ****** ****** 347.43 (48.94, 2,466.50) 275 275 275 4	2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2022 6,702 6,702 ***** **** **** **** 346.88 (249.05, 483.12) 9,650 9,652 2,952 2023 1,981 1,981 **** **** **** **** **** 386.19 (200.94, 742.22) 2,539 2,540 3944	2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8
2022 1,647 1,647 ***** **** **** **** **** **** ****	Victoza, A	Atrial Fibrilla	tion and Flu	itter							
Trulicity, Atrial Fibrillation and Flutter 2022 65,426 65,426 ***** **** ***** 357.85 (323.09, 396.34) 117,013 117,680 29,03 18,223 18,223 **** **** ***** 372.46 (297.90, 465.68) 27,354 27,574 3,333 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 **** **** **** ***** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 **** **** **** **** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 **** **** **** **** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 **** **** **** **** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 **** **** **** **** 41.71 (5.87, 296.10) 2,587 2,587 711	2022	6,702	6,702	****	****	****	****	346.88 (249.05, 483.12)	9,650	9,652	2,953.8
2022 65,426 65,426 ***** **** **** ***** 357.85 (323.09, 396.34) 117,013 117,680 29,023 18,223 18,223 **** **** **** 372.46 (297.90, 465.68) 27,354 27,574 3,33 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 **** **** **** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 **** **** **** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 **** **** **** **** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 **** **** **** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 **** **** **** 41.71 (5.87, 296.10) 2,587 2,587 711	2023	1,981	1,981	****	****	****	****	386.19 (200.94, 742.22)	2,539	2,540	394.1
2023 18,223 18,223 ****	Trulicity,	Atrial Fibrilla	ation and Fl	utter							
2023 18,223 18,223 ***** ****** ****** 372.46 (297.90, 465.68) 27,354 27,574 3,33 Xultophy, Atrial Fibrillation and Flutter 2022 381 381 ****** ****** ****** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 ****** ****** ****** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 ****** ****** ****** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 ****** ****** ****** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 ***** ****** ****** 41.71 (5.87, 296.10) 2,587 2,587 711	2022	65,426	65,426	****	****	****	****	357.85 (323.09, 396.34)	117,013	117,680	29,015.4
Xultophy, Atrial Fibrillation and Flutter 2022 381 381 ***** **** **** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 **** **** **** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 **** **** **** **** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 **** **** **** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 **** **** **** 41.71 (5.87, 296.10) 2,587 2,587 711	2023			****	****	****	****	372.46 (297.90, 465.68)	27,354	27,574	3,338.6
2022 381 381 ***** **** **** 149.19 (21.01, 1,059.11) 501 501 183 2023 213 213 ***** **** **** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 ***** **** **** **** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 **** **** **** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 **** **** **** 41.71 (5.87, 296.10) 2,587 2,587 711	Xultophy,	, Atrial Fibril	lation and F	lutter							
2023 213 213 ***** **** **** 347.43 (48.94, 2,466.50) 275 275 41 Mounjaro, Sinus Tachycardia 2022 11,647 11,647 ***** **** **** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 **** **** **** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 **** **** **** 41.71 (5.87, 296.10) 2,587 2,587 711					****	****	****	149.19 (21.01, 1,059.11)	501	501	183.4
2022 11,647 11,647 ***** ***** ***** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 ***** ***** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 ***** ****			213	****	****	****	****	, , , ,	275	275	41.1
2022 11,647 11,647 ***** ***** ***** 107.42 (65.81, 175.34) 19,952 20,185 4,54 2023 10,971 10,971 ***** ***** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 ***** ****	Mounjard	, Sinus Tach	ycardia								
2023 10,971 10,971 ***** ***** ***** 163.59 (103.07, 259.65) 17,200 17,475 1,85 Bydureon, Sinus Tachycardia 2022 1,642 1,642 ***** ***** ***** 41.71 (5.87, 296.10) 2,587 2,587 711			-	****	****	****	****	107.42 (65.81, 175.34)	19,952	20,185	4,546.2
Bydureon, Sinus Tachycardia 2022 1,642 ***** ****** ****** 41.71 (5.87, 296.10) 2,587 2,587 711		-	-	****	****	****	****	•	· · · · · · · · · · · · · · · · · · ·	•	1,855.3
2022 1,642 1,642 ***** ***** ***** 41.71 (5.87, 296.10) 2,587 2,587 711	Bydureon	, Sinus Tach	ycardia					· · · · · · · · · · · · · · · · · · ·	•		
			-	****	****	****	****	41.71 (5.87, 296.10)	2,587	2,587	711.1
<u> </u>	2023	350	350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	481	481	65.4



		Number	Number of Exposure	Number of Exposure			d Sentinel Distributed Database	Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	÷
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
-	Sinus Tachy									
2022	94,901	94,901	****	****	****	****	115.91 (99.77, 134.65)	146,987	147,344	43,770.8
2023	44,512	44,512	****	****	****	****	151.36 (119.75, 191.32)	58,999	59,240	7,031.7
-	, Sinus Tachy									
2022	29,615	29,615	****	****	****	****	95.59 (70.64, 129.35)	44,844	45,708	13,315.3
2023	10,309	10,309	****	****	****	****	136.69 (82.40, 226.73)	13,418	13,796	1,804.0
Wegovy,	Sinus Tachyo	cardia								
2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
2023	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,050	1,077	85.6
Saxenda,	Sinus Tachy	cardia								
2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8
Victoza, S	Sinus Tachyc	ardia								
2022	6,702	6,702	****	****	****	****	148.66 (89.62, 246.59)	9,650	9,652	2,953.8
2023	1,981	1,981	****	****	****	****	214.55 (89.30, 515.47)	2,539	2,540	394.1
Trulicity,	Sinus Tachyo	cardia								
2022	65,426	65,426	****	****	****	****	101.13 (83.45, 122.56)	117,013	117,680	29,015.4
2023	18,223	18,223	****	****	****	****	116.09 (77.81, 173.20)	27,354	27,574	3,338.6
Xultophy	, Sinus Tachy	/cardia								
2022	381	381	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	501	501	183.4
2023	213	213	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	275	275	41.1
Mounjard	o, Supravent	ricular Tach	ycardia	· · · · ·			· · ·			
2022	11,647	11,647	****	****	****	****	26.85 (10.08, 71.55)	19,952	20,185	4,546.2
2023	10,971	10,971	****	****	****	****	63.62 (30.33, 133.45)	17,200	17,475	1,855.3
	n, Supravent		ycardia				, , , , ,	•	,	, -
2022	1,642	1,642	****	****	****	****	41.71 (5.87, 296.10)	2,587	2,587	711.1
2023	350	350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	481	481	65.4
	Supraventri			,,,			,,,	-	-	
2022	94,901	94,901	****	****	****	****	42.70 (33.36, 54.66)	146,987	147,344	43,770.8
2023	44,512	44,512	****	****	****	****	51.90 (34.78, 77.43)	58,999	59,240	7,031.7
	,	,					= = (5 5)	55,555	00,= .0	.,



		Number	Number of Exposure	Number of Exposure			d Sentinel Distributed Database	Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	•	Adjusted for	Total
	of Patients	Exposure	with an Event	per 100 Exposure Episodes (95% Confidence Interval)	Years	Days	·	Same-Day	Same-Day	Observable
Pyholeus	Supraventr	Episodes		(95% Confidence interval)	at KISK	at Risk	Interval)	Dispensings)	Dispensings)	Years
2022	29,615	29,615	****	****	****	****	27.31 (15.51, 48.09)	44,844	45,708	13,315.3
2022	10,309	10,309	****	****	****	****	36.45 (13.68, 97.12)	13,418	13,796	1,804.0
_	Supraventri		ardia				30.43 (13.00, 37.12)	15,410	13,730	1,004.0
2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
2023	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,050	1,077	85.6
	Supraventri		cardia					,	,-	
2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8
Victoza, S	upraventric	ular Tachyca	ardia	· · · · · ·			·			
2022	6,702	6,702	****	****	****	****	39.64 (14.88, 105.63)	9,650	9,652	2,953.8
2023	1,981	1,981	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,539	2,540	394.1
Trulicity,	Supraventri	cular Tachyo	ardia							
2022	65,426	65,426	****	****	****	****	40.84 (30.18, 55.26)	117,013	117,680	29,015.4
2023	18,223	18,223	****	****	****	****	43.53 (22.65, 83.67)	27,354	27,574	3,338.6
Xultophy,	, Supraventr	icular Tachy	cardia							
2022	381	381	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	501	501	183.4
2023	213	213	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	275	275	41.1
Mounjard	o, Other Tacl	hycardia								
2022	11,647	11,647	****	****	****	****	6.71 (0.95, 47.66)	19,952	20,185	4,546.2
2023	10,971	10,971	****	****	****	****	45.44 (18.91, 109.18)	17,200	17,475	1,855.3
	, Other Tack	-								
2022	1,642	1,642	****	****	****	****	83.42 (20.86, 333.54)	2,587	2,587	711.1
2023	350	350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	481	481	65.4
	Other Tachy									
2022	94,901	94,901	****	****	*****	****	27.11 (19.89, 36.96)	146,987	147,344	43,770.8
2023	44,512	44,512	****	****	*****	****	41.08 (26.21, 64.41)	58,999	59,240	7,031.7
	Other Tach									
2022	29,615	29,615	****	****	****	****	9.10 (3.42, 24.26)	44,844	45,708	13,315.3
2023	10,309	10,309	****	****	****	****	45.56 (18.96, 109.47)	13,418	13,796	1,804.0



of Patients Exposure Episodes with an Episode (95% Confidence Interval) 4 Risk at Risk Interval) Dispensings) Same-Day Dispensings) Observables Wegovy, Other Tachycardia "**********************************		Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Total	Total	d Sentinel Distributed Database Event Rate per 10,000 Patient-	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining Dispensings (Not Adjusted for	Total
Wegovy, Other Tachycardia			-		•		•	·	•	•	Observable
2022 86 86 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 47.5 2023 675 675 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,050 1,077 85.6	14/2-2-1-1		•	Event	(95% Confidence Interval)	at Kisk	at KISK	interval)	Dispensings)	Dispensings)	Years
2022 675 675 0 0.00 (0.00, 0.00) *********************************		-			0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	420	420	47.5
Saxenda, Other Tachycardia Saxenda, Other											
2022 327 327 0 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 516 516 516 180.8 2023 58 58 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 74 74 74 8.8 **********************************				0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	1,050	1,077	85.6
2022 58 58 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 74 74 74 8.8		•			0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	F4.C	F4.6	100.0
Victoza, Other Tachycardia 2022 6,702 6,702 ****** ******* ******* 49.55 (20.63, 119.06) 9,650 9,652 2,953.8 2023 1,981 1,981 ****** ****** ****** \$\$85.82 (21.46, 343.15) 2,539 2,540 394.1 Trulicity, Other Tachycardia 2022 65,426 65,426 ****** ****** ****** 48.37 (26.03,89.90) 27,354 27,574 3,338.6 Xultophy, Other Tachycardia 2022 381 381 ****** ******* 149.19 (21.01, 1,059.11) 501 501 183.4 2023 213 213 0 0.00 (0.00, 0.00) ****** 149.19 (21.01, 1,059.11) 501 501 183.4 2023 213 213 0 0.00 (0.00, 0.00) ****** 149.19 (21.01, 1,059.11) 501 501 183.4 2023 213 213 0 0.00 (0.00, 0.00) ******* 149.52 20.185 4,546.2	_				. , ,			` ,			
2022 6,702 6,702 1,981 1,981 ***** ***** ***** ***** ***** ***** ****				0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			8.8
2022 1,981 1,981 1,981 ***** ***** ***** ****** ******				de de de de de		de de de de de	di di di di di				
Trulicity, Other Tachycardia		•	•					, , ,	•	•	
2022 65,426 65,426 ***** **** ***** ***** ***** ***** ****				****	****	*****	****	85.82 (21.46, 343.15)	2,539	2,540	394.1
18,223 12,223 18,203 12,223 18,235 12,223 18,203 12,223 18,203 18,235 12,223 18,203 12,223 18,203 18,235 12,223 18,203 12,223 18,203 18,235 12,223 18,203 12,223 18,203 12,223 18,235 12,223 18,203 12,223 18,235 12,223 18,235 12,223 18,235 12,223 18,235 12,223 18,235 12,223 18,235 12,223 18,235 12,223 18,235 12,223 18,235 12,235 1											
Kultophy, Other Tachycardia 40.57 (20.05, 05.30) 27,534 27,534 3,505 2022 381 381 ****** ****** ****** 149.19 (21.01, 1,059.11) 501 501 183.4 2023 213 213 0 0.00 (0.00, 0.00) ******* 0.00 (0.00, 0.00) 275 275 41.1 Mounjaro, Cardiac Arrest 2022 11,647 11,647 ****** ****** 6.71 (0.95, 47.66) 19,952 20,185 4,546.2 2023 10,971 10,971 0 0.00 (0.00, 0.00) ******* 0.00 (0.00, 0.00) 17,200 17,475 1,855.3 Bydureon, Cardiac Arrest 2022 1,642 ****** ****** ****** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ****** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 49,901 94,901 ****** ****** ******* ******* 12.88 (8.21, 20.19		•	•					, , ,	•	•	•
2022 381 381 381 ***** **** ***** ***** 149.19 (21.01, 1,059.11) 501 501 183.4 2023 213 213 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 275 275 41.1 Mounjaro, Cardiac Arrest 2022 11,647 11,647 ***** **** ***** 6.71 (0.95, 47.66) 19,952 20,185 4,546.2 2023 10,971 10,971 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 17,200 17,475 1,855.3 Bydureon, Cardiac Arrest 2022 1,642 1,642 ***** **** **** ***** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 481 481 65.4 Ozempic, Cardiac Arrest 2022 94,901 94,901 ***** **** **** ***** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 ***** ***** ***** 4.32 (1.08, 17.29) 58,999 59,240 7,031.7 Rybelsus, Cardiac Arrest 2022 29,615 29,615 ***** ***** ***** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** ***** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 47.5				****	****	*****	****	48.37 (26.03, 89.90)	27,354	27,574	3,338.6
2022 11,647 11,647 ***** ***** 6.71 (0.95, 47.66) 19,952 20,185 4,546.2 2023 10,971 10,971 0 0.00 (0.00, 0.00) ***** ***** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ***** ***** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ***** ***** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 ***** ***** ***** ***** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** ***** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 47.5			•								
Mounjaro, Cardiac Arrest 2022 11,647 11,647 ****** ****** ****** 6.71 (0.95, 47.66) 19,952 20,185 4,546.2 2023 10,971 10,971 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 17,200 17,475 1,855.3 Bydureon, Cardiac Arrest 2022 1,642 ****** ****** ****** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 481 481 65.4 Ozempic, Cardiac Arrest 2022 94,901 94,901 ****** ****** ****** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 ***** ****** ****** 4.32 (1.08, 17.29) 58,999 59,240 7,031.7 Rybelsus, Cardiac Arrest 2022 29,615 29,615 ****** ****** ******* <t< td=""><td></td><td></td><td></td><td>****</td><td></td><td></td><td></td><td>, , , ,</td><td></td><td></td><td></td></t<>				****				, , , ,			
2022 11,647 11,647 ***** ***** ***** ***** ***** ***** ****				0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	275	275	41.1
2022 11,047 10,971 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 17,200 17,475 1,855.3 Bydureon, Cardiac Arrest 2022 1,642 1,642 ***** **** ***** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 481 481 65.4 Dzempic, Cardiac Arrest 2022 94,901 94,901 **** **** ***** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 **** **** **** **** 4.32 (1.08, 17.29) 58,999 59,240 7,031.7 Rybelsus, Cardiac Arrest 2022 29,615 29,615 **** **** **** **** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 47.5	Mounjard	o, Cardiac Ar	rest								
Bydureon, Cardiac Arrest 2022 1,642 1,642 ****** ****** ****** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ******* 0.00 (0.00, 0.00) 481 481 65.4 Ozempic, Cardiac Arrest 2022 94,901 94,901 ****** ****** ****** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 ***** ****** ****** 4.32 (1.08, 17.29) 58,999 59,240 7,031.7 Rybelsus, Cardiac Arrest 2022 29,615 29,615 ***** ****** ****** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 128 128 47.5	2022	11,647	11,647	****	****	****		6.71 (0.95, 47.66)	19,952	20,185	4,546.2
2022 1,642 1,642 ***** **** **** **** **** **** 41.71 (5.87, 296.10) 2,587 2,587 711.1 2023 350 350 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 481 481 65.4 65.4 Compic, Cardiac Arrest 2022 94,901 94,901 ***** **** **** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 **** **** **** **** 4.32 (1.08, 17.29) 58,999 59,240 7,031.7 Rybelsus, Cardiac Arrest 2022 29,615 29,615 **** **** **** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) **** **** **** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) **** **** **** 0.00 (0.00, 0.00) 128 128 47.5	2023	10,971	10,971	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,200	17,475	1,855.3
2023 350 350 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 481 481 65.4 Compic, Cardiac Arrest 2022 94,901 94,901 ****	Bydureor	n, Cardiac Ar	rest								
Ozempic, Cardiac Arrest 2022 94,901 94,901 ***** ***** ****** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 ***** ****** ****** 4.32 (1.08, 17.29) 58,999 59,240 7,031.7 Rybelsus, Cardiac Arrest 2022 29,615 29,615 ****** ****** ****** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ******* ****** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 128 128 47.5	2022	1,642	1,642	****	****	****	****	41.71 (5.87, 296.10)	2,587	2,587	711.1
2022 94,901 94,901 ***** **** **** **** 12.88 (8.21, 20.19) 146,987 147,344 43,770.8 2023 44,512 44,512 ****	2023	350	350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	481	481	65.4
2023 44,512 44,512 *****	Ozempic,	Cardiac Arr	est								
Rybelsus, Cardiac Arrest 2022 29,615 29,615 ***** ****** ****** 4.55 (1.14, 18.20) 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ******************************** 0.00 (0.00, 0.00) 128 128 47.5	2022	94,901	94,901	****	****	****	****	12.88 (8.21, 20.19)	146,987	147,344	43,770.8
2022 29,615 29,615 ***** ***** ***** ***** 44,844 45,708 13,315.3 2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 128 128 47.5	2023	44,512	44,512	****	****	****	****	4.32 (1.08, 17.29)	58,999	59,240	7,031.7
2023 10,309 10,309 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 13,418 13,796 1,804.0 Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 128 128 47.5	Rybelsus	Cardiac Arr	est								
Wegovy, Cardiac Arrest 2022 86 86 0 0.00 (0.00, 0.00) ***** ***** ***** 0.00 (0.00, 0.00) 128 128 47.5	2022	29,615	29,615	****	****	****	****	4.55 (1.14, 18.20)	44,844	45,708	13,315.3
2022 86 86 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 128 128 47.5	2023	10,309	10,309	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,418	13,796	1,804.0
2022 86 86 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 128 128 47.5	Wegovy,	Cardiac Arre	est								
	2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
	2023	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,050	1,077	85.6



		Number	Number of Exposure	Number of Exposure			d Sentinel Distributed Database	Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not	- :
	Number	of	Episodes	Episodes with an Event	Total	Total		•	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days		Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Saxenda,	Cardiac Arre									
2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8
Victoza, (Cardiac Arre	st								
2022	6,702	6,702	****	****	****	****	29.73 (9.59, 92.19)	9,650	9,652	2,953.8
2023	1,981	1,981	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,539	2,540	394.1
Trulicity,	Cardiac Arre	est								
2022	65,426	65,426	****	****	****	****	12.64 (7.34, 21.77)	117,013	117,680	29,015.4
2023	18,223	18,223	****	****	****	****	4.84 (0.68, 34.34)	27,354	27,574	3,338.6
Xultophy	, Cardiac Arr	est								
2022	381	381	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	501	501	183.4
2023	213	213	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	275	275	41.1
Mounjard	o, Ventricula	r Tachycard	lia							
2022	11,647	11,647	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,952	20,185	4,546.2
2023	10,971	10,971	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,200	17,475	1,855.3
Bydureor	n, Ventricula	r Tachycard	lia							
2022	1,642	1,642	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,587	2,587	711.1
2023	350	350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	481	481	65.4
Ozempic,	Ventricular	Tachycardia	a							
2022	94,901	94,901	****	****	****	****	5.42 (2.71, 10.84)	146,987	147,344	43,770.8
2023	44,512	44,512	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58,999	59,240	7,031.7
Rybelsus	, Ventricular	Tachycardi	a							
2022	29,615	29,615	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44,844	45,708	13,315.3
2023	10,309	10,309	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,418	13,796	1,804.0
Wegovy,	Ventricular '	Tachycardia								
2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
2023	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,050	1,077	85.6
Saxenda,	Ventricular	Tachycardia	9							
2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8



	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Total	Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for	
	of	Exposure	with an	per 100 Exposure Episodes	Years		Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	•	Interval)	Dispensings)	Dispensings)	Years
Victoza, V	entricular T	•		1,222,22						
2022	6,702	6,702	****	****	****	****	9.91 (1.40, 70.36)	9,650	9,652	2,953.8
2023	1,981	1,981	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,539	2,540	394.1
Trulicity, \	/entricular [*]	Tachycardia		•			· · · · · ·	·		
2022	65,426	65,426	****	****	****	****	2.92 (0.94, 9.05)	117,013	117,680	29,015.4
2023	18,223	18,223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27,354	27,574	3,338.6
Xultophy,	Ventricular	Tachycardi	а							
2022	381	381	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	501	501	183.4
2023	213	213	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	275	275	41.1
Mounjaro	, Ventricula	r Fibrillation	n and Flutte	r						
2022	11,647	11,647	****	****	****	****	6.71 (0.95, 47.66)	19,952	20,185	4,546.2
2023	10,971	10,971	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,200	17,475	1,855.3
Bydureon	, Ventricula	r Fibrillatior	n and Flutte	r						
2022	1,642	1,642	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,587	2,587	711.1
2023	350	350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	481	481	65.4
Ozempic, '	Ventricular	Fibrillation	and Flutter							
2022	94,901	94,901	****	****	****	****	2.03 (0.66, 6.31)	146,987	147,344	43,770.8
2023	44,512	44,512	****	****	****	****	2.16 (0.30, 15.35)	58,999	59,240	7,031.7
Rybelsus,	Ventricular	Fibrillation	and Flutter							
2022	29,615	29,615	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44,844	45,708	13,315.3
2023	10,309	10,309	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,418	13,796	1,804.0
Wegovy, \	/entricular	Fibrillation a	and Flutter							
2022	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	128	128	47.5
2023	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,050	1,077	85.6
		Fibrillation	and Flutter							
2022	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	180.8
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	74	8.8
Victoza, V	entricular F	ibrillation a	nd Flutter							
2022	6,702	6,702	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,650	9,652	2,953.8
2023	1,981	1,981	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,539	2,540	394.1



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

			Number of					Number of Exposure Episode Defining-	Number of Exposure Episode Defining	
		Number	Exposure	Number of Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	per 100 Exposure Episodes	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Trulicity, \	Ventricular F	ibrillation a	nd Flutter							
2022	65,426	65,426	****	****	****	****	5.83 (2.62, 12.99)	117,013	117,680	29,015.4
2023	18,223	18,223	****	****	****	****	9.67 (2.42, 38.68)	27,354	27,574	3,338.6
Xultophy,	Ventricular	Fibrillation	and Flutter							
2022	381	381	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	501	501	183.4
2023	213	213	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	275	275	41.1

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable Years
Bydureon, Hospitalized Tachyarrhyt										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	****	****		****	287.08 (40.44, 2,038.06)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	****	****	****	****	697.81 (261.89, 1,859.28)	569	569	155.6
White	1,234	1,234	****	****	****	****	407.61 (194.32, 855.02)	1,957	1,957	458.7
Mounjaro, Hospitalized Tachyarrhyt	hmia						·			
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	****	****	****	****	459.49 (247.23, 853.99)	3,051	3,110	579.7
Multi-racial Native Hawaiian or Other Pacific	71	71	****	****	****	****	1,199.11 (168.91, 8,512.90)	125	127	27.0
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	****	****	****	****	214.38 (143.69, 319.84)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	634.18 (507.24, 792.90)	17,136	17,404	2,955.6
Ozempic, Hospitalized Tachyarrhyth	mia									
American Indian or Alaska Native	901	901	****	****	****	****	1,102.75 (626.26, 1,941.79)	1,363	1,368	309.0
Asian	1,746	1,746	****	****	****	****	513.57 (298.21, 884.48)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****	****	****	552.51 (450.89, 677.03)	17,505	17,562	4,581.7
Multi-racial Native Hawaiian or Other Pacific	919	919	****	****	****	****	333.84 (125.30, 889.51)	1,399	1,404	355.2
Islander	429	429	****	****	****	****	461.33 (148.79, 1,430.41)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	257.39 (223.11, 296.94)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	648.14 (599.75, 700.44)	102,542	102,840	24,988.2
Rybelsus, Hospitalized Tachyarrhyth		,							, , ,	,
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

Table 6. Summary of Exposures of In	iterest iii t	ne Napiu 30	entinei Dist	induted Database	anu sei	itiliei D	istributeu Database II OIII IVId	y 13, 2022 to	Julie 30, 2023	, by Nace
		Novelean	Number of	Number of Exposure Episodes with an Event per 100	Tatal	Tatal		Number of Exposure Episode Defining- Dispensings		
		Number	Exposure	Exposure		Total		(Adjusted	(Not	
	Number	of -	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure		Confidence	at	at	Patient-Years at Risk (95%	Day	-	Observable
	Patients	Episodes	Event	Interval) ****	Risk	Risk ****	Confidence Interval)	Dispensings)		Years
Asian	1,278	1,278	****	****			156.51 (50.48, 485.27)	1,889	1,925	453.9
Black or African American	4,150	4,150				****	465.25 (316.78, 683.33)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	****	****	****	****	229.96 (172.78, 306.06)	21,745	22,241	5,900.3
White	19,001	19,001	****	****	****	****	544.69 (462.35, 641.70)	28,167	28,736	6,939.2
Saxenda, Hospitalized Tachyarrhyth	mia									
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Trulicity, Hospitalized Tachyarrhythr	mia									
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	****	****	****	****	220.15 (91.63, 528.92)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****	****	****	559.07 (439.23, 711.61)	13,644	13,731	3,386.2
Multi-racial	373	373	****	****	****	****	317.51 (79.41, 1,269.58)	734	738	167.9
Native Hawaiian or Other Pacific										
Islander	321	321	****	****		****	387.53 (96.92, 1,549.57)	512	518	152.4
Unknown	27,633	27,633	****	****		****	325.33 (275.17, 384.64)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	638.59 (580.35, 702.68)	77,361	77,807	16,893.2
Victoza, Hospitalized Tachyarrhythm										
American Indian or Alaska Native	76	76	****	****	****	****	1,244.89 (175.35, 8,837.86)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	****	****	****	****	843.91 (467.35, 1,523.86)	1,269	1,269	391.4



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings (Adjusted	Exposure Episode Defining-	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Multi-racial Native Hawaiian or Other Pacific	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	****	****	****	****	271.80 (141.42, 522.39)	3,311	3,313	938.8
White	5,056	5,056	****	****	****	****	650.33 (490.08, 862.97)	7,158	7,159	1,888.5
Wegovy, Hospitalized Tachyarrhythi	mia									
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	58	60	7.1
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Native Hawaiian or Other Pacific										
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	****	****	****	****	1,008.98 (142.12, 7,163.06)	163	166	18.4
Xultophy, Hospitalized Tachyarrhyth										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	****	****		****	936.30 (131.89, 6,647.09)	90	90	27.8
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Native Hawaiian or Other Pacific										
Islander	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	1.6
Unknown	125	125	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	157	157	48.6
White	379	379	****	****	****	****	317.83 (79.49, 1,270.86)	504	504	140.3
Mounjaro, Atrial Fibrillation and Flu		4.4		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
American Indian or Alaska Native	44 1.45	44 145	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	70 224	71 225	11.2
Asian	145	145	0 ****	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004				****	275.69 (123.86, 613.67)	3,051	3,110	579.7
Multi-racial	71	71	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	125	127	27.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable Years
Native Hawaiian or Other Pacific										_
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	****	****	****	****	125.05 (74.06, 211.15)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	395.34 (297.92, 524.60)	17,136	17,404	2,955.6
Bydureon, Atrial Fibrillation and Flui										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	****	****	****	****	523.36 (168.79, 1,622.73)	569	569	155.6
White	1,234	1,234	****	****	****	****	291.15 (121.18, 699.51)	1,957	1,957	458.7
Ozempic, Atrial Fibrillation and Flutt	er									
American Indian or Alaska Native	901	901	****	****	****	****	918.96 (494.45, 1,707.95)	1,363	1,368	309.0
Asian	1,746	1,746	****	****	****	****	197.53 (82.22, 474.58)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****	****	****	243.58 (179.35, 330.81)	17,505	17,562	4,581.7
Multi-racial Native Hawaiian or Other Pacific	919	919	****	****	****	****	166.92 (41.75, 667.44)	1,399	1,404	355.2
Islander	429	429	****	****	****	****	307.55 (76.92, 1,229.76)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	142.39 (117.49, 172.56)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	435.82 (396.47, 479.08)	102,542	102,840	24,988.2
Rybelsus, Atrial Fibrillation and Flutt		,					- (,			,
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	****	****	****	****	104.34 (26.09, 417.20)	1,889	1,925	453.9
Black or African American	4,150	4,150	****	****	****	****	268.42 (161.82, 445.24)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1

Page 271 of 990



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)		Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Observable Years
Unknown	15,015	15,015	****	****	****		122.32 (82.65, 181.02)	21,745	22,241	5,900.3
White	19,001	19,001	****	****	****	****	407.57 (337.21, 492.59)	28,167	28,736	6,939.2
Wegovy, Atrial Fibrillation and Flutte										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0 ****	0.0
Asian	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****		0.4
Black or African American	40 ****	40 ****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	58	60	7.1
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	****	****	****	****	1,008.98 (142.12, 7,163.06)	163	166	18.4
Saxenda, Atrial Fibrillation and Flutt	er									
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Atrial Fibrillation and Flutte	r									
American Indian or Alaska Native	76	76	****	****	****	****	1,244.89 (175.35, 8,837.86)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	****	****	****	****	537.03 (256.02, 1,126.49)	1,269	1,269	391.4
Multi-racial Native Hawaiian or Other Pacific	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	****	****	****	****	151.00 (62.85, 362.79)	3,311	3,313	938.8
White	5,056	5,056	****	****	****	****	420.00 (295.37, 597.22)	7,158	7,159	1,888.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable Years
Trulicity, Atrial Fibrillation and Flutte	er									
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	****	****	****	****	176.12 (66.10, 469.26)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****	****	****	304.95 (219.97, 422.76)	13,644	13,731	3,386.2
Multi-racial	373	373	****	****	****	****	158.76 (22.36, 1,127.06)	734	738	167.9
Native Hawaiian or Other Pacific										
Islander	321	321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	512	518	152.4
Unknown	27,633	27,633	****	****	****	****	204.22 (165.32, 252.29)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	483.51 (433.18, 539.68)	77,361	77,807	16,893.2
Xultophy, Atrial Fibrillation and Flut										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	****	****	****	****	936.30 (131.89, 6,647.09)	90	90	27.8
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Native Hawaiian or Other Pacific										
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
Unknown	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	157	48.6
_ White	379	379	****	****	****	****	158.91 (22.38, 1,128.19)	504	504	140.3
Mounjaro, Sinus Tachycardia										
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	****	****		****	183.79 (68.98, 489.71)	3,051	3,110	579.7
Multi-racial	71	71	****	****	****	****	1,199.11 (168.91, 8,512.90)	125	127	27.0
Native Hawaiian or Other Pacific										
Islander	76	76	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	****	****		****	62.53 (29.81, 131.16)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	181.20 (119.31, 275.19)	17,136	17,404	2,955.6
Bydureon, Sinus Tachycardia American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.6
American maian of Alaska Native			U	0.00 (0.00, 0.00)			3.00 (0.00, 0.00)			5.0

Page 273 of 990



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Event	Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)		(Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	****	****	****		287.08 (40.44, 2,038.06)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	569	569	155.6
White	1,234	1,234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,957	1,957	458.7
Ozempic, Sinus Tachycardia										
American Indian or Alaska Native	901	901	****	****	****	****	183.79 (45.96, 734.90)	1,363	1,368	309.0
Asian	1,746	1,746	****	****	****	****	158.02 (59.31, 421.04)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****	****	****	213.88 (154.27, 296.50)	17,505	17,562	4,581.7
Multi-racial Native Hawaiian or Other Pacific	919	919	****	****	****	****	166.92 (41.75, 667.44)	1,399	1,404	355.2
Islander	429	429	****	****	****	****	153.78 (21.66, 1,091.71)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	80.78 (62.58, 104.26)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	139.18 (117.72, 164.55)	102,542	102,840	24,988.2
Rybelsus, Sinus Tachycardia										
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	****	****	****	****	52.17 (7.35, 370.36)	1,889	1,925	453.9
Black or African American	4,150	4,150	****	****	****	****	161.05 (83.80, 309.53)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	****	****	****	****	88.07 (55.49, 139.78)	21,745	22,241	5,900.3
White	19,001	19,001	****	****	****	****	110.46 (76.76, 158.96)	28,167	28,736	6,939.2
Wegovy, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	60	7.1



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings (Adjusted	Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)		Dispensings)	Years
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	163	166	18.4
Saxenda, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Native Hawaiian or Other Pacific										
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Sinus Tachycardia										
American Indian or Alaska Native	76	76	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	****	****		****	230.16 (74.23, 713.63)	1,269	1,269	391.4
Multi-racial	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Native Hawaiian or Other Pacific										
Islander	23	23	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	****	****		****	151.00 (62.85, 362.79)	3,311	3,313	938.8
White	5,056	5,056	****	****	****	****	162.58 (92.33, 286.28)	7,158	7,159	1,888.5
Trulicity, Sinus Tachycardia					ale ale ale ale ale	ale ale ale de de	2.24.55.5.53			=
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	****	****		****	44.03 (6.20, 312.58)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****		****	203.30 (136.26, 303.31)	13,644	13,731	3,386.2
Multi-racial	373	373	****	****	****	****	158.76 (22.36, 1,127.06)	734	738	167.9



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	(Not Adjusted for	Total Observable Years
Native Hawaiian or Other Pacific						-		-1 0-1	- 1 0-7	
Islander	321	321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	512	518	152.4
Unknown	27,633	27,633	****	****	****	****	92.61 (67.67, 126.76)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	95.79 (74.83, 122.62)	77,361	77,807	16,893.2
Xultophy, Sinus Tachycardia		·					· · · ·			
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	27.8
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Native Hawaiian or Other Pacific										
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
Unknown	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	157	48.6
White	379	379	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	504	504	140.3
Mounjaro, Supraventricular Tachyca	ardia									
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	3,051	3,110	579.7
Multi-racial	71	71	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	125	127	27.0
Native Hawaiian or Other Pacific										
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	****	****	****	****	26.80 (8.64, 83.09)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	65.89 (32.95, 131.75)	17,136	17,404	2,955.6
Bydureon, Supraventricular Tachyca										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)	*****		0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	0	0.00 (0.00, 0.00)	*****		0.00 (0.00, 0.00)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5

Page 276 of 990



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

Table 6. Summary of Exposures of In		Number		Number of Exposure Episodes with an Event per 100 Exposure	Total			Number of Exposure Episode Defining- Dispensings (Adjusted	Number of Exposure Episode Defining-	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Unknown	397	397	****	****		****	174.45 (24.57, 1,238.49)	569	569	155.6
White	1,234	1,234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,957	1,957	458.7
Ozempic, Supraventricular Tachycar	dia									
American Indian or Alaska Native	901	901	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,363	1,368	309.0
Asian	1,746	1,746	****	****		****	79.01 (19.76, 315.93)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****		****	71.29 (40.49, 125.54)	17,505	17,562	4,581.7
Multi-racial	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,399	1,404	355.2
Native Hawaiian or Other Pacific										
Islander	429	429	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	28.75 (18.75, 44.10)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	52.83 (40.25, 69.33)	102,542	102,840	24,988.2
Rybelsus, Supraventricular Tachycar										
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,889	1,925	453.9
Black or African American	4,150	4,150	****	****		****	17.89 (2.52, 127.04)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	****	****	****	****	14.68 (4.73, 45.51)	21,745	22,241	5,900.3
White	19,001	19,001	****	****	****	****	45.71 (25.96, 80.49)	28,167	28,736	6,939.2
Wegovy, Supraventricular Tachycard	lia						•	·	·	
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	60	7.1
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Native Hawaiian or Other Pacific				ŕ						
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	163	166	18.4



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable Years
Saxenda, Supraventricular Tachycar										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Supraventricular Tachycard			-	(2.22)			(0.00)			
American Indian or Alaska Native	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,269	1,269	391.4
Multi-racial	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Native Hawaiian or Other Pacific				, , ,			, , ,			
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	****	****	****	****	60.40 (15.11, 241.52)	3,311	3,313	938.8
White	5,056	5,056	****	****	****	****	27.10 (6.78, 108.35)	7,158	7,159	1,888.5
Trulicity, Supraventricular Tachycard	dia									
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****	****	****	33.88 (12.72, 90.28)	13,644	13,731	3,386.2
Multi-racial	373	373	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	734	738	167.9
Native Hawaiian or Other Pacific										
Islander	321	321	****	****	****	****	193.77 (27.29, 1,375.61)	512	518	152.4
Unknown	27,633	27,633	****	****	****	****	28.50 (16.18, 50.18)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	51.70 (36.94, 72.35)	77,361	77,807	16,893.2
Xultophy, Supraventricular Tachycai										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of	Number of Exposure	of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days at	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day	Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	•	Dispensings)	Years
Asian	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	27.8
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Native Hawaiian or Other Pacific			Ū	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
Unknown	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	157	48.6
White	379	379	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	504	504	140.3
Mounjaro, Other Tachycardia										
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	3,051	3,110	579.7
Multi-racial Native Hawaiian or Other Pacific	71	71	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	125	127	27.0
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	49.42 (22.20, 110.00)	17,136	17,404	2,955.6
Bydureon, Other Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	569	569	155.6
White	1,234	1,234	****	****	****	****	116.46 (29.13, 465.67)	1,957	1,957	458.7
Ozempic, Other Tachycardia										
American Indian or Alaska Native	901	901	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,363	1,368	309.0
Asian	1,746	1,746	****	****		****	79.01 (19.76, 315.93)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****	****	****	53.47 (27.82, 102.76)	17,505	17,562	4,581.7



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Event per 100 Exposure		Total		Number of Exposure Episode Defining- Dispensings (Adjusted	Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Multi-racial Native Hawaiian or Other Pacific	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,399	1,404	355.2
Islander	429	429	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	8.21 (3.69, 18.28)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	42.67 (31.53, 57.74)	102,542	102,840	24,988.2
Rybelsus, Other Tachycardia										
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,889	1,925	453.9
Black or African American	4,150	4,150	****	****	****	****	35.79 (8.95, 143.10)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	****	****	****	****	9.79 (2.45, 39.13)	21,745	22,241	5,900.3
White	19,001	19,001	****	****	****	****	19.05 (7.93, 45.76)	28,167	28,736	6,939.2
Wegovy, Other Tachycardia	,	<u> </u>					, , ,	,	·	ŕ
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	60	7.1
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Native Hawaiian or Other Pacific										
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	163	166	18.4
Saxenda, Other Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable Years
Native Hawaiian or Other Pacific		•		•			,			
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Other Tachycardia										
American Indian or Alaska Native	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,269	1,269	391.4
Multi-racial Native Hawaiian or Other Pacific	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,311	3,313	938.8
White	5,056	5,056	****	****	****	****	94.84 (45.21, 198.94)	7,158	7,159	1,888.5
Trulicity, Other Tachycardia										
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****	****	****	16.94 (4.24, 67.74)	13,644	13,731	3,386.2
Multi-racial Native Hawaiian or Other Pacific	373	373	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	734	738	167.9
Islander	321	321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	512	518	152.4
Unknown	27,633	27,633	****	****	****	****	9.50 (3.57, 25.31)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	33.45 (22.03, 50.80)	77,361	77,807	16,893.2
Xultophy, Other Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	90	90	27.8
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	1.2
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable Years
Unknown	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	157	48.6
White	379	379	****	****	****	****	158.91 (22.38, 1,128.19)	504	504	140.3
Mounjaro, Cardiac Arrest										
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	3,051	3,110	579.7
Multi-racial Native Hawaiian or Other Pacific	71	71	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	125	127	27.0
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	8.24 (1.16, 58.47)	17,136	17,404	2,955.6
Bydureon, Cardiac Arrest										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	569	569	155.6
White	1,234	1,234	****	****	****	****	58.23 (8.20, 413.40)	1,957	1,957	458.7
Ozempic, Cardiac Arrest										
American Indian or Alaska Native	901	901	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,363	1,368	309.0
Asian	1,746	1,746	****	****		****	39.51 (5.56, 280.46)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****		****	11.88 (2.97, 47.51)	17,505	17,562	4,581.7
Multi-racial Native Hawaiian or Other Pacific	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,399	1,404	355.2
Islander	429	429	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	5.48 (2.06, 14.59)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	14.22 (8.42, 24.01)	102,542	102,840	24,988.2



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable Years
Rybelsus, Cardiac Arrest										
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,889	1,925	453.9
Black or African American	4,150	4,150	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	****	****	****	****	4.89 (0.69, 34.74)	21,745	22,241	5,900.3
White	19,001	19,001	****	****	****	****	3.81 (0.54, 27.04)	28,167	28,736	6,939.2
Wegovy, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	60	7.1
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	163	166	18.4
Saxenda, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Cardiac Arrest					ala ala ala ala ala	ale ale ale electronic				
American Indian or Alaska Native	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	106	25.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Days	Event Rate per 10,000		Exposure Episode Defining- Dispensings (Not Adjusted for	
	of	Exposure		Confidence	at	at	Patient-Years at Risk (95%	Day		Observable
	Patients	Episodes	Event	Interval)	Risk	Risk ****	Confidence Interval)	Dispensings)		Years
Asian	137	137	0 ****	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969				****	76.72 (10.81, 544.65)	1,269	1,269	391.4
Multi-racial Native Hawaiian or Other Pacific	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,311	3,313	938.8
White	5,056	5,056	****	****	****	****	27.10 (6.78, 108.35)	7,158	7,159	1,888.5
Trulicity, Cardiac Arrest										
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****		****	8.47 (1.19, 60.14)	13,644	13,731	3,386.2
Multi-racial Native Hawaiian or Other Pacific	373	373	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	734	738	167.9
Islander	321	321	****	****	****	****	193.77 (27.29, 1,375.61)	512	518	152.4
Unknown	27,633	27,633	****	****	****	****	4.75 (1.19, 18.99)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	15.20 (8.18, 28.26)	77,361	77,807	16,893.2
Xultophy, Cardiac Arrest										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	90	90	27.8
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
Unknown	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	157	48.6
White	379	379	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	504	504	140.3
Mounjaro, Ventricular Tachycardia										
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,051	3,110	579.7



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Total Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Multi-racial Native Hawaiian or Other Pacific	71	71	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	125	127	27.0
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,440	16,614	2,763.0
White	10,501	10,501	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,136	17,404	2,955.6
Bydureon, Ventricular Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	376	376	113.8
Multi-racial	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Native Hawaiian or Other Pacific										
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	569	569	155.6
White	1,234	1,234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,957	1,957	458.7
Ozempic, Ventricular Tachycardia										
American Indian or Alaska Native	901	901	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,363	1,368	309.0
Asian	1,746	1,746	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****	****	****	11.88 (2.97, 47.51)	17,505	17,562	4,581.7
Multi-racial Native Hawaiian or Other Pacific	919	919	****	****	****	****	83.46 (11.76, 592.52)	1,399	1,404	355.2
Islander	429	429	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	1.37 (0.19, 9.72)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	4.06 (1.53, 10.83)	102,542	102,840	24,988.2
Rybelsus, Ventricular Tachycardia										
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,889	1,925	453.9
Black or African American	4,150	4,150	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,768	5,892	1,610.1
Multi-racial	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable Years
Native Hawaiian or Other Pacific										
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,745	22,241	5,900.3
White	19,001	19,001	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28,167	28,736	6,939.2
Wegovy, Ventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	60	7.1
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	163	166	18.4
Saxenda, Ventricular Tachycardia							·			
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Native Hawaiian or Other Pacific										
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Ventricular Tachycardia										
American Indian or Alaska Native	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	****	****	****	****	76.72 (10.81, 544.65)	1,269	1,269	391.4
Multi-racial Native Hawaiian or Other Pacific	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable Years
Unknown	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,311	3,313	938.8
White	5,056	5,056	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,158	7,159	1,888.5
Trulicity, Ventricular Tachycardia										
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,460	2,469	535.1
Black or African American	8,504	8,504	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	13,644	13,731	3,386.2
Multi-racial	373	373	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	734	738	167.9
Native Hawaiian or Other Pacific										
Islander	321	321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	512	518	152.4
Unknown	27,633	27,633	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	4.56 (1.47, 14.14)	77,361	77,807	16,893.2
Xultophy, Ventricular Tachycardia	****	****		0.00 (0.00 0.00)	***	****	0.00 (0.00 0.00)	****	****	
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	****	****	0.4
Asian			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			4.5
Black or African American	70 ****	70 ****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	90 ****	90 ****	27.8
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
	****	****	0	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Islander			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			1.6
Unknown White	125 379	125 379	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	157 504	157 504	48.6 140.3
Mounjaro, Ventricular Fibrillation a		3/9	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	304	304	140.5
American Indian or Alaska Native	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	71	11.2
Asian	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	224	225	41.0
Black or African American	2,004	2,004	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,051	3,110	579.7
Multi-racial	71	71	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	125	127	27.0
Native Hawaiian or Other Pacific	<i>,</i> -	, =	ŭ	2.20 (0.00, 0.00)			3.00 (0.00) 0.00)	120	 ,	27.0
Islander	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	24.0
Unknown	9,777	9,777	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,440	16,614	2,763.0
White	10,501	10,501	****	****	****	****	8.24 (1.16, 58.47)	17,136	17,404	2,955.6
	•	-					, , ,	•	•	*



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings (Adjusted	Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Bydureon, Ventricular Fibrillation a										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.6
Asian	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	89	89	24.7
Black or African American	256	256	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	376	376	113.8
Multi-racial Native Hawaiian or Other Pacific	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	17.6
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	569	569	155.6
White	1,234	1,234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,957	1,957	458.7
Ozempic, Ventricular Fibrillation and	d Flutter									
American Indian or Alaska Native	901	901	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,363	1,368	309.0
Asian	1,746	1,746	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,613	2,619	614.2
Black or African American	12,374	12,374	****	****	****	****	5.94 (0.84, 42.18)	17,505	17,562	4,581.7
Multi-racial Native Hawaiian or Other Pacific	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,399	1,404	355.2
Islander	429	429	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	602	603	175.3
Unknown	53,485	53,485	****	****	****	****	1.37 (0.19, 9.72)	79,962	80,188	19,778.9
White	69,559	69,559	****	****	****	****	2.03 (0.51, 8.12)	102,542	102,840	24,988.2
Rybelsus, Ventricular Fibrillation an										
American Indian or Alaska Native	83	83	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	126	129	33.5
Asian	1,278	1,278	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,889	1,925	453.9
Black or African American	4,150	4,150	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	5,768	5,892	1,610.1
Multi-racial Native Hawaiian or Other Pacific	220	220	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	332	96.2
Islander	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	249	86.1
Unknown	15,015	15,015	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,745	22,241	5,900.3
White	19,001	19,001	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28,167	28,736	6,939.2
Wegovy, Ventricular Fibrillation and										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	(Not Adjusted for	Total Observable Years
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	60	7.1
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	604	604	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	922	944	103.4
White	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	163	166	18.4
Saxenda, Ventricular Fibrillation and	l Flutter									
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.4
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	344	344	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	532	532	168.5
White	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	16.5
Victoza, Ventricular Fibrillation and	Flutter									
American Indian or Alaska Native	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	106	25.0
Asian	137	137	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	182	182	52.9
Black or African American	969	969	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,269	1,269	391.4
Multi-racial Native Hawaiian or Other Pacific	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	39.5
Islander	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	11.8
Unknown	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,311	3,313	938.8
White	5,056	5,056	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,158	7,159	1,888.5
Trulicity, Ventricular Fibrillation and	Flutter									
American Indian or Alaska Native	302	302	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	551	555	111.7
Asian	1,465	1,465	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,460	2,469	535.1
Black or African American	8,504	8,504	****	****	****	****	8.47 (1.19, 60.14)	13,644	13,731	3,386.2



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings (Adjusted	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Multi-racial Native Hawaiian or Other Pacific	373	373	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	734	738	167.9
Islander	321	321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	512	518	152.4
Unknown	27,633	27,633	****	****	****	****	4.75 (1.19, 18.99)	49,105	49,436	11,107.6
White	45,051	45,051	****	****	****	****	7.60 (3.16, 18.27)	77,361	77,807	16,893.2
Xultophy, Ventricular Fibrillation and	d Flutter									
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
Black or African American	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	27.8
Multi-racial Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
Unknown	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	157	157	48.6
White	379	379	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	504	504	140.3

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

NaN: Not a number

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Number of Exposure Exposure Exposure Episode Episode Episode Pofining Defining Defin	
Number Friends with	
Number Episodes with Defining- Defining	-
of an Event per Dispensings Dispensing	gs
Number Exposure 100 Exposure Total Total (Adjusted (Not	
Number of Episodes Episodes (95% Years Days Event Rate per 10,000 for Same- Adjusted	or Total
of Exposure with an Confidence at at Patient-Years at Risk (95% Day Same-Day	y Observable
Patients Episodes Event Interval) Risk Risk Confidence Interval) Dispensings) Dispensin	=
Bydureon, Hospitalized Tachyarrhythmia	50,
Evidence of Other cardiac disease 812 812 ***** ***** 808.33 (420.58, 1,553.57) 1,248 1,248	309.5
No evidence of Other cardiac 1,180 1,180 ***** ***** ***** 181.36 (58.49, 562.33) 1,820 1,820	467.0
Mounjaro, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 9,117 9,117 ***** ***** 747.32 (597.72, 934.35) 14,837 15,047	2,566.5
No evidence of Other cardiac 13,501 13,501 ***** ***** ***** 224.43 (161.14, 312.58) 22,315 22,613	3,835.0
Ozempic, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 57,346 57,346 ***** ***** ***** 834.70 (773.25, 901.03) 84,314 84,575	20,663.0
No evidence of Other cardiac 82,067 82,067 ***** ***** ***** 255.51 (227.91, 286.45) 121,672 122,009	30,139.5
Rybelsus, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 13,529 13,529 ***** ***** **** 773.62 (656.29, 911.92) 19,873 20,269	5,033.3
No evidence of Other cardiac 26,395 26,395 ***** ***** ***** 210.64 (168.47, 263.35) 38,389 39,235	10,085.9
Saxenda, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 127 127 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 190 190	65.5
No evidence of Other cardiac 258 258 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 400 400	124.1
Trulicity, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 33,645 33,645 ***** ***** **** 891.61 (811.28, 979.89) 57,578 57,928	12,834.2
No evidence of Other cardiac 50,004 50,004 ***** ***** ***** 267.39 (232.86, 307.03) 86,789 87,326	19,519.8
Victoza, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 3,666 3,666 ***** **** **** 993.64 (755.16, 1,307.45) 5,098 5,099	1,400.5
No evidence of Other cardiac 5,017 5,017 ***** ***** 246.99 (155.61, 392.02) 7,091 7,093	1,947.4
Wegovy, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 274 274 ***** ***** ***** 397.44 (55.98, 2,821.58) 443 458	49.4
No evidence of Other cardiac 487 487 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 735 747	83.7
Xultophy, Hospitalized Tachyarrhythmia	
Evidence of Other cardiac disease 241 241 ***** ***** 515.13 (128.83, 2,059.75) 326 326	88.7
No evidence of Other cardiac 353 353 ***** ***** 175.47 (24.72, 1,245.75) 450 450	135.7
Mounjaro, Atrial Fibrillation and Flutter	



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Cardiac Disease				Number of				- Francisco	- Fyransii in a	
								Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with				Defining-	Defining-	
			of	an Event per				Dispensings	•	
		Number	Exposure	100 Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Evidence of Other cardiac disease	9,117	9,117	****	****		****	524.09 (401.39, 684.29)	14,837	15,047	2,566.5
No evidence of Other cardiac	13,501	13,501	****	****	****	****	89.77 (53.17, 151.58)	22,315	22,613	3,835.0
Bydureon, Atrial Fibrillation and Flut	tter									
Evidence of Other cardiac disease	812	812	****	****	****	****	628.70 (299.72, 1,318.79)	1,248	1,248	309.5
No evidence of Other cardiac	1,180	1,180	****	****	****	****	60.45 (8.52, 429.17)	1,820	1,820	467.0
Ozempic, Atrial Fibrillation and Flutt	er									
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	593.31 (541.87, 649.64)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	****	****	****	****	109.50 (91.96, 130.39)	121,672	122,009	30,139.5
Rybelsus, Atrial Fibrillation and Flutt	er									
Evidence of Other cardiac disease	13,529	13,529	****	****	****	****	615.62 (511.96, 740.27)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	****	****	****	****	98.48 (71.04, 136.53)	38,389	39,235	10,085.9
Wegovy, Atrial Fibrillation and Flutte	er									
Evidence of Other cardiac disease	274	274	****	****	****	****	397.44 (55.98, 2,821.58)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Atrial Fibrillation and Flutt	er									
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Atrial Fibrillation and Flutte	r									
Evidence of Other cardiac disease	3,666	3,666	****	****	****	****	662.43 (473.32, 927.09)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	****	****	****	****	137.21 (73.83, 255.02)	7,091	7,093	1,947.4
Trulicity, Atrial Fibrillation and Flutte	er									
Evidence of Other cardiac disease	33,645	33,645	****	****	****	****	699.22 (628.51, 777.88)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	****	****	****	****	142.34 (117.77, 172.04)	86,789	87,326	19,519.8
Xultophy, Atrial Fibrillation and Flut										
Evidence of Other cardiac disease	241	241	****	****	****	****	257.56 (36.28, 1,828.52)	326	326	88.7
No evidence of Other cardiac	353	353	****	****	****	****	175.47 (24.72, 1,245.75)	450	450	135.7
Mounjaro, Sinus Tachycardia										
Evidence of Other cardiac disease	9,117	9,117	****	****	****	****	155.29 (95.13, 253.48)	14,837	15,047	2,566.5



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Cardiac Disease										
				Number of Exposure				Exposure Episode	Exposure Episode	
			Number	Episodes with				Defining-	Defining-	
			of	an Event per				Dispensings	•	
		Number	Exposure	100 Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)		Dispensings)	Years
No evidence of Other cardiac	13,501	13,501	****	****	****	****	115.42 (72.72, 183.20)	22,315	22,613	3,835.0
Bydureon, Sinus Tachycardia										
Evidence of Other cardiac disease	812	812	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,248	1,248	309.5
No evidence of Other cardiac	1,180	1,180	****	****	****	****	60.45 (8.52, 429.17)	1,820	1,820	467.0
Ozempic, Sinus Tachycardia										
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	137.21 (113.63, 165.69)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	****	****	****	****	115.59 (97.52, 137.00)	121,672	122,009	30,139.5
Rybelsus, Sinus Tachycardia										
Evidence of Other cardiac disease	13,529	13,529	****	****	****	****	119.86 (78.92, 182.03)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	****	****	****	****	95.74 (68.74, 133.35)	38,389	39,235	10,085.9
Wegovy, Sinus Tachycardia										
Evidence of Other cardiac disease	274	274	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Sinus Tachycardia										
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Sinus Tachycardia										
Evidence of Other cardiac disease	3,666	3,666	****	****	****	****	214.32 (118.69, 386.99)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	****	****	****	****	123.49 (64.25, 237.34)	7,091	7,093	1,947.4
Trulicity, Sinus Tachycardia							·			
Evidence of Other cardiac disease	33,645	33,645	****	****	****	****	119.98 (92.76, 155.20)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	****	****	****	****	93.12 (73.67, 117.70)	86,789	87,326	19,519.8
Xultophy, Sinus Tachycardia							·			
Evidence of Other cardiac disease	241	241	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	326	88.7
No evidence of Other cardiac	353	353	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	450	450	135.7
Mounjaro, Supraventricular Tachyca	rdia			,			·			
Evidence of Other cardiac disease	9,117	9,117	****	****	****	****	87.35 (45.45, 167.88)	14,837	15,047	2,566.5
No evidence of Other cardiac	13,501	13,501	****	****	****	****	12.82 (3.21, 51.28)	22,315	22,613	3,835.0

Page 293 of 990



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Cardiac Disease										
				Number of				Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with				Defining-	Defining-	
			of	an Event per				Dispensings	Dispensings	
		Number	Exposure	100 Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	•	Event	Interval)	Risk	Risk	Confidence Interval)	•	Dispensings)	Years
Bydureon, Supraventricular Tachyca		'		•			<u> </u>	, ,	. ,	
Evidence of Other cardiac disease	812	812	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,248	1,248	309.5
No evidence of Other cardiac	1,180	1,180	****	****	****	****	60.45 (8.52, 429.17)	1,820	1,820	467.0
Ozempic, Supraventricular Tachycard	dia									
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	78.77 (61.41, 101.03)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	****	****	****	****	21.73 (14.68, 32.15)	121,672	122,009	30,139.5
Rybelsus, Supraventricular Tachycard	dia									
Evidence of Other cardiac disease	13,529	13,529	****	****	****	****	54.48 (29.31, 101.25)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	****	****	****	****	16.41 (7.37, 36.53)	38,389	39,235	10,085.9
Wegovy, Supraventricular Tachycard	lia									
Evidence of Other cardiac disease	274	274	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Supraventricular Tachycard	dia									
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Supraventricular Tachycardi	a									
Evidence of Other cardiac disease	3,666	3,666	****	****		****	38.97 (9.75, 155.81)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	****	****	****	****	27.44 (6.86, 109.73)	7,091	7,093	1,947.4
Trulicity, Supraventricular Tachycard										
Evidence of Other cardiac disease	33,645	33,645	****	****		****	59.99 (41.69, 86.33)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	****	****	****	****	29.27 (19.27, 44.45)	86,789	87,326	19,519.8
Xultophy, Supraventricular Tachycar										
Evidence of Other cardiac disease	241	241	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	326	326	88.7
No evidence of Other cardiac	353	353	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	450	450	135.7
Mounjaro, Other Tachycardia										
Evidence of Other cardiac disease	9,117	9,117	****	****		****	38.82 (14.57, 103.44)	14,837	15,047	2,566.5
No evidence of Other cardiac	13,501	13,501	****	****	****	****	12.82 (3.21, 51.28)	22,315	22,613	3,835.0
Bydureon, Other Tachycardia										



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Cardiac Disease										
				Number of				Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with				Defining-	Defining-	
			of	an Event per				Dispensings	Dispensings	
		Number	Exposure	100 Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000		Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	•	Observable
	Patients	•	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	•	Years
Evidence of Other cardiac disease	812	812	****	****		****	179.63 (44.92, 718.26)	1,248	1,248	309.5
No evidence of Other cardiac	1,180	1,180	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,820	1,820	467.0
Ozempic, Other Tachycardia	1,100	1,100		0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	1,820	1,820	407.0
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	48.28 (35.13, 66.35)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	****	****		****	18.25 (11.90, 27.99)	64,514 121,672	64,575 122,009	30,139.5
	82,007	82,007					18.23 (11.90, 27.99)	121,072	122,009	50,159.5
Rybelsus, Other Tachycardia	42.520	42.520	****	****	****	****	24 70 (0.40, 50.06)	40.072	20.260	5.022.2
Evidence of Other cardiac disease	13,529	13,529	****	****		****	21.79 (8.18, 58.06)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	4444	4.4.4.4.4.	4, 4, 4, 4, 4,	4.4.4.4.	13.68 (5.69, 32.86)	38,389	39,235	10,085.9
Wegovy, Other Tachycardia						at at at at at				
Evidence of Other cardiac disease	274	274	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Other Tachycardia										
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Other Tachycardia										
Evidence of Other cardiac disease	3,666	3,666	****	****	****	****	97.42 (40.55, 234.05)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	****	****	****	****	27.44 (6.86, 109.73)	7,091	7,093	1,947.4
Trulicity, Other Tachycardia										
Evidence of Other cardiac disease	33,645	33,645	****	****	****	****	35.17 (21.86, 56.57)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	****	****	****	****	14.63 (8.10, 26.42)	86,789	87,326	19,519.8
Xultophy, Other Tachycardia										
Evidence of Other cardiac disease	241	241	****	****	****	****	257.56 (36.28, 1,828.52)	326	326	88.7
No evidence of Other cardiac	353	353	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	450	450	135.7
Mounjaro, Cardiac Arrest				•			· · · ·			
Evidence of Other cardiac disease	9,117	9,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,837	15,047	2,566.5
No evidence of Other cardiac	13,501	13,501	****	****	****	****	6.41 (0.90, 45.52)	22,315	22,613	3,835.0
Bydureon, Cardiac Arrest	· ·	·					, , ,			,
Evidence of Other cardiac disease	812	812	****	****	****	****	89.81 (12.65, 637.62)	1,248	1,248	309.5

Page 295 of 990



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Calulat Disease										
				Number of				Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with				Defining-	Defining-	
			of	an Event per				Dispensings	Dispensings	
		Number	Exposure	100 Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
No evidence of Other cardiac	1,180	1,180	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,820	1,820	467.0
Ozempic, Cardiac Arrest							·			
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	16.52 (9.59, 28.44)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	****	****	****	****	6.95 (3.48, 13.90)	121,672	122,009	30,139.5
Rybelsus, Cardiac Arrest										
Evidence of Other cardiac disease	13,529	13,529	****	****	****	****	10.90 (2.72, 43.57)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38,389	39,235	10,085.9
Wegovy, Cardiac Arrest										
Evidence of Other cardiac disease	274	274	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Cardiac Arrest										
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Cardiac Arrest										
Evidence of Other cardiac disease	3,666	3,666	****	****	****	****	58.45 (18.85, 181.23)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,091	7,093	1,947.4
Trulicity, Cardiac Arrest										
Evidence of Other cardiac disease	33,645	33,645	****	****	****	****	18.62 (9.69, 35.78)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	****	****	****	****	6.65 (2.77, 15.98)	86,789	87,326	19,519.8
Xultophy, Cardiac Arrest										
Evidence of Other cardiac disease	241	241	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	326	88.7
No evidence of Other cardiac	353	353	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	450	450	135.7
Mounjaro, Ventricular Tachycardia										
Evidence of Other cardiac disease	9,117	9,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,837	15,047	2,566.5
No evidence of Other cardiac	13,501	13,501	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22,315	22,613	3,835.0
Bydureon, Ventricular Tachycardia										
Evidence of Other cardiac disease	812	812	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,248	1,248	309.5
No evidence of Other cardiac	1,180	1,180	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,820	1,820	467.0

Page 296 of 990



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

Cardiac Disease				N				F	F	
				Number of				Exposure	Exposure	
				Exposure				Episode	Episode	
			Number	Episodes with				Defining-	Defining-	
			of	an Event per				Dispensings	•	
		Number	Exposure	100 Exposure	Total	Total		(Adjusted	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Ozempic, Ventricular Tachycardia										
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	7.62 (3.42, 16.97)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	****	****	****	****	1.74 (0.43, 6.95)	121,672	122,009	30,139.5
Rybelsus, Ventricular Tachycardia										
Evidence of Other cardiac disease	13,529	13,529	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38,389	39,235	10,085.9
Wegovy, Ventricular Tachycardia										
Evidence of Other cardiac disease	274	274	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Ventricular Tachycardia										
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Ventricular Tachycardia										
Evidence of Other cardiac disease	3,666	3,666	****	****		****	19.48 (2.74, 138.32)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,091	7,093	1,947.4
Trulicity, Ventricular Tachycardia										
Evidence of Other cardiac disease	33,645	33,645	****	****		****	6.21 (2.00, 19.24)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86,789	87,326	19,519.8
Xultophy, Ventricular Tachycardia										
Evidence of Other cardiac disease	241	241	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	326	326	88.7
No evidence of Other cardiac	353	353	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	450	450	135.7
Mounjaro, Ventricular Fibrillation an	nd Flutter									
Evidence of Other cardiac disease	9,117	9,117	****	****	****	****	9.71 (1.37, 68.90)	14,837	15,047	2,566.5
No evidence of Other cardiac	13,501	13,501	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22,315	22,613	3,835.0
Bydureon, Ventricular Fibrillation an	d Flutter									
Evidence of Other cardiac disease	812	812	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,248	1,248	309.5
No evidence of Other cardiac	1,180	1,180	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,820	1,820	467.0
Ozempic, Ventricular Fibrillation and	l Flutter									



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days at	Event Rate per 10,000 Patient-Years at Risk (95%	Exposure Episode Defining- Dispensings (Adjusted for Same- Day	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	•	Dispensings)	Years
Evidence of Other cardiac disease	57,346	57,346	****	****	****	****	5.08 (1.91, 13.54)	84,314	84,575	20,663.0
No evidence of Other cardiac	82,067	82,067	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	121,672	122,009	30,139.5
Rybelsus, Ventricular Fibrillation and	l Flutter									
Evidence of Other cardiac disease	13,529	13,529	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,873	20,269	5,033.3
No evidence of Other cardiac	26,395	26,395	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38,389	39,235	10,085.9
Wegovy, Ventricular Fibrillation and	Flutter									
Evidence of Other cardiac disease	274	274	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	443	458	49.4
No evidence of Other cardiac	487	487	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	735	747	83.7
Saxenda, Ventricular Fibrillation and	Flutter									
Evidence of Other cardiac disease	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	65.5
No evidence of Other cardiac	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	400	124.1
Victoza, Ventricular Fibrillation and I	Flutter									
Evidence of Other cardiac disease	3,666	3,666	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,098	5,099	1,400.5
No evidence of Other cardiac	5,017	5,017	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,091	7,093	1,947.4
Trulicity, Ventricular Fibrillation and	Flutter									
Evidence of Other cardiac disease	33,645	33,645	****	****	****	****	14.48 (6.90, 30.38)	57,578	57,928	12,834.2
No evidence of Other cardiac	50,004	50,004	****	****	****	****	1.33 (0.19, 9.44)	86,789	87,326	19,519.8
Xultophy, Ventricular Fibrillation and	d Flutter									
Evidence of Other cardiac disease	241	241	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	326	326	88.7
No evidence of Other cardiac	353	353	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	450	450	135.7

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure S- Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Bydureon, Hos	pitalized Ta	chyarrhythr	nia							
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	****	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	25	25	****	****	****	****	2,947.94 (415.24, 20,928.40)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group)									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	****	****	****	****	749.46 (187.43, 2,996.75)	268	268	75.8
65-74 years	143	143	****	****	****	****	928.21 (232.14, 3,711.48)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	****	****	****	****	462.02 (115.55, 1,847.41)	537	537	133.3
65-74 years	626	626	****	****	****	****	209.58 (52.41, 838.02)	1,024	1,024	231.4
75-84 years	211	211	****	****	****	****	727.37 (181.91, 2,908.43)	313	313	67.9
≥ 85 years	16	16	****	****	****	****	8,320.05 (1,171.95, 59,066.72)	21	21	5.6
Mounjaro, Hos	pitalized Ta	achyarrhythi	mia							
American India	n or Alaska	Native								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
Black or Africar							,	- 10 k 01101112407	p	
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	****	****	****	****	754.94 (359.90, 1,583.59)	1,344	1,359	254.2
65-74 years	919	919	****	****	****	****	302.00 (97.40, 936.39)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	****	****	****	****	6,087.50 (857.48, 43,217.15)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	* * * * *	***	0.2
Unknown			_							
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	*****	****	*****	****	198.06 (123.12, 318.60)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	****	****	****	****	492.20 (221.12, 1,095.58)	1,813	1,835	294.4
75-84 years	186	186 11		0.00 (0.00, 0.00)	****	****	538.48 (75.85, 3,822.84)	291 15	295 15	47.9 1.8
≥ 85 years <i>White</i>	11	11	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	15	13	1.8
	126	126	0	0.00.10.00.0.00	****	****	0.00 (0.00, 0.00)	777	2/1	20.1
0-40 years	136	136	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237 4,972	241 5,050	39.1 892.0
41-64 years	2,914 5,693	2,914 5,693	****	****	****	****	636.53 (419.12, 966.71) 636.66 (470.51, 861.50)	4,972 9,225	5,050 9,374	892.0 1,566.5
65-74 years	5,095	5,035					030.00 (470.31, 001.30)	9,223	9,374	1,300.3

cder_mpl1p_wp077 Page 301 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,679	1,679	****	****	****	****	595.56 (329.82, 1,075.41)	2,590	2,625	440.7
75 61 years	1,073	2,073					333.30 (323.32, 1,0,3.11)	2,330	2,023	11017
≥ 85 years	79	79	****	****	****	****	2,596.87 (649.45, 10,383.70)	112	114	17.3
Ozempic, Hosp	italized Tac	hyarrhythm	ia							
American India	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	****	****	****	****	839.46 (270.74, 2,602.86)	437	439	97.9
65-74 years	403	403	****	****	****	****	814.97 (305.87, 2,171.46)	623	626	134.3
75-84 years	169	169	****	****	****	****	2,540.34 (1,057.34, 6,103.34)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0.40	400	406	****	****	****	****	4 524 00 (202 00 6 427 70)	452	453	27.2
0-40 years	106	106	****	****	****	****	1,534.99 (383.89, 6,137.70)	152 684	152	37.2 167.6
41-64 years 65-74 years	440 825	440 825	****	****	****	****	308.94 (77.26, 1,235.33) 588.27 (280.45, 1,233.98)	1,204	686 1,207	280.7
75-84 years	825 318	825 318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,204 480	481	280.7 109.9
75-64 years	310	310	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	400	401	109.9
≥ 85 years	57	57	****	****	****	****	2,494.03 (623.73, 9,972.46)	93	93	18.8
Black or Africar							_, (0_0, 0,0, 0,0)			
0-40 years	404	404	****	****	****	****	618.47 (199.47, 1,917.66)	543	545	141.9
41-64 years	4,747	4,747	****	****	****	****	596.41 (433.97, 819.65)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	****	****	****	****	523.40 (386.80, 708.24)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	****	****	****	****	552.29 (297.16, 1,026.46)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	****	****	****	****	586.56 (82.62, 4,164.17)	198	199	50.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	•	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
11.51	Patients	Episodes	Event ****	Interval) ****	****	at Risk		Dispensings)	Dispensings)	Years
41-64 years	699	699	***	****	****	****	109.49 (15.42, 777.29)	1,070	1,074	269.6
65-74 years	****	****	****	****	****	****	1,018.26 (143.43, 7,228.96)	114	114	32.1
75-84 years	****	****	****	****	****	****	6,201.19 (873.49, 44,024.27)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
75-84 years	97	97	****	****	****	****	2,151.90 (694.02, 6,672.27)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,863	4,863	****	****	****	****	197.24 (112.01, 347.32)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	****	****	****	215.96 (179.00, 260.56)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	****	****	****	****	337.84 (252.24, 452.48)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	****	****	****	****	745.15 (490.64, 1,131.67)	3,092	3,099	773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White										
0-40 years	1,070	1,070	****	****	****	****	424.47 (190.70, 944.83)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	606.86 (514.22, 716.19)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	****	****	****	557.48 (498.02, 624.04)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	****	****	****	****	920.53 (791.70, 1,070.33)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	****	****	****	****	1,477.63 (963.42, 2,266.30)	1,509	1,511	374.1

Rybelsus, Hospitalized Tachyarrhythmia American Indian or Alaska Native



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group) ·									
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings (Adjusted for Same-Day	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
0.40	Patients ****	Episodes ****	Event	Interval)	*****	at Risk	Interval)	Dispensings)	Dispensings)	Years
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29 ****	29 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years ≥ 85 years	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	19 ****	19 ****	3.3 0.8
Asian			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.8
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	****	****	****	****	213.53 (53.40, 853.82)	913	929	228.9
75-84 years	327	327	****	****	****	****	200.08 (28.18, 1,420.45)	498	506	108.9
> 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7
Black or Africar			-	(3.33)			(3.55)			
0-40 years	105	105	****	****	****	****	1,660.60 (415.30, 6,639.99)	151	156	37.2
41-64 years	1,202	1,202	****	****	****	****	252.17 (94.64, 671.89)	1,731	1,774	474.3
65-74 years	2,116	2,116	****	****	****	****	480.57 (284.62, 811.44)	2,914	2,978	819.2
75-84 years	638	638	****	****	****	****	350.85 (113.16, 1,087.87)	850	859	245.9
≥ 85 years	89	89	****	****	****	****	2,645.46 (853.20, 8,202.61)	122	125	33.5
Multi-racial										
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia		-								
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for	
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk		Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown										
0-40 years	967	967	****	****	****	****	246.92 (79.63, 765.60)	1,381	1,409	369.7
41-64 years	9,300	9,300	****	****	****	****	204.78 (139.43, 300.76)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	****	****	****	****	220.74 (122.24, 398.59)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	****	****	****	****	379.70 (158.04, 912.26)	1,442	1,467	368.1
≥ 85 years	164	164	****	****	****	****	881.93 (220.56, 3,526.42)	252	255	61.1
White										
0-40 years	245	245	****	****	****	****	330.33 (46.53, 2,345.15)	358	365	89.7
41-64 years	3,517	3,517	****	****	****	****	365.65 (230.37, 580.36)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	****	****	****	****	362.56 (274.79, 478.37)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	****	****	****	****	948.87 (738.28, 1,219.54)	6,958	7,090	1,668.0
≥ 85 years	629	629	****	****	****	****	1,608.05 (933.72, 2,769.39)	944	951	217.3
Saxenda, Hosp	italized Tac	hyarrhythm	ia							
American India	ın or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	· ·	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Trulicity, Hospitalized Tachyarrhythmia



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
American India	n or Alaska			•			,		, , ,	
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	****	****	****	****	273.37 (38.51, 1,940.74)	432	432	98.9
65-74 years	703	703	****	****	****	****	173.58 (43.41, 694.06)	1,195	1,201	258.5
75-84 years	358	358	****	****	****	****	185.35 (26.11, 1,315.86)	578	580	126.3
≥ 85 years	83	83	****	****	****	****	755.43 (106.41, 5,363.04)	158	158	26.8
Black or Africar	American									
0-40 years	263	263	****	****	****	****	290.04 (40.85, 2,059.10)	440	441	103.6
41-64 years	2,772	2,772	****	****	****	****	659.66 (445.73, 976.25)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	****	****	****	****	332.42 (212.03, 521.16)	6,368	6,405	1,623.8
75-84 years	1,264	1,264	****	****	****	****	1,023.16 (644.63, 1,623.96)	1,947	1,957	496.8
≥ 85 years	152	152	****	****	****	****	1,532.30 (494.19, 4,751.11)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	****	****	****	****	423.45 (105.90, 1,693.20)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
75-84 years ≥ 85 years	75 ****	75 ****	**** 0	***** 0.00 (0.00, 0.00)	****	****	1,802.81 (450.87, 7,208.62) 0.00 (0.00, 0.00)	113 14	113 14	35.3 5.7
Unknown										
0-40 years	2,069	2,069	****	****	****	****	319.79 (166.39, 614.62)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	229.02 (178.19, 294.35)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	****	****	****	****	404.72 (295.70, 553.93)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	****	****	****	****	924.50 (624.69, 1,368.20)	3,179	3,197	717.0
≥ 85 years White	240	240	****	****	****	****	935.66 (301.76, 2,901.14)	400	401	86.0
0-40 years	599	599	****	****	****	****	231.52 (57.90, 925.72)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	496.85 (391.05, 631.27)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	593.99 (518.34, 680.68)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	****	****	****	****	821.94 (688.30, 981.53)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	****	****	****	****	1,272.65 (837.97, 1,932.81)	2,318	2,326	462.5
Victoza, Hospit	alized Tach	yarrhythmia	1							
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	****	****	****	****	9,413.66 (1,325.99, 66,830.65)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	59	 59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or African	American									
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	****	****	****	****	1,110.69 (498.98, 2,472.30)	542	542	160.8
65-74 years	398	398	****	****	****	****	543.58 (175.31, 1,685.44)	509	509	165.7
75-84 years	98	98	****	****	****	****	1,510.86 (377.85, 6,041.23)	122	122	37.0
2 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial	14	17	J	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	20	20	3.3
0-40 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	_	_						-	-	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown				, , ,			• • •			
0-40 years	195	195	****	****	****	****	379.20 (53.41, 2,692.10)	283	283	79.5
41-64 years	1,362	1,362	****	****	****	****	155.59 (50.18, 482.44)	1,977	1,978	566.7
65-74 years	605	605	****	****	****	****	446.20 (167.46, 1,188.89)	822	823	229.4
, 75-84 years	153	153	****	****	****	****	505.26 (71.17, 3,586.98)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group)									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	****	****	****	****	559.72 (309.97, 1,010.71)	2,071	2,071	556.2
65-74 years	2,380	2,380	****	****	****	****	586.12 (382.15, 898.95)	3,345	3,346	883.0
·	•						,	•	•	
75-84 years	1,040	1,040	****	****	****	****	983.32 (592.80, 1,631.09)	1,406	1,406	362.4
≥ 85 years	110	110	****	****	****	****	722.55 (101.78, 5,129.63)	146	146	37.5
Wegovy, Hospi	talized Tacl	hyarrhythmi	ia							
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable
75-84 years	0	0	Event 0	NaN	0.0	0	NaN	0	0	Years 0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	-	ū	-	Nuiv	0.0	U	Naiv	O	v	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown		•	J		0.0	Ū		·	· ·	0.0
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	Ö	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	97	10.5
,			_	(,,			(2,2,2,2,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,7,2,2,2,7,2			
65-74 years	26	26	****	****	****	****	4,390.02 (618.37, 31,166.22)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Xultophy, Hosp	italized Tac	hyarrhythm	nia	,						
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	****	****	****	****	1,278.89 (180.14, 9,079.23)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day	
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	****	****	****	****	1,324.57 (331.26, 5,296.34)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Atri	al Fibrillatio	on and Flutte	er							
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or African	American									
0-40 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	****	****	****	****	539.24 (224.44, 1,295.57)	1,344	1,359	254.2
65-74 years	919	919	****	****	****	****	100.67 (14.18, 714.67)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1

Page 313 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure SEPISODE DEFINING- Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other F	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	****	****	****	****	104.85 (54.56, 201.52)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	****	****	****	****	328.13 (123.15, 874.29)	1,813	1,835	294.4
75-84 years	186	186	****	****	****	****	538.48 (75.85, 3,822.84)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	****	****	****	****	347.20 (197.17, 611.36)	4,972	5,050	892.0
65-74 years	5,693	5,693	****	****	****	****	378.97 (256.07, 560.85)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	****	****	****	****	541.42 (291.31, 1,006.26)	2,590	2,625	440.7
							1,298.44 (182.90,			
≥ 85 years	79	79	****	****	****	****	9,218.02)	112	114	17.3
Bydureon, Atria	al Fibrillatio	n and Flutte	er				·			
American India										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Asian										
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	****	****	****	****	374.73 (52.78, 2,660.34)	268	268	75.8
65-74 years	143	143	****	****	****	****	928.21 (232.14, 3,711.48)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2

cder_mpl1p_wp077 Page 315 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	•	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
White			-	(,,			2.02 (2.02)			
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	****	****	****	****	462.02 (115.55, 1,847.41)	537	537	133.3
65-74 years	626	626	****	****	****	****	104.79 (14.76, 743.95)	1,024	1,024	231.4
75-84 years	211	211	****	****	****	****	363.69 (51.23, 2,581.93)	313	313	67.9
							8,320.05 (1,171.95,			
≥ 85 years	16	16	****	****	****	****	59,066.72)	21	21	5.6
Ozempic, Atria	Fibrillation	and Flutter	r							
American India	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	****	****	****	****	559.64 (139.96, 2,237.75)	437	439	97.9
65-74 years	403	403	****	****	****	****	611.23 (197.13, 1,895.20)	623	626	134.3
							2,540.34 (1,057.34,			
75-84 years	169	169	****	****	*****	*****	6,103.34)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	****	****	****	****	767.49 (108.11, 5,448.69)	152	152	37.2
41-64 years	440	440	****	****	****	****	154.47 (21.76, 1,096.65)	684	686	167.6
65-74 years	825	825	****	****	****	****	252.12 (81.31, 781.72)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	480	481	109.9
≥ 85 years	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	93	93	18.8
Black or African	American									
0-40 years	404	404	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	543	545	141.9
41-64 years	4,747	4,747	****	****	****	****	235.42 (141.93, 390.51)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	****	****	****	****	261.70 (170.63, 401.38)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	****	****	****	****	276.14 (114.94, 663.45)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial		<u>-</u>								
0-40 years	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	199	50.1
41-64 years	699	699	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,070	1,074	269.6
							1,018.26 (143.43,			
65-74 years	****	****	****	****	****	****	7,228.96)	114	114	32.1
							6,201.19 (873.49,			
75-84 years	****	****	****	****	****	****	44,024.27)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid		-	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
							1,434.60 (358.78,			
75-84 years	97	97	****	****	****	****	5,736.32)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,863	4,863	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	****	****	****	105.01 (80.22, 137.45)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	****	****	****	****	232.73 (163.67, 330.93)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	****	****	*****	*****	677.40 (437.03, 1,049.99)	3,092	3,099	773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	235	235	56.0
White	4.070	4 070	****	****	****	****	70.75 (0.07.502.24)	4.672	4.670	205.7
0-40 years	1,070	1,070	****	****	****	****	70.75 (9.97, 502.24)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	299.10 (236.23, 378.69)	25,369	25,448	6,316.8
65-74 years	37,400 12,254	37,400 13.254	****	****	****	****	385.81 (336.89, 441.83)	55,242	55,400	13,251.3 4,650.3
75-84 years	13,254	13,254					713.55 (601.24, 846.83) 1,336.91 (852.74,	18,749	18,802	4,030.3
≥ 85 years	1,078	1,078	****	****	****	****	2,095.96)	1,509	1,511	374.1
= 05 years	1,070	1,070					2,055.501	1,303	1,511	3/4.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Atria								- J		
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	****	****	****	****	213.53 (53.40, 853.82)	913	929	228.9
75-84 years	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	498	506	108.9
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7
Black or Africar	n American									
0-40 years	105	105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	151	156	37.2
41-64 years	1,202	1,202	****	****	****	****	63.04 (8.88, 447.55)	1,731	1,774	474.3
65-74 years	2,116	2,116	****	****	****	****	343.27 (184.69, 637.99)	2,914	2,978	819.2
75-84 years	638	638	****	****	****	****	116.95 (16.47, 830.27)	850	859	245.9
≥ 85 years	89	89	****	****	****	****	2,645.46 (853.20,8,202.61)	122	125	33.5
Multi-racial										
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	****	****	NaN	0	0	0.0
Native Hawaiia		•								
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown			-	(,,			(3.55)			
0-40 years	967	967	****	****	****	****	82.31 (11.59, 584.32)	1,381	1,409	369.7
41-64 years	9,300	9,300	****	****	****	****	102.39 (59.45, 176.34)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	****	****	****	****	100.33 (41.76, 241.06)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	****	****	****	****	379.70 (158.04, 912.26)	1,442	1,467	368.1
≥ 85 years	164	164	****	****	****	****	440.96 (62.11, 3,130.54)	252	255	61.1
White										
0-40 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	358	365	89.7
41-64 years	3,517	3,517	****	****	****	****	223.45 (123.75, 403.49)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	****	****	****	****	268.29 (194.39, 370.30)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	****	****	****	****	762.21 (576.06, 1,008.50)	6,958	7,090	1,668.0
							1,236.96 (665.55,			
≥ 85 years	629	629	****	****	****	****	2,298.98)	944	951	217.3
Wegovy, Atrial	Fibrillation	and Flutter								
American Indiai	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Page 319 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Number of Exposure Episode Defining Dispensings	Number of Exposure - Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	•	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other i	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 4,390.02 (618.37,	97	97	10.5
65-74 years	26	26	****	****	****	****	31,166.22)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
≥ 85 years	Number of Patients ****	Number of Exposure Episodes ****	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) 0.00 (0.00, 0.00)	Total Years at Risk ****	Total Days at Risk ****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval) 0.00 (0.00, 0.00)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings) *****	
Saxenda, Atrial	l Fibrillation	and Flutter		0.00 (0.00) 0.00)			0.00 (0.00)			
American India										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	'									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial I										
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
							9,413.66 (1,325.99,			
75-84 years	****	****	****	****	****	****	66,830.65)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Black or African	American									
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	****	****	****	****	555.34 (179.11, 1,721.92)	542	542	160.8
65-74 years	398	398	****	****	****	****	543.58 (175.31, 1,685.44)	509	509	165.7
75-84 years	98	98	****	****	****	*****	755.43 (106.41, 5,363.04)	122	122	37.0
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	283	283	79.5
41-64 years	1,362	1,362	****	****	****	****	51.86 (7.31, 368.20)	1,977	1,978	566.7
65-74 years	605	605	****	****	****	****	334.65 (107.93, 1,037.63)	822	823	229.4
75-84 years	153	153	****	****	****	****	505.26 (71.17, 3,586.98)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	****	****	****	****	305.30 (137.16, 679.58)	2,071	2,071	556.2
65-74 years	2,380	2,380	****	****	****	****	334.93 (190.21, 589.76)	3,345	3,346	883.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
			****	****	****	****				
75-84 years	1,040	1,040			****	****	852.21 (494.84, 1,467.68)	1,406	1,406	362.4
≥ 85 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	37.5
Trulicity, Atrial										
American India	n or Alaska ****	Native ****	•	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5 4
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47 ****	47 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73 ****	74 ****	15.5
≥ 85 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)		*****	8.0
Asian			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	07	00	24.7
0-40 years	55	55	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	****	****	****	****	273.37 (38.51, 1,940.74)	432	432	98.9
65-74 years	703	703	****	****	****	****	86.79 (12.22, 616.14)	1,195	1,201	258.5
75-84 years	358 83	358 83	****	****	****	****	185.35 (26.11, 1,315.86)	578	580	126.3
≥ 85 years Black or African		83					755.43 (106.41, 5,363.04)	158	158	26.8
-		262	0	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	440	4.44	402.6
0-40 years	263	263	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	441	103.6
41-64 years	2,772	2,772	****	****	****	****	369.41 (218.78, 623.74)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	****	****	****	****	174.96 (94.14, 325.17)	6,368	6,405	1,623.8
75-84 years	1,264	1,264					568.42 (305.84, 1,056.45) 1,021.54 (255.48,	1,947	1,957	496.8
≥ 85 years	152	152	****	****	****	****	4,084.65)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	****	****	****	****	211.73 (29.82, 1,503.12)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	-	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	113	35.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.7
Unknown				, , ,			, , ,			
0-40 years	2,069	2,069	****	****	****	****	106.60 (34.38, 330.52)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	116.39 (81.85, 165.50)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	****	****	****	****	290.57 (200.62, 420.83)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	****	****	****	****	813.56 (535.68, 1,235.57)	3,179	3,197	717.0
≥ 85 years	240	240	****	****	****	****	623.77 (156.00, 2,494.18)	400	401	86.0
White										
0-40 years	599	599	0	0.00 (0.00, 0.00)	`	****	0.00 (0.00, 0.00)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	259.55 (186.35, 361.49)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	453.39 (387.93, 529.89)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	****	****	****	****	693.93 (572.06, 841.76)	17,250	17,332	3,776.9
•							1,272.65 (837.97,			
≥ 85 years	1,335	1,335	****	****	****	****	1,932.81)	2,318	2,326	462.5
Xultophy, Atria	l Fibrillatio	n and Flutte	r							
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
CE 74	Patients ****	Episodes ****	Event	Interval)	****	at Risk	Interval)	Dispensings) ****	Dispensings) ****	Years
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)		4444	0.5
Black or Africa	n American ****	****			ale ale ale ale ale	ale ale ale ale ale	(****	****	
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	****		****	****	1,278.89 (180.14,9,079.23)	66	66	20.2
75-84 years	****	*****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	***	****	0.00 (0.00, 0.00)	* * * * *	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid		•								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	****	****	****	****	662.28 (93.29, 4,701.78)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Sini	•									
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	****	****	****	****	215.70 (53.94, 862.47)	1,344	1,359	254.2
65-74 years	919	919	****	****	****	****	201.33 (50.35, 805.04)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial							6 007 50 (057 40			
0.40	ماد ماد ماد ماد	****	ماد ماد ماد ماد	****	الدعاد عاديان بان	اد ماد ماد بان بان ا	6,087.50 (857.48,			
0-40 years	****		****		****	****	43,217.15)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group)									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	•	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other I	Pacific Island	der							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	****	****	****	****	69.90 (31.40, 155.60)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	****	****	****	****	82.03 (11.55, 582.38)	1,813	1,835	294.4
75-84 years	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	****	****	****	****	289.33 (155.67, 537.74)	4,972	5,050	892.0
65-74 years	5,693	5,693	****	****	****	****	151.59 (81.56, 281.73)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	****	****	****	****	54.14 (7.63, 384.37) 1,298.44 (182.90,	2,590	2,625	440.7
≥ 85 years	79	79	****	****	****	****	9,218.02)	112	114	17.3
Bydureon, Sinu	ıs Tachycar	dia								
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	Ö	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American			, , ,			, , ,			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
•				, , ,			2,947.94 (415.24,			
75-84 years	25	25	****	****	****	****	20,928.40)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	268	268	75.8
65-74 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	537	537	133.3
65-74 years	626	626	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,024	1,024	231.4
75-84 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	313	67.9
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	5.6
Ozempic, Sinus	Tachycard	ia								
American India	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	****	****	****	****	279.82 (39.42, 1,986.54)	437	439	97.9
65-74 years	403	403	****	****	****	****	203.74 (28.70, 1,446.44)	623	626	134.3
75-84 years	169	169	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	****	****	****	****	767.49 (108.11, 5,448.69)	152	152	37.2
41-64 years	440	440	****	****	****	****	154.47 (21.76, 1,096.65)	684	686	167.6
65-74 years	825	825	****	****	****	****	168.08 (42.03, 672.07)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	480	481	109.9
≥ 85 years	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	93	93	18.8
Black or Africar	n American									
0-40 years	404	404	****	****	****	****	618.47 (199.47, 1,917.66)	543	545	141.9
41-64 years	4,747	4,747	****	****	****	****	266.81 (165.87, 429.20)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	****	****	****	****	162.00 (94.07, 279.01)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	****	****	****	****	165.69 (53.44, 513.73)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	****	****	****	****	586.56 (82.62, 4,164.17)	198	199	50.1
41-64 years	699	699	****	****	****	****	109.49 (15.42, 777.29)	1,070	1,074	269.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for	
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	·	Dispensings)	Dispensings)	Years
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	114	32.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other F	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
75-84 years	97	97	****	****	****	****	717.30 (101.04, 5,092.36)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown				, , ,						
0-40 years	4,863	4,863	****	****	****	****	180.81 (100.13, 326.48)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	****	****	****	77.27 (56.46, 105.76)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	****	****	****	****	52.55 (25.05, 110.24)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	****	****	****	****	67.74 (16.94, 270.86)	3,092	3,099	, 773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White										
0-40 years	1,070	1,070	****	****	****	****	353.73 (147.23, 849.85)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	247.08 (190.59, 320.32)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	****	****	****	99.68 (76.35, 130.15)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	****	****	****	****	114.39 (74.58, 175.44)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,509	1,511	374.1
Rybelsus, Sinus	Tachycard	ia								
American Indiai	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										

cder_mpl1p_wp077 Page 331 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	•	Dispensings)	Dispensings)	Years
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	913	929	228.9
75-84 years	327	327	****	****	****	****	200.08 (28.18, 1,420.45)	498	506	108.9
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7
Black or African			-	(,,			2.02 (2.02)			
, , ,							1,660.60 (415.30,			
0-40 years	105	105	****	****	****	****	6,639.99)	151	156	37.2
41-64 years	1,202	1,202	****	****	****	****	189.12 (61.00, 586.41)	1,731	1,774	474.3
65-74 years	2,116	2,116	****	****	****	****	102.98 (33.21, 319.30)	2,914	2,978	819.2
75-84 years	638	638	****	****	****	****	116.95 (16.47, 830.27)	850	859	245.9
≥ 85 years	89	89	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	125	33.5
, Multi-racial				, , ,			, , ,			
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	****	****	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown										
0-40 years	967	967	****	****	****	****	164.61 (41.17, 658.21)	1,381	1,409	369.7
41-64 years	9,300	9,300	****	****	****	****	86.64 (47.98, 156.44)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	****	****	****	****	100.33 (41.76, 241.06)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,442	1,467	368.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
≥ 85 years	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	252	255	61.1
White										
0-40 years	245	245	****	****	****	****	330.33 (46.53, 2,345.15)	358	365	89.7
41-64 years	3,517	3,517	****	****	****	****	142.20 (67.79, 298.27)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	****	****	****	****	72.51 (39.01, 134.77)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	****	****	****	****	155.55 (83.69, 289.11)	6,958	7,090	1,668.0
≥ 85 years	629	629	****	****	****	****	123.70 (17.42, 878.16)	944	951	217.3
Wegovy, Sinus										
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group				Number of				Number of	Number of	
				Exposure Episodes				Exposure	Exposure	
			Number of	with an Event per				•	- Episode Defining-	
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	•	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia		-		IVUIV	0.0	O	IVAIV	O	Ü	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	Ū	ŭ	Ü	· · · · · · · · · · · · · · · · · · ·	0.0	Ŭ	11411	Ü	ŭ	0.0
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	Ö	NaN	0.0	0	NaN	0	0	0.0
White	•	_	-					-	-	
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	97	10.5
65-74 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Sinus	Tachycardi	а		, , ,			, , ,			
American India										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other F	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	****	****	NaN	0	0	0.0
Victoza, Sinus T	achycardia									
American India	n or Alaska	Native								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or African										
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	****	****	****	****	185.11 (26.07, 1,314.19)	542	542	160.8
65-74 years	398	398	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 1,510.86 (377.85,	509	509	165.7
75-84 years	98	98	****	****	****	****	6,041.23)	122	122	37.0
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial				,			•			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	****	****	****	****	379.20 (53.41, 2,692.10)	283	283	79.5
41-64 years	1,362	1,362	****	****	****	****	103.73 (25.94, 414.76)	1,977	1,978	566.7
65-74 years	605	605	****	****	****	****	111.55 (15.71, 791.93)	822	823	229.4
75-84 years	153	153	****	****	****	****	505.26 (71.17, 3,586.98)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	****	****	****	****	254.42 (105.89, 611.26)	2,071	2,071	556.2
65-74 years	2,380	2,380	****	****	****	****	167.46 (75.23, 372.76)	3,345	3,346	883.0
75-84 years	1,040	1,040	****	****	****	****	65.55 (9.23, 465.39)	1,406	1,406	362.4
≥ 85 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	37.5
Trulicity, Sinus	Tachycardia	a								
American India	n or Alaska	Native								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	432	432	98.9
65-74 years	703	703	****	****	****	****	86.79 (12.22, 616.14)	1,195	1,201	258.5
75-84 years	358	358	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	578	580	126.3
≥ 85 years	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	158	26.8
Black or African	American			, , ,			• • •			
0-40 years	263	263	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	441	103.6
41-64 years	2,772	2,772	****	****	****	****	263.86 (141.97, 490.41)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	****	****	****	****	157.46 (81.93, 302.63)	6,368	6,405	1,623.8
, 75-84 years	1,264	1,264	****	****	****	****	284.21 (118.29, 682.83)	1,947	1,957	496.8
≥ 85 years	152	, 152	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	****	****	****	****	211.73 (29.82, 1,503.12)	565	568	125.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Native Hawaiia	n or Other I	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	113	35.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.7
Unknown										
0-40 years	2,069	2,069	****	****	****	****	213.20 (95.78, 474.55)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	82.60 (54.39, 125.44)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	****	****	****	****	93.40 (48.59, 179.50)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	****	****	****	****	73.96 (18.50, 295.73)	3,179	3,197	717.0
≥ 85 years	240	240	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	401	86.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
White		<u>-</u>		<u>-</u>						
0-40 years	599	599	****	****	****	****	231.52 (57.90, 925.72)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	163.14 (107.42, 247.77)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	80.35 (55.48, 116.37)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	****	****	****	****	74.11 (41.04, 133.82)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,318	2,326	462.5
Xultophy, Sinus	Tachycard	lia								
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure - Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia		-								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Sup	raventricula	ar Tachycard	dia							
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or African	American									
0-40 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,344	1,359	254.2
65-74 years	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other F	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	****	****	****	****	23.30 (5.83, 93.17)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	****	****	****	****	82.03 (11.55, 582.38)	1,813	1,835	294.4
75-84 years	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										

cder_mpl1p_wp077 Page 341 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	****	****	****	****	86.80 (27.99, 269.13)	4,972	5,050	892.0
65-74 years	5,693	5,693	****	****	****	****	75.79 (31.55, 182.10)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,590	2,625	440.7
≥ 85 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	114	17.3
Bydureon, Sup			lia							
American India	n or Alaska	Native								_
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	der							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	****	****	****	****	374.73 (52.78, 2,660.34)	268	268	75.8
65-74 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	537	537	133.3
65-74 years	626	626	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,024	1,024	231.4
75-84 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	313	67.9
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	5.6
Ozempic, Supra			а							
American India										
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	437	439	97.9
65-74 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	623	626	134.3
75-84 years	169	169	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	152	152	37.2
41-64 years	440	440	****	****	****	****	154.47 (21.76, 1,096.65)	684	686	167.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Dispensings	Number of Exposure g- Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	· •	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	•	Dispensings)	Dispensings)	Years
65-74 years	825	825	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 1,247.01 (175.65,	480	481	109.9
≥ 85 years	57	57	****	****	****	****	8,852.95)	93	93	18.8
Black or African	American									
0-40 years	404	404	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	543	545	141.9
41-64 years	4,747	4,747	****	****	****	****	15.69 (2.21, 111.42)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	****	****	****	****	99.70 (49.86, 199.35)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	****	****	****	****	165.69 (53.44, 513.73)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	199	50.1
41-64 years	699	699	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,070	1,074	269.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	114	32.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
75-84 years	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,863	4,863	****	****	****	****	16.44 (2.32, 116.69)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	****	****	****	25.76 (14.96, 44.36)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	****	****	****	****	52.55 (25.05, 110.24)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,092	3,099	773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings (Adjusted for	Number of Exposure Episode Defining Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	,	Dispensings)	Dispensings)	Years
0-40 years	1,070	1,070	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	26.01 (11.68, 57.89)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	****	****	****	59.07 (41.77, 83.53)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	****	****	****	****	76.26 (45.16, 128.76)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,509	1,511	374.1
Rybelsus, Supra		•	а							
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	913	929	228.9
75-84 years	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	498	506	108.9
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7
Black or African	n American									
0-40 years	105	105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	151	156	37.2
41-64 years	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,731	1,774	474.3
65-74 years	2,116	2,116	****	****	****	****	34.33 (4.84, 243.70)	2,914	2,978	819.2
75-84 years	638	638	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	850	859	245.9
≥ 85 years	89	89	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	125	33.5
Multi-racial				, , ,			•			
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
•	155	155	0	0.00 (0.00, 0.00)	****	****		226	231	66.4
•	****	****	0	0.00 (0.00, 0.00)	****	****		42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years 65-74 years 75-84 years ≥ 85 years Multi-racial 0-40 years 41-64 years 65-74 years	1,202 2,116 638 89 36 155 *****	1,202 2,116 638 89 36 155 *****	0 ***** 0 0 0	0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** **** **** **** ****	***** **** **** ****	0.00 (0.00, 0.00) 34.33 (4.84, 243.70) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	1,731 2,914 850 122 52 226 42	1,774 2,978 859 125 52 231 43	



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk		Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown										
0-40 years	967	967	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,381	1,409	369.7
41-64 years	9,300	9,300	****	****	****	****	15.75 (3.94, 62.99)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,442	1,467	368.1
≥ 85 years	164	164	****	****	****	****	440.96 (62.11, 3,130.54)	252	255	61.1
White										
0-40 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	358	365	89.7
41-64 years	3,517	3,517	****	****	****	****	40.63 (10.16, 162.45)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	****	****	****	****	36.26 (15.09, 87.11)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	****	****	****	****	62.22 (23.35, 165.79)	6,958	7,090	1,668.0
≥ 85 years	629	629	****	****	****	****	123.70 (17.42, 878.16)	944	951	217.3
Wegovy, Supra			1							
American India						_		_	_	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	•	•								
0-40 years	0 ****	0 ****	0	NaN	0.0 ****	0 ****	NaN	0 ****	0 ****	0.0
41-64 years	ጥጥ ች ች ች	ጥጥ ች ች	0	0.00 (0.00, 0.00)	ጥጥ ጥ ጥ ጥ	****	0.00 (0.00, 0.00)	ጥጥ ጥጥ	ጥጥ ጥጥ	0.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
41-64 years	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) 0.00 (0.00, 0.00)	Total Years at Risk	Total Days at Risk ****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval) 0.00 (0.00, 0.00)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years 10.5
65-74 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Supra	eventricular	Tachycardi	a							
American India	n or Alaska	Native								_
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africai										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	
Native Hawaiia				meervary	at Misk	at Misk	mervary	Dispensings	Dispensings	icuis
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	Ö	0	Ō	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Suprav		•								
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and go or out										
				Number of Exposure Episodes				Number of Exposure	Number of Exposure	
			Number of	with an Event per				-	- Episode Defining	
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient	· (Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or Africar	n American									
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	542	542	160.8
65-74 years	398	398	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	509	509	165.7
75-84 years	98	98	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	122	37.0
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	283	283	79.5
41-64 years	1,362	1,362	****	****	****	****	51.86 (7.31, 368.20)	1,977	1,978	566.7
65-74 years	605	605	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	822	823	229.4
75-84 years	153	153	****	****	****	****	505.26 (71.17, 3,586.98)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,071	2,071	556.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Number of Exposure Episode Defining Dispensings	Number of Exposure - Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	2,380	2,380	****	****	****	****	27.91 (3.93, 198.15)	3,345	3,346	883.0
75-84 years	1,040	1,040	****	****	****	****	65.55 (9.23, 465.39)	1,406	1,406	362.4
≥ 85 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	37.5
Trulicity, Supra	ventricular	Tachycardia								
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	432	432	98.9
65-74 years	703	703	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,195	1,201	258.5
75-84 years	358	358	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	578	580	126.3
≥ 85 years	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	158	26.8
Black or African	American									
0-40 years	263	263	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	441	103.6
41-64 years	2,772	2,772	****	****	****	****	26.39 (3.72, 187.33)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,368	6,405	1,623.8
75-84 years	1,264	1,264	****	****	****	****	113.68 (28.43, 454.57)	1,947	1,957	496.8
≥ 85 years	152	152	****	****	****	****	510.77 (71.95, 3,626.11)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9

Native Hawaiian or Other Pacific Islander

cder_mpl1p_wp077 Page 351 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	<u>, </u>									
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day	
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years ≥ 85 years	75 ****	75 ****	****	***** 0.00 (0.00, 0.00)	*****	****	901.41 (126.97, 6,399.38) 0.00 (0.00, 0.00)	113 14	113 14	35.3 5.7
Unknown			Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	1-7	1-7	3.7
0-40 years	2,069	2,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	15.02 (5.64, 40.01)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	****	****	****	****	51.89 (21.60, 124.66)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	****	****	****	****	73.96 (18.50, 295.73)	3,179	3,197	717.0
≥ 85 years	240	240	****	****	****	****	311.89 (43.93, 2,214.18)	400	401	86.0
White							, , , , , ,			
0-40 years	599	599	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	74.16 (39.90, 137.82)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	40.17 (23.79, 67.83)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	****	****	****	****	60.63 (31.55, 116.54)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	****	****	****	****	57.85 (8.15, 410.68)	2,318	2,326	462.5
Xultophy, Supr		•	ia							
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Takal	Tatal	Front Data was 40 000 Dations	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	· ·	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
75.04	Patients ****	Episodes ****	Event	Interval)	****	at Risk	Interval)	Dispensings) ****	Dispensings) ****	Years
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.5
Black or Africa			_							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	ın or Other I	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White				, ,			• •			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Oth										
American India		Native ****			ala ala ala ala ala		(ale ale ale ale ale	ale ale ale ale	
0-40 years	****		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,344	1,359	254.2
65-74 years	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,813	1,835	294.4
75-84 years	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	****	****	****	****	28.93 (4.08, 205.40)	4,972	5,050	892.0
65-74 years	5,693	5,693	****	****	****	****	75.79 (31.55, 182.10)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,590	2,625	440.7
≥ 85 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	114	17.3
Bydureon, Oth	er Tachycar	dia								
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	****	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1

cder_mpl1p_wp077 Page 355 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American		Ü	0.00 (0.00) 0.00)			0.00 (0.00, 0.00)			0
0-40 years	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-racial			-	(,,			2.02 (2.02)			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	ın or Other I	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	268	268	75.8
65-74 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	537	537	133.3
65-74 years	626	626	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,024	1,024	231.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	211	211	****	****	****	****	727.37 (181.91, 2,908.43)	313	313	67.9
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	5.6
Ozempic, Othe				<u> </u>			, , ,			
American India	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	437	439	97.9
65-74 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	623	626	134.3
75-84 years	169	169	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	152	152	37.2
41-64 years	440	440	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	684	686	167.6
65-74 years	825	825	****	****	****	****	168.08 (42.03, 672.07)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	480	481	109.9
≥ 85 years	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	93	93	18.8
Black or Africar	n American									
0-40 years	404	404	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	543	545	141.9
41-64 years	4,747	4,747	****	****	****	****	94.17 (42.31, 209.61)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	****	****	****	****	37.39 (12.06, 115.92)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	199	50.1
41-64 years	699	699	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,070	1,074	269.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	114	32.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia		•	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	1									
	Novelean	Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Dispensings	Number of Exposure Episode Defining Dispensings (Not	
	Number	of -	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	, •	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
75-84 years	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,863	4,863	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	****	****	****	9.91 (4.12, 23.80)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	****	****	****	****	7.51 (1.06, 53.30)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,092	3,099	773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White										
****	****	1,070	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	43.35 (23.32, 80.56)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	****	****	****	33.23 (20.93, 52.74)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	****	****	****	****	59.92 (33.18, 108.19)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	****	****	****	****	211.09 (68.08, 654.51)	1,509	1,511	374.1
Rybelsus, Othe	r Tachycard	lia								
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	913	929	228.9
75-84 years	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	498	506	108.9
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and tigo or our										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day	Total Observable
01 1 15:	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Black or Africa			_				/			
0-40 years	105	105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	151	156	37.2
41-64 years	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,731	1,774	474.3
65-74 years	2,116	2,116	****	****	*****	****	34.33 (4.84, 243.70)	2,914	2,978	819.2
75-84 years	638	638	****		*****	*****	116.95 (16.47, 830.27)	850	859	245.9
≥ 85 years	89	89	0	0.00 (0.00, 0.00)	4 4 4 4 4	4 4 4 4 4	0.00 (0.00, 0.00)	122	125	33.5
Multi-racial			_		ale ale ale ale ale	ale ale ale ale ale	()			
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid		Pacific Island ****					/		de de de de de	
0-40 years	****		0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41 ****	41 ****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60 ****	62 ****	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown										
0-40 years	967	967	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,381	1,409	369.7
41-64 years	9,300	9,300	****	****	****	****	15.75 (3.94, 62.99)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,442	1,467	368.1
≥ 85 years	164	164	0	0.00 (0.00, 0.00)	ጥጥጥጥ	ጥጥጥጥ	0.00 (0.00, 0.00)	252	255	61.1
White										
0-40 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	358	365	89.7
41-64 years	3,517	3,517	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	****	****	****	****	46.67 (15.05, 144.69)	6,958	7,090	1,668.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
≥ 85 years	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) *****	Total Years at Risk ****	Total Days at Risk ****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval) 247.39 (61.87, 989.21)	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings) 951	
Wegovy, Other										
American India	•									
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	Ū	U	U	IVUIV	0.0	J	Naiv	Ü	Ü	0.0
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	****	****	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	97	10.5
65-74 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Other										
American India	n or Alaska									
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar	n American									



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group)									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	,									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Other				•			<u>, </u>		, , ,	
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or Africa										
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	542	542	160.8
65-74 years	398	398	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	509	509	165.7
75-84 years	98	98	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	122	37.0
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	. 0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid		-								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk		Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	283	283	79.5
41-64 years	1,362	1,362	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,977	1,978	566.7
65-74 years	605	605	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	822	823	229.4
75-84 years	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	****	****	****	****	50.88 (7.17, 361.24)	2,071	2,071	556.2
65-74 years	2,380	2,380	****	****	****	****	55.82 (13.96, 223.20)	3,345	3,346	883.0
75-84 years	1,040	1,040	****	****	****	****	196.66 (63.43, 609.78)	1,406	1,406	362.4
≥ 85 years	110	110	****	****	****	****	722.55 (101.78, 5,129.63)	146	146	37.5
Trulicity, Other										
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	432	432	98.9
65-74 years	703	703	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,195	1,201	258.5
75-84 years	358	358	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	578	580	126.3
≥ 85 years	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	158	26.8
Black or African										
0-40 years	263	263	****	****	****	****	290.04 (40.85, 2,059.10)	440	441	103.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Number of Exposure Episode Defining Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
41-64 years	2,772	2,772	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,368	6,405	1,623.8
75-84 years	1,264	1,264	****	****	****	****	56.84 (8.01, 403.54)	1,947	1,957	496.8
≥ 85 years	152	152	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Native Hawaiid	n or Other I	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	113	35.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.7
Unknown										
0-40 years	2,069	2,069	****	****	****	****	35.53 (5.01, 252.26)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	7.51 (1.88, 30.02)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	****	****	****	****	36.98 (5.21, 262.53)	3,179	3,197	717.0
≥ 85 years	240	240	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	401	86.0
White										
0-40 years	599	599	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,104	1,112	213.8
41-64 years	9,360	9,360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	54.52 (34.78, 85.48)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	****	****	****	****	20.21 (6.52, 62.67)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,318	2,326	462.5

Xultophy, Other Tachycardia



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	****	****	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group) '									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	Ü	Ü	Ü	i i i i i i i i i i i i i i i i i i i	0.0	J	TVGTV	Ü	· ·	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White				, , ,			, , ,			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	****	****	****	****	662.28 (93.29, 4,701.78)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Car	diac Arrest			,			· · · · ·			
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,344	1,359	254.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

				Number of				Number of	Number of	
				Exposure Episodes				Exposure	Exposure	
			Number of	with an Event per				•	- Episode Defining-	
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-		Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk		Interval)	Dispensings)	Dispensings)	Years
65-74 years	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,360	1,396	263.1
75-84 years	187	187 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiiai		-								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,813	1,835	294.4
75-84 years	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,972	5,050	892.0
65-74 years	5,693	5,693	****	****	****	****	15.16 (2.14, 107.62)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,590	2,625	440.7
≥ 85 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	114	17.3

Bydureon, Cardiac Arrest

American Indian or Alaska Native

Page 368 of 990 cder_mpl1p_wp077



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	*****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.0
> 85 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
Asian	U	O	Ü	IVAIV	0.0	Ü	IVAIV	· ·	O	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africar	American		· ·	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			. .
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	10.7
≥ 85 years	****	****	Ö	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
, Multi-racial				, , ,			, , ,			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	268	268	75.8
65-74 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	537	537	133.3
65-74 years	626	626	****	****	****	****	104.79 (14.76, 743.95)	1,024	1,024	231.4
75-84 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	313	67.9
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	5.6
Ozempic, Cardi										
American Indiai	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	437	439	97.9
65-74 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	623	626	134.3
75-84 years	169	169	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	152	152	37.2
41-64 years	440	440	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	684	686	167.6
65-74 years	825	825	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 1,247.01 (175.65,	480	481	109.9
≥ 85 years	57	57	****	****	****	****	8,852.95)	93	93	18.8
Black or African	American						•			
0-40 years	404	404	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	543	545	141.9
41-64 years	4,747	4,747	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,913	6,942	1,781.0

Page 370 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Number of Exposure Episode Defining Dispensings	Number of Exposure - Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	, ,	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk		Interval)	Dispensings)	Dispensings)	Years
65-74 years	5,789	5,789	****	****	****	****	12.46 (1.76, 88.47)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	****	****	****	****	55.23 (7.78, 392.09)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	199	50.1
41-64 years	699	699	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,070	1,074	269.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	114	32.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiiai		-								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
75-84 years	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,863	4,863	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	****	****	****	5.94 (1.92, 18.43)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	****	****	****	****	7.51 (1.06, 53.30)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,092	3,099	773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White										
0-40 years	1,070	1,070	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	13.00 (4.19, 40.32)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	****	****	****	14.77 (7.39, 29.53)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	****	****	****	****	16.34 (5.27, 50.67)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	00	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,509	1,511	374.1

Rybelsus, Cardiac Arrest

American Indian or Alaska Native

Page 371 of 990 cder_mpl1p_wp077



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

3 2 2 2 4										
				Number of Exposure Episodes				Number of Exposure	Number of Exposure	
			Number of	with an Event per				Episode Defining	- Episode Defining	; -
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	· (Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	913	929	228.9
75-84 years	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	498	506	108.9
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7
Black or African	American									
0-40 years	105	105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	151	156	37.2
41-64 years	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,731	1,774	474.3
65-74 years	2,116	2,116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,914	2,978	819.2
75-84 years	638	638	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	850	859	245.9
≥ 85 years	89	89	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	125	33.5
Multi-racial										
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group) '									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk		Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Unknown		_pcu.cc						2 iop en en go,	Diepenenige/	100.10
0-40 years	967	967	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,381	1,409	369.7
41-64 years	9,300	9,300	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	****	****	****	****	20.07 (2.83, 142.46)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,442	1,467	368.1
≥ 85 years	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	252	255	61.1
White										
0-40 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	358	365	89.7
41-64 years	3,517	3,517	****	****	****	****	20.31 (2.86, 144.21)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,958	7,090	1,668.0
≥ 85 years	629	629	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	944	951	217.3
Wegovy, Cardia										
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.3	96	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

32 2 2 2										
				Number of Exposure Episodes				Number of Exposure	Number of Exposure	
			Number of	with an Event per				•	- Episode Defining	1
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient	•	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other i	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	97	10.5
65-74 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Cardi	ac Arrest			•						
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Page 374 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	<u>)</u>									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardia	c Arrest									
American India	ın or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or Africar										
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	****	****	****	****	185.11 (26.07, 1,314.19)	542	542	160.8
65-74 years	398	398	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	509	509	165.7
75-84 years	98	98	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	122	37.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining	Number of Exposure - Episode Defining-	
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	283	283	79.5
41-64 years	1,362	1,362	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,977	1,978	566.7
65-74 years	605	605	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	822	823	229.4
75-84 years	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,071	2,071	556.2
65-74 years	2,380	2,380	****	****	****	****	55.82 (13.96, 223.20)	3,345	3,346	883.0
75-84 years	1,040	1,040	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,406	1,406	362.4
≥ 85 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	37.5
Trulicity, Cardia	ac Arrest									
American India	n or Alaska									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and the creation										
				Number of Exposure Episodes				Number of Exposure	Number of Exposure	
			Number of	with an Event per				-	- Episode Defining	
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	• •	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk		Interval)	Dispensings)	Dispensings)	Years
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	432	432	98.9
65-74 years	703	703	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,195	1,201	258.5
75-84 years	358	358	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	578	580	126.3
≥ 85 years	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	158	26.8
Black or Africar	n American									
0-40 years	263	263	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	441	103.6
41-64 years	2,772	2,772	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	****	****	****	****	17.50 (2.46, 124.21)	6,368	6,405	1,623.8
75-84 years	1,264	1,264	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,947	1,957	496.8
≥ 85 years	152	152	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years	75	75	****	****	****	****	901.41 (126.97, 6,399.38)	113	113	35.3
≥ 85 years Unknown	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	2,069	2,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	3.75 (0.53, 26.65)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	****	****	****	****	36.98 (5.21, 262.53)	3,179	3,197	717.0
≥ 85 years	240	240	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	401	86.0
White	240	240	Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	400	401	00.0
0-40 years	599	599	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	14.83 (3.71, 59.30)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	11.48 (4.31, 30.58)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	****	****	****	****	26.95 (10.11, 71.80)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,318	2,326	462.5
Xultophy, Card	•	1,333		0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	2,310	2,320	402.5
American India		Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	-	-	-					-	-	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	****	****	Ö	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Black or African	American			, , , , ,			, , ,			
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
•				, ,			, , ,			



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
≥ 85 years	Patients ****	Episodes ****	Event 0	0.00 (0.00, 0.00)	****	at Risk	Interval) 0.00 (0.00, 0.00)	Dispensings) ****	Dispensings) ****	Years 0.2
≥ 65 years Multi-racial			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.2
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years 41-64 years	****	*****	0 0	0.00 (0.00, 0.00)	V.U ****	*****	0.00 (0.00, 0.00)	V ****	V ****	1.2
65-74 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	-	•	-	i i i i i i i i i i i i i i i i i i i	0.0	Ü	TVGTV	Ü	Ü	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
, 75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Ven										
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	Ö	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,344	1,359	254.2
65-74 years	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	ın or Other I	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7

cder_mpl1p_wp077 Page 381 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	•									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
41-64 years	7,367	7,367	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,813	1,835	294.4
75-84 years	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,972	5,050	892.0
65-74 years	5,693	5,693	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,590	2,625	440.7
≥ 85 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	114	17.3
Bydureon, Ven	tricular Tac	hycardia								
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	268	268	75.8
65-74 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	205	205	52.4
75-84 years	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	65	16.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	537	537	133.3
65-74 years	626	626	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,024	1,024	231.4
75-84 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	313	67.9
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	5.6
Ozempic, Venti	ricular Tach	ycardia								
American India	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	437	439	97.9
65-74 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	623	626	134.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	169	169	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	152	152	37.2
41-64 years	440	440	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	684	686	167.6
65-74 years	825	825	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	480	481	109.9
≥ 85 years	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	93	93	18.8
Black or African	American									
0-40 years	404	404	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	543	545	141.9
41-64 years	4,747	4,747	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	****	****	****	****	24.92 (6.23, 99.66)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	199	50.1
41-64 years	699	699	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,070	1,074	269.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 6,201.19 (873.49,	114	114	32.1
75-84 years	****	****	****	****	****	****	44,024.27)	17	17	3.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134	31.0
65-74 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339	339	101.1
75-84 years	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	38.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,863	4,863	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,044	7,066	1,759.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	·									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	
41-64 years	36,779	36,779	****	****	****	****	1.98 (0.28, 14.07)	55,531	55,691	13,797.6
65-74 years	9,509	9,509	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,092	3,099	773.7
≥ 85 years	167	167	Ö	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White				, , ,			, , ,			
0-40 years	1,070	1,070	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	****	****	****	4.33 (0.61, 30.77)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	****	****	****	3.69 (0.92, 14.76)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	****	****	****	****	5.45 (0.77, 38.67)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,509	1,511	374.1
Rybelsus, Vent	ricular Tach	ycardia								
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	913	929	228.9
75-84 years	327	327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	498	506	108.9
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	123	124	23.7
Black or Africar	n American									
0-40 years	105	105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	151	156	37.2
41-64 years	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,731	1,774	474.3
65-74 years	2,116	2,116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,914	2,978	819.2
75-84 years	638	638	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	850	859	245.9
≥ 85 years	89	89	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	125	33.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Multi-racial										
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler 💮							
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown										
0-40 years	967	967	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,381	1,409	369.7
41-64 years	9,300	9,300	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,442	1,467	368.1
≥ 85 years	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	252	255	61.1
White										
0-40 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	358	365	89.7
41-64 years	3,517	3,517	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,958	7,090	1,668.0
≥ 85 years	629	629	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	944	951	217.3
Wegovy, Ventr	icular Tachy	ycardia								
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total	Total	Event Rate per 10,000 Patient-	Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total Observable
	Patients	Exposure Episodes	Event	Interval)	Years at Risk	Days at Risk	Years at Risk (95% Confidence Interval)	Same-Day Dispensings)	Same-Day Dispensings)	Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0 Dispensings)	0	0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	Ü	Ü	Ü	i i i i i i i i i i i i i i i i i i i	0.0	J	TVGTV	Ü	Ü	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	Ö	Ö	Ö	NaN	0.0	0	NaN	0	0	0.0
Black or Africar	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	97	10.5
65-74 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Ventr	icular Tach	ycardia								
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	Ö	Ö	NaN	0.0	Ö	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventri	•									
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	3.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group				Number of Exposure Episodes				Number of Exposure	Number of Exposure	
			Number of	with an Event per				· ·	g- Episode Defining	
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	•	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or Africar	n American									
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	****	****	****	****	185.11 (26.07, 1,314.19)	542	542	160.8
65-74 years	398	398	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	509	509	165.7
75-84 years	98	98	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	122	37.0
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	283	283	79.5
41-64 years	1,362	1,362	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,977	1,978	566.7
65-74 years	605	605	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	822	823	229.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	•	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
75-84 years	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,071	2,071	556.2
65-74 years	2,380	2,380	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,345	3,346	883.0
75-84 years	1,040	1,040	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,406	1,406	362.4
≥ 85 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	37.5
Trulicity, Ventr	icular Tachy	/cardia								
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	432	432	98.9
65-74 years	703	703	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,195	1,201	258.5
75-84 years	358	358	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	578	580	126.3
≥ 85 years	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	158	26.8
Black or African										
0-40 years	263	263	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	441	103.6
41-64 years	2,772	2,772	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,368	6,405	1,623.8
75-84 years	1,264	1,264	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,947	1,957	496.8
≥ 85 years	152	152	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	
41-64 years	278	278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Native Hawaiia	n or Other I	Pacific Islana	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	113	35.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.7
Unknown										
0-40 years	2,069	2,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,529	3,554	839.1
41-64 years	17,051	17,051	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,179	3,197	717.0
≥ 85 years	240	240	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	401	86.0
White										
0-40 years	599	599	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	7.42 (1.04, 52.65)	16,556	16,663	3,686.2
65-74 years	23,462	23,462	****	****	****	****	5.74 (1.44, 22.95)	40,133	40,374	8,753.8
75-84 years	10,295	10,295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,318	2,326	462.5
Xultophy, Vent		•								
American India	n or Alaska									
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
Asian		<u>-</u>		<u>-</u>			-			
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Black or Africar	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia		-	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2
Mounjaro, Ven	tricular Fib	rillation and	Flutter							
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	5.8
65-74 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	23	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.9
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	14.2
65-74 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	101	18.5
75-84 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africar	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	82	14.5
41-64 years	839	839	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,344	1,359	254.2
65-74 years	919	919	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,360	1,396	263.1
75-84 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	254	45.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.6
41-64 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	92	20.1
				•			· · · · · · · · · · · · · · · · · · ·			



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	•									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	11	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other F	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	3.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	77	16.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	1,093	1,093	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,819	1,839	301.7
41-64 years	7,367	7,367	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,502	12,630	2,117.3
65-74 years	1,120	1,120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,813	1,835	294.4
75-84 years	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	291	295	47.9
≥ 85 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	1.8
White										
0-40 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	237	241	39.1
41-64 years	2,914	2,914	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,972	5,050	892.0
65-74 years	5,693	5,693	****	****	****	****	15.16 (2.14, 107.62)	9,225	9,374	1,566.5
75-84 years	1,679	1,679	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,590	2,625	440.7
≥ 85 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	114	17.3
Bydureon, Ven	tricular Fibi	rillation and	Flutter							
American India	n or Alaska	Native								_
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	3.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	6.3
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	9.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	6.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	8.4
41-64 years	125	125	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	183	183	54.8
65-74 years	86	86	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	39.3
75-84 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	10.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.5
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.7
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other F	Pacific Islana	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	10.1
41-64 years	187	187	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	268	268	75.8
65-74 years	143	143	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	205	205	52.4
75-84 years ≥ 85 years	44 ****	44 ****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	65 ****	65 ****	16.2 1.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
White										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	20.4
41-64 years	335	335	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	537	537	133.3
65-74 years	626	626	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,024	1,024	231.4
75-84 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	313	67.9
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	5.6
Ozempic, Vent	ricular Fibri	llation and F	lutter							
American India	n or Alaska	Native								
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.7
41-64 years	283	283	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	437	439	97.9
65-74 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	623	626	134.3
75-84 years	169	169	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	241	241	61.1
≥ 85 years	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	5.0
Asian										
0-40 years	106	106	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	152	152	37.2
41-64 years	440	440	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	684	686	167.6
65-74 years	825	825	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,204	1,207	280.7
75-84 years	318	318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	480	481	109.9
≥ 85 years	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	93	93	18.8
Black or Africar	n American									
0-40 years	404	404	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	543	545	141.9
41-64 years	4,747	4,747	****	****	****	****	15.69 (2.21, 111.42)	6,913	6,942	1,781.0
65-74 years	5,789	5,789	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,109	8,129	2,133.4
75-84 years	1,318	1,318	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,786	1,791	483.7
≥ 85 years	116	116	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	155	41.8
Multi-racial										
0-40 years	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	199	50.1
41-64 years	699	699	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,070	1,074	269.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	114	32.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of	Number of	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day	
		Exposure				Days	•	•	•	
75.04	Patients ****	Episodes ****	Event	Interval)	****	at Risk		Dispensings)	Dispensings)	Years
75-84 years	0	0	0 0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	17 0	17 0	3.4 0.0
≥ 85 years Native Hawaiia	_	-		INdIN	0.0	U	INdiv	U	U	0.0
	*****	*****		0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.2
41-64 years		245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	133	134 339	31.0
65-74 years	245 97	245 97	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	339 117	339 117	101.1 38.1
75-84 years ≥ 85 years	97 ****	97 ****	0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	11 <i>/</i> ****	11 <i>/</i> ****	0.9
Unknown			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.9
0-40 years	4,863	4,863	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,044	7,066	1,759.4
41-64 years	36,779	36,779	****	0.00 (0.00, 0.00)	****	****	1.98 (0.28, 14.07)	55,531	55,691	1,739.4
65-74 years	9,509	9,509	0	0.00 (0.00, 0.01)	****	****	0.00 (0.00, 0.00)	14,060	14,097	3,392.2
75-84 years	2,167	2,167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,092	3,099	3,332.2 773.7
≥ 85 years	167	167	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	235	56.0
White	107	107	Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	233	233	30.0
0-40 years	1,070	1,070	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,673	1,679	395.7
41-64 years	16,757	16,757	****	0.01 (-0.01, 0.02)	****	****	4.33 (0.61, 30.77)	25,369	25,448	6,316.8
65-74 years	37,400	37,400	****	0.00 (-0.00, 0.01)	****	****	1.85 (0.26, 13.11)	55,242	55,400	13,251.3
75-84 years	13,254	13,254	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18,749	18,802	4,650.3
≥ 85 years	1,078	1,078	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,509	1,511	374.1
Rybelsus, Vent				(, ,				,	,-	
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	33	33	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	45	14.7
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	10.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian				·			•			
0-40 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	42	11.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Neurokou	Number of	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure		Tatal	From t Data was 40 000 Dations	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not	
	Number		Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-		Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
41 (4)	Patients	Episodes	Event	Interval)	****	at Risk	Interval)	Dispensings)	Dispensings)	Years
41-64 years	205	205	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	314	324	80.6
65-74 years	641	641	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	913	929	228.9
75-84 years ≥ 85 years	327 75	327 75	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	498 123	506 124	108.9 23.7
Black or African		/5	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	125	124	25.7
-	105	105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	151	156	37.2
0-40 years 41-64 years	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,731	1,774	37.2 474.3
•	2,116	-	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,914	•	474.3 819.2
65-74 years 75-84 years	638	2,116 638	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,914 850	2,978 859	245.9
> 85 years	89	89	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	125	33.5
Multi-racial	03	05	O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	122	123	33.3
0-40 years	36	36	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	15.2
41-64 years	155	155	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	226	231	66.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	43	14.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	Ö	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I			-		-		-	-	
0-40 years	****	****	0	0.00 (0.00, 0.00)	0.0	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	36	11.6
65-74 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	140	50.5
75-84 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	62	19.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
Unknown										
0-40 years	967	967	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,381	1,409	369.7
41-64 years	9,300	9,300	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,460	13,789	3,773.1
65-74 years	3,584	3,584	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,210	5,321	1,328.2
75-84 years	1,000	1,000	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,442	1,467	368.1
≥ 85 years	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	252	255	61.1
White										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
0-40 years	245	245	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	358	365	89.7
41-64 years	3,517	3,517	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,380	5,492	1,353.0
65-74 years	9,861	9,861	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,527	14,838	3,611.2
75-84 years	4,749	4,749	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,958	7,090	1,668.0
≥ 85 years	629	629	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	944	951	217.3
Wegovy, Ventr			lutter							
American India	n or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	4.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Number of Exposure Episode Defining Dispensings	Number of Exposure - Episode Defining Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	131	136	13.6
41-64 years	480	480	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	733	748	84.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	2.1
41-64 years	54	54	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	97	10.5
65-74 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	41	44	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Vent	ricular Fibri	llation and F	lutter							
American India	ın or Alaska	Native								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Dispensings	Number of Exposure Febisode Defining Dispensings (Not Adjusted for Same-Day	
	Patients	Episodes	Event	Interval)		at Risk	·	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.6
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Island	ler							
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	31.6
41-64 years	270	270	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	420	420	130.6
65-74 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	6.3
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
41-64 years	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) 0.00 (0.00, 0.00)	Total Years at Risk ****	Total Days at Risk ****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval) 0.00 (0.00, 0.00)	Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years 8.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	4.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventri	cular Fibrill	ation and Fl	utter							
American India	n or Alaska	Native								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	44	44	12.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	42	8.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	3.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.7
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	17.1
65-74 years	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	20.4
75-84 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	27	27	7.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Black or Africar										
0-40 years	56	56	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	24.0
41-64 years	403	403	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	542	542	160.8
65-74 years	398	398	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	509	509	165.7
75-84 years	98	98	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	122	122	37.0
≥ 85 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.9
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.1
41-64 years	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	29.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure - Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	
Native Hawaiia				mertal	at mon	at mon	meer var,	Diopensings	Diopenomigo	10015
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	6.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	283	283	79.5
41-64 years	1,362	1,362	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,977	1,978	566.7
65-74 years	605	605	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	822	823	229.4
75-84 years	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	198	198	55.3
≥ 85 years	21	21	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.9
White										
0-40 years	112	112	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	190	49.4
41-64 years	1,414	1,414	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,071	2,071	556.2
65-74 years	2,380	2,380	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,345	3,346	883.0
75-84 years	1,040	1,040	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,406	1,406	362.4
≥ 85 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	146	146	37.5
Trulicity, Ventr			lutter							
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	5.4
41-64 years	126	126	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	220	222	50.1
65-74 years	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	218	39.9
75-84 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	73	74	15.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Asian										
0-40 years	55	55	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	97	98	24.7
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	432	432	98.9
65-74 years	703	703	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,195	1,201	258.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

and Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Dispensings	Number of Exposure Episode Defining Dispensings (Not Adjusted for Same-Day Dispensings)	
75-84 years	358	358	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	578	580	126.3
≥ 85 years	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	158	26.8
Black or Africar	n American									
0-40 years	263	263	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	441	103.6
41-64 years	2,772	2,772	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,640	4,677	1,104.3
65-74 years	4,053	4,053	****	****	****	****	17.50 (2.46, 124.21)	6,368	6,405	1,623.8
75-84 years	1,264	1,264	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,947	1,957	496.8
≥ 85 years	152	152	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	249	251	57.7
Multi-racial										
0-40 years	51	51	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91	91	20.2
41-64 years	278	278	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	565	568	125.5
65-74 years	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	55	16.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	22	4.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Native Hawaiia	ın or Other I	-	ler							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	47	47	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	78	21.9
65-74 years	188	188	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	308	312	88.7
75-84 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	113	35.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.7
Unknown										
0-40 years	2,069	2,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,529	3,554	839.1
41-64 years	17,051	17,051	****	****	****	****	3.75 (0.53, 26.65)	30,931	31,157	7,033.1
65-74 years	6,395	6,395	****	****	****	****	10.38 (1.46, 73.67)	11,066	11,127	2,432.4
75-84 years	1,878	1,878	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,179	3,197	717.0
≥ 85 years	240	240	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	401	86.0
White										
0-40 years	599	599	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,104	1,112	213.8
41-64 years	9,360	9,360	****	****	****	****	22.25 (7.17, 68.98)	16,556	16,663	3,686.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Dispensings	Number of Exposure - Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	•	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
65.74	Patients	Episodes	Event *****	Interval) ****	****	at Risk	Interval)	Dispensings)	Dispensings)	Years
65-74 years	23,462	23,462	****	****	****	****	2.87 (0.40, 20.37)	40,133	40,374	8,753.8
75-84 years	10,295	10,295			****	****	6.74 (0.95, 47.83)	17,250	17,332	3,776.9
≥ 85 years	1,335	1,335	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	2,318	2,326	462.5
Xultophy, Vent			Flutter							
American India			•			_		•	•	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Black or African										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.9
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	20.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other I	Pacific Islana	ler							

Page 406 of 990



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining	Number of Exposure - Episode Defining	-
		Number	Exposure	100 Exposure				Dispensings	Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
41-64 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	27.9
65-74 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	13.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11	11	3.8
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	61	61	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	22.2
65-74 years	211	211	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	281	281	83.9
75-84 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	28.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.2

NaN: Not a number

Page 407 of 990 cder_mpl1p_wp077

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and rear								Number of	Number of	
				Number of Exposure					Exposure Episode	
			Number of	Episodes with an				Defining-	Defining-	
		Number	Exposure	Event per 100				Dispensings	Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
	•	ed Tachyar	-							
		laska Nativ								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	4.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63	21.0
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.7
Black or A	African Ame	rican								
2022	191	191	****	****	****	****	352.12 (49.60, 2,499.79)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1
Multi-rac	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2
Native Ho		Other Pacific	: Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown)									
2022	303	303	****	****	****	****	419.44 (104.90, 1,677.16)	442	442	140.9
2023	94	94	****	****	****	****	2,074.69 (518.86, 8,295.75)	127	127	14.7
White										
2022	1,074	1,074	****	****	****	****	390.45 (175.41, 869.12)	1,727	1,727	427.7
2023	160	160	****	****	****	****	553.58 (77.98, 3,930.02)	230	230	31.0
	•	zed Tachyar								
		laska Nativ								
2022	28	28	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	46	46	8.1
2023	16	16	0	0.00 (0.00, 0.00)	~~ **	***	0.00 (0.00, 0.00)	24	25	3.1
Asian										
2022	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2

Page 408 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or A	frican Ame	-		· · · ·			· · · · ·			
2022 2023	794 1,210	794 1,210	****	****	****	*****	417.29 (156.61, 1,111.84) 492.70 (221.35, 1,096.72)	1,245 1,806	1,269 1,841	348.1 231.6
Multi-raci	al									
2022 2023	39 32	39 32	*****	***** 0.00 (0.00, 0.00)	**** ****	*****	2,020.19 (284.56, 14,341.98) 0.00 (0.00, 0.00)	65 60	67 60	22.0 5.0
Native Ha	waiian or C	Other Pacific	Islander							
2022 2023	28 48	28 48	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	37 69	39 70	15.2 8.8
Unknown										
2022 2023	5,131 4,646	5,131 4,646	****	****	****	*****	245.69 (152.74, 395.23) 163.71 (78.04, 343.40)	9,218 7,222	9,311 7,303	2,126.9 636.2
White										
2022 2023	5,530 4,971	5,530 4,971	****	****	****	*****	517.00 (371.20, 720.07) 781.86 (577.81, 1,057.97)	9,183 7,953	9,294 8,110	1,993.0 962.6
	•	d Tachyarrh	•							
		laska Native								
2022 2023	747 154	747 154	****	****	****	*****	1,159.22 (641.97, 2,093.24) 718.01 (101.14, 5,097.36)	1,168 195	1,170 198	282.6 26.4
Asian										
2022 2023	1,279 467	1,279 467	****	****	****	****	400.76 (200.42, 801.37) 934.48 (388.95, 2,245.15)	1,977 636	1,980 639	530.2 84.0
Black or A	frican Ame	rican								
2022 2023	7,567 4,807	7,567 4,807	****	****	*****	***** ****	554.15 (432.89, 709.36) 549.11 (383.93, 785.36)	11,182 6,323	11,214 6,348	3,686.1 895.6
Multi-raci	al									
2022 2023	473 446	473 446	****	****	****	*****	395.78 (127.64, 1,227.16) 227.19 (32.00, 1,612.88)	784 615	786 618	287.4 67.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Ha		Other Pacific						z iepenem ge/	z iepenomge,	100.10
2022 2023	195 234	195 234	*****	***** 0.00 (0.00, 0.00)	****	*****	845.88 (272.81, 2,622.76) 0.00 (0.00, 0.00)	290 312	291 312	129.7 45.6
Unknown										
2022 2023	33,470 20,015	33,470 20,015	****	****	****	*****	266.58 (226.78, 313.35) 229.09 (168.68, 311.13)	53,925 26,037	54,047 26,141	17,321.5 2,457.4
White										
2022 2023	51,170 18,389	51,170 18,389	****	****	****	****	650.99 (596.41, 710.57) 637.93 (539.57, 754.22)	77,661 24,881	77,856 24,984	21,533.3 3,454.9
Rybelsus,	Hospitalize	ed Tachyarrl	nythmia				· · · · · ·	·	·	
American		laska Native								
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	113 13	116 13	31.6 2.0
Asian										
2022 2023	1,069 209	1,069 209	*****	***** 0.00 (0.00, 0.00)	****	****	179.80 (57.99, 557.49) 0.00 (0.00, 0.00)	1,635 254	1,666 259	410.9 43.0
Black or A	African Ame	rican								
2022 2023	2,838 1,312	2,838 1,312	****	****	****	****	439.57 (276.94, 697.69) 535.68 (267.89, 1,071.17)	4,088 1,680	4,170 1,722	1,351.5 258.6
Multi-raci	ial									
2022 2023	140 80	140 80	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	***** ****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	212 114	216 116	81.4 14.8
Native Ha	ıwaiian or C	Other Pacific	Islander							
2022 2023	100 77	100 77	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	140 101	142 107	68.6 17.4
Unknown										
2022 2023	10,665 4,350	10,665 4,350	****	****	****	*****	225.00 (163.02, 310.54) 250.37 (134.71, 465.33)	16,205 5,540	16,537 5,704	5,307.3 593.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White		·								
2022	14,730	14,730	****	****	****	****	522.88 (434.12, 629.79)	22,451	22,861	6,063.9
2023	4,271	4,271	****	****	****	****	636.83 (450.35, 900.53)	5,716	5,875	875.3
		d Tachyarrh	-							
	Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Multi-raci	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native Ha	awaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	161.4
2023	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	7.1
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	38	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
	•	d Tachyarrh	•							
American	Indian or A	laska Native	2							
2022	267	267	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	491	494	103.9
2023	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	7.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year				Number of Exposure				Number of Exposure Episode	Number of Exposure Episode	
		Number	Number of Exposure	Episodes with an Event per 100				Defining- Dispensings	Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	, -	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Asian										
2022	1,253	1,253	****	****	****	****	198.04 (74.33, 527.67)	2,170	2,177	492.0
2023	212	212	****	****	****	****	397.75 (56.03, 2,823.73)	290	292	43.2
Black or A	African Ame	rican								
2022	6,242	6,242	****	****	****	****	546.72 (414.37, 721.35)	10,393	10,462	2,906.8
2023	2,262	2,262	****	****	****	****	601.53 (368.51, 981.89)	3,251	3,269	479.4
Multi-rac	cial									
2022	249	249	****	****	****	****	417.26 (104.35, 1,668.44)	526	530	146.0
2023	124	124	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	208	208	21.8
Native H	awaiian or C	Other Pacific	Islander	, , ,			, ,			
2022	183	183	****	****	****	****	573.53 (143.43, 2,293.27)	313	317	124.1
2023	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	201	28.4
Unknowi	1			, , ,			, , ,			
2022	19,838	19,838	****	****	****	****	297.64 (245.13, 361.38)	37,401	37,641	10,001.7
2023	7,795	7,795	****	****	****	****	446.40 (320.51, 621.73)	11,704	11,795	1,105.9
White	.,	7,755					(0_0.0_, 0, 0, 0,	,,		_,
2022	37,394	37,394	****	****	****	****	631.57 (569.17, 700.80)	65,719	66,059	15,241.0
2022	7,657	7,657	****	****	****	****	679.91 (533.18, 867.03)	11,642	11,748	1,652.2
		l Tachyarrhy	vthmia				079.91 (333.18, 807.03)	11,042	11,740	1,032.2
	•	laska Native								
2022	****	****	****	****	****	****	1,321.93 (186.21, 9,384.83)	98	98	23.8
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Asian			J	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			_,_
2022	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	142	142	46.1
2022	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	6.8
			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	40	40	0.0
	African Ame		****	****	****	****	002.00 (470.20 4.727.24)	0.40	040	225.2
2022	704	704	****	****	****	****	903.89 (470.30, 1,737.21)	940	940	335.3
2023	265	265	71 71 71 71	4-4-4-4-4	44444	10 10 10 10 10	649.85 (162.52, 2,598.46)	329	329	56.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
Multi-raci	ial	<u>.</u>					·			
2022 2023	52 34	52 34	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** ****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	83 51	83 51	33.0 6.6
Native Ha	awaiian or C	Other Pacific	Islander							
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	17 12	17 12	10.1 1.8
Unknown										
2022 2023	1,696 640	1,696 640	****	****	****	*****	224.25 (100.74, 499.15) 472.00 (152.23, 1,463.50)	2,509 802	2,510 803	840.0 98.7
White										
2022 2023	4,057 999	4,057 999	****	****	****	****	624.37 (454.31, 858.08) 772.36 (415.57, 1,435.49)	5,861 1,297	5,862 1,297	1,665.6 222.9
Wegovy,	Hospitalize	d Tachyarrh	ythmia				, , , , ,	,	,	
American	Indian or A	laska Native								
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Asian										
2022 2023	0 ****	0 ****	0 0	NaN 0.00 (0.00, 0.00)	0.0 ****	0 ****	NaN 0.00 (0.00, 0.00)	0	0 ****	0.0 0.4
Black or A	African Ame	rican								
2022 2023	*****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 54	**** 56	1.5 5.6
Multi-raci	ial									
2022 2023	****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 30	**** 30	0.6 3.2
Native Ha	awaiian or C	Other Pacific	Islander							
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown 2022	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	115	115	42.1
2022	527	527	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	807	829	61.3
White			-				(,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
2023	****	****	****	****	****	****	1,066.11 (150.17, 7,568.68)	156	159	15.1
	•	ed Tachyarr	•							
		laska Native								
2022	0 ****	0 ****	0	NaN	0.0 ****	0 ****	NaN	0 ****	0 ****	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or A	frican Ame									
2022	40	40	****	****	****	****	1,724.50 (242.91, 12,242.82)	45	45	21.4
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	6.4
Multi-racio	al									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native Ha	waiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown										
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White										
2022	246	246	****	****	****	****	223.54 (31.49, 1,587.02)	331	331	114.1
2023	133	133	****	****	****	****	549.66 (77.42, 3,902.23)	173	173	26.2
Mounjaro	, Atrial Fib	rillation and	l Flutter							

Page 414 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
American	Indian or A	laska Native	?	-			-			
2022 2023	28 16	28 16	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	46 24	46 25	8.1 3.1
Asian										
2022 2023	97 48	97 48	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	158 66	159 66	32.8 8.2
	African Ame									
2022 2023	794 1,210	794 1,210	****	****	****	****	208.64 (52.18, 834.27) 328.47 (123.28, 875.19)	1,245 1,806	1,269 1,841	348.1 231.6
Multi-rac	ial									
2022 2023	39 32	39 32	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	65 60	67 60	22.0 5.0
Native Ho	awaiian or C	Other Pacific	Islander							
2022 2023	28 48	28 48	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	***** ****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	37 69	39 70	15.2 8.8
Unknown	1									
2022 2023	5,131 4,646	5,131 4,646	****	****	****	***** ****	115.62 (57.82, 231.20) 140.32 (63.04, 312.34)	9,218 7,222	9,311 7,303	2,126.9 636.2
White										
2022 2023	5,530 4,971	5,530 4,971	****	****	****	*****	369.29 (249.53, 546.52) 428.16 (284.52, 644.32)	9,183 7,953	9,294 8,110	1,993.0 962.6
_	-	rillation and								
American 2022 2023	***** *****	laska Native **** ****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	19 ****	19 ****	4.9 0.7
Asian										
2022 2023	38 18	38 18	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	63 26	63 26	21.0 3.7
Black or A	African Ame	rican								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Tatal	Event Pate nor 10 000 Patient	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	Total
	of	Exposure	with an	(95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Same-Day	Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
2022	191	191	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	298	298	100.7
2023	65	65	Ö	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1
Multi-rac	ial			, , ,			, , ,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2
Native Ho	awaiian or C	Other Pacific	Islander				• • •			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	303	303	****	****	****	****	209.72 (29.54, 1,488.88)	442	442	140.9
2023	94	94	****	****	****	****	2,074.69 (518.86, 8,295.75)	127	127	14.7
White										
2022	1,074	1,074	****	****	****	****	260.30 (97.69, 693.56)	1,727	1,727	427.7
2023	160	160	****	****	****	****	553.58 (77.98, 3,930.02)	230	230	31.0
Ozempic,	Atrial Fibri	llation and	Flutter				·			
American	Indian or A	laska Native	2							
2022	747	747	****	****	****	****	948.45 (493.49, 1,822.87)	1,168	1,170	282.6
2023	154	154	****	****	****	****	718.01 (101.14, 5,097.36)	195	198	26.4
Asian										
2022	1,279	1,279	****	****	****	****	150.28 (48.47, 465.98)	1,977	1,980	530.2
2023	467	467	****	****	****	****	373.79 (93.48, 1,494.62)	636	639	84.0
Black or A	African Ame	rican								
2022	7,567	7,567	****	****	****	****	263.88 (184.50, 377.41)	11,182	11,214	3,686.1
2023	4,807	4,807	****	****	****	****	201.34 (111.50, 363.56)	6,323	6,348	895.6
Multi-rac	ial									
2022	473	473	****	****	****	****	131.93 (18.58, 936.58)	784	786	287.4
2023	446	446	****	****	****	****	227.19 (32.00, 1,612.88)	615	618	67.8
Native Ho	awaiian or C	Other Pacific	Islander							
2022	195	195	****	****	****	****	563.92 (141.03, 2,254.85)	290	291	129.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	312	312	45.6
Unknown										
2022	33,470	33,470	****	****	****	****	154.14 (124.62, 190.66)	53,925	54,047	17,321.5
2023	20,015	20,015	****	****	****	****	106.16 (67.72, 166.44)	26,037	26,141	2,457.4
White										
2022	51,170	51,170	****	****	****	****	454.78 (409.55, 505.02)	77,661	77,856	21,533.3
2023	18,389	18,389		****	****	****	367.86 (295.06, 458.62)	24,881	24,984	3,454.9
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	116	31.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	2.0
Asian				, , ,			, , ,			
2022	1,069	1,069	****	****	****	****	119.87 (29.98, 479.29)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0
Black or A	African Ame	rican								
2022	2,838	2,838	****	****	****	****	268.63 (148.76, 485.06)	4,088	4,170	1,351.5
2023	1,312	1,312	****	****	****	****	267.84 (100.52, 713.65)	1,680	1,722	258.6
Multi-raci	ial									
2022	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	212	216	81.4
2023	80	80	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	116	14.8
		Other Pacific								
2022	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	142	68.6
2023	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	107	17.4
Unknown										
2022 2023	10,665 4,350	10,665 4,350	****	****	****	*****	115.54 (73.70, 181.14) 150.22 (67.49, 334.38)	16,205 5,540	16,537 5,704	5,307.3 593.0
	4,330	4,330					130.22 (07.43, 334.38)	3,340	5,704	333.U
White	14 720	14 720	****	****	****	****	405 11 (227 04 500 46)	22.451	22.061	6.062.0
2022 2023	14,730 4,271	14,730 4,271	****	****	****	****	405.11 (327.94, 500.46) 417.92 (272.48, 640.98)	22,451 5,716	22,861 5,875	6,063.9 875.3
2023	4,∠/⊥	4,211					717.32 (272.40, 040.30)	3,710	3,073	0/3.3



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
		<mark>lation and F</mark> laska Native								
2022	0			NaN	0.0	0	NaN	0	0	0.0
2022	0	0 0	0 0	NaN	0.0	0 0	NaN	0 0	0 0	0.0
Asian	Ü	Ü	O	IVUIV	0.0	Ū	IVAIV	Ü	Ü	0.0
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	56	5.6
Multi-raci	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	3.2
	awaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	77	77	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	115	115	42.1
2023	527	527	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	807	829	61.3
White			_							
2022	****	****	0 ****	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	****	****	3.3
2023		lation and F		4, 4, 4, 4,	4, 4, 4, 4, 4	4444	1,066.11 (150.17, 7,568.68)	156	159	15.1
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	Ö	NaN	0.0	0	NaN	0	Ö	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Page 418 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or A	African Ame	rican								
2022 2023	****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	2.7 0.7
Multi-rac	cial									
2022 2023	*****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** ****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	1.1 0.0
Native H	awaiian or C	Other Pacific	Islander							
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Unknown	1									
2022 2023	295 49	295 49	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	470 62	470 62	161.4 7.1
White										
2022 2023	*****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	38 ****	38 ****	15.6 0.9
		ation and Fl								
		laska Native								
2022 2023	*****	*****	*****	***** 0.00 (0.00, 0.00)	*****	*****	1,321.93 (186.21, 9,384.83) 0.00 (0.00, 0.00)	98 ****	98 ****	23.8 1.2
Asian										
2022 2023	110 27	110 27	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	142 40	142 40	46.1 6.8
Black or A	African Ame	rican								
2022 2023	704 265	704 265	****	****	**** ****	*****	502.16 (209.01, 1,206.47) 649.85 (162.52, 2,598.46)	940 329	940 329	335.3 56.2
Multi-rac	cial									
2022 2023	52 34	52 34	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	**** ****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	83 51	83 51	33.0 6.6



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Ha		Other Pacific		· · · ·						
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	17 12	17 12	10.1 1.8
Unknown										
2022 2023	1,696 640	1,696 640	****	****	*****	*****	112.12 (36.16, 347.65) 314.67 (78.70, 1,258.21)	2,509 802	2,510 803	840.0 98.7
White										
2022 2023	4,057 999	4,057 999	*****	****	*****	*****	427.20 (290.87, 627.43) 386.18 (160.74, 927.83)	5,861 1,297	5,862 1,297	1,665.6 222.9
		lation and F					380.18 (100.74, 327.83)	1,237	1,237	222.5
		laska Native								
2022 2023	267 35	267 35	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	491 60	494 61	103.9 7.8
Asian										
2022 2023	1,253 212	1,253 212	****	****	*****	*****	148.53 (47.90, 460.54) 397.75 (56.03, 2,823.73)	2,170 290	2,177 292	492.0 43.2
Black or A	frican Ame	rican								
2022 2023	6,242 2,262	6,242 2,262	****	****	*****	*****	317.10 (220.36, 456.31) 263.17 (125.46, 552.03)	10,393 3,251	10,462 3,269	2,906.8 479.4
Multi-raci	al									
2022 2023	249 124	249 124	**** 0	***** 0.00 (0.00, 0.00)	*****	**** ****	208.63 (29.39, 1,481.14) 0.00 (0.00, 0.00)	526 208	530 208	146.0 21.8
Native Ha	waiian or C	Other Pacific	Islander							
2022 2023	183 138	183 138	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** ****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	313 199	317 201	124.1 28.4
Unknown										
2022 2023	19,838 7,795	19,838 7,795	****	****	****	*****	186.75 (146.17, 238.60) 280.59 (184.76, 426.15)	37,401 11,704	37,641 11,795	10,001.7 1,105.9



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White		·								
2022	37,394	37,394	****	****	****	****	482.13 (428.01, 543.09)	65,719	66,059	15,241.0
2023	7,657	7,657	****	****	****	****	491.63 (369.38, 654.34)	11,642	11,748	1,652.2
		illation and								
	Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.0
Black or A	African Ame	rican								
2022	40	40	****	****	****	****	1,724.50 (242.91, 12,242.82)	45	45	21.4
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	6.4
Multi-rac	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native Ho	awaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown	1									
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White										
2022	246	246	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	331	331	114.1
2023	133	133	****	****	****	****	549.66 (77.42, 3,902.23)	173	173	26.2
	o, Sinus Tac		_		_	_		_	_	_
American		laska Native								
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	8.1
2023	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24	25	3.1



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	raticints	Lpisoucs	LVCIIC	meervary	at Misk	at misk	meer vary	Dispensings	Dispensings	icuis
2022	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2
Black or A	African Ame	rican		, , ,			, , ,			
2022	794	794	****	****	****	****	208.64 (52.18, 834.27)	1,245	1,269	348.1
2023	1,210	1,210	****	****	****	****	164.23 (41.07, 656.70)	1,806	1,841	231.6
Multi-rac	ial									
							2,020.19 (284.56,			
2022	39	39	****	****	****	****	14,341.98)	65	67	22.0
2023	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	60	5.0
Native Ho	awaiian or C	Other Pacific	Islander							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	39	15.2
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	69	70	8.8
Unknown										
2022	5,131	5,131	****	****	****	****	101.17 (48.23, 212.21)	9,218	9,311	2,126.9
2023	4,646	4,646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,222	7,303	636.2
White										
2022	5,530	5,530	****	****	****	****	88.63 (39.82, 197.28)	9,183	9,294	1,993.0
2023	4,971	4,971	****	****	****	****	297.85 (182.47, 486.19)	7,953	8,110	962.6
_	n, Sinus Tac	n ycardia Iaska Native	3							
2022	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	4.9
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	19 ****	4.9 0.7
Asian			J	3.55 (5.55, 5.55)			0.00 (0.00, 0.00)			0.7
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63	21.0
2022	38 18	38 18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.7
	African Ame		J	3.33 (3.33) 3.33)			2.22 (2.20) 2.20)	_0	_0	J.,
2022	191	191	****	****	****	****	352.12 (49.60, 2,499.79)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1

Page 422 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100				Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	, -	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	-	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
Multi-ra	Patients	Episodes	Event	Interval)	at KISK	at Risk	Interval)	Dispensings)	Dispensings)	Years
	*****	****	•	0.00 (0.00, 0.00)	****	****	0.00 (0.00 0.00)	27	27	45.4
2022 2023	****	****	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37 15	37 15	15.4 2.2
		04/ D:f: -	•	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	15	15	2.2
	*****	Other Pacific		0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	****	****	0.5
2022 2023			0	0.00 (0.00, 0.00)	0.0		0.00 (0.00, 0.00)			0.5
	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow		202	•	0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	4.40		440.0
2022	303	303	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	140.9
2023	94	94	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	127	127	14.7
White			_				/			
2022	1,074	1,074	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,727	1,727	427.7
2023	160	160	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	230	31.0
	, Sinus Tach	Naska Native	<u> </u>							
	747	747	****	****	****	****	210 77 (52 71 942 76)	1 160	1 170	202.6
2022 2023	747 154	747 154	0	0.00 (0.00, 0.00)	****	****	210.77 (52.71, 842.76) 0.00 (0.00, 0.00)	1,168 195	1,170 198	282.6 26.4
Asian	134	134	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	193	190	20.4
	4 270	4 270	****	****	****	****	450 30 (40 47 465 00)	4.077	4.000	F20.2
2022 2023	1,279 467	1,279 467	****	****	****	****	150.28 (48.47, 465.98)	1,977 636	1,980 639	530.2 84.0
	_						186.90 (26.33, 1,326.83)	030	039	84.0
	African Ame		****	****	*****	****	222 24 /424 44 224 44)	44.400	44.044	0.606.4
2022	7,567	7,567	****	****	****	****	202.31 (134.44, 304.44)	11,182	11,214	3,686.1
2023	4,807	4,807					237.95 (138.16, 409.79)	6,323	6,348	895.6
Multi-ra				****	de de de de de					
2022	473	473	****		*****	*****	263.85 (65.99, 1,055.02)	784	786	287.4
2023	446	446	0	0.00 (0.00, 0.00)	*******	****	0.00 (0.00, 0.00)	615	618	67.8
		Other Pacific								
2022	195	195	****	****	****	****	281.96 (39.72, 2,001.72)	290	291	129.7
2023	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	312	312	45.6



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown										
2022 2023	33,470 20,015	33,470 20,015	****	****	*****	*****	83.42 (62.48, 111.37) 72.64 (42.18, 125.10)	53,925 26,037	54,047 26,141	17,321.5 2,457.4
White	E4 470	54 470	****	****	****	****	422.44.(00.70.440.54)	77.664	77.056	24 522 2
2022 2023	51,170 18,389	51,170 18,389	****	****	****	****	122.14 (99.79, 149.51) 200.23 (148.50, 269.98)	77,661 24,881	77,856 24,984	21,533.3 3,454.9
	Sinus Tach						200.23 (140.30, 203.30)	24,001	24,304	3,434.3
American	Indian or A	laska Native	2							
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	113 13	116 13	31.6 2.0
Asian										
2022	1,069	1,069	****	****	****	****	59.93 (8.44, 425.48)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0
Black or A	frican Ame									
2022	2,838	2,838	****	****	****	****	146.52 (65.83, 326.15)	4,088	4,170	1,351.5
2023	1,312	1,312	****	****	****	****	200.88 (64.79, 622.86)	1,680	1,722	258.6
Multi-racio										
2022	140	140	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	212	216	81.4
2023	80	80	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	114	116	14.8
		Other Pacific		0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4.40	4.42	60.6
2022 2023	100 77	100 77	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	140 101	142 107	68.6 17.4
Unknown	//	//	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	101	107	17.4
2022	10,665	10,665	****	****	****	****	91.22 (54.99, 151.31)	16,205	16,537	5,307.3
2022	4,350	4,350	****	****	****	****	75.11 (24.22, 232.89)	5,540	5,704	593.0
White	,	,					, , = 22,	-,	-, -	
2022	14,730	14,730	****	****	****	****	94.21 (60.78, 146.03)	22,451	22,861	6,063.9
2023	4,271	4,271	****	****	****	****	179.11 (93.19, 344.24)	5,716	5,875	875.3
Wegovy, S	Sinus Tachy	/cardia								

Page 424 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
	African Ame									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	56	5.6
Multi-rac	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	3.2
Native Ho	awaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown)									
2022	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	115	115	42.1
2023	527	527	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	807	829	61.3
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	159	15.1
	Sinus Tach									
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022 2023	****	****	0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	2.7 0.7
2023 Multi-raci			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.7
2022	1UI ****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2022	****	****	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
	awaiian or C	Other Pacific	_	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.0
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	161.4
2023	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	7.1
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	38	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
	inus Tachy									
		laska Native					/			
2022	****	*****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	98 ****	98 ****	23.8
2023			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.2
Asian	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	142	143	46.1
2022 2023	110 27	110 27	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	142 40	142 40	46.1 6.8
	ء African Ame		O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	40	40	0.0
2022	704	704	****	****	****	****	301.30 (97.17, 934.21)	940	940	335.3
2023	265	265	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	329	329	56.2
Multi-raci			ū	(1.00, 0.00)			1111 (1100) 0100)			
2022	52	52	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	83	83	33.0
2023	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	6.6
	awaiian or C	Other Pacific	Islander	, , , , , , , , , , , , , , , , , , , ,			, , ,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	10.1

Page 426 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.8
Unknown										
2022	1,696	1,696	****	****	****	****	149.50 (56.11, 398.33)	2,509	2,510	840.0
2023	640	640	****	****	****	****	157.33 (22.16, 1,116.96)	802	803	98.7
White										
2022	4,057	4,057	****	****	****	****	131.45 (65.73, 262.84)	5,861	5,862	1,665.6
2023	999	999	****	****	****	****	308.94 (115.95, 823.17)	1,297	1,297	222.9
	Sinus Tachy									
		laska Native		0.00 (0.00 0.00)	4 4 4 4	****	0.00 (0.00 0.00)	404	40.4	100.0
2022 2023	267 35	267 35	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	491 60	494 61	103.9 7.8
2025 Asian	33	33	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	00	01	7.8
2022	1,253	1,253	****	****	****	****	49.51 (6.97, 351.49)	2,170	2,177	492.0
2022	212	212	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,170 290	2,177 292	492.0
	frican Ame		O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	250	232	43.2
2022	6,242	6,242	****	****	****	****	185.88 (115.56, 299.02)	10,393	10,462	2,906.8
2022	2,262	2,262	****	****	****	****	263.17 (125.46, 552.03)	3,251	3,269	479.4
Multi-racio	*	_,						3,232	3,233	
2022	249	249	****	****	****	****	208.63 (29.39, 1,481.14)	526	530	146.0
2023	124	124	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	208	208	21.8
		ther Pacific	Islander	((, ,			
2022	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	317	124.1
2023	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	201	28.4
Unknown				, , ,			, ,			
2022	19,838	19,838	****	****	****	****	87.54 (61.21, 125.20)	37,401	37,641	10,001.7
2023	7,795	7,795	****	****	****	****	114.79 (59.73, 220.62)	11,704	11,795	1,105.9
White										
2022	37,394	37,394	****	****	****	****	97.85 (75.12, 127.45)	65,719	66,059	15,241.0
2023	7,657	7,657	****	****	****	****	83.68 (41.85, 167.33)	11,642	11,748	1,652.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year										
	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years		Years at Risk (95% Confidence	• •	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
Xultophy	, Sinus Tach			<u> </u>				. ,	, , ,	
Americar	Indian or A	laska Native	е							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or A	African Ame	rican								
2022	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	21.4
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	6.4
Multi-rac	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or C	Other Pacific	: Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown	1									
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White										
2022	246	246	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	331	331	114.1
2023	133	133	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	173	173	26.2
	-	tricular Tac	-							
		laska Native								
2022	28	28	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	46	46	8.1
2023	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24	25	3.1
Asian										
2022	97	97	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2

Page 428 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
Plack or I	African Ame	Episodes	Event	intervaij	at RISK	at KISK	Interval)	Dispensings	Dispensings)	Years
	=		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4 245	4 200	240.4
2022 2023	794 1,210	794 1,210	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	1,245 1,806	1,269 1,841	348.1 231.6
		1,210	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	1,806	1,841	231.0
Multi-rac		20	•	0.00 (0.00, 0.00)	****	****	0.00 (0.00 0.00)	65	67	22.0
2022 2023	39 32	39 32	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65 60	67 60	22.0 5.0
			•	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	60	60	5.0
		Other Pacific		0.00 (0.00, 0.00)	****	****	0.00 (0.00 0.00)	27	20	45.2
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	39	15.2
2023	48	48	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	69	70	8.8
Unknown										
2022	5,131	5,131	****	****	*****	*****	28.91 (7.23, 115.58)	9,218	9,311	2,126.9
2023	4,646	4,646	***	ጥ ጥ ጥ ጥ	****	****	23.39 (3.29, 166.03)	7,222	7,303	636.2
White										
2022	5,530	5,530	****	****	****	****	29.54 (7.39, 118.13)	9,183	9,294	1,993.0
2023	4,971	4,971	*****	****	****	****	111.69 (50.18, 248.62)	7,953	8,110	962.6
	•	<mark>tricular Tacl</mark> Ilaska Native								
	*****	****		0.00.(0.00.0.00)	****	****	0.00 (0.00, 0.00)	10	10	4.0
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	19 ****	19 ****	4.9 0.7
			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.7
Asian	20	20	•	0.00 (0.00, 0.00)	****	****	0.00 (0.00 0.00)	63	62	24.0
2022	38 18	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63 26	21.0
2023	_	. 18	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	26	26	3.7
	African Ame				ala ala ala ala -tr	ala ala ala ala -t-	(:			
2022	191	191	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	4. 4. 4. 4. 4	1. 1. 1. 1. T	0.00 (0.00, 0.00)	78	78	13.1
Multi-rac		de de const			4.4			_	_	
2022	****	****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Ha		Other Pacific		meervary	at mon	at mon	micrisul,	Dispensings	Dispensings	10015
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	303	303	****	****	****	****	209.72 (29.54, 1,488.88)	442	442	140.9
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	14.7
White										
2022	1,074	1,074	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,727	1,727	427.7
2023	160	160	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	230	31.0
		ricular Tachy								
		laska Native								
2022	747	747	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,168	1,170	282.6
2023	154	154	0	0.00 (0.00, 0.00)	4. 4. 4. 4.	4.4.4.4.4	0.00 (0.00, 0.00)	195	198	26.4
Asian	4 070	4.070	****	****	******	****	50.00 (7.05.055.54)	4.077	4 000	500.0
2022 2023	1,279 467	1,279 467	****	****	****	****	50.09 (7.06, 355.64)	1,977 636	1,980 639	530.2 84.0
	467 frican Ame						186.90 (26.33, 1,326.83)	030	039	84.0
	=		****	****	****	****	(1 57 /20 25 420 46)	11 100	11 214	2.606.1
2022 2023	7,567 4,807	7,567 4,807	****	****	****	****	61.57 (29.35, 129.16) 91.52 (38.09, 219.88)	11,182 6,323	11,214 6,348	3,686.1 895.6
2023 Multi-raci	•	4,007					91.32 (38.09, 219.88)	0,323	0,348	893.0
2022	473	473	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	784	786	287.4
2022	473 446	446	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	615	618	67.8
		Other Pacific	_	0.00 (0.00) 0.00)			0.00 (0.00, 0.00)	015	010	07.0
2022	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	291	129.7
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	312	312	45.6
Unknown	<i>-</i>		-	()			(, ,	- 		
2022	33,470	33,470	****	****	****	****	25.39 (15.04, 42.87)	53,925	54,047	17,321.5
2023	20,015	20,015	****	****	****	****	39.11 (18.65, 82.04)	26,037	26,141	2,457.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White			****	****	****	****				
2022 2023	51,170 18,389	51,170 18,389	****	****	****	****	53.27 (39.23, 72.35) 51.22 (28.37, 92.49)	77,661 24,881	77,856 24,984	21,533.3 3,454.9
		ricular Tach					31.22 (28.37, 92.49)	24,001	24,904	3,434.9
	•	laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	116	31.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	2.0
Asian										
2022	1,069	1,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0
Black or A	frican Ame	rican								
2022	2,838	2,838	****	****	****	****	24.42 (3.44, 173.37)	4,088	4,170	1,351.5
2023	1,312	1,312	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,680	1,722	258.6
Multi-raci										
2022	140	140	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	212	216	81.4
2023	80	80	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	116	14.8
		Other Pacific		(ala ala ala ala ala	ale ale ale ale ale	()			
2022	100 77	100 77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	142	68.6
2023	//	//	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	101	107	17.4
Unknown 2022	10,665	10,665	****	****	****	****	12 16 (2 04 49 62)	16,205	16,537	5,307.3
2022	4,350	4,350	****	****	****	****	12.16 (3.04, 48.63) 25.04 (3.53, 177.75)	5,540	5,704	5,307.3 593.0
White	4,330	4,330					23.04 (3.33, 177.73)	3,340	3,704	333.0
2022	14,730	14,730	****	****	****	****	42.40 (22.06, 81.48)	22,451	22,861	6,063.9
2022	4,271	4,271	****	****	****	****	59.70 (19.26, 185.12)	5,716	5,875	875.3
		icular Tachy	cardia				33.7 6 (23.23) 233.22)	5,5	3,0.0	0,0.0
	•	laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	raticités	Lpisoucs	LVCIIC	mervary	at mak	at Misk	interval,	Dispensings	Dispensings	icuis
2022 2023	0 ****	0	0 0	NaN 0.00 (0.00, 0.00)	0.0	0	NaN 0.00 (0.00, 0.00)	0 ****	0 ****	0.0 0.4
Black or A	African Ame	rican								
2022 2023	****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 54	**** 56	1.5 5.6
Multi-rac	ial									
2022 2023	*****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 30	**** 30	0.6 3.2
Native Ho	awaiian or C	Other Pacific	Islander							
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Unknown)									
2022 2023	77 527	77 527	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	115 807	115 829	42.1 61.3
White										
2022 2023	*****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 156	***** 159	3.3 15.1
		ricular Tachy								
		laska Native				_		_	_	
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Asian										
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Black or A	African Ame	rican								
2022 2023	*****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	2.7 0.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-rac		Lpisoues	LVEIIC	intervary	at Misk	at Misk	interval)	Dispensings	Dispensings	icais
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	1.1 0.0
Native H	awaiian or (Other Pacific	Islander							
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Unknowr	1									
2022 2023	295 49	295 49	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	470 62	470 62	161.4 7.1
White										
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	38 ****	38 ****	15.6 0.9
	Supraventri	cular Tachyo								
Americar	n Indian or A	Naska Native	2							
2022 2023	****	*****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	98 ****	98 ****	23.8 1.2
Asian										
2022 2023	110 27	110 27	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	142 40	142 40	46.1 6.8
Black or A	African Ame	rican								
2022 2023	704 265	704 265	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	940 329	940 329	335.3 56.2
Multi-rac			-	(,)			(, ,			
2022 2023	52 34	52 34	0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	83 51	83 51	33.0 6.6
	awaiian or (****	Other Pacific ****		0.00 (0.00, 0.00)	.	****	0.00 (0.00, 0.00)	4-	4-	40.4
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	17 12	17 12	10.1 1.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown 2022	1,696	1,696	****	****	****	****	74 75 (10 60, 200 00)	2,509	2.510	840.0
2022	640	640	0	0.00 (0.00, 0.00)	****	****	74.75 (18.69, 298.89) 0.00 (0.00, 0.00)	2,509 802	2,510 803	98.7
White	040	040	Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	002	003	30.7
2022	4,057	4,057	****	****	****	****	32.86 (8.22, 131.40)	5,861	5,862	1,665.6
2023	999	999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,297	1,297	222.9
-	_ •	icular Tachy								
		laska Native								
2022	267	267	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	491	494	103.9
2023	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	7.8
Asian										
2022	1,253	1,253	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,170	2,177	492.0
2023	212	212	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	292	43.2
Black or A	frican Ame									
2022	6,242	6,242	****	****	****	****	21.87 (5.47, 87.44)	10,393	10,462	2,906.8
2023	2,262	2,262	****	****	****	****	75.19 (18.80, 300.66)	3,251	3,269	479.4
Multi-raci	al									
2022	249	249	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	530	146.0
2023	124	124	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	208	208	21.8
Native Ha	waiian or C	Other Pacific	Islander							
2022	183	183	****	****	****	****	286.76 (40.39, 2,035.82)	313	317	124.1
2023	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	201	28.4
Unknown										
2022	19,838	19,838	****	****	****	****	32.10 (17.78, 57.96)	37,401	37,641	10,001.7
2023	7,795	7,795	****	****	****	****	12.75 (1.80, 90.55)	11,704	11,795	1,105.9
White										
2022	37,394	37,394	****	****	****	****	49.81 (34.39, 72.15)	65,719	66,059	15,241.0
2023	7,657	7,657	****	****	****	****	62.76 (28.20, 139.70)	11,642	11,748	1,652.2
Xultophy,	Supravent	ricular Tach	ycardia							

Page 434 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
		laska Native								
2022 2023	0 ****	0 ****	0 0	NaN 0.00 (0.00, 0.00)	0.0 ****	0 ****	NaN 0.00 (0.00, 0.00)	0 ****	0 ****	0.0 0.4
Asian										
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	12 ****	12 ****	3.7 0.8
Black or A	African Ame	rican								
2022 2023	40 30	40 30	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	45 45	45 45	21.4 6.4
Multi-rac	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native Ho	awaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown	1									
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White										
2022	246	246	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	331	331	114.1
2023	133	133	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	173	173	26.2
	Other Ta	laska Native	<u> </u>							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	8.1
2022	26 16	26 16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24	25	3.1
Asian	-	-	ŭ	2.00 (0.00)			5.55 (5.55, 5.55)		-	J
2022	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2
Black or A	African Ame	rican								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years		Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	•	Dispensings)	Dispensings)	Years
2022	794	794	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,245	1,269	348.1
2023	1,210	1,210	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,806	1,841	231.6
Multi-rac	rial									
2022	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	22.0
2023	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	60	5.0
Native H	awaiian or C	Other Pacific	Islander							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	39	15.2
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	69	70	8.8
Unknowr	1									
2022	5,131	5,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,218	9,311	2,126.9
2023	4,646	4,646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,222	7,303	636.2
White										
2022	5,530	5,530	****	****	****	****	14.77 (2.08, 104.87)	9,183	9,294	1,993.0
2023	4,971	4,971	****	****	****	****	93.08 (38.74, 223.63)	7,953	8,110	962.6
	n, Other Tac									
Americar		laska Nativ	е							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	4.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63	21.0
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.7
	African Ame									
2022	191	191	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1
Multi-rac										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2
		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5

Page 436 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

Number of Exposure Exposure Exposure Exposure Defining De	nber of re Episode
	fining- sings (Not
	sted for Total
, , , , , , , , , , , , , , , , , , , ,	ne-Day Observable
	ensings) Years
2023 0 0 0 NaN 0.0 0 NaN 0	0.0
Unknown	
	140.9
2023 94 94 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 127	127 14.7
White	
	,727 427.7
	230 31.0
Ozempic, Other Tachycardia	
American Indian or Alaska Native	
	,170 282.6
	198 26.4
Asian	
	,980 530.2
	639 84.0
Black or African American	
	1,214 3,686.1
2023 4,807 4,807 ***** ***** ***** 73.21 (27.48, 195.08) 6,323 6,	,348 895.6
Multi-racial	
2022 473 473 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 784	786 287.4
2023 446 446 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 615	618 67.8
Native Hawaiian or Other Pacific Islander	
2022 195 195 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 290 2	291 129.7
2023 234 234 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 312	312 45.6
Unknown	
2022 33,470 33,470 ***** ***** ***** 9.07 (3.77, 21.78) 53,925 54	1,047 17,321.5
	5,141 2,457.4
White	
2022 51,170 51,170 ***** ***** ***** 37.68 (26.19, 54.23) 77,661 77	7,856 21,533.3
	1,984 3,454.9



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and real				Number of Exposure				•	Number of Exposure Episode	
			Number of	Episodes with an				Defining-	Defining-	
	Number	Number of	Exposure Episodes	Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Dispensings (Adjusted for	Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years		Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
Rybelsus,	Other Tacl		270.11	er var,	ut Hisk	<u> </u>	ec. va.,	2 is perionigs,	2 is perionings /	100.0
American	Indian or A	laska Native	2							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	116	31.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	2.0
Asian										
2022	1,069	1,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0
Black or A	\frican Ame	rican								
2022	2,838	2,838	****	****	****	****	24.42 (3.44, 173.37)	4,088	4,170	1,351.5
2023	1,312	1,312	****	****	****	****	66.96 (9.43, 475.38)	1,680	1,722	258.6
Multi-raci										
2022	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	212	216	81.4
2023	80	80	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	116	14.8
		Other Pacific								
2022	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	142	68.6
2023	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	107	17.4
Unknown										
2022	10,665	10,665	****	****	****	*****	12.16 (3.04, 48.63)	16,205	16,537	5,307.3
2023	4,350	4,350	0	0.00 (0.00, 0.00)	4, 4, 4, 4, 4,	4.4.4.4.4.	0.00 (0.00, 0.00)	5,540	5,704	593.0
White	44.700	4.4.700	****	****	****	****	4.74 (0.66, 00.44)	22.454	22.054	
2022	14,730	14,730	****	****	****	****	4.71 (0.66, 33.44)	22,451	22,861	6,063.9
2023 Wegovy	4,271 Other Tach	4,271 vcardia	4444	4.4.4.4			79.60 (29.88, 212.10)	5,716	5,875	875.3
		laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	• •	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	56	5.6
Multi-rac	rial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	3.2
Native H	awaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	1									
2022	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	115	115	42.1
2023	527	527	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	807	829	61.3
White				, , ,			, , ,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	159	15.1
	Other Tach	ycardia	-				(,,			
		laska Native	?							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Multi-rac	rial			,			, , ,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	•	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Ho		Other Pacific		intervalj	at Misk	at Misk	interval)	Dispensings	Dispensings	icais
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown		· ·	· ·		0.0	· ·		•	· ·	0.0
2022	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	161.4
2023	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	7.1
White				, , ,			, , ,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	38	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Victoza, C	Other Tachy	/cardia		, ,						
American	Indian or A	Maska Native	2							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	98	98	23.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Asian										
2022	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	142	142	46.1
2023	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	6.8
Black or A	\frican Ame	rican								
2022	704	704	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	940	940	335.3
2023	265	265	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	329	329	56.2
Multi-raci										
2022	52	52	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	83	83	33.0
2023	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	6.6
		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	10.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.8
Unknown										
2022	1,696	1,696	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,509	2,510	840.0
2023	640	640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	802	803	98.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										7 5 5 7 7
2022	4,057	4,057	****	****	****	****	82.15 (34.19, 197.38)	5,861	5,862	1,665.6
2023	999	999	****	****	****	****	154.47 (38.63, 617.66)	1,297	1,297	222.9
	Other Tach	•								
		laska Native	2							
2022	267	267	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	491	494	103.9
2023	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	7.8
Asian										
2022	1,253	1,253	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,170	2,177	492.0
2023	212	212	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	292	43.2
Black or A	African Ame	rican								
2022	6,242	6,242	****	****	****	****	21.87 (5.47, 87.44)	10,393	10,462	2,906.8
2023	2,262	2,262	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,251	3,269	479.4
Multi-rac	ial									
2022	249	249	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	530	146.0
2023	124	124	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	208	208	21.8
Native Ho	awaiian or C	Other Pacific	Islander							
2022	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	317	124.1
2023	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	201	28.4
Unknown	1									
2022	19,838	19,838	****	****	****	****	5.84 (1.46, 23.34)	37,401	37,641	10,001.7
2023	7,795	7,795	****	****	****	****	25.51 (6.38, 102.00)	11,704	11,795	1,105.9
White										
2022	37,394	37,394	****	****	****	****	24.91 (14.75, 42.05)	65,719	66,059	15,241.0
2023	7,657	7,657	****	****	****	****	83.68 (41.85, 167.33)	11,642	11,748	1,652.2
	, Other Tac	•								
		laska Native								
2022 2023	0 ****	0 ****	0 0	NaN 0.00 (0.00, 0.00)	0.0 ****	0 ****	NaN 0.00 (0.00, 0.00)	0 ****	0 ****	0.0 0.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian 2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	2.7
2022	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	12 ****	12 ****	3.7 0.8
	African Ame	rican	· ·	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			0.0
2022	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	21.4
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	6.4
Multi-rac	rial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown)									
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White										
2022	246	246	****	****	****	****	223.54 (31.49, 1,587.02)	331	331	114.1
2023	133	133	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	173	173	26.2
	o, Cardiac A									
		Naska Native								
2022	28	28	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	46	46	8.1
2023	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24	25	3.1
Asian										
2022	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2
	African Ame									
2022	794	794	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,245	1,269	348.1
2023	1,210	1,210	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,806	1,841	231.6



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-rac	cial									
2022	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	22.0
2023	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	60	5.0
Native H	awaiian or (Other Pacific	Islander							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	39	15.2
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	69	70	8.8
Unknowr	1									
2022	5,131	5,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,218	9,311	2,126.9
2023	4,646	4,646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,222	7,303	636.2
White										
2022	5,530	5,530	****	****	****	****	14.77 (2.08, 104.87)	9,183	9,294	1,993.0
2023	4,971	4,971	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,953	8,110	962.6
	n, Cardiac A									
		Maska Nativ								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19 ****	19 ****	4.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	* * * * *	* * * * *	0.7
Asian										
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63	21.0
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.7
	African Ame									
2022	191	191	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1
Multi-rac										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2
		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	202	202	•	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4.42	442	4.40.0
2022	303	303	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	140.9
2023	94	94	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	127	127	14.7
White	1 074	1.074	****	****	****	****	CE 08 (0.17, 4C1.00)	1 727	4 727	427.7
2022 2023	1,074 160	1,074 160	0	0.00 (0.00, 0.00)	****	****	65.08 (9.17, 461.99) 0.00 (0.00, 0.00)	1,727 230	1,727 230	427.7 31.0
	Cardiac Ar		<u> </u>	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	230	230	31.0
		laska Native	2							
2022	747	747	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,168	1,170	282.6
2023	154	154	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	, 195	198	26.4
Asian										
2022	1,279	1,279	****	****	****	****	50.09 (7.06, 355.64)	1,977	1,980	530.2
2023	467	467	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	636	639	84.0
Black or A	frican Ame	rican								
2022	7,567	7,567	****	****	****	****	17.59 (4.40, 70.34)	11,182	11,214	3,686.1
2023	4,807	4,807	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,323	6,348	895.6
Multi-racio	al									
2022	473	473	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	784	786	287.4
2023	446	446	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	615	618	67.8
Native Ha	waiian or C	Other Pacific	Islander							
2022	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	291	129.7
2023	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	312	312	45.6
Unknown										
2022	33,470	33,470	****	****	****	****	5.44 (1.75, 16.87)	53,925	54,047	17,321.5
2023	20,015	20,015	****	****	****	****	5.59 (0.79, 39.67)	26,037	26,141	2,457.4
White										
2022	51,170	51,170	****	****	****	****	16.89 (9.81, 29.09)	77,661	77,856	21,533.3
2023	18,389	18,389	****	****	****	****	4.66 (0.66, 33.06)	24,881	24,984	3,454.9
Rybelsus,	Cardiac Ar	rest								

Page 444 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
American		laska Native						- 1 0 - 7	-1 0-7	
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	116	31.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	2.0
Asian										
2022	1,069	1,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0
Black or A	African Ame	rican								
2022	2,838	2,838	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,088	4,170	1,351.5
2023	1,312	1,312	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,680	1,722	258.6
Multi-rac	ial									
2022	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	212	216	81.4
2023	80	80	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	116	14.8
Native H	awaiian or C	Other Pacific	Islander							
2022	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	142	68.6
2023	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	107	17.4
Unknown)									
2022	10,665	10,665	****	****	****	****	6.08 (0.86, 43.17)	16,205	16,537	5,307.3
2023	4,350	4,350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,540	5,704	593.0
White										
2022	14,730	14,730	****	****	****	****	4.71 (0.66, 33.44)	22,451	22,861	6,063.9
2023	4,271	4,271	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,716	5,875	875.3
	Cardiac Arr									
		laska Native				_		_		
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	_	_	_			_		_		
2022	0 ****	0 ****	0	NaN	0.0 ****	0 ****	NaN	0 ****	0 ****	0.0
2023			0	0.00 (0.00, 0.00)	******	*****	0.00 (0.00, 0.00)	-rr- ጥ ጥ	<i>ጉጉጥጥ</i>	0.4
Black or A	African Ame	rıcan								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	56	5.6
Multi-raci	ial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	3.2
Native Ha	ıwaiian or C	Other Pacific	: Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	115	115	42.1
2023	527	527	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	807	829	61.3
White				, , ,			` , ,			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	159	15.1
	Cardiac Arı	est								_
American	Indian or A	laska Native	е							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
2023	****	****	Ö	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Multi-raci	ial		-	(,,			(,,			-
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	0.0	16	0.00 (0.00, 0.00)	****	****	0.0
	ıwaiian or (Other Pacific		2.00 (0.00)			0.00 (0.00) 0.00)			0.0
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year										
		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	161.4
2023	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	7.1
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	38	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
	Cardiac Arre									
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	98	98	23.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Asian										
2022	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	142	142	46.1
2023	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	6.8
	African Ame									
2022	704	704	****	****	****	****	100.43 (14.15, 713.00)	940	940	335.3
2023	265	265	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	329	329	56.2
Multi-raci	ial									
2022	52	52	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	83	83	33.0
2023	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	6.6
	awaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	10.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.8
Unknown										
2022	1,696	1,696	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,509	2,510	840.0
2023	640	640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	802	803	98.7
White										
2022	4,057	4,057	****	****	****	****	32.86 (8.22, 131.40)	5,861	5,862	1,665.6
2023	999	999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,297	1,297	222.9



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year										
	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Davs	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
Trulicity,	Cardiac Arr	est		·			•	, ,	. 5,	
American	Indian or A	laska Native	2							
2022	267	267	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	491	494	103.9
2023	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	7.8
Asian										
2022	1,253	1,253	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,170	2,177	492.0
2023	212	212	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	292	43.2
	African Ame									
2022	6,242	6,242	****	****	****	****	10.93 (1.54, 77.63)	10,393	10,462	2,906.8
2023	2,262	2,262	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,251	3,269	479.4
Multi-rac										
2022	249	249	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	530	146.0
2023	124	124	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	208	208	21.8
		Other Pacific								
2022	183	183	****	****	****	*****	286.76 (40.39, 2,035.82)	313	317	124.1
2023	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	201	28.4
Unknown				****						
2022	19,838	19,838	****		****	*****	5.84 (1.46, 23.34)	37,401	37,641	10,001.7
2023	7,795	7,795	0	0.00 (0.00, 0.00)	4. 4. 4. 4. 4.	44444	0.00 (0.00, 0.00)	11,704	11,795	1,105.9
White	27.224	27.224	****	****	******	****	45.04 (0.00.00.77)	65.740	66.050	45.044.0
2022	37,394	37,394	****	****	****	****	16.01 (8.33, 30.77)	65,719	66,059	15,241.0
2023 Yultophy	7,657 , Cardiac Ar	7,657	40 40 40 40	4. 4. 4. 4.	4. 4. 4. 4. 4.	****	10.46 (1.47, 74.26)	11,642	11,748	1,652.2
		laska Native	•							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian			-	2.00 (0.00, 0.00)			0.00 (0.00) 0.00)			•••
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	3.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
				•			• • •			



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year								AL 7 C	N 1 C	
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	-	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Black or A	African Ame	rican								
2022	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	21.4
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	6.4
Multi-rac	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknowr	1									
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White							• • •			
2022	246	246	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	331	331	114.1
2023	133	133	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	173	173	26.2
Mounjar	o, Ventricul	ar Tachycar	dia	, , ,			, , ,			
Americar	n Indian or A	laska Native	2							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	8.1
2023	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24	25	3.1
Asian										
2022	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2
Black or A	African Ame	rican		, , ,			,			
2022	794	794	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,245	1,269	348.1
2023	1,210	1,210	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,806	1,841	231.6
Multi-rac		•		, , ,			, ,	•	,	
2022	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	22.0
2023	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	60	5.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

anu real	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Native Ha	waiian or C	Other Pacific	Islander							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	39	15.2
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	69	70	8.8
Unknown										
2022	5,131	5,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,218	9,311	2,126.9
2023	4,646	4,646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,222	7,303	636.2
White										
2022	5,530	5,530	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,183	9,294	1,993.0
2023	4,971	4,971	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,953	8,110	962.6
_	-	ar Tachycar								
		Maska Native								
2022	****	*****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	19 ****	19 ****	4.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63	21.0
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.7
•	frican Ame									
2022	191	191	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1
Multi-raci										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2
		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	303	303	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	140.9
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	14.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White		<u>-</u>		<u>-</u>						
2022	1,074	1,074	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,727	1,727	427.7
2023	160	160	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	230	31.0
Ozempic,	Ventricula	r Tachycard	ia							
		laska Native	2							
2022	747	747	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,168	1,170	282.6
2023	154	154	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	198	26.4
Asian										
2022	1,279	1,279	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,977	1,980	530.2
2023	467	467	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	636	639	84.0
Black or A	African Ame	rican								
2022	7,567	7,567	****	****	****	****	17.59 (4.40, 70.34)	11,182	11,214	3,686.1
2023	4,807	4,807	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,323	6,348	895.6
Multi-rac	ial									
2022	473	473	****	****	****	****	131.93 (18.58, 936.58)	784	786	287.4
2023	446	446	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	615	618	67.8
Native H	awaiian or C	Other Pacific	Islander							
2022	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	291	129.7
2023	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	312	312	45.6
Unknown	1									
2022	33,470	33,470	****	****	****	****	1.81 (0.26, 12.87)	53,925	54,047	17,321.5
2023	20,015	20,015	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26,037	26,141	2,457.4
White										
2022	51,170	51,170	****	****	****	****	5.20 (1.95, 13.85)	77,661	77,856	21,533.3
2023	18,389	18,389	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24,881	24,984	3,454.9
		r Tachycard								
		laska Native								
2022	*****	*****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	113	116	31.6
2023	ጥጥጥ ጥ	****	0	0.00 (0.00, 0.00)	ጥጥጥ	ተ ተተተ	0.00 (0.00, 0.00)	13	13	2.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian										
2022	1,069	1,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0
Black or A	African Ame	rican								
2022	2,838	2,838	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,088	4,170	1,351.5
2023	1,312	1,312	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,680	1,722	258.6
Multi-rac	ial									
2022	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	212	216	81.4
2023	80	80	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	114	116	14.8
Native H	awaiian or C	Other Pacific	Islander							
2022	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	142	68.6
2023	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	101	107	17.4
Unknown	1									
2022	10,665	10,665	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,205	16,537	5,307.3
2023	4,350	4,350	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,540	5,704	593.0
White				, , ,			• • •	•	•	
2022	14,730	14,730	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22,451	22,861	6,063.9
2023	4,271	4,271	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,716	5,875	875.3
		Tachycardi		, ,				•	,	
American	Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or A	African Ame	rican		•						
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
			-	(,)			(/ /			_



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	-	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
A 4 / t	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
Multi-rac	*****	****	•	0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	****	****	2.5
2022 2023	****	****	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			0.6
			•	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	30	30	3.2
		Other Pacific				_		_	_	
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknowr										
2022	77	77	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	115	115	42.1
2023	527	527	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	807	829	61.3
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	156	159	15.1
		r Tachycardi								
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Multi-rac	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or C	Other Pacific	Islander	•			·			
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown				• •						
2022	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	161.4
2023	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	7.1
White				, ,			• • •			
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	38	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
		Tachycardia								
		laska Native	2							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	98	98	23.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
Asian										
2022	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	142	142	46.1
2023	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	6.8
Black or A	frican Ame	rican								
2022	704	704	****	****	****	****	100.43 (14.15, 713.00)	940	940	335.3
2023	265	265	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	329	329	56.2
Multi-racio	al									
2022	52	52	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	83	83	33.0
2023	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	6.6
Native Ha	waiian or C	ther Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	10.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.8
Unknown										
2022	1,696	1,696	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,509	2,510	840.0
2023	640	640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	802	803	98.7
White										
2022	4,057	4,057	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,861	5,862	1,665.6
2023	999	999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,297	1,297	222.9
Trulicity, \	/entricular	Tachycardia	a	<u> </u>			· · · · · ·	·	·	

Page 454 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100				Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-		Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
Amorican	Patients	Episodes Iaska Native	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
				0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	40.4	102.0
2022 2023	267 35	267 35	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	491 60	494 61	103.9 7.8
2025 Asian	33	33	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	00	01	7.0
	1 252	1 252	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2 170	2 177	492.0
2022 2023	1,253 212	1,253 212	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	2,170 290	2,177 292	492.0 43.2
	African Ame		O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	250	232	43.2
2022	6,242	6,242	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,393	10,462	2,906.8
2022	2,262	2,262	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,251	3,269	2,900.8 479.4
Multi-rac	•	2,202	J	0.00 (0.00) 0.00)			0.00 (0.00, 0.00)	3,232	3,233	173.1
2022	249	249	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	530	146.0
2023	124	124	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	208	208	21.8
		Other Pacific		(,,			(2.22, 2.22)			
2022	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	313	317	124.1
2023	138	138	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	201	28.4
Unknown	,			, , ,			, ,			
2022	19,838	19,838	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37,401	37,641	10,001.7
2023	7,795	7,795	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,704	11,795	1,105.9
White										
2022	37,394	37,394	****	****	****	****	5.34 (1.72, 16.55)	65,719	66,059	15,241.0
2023	7,657	7,657	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,642	11,748	1,652.2
	-	r Tachycard								
	Indian or A	laska Native	2							
2022	0 ****	0 ****	0	NaN	0.0 ****	0 ****	NaN	0 ****	0 ****	0.0
2023	<i>ተተተ</i> ቸ	ጥጥ ችችች	0	0.00 (0.00, 0.00)	ጥጥ ጥጥ ጥ	***	0.00 (0.00, 0.00)	ጥጥ ቶ ች ች	<u> </u>	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	12 ****	12 ****	3.7
2023			0	0.00 (0.00, 0.00)	ጥጥጥ ች	****	0.00 (0.00, 0.00)	ተተተ	***	0.8
Black or A	African Ame	rıcan								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk ****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022 2023	40 30	40 30	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	45 45	45 45	21.4 6.4
Multi-raci		30	Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	43	43	0.4
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native Ha	waiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown										
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White										
2022	246	246	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	331	331	114.1
2023	133	133	on and Flutter	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	173	173	26.2
	•	laska Native								
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	8.1
2022	16	16	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	24	25	3.1
Asian			-	(5.55)			0.00 (0.00, 0.00,			
2022	97	97	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	158	159	32.8
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	8.2
Black or A	frican Ame	rican								
2022	794	794	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,245	1,269	348.1
2023	1,210	1,210	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,806	1,841	231.6
Multi-raci										
2022	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	22.0
2023	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	60	5.0
	waiian or C	Other Pacific	Islander							
2022	28	28	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	39	15.2

Page 456 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000 Patient-	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Interval)	Dispensings)	Dispensings)	Years
2023	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	69	70	8.8
Unknown										
2022	5,131	5,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,218	9,311	2,126.9
2023	4,646	4,646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,222	7,303	636.2
White										
2022	5,530	5,530	****	****	****	****	14.77 (2.08, 104.87)	9,183	9,294	1,993.0
2023	4,971	4,971	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,953	8,110	962.6
	•		n and Flutter							
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	4.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	63	63	21.0
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.7
Black or A	frican Ame	rican								
2022	191	191	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	298	298	100.7
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	78	78	13.1
Multi-raci	al									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	15.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.2
Native Ha	waiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	303	303	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	140.9
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	127	14.7
White										
2022	1,074	1,074	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,727	1,727	427.7
2023	160	160	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	230	31.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

N	lumber of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
Pa	atients	Episodes	Event	Interval)		at Risk	Interval)	Dispensings)	Dispensings)	Years
Ozempic, Ve	entricular	Fibrillation	and Flutter	·			·			
American Ind	dian or Al	aska Native								
2022	747	747	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,168	1,170	282.6
2023	154	154	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	198	26.4
Asian										
2022	1,279	1,279	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,977	1,980	530.2
2023	467	467	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	636	639	84.0
Black or Afric	can Amer	ican								
2022	7,567	7,567	****	****	****	****	8.80 (1.24, 62.45)	11,182	11,214	3,686.1
2023	4,807	4,807	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,323	6,348	895.6
Multi-racial										
2022	473	473	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	784	786	287.4
2023	446	446	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	615	618	67.8
Native Hawa	aiian or O	ther Pacific	Islander							
2022	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	290	291	129.7
2023	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	312	312	45.6
Unknown										
2022 3	33,470	33,470	****	****	****	****	1.81 (0.26, 12.87)	53,925	54,047	17,321.5
	20,015	20,015	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26,037	26,141	2,457.4
White										
2022 5	51,170	51,170	****	****	****	****	1.30 (0.18, 9.22)	77,661	77,856	21,533.3
	18,389	18,389	****	****	****	****	4.66 (0.66, 33.06)	24,881	24,984	3,454.9
Rybelsus, Ve	entricular	Fibrillation	and Flutter				· · · · · ·	·		
American Ind	dian or Al	aska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	113	116	31.6
2023 *	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	2.0
Asian										
2022	1,069	1,069	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,635	1,666	410.9
2023	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	254	259	43.0

Page 458 of 990



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	• •	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or A	African Ame	-	LVEIIC	intervalj	at Nisk	at Misk	interval)	Dispensings	Dispensings	icais
2022 2023	2,838 1,312	2,838 1,312	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	4,088 1,680	4,170 1,722	1,351.5 258.6
Multi-raci	ial									
2022 2023	140 80	140 80	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	212 114	216 116	81.4 14.8
Native Ha	awaiian or C	Other Pacific	Islander							
2022 2023	100 77	100 77	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	140 101	142 107	68.6 17.4
Unknown										
2022 2023	10,665 4,350	10,665 4,350	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	16,205 5,540	16,537 5,704	5,307.3 593.0
White										
2022 2023	14,730 4,271	14,730 4,271	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	22,451 5,716	22,861 5,875	6,063.9 875.3
			and Flutter							
American	Indian or A	laska Native	2							
2022 2023	0 0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Asian										
2022 2023	0 ****	0 ****	0 0	NaN 0.00 (0.00, 0.00)	0.0 ****	0 ****	NaN 0.00 (0.00, 0.00)	0 ****	0 ****	0.0 0.4
Black or A	African Ame	rican								
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 54	**** 56	1.5 5.6
Multi-raci	ial									
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 30	**** 30	0.6 3.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Ha		Other Pacific						2 iop chom.go,	2.000	100.10
2022 2023	0 0	0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
Unknown										
2022 2023	77 527	77 527	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	115 807	115 829	42.1 61.3
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
2023	****	*****	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	156	159	15.1
		laska Native	and Flutter							
2022	0		0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0 0	0	NaN	0.0	0	NaN	0 0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Multi-raci										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	0.0	16	0.00 (0.00, 0.00)	****	****	0.0
	awaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	295	295	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	161.4
2023	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	62	62	7.1



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

White	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	38	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
		Fibrillation a								
	1 Inaian or A *****	Alaska Native		0.00 (0.00 0.00)	*****	****	0.00 (0.00.0.00)			22.0
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	98 ****	98 ****	23.8
2023 Asian			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	*****	*****	1.2
2022	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	142	142	46.1
2023	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	40	40	6.8
Black or A	African Ame	erican		, , ,			, , ,			
2022	704	704	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	940	940	335.3
2023	265	265	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	329	329	56.2
Multi-rac	ial									
2022	52	52	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	83	83	33.0
2023	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	51	51	6.6
Native H	awaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	10.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.8
Unknown)									
2022	1,696	1,696	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,509	2,510	840.0
2023	640	640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	802	803	98.7
White										
2022	4,057	4,057	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,861	5,862	1,665.6
2023	999	999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,297	1,297	222.9
		Fibrillation								
		Naska Native								
2022	267	267	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	491	494	103.9
2023	35	35	0	0.00 (0.00, 0.00)	****	***	0.00 (0.00, 0.00)	60	61	7.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

and Year								Number of	Number of	
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Exposure Episode Defining- Dispensings	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	ratients	Lpisoues	LVEIIC	intervary	at Nisk	at Misk	interval)	Dispensings	Dispensings	icais
2022 2023	1,253 212	1,253 212	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	2,170 290	2,177 292	492.0 43.2
Black or A	frican Ame	rican		, , ,			, ,			
2022 2023	6,242 2,262	6,242 2,262	**** 0	***** 0.00 (0.00, 0.00)	****	*****	10.93 (1.54, 77.63) 0.00 (0.00, 0.00)	10,393 3,251	10,462 3,269	2,906.8 479.4
Multi-raci	al									
2022 2023	249 124	249 124	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	526 208	530 208	146.0 21.8
Native Ha	waiian or C	Other Pacific	Islander							
2022 2023	183 138	183 138	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	**** ****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	313 199	317 201	124.1 28.4
Unknown										
2022 2023	19,838 7,795	19,838 7,795	****	****	****	*****	2.92 (0.41, 20.72) 12.75 (1.80, 90.55)	37,401 11,704	37,641 11,795	10,001.7 1,105.9
White										
2022 2023	37,394 7,657	37,394 7,657	****	****	*****	*****	7.12 (2.67, 18.96) 10.46 (1.47, 74.26)	65,719 11,642	66,059 11,748	15,241.0 1,652.2
			n and Flutter							
		laska Native				_		_	_	
2022 2023	****	****	0 0	NaN 0.00 (0.00, 0.00)	0.0 ****	0 ****	NaN 0.00 (0.00, 0.00)	0 ****	0 ****	0.0 0.4
Asian										
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	12 ****	12 ****	3.7 0.8
Black or A	frican Ame	rican								
2022 2023	40 30	40 30	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	45 45	45 45	21.4 6.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-rac	rial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Unknown	1									
2022	83	83	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	42.1
2023	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	49	49	6.5
White				•						
2022	246	246	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	331	331	114.1
2023	133	133	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	173	173	26.2

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

NaN: Not a number

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Nu	mber of Ep	isodes by	Episode Le	ength					
		0-30	days	31-6	0 days	61-90	days	91-18	3 days	184-36	55 days	366-45	55 days	456+	- days
	Total			Number						Number		Number		Number	
	Number		Percent	of	Percent	Number	Percent	Number	Percent	of	Percent	of	Percent	of	Percent
	of	Number of	of Total	Episode	of Total	of	of Total	of	of Total	Episode	of Total	Episode	of Total	Episode	of Total
	Episodes	Episodes	Episodes	S	Episodes	Episodes	Episodes	Episodes	Episodes	S	Episodes	S	Episodes	S	Episodes
Bydureon	1,992	1,053	52.9%	345	17.3%	394	19.8%	167	8.4%	33	1.7%	0	0.0%	0	0.0%
Mounjaro	22,618	13,215	58.4%	5,266	23.3%	2,629	11.6%	1,383	6.1%	125	0.6%	0	0.0%	0	0.0%
Ozempic	139,413	65,739	47.2%	35,625	25.6%	23,139	16.6%	12,813	9.2%	2,083	1.5%	14	0.0%	0	0.0%
Rybelsus	39,924	23,253	58.2%	6,433	16.1%	6,278	15.7%	3,295	8.3%	****	1.7%	****	0.0%	0	0.0%
Saxenda	385	220	57.1%	76	19.7%	50	13.0%	****	8.8%	****	1.3%	0	0.0%	0	0.0%
Trulicity	83,649	40,325	48.2%	17,376	20.8%	14,999	17.9%	9,208	11.0%	1,729	2.1%	12	0.0%	0	0.0%
Victoza	8,683	4,322	49.8%	1,881	21.7%	1,599	18.4%	743	8.6%	****	1.6%	****	0.0%	0	0.0%
Wegovy	761	514	67.5%	173	22.7%	****	8.7%	****	1.1%	0	0.0%	0	0.0%	0	0.0%
Xultophy	594	258	43.4%	110	18.5%	140	23.6%	72	12.1%	14	2.4%	0	0.0%	0	0.0%

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distribution of	of At-Risk Tim	ne in Days, by Episo	ode	
								Standard
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	1	27	29	76	344	50.7	41.4
Mounjaro	22,618	1	27	27	53	309	41.8	31.4
Ozempic	139,413	1	27	37	67	383	50.8	40.4
Rybelsus	39,924	1	29	29	64	380	50.2	41.6
Saxenda	385	2	29	29	59	277	48.9	39.5
Trulicity	83,649	1	27	36	78	383	53.9	44.3
Victoza	8,683	1	29	31	75	369	52.2	42.3
Wegovy	761	1	20	27	44	124	32.0	20.7
Xultophy	594	1	29	41	89	317	58.9	46.8

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		e iroiii ivia				lumber of	Episodes	Censored	due to En	d of Expos	ure Episo	de by Epis	ode Lengt	h		
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	55 days	366-45	55 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode ¹	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	Percent of Total Episodes
Bydureon	1,992	1,617	855	52.9%	275	17.0%	339	21.0%	129	8.0%	19	1.2%	0	0.0%	0	0.0%
Mounjaro	22,618	16,068	9,574	59.6%	3,656	22.8%	1,876	11.7%	918	5.7%	44	0.3%	0	0.0%	0	0.0%
Ozempic	139,413	102,849	46,841	45.5%	26,325	25.6%	18,804	18.3%	9,695	9.4%	****	1.1%	****	0.0%	0	0.0%
Rybelsus	39,924	31,697	19,074	60.2%	4,689	14.8%	5,166	16.3%	2,404	7.6%	364	1.1%	0	0.0%	0	0.0%
Saxenda	385	322	190	59.0%	63	19.6%	41	12.7%	****	8.4%	****	0.3%	0	0.0%	0	0.0%
Trulicity	83,649	65,563	31,662	48.3%	13,195	20.1%	12,513	19.1%	7,184	11.0%	1,009	1.5%	0	0.0%	0	0.0%
Victoza	8,683	6,661	3,293	49.4%	1,435	21.5%	1,303	19.6%	545	8.2%	85	1.3%	0	0.0%	0	0.0%
Wegovy	761	378	253	66.9%	93	24.6%	****	7.7%	****	0.8%	0	0.0%	0	0.0%	0	0.0%
Xultophy	594	405	173	42.7%	74	18.3%	106	26.2%	****	10.6%	****	2.2%	0	0.0%	0	0.0%

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	t-Risk T	ime in Days, b	y Episode	
	Т	otal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Exposure Episode ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	1,617	1	27	29	79	238	51.2	37.1
Mounjaro	22,618	16,068	1	27	27	53	285	43.0	28.0
Ozempic	139,413	102,849	1	27	41	71	383	53.2	37.4
Rybelsus	39,924	31,697	1	29	29	61	332	50.4	37.6
Saxenda	385	322	4	29	29	57	186	47.5	32.0
Trulicity	83,649	65,563	1	27	40	80	344	54.7	40.4
Victoza	8,683	6,661	1	29	32	82	302	53.9	39.7
Wegovy	761	378	1	27	27	49	124	36.6	16.9
Xultophy	594	405	2	29	49	89	241	61.3	43.0

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinei Distribu		200 110111 1410	, 20, 2022			er of Episo	des Censo	ored due t	o Occurre	nce of Ou	tcome of	Interest by	y Episode I	ength		
		Total	0-30	days		days		days		3 days		55 days	366-45		456+	days
		Number of														
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	of	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	of Interest ¹	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon, Hospitalized Tachyarrhythmi	1,992	****	****	58.3%	****	25.0%	****	16.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Hospitalized Tachyarrhythmi	22,618	112	71	63.4%	26	23.2%	****	10.7%	****	2.7%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Hospitalized Tachyarrhythmi	139,413	951	529	55.6%	241	25.3%	101	10.6%	66	6.9%	14	1.5%	0	0.0%	0	0.0%
Rybelsus, Hospitalized Tachyarrhythmi	39,924	219	120	54.8%	55	25.1%	26	11.9%	****	7.3%	****	0.9%	0	0.0%	0	0.0%
Saxenda, Hospitalized Tachyarrhythmi	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity, Hospitalized Tachyarrhythmi	83,649	632	379	60.0%	128	20.3%	67	10.6%	****	7.9%	****	1.3%	0	0.0%	0	0.0%
Victoza, Hospitalized Tachyarrhythmi	8,683	69	32	46.4%	17	24.6%	****	15.9%	****	13.0%	0	0.0%	0	0.0%	0	0.0%



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

sentinei Distribu					-	er of Episo	odes Censo	ored due t	o Occurre	nce of Ou	tcome of I	nterest by	y Episode I	ength_		
		Total	0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
		Number of														
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	of	Number										Number			
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
		of Interest ¹					•				_			_	-	
Wegovy, Hospitalized Tachyarrhythmi	761	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy, Hospitalized Tachyarrhythmi	594	****	0	0.0%	****	66.7%	0	0.0%	****	33.3%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Atrial Fibrillation and Flutter	22,618	68	46	67.6%	14	20.6%	****	10.3%	****	1.5%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Atrial Fibrillation and Flutter	1,992	****	****	62.5%	****	25.0%	****	12.5%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Atrial Fibrillation and Flutter	139,413	593	339	57.2%	139	23.4%	59	9.9%	44	7.4%	12	2.0%	0	0.0%	0	0.0%
Rybelsus, Atrial Fibrillation and Flutter	39,924	149	83	55.7%	34	22.8%	19	12.8%	****	7.4%	****	1.3%	0	0.0%	0	0.0%
Wegovy, Atrial Fibrillation and Flutter	761	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinei Distribu	tea batab	asc mom ivia	, 13, 202	_ to June t		er of Episo	odes Cens	ored due t	o Occurre	nce of Ou	tcome of	nterest by	/ Episode	Length		
		Total Number of Episodes Censored due to		days		days		days		3 days		5 days		5 days	456+	days
	Total	Occurrence														
	Number	of										Percent			Number	
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
Saxenda, Atrial Fibrillation and Flutter	385	of Interest ¹	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0 0	NaN	0	Episodes NaN
Victoza, Atrial Fibrillation and Flutter	8,683	44	20	45.5%	12	27.3%	****	15.9%	****	11.4%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Atrial Fibrillation and Flutter	83,649	445	280	62.9%	90	20.2%	47	10.6%	****	5.4%	****	0.9%	0	0.0%	0	0.0%
Xultophy, Atrial Fibrillation and Flutter	594	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Sinus Tachycardia	22,618	34	19	55.9%	****	29.4%	****	8.8%	****	5.9%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Sinus Tachycardia	1,992	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Sinus Tachycardia	139,413	241	134	55.6%	69	28.6%	22	9.1%	****	6.2%	****	0.4%	0	0.0%	0	0.0%
Rybelsus, Sinus Tachycardia	39,924	57	29	50.9%	18	31.6%	****	8.8%	****	8.8%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Sinus Tachycardia	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinel Distribut	ted Datab	ase from Ma	y 13, 2022	2 to June 3												
													/ Episode I			
		Total	0-30	days	31-60) days	61-90) days	91-183	3 days	184-36	55 days	366-45	5 days	456+	days
		Number of														
		Episodes														
		Censored														
		due to														
	Total	Occurrence		_						_		_		_		
	Number	of Outcome											Number			
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of Chicadae	of Total	of Chicados	of Total
Saxenda, Sinus	385	of Interest ¹	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Tachycardia	363	O	U	ivaiv	U	IValv	U	IValv	U	ivaiv	U	IValv	U	INAIN	U	INdIN
Victoza, Sinus Tachycardia	8,683	20	12	60.0%	****	15.0%	****	15.0%	****	10.0%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Sinus Tachycardia	83,649	128	64	50.0%	26	20.3%	17	13.3%	****	14.8%	****	1.6%	0	0.0%	0	0.0%
Xultophy, Sinus Tachycardia	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro, Supraventricular Tachycardia	22,618	11	****	54.5%	****	27.3%	****	18.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Supraventricular Tachycardia	1,992	****	0	0.0%	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Supraventricular Tachycardia	139,413	87	39	44.8%	34	39.1%	****	13.8%	****	1.1%	****	1.1%	0	0.0%	0	0.0%
Rybelsus, Supraventricular Tachycardia	39,924	16	****	62.5%	****	12.5%	****	12.5%	****	12.5%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Supraventricular Tachycardia	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinel Distribut	ieu Dalab	ase II UIII IVIA	y 13, 2024	to June 3		or of Enica	ados Cons	orod dus t	- Occurs	nce of Com	tcomo cf	Interest by	/ Episode I	onath		
		Total	0-30	days		er of Episo days		ored due t days		a days		55 days	366-45		456+	- days
		Number of		,-				,,	02 20			,.				,.
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	of	Number	Percent	Number	Percent	Number		Number	Percent	Number	Percent	Number	Percent	Number	
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
Courande		of Interest ¹	-										•			
Saxenda, Supraventricular Tachycardia	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Supraventricular Tachycardia	8,683	****	****	50.0%	0	0.0%	0	0.0%	****	50.0%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Supraventricular Tachycardia	83,649	51	31	60.8%	****	23.5%	****	9.8%	****	5.9%	0	0.0%	0	0.0%	0	0.0%
Xultophy, Supraventricular Tachycardia	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro, Other Tachycardia	22,618	****	****	66.7%	****	16.7%	****	16.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Other Tachycardia	1,992	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Other Tachycardia	139,413	59	33	55.9%	11	18.6%	****	13.6%	****	11.9%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Other Tachycardia	39,924	****	****	44.4%	****	22.2%	****	11.1%	****	22.2%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Other Tachycardia	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinei Distribui			,,		•	er of Episo	odes Cens	ored due t	o Occurre	nce of Ou	tcome of	Interest b	y Episode	Length		
		Total	0-30	days	31-60) days	61-90) days	91-18	3 days	184-36	55 days	366-45	5 days	456+	days
		Number of Episodes Censored														
	Total	due to Occurrence														
	Number	of	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	of Interest ¹	Episodes	Episodes	Episodes	Episodes	Episodes		Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Saxenda, Other Tachycardia	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Other Tachycardia	8,683	****	****	42.9%	****	14.3%	****	42.9%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Other Tachycardia	83,649	28	16	57.1%	****	21.4%	****	3.6%	****	14.3%	****	3.6%	0	0.0%	0	0.0%
Xultophy, Other Tachycardia	594	****	0	0.0%	0	0.0%	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Cardiac Arrest	22,618	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Cardiac Arrest	1,992	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Cardiac Arrest	139,413	21	****	47.6%	****	23.8%	****	14.3%	****	14.3%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Cardiac Arrest	39,924	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Cardiac Arrest	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Cardiac Arrest	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Cardiac Arrest	8,683	****	0	0.0%	****	33.3%	0	0.0%	****	66.7%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Cardiac Arrest	83,649	14	****	50.0%	****	21.4%	****	14.3%	****	7.1%	****	7.1%	0	0.0%	0	0.0%



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinel Distrib	uted Datab	ase from Ma	ıy 13, 202	to June 3					_	1.5						
													y Episode			, ,
		Total Number of Episodes Censored		days	31-60) days	61-90) days	91-18	3 days	184-36	55 days	366-45	5 days	456+	· days
	Total	due to Occurrence														
	Number		Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	of Interest ¹	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Xultophy, Cardiac Arrest	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro, Ventricular Tachycardia	22,618	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bydureon, Ventricular Tachycardia	1,992	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic, Ventricular Tachycardia	139,413	****	****	50.0%	****	37.5%	****	12.5%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Ventricular Tachycardia	39,924	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Wegovy, Ventricular Tachycardia	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Ventricular Tachycardia	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Ventricular Tachycardia	8,683	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		use 110111 1110		to June s	-	er of Episc	des Censo	ored due t	o Occurre	nce of Ou	tcome of	Interest by	/ Episode	Length		
		Total	0-30	days	31-60) days	61-90	days	91-18	3 days	184-36	55 days	366-45	5 days	456+	- days
	Total	Number of Episodes Censored due to Occurrence														
	Number	of			Number							Percent			Number	
	of Enicodos	Outcome of Interest ¹	of Enicodes	of Total	of Enicodos	of Total	of Enicodos	of Total	of Enicodes	of Total	of Enicodos	of Total	of Enicodes	of Total	of Enicodos	of Total
Trulicity, Ventricular Tachycardia	83,649	****	*****	100.0%	0	0.0%	0	0.0%	0 0	0.0%	0	0.0%	0 0	0.0%	0	0.0%
Xultophy, Ventricular Tachycardia	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro, Ventricular Fibrillation and Flutter	22,618	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Ventricular Fibrillation and Flutter	1,992	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic, Ventricular Fibrillation and Flutter	139,413	****	****	75.0%	****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Ventricular Fibrillation and Flutter	39,924	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinel Distribu	ited Datab	ase from ivia	y 13, 2024	z to June s												
		Total	0-30	days		er of Episo days		ored due 1 O days		nce of Ou 3 days		Interest by 55 days	1	Length 55 days	456+	- days
	Total Number	Number of Episodes Censored due to Occurrence of		Porcont	Number	Porcont	Number	Porcont	Number	Porcent	Number	Porcent	Number	Porcent	Number	Dorcont
	of	Outcome	of	of Total	Number of	of Total	Number of	of Total	of	of Total	Number of	of Total	Number of	of Total	Number of	Percent of Total
																Episodes
Wegovy, Ventricular Fibrillation and Flutter	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Ventricular Fibrillation and Flutter	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Ventricular Fibrillation and Flutter	8,683	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity, Ventricular Fibrillation and Flutter	83,649	****	****	87.5%	****	12.5%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy, Ventricular Fibrillation and Flutter	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to occurrence of request-defined event.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

Sentinei Distributeu Database Irolli Way 1.	,	(Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon, Hospitalized Tachyarrhythmia	1,992	****	2	14	21	46	89	33.3	29.2
Mounjaro, Hospitalized Tachyarrhythmia	22,618	112	1	9	19	38	166	28.7	29.6
Ozempic, Hospitalized Tachyarrhythmia	139,413	951	1	11	26	51	354	38.5	40.1
Rybelsus, Hospitalized Tachyarrhythmia	39,924	219	1	14	28	52	278	40.4	40.5
Saxenda, Hospitalized Tachyarrhythmia	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity, Hospitalized Tachyarrhythmia	83,649	632	1	11	24	51	326	37.3	41.0
Victoza, Hospitalized Tachyarrhythmia	8,683	69	1	12	35	72	174	44.9	41.6
Wegovy, Hospitalized Tachyarrhythmia	761	****	34	34	34	34	34	34.0	NaN
Xultophy, Hospitalized Tachyarrhythmia	594	****	38	38	57	116	116	70.3	40.7
Mounjaro, Atrial Fibrillation and Flutter	22,618	68	1	9	18	39	119	26.2	24.8
Bydureon, Atrial Fibrillation and Flutter	1,992	****	2	9	18	38	89	27.6	28.2
Ozempic, Atrial Fibrillation and Flutter	139,413	593	1	11	24	51	274	39.2	42.5
Rybelsus, Atrial Fibrillation and Flutter	39,924	149	1	14	27	54	278	42.3	44.0
Wegovy, Atrial Fibrillation and Flutter	761	****	34	34	34	34	34	34.0	NaN
Saxenda, Atrial Fibrillation and Flutter	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Atrial Fibrillation and Flutter	8,683	44	1	12	36	69	155	43.7	38.3
Trulicity, Atrial Fibrillation and Flutter	83,649	445	1	10	22	44	326	34.0	37.9
Xultophy, Atrial Fibrillation and Flutter	594	****	38	38	48	57	57	47.5	13.4
Mounjaro, Sinus Tachycardia	22,618	34	1	10	24	36	166	33.8	37.9
Bydureon, Sinus Tachycardia	1,992	****	22	22	22	22	22	22.0	NaN
Ozempic, Sinus Tachycardia	139,413	241	1	12	26	49	354	35.7	36.7
Rybelsus, Sinus Tachycardia	39,924	57	1	17	28	49	176	39.1	35.3
Wegovy, Sinus Tachycardia	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Sinus Tachycardia	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Sinus Tachycardia	8,683	20	1	10	18	59	113	33.2	33.6
Trulicity, Sinus Tachycardia	83,649	128	1	11	29	69	225	46.6	47.6
Xultophy, Sinus Tachycardia	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Supraventricular Tachycardia	22,618	11	4	12	24	49	86	33.2	26.9



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

Sentinei Distributed Database from May 13	, _3 10 10 10 10 00, 20			Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon, Supraventricular Tachycardia	1,992	****	88	88	88	88	88	88.0	NaN
Ozempic, Supraventricular Tachycardia	139,413	87	1	13	32	52	189	36.2	29.3
Rybelsus, Supraventricular Tachycardia	39,924	16	1	16	24	55	170	45.4	52.3
Wegovy, Supraventricular Tachycardia	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Supraventricular Tachycardia	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Supraventricular Tachycardia	8,683	****	6	7	73	156	174	81.5	87.3
Trulicity, Supraventricular Tachycardia	83,649	51	1	7	25	44	150	31.3	31.1
Xultophy, Supraventricular Tachycardia	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Other Tachycardia	22,618	****	7	7	16	49	75	28.3	27.7
Bydureon, Other Tachycardia	1,992	****	17	17	19	20	20	18.5	2.1
Ozempic, Other Tachycardia	139,413	59	1	10	27	61	155	40.5	37.2
Rybelsus, Other Tachycardia	39,924	****	5	28	40	71	165	58.0	51.8
Wegovy, Other Tachycardia	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Other Tachycardia	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Other Tachycardia	8,683	****	5	8	38	80	83	43.4	35.3
Trulicity, Other Tachycardia	83,649	28	3	14	25	59	194	44.3	45.0
Xultophy, Other Tachycardia	594	****	116	116	116	116	116	116.0	NaN
Mounjaro, Cardiac Arrest	22,618	****	37	37	37	37	37	37.0	NaN
Bydureon, Cardiac Arrest	1,992	****	49	49	49	49	49	49.0	NaN
Ozempic, Cardiac Arrest	139,413	21	3	6	37	69	165	43.7	42.7
Rybelsus, Cardiac Arrest	39,924	****	2	2	10	18	18	10.0	11.3
Wegovy, Cardiac Arrest	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Cardiac Arrest	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Cardiac Arrest	8,683	****	39	39	133	142	142	104.7	57.0
Trulicity, Cardiac Arrest	83,649	14	1	17	33	65	192	49.1	50.9
Xultophy, Cardiac Arrest	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Ventricular Tachycardia	22,618	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bydureon, Ventricular Tachycardia	1,992	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of <i>i</i>	At-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ozempic, Ventricular Tachycardia	139,413	****	1	15	32	43	71	31.3	23.1
Rybelsus, Ventricular Tachycardia	39,924	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy, Ventricular Tachycardia	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Ventricular Tachycardia	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Ventricular Tachycardia	8,683	****	11	11	11	11	11	11.0	NaN
Trulicity, Ventricular Tachycardia	83,649	****	5	5	18	26	26	16.3	10.6
Xultophy, Ventricular Tachycardia	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flutter	22,618	****	33	33	33	33	33	33.0	NaN
Bydureon, Ventricular Fibrillation and Flutter	1,992	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic, Ventricular Fibrillation and Flutter	139,413	****	7	7	12	37	57	22.0	23.8
Rybelsus, Ventricular Fibrillation and Flutter	39,924	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy, Ventricular Fibrillation and Flutter	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Ventricular Fibrillation and Flutter	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Ventricular Fibrillation and Flutter	8,683	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity, Ventricular Fibrillation and Flutter	83,649	****	1	4	15	25	38	15.8	13.9
Xultophy, Ventricular Fibrillation and Flutter	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to occurrence of request-defined event.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number



Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

				Nu	mber of E	pisodes C	ensored d	ue to Occ	urrence o	f User-Def	ined Cens	oring Crit	eria by Epi	isode Len	gth	
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
		Total														
		Number of														
		Episodes														
		Censored														
		due to														
		Occurrence														
	Total	of User-		_		_				_		_		_		_
	Number	Defined	Number		Number		Number		Number		Number		Number		Number	Percent
	of	Censoring	of	of Total	of	of Total		of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Criteria ¹		Episodes	Episodes		Episodes						Episodes		Episodes	
Bydureon	1,992	217	121	55.8%	44	20.3%	34	15.7%	****	5.1%	****	3.2%	0	0.0%	0	0.0%
Mounjaro	22,618	1,563	1,046	66.9%	307	19.6%	146	9.3%	****	3.8%	****	0.3%	0	0.0%	0	0.0%
Ozempic	139,413	12,247	7,017	57.3%	3,040	24.8%	1,256	10.3%	819	6.7%	115	0.9%	0	0.0%	0	0.0%
Rybelsus	39,924	3,153	1,866	59.2%	642	20.4%	362	11.5%	257	8.2%	26	0.8%	0	0.0%	0	0.0%
Saxenda	385	32	19	59.4%	****	25.0%	****	12.5%	****	3.1%	0	0.0%	0	0.0%	0	0.0%
Trulicity	83,649	8,705	5,118	58.8%	1,878	21.6%	935	10.7%	688	7.9%	86	1.0%	0	0.0%	0	0.0%
Victoza	8,683	1,181	691	58.5%	248	21.0%	140	11.9%	****	7.8%	****	0.8%	0	0.0%	0	0.0%
Wegovy	761	43	****	86.0%	****	9.3%	****	4.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy	594	65	35	53.8%	15	23.1%	****	12.3%	****	10.8%	0	0.0%	0	0.0%	0	0.0%

Page 480 of 990 cder_mpl1p_wp077

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

		15 To 10 To		Distr	ibution of A	t-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,992	217	1	12	26	56	344	42.6	50.7
Mounjaro	22,618	1,563	1	10	20	40	241	29.5	29.9
Ozempic	139,413	12,247	1	12	25	49	356	36.7	37.2
Rybelsus	39,924	3,153	1	12	25	53	329	38.4	39.1
Saxenda	385	32	2	10	25	52	166	33.3	33.7
Trulicity	83,649	8,705	1	11	24	51	337	37.4	39.3
Victoza	8,683	1,181	1	12	25	52	297	38.0	38.3
Wegovy	761	43	1	8	17	27	74	20.5	15.6
Xultophy	594	65	2	13	28	57	170	40.0	38.6

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

cder_mpl1p_wp077 Page 481 of 990

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Number	of Episod	es Censor	ed due to	Evidence	of Death	by Episod	e Length			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ¹	•	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	of	of Total	Number of Episodes	of Total	Number of Episodes	Percent of Total Episodes
Bydureon	1,992	****	****	50.0%	****	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro	22,618	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic	139,413	33	24	72.7%	****	12.1%	****	6.1%	****	9.1%	0	0.0%	0	0.0%	0	0.0%
Rybelsus	39,924	****	****	62.5%	****	25.0%	****	12.5%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Saxenda	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity	83,649	58	37	63.8%	****	17.2%	****	8.6%	****	8.6%	****	1.7%	0	0.0%	0	0.0%
Victoza	8,683	****	****	66.7%	****	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Wegovy	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Xultophy	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

cder_mpl1p_wp077 Page 482 of 990

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distri	ibution of A	At-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,992	****	7	7	28	49	49	28.0	29.7
Mounjaro	22,618	****	7	7	11	15	15	11.0	5.7
Ozempic	139,413	33	3	15	22	33	165	32.4	34.6
Rybelsus	39,924	****	9	18	23	51	71	32.9	21.7
Saxenda	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	83,649	58	1	9	20	52	192	36.6	40.9
Victoza	8,683	****	3	13	23	37	39	23.0	13.9
Wegovy	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.



Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Numb	er of Epis	odes Cens	ored due	to Disenro	llment by	Episode	Length			
			0-30	days	31-60) days	61-90) days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ¹	Number of Episodes	of Total	of	of Total	_	of Total		of Total	Number of Episodes	of Total		of Total	Number of Episodes	of Total
Bydureon	1,992	327	160	48.9%	66	20.2%	45	13.8%	44	13.5%	12	3.7%	0	0.0%	0	0.0%
Mounjaro	22,618	1,865	1,130	60.6%	432	23.2%	184	9.9%	****	6.2%	****	0.2%	0	0.0%	0	0.0%
Ozempic	139,413	14,535	6,678	45.9%	3,401	23.4%	2,058	14.2%	2,002	13.8%	****	2.7%	****	0.0%	0	0.0%
Rybelsus	39,924	5,086	2,331	45.8%	1,073	21.1%	718	14.1%	777	15.3%	187	3.7%	0	0.0%	0	0.0%
Saxenda	385	****	****	50.0%	****	30.0%	0	0.0%	****	20.0%	0	0.0%	0	0.0%	0	0.0%
Trulicity	83,649	11,811	4,967	42.1%	2,755	23.3%	1,680	14.2%	1,952	16.5%	457	3.9%	0	0.0%	0	0.0%
Victoza	8,683	1,245	572	45.9%	303	24.3%	173	13.9%	152	12.2%	45	3.6%	0	0.0%	0	0.0%
Wegovy	761	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy	594	76	22	28.9%	22	28.9%	11	14.5%	****	19.7%	****	7.9%	0	0.0%	0	0.0%

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,992	327	1	16	32	74	232	51.4	49.9
Mounjaro	22,618	1,865	1	15	24	46	232	34.8	31.1
Ozempic	139,413	14,535	1	18	36	71	383	51.2	47.5
Rybelsus	39,924	5,086	1	17	38	75	262	54.5	50.6
Saxenda	385	****	8	25	32	60	127	48.1	38.4
Trulicity	83,649	11,811	1	18	41	78	291	56.7	51.4
Victoza	8,683	1,245	1	17	36	68	248	52.2	50.2
Wegovy	761	****	1	10	13	16	24	12.3	7.8
Xultophy	594	76	2	29	54	105	227	70.5	58.5

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Num	ber of Epi	sodes Cer	sored due	e to End o	f Data by I	Episode Le	ength			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
	Total Number	Total Number of Episodes Censored	Number		Number		Number			Percent			Number		Number	
	of Episodes	due to End of Data ¹	•	of Total Episodes		of Total Episodes	of Episodes	of Total Episodes	of Episodes	of Total Episodes		of Total Episodes	of Episodes	of Total Episodes	of Episodes	of Total Episodes
Bydureon	1,992	455	225	49.5%	83	18.2%	58	12.7%	70	15.4%	19	4.2%	0	0.0%	0	0.0%
Mounjaro	22,618	6,524	3,520	54.0%	1,649	25.3%	774	11.9%	503	7.7%	78	1.2%	0	0.0%	0	0.0%
Ozempic	139,413	36,867	17,482	47.4%	9,205	25.0%	4,915	13.3%	4,109	11.1%	1,145	3.1%	11	0.0%	0	0.0%
Rybelsus	39,924	9,529	4,308	45.2%	2,043	21.4%	1,389	14.6%	1,344	14.1%	****	4.6%	****	0.1%	0	0.0%
Saxenda	385	32	12	37.5%	****	15.6%	****	15.6%	****	18.8%	****	12.5%	0	0.0%	0	0.0%
Trulicity	83,649	19,758	7,774	39.3%	4,709	23.8%	3,060	15.5%	3,131	15.8%	1,072	5.4%	12	0.1%	0	0.0%
Victoza	8,683	1,931	816	42.3%	465	24.1%	318	16.5%	246	12.7%	****	4.4%	****	0.1%	0	0.0%
Wegovy	761	354	233	65.8%	79	22.3%	****	10.2%	****	1.7%	0	0.0%	0	0.0%	0	0.0%
Xultophy	594	193	72	37.3%	40	20.7%	34	17.6%	****	19.2%	****	5.2%	0	0.0%	0	0.0%

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,992	455	1	16	32	77	327	54.1	55.4
Mounjaro	22,618	6,524	1	15	28	53	309	40.3	38.4
Ozempic	139,413	36,867	1	16	33	65	383	49.5	50.2
Rybelsus	39,924	9,529	1	17	37	77	380	56.4	56.5
Saxenda	385	32	3	15	54	104	277	78.0	80.4
Trulicity	83,649	19,758	1	19	44	80	383	61.3	58.9
Victoza	8,683	1,931	1	18	40	75	369	56.7	55.3
Wegovy	761	354	1	10	22	42	118	28.7	23.9
Xultophy	594	193	1	20	47	89	317	64.0	58.8

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Number	of Episode	es Censore	d due to	End of Stu	dy Period	by Episod	le Length			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
		Total														
		Number of														
		Episodes														
	Total	Censored														
	Number	due to End	Number	Percent												
	of	of Study	of	of Total												
	Episodes	Period ¹	Episodes													
Bydureon	1,992	0	0	NaN												
Mounjaro	22,618	0	0	NaN												
Ozempic	139,413	0	0	NaN												
Rybelsus	39,924	0	0	NaN												
Saxenda	385	0	0	NaN												
Trulicity	83,649	0	0	NaN												
Victoza	8,683	0	0	NaN												
Wegovy	761	0	0	NaN												
Xultophy	594	0	0	NaN												



Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
	Т	otal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Study Period ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro	22,618	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic	139,413	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Rybelsus	39,924	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	83,649	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza	8,683	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN



Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

						Nur	mber of Epi	sodes by C	bservable	Time					
		0-30	days	31-6	0 days	61-90	days	91-183	3 days	184-36	55 days	366-45	55 days	456+	- days
	Total		Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	Number of	Number of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Episodes	Episodes	Episode	Episodes	Episodes	Episodes	Episodes	Episodes	Episode	Episodes	Episode	Episodes	Episode	Episodes
Bydureon	1,992	252	12.7%	217	10.9%	207	10.4%	665	33.4%	626	31.4%	25	1.3%	0	0.0%
Mounjaro	22,618	3,964	17.5%	4,135	18.3%	3,488	15.4%	7,441	32.9%	3,590	15.9%	0	0.0%	0	0.0%
Ozempic	139,413	19,281	13.8%	19,147	13.7%	17,720	12.7%	41,708	29.9%	40,499	29.0%	1,058	0.8%	0	0.0%
Rybelsus	39,924	4,765	11.9%	4,975	12.5%	4,829	12.1%	12,877	32.3%	12,187	30.5%	291	0.7%	0	0.0%
Saxenda	385	18	4.7%	27	7.0%	27	7.0%	120	31.2%	****	49.6%	****	0.5%	0	0.0%
Trulicity	83,649	9,027	10.8%	9,977	11.9%	10,184	12.2%	27,610	33.0%	26,110	31.2%	741	0.9%	0	0.0%
Victoza	8,683	948	10.9%	1,085	12.5%	1,047	12.1%	2,854	32.9%	2,657	30.6%	92	1.1%	0	0.0%
Wegovy	761	248	32.6%	218	28.6%	166	21.8%	81	10.6%	48	6.3%	0	0.0%	0	0.0%
Xultophy	594	75	12.6%	68	11.4%	81	13.6%	195	32.8%	****	28.8%	****	0.7%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

				Distribution of Ob	servable Time	in Days, by Episode		
	Total Number of							Standard
	Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	2	66	135	206	384	142.4	92.5
Mounjaro	22,618	2	43	87	149	359	103.4	74.1
Ozempic	139,413	2	55	116	199	410	133.1	92.6
Rybelsus	39,924	2	62	127	202	384	138.3	91.1
Saxenda	385	4	110	184	254	372	179.9	87.5
Trulicity	83,649	2	66	130	205	389	141.3	90.8
Victoza	8,683	2	65	130	205	412	140.8	91.6
Wegovy	761	2	23	50	79	363	63.9	65.6
Xultophy	594	2	63	121	204	381	138.0	94.4

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13,2022 to June 30, 2023¹

						Number	of Episode	es Censore	d due to	Evidence o	of Death b	y Observa	able Time			
			0-30	days	31-60	days		days		3 days		5 days	1	55 days	456+	days
		Total														
		Number of														
		Episodes														
	Total	Censored														
	Number	due to	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Evidence of	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Death ²	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes								
Bydureon	1,992	16	****	12.5%	****	37.5%	****	12.5%	****	25.0%	****	12.5%	0	0.0%	0	0.0%
Mounjaro	22,618	20	****	20.0%	****	35.0%	****	20.0%	****	15.0%	****	10.0%	0	0.0%	0	0.0%
Ozempic	139,413	336	62	18.5%	42	12.5%	51	15.2%	131	39.0%	50	14.9%	0	0.0%	0	0.0%
Rybelsus	39,924	113	13	11.5%	22	19.5%	19	16.8%	****	43.4%	****	8.8%	0	0.0%	0	0.0%
Saxenda	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity	83,649	433	72	16.6%	70	16.2%	76	17.6%	166	38.3%	49	11.3%	0	0.0%	0	0.0%
Victoza	8,683	49	****	18.4%	14	28.6%	****	12.2%	16	32.7%	****	8.2%	0	0.0%	0	0.0%
Wegovy	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Xultophy	594	****	0	0.0%	0	0.0%	****	33.3%	****	66.7%	0	0.0%	0	0.0%	0	0.0%



Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13,2022 to June 30, 2023¹ (Continued)

				Distrib	ution of Ob	servable	Time in Days	, by Episo	de
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ²	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,992	16	8	42	64	131	360	100.6	91.8
Mounjaro	22,618	20	8	33	51	114	245	77.4	65.6
Ozempic	139,413	336	4	49	96	149	363	106.8	73.9
Rybelsus	39,924	113	8	50	96	127	260	97.0	57.5
Saxenda	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	83,649	433	2	47	90	147	345	101.0	67.2
Victoza	8,683	49	4	40	75	129	318	87.3	62.9
Wegovy	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	594	****	84	84	166	178	178	142.7	51.2



Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

						Numbe	r of Episo	des Censo	red due t	o Disenro	llment by	Observab	ole Time			
			0-30	days	31-60	days	61-90) days	91-18	3 days	184-36	55 days	366-45	5 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ²	of	of Total	Number of Episode s	of Total	of	of Total	of	of Total	of	of Total	of	of Total		of Total
Bydureon	1,992	1,114	168	15.1%	137	12.3%	126	11.3%	429	38.5%	254	22.8%	0	0.0%	0	0.0%
Mounjaro	22,618	4,744	1,169	24.6%	1,194	25.2%	945	19.9%	1,287	27.1%	149	3.1%	0	0.0%	0	0.0%
Ozempic	139,413	52,607	6,885	13.1%	6,739	12.8%	7,866	15.0%	19,898	37.8%	11,147	21.2%	72	0.1%	0	0.0%
Rybelsus	39,924	16,920	2,347	13.9%	2,310	13.7%	2,349	13.9%	6,258	37.0%	****	21.6%	****	0.0%	0	0.0%
Saxenda	385	33	****	18.2%	****	24.2%	****	6.1%	****	27.3%	****	24.2%	0	0.0%	0	0.0%
Trulicity	83,649	40,348	5,167	12.8%	5,564	13.8%	5,457	13.5%	15,377	38.1%	****	21.7%	****	0.0%	0	0.0%
Victoza	8,683	4,258	585	13.7%	626	14.7%	538	12.6%	1,579	37.1%	****	21.7%	****	0.1%	0	0.0%
Wegovy	761	19	****	47.4%	****	15.8%	****	21.1%	****	10.5%	****	5.3%	0	0.0%	0	0.0%
Xultophy	594	209	22	10.5%	34	16.3%	34	16.3%	81	38.8%	38	18.2%	0	0.0%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

			[Distrib	ution of Ob	servable	Time in Days	, by Episo	de
	Tot	al Number of Episodes Censored due							Standard
	Total Number of Episodes	to Disenrollment ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	1,114	2	53	120	177	360	117.7	70.6
Mounjaro	22,618	4,744	2	31	61	102	328	71.9	51.5
Ozempic	139,413	52,607	2	59	111	173	410	115.9	68.9
Rybelsus	39,924	16,920	2	55	110	173	379	114.7	68.7
Saxenda	385	33	9	40	93	173	318	117.2	93.3
Trulicity	83,649	40,348	2	58	114	173	389	116.2	68.2
Victoza	8,683	4,258	2	54	114	173	412	115.7	70.2
Wegovy	761	19	2	14	31	77	208	49.6	49.7
Xultophy	594	209	3	59	107	170	233	113.8	65.9

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

cder_mpl1p_wp077 Page 495 of 990

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

	•					Numb	er of Epis	odes Cens	ored due	to End of	Data by C	Observable	e Time			
			0-30	days	31-60	days	61-90) days	91-18	3 days	184-36	55 days	366-45	5 days	456+	· days
	Total Number	Censored due	•	of Total	Number of	of Total	of	of Total	of	of Total	of	of Total	_	of Total	_	of Total
	of Episodes	to End of Data ²	Episode s	Episode	Episode s	Episode	Episode s	Episode s	Episode	Episode s	Episode	Episode s	Episode s	Episode s	Episode s	Episode s
Bydureon	1,992	1,875	234	12.5%	188	10.0%	191	10.2%	626	33.4%	611	32.6%	25	1.3%	0	0.0%
Mounjaro	22,618	21,463	3,670	17.1%	3,861	18.0%	3,272	15.2%	7,119	33.2%	3,541	16.5%	0	0.0%	0	0.0%
Ozempic	139,413	131,018	17,817	13.6%	17,849	13.6%	16,431	12.5%	38,773	29.6%	39,090	29.8%	1,058	0.8%	0	0.0%
Rybelsus	39,924	37,408	4,315	11.5%	4,588	12.3%	4,438	11.9%	12,010	32.1%	11,766	31.5%	291	0.8%	0	0.0%
Saxenda	385	358	12	3.4%	19	5.3%	25	7.0%	112	31.3%	****	52.5%	****	0.6%	0	0.0%
Trulicity	83,649	78,057	8,052	10.3%	9,057	11.6%	9,398	12.0%	25,628	32.8%	25,181	32.3%	741	0.9%	0	0.0%
Victoza	8,683	8,060	829	10.3%	970	12.0%	960	11.9%	2,648	32.9%	2,561	31.8%	92	1.1%	0	0.0%
Wegovy	761	750	242	32.3%	216	28.8%	164	21.9%	81	10.8%	47	6.3%	0	0.0%	0	0.0%
Xultophy	594	565	73	12.9%	64	11.3%	73	12.9%	184	32.6%	****	29.6%	****	0.7%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

			[Distrib	ution of Ob	servable	Time in Days	, by Episo	de
		tal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Data ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	1,875	2	68	138	208	384	145.1	93.1
Mounjaro	22,618	21,463	2	44	90	152	359	105.0	74.7
Ozempic	139,413	131,018	2	55	117	201	410	134.9	93.5
Rybelsus	39,924	37,408	2	64	130	205	384	140.6	91.8
Saxenda	385	358	4	117	190	256	372	186.7	84.8
Trulicity	83,649	78,057	2	68	134	207	389	143.9	91.5
Victoza	8,683	8,060	2	67	134	208	412	143.9	92.2
Wegovy	761	750	2	23	51	79	363	64.2	65.7
Xultophy	594	565	2	63	122	207	381	139.2	95.6

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13,2022 to June 30, 2023¹

						Number o	of Episode	s Censore	d due to E	nd of Stud	dy Period	by Observ	able Time			
			0-30	days	31-60) days	61-90	days	91-18	3 days	184-36	5 days	366-45	55 days	456+	days
		Total														
		Number of														
		Episodes														
	Total	Censored														
	Number	due to End			Number		Number		Number		Number		Number		Number	Percent
	of	of Study	of	of Total	of	of Total		of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Period ²	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,992	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro	22,618	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic	139,413	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Rybelsus	39,924	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda	385	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity	83,649	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza	8,683	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Wegovy	761	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Xultophy	594	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13,2022 to June 30, 2023¹ (Continued)

				Distrib	ution of Ob	servable	Time in Days	, by Episo	de
	To	otal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Study Period ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,992	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro	22,618	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic	139,413	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Rybelsus	39,924	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda	385	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	83,649	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza	8,683	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy	761	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	594	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time. and does not consider episode end. outcome

²Represents episodes censored due to user-specified study end date.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 23a. Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 500 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23b. Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 501 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23c. Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
024.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, Unspecified Trimester				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 502 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23d. Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
024.110	Pre-Existing Type 2 Diabetes Mellitus, In	DV	10	****
O24.119	Pregnancy, Unspecified Trimester	DX	10	
000.0	Complete Or Unspecified Spontaneous	51/	4.0	****
003.9	Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 503 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23e. Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Dentine Distributed Database no.	11 May 13, 2022 to June 30, 2023 for Episode	- Transaction			
		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,887	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	351	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	77	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	23	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
5 ,	Laparoscopy, Surgical; With Removal Of		•		,
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
30001	Oophorectomy And/Or Salpingectomy)	17	CT		,
Vultanhy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Xultophy10036	Saxenda		-	****	-
Saxenda		RX	N/A		N/A
	Laparoscopy, Surgical; With Removal Of			ale ale ale ale ale	
58661	Adnexal Structures (Partial Or Total	PX	C4	****	IP
	Oophorectomy And/Or Salpingectomy)				
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
003.9	Abortion Without Complication	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
024.111	Pregnancy, First Trimester	DX	10		ED
000.201	Right Ovarian Pregnancy Without	DX	10	****	ED
000.202	Intrauterine Pregnancy	27.			
	Pre-Existing Type 1 Diabetes Mellitus, In				
O24.011		DX	10	****	AV
	Pregnancy, First Trimester				
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
	Pregnancy, First Trimester				
	Obesity Complicating Pregnancy, First				
099.211	Trimester	DX	10	****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, First Trimester				
	Pre-Existing Type 2 Diabetes Mellitus, In				
024.119	Pregnancy, Unspecified Trimester	DX	10	****	AV
	Unspecified Pre-Existing Diabetes Mellitus				
024.311	In Pregnancy, First Trimester	DX	10	****	AV
	in Fregulaticy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4.4.4.4.4.	N/A
Trulicity	Trulicity	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
zergeneyaepartmentencounter	zmergency Department Encounter	IVA	11/7		
Trulicity	Trulicity	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A		N/A

cder_mpl1p_wp077 Page 504 of 990



Table 23e. Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
003.4	Incomplete Spontaneous Abortion Without Complication	DX	10	****	AV

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 505 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23f. Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of Adnexal			
58661	Structures (Partial Or Total Oophorectomy And/Or	PX	C4	12
	Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
024.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Autophy10030	Complete Or Unspecified Spontaneous Abortion	IX	N/A	
003.9	Without Complication	DX	10	****
	Incomplete Spontaneous Abortion Without			
003.4	·	DX	10	****
	Complication			
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
	Dro Existing Type 1 Dishetes Mellitus In Drognancy			
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy,	DX	10	****
	First Trimester			
024.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy,	DX	10	****
	Unspecified Trimester			
O00.201	Right Ovarian Pregnancy Without Intrauterine	DX	10	****
	Pregnancy		-	
024.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****
	Pregnancy, First Trimester		_•	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 506 of 990



Table 23g. Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 507 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23h. Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
·	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 508 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23i. Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		0-1-	O- 4-	0	5
		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Туре	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	15	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 509 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23j. Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 510 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23k. Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	15	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
	Unspecified Pre-Existing Diabetes				
024.311	Mellitus In Pregnancy, First Trimester	DX	10	****	AV
024.311	Unspecified Pre-Existing Diabetes	DX	10	4. 4. 4. 4. 4.	OA
	Mellitus In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	ጥ ጥ ጥ ጥ	N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 511 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23I. Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
	Unspecified Pre-Existing Diabetes Mellitus			
O24.311	In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 512 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23m. Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX RX RX RX	N/A N/A N/A N/A	47 20 18 12	N/A N/A N/A N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Xultophy10036 O03.9 O03.9 O03.9	Xultophy 100/3.6 Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous	DX DX DX DX	N/A 10 10 10	****	N/A AV OA ED
Saxenda	Abortion Without Complication Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 513 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23n. Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	12
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 514 of 990



Table 23o. Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	12	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 515 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23p. Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	12
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 516 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23q. Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter Inpatientencounter	Emergency Department Encounter Inpatient Encounter	RX RX	N/A N/A	****	N/A N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 517 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23r. Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	51
Inpatientencounter	Inpatient Encounter	RX	N/A	16
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 518 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23s. Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	92	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, Unspecified Trimester				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 519 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23t. Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
024.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 520 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23u. Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 521 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23v. Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 522 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23w. Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Jenemer Distributed Butabase nor	11 May 13, 2022 to June 30, 2023 for Episode	Truncation			
		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,887	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	351	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
, Victoza	, Victoza	RX	N/A	77	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	23	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
.	Laparoscopy, Surgical; With Removal Of		•		•
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A
Saxerraa	Laparoscopy, Surgical; With Removal Of	101	11,71		, , .
58661	Adnexal Structures (Partial Or Total	PX	C4	****	IP
30001	Oophorectomy And/Or Salpingectomy)	17	CŦ		"
	Complete Or Unspecified Spontaneous				
003.9		DX	10	****	AV
	Abortion Without Complication				
024.444	Pre-Existing Type 2 Diabetes Mellitus, In	D.V	40		
024.111	Pregnancy, First Trimester	DX	10	****	ED
O00.201	Right Ovarian Pregnancy Without	DX	10		ED
	Intrauterine Pregnancy				
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****	AV
024.011	Pregnancy, First Trimester	DΛ	10		,,,,
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
024.111	Pregnancy, First Trimester	DX	10		LD
	Obesity Complicating Pregnancy, First				
099.211	Trimester	DX	10	****	AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, First Trimester				
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	AV
	Unspecified Pre-Existing Diabetes Mellitus				
024.311	In Pregnancy, First Trimester	DX	10	****	AV
	mirregilaticy, rinse trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
		11/1			
Trulicity	Trulicity	RX	N/A	****	N/A
	Inpatient Encounter			4-4-4-4-4-4	N/A

cder_mpl1p_wp077 Page 523 of 990



Table 23w. Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
003.4	Incomplete Spontaneous Abortion	DX	10	****	AV
	Without Complication	DX			AV

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 524 of 990



Table 23v. Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	12
	Oophorectomy And/Or Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
	Pre-Existing Type 2 Diabetes Mellitus, In		-	
024.111	Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
	Complete Or Unspecified Spontaneous		-	
003.9	Abortion Without Complication	DX	10	****
	Incomplete Spontaneous Abortion Without			
003.4	Complication	DX	10	****
	Obesity Complicating Pregnancy, First			
099.211	Trimester	DX	10	****
	Pre-Existing Type 1 Diabetes Mellitus, In			
O24.011		DX	10	****
	Pregnancy, First Trimester			
024.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, Unspecified Trimester			
000.201	Right Ovarian Pregnancy Without Intrauterine	DX	10	****
	Pregnancy		-	
024.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****
U24.311	Pregnancy, First Trimester	<i>Σ</i> Λ 10		

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 525 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23y. Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 526 of 990



Table 23z. Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
•	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 527 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23aa. Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	23	N/A
Linergencydepartmentencounter	Encounter	IVA	IN/A	23	N/A
Ozempic	Ozempic	RX	N/A	12	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 528 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ab. Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	12
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 529 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ac. Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
	Emergency Department	RX	N/A	45	N1 / A
Emergencydepartmentencounter	Encounter	KX	IN/A	15	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 530 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ad. Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 531 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ae. Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX RX RX RX	N/A N/A N/A N/A	47 20 18 12	N/A N/A N/A N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Xultophy10036	Xultophy 100/3.6 Complete Or Unspecified Spontaneous	RX	N/A	****	N/A
O03.9 O03.9 O03.9	Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous	DX DX DX	10 10 10	****	OA AV ED
Saxenda	Abortion Without Complication Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 532 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23af. Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	12
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 533 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ag. Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	15	N/A
•	Laparoscopy, Surgical; With Removal Of		,		•
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
5 ,	Unspecified Pre-Existing Diabetes Mellitus		,		•
024.311	In Pregnancy, First Trimester	DX	10		AV
O24.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****	OA
	In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	ate ale ale ale ale	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
${\it Emergency department} encounter$	Emergency Department Encounter	RX	N/A	21 - 21 - 21 - 21 - 21 - 21 - 21 - 21 -	N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 534 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ah. Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
024.311	Unspecified Pre-Existing Diabetes	DX	10	****
Saxenda	Mellitus In Pregnancy, First Trimester Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells. The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

cder_mpl1p_wp077 Page 535 of 990



Table 23ai. Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 536 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23aj. Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 537 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ak. Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
024.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10		AV
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 538 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23al. Total Code Counts of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 539 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23am. Full Code Distribution of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 540 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23an. Total Code Counts of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 541 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ao. Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,887	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	351	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	77	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	23	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	IP
	Oophorectomy And/Or Salpingectomy)				
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
003.9	Abortion Without Complication	DΛ	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.111	Pregnancy, First Trimester	DX	10	****	ED
000.201	Right Ovarian Pregnancy Without	DX	10	4.4.4.4.4.	ED
	Intrauterine Pregnancy				
	Pre-Existing Type 1 Diabetes Mellitus, In			ala ala ala ala ala	
O24.011	Pregnancy, First Trimester	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.111	Pregnancy, First Trimester	DX	10	****	ED
	Obesity Complicating Pregnancy, First				
099.211	Trimester	DX	10		AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	AV
024.111	Pregnancy, First Trimester	DA	10		ΛV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119		DX	10	****	AV
	Pregnancy, Unspecified Trimester				
024.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****	AV
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4.4.4.4.4.	N/A
Trulicity	Trulicity	RX	N/A	ملد ملد ماد ماد طو	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A		N/A

cder_mpl1p_wp077 Page 542 of 990



Table 23ao. Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
003.4	Incomplete Spontaneous Abortion Without	DX	10	****	AV
005.4	Complication	DΛ	10		AV

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 543 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ap. Total Code Counts of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	12
	Oophorectomy And/Or Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
	Pre-Existing Type 2 Diabetes Mellitus, In			
024.111	Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
. ,	Complete Or Unspecified Spontaneous		10	
003.9	Abortion Without Complication	DX		****
	Incomplete Spontaneous Abortion Without			
003.4	Complication	DX	10	****
	Obesity Complicating Pregnancy, First			
099.211	Trimester	DX	10	****
	Pre-Existing Type 1 Diabetes Mellitus, In			
O24.011	- · · · · · · · · · · · · · · · · · · ·	DX	10	****
	Pregnancy, First Trimester			
024.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, Unspecified Trimester			
O00.201	Right Ovarian Pregnancy Without	DX	10	****
	Intrauterine Pregnancy			
024.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****
024.311	In Pregnancy, First Trimester	DA.	10	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 544 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23aq. Full Code Distribution of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 545 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ar. Total Code Counts of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
•	Laparoscopy, Surgical; With Removal Of		·	
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 546 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23as. Full Code Distribution of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	12	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
_Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 547 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23at. Total Code Counts of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	
Emergencydepartmentencounter	Emergency Department	RX	N/A	23	
Emergencydepartmentencounter	Encounter	ľΛ	N/A	23	
Ozempic	Ozempic	RX	N/A	12	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	
Mounjaro	Mounjaro	RX	N/A	****	
Trulicity	Trulicity	RX	N/A	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 548 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23au. Full Code Distribution of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Codo	Codo Deservintion	Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	15	N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 549 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23av. Total Code Counts of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
<u>Victoza</u>	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 550 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23aw. Full Code Distribution of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	RX RX RX RX	N/A N/A N/A N/A	47 20 18 12	N/A N/A N/A N/A
Xultophy10036	Oophorectomy And/Or Salpingectomy) Xultophy 100/3.6 Complete Or Unspecified Spontaneous	RX	N/A	****	N/A
O03.9 O03.9 O03.9	Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication	DX DX DX	10 10 10	****	AV ED OA
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 551 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ax. Total Code Counts of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	12
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 552 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ay. Full Code Distribution of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	15	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
5 ,	Unspecified Pre-Existing Diabetes Mellitus		•		•
024.311	In Pregnancy, First Trimester	DX	10		AV
024.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****	OA
	In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 553 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23az. Total Code Counts of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
	Unspecified Pre-Existing Diabetes Mellitus			
024.311	In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 554 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ba. Full Code Distribution of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 555 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bb. Total Code Counts of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 556 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bc. Full Code Distribution of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
024.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, Unspecified Trimester				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 557 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bd. Total Code Counts of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
024.110	Pre-Existing Type 2 Diabetes Mellitus, In	51/	10	****
O24.119	Pregnancy, Unspecified Trimester	DX	10	
000.0	Complete Or Unspecified Spontaneous	51/		****
O03.9	Abortion Without Complication	DX	10	***
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 558 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23be. Full Code Distribution of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 559 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bf. Total Code Counts of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 560 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,887	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Trulicity Mounjaro Rybelsus Victoza	Trulicity Mounjaro Rybelsus Victoza	RX RX RX RX	N/A N/A N/A N/A	***** 351 ****	N/A N/A N/A N/A
Bydureonbcise Wegovy	Bydureon Bcise Wegovy Laparoscopy, Surgical; With Removal Of	RX RX	N/A N/A	23 ****	N/A N/A
58661 Xultophy10036	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Xultophy 100/3.6	PX RX	C4 N/A	****	AV N/A
Saxenda	Saxenda Laparoscopy, Surgical; With Removal Of	RX	N/A	****	N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Complete Or Unspecified Spontaneous	PX DX	C4	****	IP
003.9	Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In		10		AV
O24.111 O00.201	Pregnancy, First Trimester Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX DX	10 10	****	ED ED
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First	DX	10	****	ED
O99.211	Trimester	DX	10	****	AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****	AV
024.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	****	AV
Rybelsus Emergencydepartmentencounter	Rybelsus Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Trulicity Emergencydepartmentencounter	Trulicity Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Trulicity Inpatientencounter	Trulicity Inpatient Encounter	RX RX	N/A N/A	****	N/A N/A

cder_mpl1p_wp077 Page 561 of 990



Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
003.4	Incomplete Spontaneous Abortion Without	DX	10	****	AV
	Complication	DX	10		

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 562 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bh. Total Code Counts of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	12
	Oophorectomy And/Or Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
024.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
	Complete Or Unspecified Spontaneous			****
O03.9	Abortion Without Complication	DX	10	***
003.4	Incomplete Spontaneous Abortion	DV	10	****
003.4	Without Complication	DX	10	ate ate ate ate
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
024.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
024.011	Pregnancy, First Trimester	DΛ	10	
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, Unspecified Trimester	DΧ	10	
O00.201	Right Ovarian Pregnancy Without	DV	10	****
	Intrauterine Pregnancy	DX	10	ate ate ate ate
024.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****
024.311	In Pregnancy, First Trimester	DΛ	10	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 563 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bi. Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036 Bydureonbcise	Xultophy 100/3.6 Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX RX	N/A N/A	*****	N/A N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 564 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bj. Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
•	Laparoscopy, Surgical; With Removal Of		•	
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 565 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bk. Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	12	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 566 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bl. Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	0.1.0			
Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	12
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 567 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bm. Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 568 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bn. Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 569 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bo. Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX RX RX RX	N/A N/A N/A N/A	47 20 18 12	N/A N/A N/A N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Xultophy10036	Xultophy 100/3.6 Complete Or Unspecified Spontaneous	RX	N/A	****	N/A
O03.9 O03.9 O03.9	Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous	DX DX DX	10 10 10	****	OA AV ED
Saxenda	Abortion Without Complication Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 570 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bp. Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	12
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 571 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bq. Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4.4.4.4.4	N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	15	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
5 ,	Unspecified Pre-Existing Diabetes Mellitus		•		•
024.311	In Pregnancy, First Trimester	DX	10	****	AV
024.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****	OA
	In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 572 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23br. Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
	Unspecified Pre-Existing Diabetes Mellitus			
024.311	In Pregnancy, First Trimester	DX 10		****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 573 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bs. Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter Emergency Department	RX	N/A	****	N/A
Emergencydepartmentencounter	Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 574 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bt. Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydenartmentenceunter	Emergency Department	RX	N/A	****
Emergencydepartmentencounter	Encounter	KX	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 575 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bu. Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
024.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, Unspecified Trimester				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	<u> </u>	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 576 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bv. Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 577 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bw. Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 578 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bx. Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 579 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,887	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	634	N/A N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	351 ****	N/A
Rybelsus	Rybelsus	RX	N/A		N/A
Victoza	Victoza	RX	N/A	77 22	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	23 ****	N/A
Wegovy	Wegovy	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	AV
Xultophy10036	Oophorectomy And/Or Salpingectomy) Xultophy 100/3.6	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A N/A
Saxerida	Laparoscopy, Surgical; With Removal Of	IVX	IN/A		N/A
58661	Adnexal Structures (Partial Or Total	PX	C4	****	IP
	Oophorectomy And/Or Salpingectomy)				
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.111	Pregnancy, First Trimester	DX	10	****	ED
000.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
024.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED
	Obesity Complicating Pregnancy, First				
099.211	Trimester	DX	10	****	AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
024.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****	AV
024.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	****	AV
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	ale ale ale ale ale	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A

cder_mpl1p_wp077 Page 580 of 990



Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
003.4	Incomplete Spontaneous Abortion	DX	10	****	AV
003.4	Without Complication	DΛ	10		Λν

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 581 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bz. Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Distributed Batabase Holli May 15	Code					
Code	Code Description	Category	Code Type	Overall Counts		
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056		
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522		
Trulicity	Trulicity	RX	N/A	600		
Mounjaro	Mounjaro	RX	N/A	351		
Rybelsus	Rybelsus	RX	N/A	223		
Victoza	Victoza	RX	N/A	77		
Bydureonbcise	Bydureon Bcise	RX	N/A	23		
	Laparoscopy, Surgical; With Removal Of					
58661	Adnexal Structures (Partial Or Total	PX	C4	12		
	Oophorectomy And/Or Salpingectomy)					
Wegovy	Wegovy	RX	N/A	****		
	Pre-Existing Type 2 Diabetes Mellitus, In	BV.		****		
024.111	Pregnancy, First Trimester	DX	10	ጥጥጥ ጥ		
Saxenda	Saxenda	RX	N/A	****		
Xultophy10036	Xultophy 100/3.6	RX	N/A	****		
	Complete Or Unspecified Spontaneous	57		****		
003.9	Abortion Without Complication	DX	10	ጥጥጥ ጥ		
003.4	Incomplete Spontaneous Abortion	5.7	40	****		
003.4	Without Complication	DX	10	ጥጥጥ ጥ		
000 044	Obesity Complicating Pregnancy, First			****		
099.211	Trimester	DX	10	****		
	Pre-Existing Type 1 Diabetes Mellitus, In					
024.011	Pregnancy, First Trimester	DX	10	****		
	Pre-Existing Type 2 Diabetes Mellitus, In					
O24.119	Pregnancy, Unspecified Trimester	DX	10	****		
	Right Ovarian Pregnancy Without					
O00.201	Intrauterine Pregnancy	DX	10	****		
	Unspecified Pre-Existing Diabetes Mellitus					
024.311		DX	10	****		
	In Pregnancy, First Trimester					

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 582 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	1	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 583 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cb. Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
·	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 584 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cc. Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 585 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cd. Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 586 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ce. Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	15	N/A
84	Encounter		,		
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 587 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cf. Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 588 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cg. Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX RX RX RX	N/A N/A N/A N/A	47 20 18 12	N/A N/A N/A N/A
58661 Xultophy10036	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Xultophy 100/3.6	PX RX	C4 N/A	****	AV N/A
O03.9 O03.9 O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous	DX DX DX	10 10 10	****	ED OA AV
Saxenda	Abortion Without Complication Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 589 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ch. Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	12
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 590 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ci. Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7777	N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX	N/A	15	N/A
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy Unspecified Pre-Existing Diabetes	RX	N/A	****	N/A
O24.311	Mellitus In Pregnancy, First Trimester	DX	10	****	AV
024.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		OA
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	ner ner ner ner	N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 591 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cj. Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
	Unspecified Pre-Existing Diabetes Mellitus			
024.311	In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 592 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ck. Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 593 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cl. Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 594 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cm. Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	4. 4. 4. 4. 4.	AV
	Pregnancy, Unspecified Trimester				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 595 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cn. Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
024.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 596 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23co. Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 597 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cp. Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 598 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cq. Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,887	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	62.4	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	634	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	, Mounjaro	RX	N/A	351	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	77	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	23	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	IP
	Oophorectomy And/Or Salpingectomy)				
003.0	Complete Or Unspecified Spontaneous	DV	10	****	A) /
003.9	Abortion Without Complication	DX	10	44444	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
024.111	Pregnancy, First Trimester	DX	10	****	ED
000.201	Right Ovarian Pregnancy Without	DX	10	****	ED
	Intrauterine Pregnancy				
	Pre-Existing Type 1 Diabetes Mellitus, In			ale ale ale ale ale	
024.011	Pregnancy, First Trimester	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.111	Pregnancy, First Trimester	DX	10	****	ED
	Obesity Complicating Pregnancy, First				
099.211	Trimester	DX	10		AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	AV
	Pregnancy, First Trimester				
	Pre-Existing Type 2 Diabetes Mellitus, In				
024.119	Pregnancy, Unspecified Trimester	DX	10	****	AV
	Unspecified Pre-Existing Diabetes Mellitus In				
024.311	Pregnancy, First Trimester	DX	10	****	AV
Rybelsus	Rybelsus	RX	N/A		N/A
-	•			****	· ·
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	an record for for	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter Incomplete Spontaneous Abortion Without	RX	N/A		N/A
003.4	Complication	DX	10	****	AV

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 599 of 990



Table 23cr. Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	12
	Oophorectomy And/Or Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
5 ,	Pre-Existing Type 2 Diabetes Mellitus, In		-	****
024.111	Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
• •	Complete Or Unspecified Spontaneous		10	ملد ملد ملد والت
003.9	Abortion Without Complication	DX		****
000 4	Incomplete Spontaneous Abortion Without			planeta ala ala di
003.4	Complication	DX	10	****
	Obesity Complicating Pregnancy, First			
O99.211	Trimester	DX	10	****
	Pre-Existing Type 1 Diabetes Mellitus, In			
O24.011	Pregnancy, First Trimester	DX	10	****
	Pre-Existing Type 2 Diabetes Mellitus, In			
024.119	Pregnancy, Unspecified Trimester	DX	10	****
O00.201	Right Ovarian Pregnancy Without			
		DX	10	****
	Intrauterine Pregnancy			
O24.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****
	In Pregnancy, First Trimester			

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 600 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cs. Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 601 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ct. Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 602 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cu. Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	12	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 603 of 990



Table 23cv. Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	12
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 604 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cw. Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 605 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cx. Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
		<u> </u>		
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 606 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cy. Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise	RX RX RX RX	N/A N/A N/A N/A	47 20 18 12	N/A N/A N/A N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Xultophy10036	Xultophy 100/3.6 Complete Or Unspecified Spontaneous	RX	N/A	****	N/A
O03.9 O03.9 O03.9	Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication	DX DX DX	10 10 10	****	AV OA ED
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 607 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23cz. Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	12
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 608 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23da. Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	• ****	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Mounjaro Rybelsus Victoza Bydureonbcise	Mounjaro Rybelsus Victoza Bydureon Bcise	RX RX RX RX	N/A N/A N/A N/A	164 **** **** 15	N/A N/A N/A N/A
58661 Yultanby10036	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Xultophy 100/3.6	PX RX	C4 N/A	****	AV N/A
Xultophy10036 Wegovy	Wegovy Laparoscopy, Surgical; With Removal Of	RX	N/A N/A	****	N/A N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Unspecified Pre-Existing Diabetes Mellitus	PX	C4	****	AV
O24.311 O24.311	In Pregnancy, First Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX DX	10 10	****	AV OA
Rybelsus Emergencydepartmentencounter	Rybelsus Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Victoza Emergencydepartmentencounter	Victoza Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 609 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23db. Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
<i>,</i>	Unspecified Pre-Existing Diabetes Mellitus		•	
024.311	In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 610 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dc. Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	44	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	9	****
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	7	****
Ozempic	Ozempic	RX	N/A	3	****
Rybelsus	Rybelsus	RX	N/A	1	****
Trulicity	Trulicity	RX	N/A	1	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 611 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dd. Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	51
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 612 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23de. Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, Unspecified Trimester				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 613 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23df. Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 614 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dg. Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 615 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dh. Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 616 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dg. Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code Code Description		· · · · · ·				
Emergency Department Encounter Impatient Encounter RX N/A 8,420 N/A Inpatient Encounter Inpatient Encounter RX N/A ***** N/A Inpatient Encounter Inpatient Encounter RX N/A ***** N/A N/A Impatient Encounter Inpatient Encounter RX N/A N/A N/A N/A N/A Impatient Encounter Emergency Department Encounter RX N/A N			Code	Code	Overall	Encounter
Inpatientencounter						Care Setting
Inpatientencounter				-		N/A
Emergencydepartmentencounter Emergency Department Encounter RX N/A N// Trulicity Trulicity RX N/A ***** N/A Mounjaro Mounjaro RX N/A ***** N/A Rybelsus Rybelsus RX N/A ***** N/A Victoza Victoza RX N/A 77 N/A Bydureonbcise Bydureon Bcise RX N/A 23 N/A Wegovy Wegovy RX N/A 23 N/A Wegovy Laparoscopy, Surgical; With Removal Of RX N/A 28 N/A Sacenda Saxenda RX N/A ***** N/A Saxenda Laparoscopy, Surgical; With Removal Of RX N/A ****** N/A Saxenda Laparoscopy, Surgical; With Removal Of RX N/A ****** N/A Saxenda Laparoscopy, Surgical; With Removal Of RX N/A ****** N/A Saxenda		•			****	N/A
Trulicity	•	•			****	N/A
Mounjaro Mounjaro RX N/A 351 N/R Rybelsus Rybelsus RX N/A ******* N/V Victoza Victoza RX N/A 77 N/V Bydureonbcise Bydureon Bcise RX N/A 23 N/V Wegovy Wegovy RX N/A 8 N/A 58661 Adnexal Structures (Partial Or Total Ophylous) PX C4 11 AV Sakenda Saxenda RX N/A ****** N/A Saxenda Prescriber of Dopher Or Unspecified Spontaneous Abortion Without Complication Pregnancy Frest Trimester <td>Emergencydepartmentencounter</td> <td>Emergency Department Encounter</td> <td>RX</td> <td>•</td> <td></td> <td>N/A</td>	Emergencydepartmentencounter	Emergency Department Encounter	RX	•		N/A
Rybelsus Rybelsus RX N/A ****** N/A Victoza Victoza RX N/A 77 N/A Bydureon Bcise RX N/A 23 N/A Wegovy Wegovy RX N/A 8 N/A Wegovy Wegovy RX N/A 8 N/A Wegovy Wegovy RX N/A 8 N/A Wegovy Adnexal Structures (Partial Or Total PX C4 11 AM 58661 Adnexal Structures (Partial Or Total PX C4 ****** N/A Saxenda Saxenda RX N/A ****** N/A Saxenda Saxenda RX N/A ****** N/A Saxenda Laparoscopy, Surgical; With Removal Of RX N/A ******* N/A Saxenda RX N/A ******* N/A ******* N/A Saxenda RX N/A ******* N/A	•	•		-		N/A
Nyterous		-		-		N/A
Bydureonbcise Bydureon Bcise RX N/A 23 N/A Wegovy Wegovy RX N/A 8 N/A 8 N/A SA SASCALA SASC		•		-		N/A
Wegovy Kegovy RX N/A 8 N/A 58661 Laparoscopy, Surgical; With Removal Of PX C4 11 AV 58661 Adnexal Structures (Partial Or Total Ophnorectomy) PX C4 11 AV Xultophy10036 Xultophy 100/3.6 RX N/A ******* N/A Saxenda Saxenda RX N/A ******* N/A 58661 Adnexal Structures (Partial Or Total Optical				-		N/A
Laparoscopy, Surgical; With Removal Of 58661 Adnexal Structures (Partial Or Total PX C4 11 AV Oophorectomy And/Or Salpingectomy) Xultophy10036 Xultophy 100/3.6 RX N/A ***** N/A Saxenda Saxenda RX N/A ***** N/A Saxenda Laparoscopy, Surgical; With Removal Of S8661 Adnexal Structures (Partial Or Total PX C4 ***** N/A Saxenda Dophorectomy And/Or Salpingectomy) Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester DX 10 ***** DX O024.111 Precent Pregnancy Without DX 10 ***** DX O24.111 Precent Pregnancy Without DX 10 ***** DX O24.111 Precent Pregnancy First Trimester DX 10 ***** DX O24.111 Precent Diabetes Mellitus, In Pregnancy, First Trimester DX 10 ***** DX O24.111 Precent Diabetes Mellitus, In Pregnancy, First Trimester DX 10 ***** DX O24.111 Precent DX 10 ***** DX O24.111 Pr	-			-		
S8661 Adnexal Structures (Partial Or Total PX C4 11 AV C4 Dophorectomy And/Or Salpingectomy) Xultophy10036 Xultophy 100/3.6 RX N/A ***** N/A Saxenda RX N/A ***** N/A ****** N/A Saxenda RX N/A ***** N/A Saxenda RX N/A ****** N/A Saxenda RX N/A ******* N/A Saxenda RX N/A ****** N/A Saxenda RX N/A ****** N/A Saxenda RX N/A ******* N/A Saxenda RX N/A ******* N/A Saxenda RX N/A ****** N/A Saxenda RX N/A ******* N/A Saxenda RX N/A ******* N/A Saxenda RX N/A *********** N/A Saxenda RX N/A ***************** N/A Saxenda RX N/A ***********************************	wegovy		KX	IN/A	8	N/A
Xultophy10036 Xultophy100/3.6 RX N/A ***** N/. Saxenda Saxenda RX N/A ***** N/. Saxenda Laparoscopy, Surgical; With Removal Of Caphorectomy And/Or Salpingectomy) Sakefill Adnexal Structures (Partial Or Total PX C4 ***** IP Oophorectomy And/Or Salpingectomy) Oo3.9 Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester DX 10 ***** PEC OO0.201 Right Ovarian Pregnancy Without DX 10 ***** Pregnancy, First Trimester Pregnancy, First Trimester DX 10 ***** Pregnancy, First Trimester Pregnancy, First Trimester DX 10 ***** Pregnancy, First Trimester Obesity Complicating Pregnancy, First Trimester Obesity Complicating Pregnancy, First Trimester DX 10 ***** Pregnancy, First Trimester DX 10 ****** AND Pregnancy, First	58661		PΧ	C4	11	Δ\/
Xultophy10036 Xultophy1003.6 Saxenda Saxenda RX N/A ***** N/A Saxenda RX N/A ***** N/A Saxenda RX N/A ***** N/A Laparoscopy, Surgical; With Removal Of S8661 Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Pregnancy, First Trimester Obesity Complicating Pregnancy, First Oo4.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Oo4.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Oo4.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Oo4.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Oo4.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Trimester Obesity Complication Obesity Complication Obesity Complication Obesity Complicatio	30001	•	17	CŦ	11	Α.
Saxenda Saxenda RX N/A ***** N/A Laparoscopy, Surgical; With Removal Of 58661 Adnexal Structures (Partial Or Total PX C4 ***** IP Oophorectomy And/Or Salpingectomy) Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In O24.111 Pregnancy, First Trimester DX 10 ***** EECO O24.011 Pre-Existing Type 1 Diabetes Mellitus, In Pre-Existing Type 2 Diabetes Mellitus, In Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester DX 10 ***** AV O24.111 Pregnancy, First Trimester DX 10 ***** EECO Obesity Complicating Pregnancy, First O99.211 Trimester DX 10 ***** AV O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.112 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.113 Pregnancy, Unspecified Trimester O24.311 Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus RX N/A ***** N/A Emergencydepartmentencounter Emergency Department Encounter Trulicity RX N/A ****** N/A ******* N/A ***********************************	Xultophy10036		RX	N/A	****	N/A
Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total PX C4 ***** IP Oophorectomy And/Or Salpingectomy) Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In O24.111 Pregnancy, First Trimester DX 10 ***** Pregnancy Without DX 10 ***** Pregnancy Pre-Existing Type 1 Diabetes Mellitus, In O24.011 Pregnancy, First Trimester DX 10 ***** Pregnancy, First Trimester DX 10 ****** Pregnancy, First Trimester Pregnancy, Fi		• • •		-	****	N/A
Adnexal Structures (Partial Or Total PX C4 ***** IP Oophorectomy And/Or Salpingectomy) Oo3.9 Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In O24.111 Pregnancy, First Trimester DX 10 ***** AVAIDAD TO TOTAL DY 10 TOTAL DY				,		,
Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In O24.111 Pregnancy, First Trimester ODX 10 ***** ED O00.201 Right Ovarian Pregnancy Intrauterine Pregnancy Intrauterine Pregnancy O24.011 Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O24.111 Pregnancy, Unspecified Trimester O24.111 Pregnancy, Unspecified Trimester O24.111 Pregnancy, First Trimester O25. NA	58661		PX	C4	****	IP
Complete Or Unspecified Spontaneous Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In O24.111 Pregnancy, First Trimester ODX 10 ***** ED O00.201 Right Ovarian Pregnancy Intrauterine Pregnancy Intrauterine Pregnancy O24.011 Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O24.111 Pregnancy, Unspecified Trimester O24.111 Pregnancy, Unspecified Trimester O24.111 Pregnancy, First Trimester O25. NA		Oophorectomy And/Or Salpingectomy)				
Abortion Without Complication Pre-Existing Type 2 Diabetes Mellitus, In O24.111 Pregnancy, First Trimester O24.011 Right Ovarian Pregnancy Without DX 10 ****** O24.011 Pregnancy, First Trimester O24.011 Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O24.119 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester O24.111 In Pregnancy, Unspecified Trimester O24.111 Pregnancy, First Trimester O25. President Present Program President Present Pre	003.0		DV	40	****	A) (
O24.111 Pregnancy, First Trimester DX 10 ***** ED (D00.201 Right Ovarian Pregnancy Without DX 10 ED (D00.201 Pregnancy, First Trimester DX 10 ***** DX 10 ****** DX 10 **	003.9	Abortion Without Complication	DX	10	* * * * *	AV
O00.201 Right Ovarian Pregnancy Without Intrauterine Pregnancy O24.011 Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O99.211 Trimester O24.111 Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O24.111 Pregnancy, First Trimester O24.112 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.113 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.114 Pregnancy, Unspecified Trimester O24.115 Pregnancy, Unspecified Trimester O24.116 Pregnancy, First Trimester O24.117 Pregnancy, Unspecified Trimester O24.118 Pregnancy, First Trimester O24.119 Pregnancy, Unspecified Trimester O24.119 Pregnancy, Unspecified Trimester O24.119 Pregnancy, Unspecified Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus Rybelsus RX N/A ****** N/A Emergencydepartmentencounter Emergency Department Encounter Trulicity RX N/A ****** N/A ******* N/A ****** N/A ****** N/A ****** N/A ****** N/A ******* N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** **** **** **** **** **** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** **		Pre-Existing Type 2 Diabetes Mellitus, In				
O00.201 Right Ovarian Pregnancy Without Intrauterine Pregnancy O24.011 Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester O24.112 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.119 Pregnancy, Unspecified Trimester O24.311 In Pregnancy, First Trimester Rybelsus Rybelsus Rybelsus RX N/A ****** N/A Emergencydepartmentencounter Emergency Department Encounter Trulicity Trulicity RX N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** **** N/A ***** **** **** **** ***	024.111	Pregnancy, First Trimester	DX	10	****	ED
O24.011 PreeExisting Type 1 Diabetes Mellitus, In Pregnancy, First Trimester O24.111 O24.111 O24.111 O24.111 O24.111 PreeDiancy, First Trimester Obesity Complicating Pregnancy, First O99.211 Trimester O24.111 O24.111 O24.111 PreeDiancy, First Trimester O24.111 O25. O26. O26. O27. O27. O28. O28. O28. O29. O2	O00.201	Right Ovarian Pregnancy Without	DX	10		ED
O24.111 Pregnancy, First Trimester O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester Obesity Complicating Pregnancy, First O99.211 Trimester O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.119 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester O24.311 Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A ***** N/A Trulicity Trulicity RX N/A ***** N/A ***** N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** N/A ****** N/A ****** N/A ****** N/A ****** N/A ***** N/A ****** N/A ***** **** **** **** ***		Intrauterine Pregnancy				
O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O24.111 Pregnancy, First Trimester Obesity Complicating Pregnancy, First O99.211 Trimester O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.119 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester O24.311 In Pregnancy, First Trimester Rybelsus Rybelsus Rybelsus RX N/A ***** N/A Emergencydepartmentencounter Trulicity Pre-Existing Type 2 Diabetes Mellitus DX 10 ***** DX 10 ****** AV DX 10 ****** AV AV AV AV AV AV AV AV	024 011	Pre-Existing Type 1 Diabetes Mellitus, In	DV	10	****	۸۱/
Pregnancy, First Trimester Obesity Complicating Pregnancy, First O99.211 Trimester O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.119 Pregnancy, Unspecified Trimester O24.311 Pregnancy, First Trimester O24.311 Pregnancy, First Trimester Rybelsus Rybelsus Rybelsus RX N/A RX RX RX N/A RX	024.011	Pregnancy, First Trimester	DX	10		AV
Obesity Complicating Pregnancy, First O99.211 Trimester O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.119 Pregnancy, First Trimester O24.311 Pregnancy, Unspecified Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A ***** N/A Trulicity Pregnancy, First Trimester RX N/A ***** ***	024 111	Pre-Existing Type 2 Diabetes Mellitus, In	DV	10	****	ED
O99.211 O24.111 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester O24.119 Pregnancy, Unspecified Trimester O24.311 Pregnancy, First Trimester O24.311 Pregnancy, First Trimester Rybelsus Rybelsus Rybelsus RX N/A ***** N/A Emergencydepartmentencounter Trulicity DX 10 ***** AN DX 10 ***** AN DX 10 ***** AN	024.111	• • • • • • • • • • • • • • • • • • • •	DX	10		LD
O24.111 Pregnancy, First Trimester O24.119 Pregnancy, Unspecified Trimester O24.311 In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A ***** N/A Emergencydepartmentencounter Trulicity RX N/A ***** N/A Trulicity RX N/A ****** N/A AND TRIMESTER DX 10 ****** AND TRULICITY RX N/A ****** N/A ***********************************		Obesity Complicating Pregnancy, First				
Pregnancy, First Trimester O24.119 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A Emergencydepartmentencounter Trulicity Pregnancy, First Trimester RX N/A ***** N/A ***** N/A ***** N/A ***** N/A ***** N/A ****** N/A ****** N/A ***** N/A ****** N/A ***** N/A ****** N/A ****** N/A ***** N/A ****** N/A ***** N/A ***** N/A ***** N/A ****** N/A ****** N/A ***** N/A ****** N/A ***** N/A ***** N/A ****** N/A ***** N/A ***** N/A ***** N/A ****** N/A ****** N/A ***** N/A ****** N/A ***** N/A ****** N/A ***** N/A ****** N/A ***** N/A ****** N/A ***** N/A ***** N/A ***** N/A ****** N/A ***** N/A **** ***	099.211	Trimester			****	AV
O24.119 Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A Emergencydepartmentencounter Trulicity Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester DX 10 ***** AV AV AV AV AV AV AV AV A	024.111		DX	10		AV
Pregnancy, Unspecified Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A Emergencydepartmentencounter Trulicity Pregnancy, Unspecified Trimester DX 10 ***** AV AV AV AV AV AV AV AV		- ·				
Pregnancy, Unspecified Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A Emergencydepartmentencounter Trulicity Pregnancy, Unspecified Trimester DX 10 ***** AV AV AV AV ***** N/A ***** N/A ***** N/A ***** N/A ******	024.119		DX	10	****	AV
Rybelsus Rybelsus RX N/A ***** N/A Emergencydepartmentencounter Emergency Department Encounter RX N/A N/A Trulicity RX N/A ***** N/A ************************************	0213		D/A			,
Rybelsus Rybelsus RX N/A ***** N/A Emergencydepartmentencounter Emergency Department Encounter RX N/A N/A Trulicity RX N/A ***** N/A ************************************	024.311		DX	10	****	AV
Emergencydepartmentencounter Emergency Department Encounter RX N/A N/A Trulicity RX N/A						
Trulicity RX N/A **** N/A	-	•			****	N/A
•						N/A N/A
Emergencydenartmentencounter Emergency Department Encounter DV N/A	•	Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Trulicity RX N/A N/A						N/A N/A
ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ ተ	•	•			****	N/A
Incomplete Spontaneous Abortion	•	•				
O03.4 Without Complication DX 10 ***** AV	003.4		DX	10	****	AV

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 617 of 990



Table 23dj. Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	s, 2022 to June 30, 2023 for Episode Truncation	Code	Code	
Code	Code Description	Category	Туре	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	12
	Oophorectomy And/Or Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
024.111	Pregnancy, First Trimester	DX	10	
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
003.0	Complete Or Unspecified Spontaneous	DV	10	****
003.9	Abortion Without Complication	DX	10	
002.4	Incomplete Spontaneous Abortion Without	5.7	4.0	****
003.4	Complication	DX	10	****
000.044	Obesity Complicating Pregnancy, First	5.7	4.0	****
099.211	Trimester	DX	10	****
	Pre-Existing Type 1 Diabetes Mellitus, In			
O24.011	Pregnancy, First Trimester	DX	10	****
	Pre-Existing Type 2 Diabetes Mellitus, In			
024.119	Pregnancy, Unspecified Trimester	DX	10	****
	Right Ovarian Pregnancy Without			
000.201	Intrauterine Pregnancy	DX 10		****
	Unspecified Pre-Existing Diabetes Mellitus In			
O24.311	-	DX	10	****
	Pregnancy, First Trimester			

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 618 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dk. Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A		N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 619 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dl. Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
·	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 620 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dm. Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 621 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dn. Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 622 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dm. Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	r Emergency Department Encounter	RX	N/A	15	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
<u>Victoza</u>	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 623 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dp. Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
<u>Victoza</u>	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 624 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dq. Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise Laparoscopy, Surgical; With Removal Of	RX RX RX RX	N/A N/A N/A N/A	47 20 18 ****	N/A N/A N/A N/A
58661	Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Xultophy10036	Xultophy 100/3.6 Complete Or Unspecified Spontaneous	RX	N/A	****	N/A
O03.9 O03.9 O03.9	Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication	DX DX DX	10 10 10	****	AV OA ED
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 625 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dr. Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 626 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ds. Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Code	code Description	Category	турс	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	15	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
	Unspecified Pre-Existing Diabetes				
024.311	Mellitus In Pregnancy, First Trimester	DX	10	****	AV
024.311	Unspecified Pre-Existing Diabetes	DX	10	****	OA
	Mellitus In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	ale ale ale ale	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	ate ate ate ate	N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 627 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dt. Total Code Counts of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
024.311	Unspecified Pre-Existing Diabetes Mellitus		•	****
	In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 628 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23du. Full Code Distribution of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	44	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus Trulicity	Rybelsus Trulicity	RX RX	N/A N/A	****	N/A N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 629 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dv. Total Code Counts of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydenartmentenceunter	Emergency Department	RX	N/A	51
Emergencydepartmentencounter	Encounter	KΛ	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	16
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX N/A		****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 630 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dw. Full Code Distribution of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,105	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	48	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
024.110	Pre-Existing Type 2 Diabetes Mellitus, In	DV	10		0.4
024.119	Pregnancy, Unspecified Trimester	DX	10	****	OA
024.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10		AV
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4. 4. 4. 4.	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 631 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dx. Total Code Counts of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,216
Inpatientencounter	Inpatient Encounter	RX	N/A	284
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	48
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O24.119	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, Unspecified Trimester	DX	10	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 632 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dy. Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	125	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	28	N/A
Ozempic	Ozempic	RX	N/A	21	N/A
Trulicity	Trulicity	RX	N/A	15	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 633 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23dz. Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	134
Inpatientencounter	Inpatient Encounter	RX	N/A	37
Ozempic	Ozempic	RX	N/A	21
Trulicity	Trulicity	RX	N/A	15
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 634 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ea. Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	8,420	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	351	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	77	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	23	N/A
Wegovy	Wegovy	RX	N/A	8	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	11	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Saxenda	Saxenda	RX	N/A	****	N/A
	Laparoscopy, Surgical; With Removal Of				
58661	Adnexal Structures (Partial Or Total	PX	C4	****	IP
	Oophorectomy And/Or Salpingectomy)				
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
003.9	Abortion Without Complication	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.111	Pregnancy, First Trimester	DX	10	****	ED
O00.201	Right Ovarian Pregnancy Without	DX	10		ED
	Intrauterine Pregnancy				
024.044	Pre-Existing Type 1 Diabetes Mellitus, In	DV	10	****	A) /
O24.011	Pregnancy, First Trimester	DX	10		AV
024444	Pre-Existing Type 2 Diabetes Mellitus, In	D.V	40	****	
O24.111	Pregnancy, First Trimester	DX	10	4. 4. 4. 4. 4.	ED
	Obesity Complicating Pregnancy, First				
099.211	Trimester	DX	10	****	AV
024.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	AV
	Pregnancy, First Trimester				
	Pre-Existing Type 2 Diabetes Mellitus, In				
O24.119	Pregnancy, Unspecified Trimester	DX	10	****	AV
	Unspecified Pre-Existing Diabetes Mellitus				
O24.311	In Pregnancy, First Trimester	DX	10	****	AV
			_		
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	ጥጥ ች ች ች	N/A
Trulicity	Trulicity	RX	NI/A		N/A
Trulicity	Trulicity		N/A	****	
Inpatientencounter	Inpatient Encounter	RX	N/A		N/A

cder_mpl1p_wp077 Page 635 of 990



Table 23ea. Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O03.4	Incomplete Spontaneous Abortion Without Complication	DX	10	****	AV

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 636 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23eb. Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	11 Way 15, 2022 to June 50, 2025 for Episode	Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	9,056
Inpatientencounter	Inpatient Encounter	RX	N/A	2,522
Trulicity	Trulicity	RX	N/A	600
Mounjaro	Mounjaro	RX	N/A	351
Rybelsus	Rybelsus	RX	N/A	223
Victoza	Victoza	RX	N/A	77
Bydureonbcise	Bydureon Bcise	RX	N/A	23
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	12
	Oophorectomy And/Or Salpingectomy)			
Wegovy	Wegovy	RX	N/A	****
	Pre-Existing Type 2 Diabetes Mellitus, In			
024.111	Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
	Complete Or Unspecified Spontaneous		10	
003.9	Abortion Without Complication	DX		****
	Incomplete Spontaneous Abortion			
003.4	Without Complication	DX	10	****
	Obesity Complicating Pregnancy, First			
099.211	Trimester	DX	10	****
	Pre-Existing Type 1 Diabetes Mellitus, In			
024.011	Pregnancy, First Trimester	DX	10	****
	Pre-Existing Type 2 Diabetes Mellitus, In			
O24.119	·	DX	10	****
	Pregnancy, Unspecified Trimester			
O00.201	Right Ovarian Pregnancy Without	DX	10	****
	Intrauterine Pregnancy			
024.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****
02.11011	In Pregnancy, First Trimester			

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 637 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ec. Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,025	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	103	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	13	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
•	Laparoscopy, Surgical; With Removal Of		•		·
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A		N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 638 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ed. Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	2,164
Inpatientencounter	Inpatient Encounter	RX	N/A	628
Ozempic	Ozempic	RX	N/A	311
Trulicity	Trulicity	RX	N/A	103
Mounjaro	Mounjaro	RX	N/A	62
Victoza	Victoza	RX	N/A	13
Wegovy	Wegovy	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
·	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 639 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ee. Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 640 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ef. Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	23
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 641 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ee. Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 642 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23eh. Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	15
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 643 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ei. Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	708	N/A
Inpatientencounter Ozempic	Inpatient Encounter Ozempic	RX RX	N/A N/A	165 152	N/A N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	55	N/A N/A
Trulicity Mounjaro Rybelsus Bydureonbcise	Trulicity Mounjaro Rybelsus Bydureon Bcise	RX RX RX RX	N/A N/A N/A N/A	47 20 18 ****	N/A N/A N/A N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Xultophy10036	Xultophy 100/3.6 Complete Or Unspecified Spontaneous	RX	N/A	****	N/A
O03.9 O03.9 O03.9	Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication Complete Or Unspecified Spontaneous Abortion Without Complication	DX DX DX	10 10 10	****	AV OA ED
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 644 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ej. Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	763
Inpatientencounter	Inpatient Encounter	RX	N/A	220
Ozempic	Ozempic	RX	N/A	152
Trulicity	Trulicity	RX	N/A	47
Mounjaro	Mounjaro	RX	N/A	20
Rybelsus	Rybelsus	RX	N/A	18
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 645 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ek. Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	5,804	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	496	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	164	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	, Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	15	N/A
•	Laparoscopy, Surgical; With Removal Of		-		
58661	Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
-5- /	Unspecified Pre-Existing Diabetes		,		,
024.311	Mellitus In Pregnancy, First Trimester	DX	10		AV
024.311	Unspecified Pre-Existing Diabetes	DX	10	****	OA
	Mellitus In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	ale ale ale ale	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	at at at at at	N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 646 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23el. Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,245
Inpatientencounter	Inpatient Encounter	RX	N/A	2,054
Ozempic	Ozempic	RX	N/A	496
Mounjaro	Mounjaro	RX	N/A	164
Rybelsus	Rybelsus	RX	N/A	116
Victoza	Victoza	RX	N/A	39
Bydureonbcise	Bydureon Bcise	RX	N/A	15
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	****
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
024.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 647 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23em. Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	44	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter Emergencydepartmentencounter	Inpatient Encounter Emergency Department Encounter	RX RX	N/A N/A	****	N/A N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus Trulicity	Rybelsus Trulicity	RX RX	N/A N/A	****	N/A N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 648 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23en. Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	51
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 649 of 990

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydu	reon	Mour	njaro	Ozer	npic	Rybe	elsus	Saxe	nda
	Remaining	Excluded								
Members meeting enrollment and demographic	requirement	S								
Enrolled at any point during the query period Had required coverage type (medical and/or	102,111,871	N/A								
drug coverage)		38,049,183	64,062,688			38,049,183		38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and										
Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event										
Had any cohort-defining claim during the query										
period	28,331	63,995,494	111,549	63,912,276		63,263,902	144,832	63,878,993	35,314	63,988,511
Claim recorded during specified age range Episode defining index claim recorded during	28,331	0	111,549	0	759,923	0	144,832	0	35,314	0
the query period	25,705	2,626	111,549	0	732,176	27,747	138,261	6,571	34,747	567
Members with required pre-index history										
Had sufficient pre-index continuous enrollment	23,008	2,697	95,145	16,404	635,243	96,933	120,540	17,721	32,171	2,576
Met inclusion and exclusion criteria ¹	2,005	21,003	22,807	72,338	140,273	494,970	40,152	80,388	385	31,786
Evidence of gestational diabetes Evidence of insulin with no evidence of any	N/A	****	N/A	65	N/A	414	N/A	28	N/A	62
anti-diabetic drug	N/A	2,016	N/A	5,575	N/A	49,381	N/A	4,352	N/A	190
Evidence of other secondary diabetes illness	N/A	1,345	N/A	2,982	N/A	26,598	N/A	4,625	N/A	72
Evidence of pregnancy	N/A	19	N/A	288	N/A	1,546	N/A	129	N/A	309
Evidence of short-acting GLP-1 receptor	N/A	87	N/A	501	N/A	1,742	N/A	255	N/A	****
Evidence of type 1 diabetes	N/A	947	N/A	2,656	N/A	21,651	N/A	2,403	N/A	185
Evidence of washout	N/A	20,368	N/A	56,735	N/A	418,719	N/A	69,274	N/A	22,421
No evidence of inclusion criteria	N/A	5,523	N/A	44,943	N/A	270,541	N/A	35,351	N/A	31,229
Met event incidence criteria	2,005	0	22,807	0	140,273	0	40,152	0	385	0
Members with required post-index follow-up										
Had sufficient post-index continuous enrollment	2,005	0	22,807	0	140,273	0	40,152	0	385	0
Had minimum days' supply on index date	2,005	0	22,807	0	140,273	0	40,152	0	385	0
Had index episode of at least required length	2,005	0	22,807	0	140,273	0	40,152	0	385	0
Had index episode longer than blackout period	1,992	13	22,618	189	139,413	860	39,924	228	385	0
Did not have an event during blackout period	1,992	0	22,618	0	139,413	0	39,924	0	385	0
Final cohort										
Number of members	1,992	N/A	22,618	N/A	139,413	N/A	39,924	N/A	385	N/A
Number of episodes	1,992	N/A	22,618	N/A	139,413	N/A	39,924	N/A	385	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077



Table 24. Summary of Patient Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

(Continued)					147			
	Truli		Vict		Wegovy		Xulto	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				<u> </u>		<u> </u>		
Enrolled at any point during the query period	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
Had required coverage type (medical and/or drug coverage)	64,062,688		64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event	04,023,023	30,420	04,023,023	30,420	04,023,823	30,420	04,023,023	30,420
Had any cohort-defining claim during the query period	600,556	63,423,269	130,989	63,892,836	75,900	63,947,925	7,954	64,015,871
Claim recorded during specified age range	600,556	05,425,205	130,989	03,032,030	75,900	03,347,323	7,954 7,954	04,013,071
Episode defining index claim recorded during the query period	563,759	36,797	119,663	11,326	75,220	680	7,348	606
Members with required pre-index history	303,733	30,737	115,005	11,320	73,220	000	7,540	000
Had sufficient pre-index continuous enrollment	483,182	80,577	104,388	15,275	67,939	7,281	6,512	836
Met inclusion and exclusion criteria ¹	84,095	399,087	8,740	95,648	779	67,160	****	****
Evidence of gestational diabetes	N/A	78	N/A	18	N/A	106	N/A	0
Evidence of insulin with no evidence of any anti-diabetic drug	N/A	51,320	N/A	14,039	N/A	391	N/A	519
Evidence of other secondary diabetes illness	N/A	28,684	N/A	6,028	N/A	130	N/A	425
Evidence of pregnancy	N/A	477	N/A	137	N/A	591	N/A	****
Evidence of short-acting GLP-1 receptor agonist	N/A	1,097	N/A	184	N/A	****	N/A	80
Evidence of type 1 diabetes	N/A	19,943	N/A	4,907	N/A	425	N/A	378
Evidence of washout	N/A	375,624	N/A	90,874	N/A	36,081	N/A	5,713
No evidence of inclusion criteria	N/A	141,086	N/A	36,110	N/A	65,916	N/A	1,938
Met event incidence criteria	84,095	Ó	8,740	Ô	, 779	Ô	597	Ô
Members with required post-index follow-up	·		·					
Had sufficient post-index continuous enrollment	84,095	0	8,740	0	779	0	****	0
Had minimum days' supply on index date	84,095	0	8,740	0	779	0	****	0
Had index episode of at least required length	84,095	0	8,740	0	779	0	****	0
Had index episode longer than blackout period	83,649	446	8,683	57	761	18	594	****
Did not have an event during blackout period	83,649	0	8,683	0	761	0	594	0
Final cohort								
Number of members	83,649	N/A	8,683	N/A	761	N/A	594	N/A
Number of episodes	83,649	N/A	8,683	N/A	761	N/A	594	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	07/01/2017	05/31/2023
DP02	07/01/2017	05/31/2023
DP03	01/01/2000	10/31/2022
DP04	01/01/2017	03/31/2023
DP05	01/01/2010	12/31/2022
DP06	01/01/2017	04/30/2023
DP07	07/01/2017	06/30/2023

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

cder_mpl1p_wp077 Page 652 of 990



Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request

Generic Name	Brand Name	
	Mounjaro (tirzepatide)	
tirzepatide	Mounjaro	
	Bydureon, Bydureon BCISE (exenatide synthetic)	
exenatide microspheres	Bydureon	
exenatide microspheres	Bydureon BCise	
	Ozempic (semaglutide)	
semaglutide	Ozempic	
	Rybelsus (semaglutide)	
semaglutide	Rybelsus	
	Wegovy (semaglutide)	
semaglutide	Wegovy	
	Saxenda (liraglutide)	
liraglutide	Saxenda	
	Victoza (liraglutide)	
liraglutide	Victoza 2-Pak	
liraglutide	Victoza 3-Pak	
	Trulicity (dulaglutide)	
dulaglutide	Trulicity	
	Xultophy (insulin degludec/liraglutide)	

insulin degludec/liraglutide Xultophy 100/3.6

cder_mpl1p_wp077 Page 653 of 990



Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Tachyarrhythmia in this Request

		Code	
Code	Description	Category	Code Type
	Atrial Fibrillation and Flutter		
148	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
148.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
148.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
148.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
148.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
148.3	Typical atrial flutter	Diagnosis	ICD-10-CM
148.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
148.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
148.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
148.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
	Sinus Tachycardia		
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
	Supraventricular Tachycardia		
147.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
147.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
149.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
149.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
149.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
	Other Tachycardia		
147	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
149	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
149.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
149.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
149.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
149.49	Other premature depolarization	Diagnosis	ICD-10-CM
149.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
	Cardiac Arrest		
146	Cardiac arrest	Diagnosis	ICD-10-CM
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
	Ventricular Fibrillation and Flutter		
149.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
149.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
149.02	Ventricular flutter	Diagnosis	ICD-10-CM
	Ventricular Tachycardia		
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 654 of 990



to Benne II	iciasion of Exclusion Citiena in this nequest	Code	
Code	Description	Category	Code Type
555.5	Type 2 Diabetes Mellitus		
E11	Type 2 diabetes mellitus	Diagnosis	ICD-10-CM
E11.0	Type 2 diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-	Diagnosis	ICD-10-CM
	hyperosmolar coma (NKHHC)	J	
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.1	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.2	Type 2 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.3	Type 2 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, right eve		
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E44 0040	edema, left eve		100 10 014
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
F44 2240	edema, bilateral	Diamonia	ICD 40 CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.329	edema, unspecified eve	Diagnosis	ICD-10-CM
E11.529	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CIVI
E11.3291	edema Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E11.5291		Diagnosis	ICD-10-CIVI
E11.3292	edema. right eve Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
L11.3232	edema. left eve	Diagnosis	ICD-10-CIVI
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
L11.3233	edema, bilateral	Diagnosis	ICD TO CIVI
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
211.3233	edema. unspecified eve	Diagnosis	100 10 0111
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular		ICD-10-CM
	edema	. 0	
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, right eve	Ü	
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, left eve	S	
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, bilateral	=	
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema. unspecified eve		

cder_mpl1p_wp077 Page 655 of 990



to Define II	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E11.3391	macular edema Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E11.3392	macular edema. right eve Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E11.3393	macular edema. left eve Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eve	Diagnosis	ICD-10-CM
E11.34 E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E11.3411	edema Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.3412	edema, right eve Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.3413	edema. left eve Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema. bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eve	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E11.3491	macular edema Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. right eve	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. left eve	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. unspecified eve	Diagnosis	ICD-10-CM
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
E11.3512	eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left	Diagnosis	ICD-10-CM
E11.3513	eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnosis	ICD-10-CM
E11.3519	bilateral Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnosis	ICD-10-CM
E11.352	unspecified eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3521	detachment involving the macula Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3522	detachment involving the macula, right eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3523	detachment involving the macula. left eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula. bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 656 of 990



to Define ii	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.353	detachment involving the macula. unspecified eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3531	detachment not involving the macula Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3532	detachment not involving the macula. right eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3533	detachment not involving the macula, left eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3539	detachment not involving the macula, bilateral Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.354	detachment not involving the macula, unspecified eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.3541	retinal detachment and rhegmatogenous retinal detachment Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.3542	retinal detachment and rhegmatogenous retinal detachment, right eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.3543	retinal detachment and rhegmatogenous retinal detachment, left eve Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.3549	retinal detachment and rhegmatogenous retinal detachment, bilateral Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.355	retinal detachment and rhegmatogenous retinal detachment, unspecified eve Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, dispective deema	Diagnosis	ICD-10-CM
		_	
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
E11.3592	right eve Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
E11.3593	left eve Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
E11.3599	bilateral Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
E11.36	unspecified eve Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37	Type 2 diabetes mellitus with diabetic catalact Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CW
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right	Diagnosis	ICD-10-CW
	eve	_	
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eve	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.4	Type 2 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
		ū	

cder_mpl1p_wp077 Page 657 of 990



to bellile if	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.5	Type 2 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.6	Type 2 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E11.61	Type 2 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.62	Type 2 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.63	Type 2 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Type 1 Diabetes Mellitus		
E10	Type 1 diabetes mellitus	Diagnosis	ICD-10-CM
E10.1	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.2	Type 1 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.3	Type 1 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema. right eve		
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema. left eve		
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, bilateral		

cder_mpl1p_wp077 Page 658 of 990



to bellife ii	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.329	edema. unspecified eve Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E10.3291	edema Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eve	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eve	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eve	Diagnosis	ICD-10-CM
E10.33 E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E10.3311	edema Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eve	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eve	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eve	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eve	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema. left eve	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eve	Diagnosis	ICD-10-CM
E10.34 E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E10.3411	edema Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.3412	edema, right eve Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.3413	edema. left eve Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.3419	edema, bilateral Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.349	edema, unspecified eve Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E10.3491	macular edema Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E10.3492	macular edema, right eve Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eve	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 659 of 990



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

to Benne n	iciasion of Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
E40 2400	macular edema. bilateral	. .	100 40 614
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
	eve		
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left	Diagnosis	ICD-10-CM
E10 2E12	eve	Diagnosis	ICD 10 CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnosis	ICD-10-CM
	unspecified eve	Ü	
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
540 2524	detachment involving the macula	. .	100 40 614
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E10.3522	detachment involving the macula. right eve Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
110.5522	detachment involving the macula. left eve	Diagnosis	100 10 0141
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula. bilateral		
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E10.353	detachment involving the macula. unspecified eve Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E10.555	detachment not involving the macula	Diagnosis	ICD-10-CIVI
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, right eve	· ·	
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
F10 2F22	detachment not involving the macula, left eve	Diagnasia	ICD 10 CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, unspecified eve	Ü	
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment		
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E10.3542	retinal detachment and rhegmatogenous retinal detachment, right eve Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
L10.5542	retinal detachment and rhegmatogenous retinal detachment. left eve	Diagnosis	ICD TO CIVI
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, bilateral		
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
F10 2FF	retinal detachment and rhegmatogenous retinal detachment, unspecified eve	Diagnasia	ICD 10 CM
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 660 of 990



	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	right eve	•	
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	left eve	•	
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	bilateral	•	
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	unspecified eye	_	
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right	Diagnosis	ICD-10-CM
	eve		
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left	Diagnosis	ICD-10-CM
	eve		
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
	bilateral		
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
	unspecified eve		
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.4	Type 1 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.5	Type 1 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.6	Type 1 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E10.61	Type 1 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.62	Type 1 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.63	Type 1 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.64	Type 1 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 661 of 990



to beline ii	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
024.4	Gestational diabetes mellitus	Diagnosis	ICD-10-CM
024.41	Gestational diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.410	Gestational diabetes mellitus in pregnancy, diet controlled	Diagnosis	ICD-10-CM
024.414	Gestational diabetes mellitus in pregnancy, insulin controlled	Diagnosis	ICD-10-CM
024.415	Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.419	Gestational diabetes mellitus in pregnancy, unspecified control	Diagnosis	ICD-10-CM
024.42	Gestational diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
024.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.43	Gestational diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.430	Gestational diabetes mellitus in the puerperium, diet controlled	Diagnosis	ICD-10-CM
024.434	Gestational diabetes mellitus in the puerperium, insulin controlled	Diagnosis	ICD-10-CM
O24.435	Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.439	Gestational diabetes mellitus in the puerperium, unspecified control	Diagnosis	ICD-10-CM
	Other Secondary Diabetes Illnesses		
E08	Diabetes mellitus due to underlying condition	Diagnosis	ICD-10-CM
E08.0	Diabetes mellitus due to underlying condition with hyperosmolarity	Diagnosis	ICD-10-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic	Diagnosis	ICD-10-CM
	hyperglycemic-hyperosmolar coma (NKHHC)		
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.1	Diabetes mellitus due to underlying condition with ketoacidosis	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.2	Diabetes mellitus due to underlying condition with kidney complications	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.3	Diabetes mellitus due to underlying condition with ophthalmic complications	Diagnosis	ICD-10-CM
E08.31	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with	Diagnosis	ICD-10-CM
500 040	macular edema		100 10 011
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
500.00	without macular edema	D: :	100 40 614
E08.32	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
F00 224	retinopathy Dish share well-the standard in a sea distance with well-displayed in dish ship.	Dii-	ICD 40 CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
E00 2211	retinopathy with macular edema	Diamaria	ICD 10 CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
E00 2212	retinopathy with macular edema, right eve	Diagnosis	ICD 10 CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3213	retinopathy with macular edema. left eve Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
LUO.3213		Diagilusis	ICD-TO-CIVI
E08.3219	retinopathy with macular edema. bilateral Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
LU0.3219	· · · · · · · · · · · · · · · · · ·	Diagilusis	ICD-TO-CIVI
E08.329	retinopathy with macular edema, unspecified eve Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
LU0.323		Diagilusis	ICD-TO-CIAI
	retinopathy without macular edema		

cder_mpl1p_wp077 Page 662 of 990



15 Definite ii	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3292	retinopathy without macular edema. right eve Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3293	retinopathy without macular edema. left eve Diabetes mellitus due to underlying condition with mild nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3299	retinopathy without macular edema. bilateral Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.33	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3312	retinopathy with macular edema, right eve Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3313	retinopathy with macular edema, left eve Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3319	retinopathy with macular edema, bilateral Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.339	retinopathy with macular edema, unspecified eve Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3391	retinopathy without macular edema Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3392	retinopathy without macular edema, right eve Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3393	retinopathy without macular edema. left eve Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3399	retinopathy without macular edema, bilateral Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.34	retinopathy without macular edema, unspecified eve Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.341	retinopathy Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3411	retinopathy with macular edema Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3412	retinopathy with macular edema, right eve Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3413	retinopathy with macular edema. left eve Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3419	retinopathy with macular edema, bilateral Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.349	retinopathy with macular edema, unspecified eve Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3491	retinopathy without macular edema Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3492	retinopathy without macular edema. right eve Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.3493	retinopathy without macular edema. left eve Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 663 of 990



	iciusion of Exclusion Criteria in this Nequest	Code	
Code	Description	Category	Code Type
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
E08.35	retinopathy without macular edema. unspecified eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3511	macular edema Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3512	macular edema, right eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3513	macular edema. left eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3519	macular edema, bilateral Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.352	macular edema, unspecified eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3521	traction retinal detachment involving the macula Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3522	traction retinal detachment involving the macula, right eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3523	traction retinal detachment involving the macula. left eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3529	traction retinal detachment involving the macula, bilateral Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.353	traction retinal detachment involving the macula, unspecified eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3531	traction retinal detachment not involving the macula Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3532	traction retinal detachment not involving the macula, right eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3533	traction retinal detachment not involving the macula. left eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3539	traction retinal detachment not involving the macula. bilateral Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.354	traction retinal detachment not involving the macula. unspecified eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3541	combined traction retinal detachment and rhegmatogenous retinal detachment Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3542	combined traction retinal detachment and rhegmatogenous retinal detachment. right eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3543	combined traction retinal detachment and rhegmatogenous retinal detachment. left eve Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E08.3549	combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment,	Diagnosis	ICD-10-CM
E08.355	Unspecified eve Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
E08.3551	retinopathy Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
E08.3552	retinopathy. right eve Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy. left eve	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 664 of 990



to Define ii	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
	retinopathy. bilateral	_	
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
	retinopathy. unspecified eve		
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema		
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, right eve		
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E00 2E02	without macular edema, left eve	Diamasia	ICD 10 CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.3599	without macular edema. bilateral Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
LU0.3333	without macular edema, unspecified eye	Diagnosis	ICD-10-CIVI
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment	g	
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment, right eve	J	
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment. left eve		
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment, bilateral		
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment, unspecified eve		
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.4	Diabetes mellitus due to underlying condition with neurological complications	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological	Diagnosis	ICD-10-CM
	complication		
E08.5	Diabetes mellitus due to underlying condition with circulatory complications	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without	Diagnosis	ICD-10-CM
	gangrene		
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with	Diagnosis	ICD-10-CM
500 50	gangrene	5	100 40 614
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.6	Diabetes mellitus due to underlying condition with other specified complications	Diagnosis	ICD-10-CM
E08.61 E08.610	Diabetes mellitus due to underlying condition with diabetic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM ICD-10-CM
E08.62	Diabetes mellitus due to underlying condition with other diabetic arthropathy Diabetes mellitus due to underlying condition with skin complications	Diagnosis Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 665 of 990



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

to Definite in	iciusion of Exclusion Criteria in this nequest	Code	
Code	Description	Category	Code Type
E08.63	Diabetes mellitus due to underlying condition with oral complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E13	Other specified diabetes mellitus	Diagnosis	ICD-10-CM
E13.0	Other specified diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-	Diagnosis	ICD-10-CM
	hyperosmolar coma (NKHHC)	J	
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.1	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.2	Other specified diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.3	Other specified diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E13.31	Other specified diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema		
E13.32	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema		
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, right eve		
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, left eve		
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, bilateral		
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, unspecified eve		
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema		
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, right eve	_	
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, left eve	J	
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, bilateral	-	
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, unspecified eve	-	
E13.33	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	,	3	-

cder_mpl1p_wp077 Page 666 of 990



to Define Ir	clusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3311	macular edema Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3312	macular edema. right eve Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3313	macular edema. left eve Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3319	macular edema. bilateral Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.339	macular edema. unspecified eve Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3391	without macular edema Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3392	without macular edema, right eve Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3393	without macular edema. left eve Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3399	without macular edema, bilateral Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.34 E13.341	without macular edema. unspecified eve Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E13.3411	macular edema Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3412	macular edema, right eve Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3413	macular edema. left eve Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3419	macular edema, bilateral Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.349	macular edema. unspecified eve Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3491	without macular edema Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3492	without macular edema. right eve Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3493	without macular edema. left eve Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3499	without macular edema. bilateral Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.35 E13.351	without macular edema, unspecified eve Other specified diabetes mellitus with proliferative diabetic retinopathy Other specified diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E13.3511	edema Other specified diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E13.3512	edema, right eve Other specified diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E13.3513	edema. left eve Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema. bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 667 of 990



to Benne i	nclusion or Exclusion Criteria in this Request	Code		
Code	Description	Category	Code Type	
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM	
E13.352	edema. unspecified eve Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3521	retinal detachment involving the macula Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3522	retinal detachment involving the macula. right eve Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3523	retinal detachment involving the macula, left eve Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3529	retinal detachment involving the macula, bilateral Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.353	retinal detachment involving the macula, unspecified eve Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3531	retinal detachment not involving the macula Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3532	retinal detachment not involving the macula, right eve Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3533	retinal detachment not involving the macula, left eve Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.3539	retinal detachment not involving the macula, bilateral Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM	
E13.354	retinal detachment not involving the macula, unspecified eve Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM	
E13.3541	traction retinal detachment and rhegmatogenous retinal detachment Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM	
E13.3542	traction retinal detachment and rhegmatogenous retinal detachment, right eve Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM	
E13.3543	traction retinal detachment and rhegmatogenous retinal detachment. left eve Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM	
E13.3549	traction retinal detachment and rhegmatogenous retinal detachment. bilateral Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM	
	traction retinal detachment and rhegmatogenous retinal detachment, unspecified eve	Ü		
E13.355	Other specified diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM	
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM	
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM	
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM	
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified	Diagnosis	ICD-10-CM	
E13.359	eve Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM	
E13.3591	edema Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM	
E13.3592	edema. right eve Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM	
E13.3593	edema. left eve Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM	
E13.3599	edema, bilateral Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM	
E13.36	edema, unspecified eve Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM	

cder_mpl1p_wp077 Page 668 of 990



to Define Ir	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E13.37	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
	treatment	-	
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
	treatment. right eve		
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
	treatment. left eve		
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
	treatment, bilateral		
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
E42.20	treatment, unspecified eve	Diamania	ICD 10 CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.4	Other specified diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.5	Other specified diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E13.51 E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.59 E13.6		Diagnosis	ICD-10-CM
E13.61	Other specified diabetes mellitus with other specified complications Other specified diabetes mellitus with diabetic arthropathy	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic artificiating Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.62	Other specified diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with root dicer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.63	Other specified diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with hypergyeering	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
£13.3	Pregnancy	Diagnosis	TED TO CIVI
000	Ectopic pregnancy	Diagnosis	ICD-10-CM
00000	Abdominal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
00001	Abdominal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
000101	Right tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000102	Left tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000109	Unspecified tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000111	Right tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
000112	Left tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
		-	

cder_mpl1p_wp077 Page 669 of 990



to Deline II	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O00119	Unspecified tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00201	Right ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00202	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00209	Unspecified ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00211	Right ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00212	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00219	Unspecified ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
800O	Other ectopic pregnancy	Diagnosis	ICD-10-CM
O800O	Other ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0081	Other ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O009	Ectopic pregnancy, unspecified	Diagnosis	ICD-10-CM
O0090	Unspecified ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0091	Unspecified ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O01	Hydatidiform mole	Diagnosis	ICD-10-CM
O01.0	Classical hydatidiform mole	Diagnosis	ICD-10-CM
001.1	Incomplete and partial hydatidiform mole	Diagnosis	ICD-10-CM
O01.9	Hydatidiform mole, unspecified	Diagnosis	ICD-10-CM
O02.0	Blighted ovum and nonhydatidiform mole	Diagnosis	ICD-10-CM
O02.1	Missed abortion	Diagnosis	ICD-10-CM
O0289	Other abnormal products of conception	Diagnosis	ICD-10-CM
O029	Abnormal products of conception, unspecified	Diagnosis	ICD-10-CM
O03	Spontaneous abortion	Diagnosis	ICD-10-CM
O03.0	Genital tract and pelvic infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.1	Delayed or excessive hemorrhage following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.2	Embolism following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.3	Other and unspecified complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.30	Unspecified complication following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.31	Shock following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.32	Renal failure following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.33	Metabolic disorder following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.34	Damage to pelvic organs following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.35	Other venous complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.36	Cardiac arrest following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.37	Sepsis following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.38	Urinary tract infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O03.39	Incomplete spontaneous abortion with other complications	Diagnosis	ICD-10-CM
O03.4	Incomplete spontaneous abortion without complication	Diagnosis	ICD-10-CM
003.5	Genital tract and pelvic infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.6	Delayed or excessive hemorrhage following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.7	Embolism following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.8	Other and unspecified complications following complete or unspecified spontaneous	Diagnosis	ICD-10-CM
000.0	abortion	2.0600.0	.02 20 0
O03.80	Unspecified complication following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.81	Shock following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.82	Renal failure following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.83	Metabolic disorder following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.84	Damage to pelvic organs following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.85	Other venous complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 670 of 990



to Define	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
003.86	Cardiac arrest following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.87	Sepsis following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.88	Urinary tract infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.89	Complete or unspecified spontaneous abortion with other complications	Diagnosis	ICD-10-CM
O03.9	Complete or unspecified spontaneous abortion without complication	Diagnosis	ICD-10-CM
O04.5	Genital tract and pelvic infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.6	Delayed or excessive hemorrhage following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.7	Embolism following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.80	(Induced) termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
004.81	Shock following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.82	Renal failure following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.83	Metabolic disorder following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.84	Damage to pelvic organs following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.85	Other venous complications following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.86	Cardiac arrest following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.87	Sepsis following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.88	Urinary tract infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.89	(Induced) termination of pregnancy with other complications	Diagnosis	ICD-10-CM
007.30	Failed attempted termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
007.35	Other venous complications following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.36	Cardiac arrest following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.38	Urinary tract infection following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.39	Failed attempted termination of pregnancy with other complications	Diagnosis	ICD-10-CM
0800	Genitl trct and pelvic infct fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0081	Delayed or excess hemor fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O082	Embolism following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O083	Shock following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O084	Renal failure following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O085	Metabolic disorders following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O086	Damage to pelvic organs and tiss fol an ect and molar preg	Diagnosis	ICD-10-CM
O087	Oth venous comp following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0881	Cardiac arrest following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0882	Sepsis following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0883	Urinary tract infection fol an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0889	Other complications following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0089	Unsp complication following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O10.02	Pre-existing essential hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.12	Pre-existing hypertensive heart disease complicating childbirth	Diagnosis	ICD-10-CM
010.22	Pre-existing hypertensive chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
O10.32	Pre-existing hypertensive heart and chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
010.42	Pre-existing secondary hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.92	Unspecified pre-existing hypertension complicating childbirth	Diagnosis	ICD-10-CM
011.4	Pre-existing hypertension with pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
012.04	Gestational edema, complicating childbirth	Diagnosis	ICD-10-CM
012.14	Gestational proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
012.24	Gestational edema with proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
013.4	Gestational [pregnancy-induced] hypertension without significant proteinuria,	Diagnosis	ICD-10-CM
	complicating childbirth		
014.04	Mild to moderate pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
014.14	Severe pre-eclampsia complicating childbirth	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 671 of 990



to belille i	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O14.24	HELLP syndrome, complicating childbirth	Diagnosis	ICD-10-CM
014.94	Unspecified pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
O16.4	Unspecified maternal hypertension, complicating childbirth	Diagnosis	ICD-10-CM
O24	Diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
O24.0	Pre-existing type 1 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.01	Pre-existing type 1 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
O24.011	Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.012	Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.013	Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.019	Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.02	Pre-existing type 1 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
024.03	Pre-existing type 1 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
024.1	Pre-existing type 2 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.11	Pre-existing type 2 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
024.111	Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.112	Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.113	Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.119	Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.12	Pre-existing type 2 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
024.13	Pre-existing type 2 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
O24.3	Unspecified pre-existing diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.31	Unspecified pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.311	Unspecified pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.312	Unspecified pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.313	Unspecified pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.319	Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.32	Unspecified pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.33	Unspecified pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
024.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
024.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
024.8	Other pre-existing diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
O24.81	Other pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.811	Other pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.812	Other pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.813	Other pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.819	Other pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.82	Other pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
024.83	Other pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
024.9	Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.91	Unspecified diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.911	Unspecified diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.912	Unspecified diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.913	Unspecified diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.919	Unspecified diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.92	Unspecified diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
024.93	Unspecified diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
025.2	Malnutrition in childbirth	Diagnosis	ICD-10-CM
026.62	Liver and biliary tract disorders in childbirth	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 672 of 990



to Define ii	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O26.72	Subluxation of symphysis (pubis) in childbirth	Diagnosis	ICD-10-CM
O31.00X0	Papyraceous fetus, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.00X1	Papyraceous fetus, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.00X2	Papyraceous fetus, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.00X3	Papyraceous fetus, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.00X4	Papyraceous fetus, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.00X5	Papyraceous fetus, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.00X9	Papyraceous fetus, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.02X0	Papyraceous fetus, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.02X1	Papyraceous fetus, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.02X2	Papyraceous fetus, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.02X3	Papyraceous fetus, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.02X4	Papyraceous fetus, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.02X5	Papyraceous fetus, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.02X9	Papyraceous fetus, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.03X0	Papyraceous fetus, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.03X1	Papyraceous fetus, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.03X2	Papyraceous fetus, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.03X3	Papyraceous fetus, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.03X4	Papyraceous fetus, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.03X5	Papyraceous fetus, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.03X9	Papyraceous fetus, third trimester, other fetus	Diagnosis	ICD-10-CM
031.1	Continuing pregnancy after spontaneous abortion of one fetus or more	Diagnosis	ICD-10-CM
031.10	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester		
O31.10X0	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, not applicable or unspecified		
O31.10X1	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, fetus 1		
O31.10X2	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, fetus 2		
O31.10X3	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, fetus 3		
O31.10X4	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, fetus 4		
O31.10X5	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, fetus 5		
O31.10X9	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified	Diagnosis	ICD-10-CM
	trimester, other fetus		
031.11	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester	Diagnosis	ICD-10-CM
O31.11X0	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, not	Diagnosis	ICD-10-CM
	applicable or unspecified		
O31.11X1	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester,	Diagnosis	ICD-10-CM
	fetus 1		
O31.11X2	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester,	Diagnosis	ICD-10-CM
	fetus 2		
O31.11X3	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester,	Diagnosis	ICD-10-CM
	fetus 3		
O31.11X4	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester,	Diagnosis	ICD-10-CM
	fetus 4		

cder_mpl1p_wp077 Page 673 of 990



to Define II	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O31.11X5	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester,	Diagnosis	ICD-10-CM
001111110	fetus 5	2108.100.0	.02 20 0
O31.11X9	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester,	Diagnosis	ICD-10-CM
	other fetus		
031.12	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester	Diagnosis	ICD-10-CM
O31.12X0	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	not applicable or unspecified		
O31.12X1	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
024 4272	fetus 1	Diai-	ICD 40 CN4
O31.12X2	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
O31.12X3	fetus 2 Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
031.12/3	fetus 3	Diagnosis	ICD-10-CIVI
O31.12X4	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
0011111	fetus 4	2108.100.0	.02 20 0
O31.12X5	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	fetus 5		
O31.12X9	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	other fetus		
031.13	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.13X0	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
024 4274	not applicable or unspecified	Diamaria	ICD 10 CM
O31.13X1	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
O31.13X2	fetus 1 Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
001.107.1	fetus 2	2108.100.0	.02 20 0
O31.13X3	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
	fetus 3		
O31.13X4	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
	fetus 4		
O31.13X5	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
024 4270	fetus 5	Diamenia	ICD 10 CM
O31.13X9	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester,	Diagnosis	ICD-10-CM
031.2	other fetus Continuing pregnancy after intrauterine death of one fetus or more	Diagnosis	ICD-10-CM
031.20	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester	_	ICD-10-CM
O31.20X0	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,		ICD-10-CM
	not applicable or unspecified	Ü	
O31.20X1	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,	Diagnosis	ICD-10-CM
	fetus 1		
O31.20X2	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,	Diagnosis	ICD-10-CM
	fetus 2		
O31.20X3	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,	Diagnosis	ICD-10-CM
O21 20V4	fetus 3 Continuing programs, after intrautoring death of one fetus or more unspecified trimester.	Diagnosis	ICD 10 CM
O31.20X4	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 4	DiagiiUSIS	ICD-10-CM
O31.20X5	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,	Diagnosis	ICD-10-CM
001.20/.0	fetus 5	J 0110010	
O31.20X9	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,	Diagnosis	ICD-10-CM
	other fetus		

cder_mpl1p_wp077 Page 674 of 990



to Define Ir	nclusion or Exclusion Criteria in this Request	Codo	
Cada	Description	Code	Code Tune
Code	Description Continuing program of the introduction double of any fature or sound tripocator.	Category	Code Type
O31.22 O31.22X0	Continuing pregnancy after intrauterine death of one fetus or more, second trimester Continuing pregnancy after intrauterine death of one fetus or more, second trimester, not	Diagnosis	ICD-10-CM ICD-10-CM
031.2270		Diagnosis	ICD-10-CIVI
O31.22X1	applicable or unspecified Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
O31.22X1	fetus 1	Diagnosis	ICD-10-CIVI
O31.22X2	Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
031.22/12	fetus 2	Diagnosis	TED TO CIVI
O31.22X3	Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
001.11.10	fetus 3	2108.100.0	.02 20 0
O31.22X4	Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	fetus 4	.0	
O31.22X5	Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	fetus 5	Ü	
O31.22X9	Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	other fetus	J	
031.23	Continuing pregnancy after intrauterine death of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.23X0	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, not	Diagnosis	ICD-10-CM
	applicable or unspecified	_	
O31.23X1	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X2	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X3	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X4	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X5	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X9	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, other	Diagnosis	ICD-10-CM
	fetus		
O36.4	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
O36.4XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O36.4XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O36.4XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O36.4XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O36.4XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O36.4XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
048.0	Post-term pregnancy	Diagnosis	ICD-10-CM
048.1	Prolonged pregnancy	Diagnosis	ICD-10-CM
O60.12X0	Preterm labor second trimester with preterm delivery second trimester, not applicable or	Diagnosis	ICD-10-CM
060.4374	unspecified	5	100 40 614
O60.12X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.12X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.12X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.12X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.12X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.12X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O60.13X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or	Diagnosis	ICD-10-CM
060 1371	unspecified	Diagnosis	ICD 10 CM
060.13X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
060.13X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM ICD-10-CM
060.13X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3 Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.13X4 O60.13X5	Preterm labor second trimester with preterm delivery third trimester, fetus 4 Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis Diagnosis	ICD-10-CM
000.1373	rieteriirianor second triinester with preteriirdenvery triild triinester, letus s	PIARITOSIS	ICD-TO-CIAI

cder_mpl1p_wp077 Page 675 of 990



to Define ii	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O60.13X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.14X0	Preterm labor third trimester with preterm delivery third trimester, not applicable or	Diagnosis	ICD-10-CM
	unspecified		
O60.14X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.14X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.14X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.14X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.14X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.14X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.22X0	Term delivery with preterm labor, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.22X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.22X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.22X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.22X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.22X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.22X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O60.23X0	Term delivery with preterm labor, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.23X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.23X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.23X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.23X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.23X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.23X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O63.2	Delayed delivery of second twin, triplet, etc.	Diagnosis	ICD-10-CM
O67.0	Intrapartum hemorrhage with coagulation defect	Diagnosis	ICD-10-CM
O67.8	Other intrapartum hemorrhage	Diagnosis	ICD-10-CM
067.9	Intrapartum hemorrhage, unspecified	Diagnosis	ICD-10-CM
068	Labor and delivery complicated by abnormality of fetal acid-base balance	Diagnosis	ICD-10-CM
O69.0XX0	Labor and delivery complicated by prolapse of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.0XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O69.0XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O69.0XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O69.0XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O69.0XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O69.0XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O69.1XX0	Labor and delivery complicated by cord around neck, with compression, not applicable or	Diagnosis	ICD-10-CM
060 43/44	unspecified	Dii-	ICD 40 CN4
069.1XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
069.1XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
069.1XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.1XX4 O69.1XX5	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM ICD-10-CM
	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	
O69.1XX9 O69.2XX0	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
069.2880	Labor and delivery complicated by other cord entanglement, with compression, not	Diagnosis	ICD-10-CM
O69.2XX1	applicable or unspecified Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
069.2XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1 Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis Diagnosis	ICD-10-CM
069.2XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2 Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM
069.2XX3 069.2XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 3 Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM
O69.2XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM
JUJ.ZAAJ	Labor and delivery complicated by other cord entanglement, with complession, letus 3	Piagilusis	ICD-TO-CIAI

cder_mpl1p_wp077 Page 676 of 990



to Delinie II	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O69.2XX9	Labor and delivery complicated by other cord entanglement, with compression, other	Diagnosis	ICD-10-CM
O69.3XX0	Labor and delivery complicated by short cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.3XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O69.3XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O69.3XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM
O69.3XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O69.3XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O69.3XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O69.4XX0	Labor and delivery complicated by vasa previa, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.4XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O69.4XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O69.4XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O69.4XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O69.4XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O69.4XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O69.5XX0	Labor and delivery complicated by vascular lesion of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.5XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O69.5XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O69.5XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O69.5XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O69.5XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O69.5XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O69.81X0	Labor and delivery complicated by cord around neck, without compression, not applicable	Diagnosis	ICD-10-CM
	or unspecified	J	
O69.81X1	Labor and delivery complicated by cord around neck, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.81X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.81X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.81X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.81X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.81X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O69.82X0	Labor and delivery complicated by other cord entanglement, without compression, not	Diagnosis	ICD-10-CM
	applicable or unspecified		
O69.82X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.82X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.82X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.82X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.82X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.82X9	Labor and delivery complicated by other cord entanglement, without compression, other	Diagnosis	ICD-10-CM
	fetus		
O69.89X0	Labor and delivery complicated by other cord complications, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.89X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM
O69.89X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM
O69.89X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O69.89X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O69.89X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O69.89X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM
O69.9XX0	Labor and delivery complicated by cord complication, unspecified, not applicable or	Diagnosis	ICD-10-CM
	unspecified		
O69.9XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 677 of 990



to Define Ir	nclusion or Exclusion Criteria in this Request	Code	
Codo	Description		Code Type
Code O69.9XX2	Description Labor and delivery complicated by cord complication, unspecified, fetus 2	Category	ICD-10-CM
069.9XX3	Labor and delivery complicated by cord complication, unspecified, fetus 2 Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis Diagnosis	ICD-10-CIVI
069.9XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CW
O69.9XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CIVI
O69.9XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	-	ICD-10-CW
070.0	First degree perineal laceration during delivery	Diagnosis Diagnosis	ICD-10-CIVI
070.0	Second degree perineal laceration during delivery	Diagnosis	ICD-10-CW
070.1	Third degree perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CW
070.20	Third degree perineal laceration during delivery, dispectified Third degree perineal laceration during delivery, Illa	Diagnosis	ICD-10-CIVI
070.21	Third degree perineal laceration during delivery, IIIb	Diagnosis	ICD-10-CW
070.22	Third degree perineal laceration during delivery, illo	Diagnosis	ICD-10-CIVI
070.23	Fourth degree perineal laceration during delivery	Diagnosis	ICD-10-CIVI
070.3	Anal sphincter tear complicating delivery, not associated with third degree laceration	Diagnosis	ICD-10-CW
070.4	Perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CW
070.9			
074.0	Aspiration pneumonitis due to anesthesia during labor and delivery Other pulmonary complications of anesthesia during labor and delivery	Diagnosis Diagnosis	ICD-10-CM
074.1	Cardiac complications of anesthesia during labor and delivery	-	ICD-10-CM ICD-10-CM
074.2		Diagnosis	ICD-10-CIVI
074.3	Central nervous system complications of anesthesia during labor and delivery	Diagnosis	
	Toxic reaction to local anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.5	Spinal and epidural anesthesia-induced headache during labor and delivery	Diagnosis	ICD-10-CM
074.6	Other complications of spinal and epidural anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.7	Failed or difficult intubation for anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.8	Other complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.9	Complication of anesthesia during labor and delivery, unspecified	Diagnosis	ICD-10-CM
075.0	Maternal distress during labor and delivery	Diagnosis	ICD-10-CM
075.1	Shock during or following labor and delivery	Diagnosis	ICD-10-CM
075.5	Delayed delivery after artificial rupture of membranes	Diagnosis	ICD-10-CM
075.81	Maternal exhaustion complicating labor and delivery	Diagnosis	ICD-10-CM
075.82	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39	Diagnosis	ICD-10-CM
075.00	completed weeks gestation. with delivery by (planned) cesarean section	5 : .	100 40 614
075.89	Other specified complications of labor and delivery	Diagnosis	ICD-10-CM
075.9	Complication of labor and delivery, unspecified	Diagnosis	ICD-10-CM
076	Abnormality in fetal heart rate and rhythm complicating labor and delivery	Diagnosis	ICD-10-CM
077.0	Labor and delivery complicated by meconium in amniotic fluid	Diagnosis	ICD-10-CM
077.8	Labor and delivery complicated by other evidence of fetal stress	Diagnosis	ICD-10-CM
077.9	Labor and delivery complicated by fetal stress, unspecified	Diagnosis	ICD-10-CM
080	Encounter for full-term uncomplicated delivery	Diagnosis	ICD-10-CM
082	Encounter for cesarean delivery without indication	Diagnosis	ICD-10-CM
088.02	Air embolism in childbirth	Diagnosis	ICD-10-CM
088.12	Amniotic fluid embolism in childbirth	Diagnosis	ICD-10-CM
088.22	Thromboembolism in childbirth	Diagnosis	ICD-10-CM
088.32	Pyemic and septic embolism in childbirth	Diagnosis	ICD-10-CM
088.82	Other embolism in childbirth	Diagnosis	ICD-10-CM
O98.02	Tuberculosis complicating childbirth	Diagnosis	ICD-10-CM
098.12	Syphilis complicating childbirth	Diagnosis	ICD-10-CM
098.22	Gonorrhea complicating childbirth	Diagnosis	ICD-10-CM
098.32	Other infections with a predominantly sexual mode of transmission complicating childbirth	Diagnosis	ICD-10-CM
O98.42	Viral henatitis complicating childhirth	Diagnosis	ICD-10 CM
098.42 098.52	Viral hepatitis complicating childbirth Other viral diseases complicating childbirth	Diagnosis	ICD-10-CM
030.52	Other viral diseases complicating childbirth	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 678 of 990



to bellile ii	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
098.62	Protozoal diseases complicating childbirth	Diagnosis	ICD-10-CM
098.72	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98.82	Other maternal infectious and parasitic diseases complicating childbirth	Diagnosis	ICD-10-CM
098.92	Unspecified maternal infectious and parasitic disease complicating childbirth	Diagnosis	ICD-10-CM
099.02	Anemia complicating childbirth	Diagnosis	ICD-10-CM
099.12	Other diseases of the blood and blood-forming organs and certain disorders involving the	Diagnosis	ICD-10-CM
	immune mechanism complicating childbirth	J	
099.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
099.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
099.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
099.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
099.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
099.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.284	Endocrine, nutritional and metabolic diseases complicating childbirth	Diagnosis	ICD-10-CM
099.314	Alcohol use complicating childbirth	Diagnosis	ICD-10-CM
099.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
099.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
099.344	Other mental disorders complicating childbirth	Diagnosis	ICD-10-CM
O99.354	Diseases of the nervous system complicating childbirth	Diagnosis	ICD-10-CM
O99.42	Diseases of the circulatory system complicating childbirth	Diagnosis	ICD-10-CM
O99.52	Diseases of the respiratory system complicating childbirth	Diagnosis	ICD-10-CM
O99.62	Diseases of the digestive system complicating childbirth	Diagnosis	ICD-10-CM
O99.72	Diseases of the skin and subcutaneous tissue complicating childbirth	Diagnosis	ICD-10-CM
099.814	Abnormal glucose complicating childbirth	Diagnosis	ICD-10-CM
O99.824	Streptococcus B carrier state complicating childbirth	Diagnosis	ICD-10-CM
099.834	Other infection carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.22	Injury, poisoning and certain other consequences of external causes complicating	Diagnosis	ICD-10-CM
	childbirth		
O9A.32	Physical abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.42	Sexual abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.52	Psychological abuse complicating childbirth	Diagnosis	ICD-10-CM
P03.0	Newborn affected by breech delivery and extraction	Diagnosis	ICD-10-CM
P03.2	Newborn affected by forceps delivery	Diagnosis	ICD-10-CM
P03.3	Newborn affected by delivery by vacuum extractor [ventouse]	Diagnosis	ICD-10-CM
P03.4	Newborn affected by Cesarean delivery	Diagnosis	ICD-10-CM
P03.5	Newborn affected by precipitate delivery	Diagnosis	ICD-10-CM
P07.00	Extremely low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.01	Extremely low birth weight newborn, less than 500 grams	Diagnosis	ICD-10-CM
P07.02	Extremely low birth weight newborn, 500-749 grams	Diagnosis	ICD-10-CM
P07.03	Extremely low birth weight newborn, 750-999 grams	Diagnosis	ICD-10-CM
P07.10	Other low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.14	Other low birth weight newborn, 1000-1249 grams	Diagnosis	ICD-10-CM
P07.15	Other low birth weight newborn, 1250-1499 grams	Diagnosis	ICD-10-CM
P07.16	Other low birth weight newborn, 1500-1749 grams	Diagnosis	ICD-10-CM
P07.17	Other low birth weight newborn, 1750-1999 grams	Diagnosis	ICD-10-CM
P07.18	Other low birth weight newborn, 2000-2499 grams	Diagnosis	ICD-10-CM
P07.20	Extreme immaturity of newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.21	Extreme immaturity of newborn, gestational age less than 23 completed weeks	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 679 of 990



	Inclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
P07.22	Extreme immaturity of newborn, gestational age 23 completed weeks	Diagnosis	ICD-10-CM
P07.23	Extreme immaturity of newborn, gestational age 24 completed weeks	Diagnosis	ICD-10-CM
P07.24	Extreme immaturity of newborn, gestational age 25 completed weeks	Diagnosis	ICD-10-CM
P07.25	Extreme immaturity of newborn, gestational age 26 completed weeks	Diagnosis	ICD-10-CM
P07.26	Extreme immaturity of newborn, gestational age 27 completed weeks	Diagnosis	ICD-10-CM
P07.30	Preterm newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.31	Preterm newborn, gestational age 28 completed weeks	Diagnosis	ICD-10-CM
P07.32	Preterm newborn, gestational age 29 completed weeks	Diagnosis	ICD-10-CM
P07.33	Preterm newborn, gestational age 30 completed weeks	Diagnosis	ICD-10-CM
P07.34	Preterm newborn, gestational age 31 completed weeks	Diagnosis	ICD-10-CM
P07.35	Preterm newborn, gestational age 32 completed weeks	Diagnosis	ICD-10-CM
P07.36	Preterm newborn, gestational age 33 completed weeks	Diagnosis	ICD-10-CM
P07.37	Preterm newborn, gestational age 34 completed weeks	Diagnosis	ICD-10-CM
P07.38	Preterm newborn, gestational age 35 completed weeks	Diagnosis	ICD-10-CM
P07.39	Preterm newborn, gestational age 36 completed weeks	Diagnosis	ICD-10-CM
P08.21	Post-term newborn	Diagnosis	ICD-10-CM
P08.22	Prolonged gestation of newborn	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM
Z33.2	Encounter for elective termination of pregnancy	Diagnosis	ICD-10-CM
Z37.0	Single live birth	Diagnosis	ICD-10-CM
Z37.1	Single stillbirth	Diagnosis	ICD-10-CM
Z37.2	Twins, both liveborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.4	Twins, both stillborn	Diagnosis	ICD-10-CM
Z37.50	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z37.51	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z37.52	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z37.53	Quintuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.54	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.59	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z37.6	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.7	Other multiple births, all stillborn	Diagnosis	ICD-10-CM
Z37.9	Outcome of delivery, unspecified	Diagnosis	ICD-10-CM
Z38.00	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.01	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.1	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.2	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 680 of 990



13 200 11	iclusion of Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
Z38.30	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.31	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.4	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.5	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z38.61	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.62	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.63	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.64	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.65	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.66	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.68	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.69	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.7	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.8	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3A.20	20 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.21	21 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.22	22 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.23	23 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.24	24 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.25	25 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.26	26 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.27	27 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.28	28 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.29	29 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.30	30 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.31	31 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.32	32 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.33	33 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.34	34 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.35	35 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.36	36 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.37	37 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.38	38 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.39	39 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.40	40 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.41	41 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.42	42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.49	Greater than 42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
0W8NXZZ	Division of Female Perineum, External Approach	Procedure	ICD-10-PCS
10900ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Open Approach	Procedure	ICD-10-PCS
10903ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10904ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous	Procedure	ICD-10-PCS
10907ZC	Endoscopic Approach Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or	Procedure	ICD-10-PCS
10908ZC	Artificial Opening Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or	Procedure	ICD-10-PCS
1040077	Artificial Opening Endoscopic Abortion of Products of Conception, Open Approach	Procedure	ICD-10-DCS
10A00ZZ 10A03ZZ	Abortion of Products of Conception, Open Approach Abortion of Products of Conception, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
10, 10022		occurre	.02 10 1 03

cder_mpl1p_wp077 Page 681 of 990



to Define in	clusion of Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
10A04ZZ	Abortion of Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10A07Z6	Abortion of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZW	Abortion of Products of Conception, Laminaria, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZX	Abortion of Products of Conception, Abortifacient, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A08ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D00Z0	Extraction of Products of Conception, High, Open Approach	Procedure	ICD-10-PCS
10D00Z1	Extraction of Products of Conception, Low, Open Approach	Procedure	ICD-10-PCS
10D00Z2	Extraction of Products of Conception, Extraperitoneal, Open Approach	Procedure	ICD-10-PCS
10D07Z3	Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z4	Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z5	Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z6	Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z8	Extraction of Products of Conception, Other, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D17Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D18Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
10D27ZZ	Extraction of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10D28ZZ	Extraction of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
10E0XZZ	Delivery of Products of Conception, External Approach	Procedure	ICD-10-PCS
10S07ZZ	Reposition Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10T20ZZ	Resection of products of conception, ectopic, open approach	Procedure	ICD-10-PCS
10T23ZZ	Resection of products of conception, ectopic, percutaneous approach	Procedure	ICD-10-PCS
10T24ZZ	Resection of products of conception, ectopic, percutaneous endoscopic approach	Procedure	ICD-10-PCS
10T27ZZ	Resection of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10T28ZZ	Resection of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
58661	Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy	Procedure	CPT-4
	and/or salpingectomv)		
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)	Procedure	CPT-4
58700	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)	Procedure	CPT-4
58770	Salpingostomy (salpingoneostomy)	Procedure	CPT-4
59100	Surgical treatment of ectopic pregnancy: tubal or ovarian, requiring salpingectomy and/or	Procedure	CPT-4
	oophorectomy, abdominal or vaginal approach		
59830	TREATMENT OF SEPTIC ABORTION, COMPLETED SURGICALLY	Procedure	CPT-4
59840	INDUCED ABORTION, BY DILATION AND CURETTAGE	Procedure	CPT-4
59841	INDUCED ABORTION, BY DILATION AND EVACUATION	Procedure	CPT-4
59850	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS	Procedure	CPT-4
59851	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH DILATION	Procedure	CPT-4
50053	AND CURETTAGE AND/OR EVACUATION		CDT 4
59852	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH	Procedure	CPT-4
59855	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES	Procedure	CPT-4
59856	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH DILATION AND	Procedure	CPT-4
59857	CURETTAGE AND/OR EVACUATION INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH HYSTEROTOMY	Procedure	CPT-4
59870	Evacuation and curettage of uterus for hydatidiform mole	Procedure	CPT-4
01964	ANESTHESIA FOR ABORTION PROCEDURES	Procedure	CPT-4
01965	Anesthesia for incomplete or missed abortion procedures	Procedure	CPT-4
01966	Anesthesia for induced abortion procedures	Procedure	CPT-4
31300		occurre	J

cder_mpl1p_wp077 Page 682 of 990



to Define i	Inclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
59120	Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or	Procedure	CPT-4
	oophorectomv. abdominal or vaginal approach		
59121	Surgical treatment of ectopic pregnancy; tubal or ovarian, without salpingectomy and/or	Procedure	CPT-4
50405	oophorectomv		
59125	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59126	Surgical Treatment of Ectopic Pregnancy	Procedure	CPT-4
59130 59135	Surgical treatment of ectopic pregnancy; abdominal pregnancy Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy requiring total	Procedure Procedure	CPT-4 CPT-4
33133		riocedule	CF1-4
59136	hvsterectomv Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy with partial	Procedure	CPT-4
33130	resection of uterus	rroccaure	CITT
59140	Surgical treatment of ectopic pregnancy; cervical, with evacuation	Procedure	CPT-4
59150	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or	Procedure	CPT-4
	oophorectomy		
59151	Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy	Procedure	CPT-4
59400	Routine obstetric care including antepartum care, vaginal delivery (with or without	Procedure	CPT-4
	episiotomy, and/or forceps) and postpartum care		
59409	Vaginal delivery only (with or without episiotomy and/or forceps);	Procedure	CPT-4
59410	Vaginal delivery only (with or without episiotomy and/or forceps); including postpartum	Procedure	CPT-4
	care		
59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	Procedure	CPT-4
59514	Cesarean delivery only;	Procedure	CPT-4
59515	Cesarean delivery only; including postpartum care	Procedure	CPT-4
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without	Procedure	CPT-4
50643	episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery		CDT 4
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or	Procedure	CPT-4
59614	forceps): Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or	Procedure	CPT-4
39014		Procedure	CP1-4
59618	forceps): including postpartum care Routine obstetric care including antepartum care, cesarean delivery, and postpartum care,	Procedure	CPT-4
33010	following attempted vaginal delivery after previous cesarean delivery	rrocedure	CI I-4
59620	Cesarean delivery only, following attempted vaginal delivery after previous cesarean	Procedure	CPT-4
33020	delivery;		C
59622	Cesarean delivery only, following attempted vaginal delivery after previous cesarean	Procedure	CPT-4
	delivery: including postpartum care		
59812	Treatment of incomplete abortion, any trimester, completed surgically	Procedure	CPT-4
59820	Treatment of missed abortion, completed surgically; first trimester	Procedure	CPT-4
59821	Treatment of missed abortion, completed surgically; second trimester	Procedure	CPT-4
S0190	Mifepristone, oral, 200 mg	Procedure	HCPCS
S0191	Misoprostol, oral, 200 mcg	Procedure	HCPCS
S0199	Medically induced abortion by oral ingestion of medication including all associated	Procedure	HCPCS
	services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by		
	HCG, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of		
	ahortion) except drugs	_	
S2260	Induced abortion, 17 to 24 weeks	Procedure	HCPCS
S2265	Induced abortion, 25 to 28 weeks	Procedure	HCPCS
S2266	Induced abortion, 29 to 31 weeks	Procedure	HCPCS
S2267	Induced abortion, 32 weeks or greater	Procedure	HCPCS

cder_mpl1p_wp077 Page 683 of 990



Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Used to Define Inclusion or Exclusion Criteria in this Request Brand Name
	ide-1 Receptor Agonists (SA GLP-1 RAs)
exenatide	Byetta
lixisenatide	Adlyxin
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
	Insulin
insulin aspart	insulin aspart U-100
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin degludec	insulin degludec
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U-100 Insuln
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
insulin glargine, human recombinant analog	Basaglar Tempo Pen(U-100)Insln
insulin glargine, human recombinant analog	insulin glargine
insulin glargine, human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine, human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine-yfgn	insulin glargine-yfgn
insulin glargine-yfgn	Semglee(insulin glargine-yfgn)
insulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insuln
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
insulin lispro-aabc	Lyumjev U-100 Insulin
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin

cder_mpl1p_wp077 Page 684 of 990



Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U-100 Insuln
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Ora	al Antidiabetics
acarbose	acarbose
acarbose	Precose
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
alogliptin benzoate/pioglitazone HCl	Oseni
bromocriptine mesylate	Cycloset
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	glipizide
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide/metformin HCl	glipizide-metformin
glyburide	glyburide
glyburide,micronized	glyburide micronized
glyburide,micronized	Glynase
glyburide/metformin HCl	glyburide-metformin
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glumetza
metformin HCl	metformin

cder_mpl1p_wp077 Page 685 of 990

Riomet

metformin HCl



Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name			
metformin HCl	Riomet ER			
mifepristone	Korlym			
miglitol	miglitol			
nateglinide	nateglinide			
pioglitazone HCl	Actos			
pioglitazone HCl	pioglitazone			
pioglitazone HCl/glimepiride	DUETACT			
pioglitazone HCl/glimepiride	pioglitazone-glimepiride			
pioglitazone HCI/metformin HCI	Actoplus MET			
pioglitazone HCl/metformin HCl	pioglitazone-metformin			
repaglinide	repaglinide			
repaglinide/metformin HCl	repaglinide-metformin			
saxagliptin HCl	Onglyza			
saxagliptin HCI/metformin HCI	Kombiglyze XR			
sitagliptin phosphate	Januvia			
sitagliptin phosphate/metformin HCl	Janumet			
sitagliptin phosphate/metformin HCl	Janumet XR			
Non-Oral Antidiabetics				
pramlintide acetate	SymlinPen 60			

pramlintide acetate SymlinPen 120

Page 686 of 990 $cder_mpl1p_wp077$



riocedure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
	Alcohol Use or Abuse		
F10	Alcohol related disorders	Diagnosis	ICD-10-CM
F10.1	Alcohol abuse	Diagnosis	ICD-10-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.12	Alcohol abuse with intoxication	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.15	Alcohol abuse with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.18	Alcohol abuse with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.28	Alcohol dependence with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
		J	

cder_mpl1p_wp077 Page 687 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.9	Alcohol use, unspecified	Diagnosis	ICD-10-CM
F10.92	Alcohol use, unspecified with intoxication	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.95	Alcohol use, unspecified with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.98	Alcohol use, unspecified with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
142.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.2	Alcoholic gastritis	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51	Toxic effect of alcohol	Diagnosis	ICD-10-CM
T51.0	Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X	Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X1	Toxic effect of ethanol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
	· · · · · · · · · · · · · · · · · · ·	_	

cder_mpl1p_wp077 Page 688 of 990



Procedure	Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
T51.0X1D	Toxic effect of ethanol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.0X1S	Toxic effect of ethanol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.0X2	Toxic effect of ethanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X3	Toxic effect of ethanol, assault	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X3D	Toxic effect of ethanol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X3S	Toxic effect of ethanol, assault, sequela	Diagnosis	ICD-10-CM
T51.0X4	Toxic effect of ethanol, undetermined	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.0X4D	Toxic effect of ethanol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X4S	Toxic effect of ethanol, undetermined, sequela	Diagnosis	ICD-10-CM
T51.8	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X1	Toxic effect of other alcohols, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.8X1A	Toxic effect of other alcohols, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.8X1D	Toxic effect of other alcohols, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.8X1S	Toxic effect of other alcohols, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.8X2	Toxic effect of other alcohols, intentional self-harm	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.8X3	Toxic effect of other alcohols, assault	Diagnosis	ICD-10-CM
T51.8X3A	Toxic effect of other alcohols, assault, initial encounter	Diagnosis	ICD-10-CM
T51.8X3D	Toxic effect of other alcohols, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X3S	Toxic effect of other alcohols, assault, sequela	Diagnosis	ICD-10-CM
T51.8X4	Toxic effect of other alcohols, undetermined	Diagnosis	ICD-10-CM
T51.8X4A	Toxic effect of other alcohols, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.8X4D	Toxic effect of other alcohols, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X4S	Toxic effect of other alcohols, undetermined, sequela	Diagnosis	ICD-10-CM
T51.9	Toxic effect of unspecified alcohol	Diagnosis	ICD-10-CM
T51.91	Toxic effect of unspecified alcohol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.91XA	Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.91XD	Toxic effect of unspecified alcohol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.91XS	Toxic effect of unspecified alcohol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.92	Toxic effect of unspecified alcohol, intentional self-harm	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.93	Toxic effect of unspecified alcohol, assault	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 689 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
T51.93XA	Toxic effect of unspecified alcohol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.93XD	Toxic effect of unspecified alcohol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.93XS	Toxic effect of unspecified alcohol, assault, sequela	Diagnosis	ICD-10-CM
T51.94	Toxic effect of unspecified alcohol, undetermined	Diagnosis	ICD-10-CM
T51.94XA	Toxic effect of unspecified alcohol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.94XD	Toxic effect of unspecified alcohol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.94XS	Toxic effect of unspecified alcohol, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.4	Alcohol abuse counseling and surveillance	Diagnosis	ICD-10-CM
	Obesity		
Z68.3	Body mass index [BMI] 30-39, adult	Diagnosis	ICD-10-CM
Z68.4	Body mass index [BMI] 40 or greater, adult	Diagnosis	ICD-10-CM
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
099.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
099.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
099.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
099.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
099.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
099.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index [BMI] 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index [BMI] 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index [BMI] 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index [BMI] 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index [BMI] 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index [BMI] 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index [BMI] 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index [BMI] 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index [BMI] 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index [BMI] 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index [BMI]40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index [BMI] 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index [BMI] 50.0-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index [BMI] 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index [BMI] 70 or greater, adult	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 690 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
Z98.84	Bariatric surgery status	Diagnosis	ICD-10-CM
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
	Approach		
0D160Z9 0D160ZA	Bypass Stomach to Duodenum, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0D160ZA 0D160ZB	Bypass Stomach to Jejunum, Open Approach Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
OD164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
OD164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 691 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
0046010	Artificial Opening Endoscopic		100 40 000
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0016014	Endoscopic	Duagadiina	ICD 10 DCC
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0010010	Endoscopic	riocedure	ICD-10-PC3
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
ODIOOL	Opening Endoscopic	Troccaure	100 101 05
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
02200.00	Artificial Opening Endoscopic		.02 20 . 00
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB 0D190K9	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9 0D190KA	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0D190KA 0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB 0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 692 of 990



		Code	
Code	Description	Category	Code Type
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
DD194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
DD194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
DD194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
DD194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
D10074	Artificial Opening Endoscopic	Dunnadiiina	ICD 10 DCC
D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
/0136/Б	Opening Endoscopic	riocedule	ICD-10-PC3
D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
2 2 3 3 3 3	Opening Endoscopic		.02 20 . 00
D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
DD1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 693 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
OD1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 694 of 990



Tocadic	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	_Code Type
OD1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
OD1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
OD1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
ODB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
ODB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
ODB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
ODB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
ODBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
OTRBO7Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
	Tobacco Use		
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.21	Nicotine dependence, cigarettes	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
. 17.1210			.00 10 0111

cder_mpl1p_wp077 Page 695 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.22	Nicotine dependence, chewing tobacco	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.29	Nicotine dependence, other tobacco product	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
T65.21	Toxic effect of chewing tobacco	Diagnosis	ICD-10-CM
T65.211	Toxic effect of chewing tobacco, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.211D	Toxic effect of chewing tobacco, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.211S	Toxic effect of chewing tobacco, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.213	Toxic effect of chewing tobacco, assault	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.213D	Toxic effect of chewing tobacco, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.213S	Toxic effect of chewing tobacco, assault, sequela	Diagnosis	ICD-10-CM
T65.214	Toxic effect of chewing tobacco, undetermined	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.214D	Toxic effect of chewing tobacco, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.214S	Toxic effect of chewing tobacco, undetermined, sequela	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.221D	Toxic effect of tobacco cigarettes, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.221S	Toxic effect of tobacco cigarettes, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.223D	Toxic effect of tobacco cigarettes, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.223S	Toxic effect of tobacco cigarettes, assault, sequela	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 696 of 990



Fiocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.224D	Toxic effect of tobacco cigarettes, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.224S	Toxic effect of tobacco cigarettes, undetermined, sequela	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.291D	Toxic effect of other tobacco and nicotine, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.291S	Toxic effect of other tobacco and nicotine, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.293D	Toxic effect of other tobacco and nicotine, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.293S	Toxic effect of other tobacco and nicotine, assault, sequela	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.294D	Toxic effect of other tobacco and nicotine, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.294S	Toxic effect of other tobacco and nicotine, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z72.0	Tobacco use	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
1032F	Current tobacco smoker or currently exposed to secondhand smoke (asthma)	Procedure	HCPCS
1034F	Current tobacco smoker (cad, cap, copd, pv) (dm)	Procedure	HCPCS
1035F	Current smokeless tobacco user (eg, chew, snuff) (pv)	Procedure	HCPCS
4000F	Tobacco use cessation intervention, counseling (copd, cap, cad, asthma) (dm) (pv)	Procedure	HCPCS
4001F	Tobacco use cessation intervention, pharmacologic therapy (copd, cad, cap, pv, asthma) (dm) (pv)	Procedure	HCPCS
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling,	Procedure	HCPCS
	pharmacotherapy, or both), if identified as a tobacco user (pv, cad)		
99406	Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes	Procedure	HCPCS
99407	Smoking and tobacco use intensive counseling, greater than 10 minutes	Procedure	HCPCS
C9801	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
C9802	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
D1320	Tobacco counseling for the control and prevention of oral disease	Procedure	HCPCS
G0375	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTERMEDIATE, GREATER THAN 3 MINUTES UP TO 10 MINUTES	Procedure	HCPCS
G0376	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTENSIVE, GREATER THAN 10 MINUTES	Procedure	HCPCS
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS

cder_mpl1p_wp077 Page 697 of 990



		Code	
Code	Description	Category	Code Type
60437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive,	Procedure	HCPCS
	greater than 10 minutes		
G8093	Newly diagnosed chronic obstructive pulmonary disease (copd) patient documented to	Procedure	HCPCS
	have received smoking cessation intervention, within 3 months of diagnosis		
38094	Newly diagnosed chronic obstructive pulmonary disease (copd) patient not documented	Procedure	HCPCS
	to have received smoking cessation intervention, within 3 months of diagnosis		
68402	Tobacco (smoke) use cessation intervention, counseling	Procedure	HCPCS
68403	Tobacco (smoke) use cessation intervention not counseled	Procedure	HCPCS
68453	Tobacco use cessation intervention, counseling	Procedure	HCPCS
68454	Tobacco use cessation intervention not counseled, reason not specified	Procedure	HCPCS
8455	Current tobacco smoker	Procedure	HCPCS
68456	Current smokeless tobacco user	Procedure	HCPCS
38686	Currently a tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
68688	Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand	Procedure	HCPCS
	smoke		
68690	Current tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
68692	Current smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke	Procedure	HCPCS
59016	Smoking cessation counseling, individual, in the absence of or in addition to any other	Procedure	HCPCS
	evaluation and management service, per session (6-10 minutes) âdemo project code only		
9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
69458	Patient documented as tobacco user and received tobacco cessation intervention (must	Procedure	HCPCS
33 130	include at least one of the following: advice given to quit smoking or tobacco use,		1101 00
	counseling on the benefits of q		
20045			
39645	Patients who did not abstain from smoking prior to anesthesia on the day of surgery or	Procedure	HCPCS
	procedure		
59792	Most recent tobacco status is not tobacco free	Procedure	HCPCS
59902	Patient screened for tobacco use and identified as a tobacco user	Procedure	HCPCS
59906	Patient identified as a tobacco user received tobacco cessation intervention (counseling	Procedure	HCPCS
	and/or pharmacotherapy)		
39908	Patient identified as tobacco user did not receive tobacco cessation intervention	Procedure	HCPCS
	(counseling and/or pharmacotherapy), reason not given		
G9909	Documentation of medical reason(s) for not providing tobacco cessation intervention if	Procedure	HCPCS
	identified as a tobacco user (eg, limited life expectancy, other medical reason)		
4990	Nicotine patches, legend	Procedure	HCPCS
4991	Nicotine patches, non-legend	Procedure	HCPCS
4995	Smoking cessation gum	Procedure	HCPCS
9075	Smoking cessation treatment	Procedure	HCPCS
	Arrhythmia		
44	Atrioventricular and left bundle-branch block	Diagnosis	ICD-10-CM
44.0	Atrioventricular block, first degree	Diagnosis	ICD-10-CM
44.1	Atrioventricular block, second degree	Diagnosis	ICD-10-CM
44.2	Atrioventricular block, complete	Diagnosis	ICD-10-CM
44.3	Other and unspecified atrioventricular block	Diagnosis	ICD-10-CM
	·	_	
44.30	Unspecified atrioventricular block	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 698 of 990



Tocedul	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
144.39	Other atrioventricular block	Diagnosis	ICD-10-CM
144.4	Left anterior fascicular block	Diagnosis	ICD-10-CM
144.5	Left posterior fascicular block	Diagnosis	ICD-10-CM
144.6	Other and unspecified fasicular block	Diagnosis	ICD-10-CM
144.60	Unspecified fascicular block	Diagnosis	ICD-10-CM
144.69	Other fascicular block	Diagnosis	ICD-10-CM
144.7	Left bundle-branch block, unspecified	Diagnosis	ICD-10-CM
145	Other conduction disorders	Diagnosis	ICD-10-CM
145.0	Right fascicular block	Diagnosis	ICD-10-CM
145.1	Other and unspecified right bundle-branch block	Diagnosis	ICD-10-CM
145.10	Unspecified right bundle-branch block	Diagnosis	ICD-10-CM
145.19	Other right bundle-branch block	Diagnosis	ICD-10-CM
145.2	Bifascicular block	Diagnosis	ICD-10-CM
145.3	Trifascicular block	Diagnosis	ICD-10-CM
145.4	Nonspecific intraventricular block	Diagnosis	ICD-10-CM
145.5	Other specified heart block	Diagnosis	ICD-10-CM
145.6	Pre-excitation syndrome	Diagnosis	ICD-10-CM
145.8	Other specified conduction disorders	Diagnosis	ICD-10-CM
145.89	Other specified conduction disorders	Diagnosis	ICD-10-CM
145.9	Conduction disorder, unspecified	Diagnosis	ICD-10-CM
146	Cardiac arrest	Diagnosis	ICD-10-CM
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
147	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
147.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
148	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
148.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
148.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
148.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
148.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
148.3	Typical atrial flutter	Diagnosis	ICD-10-CM
148.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
148.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
148.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
148.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 699 of 990



Troccadie	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
149	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
149.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
149.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
149.02	Ventricular flutter	Diagnosis	ICD-10-CM
149.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
149.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
149.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
149.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
149.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
149.49	Other premature depolarization	Diagnosis	ICD-10-CM
149.5	Sick sinus syndrome	Diagnosis	ICD-10-CM
149.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
149.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00	Abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
R00.1	Bradycardia, unspecified	Diagnosis	ICD-10-CM
R00.2	Palpitations	Diagnosis	ICD-10-CM
R00.8	Other abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.9	Unspecified abnormalities of heart beat	Diagnosis	ICD-10-CM
	Cerebrovascular Disease/Stroke/Transient Ischemic Attack		
G43.5	Persistent migraine aura without cerebral infarction	Diagnosis	ICD-10-CM
G43.50	Persistent migraine aura without cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.501	Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.509	Persistent migraine aura without cerebral infarction, not intractable, without status	Diagnosis	ICD-10-CM
G45.509	migrainosus	Diagnosis	ICD-10-CIVI
G43.51	Persistent migraine aura without cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.511	Persistent migraine aura without cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.519	Persistent migraine aura without cerebral infarction, intractable, without status	Diagnosis	ICD-10-CM
	migrainosus		
G43.6	Persistent migraine aura with cerebral infarction	Diagnosis	ICD-10-CM
G43.60	Persistent migraine aura with cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.601	Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.609	Persistent migraine aura with cerebral infarction, not intractable, without status	Diagnosis	ICD-10-CM
	migrainosus		
G43.61	Persistent migraine aura with cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.611	Persistent migraine aura with cerebral infarction, intractable, with status migrainesus	Diagnosis	ICD-10-CM
G43.619	Persistent migraine aura with cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G45 G45.0	Transient cerebral ischemic attacks and related syndromes Vertebro-basilar artery syndrome	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
G45.0 G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 700 of 990



	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.4	Transient global amnesia	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
160	Nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
160.0	Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.1	Nontraumatic subarachnoid hemorrhage from middle cerebral artery	Diagnosis	ICD-10-CM
160.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
160.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
160.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
160.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
160.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
160.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
160.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
160.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery	Diagnosis	ICD-10-CM
160.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
160.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
160.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
160.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
160.5	Nontraumatic subarachnoid hemorrhage from vertebral artery	Diagnosis	ICD-10-CM
160.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
160.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
160.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
160.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
160.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
160.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
160.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
161	Nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
161.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
161.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
161.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
161.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
161.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
161.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
161.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
161.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
161.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
162	Other and unspecified nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
162.0	Nontraumatic subdural hemorrhage	Diagnosis	ICD-10-CM
162.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 701 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
162.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
162.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
162.03	Nontraumatic chronic subdural hemorrhage	Diagnosis	ICD-10-CM
162.1	Nontraumatic extradural hemorrhage	Diagnosis	ICD-10-CM
162.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
163	Cerebral infarction	Diagnosis	ICD-10-CM
163.0	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CM
163.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.01	Cerebral infarction due to thrombosis of vertebral artery	Diagnosis	ICD-10-CM
163.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
163.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
163.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
163.03	Cerebral infarction due to thrombosis of carotid artery	Diagnosis	ICD-10-CM
163.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
163.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
163.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
163.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
163.1	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CM
163.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.11	Cerebral infarction due to embolism of vertebral artery	Diagnosis	ICD-10-CM
163.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
163.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
163.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
163.13	Cerebral infarction due to embolism of carotid artery	Diagnosis	ICD-10-CM
163.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
163.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
163.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
163.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
163.2	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CM
163.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
163.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries	Diagnosis	ICD-10-CM
163.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
163.211	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CW
163.212	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries		
103.213	Cerebral infarction due to unspecified occidsion of steriosis of bilateral vertebral afteries	Diagnosis	ICD-10-CM
163.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
163.23	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries	Diagnosis	ICD-10-CM
163.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
163.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 702 of 990



Procedure	Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
163.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
	·	J	
163.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
	,		
163.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
103.23	cerestal interestion and to unspecified occidation of stemosis of other precential arteries	Diagnosis	100 10 0141
163.3	Cerebral infarction due to thrombosis of cerebral arteries	Diagnosis	ICD-10-CM
163.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.31	Cerebral infarction due to thrombosis of middle cerebral artery	Diagnosis	ICD-10-CM
163.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
163.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
163.313	Cerebral infarction due to thrombosis of left middle cerebral arteries	Diagnosis	ICD-10-CM
163.319	Cerebral infarction due to thrombosis of bhateral middle cerebral artery	Diagnosis	ICD-10-CM
163.32	Cerebral infarction due to thrombosis of dispectived initiale cerebral artery		
	•	Diagnosis	ICD-10-CM
163.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.33	Cerebral infarction due to thrombosis of posterior cerebral artery	Diagnosis	ICD-10-CM
163.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.34	Cerebral infarction due to thrombosis of cerebellar artery	Diagnosis	ICD-10-CM
163.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
163.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
163.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
163.4	Cerebral infarction due to embolism of cerebral arteries	Diagnosis	ICD-10-CM
163.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.41	Cerebral infarction due to embolism of middle cerebral artery	Diagnosis	ICD-10-CM
163.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
163.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
163.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
163.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.42	Cerebral infarction due to embolism of anterior cerebral artery	Diagnosis	ICD-10-CM
163.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.43	Cerebral infarction due to embolism of posterior cerebral artery	Diagnosis	ICD-10-CM
163.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
	_ · · · · · · · · · · · · · · · · · · ·		
163.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.44	Cerebral infarction due to embolism of cerebellar artery	Diagnosis	ICD-10-CM
163.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
163.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 703 of 990



		Code	
Code	Description	Category	Code Type
163.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
163.5	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CM
163.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.51	Cerebral infarction due to unspecified occlusion or stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
163.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
103.312	cerebral infarction due to unspecified occidison of steriosis of left infidule cerebral aftery	บเล _็ นเบงเง	ICD-TO-CIAI
163.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral	Diagnosis	ICD-10-CM
	arteries		
163.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral	Diagnosis	ICD-10-CM
	artery		
163.52	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
163.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral	Diagnosis	ICD-10-CM
	artery		
163.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral	Diagnosis	ICD-10-CM
	arteries		
163.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior	Diagnosis	ICD-10-CM
	cerebral artery		
163.53	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
163.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral	Diagnosis	ICD-10-CM
	artery		
163.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral	Diagnosis	ICD-10-CM
	artery		
163.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral	Diagnosis	ICD-10-CM
	arteries		
163.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior	Diagnosis	ICD-10-CM
	cerebral artery		
163.54	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery	Diagnosis	ICD-10-CM
163.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
163.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
163.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
162 540	Corobral inforction due to uneposition assistance is of warmaritied assistance.	Diagnosis	ICD 10 CN4
163.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar	Diagnosis	ICD-10-CM
163.50	artery	Diagnasia	ICD 10 CM
163.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
163.6 163.8	Other cerebral infarction	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
163.81	Other cerebral infarction Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CIVI
163.89	Other cerebral infarction	Diagnosis	ICD-10-CIVI
.00.00	outer cereation murcuon	2145110313	.55 10 6141

cder_mpl1p_wp077 Page 704 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
163.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
165	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
165.0	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CM
165.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
165.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
165.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
165.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
165.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
165.2	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CM
165.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
165.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
165.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
165.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
165.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
165.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
166	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
166.0	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
166.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
166.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
166.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
166.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
166.1	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
166.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
166.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
166.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
166.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
166.2	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
166.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
166.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
166.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
166.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
166.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
166.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
166.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
167	Other cerebrovascular diseases	Diagnosis	ICD-10-CM
167.0	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CM
167.1	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CM
167.2	Cerebral atherosclerosis	Diagnosis	ICD-10-CM
167.3	Progressive vascular leukoencephalopathy	Diagnosis	ICD-10-CM
167.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
167.5	Moyamoya disease	Diagnosis	ICD-10-CM
167.7	Cerebral arteritis, not elsewhere classified	Diagnosis	ICD-10-CM
167.7	Other specified cerebrovascular diseases	Diagnosis	ICD-10-CM
167.81	Acute cerebrovascular insufficiency	Diagnosis	ICD-10-CM
167.81	Cerebral ischemia	Diagnosis	ICD-10-CM
167.83	Posterior reversible encephalopathy syndrome	Diagnosis	ICD-10-CM
167.84	Cerebral vasospasm and vasoconstriction	-	ICD-10-CM
167.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
167.841	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis Diagnosis	ICD-10-CM
167.85	Hereditary cerebrovascular diseases	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 705 of 990



		Code	
Code	Description	Category	Code Type
167.850	Cerebral autosomal dominant arteriopathy with subcortical infarcts and	Diagnosis	ICD-10-CM
	leukoencephalopathy		
167.858	Other hereditary cerebrovascular disease	Diagnosis	ICD-10-CM
167.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
167.9	Cerebrovascular disease, unspecified	Diagnosis	ICD-10-CM
168	Cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
168.0	Cerebral amyloid angiopathy	Diagnosis	ICD-10-CM
168.2	Cerebral arteritis in other diseases classified elsewhere	Diagnosis	ICD-10-CM
168.8	Other cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
169	Sequelae of cerebrovascular disease	Diagnosis	ICD-10-CM
169.0	Sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.00	Unspecified sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.01	Cognitive deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.010	Attention and concentration deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.011	Memory deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.012	Visuospatial deficit and spatial neglect following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.013	Deuchamatar deficit following nontroumatic cubarachnoid homorrhago	Diagnosis	ICD-10-CM
	Psychomotor deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	
169.014	Frontal lobe and executive function deficit following nontraumatic subarachnoid	Diagnosis	ICD-10-CM
	hemorrhage		
169.015	Cognitive social or emotional deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.018	Other symptoms and signs involving cognitive functions following nontraumatic	Diagnosis	ICD-10-CM
	subarachnoid hemorrhage		
169.019	Unspecified symptoms and signs involving cognitive functions following nontraumatic	Diagnosis	ICD-10-CM
	subarachnoid hemorrhage	J	
169.02	Speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.020	Aphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.020	Dysphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.021	Dysarthria following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CIVI
169.022	Fluency disorder following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CIVI
169.028	Other speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CIVI
		_	
169.03	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	right dominant side		
169.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	left dominant side		
169.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	right non-dominant side	J	
160 024	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD 10 CM
169.034		Diagnosis	ICD-10-CM
	left non-dominant side		
169.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	unspecified side		
169.04	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	right dominant side	_	
	3		

cder_mpl1p_wp077 Page 706 of 990



		Code	
Code	Description	Category	Code Type
169.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
69.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
69.05	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
69.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
69.06	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
69.061	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
69.062	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
69.063	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
69.064	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
69.065	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral	Diagnosis	ICD-10-CM
69.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
69.09	Other sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
69.090	Apraxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
69.091	Dysphagia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.092	Facial weakness following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
69.093	Ataxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.098	Other sequelae following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.1	Sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.10	Unspecified sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
69.11	Cognitive deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
69.110	Attention and concentration deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
69.111	Memory deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.112	Visuospatial deficit and spatial neglect following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.113	Psychomotor deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 707 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.114	Frontal lobe and executive function deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.115 169.118	Cognitive social or emotional deficit following nontraumatic intracerebral hemorrhage Other symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.119	Unspecified symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.12 169.120 169.121 169.122 169.123 169.128	Speech and language deficits following nontraumatic intracerebral hemorrhage Aphasia following nontraumatic intracerebral hemorrhage Dysphasia following nontraumatic intracerebral hemorrhage Dysarthria following nontraumatic intracerebral hemorrhage Fluency disorder following nontraumatic intracerebral hemorrhage Other speech and language deficits following nontraumatic intracerebral hemorrhage Monoplegia of upper limb following nontraumatic intracerebral hemorrhage	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
169.131 169.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left	Diagnosis Diagnosis	ICD-10-CM
169.133	dominant side Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.14 169.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.15 169.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 708 of 990



		Code	
Code	Description	Category	Code Type
169.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.16	Other paralytic syndrome following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.161	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
169.162	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.163	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.164	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.165	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral	Diagnosis	ICD-10-CM
169.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.19	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.190	Apraxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.191	Dysphagia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.192	Facial weakness following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.193	Ataxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.198	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.2	Sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.20	Unspecified sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.21	Cognitive deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.210	Attention and concentration deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.211	Memory deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.212	Visuospatial deficit and spatial neglect following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.213	Psychomotor deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.214	Frontal lobe and executive function deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.215	Cognitive social or emotional deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.218	Other symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.219	Unspecified symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.22	Speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.220	Aphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.221	Dysphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.222	Dysarthria following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.223	Fluency disorder following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 709 of 990



	codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.228	Other speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.23 169.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.24 169.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.25 169.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.26 169.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 710 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request		
CI-	Paradiation.	Code	Codo Tomo
Code	Description 6 the second secon	Category	Code Type
169.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral	Diagnosis	ICD-10-CM
169.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.29	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.290	Apraxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.291	Dysphagia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.292	Facial weakness following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.293	Ataxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.298	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.3	Sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.30	Unspecified sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.31	Cognitive deficits following cerebral infarction	Diagnosis	ICD-10-CM
169.310	Attention and concentration deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.311	Memory deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.312	Visuospatial deficit and spatial neglect following cerebral infarction	Diagnosis	ICD-10-CM
169.313	Psychomotor deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.314	Frontal lobe and executive function deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.315	Cognitive social or emotional deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.318	Other symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
169.319	Unspecified symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
169.32	Speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
169.320	Aphasia following cerebral infarction	Diagnosis	ICD-10-CM
169.321	Dysphasia following cerebral infarction	Diagnosis	ICD-10-CM
169.322	Dysarthria following cerebral infarction	Diagnosis	ICD-10-CM
169.323	Fluency disorder following cerebral infarction	Diagnosis	ICD-10-CM
169.328	Other speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
169.33	Monoplegia of upper limb following cerebral infarction	Diagnosis	ICD-10-CM
169.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
169.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
169.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
169.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.34	Monoplegia of lower limb following cerebral infarction	Diagnosis	ICD-10-CM
169.341	Monoplegia of lower limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
169.342	Monoplegia of lower limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.343	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
169.344	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
169.349	Monoplegia of lower limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.35	Hemiplegia and hemiparesis following cerebral infarction	Diagnosis	ICD-10-CM
169.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 711 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request		
		Code	_
Code	Description	Category	Code Type
169.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant	Diagnosis	ICD-10-CM
	side		
169.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
		•	
169.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.36	Other paralytic syndrome following cerebral infarction	Diagnosis	ICD-10-CM
169.361	Other paralytic syndrome following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
169.362	Other paralytic syndrome following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.363	Other paralytic syndrome following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
169.364	Other paralytic syndrome following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
169.365	Other paralytic syndrome following cerebral infarction, bilateral	Diagnosis	ICD-10-CIVI
169.369	Other paralytic syndrome following cerebral infarction, bliateral Other paralytic syndrome following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CIVI
169.39		-	
169.39	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
	Apraxia following cerebral infarction	Diagnosis	ICD-10-CM
169.391	Dysphagia following cerebral infarction	Diagnosis	ICD-10-CM
169.392	Facial weakness following cerebral infarction	Diagnosis	ICD-10-CM
169.393	Ataxia following cerebral infarction	Diagnosis	ICD-10-CM
169.398	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.8	Sequelae of other cerebrovascular diseases	Diagnosis	ICD-10-CM
169.80	Unspecified sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
169.81	Cognitive deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.810	Attention and concentration deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.811	Memory deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.812	Visuospatial deficit and spatial neglect following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.813	Psychomotor deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.814	Frontal lobe and executive function deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.815	Cognitive social or emotional deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.818	Other symptoms and signs involving cognitive functions following other cerebrovascular	Diagnosis	ICD-10-CM
	disease		
169.819	Unspecified symptoms and signs involving cognitive functions following other	Diagnosis	ICD-10-CM
103.013	cerebrovascular disease	Diagnosis	100 10 0.0
169.82	Speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.820	Aphasia following other cerebrovascular disease	Diagnosis	ICD-10-CIVI
169.821	Dysphasia following other cerebrovascular disease	Diagnosis	ICD-10-CW
	- · · · · · · · · · · · - · · · · · · ·		
169.822	Dysarthria following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.823	Fluency disorder following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.828	Other speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.83	Monoplegia of upper limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.831	Monoplegia of upper limb following other cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	dominant side		
169.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant	Diagnosis	ICD-10-CM
	side	-	
160 822		Diagnosis	ICD 10 CM
169.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-	Diagnosis	ICD-10-CM
	dominant side		

cder_mpl1p_wp077 Page 712 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.84	Monoplegia of lower limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
169.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
169.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
169.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.85 169.851	Hemiplegia and hemiparesis following other cerebrovascular disease Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
169.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
169.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.86 169.861	Other paralytic syndrome following other cerebrovascular disease Other paralytic syndrome following other cerebrovascular disease affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
169.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
169.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.865 169.869	Other paralytic syndrome following other cerebrovascular disease, bilateral Other paralytic syndrome following other cerebrovascular disease affecting unspecified side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.89 169.890 169.891 169.892 169.893	Other sequelae of other cerebrovascular disease Apraxia following other cerebrovascular disease Dysphagia following other cerebrovascular disease Facial weakness following other cerebrovascular disease Ataxia following other cerebrovascular disease	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 713 of 990



riocedure	codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.898	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
169.9	Sequelae of unspecified cerebrovascular diseases	Diagnosis	ICD-10-CM
169.90	Unspecified sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.91	Cognitive deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.910	Attention and concentration deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.911	Memory deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.912	Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.913	Psychomotor deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.914	Frontal lobe and executive function deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.915	Cognitive social or emotional deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.918	Other symptoms and signs involving cognitive functions following unspecified	Diagnosis	ICD-10-CM
	cerebrovascular disease		
169.919	Unspecified symptoms and signs involving cognitive functions following unspecified	Diagnosis	ICD-10-CM
160.00	cerebrovascular disease	5	100 40 614
169.92	Speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.920	Aphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.921	Dysphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.922	Dysarthria following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.923	Fluency disorder following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.928	Other speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.93	Monoplegia of upper limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
169.932	dominant side Monoplegia of upper limb following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
	dominant side	. 0	
169.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	non-dominant side	J	
169.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non	- Diagnosis	ICD-10-CM
	dominant side	J	
169.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
	unspecified side	J	
169.94	Monoplegia of lower limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	dominant side	J	
169.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
	dominant side		
169.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	non-dominant side		
169.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-	· Diagnosis	ICD-10-CM
	dominant side		
169.949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
	unspecified side		
169.95	Hemiplegia and hemiparesis following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	dominant side		
169.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
	dominant side		

cder_mpl1p_wp077 Page 714 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	non-dominant side	J	
169.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
	non-dominant side		
169.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
	unspecified side		
169.96	Other paralytic syndrome following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.961	Other paralytic syndrome following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	dominant side		
169.962	Other paralytic syndrome following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
	dominant side		
169.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	non-dominant side		
169.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-	- Diagnosis	ICD-10-CM
160.065	dominant side	Diamaria	ICD 40 CM
169.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
169.969	Other paralytic syndrome following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
169.99	unspecified side Other sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.990	Apraxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.991	Dysphagia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.992	Facial weakness following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.993	Ataxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.998	Other sequelae following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
P91.82	Neonatal cerebral infarction	Diagnosis	ICD-10-CM
P91.821	Neonatal cerebral infarction, right side of brain	Diagnosis	ICD-10-CM
P91.822	Neonatal cerebral infarction, left side of brain	Diagnosis	ICD-10-CM
P91.823	Neonatal cerebral infarction, bilateral	Diagnosis	ICD-10-CM
P91.829	Neonatal cerebral infarction, unspecified side	Diagnosis	ICD-10-CM
Q28.0	Arteriovenous malformation of precerebral vessels	Diagnosis	ICD-10-CM
Q28.2	Arteriovenous malformation of cerebral vessels	Diagnosis	ICD-10-CM
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without	Diagnosis	ICD-10-CM
	residual deficits		
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	Procedure	CPT-4
61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic	Procedure	CPT-4
	stenosis). including balloon angioplasty. if performed		
F00.33	Chronic Kidney Disease	Dia == !-	ICD 10 CM
E08.22 E09.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E10.22	Type 2 diabetes mellitus with diabetic chronic kidney disease Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.22 E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
112.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage	Diagnosis	ICD-10-CM
	renal disease	2145110313	.05 10 0101
112.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease,	Diagnosis	ICD-10-CM
,	or unspecified chronic kidney disease	2105110313	.02 20 0141
113.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	Diagnosis	ICD-10-CM
.=.=	stage 4 chronic kidney disease, or unspecified chronic kidney disease		
113.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM
		J	- '

cder_mpl1p_wp077 Page 715 of 990



riocedure	e Codes Used to Define Baseline Characteristics in this Request		Code	
Code	Description	Category	Code Type	
113.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through	Diagnosis	ICD-10-CM	
113.11	stage 4 chronic kidnev disease, or unspecified chronic kidnev disease Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic	Diagnosis	ICD-10-CM	
I13.2	kidney disease, or end stage renal disease Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic	Diagnosis	ICD-10-CM	
	kidney disease, or end stage renal disease			
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM	
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM	
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM	
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM	
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM	
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM	
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM	
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM	
R34	Anuria and oliguria	Diagnosis	ICD-10-CM	
Z49.01	Encounter for fitting and adjustment of extracorporeal dialysis catheter	Diagnosis	ICD-10-CM	
Z49.02	Encounter for fitting and adjustment of peritoneal dialysis catheter	Diagnosis	ICD-10-CM	
Z49.31	Encounter for adequacy testing for hemodialysis	Diagnosis	ICD-10-CM	
Z49.32	Encounter for adequacy testing for peritoneal dialysis	Diagnosis	ICD-10-CM	
Z99.2	Dependence on renal dialysis	Diagnosis	ICD-10-CM	
36147	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis	Procedure	CPT-4	
	(graft/fistula); initial access with complete radiological evaluation of dialysis access,			
	including fluoroscopy, image documentation and report (includes access of shunt,			
	injection[s] of contrast, and all necessary imaging from the arterial anastomosis and			
	adjacent artery through entire venous outflow including the inferior or superior vena cava)			
264.40	·		CDT 4	
36148	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis	Procedure	CPT-4	
	(graft/fistula); additional access for therapeutic intervention (List separately in addition to			
	code for primary procedure)			
36818	Arteriovenous anastomosis, open; by upper arm cephalic vein transposition	Procedure	CPT-4	
36819	Arteriovenous anastomosis, open; by upper arm basilic vein transposition	Procedure	CPT-4	
36820	Arteriovenous anastomosis, open; by forearm vein transposition	Procedure	CPT-4	
36821	Arteriovenous anastomosis, open; direct, any site (eg, Cimino type) (separate procedure)	Procedure	CPT-4	
36825	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis	Procedure	CPT-4	
36830	(separate procedure): autogenous graft Creation of arteriovenous fistula by other than direct arteriovenous anastomosis	Procedure	CPT-4	
30030	(separate procedure); nonautogenous graft (eg., biological collagen, thermoplastic graft)	rroccaare	CITT	
36831	Thrombectomy, open, arteriovenous fistula without revision, autogenous or	Procedure	CPT-4	
36832	nonautogenous dialysis graft (separate procedure) Revision, open, arteriovenous fistula; without thrombectomy, autogenous or	Procedure	CPT-4	
36833	nonautogenous dialysis graft (separate procedure) Revision, open, arteriovenous fistula; with thrombectomy, autogenous or nonautogenous	Procedure	CPT-4	
	dialysis graft (separate procedure)			
36870	Thrombectomy, percutaneous, arteriovenous fistula, autogenous or nonautogenous graft (includes mechanical thrombus extraction and intra-graft thrombolysis)	Procedure	CPT-4	
50360	Renal allotransplantation, implantation of graft; without recipient nephrectomy	Procedure	CPT-4	
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	Procedure	CPT-4	
	2 2 3 3 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5			

cder_mpl1p_wp077 Page 716 of 990



		Code	
Code	Description	Category	Code Type
75791	Angiography, arteriovenous shunt (eg, dialysis patient fistula/graft), complete evaluation of dialysis access, including fluoroscopy, image documentation and report (includes injections of contrast and all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava), radiological supervision and interpretation	Procedure	CPT-4
90935	Hemodialysis procedure with single evaluation by a physician or other qualified health	Procedure	CPT-4
90937	care professional Hemodialysis procedure requiring repeated evaluation(s) with or without substantial	Procedure	CPT-4
90945	revision of dialvsis prescription Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90947	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial revision of dialysis prescription	Procedure	CPT-4
90951	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90952	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90953	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90954	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90955	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90956	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4

cder_mpl1p_wp077 Page 717 of 990



	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
90957	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90958	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90959	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90960	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90961	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90962	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90963	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90964	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90965	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90966	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older	Procedure	CPT-4
90967	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age	Procedure	CPT-4
90968	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 2-11 years of age	Procedure	CPT-4
90969	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 12-19 years of age	Procedure	CPT-4
90970	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 20 years of age and older	Procedure	CPT-4
	Chronic Obstructive Pulmonary Disease		
J44.0 J44.1	Chronic obstructive pulmonary disease with (acute) lower respiratory infection Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 718 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
	Congenital Heart Disease		
197.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
197.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
197.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
P29.3	Persistent fetal circulation	Diagnosis	ICD-10-CM
P29.38	Other persistent fetal circulation	Diagnosis	ICD-10-CM
P29.8	Other cardiovascular disorders originating in the perinatal period	Diagnosis	ICD-10-CM
Q20	Congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.0	Common arterial trunk	Diagnosis	ICD-10-CM
Q20.1	Double outlet right ventricle	Diagnosis	ICD-10-CM
Q20.2	Double outlet left ventricle	Diagnosis	ICD-10-CM
Q20.3	Discordant ventriculoarterial connection	Diagnosis	ICD-10-CM
Q20.4	Double inlet ventricle	Diagnosis	ICD-10-CM
Q20.5	Discordant atrioventricular connection	Diagnosis	ICD-10-CM
Q20.6	Isomerism of atrial appendages	Diagnosis	ICD-10-CM
Q20.8	Other congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.9	Congenital malformation of cardiac chambers and connections, unspecified	Diagnosis	ICD-10-CM
Q21	Congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.0	Ventricular septal defect	Diagnosis	ICD-10-CM
Q21.1	Atrial septal defect	Diagnosis	ICD-10-CM
Q21.2	Atrioventricular septal defect	Diagnosis	ICD-10-CM
Q21.3	Tetralogy of Fallot	Diagnosis	ICD-10-CM
Q21.4	Aortopulmonary septal defect	Diagnosis	ICD-10-CM
Q21.8	Other congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.9	Congenital malformation of cardiac septum, unspecified	Diagnosis	ICD-10-CM
Q22	Congenital malformations of pulmonary and tricuspid valves	Diagnosis	ICD-10-CM
Q22.0	Pulmonary valve atresia	Diagnosis	ICD-10-CM
Q22.1	Congenital pulmonary valve stenosis	Diagnosis	ICD-10-CM
Q22.2	Congenital pulmonary valve insufficiency	Diagnosis	ICD-10-CM
Q22.3	Other congenital malformations of pulmonary valve	Diagnosis	ICD-10-CM
Q22.4	Congenital tricuspid stenosis	Diagnosis	ICD-10-CM
Q22.5	Ebstein's anomaly	Diagnosis	ICD-10-CM
Q22.6	Hypoplastic right heart syndrome	Diagnosis	ICD-10-CM
Q22.8	Other congenital malformations of tricuspid valve	Diagnosis	ICD-10-CM
Q22.9	Congenital malformation of tricuspid valve, unspecified	Diagnosis	ICD-10-CM
Q23	Congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.0	Congenital stenosis of aortic valve	Diagnosis	ICD-10-CM
Q23.1	Congenital insufficiency of aortic valve	Diagnosis	ICD-10-CM
Q23.2	Congenital mitral stenosis	Diagnosis	ICD-10-CM
Q23.3	Congenital mitral insufficiency	Diagnosis	ICD-10-CM
Q23.4	Hypoplastic left heart syndrome	Diagnosis	ICD-10-CM
Q23.8	Other congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.9	Congenital malformation of aortic and mitral valves, unspecified	Diagnosis	ICD-10-CM
Q24	Other congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.0	Dextrocardia	Diagnosis	ICD-10-CM
Q24.1	Levocardia	Diagnosis	ICD-10-CM
Q24.1 Q24.2	Cor triatriatum	Diagnosis	ICD-10-CM
Q24.2 Q24.3	Pulmonary infundibular stenosis	Diagnosis	ICD-10-CM
Q24.4	Congenital subaortic stenosis	Diagnosis	ICD-10-CM
Q27.7	congenital supportie steriosis	Diagnosis	ICD TO-CIVI

cder_mpl1p_wp077 Page 719 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
Q24.5	Malformation of coronary vessels	Diagnosis	ICD-10-CM
Q24.6	Congenital heart block	Diagnosis	ICD-10-CM
Q24.8	Other specified congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.9	Congenital malformation of heart, unspecified	Diagnosis	ICD-10-CM
Q25.0	Patent ductus arteriosus	Diagnosis	ICD-10-CM
Q25.1	Coarctation of aorta	Diagnosis	ICD-10-CM
Q25.21	Interruption of aortic arch	Diagnosis	ICD-10-CM
Q25.29	Other atresia of aorta	Diagnosis	ICD-10-CM
Q25.3	Supravalvular aortic stenosis	Diagnosis	ICD-10-CM
Q25.40	Congenital malformation of aorta unspecified	Diagnosis	ICD-10-CM
Q25.41	Absence and aplasia of aorta	Diagnosis	ICD-10-CM
Q25.42	Hypoplasia of aorta	Diagnosis	ICD-10-CM
Q25.43	Congenital aneurysm of aorta	Diagnosis	ICD-10-CM
Q25.44	Congenital dilation of aorta	Diagnosis	ICD-10-CM
Q25.45	Double aortic arch	Diagnosis	ICD-10-CM
Q25.46	Tortuous aortic arch	Diagnosis	ICD-10-CM
Q25.47	Right aortic arch	Diagnosis	ICD-10-CM
Q25.48	Anomalous origin of subclavian artery	Diagnosis	ICD-10-CM
Q25.49	Other congenital malformations of aorta	Diagnosis	ICD-10-CM
Q25.5	Atresia of pulmonary artery	Diagnosis	ICD-10-CM
Q25.6	Stenosis of pulmonary artery	Diagnosis	ICD-10-CM
Q25.71	Coarctation of pulmonary artery	Diagnosis	ICD-10-CM
Q25.72	Congenital pulmonary arteriovenous malformation	Diagnosis	ICD-10-CM
Q25.79	Other congenital malformations of pulmonary artery	Diagnosis	ICD-10-CM
Q25.8	Other congenital malformations of other great arteries	Diagnosis	ICD-10-CM
Q25.9	Congenital malformation of great arteries, unspecified	Diagnosis	ICD-10-CM
Q26.0	Congenital stenosis of vena cava	Diagnosis	ICD-10-CM
Q26.1	Persistent left superior vena cava	Diagnosis	ICD-10-CM
Q26.2	Total anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.3	Partial anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.4	Anomalous pulmonary venous connection, unspecified	Diagnosis	ICD-10-CM
Q87.40	Marfan's syndrome, unspecified	Diagnosis	ICD-10-CM
Q87.41	Marfan's syndrome with cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.410	Marfan's syndrome with aortic dilation	Diagnosis	ICD-10-CM
Q87.418	Marfan's syndrome with other cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.82	Arterial tortuosity syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.1	Trisomy 18, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.2	Trisomy 18, translocation	Diagnosis	ICD-10-CM
Q91.3	Trisomy 18, unspecified	Diagnosis	ICD-10-CM
Q91.4	Trisomy 13, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.5	Trisomy 13, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.6	Trisomy 13, translocation	Diagnosis	ICD-10-CM
Q91.7	Trisomy 13, unspecified	Diagnosis	ICD-10-CM
Q93.81	Velo-cardio-facial syndrome	Diagnosis	ICD-10-CM
Q93.82	Williams syndrome	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 720 of 990



riocedure	codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
02Q50ZZ	Repair Atrial Septum, Open Approach	Procedure	ICD-10-PCS
02QM0ZZ	Repair Ventricular Septum, Open Approach	Procedure	ICD-10-PCS
02U507Z	Supplement Atrial Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02U50JZ	Supplement Atrial Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02U53JZ	Supplement Atrial Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02UM07Z	Supplement Ventricular Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02UM0JZ	Supplement Ventricular Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02UM3JZ	Supplement Ventricular Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure	Procedure	CPT-4
33720	Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass	Procedure	CPT-4
33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to create effective	Procedure	CPT-4
	atrial flow, including all imaging guidance by the proceduralist, when performed, any		
	method (eg, Rashkind, Sang-Park, balloon, cutting balloon, blade)		
33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac	Procedure	CPT-4
007.10	anomalies to establish effective intracardiac flow, including all imaging guidance by the		C.
	proceduralist, when performed, left and right heart diagnostic cardiac catherization for		
	congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial		
	septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden		
	baffles); initial intracardiac shunt		
22746	T		CDT 4
33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac	Procedure	CPT-4
	anomalies to establish effective intracardiac flow, including all imaging guidance by the		
	proceduralist, when performed, left and right heart diagnostic cardiac catherization for		
	congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial		
	septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden		
	baffles); each additional intracardiac shunt location (List separately in addition to code for		
	primary procedure)		
33924	Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in	Procedure	CPT-4
	conjunction with a congenital heart procedure (List separately in addition to code for		
	primary procedure)		
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure	Procedure	CPT-4
70072	and morphology (including 3D image postprocessing, assessment of cardiac function, and		C.
	evaluation of venous structures, if performed)		
75572		Dunnandous	CDT 4
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure	Procedure	CPT-4
	and morphology in the setting of congenital heart disease (including 3D image		
	postprocessing, assessment of LV cardiac function, RV structure and function and		
	evaluation of venous structures, if performed)		
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	Procedure	CPT-4
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited	Procedure	CPT-4
	study		
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe	Procedure	CPT-4
	placement. image acquisition. interpretation and report	_	
93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of	Procedure	CPT-4
	transesophageal probe only		

cder_mpl1p_wp077 Page 721 of 990



Code	Description	Code Category	Code Type
93317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition,	Procedure	CPT-4
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	interpretation and report only		C
93530	Right heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93531	Combined right heart catheterization and retrograde left heart catheterization, for	Procedure	CPT-4
	congenital cardiac anomalies		
93532	Combined right heart catheterization and transseptal left heart catheterization through	Procedure	CPT-4
	intact septum with or without retrograde left heart catheterization, for congenital cardiac		
	anomalies		
93533	Combined right heart catheterization and transseptal left heart catheterization through	Procedure	CPT-4
	existing septal opening, with or without retrograde left heart catheterization, for		
	congenital cardiac anomalies		
02562	-	Dunandana	CDT 4
93563	Injection procedure during cardiac catheterization including imaging supervision,	Procedure	CPT-4
	interpretation, and report; for selective coronary angiography during congenital heart		
	catheterization (List separately in addition to code for primary procedure)		
93564	Injection procedure during cardiac catheterization including imaging supervision,	Procedure	CPT-4
	interpretation, and report; for selective opacification of aortocoronary venous or arterial		
	bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary		
	artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal		
	mammary), whether native or used for bypass to one or more coronary arteries during		
	congenital heart catheterization, when performed (List separately in addition to code for		
	primary procedure)		
	provide processing,		
93580	Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan	Procedure	CPT-4
	fenestration, atrial septal defect) with implant		
93581	Percutaneous transcatheter closure of a congenital ventricular septal defect with implant	Procedure	CPT-4
100.91	Heart Failure Rheumatic heart failure	Diagnosis	ICD 10 CM
109.81 111.0	Hypertensive heart disease with heart failure	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
111.0 113.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	Diagnosis	ICD-10-CM
113.0	stage 4 chronic kidney disease. or unspecified chronic kidney disease	Diagnosis	ICD-10-CIVI
113.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic	Diagnosis	ICD-10-CM
113.2	kidnev disease. or end stage renal disease	Diagnosis	ICD 10 CIVI
150	Heart failure	Diagnosis	ICD-10-CM
150.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
150.2	Systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
		_	ICD-10-CM
150.21	Acute systolic (congestive) heart failure	Diagnosis	ICD TO CIVI
	Acute systolic (congestive) heart failure Chronic systolic (congestive) heart failure	Diagnosis Diagnosis	ICD-10-CM
150.22			
150.22 150.23	Chronic systolic (congestive) heart failure Acute on chronic systolic (congestive) heart failure Diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.22 150.23 150.3 150.30	Chronic systolic (congestive) heart failure Acute on chronic systolic (congestive) heart failure Diastolic (congestive) heart failure Unspecified diastolic (congestive) heart failure	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
150.22 150.23 150.3 150.30 150.31	Chronic systolic (congestive) heart failure Acute on chronic systolic (congestive) heart failure Diastolic (congestive) heart failure Unspecified diastolic (congestive) heart failure Acute diastolic (congestive) heart failure	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
150.22 150.23 150.3 150.30 150.31	Chronic systolic (congestive) heart failure Acute on chronic systolic (congestive) heart failure Diastolic (congestive) heart failure Unspecified diastolic (congestive) heart failure Acute diastolic (congestive) heart failure Chronic diastolic (congestive) heart failure	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
150.22 150.23 150.3 150.30 150.31 150.32	Chronic systolic (congestive) heart failure Acute on chronic systolic (congestive) heart failure Diastolic (congestive) heart failure Unspecified diastolic (congestive) heart failure Acute diastolic (congestive) heart failure Chronic diastolic (congestive) heart failure Acute on chronic diastolic (congestive) heart failure	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I50.21 I50.22 I50.23 I50.3 I50.30 I50.31 I50.32 I50.33 I50.4 I50.40	Chronic systolic (congestive) heart failure Acute on chronic systolic (congestive) heart failure Diastolic (congestive) heart failure Unspecified diastolic (congestive) heart failure Acute diastolic (congestive) heart failure Chronic diastolic (congestive) heart failure	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 722 of 990



riocedule	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.8	Other heart failure	Diagnosis	ICD-10-CM
150.81	Right heart failure	Diagnosis	ICD-10-CM
150.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
150.811	Acute right heart failure	Diagnosis	ICD-10-CM
150.812	Chronic right heart failure	Diagnosis	ICD-10-CM
150.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
150.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
150.82	Biventricular heart failure	Diagnosis	ICD-10-CM
150.83	High output heart failure	Diagnosis	ICD-10-CM
150.84	End stage heart failure	Diagnosis	ICD-10-CM
150.89	Other heart failure	Diagnosis	ICD-10-CM
150.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
197.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
197.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
197.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
	Hyperlipidemia		
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
	Hypertensive Disease		
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
111.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage	Diagnosis	ICD-10-CM
	renal disease		
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease,	Diagnosis	ICD-10-CM
	or unspecified chronic kidney disease		
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	Diagnosis	ICD-10-CM
	stage 4 chronic kidney disease, or unspecified chronic kidney disease		
113.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM
113.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through	Diagnosis	ICD-10-CM
	stage 4 chronic kidnev disease. or unspecified chronic kidnev disease		
113.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic	Diagnosis	ICD-10-CM
	kidnev disease. or end stage renal disease		
l13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic	Diagnosis	ICD-10-CM
	kidnev disease. or end stage renal disease		
115.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 723 of 990



Procedure	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
115.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
115.2	Other secondary hypertension	Diagnosis	ICD-10-CM
115.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
116.0	Hypertensive urgency	Diagnosis	ICD-10-CM
116.1	Hypertensive emergency	Diagnosis	ICD-10-CM
116.9	Hypertensive crisis, unspecified	Diagnosis	ICD-10-CM
167.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
	Thyroid Disease	1	
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
	Ischemic Heart Disease/Coronary Artery Disease/Myocardial Infarction		
120	Angina pectoris	Diagnosis	ICD-10-CM
120.0	Unstable angina	Diagnosis	ICD-10-CM
120.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
120.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
120.9	A series of a section of the series of the s		
	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
121.01		Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
I21.01 I21.02	Angina pectoris, unspecified ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary		
	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary	Diagnosis Diagnosis	ICD-10-CM
121.02	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
I21.02 I21.09	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9 I22.0 I22.1	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9 I22.0	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 724 of 990



riocedure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
123.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.2	ventricular septar defect as carrent complication following acute myocardia imarction	Diagnosis	ICD 10 CIVI
123.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
123.7	Postinfarction angina	Diagnosis	ICD-10-CM
123.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
124	Other acute ischemic heart diseases	Diagnosis	ICD-10-CM
124.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
124.1	Dressler's syndrome	Diagnosis	ICD-10-CM
124.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
124.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
125.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
125.11	Atherosclerotic heart disease of native coronary artery with angina pectoris	Diagnosis	ICD-10-CM
125.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
	, , ,	Ü	
125.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with	Diagnosis	ICD-10-CM
	documented spasm		
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.3	Aneurysm of heart	Diagnosis	ICD-10-CM
125.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
125.42	Coronary artery dissection	Diagnosis	ICD-10-CM
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
125.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
125.7	Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
125.70	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris	Diagnosis	ICD-10-CM
125.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
125.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.71	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
125.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 725 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
125.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
	with documented spasm		
125.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of	Diagnosis	ICD-10-CM
	angina pectoris		
125.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina	Diagnosis	ICD-10-CM
125.72	pectoris Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
123.72	Actier oscierosis or autologous artery coronary artery bypass grant(s) with angina pectoris	Diagnosis	ICD-10-CIVI
125.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina	Diagnosis	ICD-10-CM
	pectoris	Ū	
125.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
	with documented spasm		
125.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of	Diagnosis	ICD-10-CM
125.729	angina pectoris Atheres slerge is of autologous artery seronary artery bypass graft(s) with unspecified	Diagnosis	ICD 10 CM
125.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.73	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina	Diagnosis	ICD-10-CM
	pectoris	. 6	
125.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable	Diagnosis	ICD-10-CM
	angina pectoris		
125.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina	Diagnosis	ICD-10-CM
125 720	pectoris with documented spasm	5	100 40 604
125.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with	Diagnosis	ICD-10-CM
123.733	unspecified angina pectoris	Diagnosis	ICD 10 CIVI
125.75	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
125.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
125.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with	Diagnosis	ICD-10-CM
125.758	documented spasm Atherosclerosis of native coronary artery of transplanted heart with other forms of angina	Diagnosis	ICD-10-CM
123.730	pectoris	Diagnosis	ICD-10-CIVI
125.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina	Diagnosis	ICD-10-CM
	pectoris	_	
125.76	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina	Diagnosis	ICD-10-CM
	pectoris		
125.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable	Diagnosis	ICD-10-CM
125 761	angina Atheres slerge is of hypass graft of corenary artery of transplanted heart with angina	Diagnosis	ICD 10 CM
125.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms	Diagnosis	ICD-10-CM
	of angina pectoris	J	

cder_mpl1p_wp077 Page 726 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
125.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified	Diagnosis	ICD-10-CM
	angina pectoris	J	
125.79	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
125.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
1231730	There is seen and the containst and the contains	2146116313	102 10 011
125.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with	Diagnosis	ICD-10-CM
123.791	documented spasm	Diagnosis	ICD-10-CIVI
125 700	·	Diamonia	ICD 40 CM
125.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina	Diagnosis	ICD-10-CM
	pectoris		
125.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
125.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
125.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina	Diagnosis	ICD-10-CM
	pectoris		
125.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
125.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
125.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
125.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
125.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
0210083	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
0210088	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0210089	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0210093	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0210098	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
0210038		rroccaure	1CD-10-1 C3
024 0000	Venous Tissue, Open Approach		100 40 000
0210099	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0210483	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0210488	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 727 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0210489	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0210493	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0210498	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0210499	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0211083	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211088	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0211089	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0211093	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0211098	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
0211099	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
0211483	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
0244400	Percutaneous Endoscopic Approach		100 40 000
0211488	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
0244400	Tissue, Percutaneous Endoscopic Approach	Dunnadium	ICD 10 DCC
0211489	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
0211493	Percutaneous Endoscopic Approach Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
0211493	Tissue, Percutaneous Endoscopic Approach	riocedule	ICD-10-FC3
0211498	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
0211430	Venous Tissue, Percutaneous Endoscopic Approach	Troccaure	100 101 05
0211499	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0212083	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
0212088	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0212089	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0212093	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0212098	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
0212099	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		

cder_mpl1p_wp077 Page 728 of 990



Code	Description	Code Category	Code Type
0212483	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0212488	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0212489	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0212493	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0212498	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
0040400	Venous Tissue, Percutaneous Endoscopic Approach		100 10 000
0212499	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
0213083	Venous Tissue, Percutaneous Endoscopic Approach Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic	Procedure	ICD-10-PCS
0213063	Tissue, Open Approach	riocedule	ICD-10-PC3
0213088	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
0213000	Zooplastic Tissue, Open Approach	Troccaure	100 10 1 05
0213089	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Zooplastic Tissue, Open Approach		
0213093	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
0213098	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Open Approach		
0213099	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Open Approach		
0213483	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic	Procedure	ICD-10-PCS
0040400	Tissue, Percutaneous Endoscopic Approach		100 10 000
0213488	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
0212400	Zooplastic Tissue, Percutaneous Endoscopic Approach	Dragadura	ICD 10 DCC
0213489	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213493	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous	Procedure	ICD-10-PCS
0213433	Venous Tissue, Percutaneous Endoscopic Approach	rrocedure	1CD-10-1 C3
0213498	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
0220.00	Autologous Venous Tissue, Percutaneous Endoscopic Approach		.02 20 . 00
0213499	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Percutaneous Endoscopic Approach		
0270046	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Open Approach		
0270056	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0270066	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0270076	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		

cder_mpl1p_wp077 Page 729 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Approach		
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Endoscopic Approach		
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0271046	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Open Approach		
0271056	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0271066	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0271076	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0274256	Device, Percutaneous Approach	Dan en de con	ICD 40 DCC
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0271266	Devices, Percutaneous Approach	Dunnadiii	ICD 10 DCC
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
02/13/0	Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PC3
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
02/1440	Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0271430	Devices, Percutaneous Endoscopic Approach	Troccaure	100 101 05
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
0271400	Intraluminal Devices, Percutaneous Endoscopic Approach	rioccaare	100 10 1 05
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
02/14/0	Intraluminal Devices, Percutaneous Endoscopic Approach	rioccaare	100 101 05
0272046	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Open Approach	300010	111 10 7 00
0272056	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
	the the		

cder_mpl1p_wp077 Page 730 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0272066	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0272076	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Approach		
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Endoscopic Approach		
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach	_	
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0273046	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting	Procedure	ICD-10-PCS
227225	Intraluminal Device, Open Approach		100 10 000
0273056	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
0272066	Intraluminal Devices, Open Approach	5 1	100 40 000
0273066	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
0272076	Intraluminal Devices, Open Approach	Dunnadiina	ICD 10 DCC
0273076	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug- eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272246		Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PC3
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
02/3330	Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PC3
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
0273300	Intraluminal Devices, Percutaneous Approach	rrocedure	10-10-1 03
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-	Procedure	ICD-10-PCS
0273370	eluting Intraluminal Devices, Percutaneous Approach	rroccaure	100 10 1 05
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting	Procedure	ICD-10-PCS
0270110	Intraluminal Device, Percutaneous Endoscopic Approach		.02 20 . 00
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach	_	
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-	Procedure	ICD-10-PCS
	eluting Intraluminal Devices, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 731 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02700E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0274056	Percutaneous Endoscopic Approach	Danasakana	100 40 000
02710E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0271310	Percutaneous Approach	rroccaure	100 10 1 05
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02720E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0272056	Percutaneous Endoscopic Approach	Danasakana	100 40 000
02730E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal	Procedure	ICD-10-PCS
02733L0	Devices, Percutaneous Approach	riocedule	ICD-10-FC3
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
021008C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021008F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021008W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
024 000 0			100 40 000
021009C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
021009F	Open Approach Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
0210031	Tissue, Open Approach	Trocedure	1CD-10-1 C3
021009W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02100A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
02100A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02100A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach	_	
02100AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 732 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02100AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02100AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02100J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
02100J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0210030	Substitute, Open Approach	rroccaare	102 10 1 00
02100J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0210033	Substitute, Open Approach	rroccaare	100 10 1 05
02100JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0210030	Approach	Trocedure	100-10-1 03
02100JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0210031	Open Approach	riocedure	ICD-10-FC3
02100JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021003	bypass coronary Artery, One Artery from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PC3
02100K3	Bunass Caronary Artery One Artery from Caronary Artery with Nanaytalogous Tissue	Drocoduro	ICD-10-PCS
U21UUK3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PC3
02100//0		Drocoduro	ICD 10 DCC
02100K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
024.001/0	Tissue Substitute, Open Approach	Dun dun -	ICD 40 DCC
02100K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
024.001/.0	Tissue Substitute, Open Approach		160 40 066
02100KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0040045	Substitute, Open Approach		100 10 000
02100KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
00400444	Substitute, Open Approach		100 10 000
02100KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02100Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02100Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100Z9 02100ZC	Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach Bypass Coronary Artery, One Artery from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
		Procedure	ICD-10-PCS
02100ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021048C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
0240405	Percutaneous Endoscopic Approach	Duagadiina	ICD 10 DCC
021048F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
02404014	Percutaneous Endoscopic Approach	Dun dun -	ICD 40 DCC
021048W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
0040400	Endoscopic Approach		100 10 000
021049C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach	_	
021049F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 733 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
021049W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02104A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02104AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02104AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02104J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02104JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0240415	Percutaneous Endoscopic Approach	Danasakana	ICD 40 DCC
02104JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
02104JW	Percutaneous Endoscopic Approach Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
021041	Endoscopic Approach	Procedure	ICD-10-PC3
02104K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
02104113	Substitute, Percutaneous Endoscopic Approach	rroccaare	100 10 1 05
02104K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Percutaneous Endoscopic Approach		
02104K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Percutaneous Endoscopic Approach		
02104KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02104KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02104KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02104Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02104Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 734 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02104ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02104ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0211000	Approach	Dunnanduun	ICD 10 DCC
021108C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021108W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021109C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
021109F	Tissue, Open Approach Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous	Dracadura	ICD-10-PCS
021109F	Tissue, Open Approach	Procedure	ICD-10-PC3
021109W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02110A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02110A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
02110/13	Arterial Tissue, Open Approach	rroccaare	105 10 1 05
02110AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02110AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
021100	Tissue, Open Approach	Dunnanduun	ICD 10 DCC
02110AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02110J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02110J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
02110JC	Substitute, Open Approach Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0211030	Open Approach	Trocedure	10-10-1 03
02110JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02110JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0244042	Approach	Daniel I	100 40 000
02110K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		

cder_mpl1p_wp077 Page 735 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02110K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
OZIIONS	Tissue Substitute, Open Approach	Troccaure	100 10 1 03
02110KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02110KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02110KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02110Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02110Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02110ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021148C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021148F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021148W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021149C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021149F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021149W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02114A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02114A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02114AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02114AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02114AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02114J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 736 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02114JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021208C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021209C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02120A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 737 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02120A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02120AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02120AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02120AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
0040010	Approach		100 10 000
02120J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0212010	Open Approach Press Coronary Artery Three Arteries from Right Internal Mammany with Synthetic	Dragadura	ICD 10 DCC
02120J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0212033	Substitute, Open Approach	1100000010	105 10 1 05
02120JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02120JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02120JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
02120K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02120K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
0212070	Nonautologous Tissue Substitute, Open Approach	Dragadura	ICD 10 DCC
02120K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
OZIZONO	Substitute, Open Approach	Troccaure	100 101 05
02120KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02120KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02120Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02120Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120Z9 02120ZC	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Open Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
02120ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021248C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021248F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021248W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 738 of 990



Code Description Category Code Type 021249C Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Endoscopic Approach ICD-10-PCS 021249F Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 021249W Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124A3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124A8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124A8 Bypass Coronary Artery, Three Arteries from Introacic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124AC Bypass Coronary Artery, Three Arteries from Noracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124AB Bypass Coronary Artery, Three Arteries from Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124AB Bypa	Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Tissue, Percutaneous Endoscopic Approach 21249F 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach 212498 8ypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach 2124A3 8ypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 2124A8 8ypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 2124A9 8ypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 2124A0 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 2124AC 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 2124AF 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 2124AW 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Tissue, Percutaneous Endoscopic Approach 2124AW 8ypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 2124BB Sypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 2124BB Sypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 2124BC Sypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 2124BC Sypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Procedure ICD-10-	Code	Description		Code Type
021249F Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach ICD-10-PCS 021249W Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Procedure ICD-10-PCS 02124A3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124A8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124A9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124A0 Bypass Coronary Artery, Three Arteries from Horacic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124AF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124AW Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach Procedure ICD-10-PCS 02124B Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach Procedure <td>021249C</td> <td>Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous</td> <td>Procedure</td> <td>ICD-10-PCS</td>	021249C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
Tissue, Percutaneous Endoscopic Approach 02124AB Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach 02124AB Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124AB Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Procedure ICD-10-PCS Arterial Tissue, Percutaneous Endoscopic Approach 02124AB Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Procedure ICD-10-PCS Arterial Tissue, Percutaneous Endoscopic Approach 02124AC Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124AC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124AB Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124AB Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124B Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 02124B Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 02124JB Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 02124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 02124JG Bypass Coronary Artery, Three Arteries from Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 02124JG Bypass Coronary Artery, Three Arteries from Mortany With Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 02124JG Bypass		Tissue, Percutaneous Endoscopic Approach		
021249WBypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124A3Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124A8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124A9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ACBypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124AFBypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ABBypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124I3Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124I8Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ICBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ISBypass Coronary Artery, Three Arteries from Coronary Artery wi	021249F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
Percutaneous Endoscopic Approach 972124A3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 972124A8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Procedure ICD-10-PCS Arterial Tissue, Percutaneous Endoscopic Approach 972124A9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Procedure ICD-10-PCS Arterial Tissue, Percutaneous Endoscopic Approach 972124AC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 972124AC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 972124AC Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 972124AB Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 972124B Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue ICD-10-PCS Nonautologous Tiss		Tissue, Percutaneous Endoscopic Approach		
02124A3Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124A8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124A9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ACBypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ABBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ABBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ABBypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124BBypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124WBBypass Coronary Artery, Three Arte	021249W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue,	Procedure	ICD-10-PCS
Tissue, Percutaneous Endoscopic Approach 102124A8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Procedure ICD-10-PCS Arterial Tissue, Percutaneous Endoscopic Approach 102124A9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Procedure ICD-10-PCS Arterial Tissue, Percutaneous Endoscopic Approach 102124AC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 102124AF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Procedure ICD-10-PCS Tissue, Percutaneous Endoscopic Approach 102124AW Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 102124J3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124J8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 102124J9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 102124J1 Bypass Coronary Artery, Three Arteries from Horacic Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124J1 Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124J1 Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 102124K8 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 102124K9 Bypass Coronary Artery		Percutaneous Endoscopic Approach		
02124A8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124A9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124ACBypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124AFBypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124AWBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J3Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, ProcedureICD-10-PCS02124J8Bypass Coronary Artery, Three Arteries from Eleft Internal Mammary with SyntheticProcedureICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with SyntheticProcedureICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, ProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, ProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, ProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachP	02124A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial	Procedure	ICD-10-PCS
Atterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Procedure ICD-10-PCS Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Procedure ICD-10-PCS Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute,		Tissue, Percutaneous Endoscopic Approach		
02124A9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with AutologousProcedureICD-10-PCS02124ACBypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous ArterialProcedureICD-10-PCS02124AFBypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous ArterialProcedureICD-10-PCS02124AWBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J3Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JBBypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous TissueProcedureICD-10-PCS02124JBBypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous TissueProcedureICD-10-PCS02124KBBypass Coronary Artery, Three Arteries from Left Internal Mammary	02124A8		Procedure	ICD-10-PCS
Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Procedure 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure 8ypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure 8ypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure 8ypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue 8ypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue 8ypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous 8ypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologou				
02124ACBypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS ICD-10-PCS Tissue, Percutaneous Endoscopic Approach02124AWBypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial ProcedureICD-10-PCS ICD-10-PCS ICD-10-PCS ProcedureICD-10-PCS ICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JBBypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JBBypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous TissueProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KB <td< td=""><td>02124A9</td><td></td><td>Procedure</td><td>ICD-10-PCS</td></td<>	02124A9		Procedure	ICD-10-PCS
Tissue, Percutaneous Endoscopic Approach 02124AF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124AW Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 02124J3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach 02124J8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach 02124J9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach 02124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach 02124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 02124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach 02124JW Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124K8 Bypass Coronary Artery, Three Arteries from Eight Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124KE Bypass Coronary Artery, Three Arteries from Ethe Internal Mammary with Nonautologous Tissue Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Bypass Coronary Artery, Three Arteries from Ethe Internal Mammary with Nonautologous Tissue Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Bypass Coronary Artery, Three Arteries from Thoracic Ar				
02124AFBypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS Procedure02124AWBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J3Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124WBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous TissueProcedureICD-10-PCS02124K9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with NonautologousProcedureICD-10-PCS02124K6Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous TissueProcedureICD-10-PCS <td>02124AC</td> <td></td> <td>Procedure</td> <td>ICD-10-PCS</td>	02124AC		Procedure	ICD-10-PCS
Tissue, Percutaneous Endoscopic Approach 92124AW Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 92124J3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 92124J8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach 92124J9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 92124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 92124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 92124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 92124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 92124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue ICD-10-PCS Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 92124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 92124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 92124KF Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach				
02124AW Percutaneous Endoscopic ApproachBypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J3Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K3Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K6Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous TissueProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous TissueProcedureICD-10-PCS02124KFBypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous <td>02124AF</td> <td></td> <td>Procedure</td> <td>ICD-10-PCS</td>	02124AF		Procedure	ICD-10-PCS
Percutaneous Endoscopic Approach 102124J3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124J8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 102124J9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 102124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach 102124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 102124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach 102124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach 102124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 102124KF Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach				
02124J3Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K3Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous TissueProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Left Internal Mammary with NonautologousProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous TissueProcedureICD-10-PCS02124KFBypass Coronary Artery, Three Arteries from Thoracic Artery with NonautologousProcedureICD-10-PCS	02124AW		Procedure	ICD-10-PCS
Percutaneous Endoscopic Approach D2124J8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach D2124J9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach D2124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach D2124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach D2124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach D2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Procedure ICD-10-PCS Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue ICD-10-PCS Substitute, Percutaneous Endoscopic Approach	0040410			100 10 000
02124J8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedure ICD-10-PCS02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K3Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous TissueProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous TissueProcedureICD-10-PCS02124KFBypass Coronary Artery, Three Arteries from Thoracic Artery with NonautologousProcedureICD-10-PCS02124KFBypass Coronary Artery, Three Arteries from Abdominal Artery with NonautologousProcedureICD-10-PCS	02124J3		Procedure	ICD-10-PCS
Substitute, Percutaneous Endoscopic Approach O2124J9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach O2124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach O2124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach O2124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach O2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach O2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach O2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach O2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach O2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach O2124KF Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach O2124KF Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach	0242410		Dunandana	ICD 40 DCC
02124J9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K3Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KFBypass Coronary Artery, Three Arteries from Abdominal Artery with NonautologousProcedureICD-10-PCS	02124J8		Procedure	ICD-10-PCS
Substitute, Percutaneous Endoscopic Approach O2124JC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach O2124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach O2124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach O2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach O2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach O2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach O2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach O2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach O2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach	0242410		Dua aa duua	ICD 10 DCC
02124JCBypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JFBypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124JWBypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K3Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K8Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124K9Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KCBypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS02124KFBypass Coronary Artery, Three Arteries from Abdominal Artery with NonautologousProcedureICD-10-PCS	02124J9		Procedure	ICD-10-PCS
Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach D2124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure ICD-10-PCS Percutaneous Endoscopic Approach D2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS ICD-10-PCS	0212416		Drocoduro	ICD 10 DCS
D2124JF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Procedure Percutaneous Endoscopic Approach D2124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Procedure Percutaneous Endoscopic Approach D2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS ICD-10-	UZ1Z4JC		Procedure	ICD-10-PC3
Percutaneous Endoscopic Approach 02124JW Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach 02124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach	02124IE		Procedure	ICD-10-DCS
D2124K3 Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach D2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS	0212411		riocedure	ICD-10-FC3
Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach	02124IW		Procedure	ICD-10-PCS
D2124K3 Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Procedure Substitute, Percutaneous Endoscopic Approach D2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D2124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach D2124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach D2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS	0212-300		rroccaare	100 101 05
Substitute, Percutaneous Endoscopic Approach 02124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Procedure ICD-10-PCS Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 02124K9 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach 02124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 02124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS	02124K3		Procedure	ICD-10-PCS
D2124K8 Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach	OZIZ-IKS		rroccaare	100 10 1 05
Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure ICD-10-PCS Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS ICD-10-PCS	02124K8		Procedure	ICD-10-PCS
 Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Procedure Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS 	00			.02 20 . 00
Tissue Substitute, Percutaneous Endoscopic Approach 02124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 02124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS	02124K9		Procedure	ICD-10-PCS
02124KC Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Procedure ICD-10-PCS Substitute, Percutaneous Endoscopic Approach 02124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS				
Substitute, Percutaneous Endoscopic Approach O2124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS	02124KC		Procedure	ICD-10-PCS
02124KF Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Procedure ICD-10-PCS				
	02124KF	• • • •	Procedure	ICD-10-PCS
πορασταιτίατε, εξεταιαπεσίο επαθρουρίο Αρρισαίτι		Tissue Substitute, Percutaneous Endoscopic Approach		
02124KW Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Procedure ICD-10-PCS	02124KW		Procedure	ICD-10-PCS
Percutaneous Endoscopic Approach				
02124Z3 Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Procedure ICD-10-PCS	02124Z3		Procedure	ICD-10-PCS
Approach		Approach		

cder_mpl1p_wp077 Page 739 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02124Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02124Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02124ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
2242475	Approach		100 40 000
02124ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
021308C	Approach Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic	Procedure	ICD-10-PCS
U213U6C	Tissue, Open Approach	riocedule	ICD-10-PC3
021308F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic	Procedure	ICD-10-PCS
021300.	Tissue, Open Approach	110000010	102 10 1 03
021308W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021309C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
021309F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
021309W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous	Procedure	ICD-10-PCS
0212042	Tissue, Open Approach	Dragadura	ICD 10 DCC
02130A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
02130/10	Autologous Arterial Tissue, Open Approach	Troccaure	100 101 05
02130A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Arterial Tissue, Open Approach		
02130AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02130AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02130AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial	Procedure	ICD-10-PCS
0242012	Tissue, Open Approach	Dan en elemen	ICD 40 DCC
02130J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic	Procedure	ICD-10-PCS
02130J8	Substitute, Open Approach Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
0213030	Synthetic Substitute, Open Approach	Trocedure	1CD-10-1 C3
02130J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Synthetic Substitute, Open Approach		
02130JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02130JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02130JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 740 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02130K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130Z3 02130Z8	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Open Approach Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
02130Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130ZC 02130ZF	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Open Approach Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
021348C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 741 of 990



Troccaure	Codes Osed to Define basefine Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02134J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Synthetic Substitute, Percutaneous Endoscopic Approach		
02134J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Synthetic Substitute, Percutaneous Endoscopic Approach		
02134JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02134K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Percutaneous Endoscopic Approach		
02134K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach		
02134K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach		
02134KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Percutaneous Endoscopic Approach		
02134KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach		
02134KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
)2134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
)2134Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
)2134Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
)2134ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Percutaneous	Procedure	ICD-10-PCS
,	Endoscopic Approach		.02 20 . 00
02134ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Percutaneous	Procedure	ICD-10-PCS
,215 .2.	Endoscopic Approach	rroccaare	105 10 1 05
)21K0Z8	Bypass Right Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
)21K0Z9	Bypass Right Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0ZC	Bypass Right Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZF	Bypass Right Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZW	Bypass Right Ventricle to Aorta, Open Approach	Procedure	ICD-10-PCS
021K4Z8	Bypass Right Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4Z9	Bypass Right Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
-	5		
D21K4ZC	Bypass Right Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZF	Bypass Right Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 742 of 990



riocedure	codes osed to Define baseline characteristics in this kequest	Code	
Code	Description	Category	Code Type
021K4ZW	Bypass Right Ventricle to Aorta, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L08P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L09P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0Z8	Bypass Left Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0Z9	Bypass Left Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0ZC	Bypass Left Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZF	Bypass Left Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZP	Bypass Left Ventricle to Pulmonary Trunk, Open Approach	Procedure	ICD-10-PCS
021L0ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZR	Bypass Left Ventricle to Left Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L48P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L48Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L48R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L49P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 743 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
021L49Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L49R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L4AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L4JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L4JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L4KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4Z8	Bypass Left Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z9	Bypass Left Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZC	Bypass Left Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZF	Bypass Left Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZP	Bypass Left Ventricle to Pulmonary Trunk, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZR 027004Z	Bypass Left Ventricle to Left Pulmonary Artery, Percutaneous Endoscopic Approach Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS ICD-10-PCS
0270042	Approach	Procedure	ICD-10-PC3
027005Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Open	Drocedure	ICD-10-PCS
0270032	Approach	riocedure	ICD-10-1 C3
027006Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0270002	Open Approach	Trocedure	10-10-10-1
027007Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0270072	Devices, Open Approach	riocedure	ICD-10-1 C3
02700D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
0270000	Approach	Tocedure	ICD-10-FC3
02700DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700DZ 02700EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
J., JULL	2 3. 30.01, The factory with two medianinal bevices, Open Approach	. roccaure	.02 10 1 03
02700F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
	Free rr FFT		

cder_mpl1p_wp077 Page 744 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02700FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02700ZZ	Dilation of Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 745 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0070457	Percutaneous Endoscopic Approach	5 .	100 40 000
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
02704G6	Endoscopic Approach Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
0270400	Devices, Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0270102	Percutaneous Endoscopic Approach	110000010	100 10 1 00
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027104Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
027105Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
027106Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
027107Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0271006	Devices, Open Approach Dilation of Coronary Artery, Two Arteries, Bifurcation, with Introluminal Device, Open	Drocoduro	ICD 10 DCS
02710D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , , ,		
02710F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
02710FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
02710GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
02710T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
	Device, Open Approach		

cder_mpl1p_wp077 Page 746 of 990



riocedure	Codes osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02710TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
02710Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02710ZZ	Dilation of Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0274257	Percutaneous Approach	Dun and	ICD 40 DCC
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
027136Z	Percutaneous Approach Dilation of Coronary Artony, Two Artories with Three Drug eluting Introluminal Devices	Procedure	ICD 10 DCC
02/1302	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0271372	Devices, Percutaneous Approach	rroccaure	100 101 05
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
0271267	Devices, Percutaneous Approach	Dunnadiina	ICD 10 DCC
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
02/13/0	Device, Percutaneous Approach	Trocedure	1CD-10-1 C3
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
0274407	Percutaneous Endoscopic Approach	Dun and	ICD 40 DCC
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
02714EZ	Endoscopic Approach Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
02/1 7 LL	Endoscopic Approach	rioccuure	100 10-1 03

cder_mpl1p_wp077 Page 747 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Endoscopic Approach		
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
0272047	Percutaneous Endoscopic Approach	Duagadiina	ICD 10 DCC
027204Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
027205Z	Approach Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0272032	Open Approach	Procedure	ICD-10-PC3
027206Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0272002	Open Approach	riocedure	ICD-10-FC3
027207Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0272072	Devices, Open Approach	rroccaare	100 10 1 00
02720D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
02720DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
02720FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
02720G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		100 10 000
02720GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
0272076	Approach	Due duu-	ICD 40 DCC
02720T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Open	Drocoduro	ICD 10 DCS
0272012	Approach	Procedure	ICD-10-PCS
02720Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02720ZZ	Dilation of Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 748 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0272266	Approach	Dunandous	ICD 40 DCC
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
02723GZ	Devices, Percutaneous Approach Dilation of Coronary Artery, Three Arteries with Four or More Introluminal Devices	Procedure	ICD-10-PCS
0272302	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PC3
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
0272310	Device, Percutaneous Approach	Trocedure	1CD-10-1 C3
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
02,23.2	Percutaneous Approach	1100000010	102 10 1 03
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070456	Endoscopic Approach		100 10 000
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0272457	Percutaneous Endoscopic Approach	Dun and duna	ICD 40 DCC
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0272466	Endoscopic Approach Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal	Drocoduro	ICD 10 DCS
02724G6	Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0212402	Percutaneous Endoscopic Approach	Trocedure	1CD-10-LC3
	. c. catarico do Endoscopio Approden		

cder_mpl1p_wp077 Page 749 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Endoscopic Approach		
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027304Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0272057	Open Approach Dilation of Coronary Artory, Four or More Artories with Two Drug cluting Introluminal	Dragadura	ICD 10 DCC
027305Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
027306Z	Devices, Open Approach Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0273002	Devices, Open Approach	Trocedure	1CD-10-1 C3
027307Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting	Procedure	ICD-10-PCS
02/00/2	Intraluminal Devices, Open Approach		.02 20 . 00
02730D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
02730DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
02730EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
02730F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		100 10 000
02730FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
0272006	Approach Dilation of Coronary Artony Four or More Artories, Bifurcation, with Four or More	Dracadura	ICD-10-PCS
02730G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PC3
02730GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal	Procedure	ICD-10-PCS
0273002	Devices, Open Approach	Troccaure	100 101 05
02730T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive	Procedure	ICD-10-PCS
	Intraluminal Device, Open Approach		
02730TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
02730Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02730ZZ	Dilation of Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0272257	Percutaneous Approach	Duanaduun	ICD 10 DCC
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0273302	Devices, Percutaneous Approach	riocedule	ICD-10-FC3
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting	Procedure	ICD-10-PCS
32.00,2	Intraluminal Devices, Percutaneous Approach		
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 750 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
ode	Description	Category	Code Type
2733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
2733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
2733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
2733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
2733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
2733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive	Procedure	ICD-10-PCS
272277	Intraluminal Device, Percutaneous Approach		100 40 000
2733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
272447	Percutaneous Approach	Dunandiina	ICD 10 DCC
27344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
27345Z	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
2/3432	Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
27346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
273402	Devices, Percutaneous Endoscopic Approach	rrocedure	1CD-10-1 C3
27347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting	Procedure	ICD-10-PCS
275472	Intraluminal Devices, Percutaneous Endoscopic Approach	rroccaare	100 101 03
2734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
_, _ , _ ,	Percutaneous Endoscopic Approach		.02 20 . 00
2734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
2734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
2734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
2734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
2734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
2734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
2734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive	Procedure	ICD-10-PCS
	• • • • • • • • • • • • • • • • • • • •		
2734TZ		Procedure	ICD-10-PCS
	· ··		
		Procedure	ICD-10-PCS
			ICD-10-PCS ICD-10-PCS
200320		riocedure	ICD-10-LC3
	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure Procedure	i i

cder_mpl1p_wp077 Page 751 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Cada	
Codo	Description	Code	Codo Tuno
Code 02C03ZZ	Description Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach	Category	_Code Type
02C03ZZ 02C04Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0200420	Endoscopic Approach	riocedure	1CD-10-1 C3
0200477		Dragodura	ICD 10 DCC
02C04ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02C10Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C10ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
02C13Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02C13ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C14Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02C14ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02C20Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C20ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
02C23Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02C23ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C24Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02C24ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02C30Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Open	Procedure	ICD-10-PCS
	Approach		
02C30ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
02C33Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02C33ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous	Procedure	ICD-10-PCS
0203322	Approach	rioccaare	100 10 1 05
02C34Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation,	Procedure	ICD-10-PCS
0203420	Percutaneous Endoscopic Approach	riocedure	1CD-10-1 C3
0262477	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous	Dragodura	ICD 10 DCC
02C34ZZ		Procedure	ICD-10-PCS
2527247	Endoscopic Approach	- 1	100 10 000
3E07017	Introduction of Other Thrombolytic into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E070PZ	Introduction of Platelet Inhibitor into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E07317	Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E073PZ X2C0361	Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy	Procedure Procedure	ICD-10-PCS ICD-10-PCS
AZC0301	Technology, Percutaneous Approach, New Technology Group 1	Trocedure	1CD-10-LC3
V2C12C1		Drocod	ICD 10 PCC
X2C1361	Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy	Procedure	ICD-10-PCS
	Technology, Percutaneous Approach, New Technology Group 1		

cder_mpl1p_wp077 Page 752 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
X2C2361	Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy	Procedure	ICD-10-PCS
	Technology, Percutaneous Approach, New Technology Group 1		
X2C3361	Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital	Procedure	ICD-10-PCS
	Atherectomy Technology, Percutaneous Approach, New Technology Group 1		
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List	Procedure	CPT-4
33322	separately in addition to code for primary procedure)	rroccaare	CI I I
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts	Procedure	CPT-4
33323		riocedure	CF1-4
22525	(List separately in addition to code for primary procedure)	Dunnadium	CDT 4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More	Procedure	CPT-4
	Coronary Grafts		
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month	Procedure	CPT-4
	after original operation (List separately in addition to code for primary procedure)		
	,		
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33560	Myocardial Operation Combined With Coronary Bypass Procedure	Procedure	CPT-4
33570	CORONARY ANGIOPLASTY W/BYPASS	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or	Procedure	CPT-4
	right coronary artery performed in conjunction with coronary artery bypass graft		
	procedure, each vessel (List separately in addition to primary procedure)		
	processing each resser (List separately in addition to printerly procedure)		
33575	CORON ANGIOPLSTY W/BYPASS; COMBO W/VASCULARIZAT	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		

cder_mpl1p_wp077 Page 753 of 990



		Code	
Code	Description	Category	Code Type
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92973	Percutaneous transluminal coronary thrombectomy mechanical (List separately in addition to code for primary procedure)	Procedure	CPT-4

cder_mpl1p_wp077 Page 754 of 990



		Code	
Code	Description	Category	Code Type
92974	Transcatheter placement of radiation delivery device for subsequent coronary	Procedure	CPT-4
02077	intravascular brachytherapy (List separately in addition to code for primary procedure)		CDT 4
92977	Thrombolysis, coronary; by intravenous infusion Transcatheter placement of an intraversary stant(s), persutaneous, with or without	Procedure	CPT-4
92980	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	CPT-4
22224			ODT 4
92981	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92982	Percutaneous transluminal coronary balloon angioplasty; single vessel	Procedure	CPT-4
92984	Percutaneous transluminal coronary balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92995	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; single vessel	Procedure	CPT-4
92996	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with	Procedure	CPT-4
	or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)		
C1034	Catheter, coronary angioplasty, surpass superfusion catheter, long 30 surpass superfusion catheter	Procedure	HCPCS
C1100	Guide wire, percutaneous transluminal coronary angioplasty, medtronic ave gt1 guide wire, medtronic ave gt2 fusion guide wire, interventional technologies trackwire, interventional technologies trackwire support, interventional technologies trackwire extra support	Procedure	HCPCS
C1101	Catheter, percutaneous transluminal coronary angioplasty guide, medtronic ave 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave z2 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave vector x guide catheter. note: only the medtronic ave z2 zuma guide catheters are effective october 1, 2000. the medtronic ave zuma guide catheters were effective august 1, 2000.	Procedure	HCPCS
C1366	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque iron man, hi-torque balance middleweight, hi-torque all star, hi-torque balance heavyweight, hi-torque balance trek	Procedure	HCPCS
C1367	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque cross it, hi-torque cross-it 100xt, hi-torque cross-it 200xt, hi-torque cross-it 300xt, hi-torque wiggle	Procedure	HCPCS
C1500	Atherectomy system, peripheral, rotablator rotational angioplasty system with rotalink exchangeable catheter, advancer, and guide wire	Procedure	HCPCS
C1725	Catheter, transluminal angioplasty, nonlaser (may include guidance, infusion/perfusion capability)	Procedure	HCPCS
C1885 C1930	Catheter, transluminal angioplasty, laser Catheter, percutaneous transluminal coronary angioplasty, coyote dilatation catheter 20mm/30mm/40mm	Procedure Procedure	HCPCS HCPCS

cder_mpl1p_wp077 Page 755 of 990



Troccaure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
C1933	Catheter, opti-plast centurion 5.5f pta catheter (shaft length 50 cm to 120 cm), opti-plast xl 5.5f pta catheter (shaft length 75 cm to 120 cm), opti-plast pta catheter (5.5 fr), tru trac 5fr percutaneous transluminal angioplasty balloon dilatation catheter, optiplast xt 5 fr percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C1948	Catheter, pursuit balloon angioplasty catheter, cook accent balloon angioplasty catheter	Procedure	HCPCS
C1981	Catheter ,coronary angioplasty balloon, adante, bonnie, bonnie 15mm, bonnie monorail 30mm or 40mm, bonnie sliding rail, bypass speedy, chubby, chubby sliding rail, coyote 20mm, coyote 9/15/25mm, maxxum, nc ranger, nc ranger 9mm, ranger 20mm, long ranger 30mm or 40mm, nc ranger 16/18mm, nc ranger 22/25/30mm, nc big ranger, quantum ranger, quantum ranger 1/4 sizes, quantum ranger 9/16/18mm, quantum ranger 22/30mm, quantum ranger 25mm, ranger lp 20/30/40, viva/long viva, ace - 1cm, ace - 2cm, ace graft, long ace, pivot cobra (10, 14, 18, 30, 40mm in lengths) note: only the bonnie monorail 30mm or 40mm, long ranger 30mm or 40mm, and ranger 20mm are effective 01/01/01. the other catheters were effective 08/01/00.	Procedure	HCPCS
C2605	Catheter, spectranetics extreme laser catheter, spectranetics extreme 0.9mm coronary angioplasty catheter (model 110-001)	Procedure	HCPCS
C2623	Catheter, transluminal angioplasty, drug-coated, nonlaser	Procedure	HCPCS
C3551	Guide wire, percutaneous transluminal coronary angioplasty, choice, luge, patriot, pt graphix intermediate, trooper, mailman 182/300 cm, glidewire gold guidewire, platinum plus guidewire, platinum plus guidewire with glidex hydrophilic coating, jagwire single-use high performance guide wire, merit medical systems extender guidewire, merit medical systems tomcat ptca guidewire, platinum plus guidewire (0.014 and 0.018 in diameters)	Procedure	HCPCS
C8526 C9600	Optiplast xt 5f percutaneous transluminal angioplasty catheter (various sizes) Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure Procedure	HCPCS HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	HCPCS

cder_mpl1p_wp077 Page 756 of 990



	codes Oseu to Define Basenne Characteristics in this nequest	Code	
Code	Description	Category	_Code Type
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary	Procedure	HCPCS
G0290	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	HCPCS
G0291	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel	Procedure	HCPCS
52205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), 2 coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
52208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
52209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using 2 arterial grafts and single venous graft	Procedure	HCPCS
	Left Ventricular Hypertrophy		
142.1 142.2 151.7	Obstructive hypertrophic cardiomyopathy Other hypertrophic cardiomyopathy Cardiomegaly	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM
170.4	Peripheral Artery Disease	Diam.	100.40.011
170.1 170.201	Atherosclerosis of renal artery Unspecified atherosclerosis of native arteries of extremities, right leg	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 757 of 990



Code Description	riocedure	codes osed to Define Baseline Characteristics in this nequest	Code	
Unspecified atherosclerosis of native arteries of extremities, bilateral legs Diagnosis CD-10-CM	Code	Description		Code Type
170.203 Unspecified atherosclerosis of native arteries of extremities, bilateral legs Unspecified atherosclerosis of native arteries of extremities, unspecified extremity Diagnosis ICD-10-CM 170.211 Atherosclerosis of native arteries of extremities, unspecified extremity Diagnosis ICD-10-CM 170.212 Atherosclerosis of native arteries of extremities with intermittent claudication, right leg Diagnosis ICD-10-CM 170.213 Atherosclerosis of native arteries of extremities with intermittent claudication, left leg Diagnosis ICD-10-CM ICD				
170.208 Unspecified atherosclerosis of native arteries of extremities, unspecified extremity Diagnosis ICD-10-CM				
170.219 Unspecified atherosclerosis of native arteries of extremities with intermittent claudication, right leg Diagnosis ICD-10-CM 170.211				
Atherosclerosis of native arteries of extremities with intermittent claudication, left leg Diagnosis ICD-10-CM			_	
170.212 Atherosclerosis of native arteries of extremities with intermittent claudication, left leg Diagnosis ICD-10-CM legs 170.213 Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral Diagnosis ICD-10-CM legs 170.218 Atherosclerosis of native arteries of extremities with intermittent claudication, other Diagnosis ICD-10-CM extremity 170.219 Atherosclerosis of native arteries of extremities with intermittent claudication, Diagnosis ICD-10-CM unspecified extremity 170.221 Atherosclerosis of native arteries of extremities with rest pain, right leg Diagnosis ICD-10-CM unspecified extremity Diagnosis ICD-10-CM I70.222 Atherosclerosis of native arteries of extremities with rest pain, left leg Diagnosis ICD-10-CM I70.223 Atherosclerosis of native arteries of extremities with rest pain, left leg Diagnosis ICD-10-CM I70.224 Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity Diagnosis ICD-10-CM I70.225 Atherosclerosis of native arteries of right leg with ulceration of thigh Diagnosis ICD-10-CM I70.231 Atherosclerosis of native arteries of right leg with ulceration of an extremity Diagnosis ICD-10-CM I70.232 Atherosclerosis of native arteries of right leg with ulceration of and Diagnosis ICD-10-CM I70.234 Atherosclerosis of native arteries of right leg with ulceration of hore part of foot Diagnosis ICD-10-CM I70.235 Atherosclerosis of native arteries of right leg with ulceration of other part of foot Diagnosis ICD-10-CM I70.236 Atherosclerosis of native arteries of right leg with ulceration of other part of foot Diagnosis ICD-10-CM I70.236 Atherosclerosis of native arteries of right leg with ulceration of other part of foot Diagnosis ICD-10-CM I70.241 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM I70.244 Atherosclerosis of native ar				
170.213	170.211	Action of the fire arteries of extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CIVI
Inc.	170.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity 170.221 Atherosclerosis of native arteries of extremities with rest pain, right leg Diagnosis ICD-10-CM 170.222 Atherosclerosis of native arteries of extremities with rest pain, left leg Diagnosis ICD-10-CM 170.223 Atherosclerosis of native arteries of extremities with rest pain, left leg Diagnosis ICD-10-CM 170.223 Atherosclerosis of native arteries of extremities with rest pain, bilateral legs Diagnosis ICD-10-CM 170.229 Atherosclerosis of native arteries of extremities with rest pain, bilateral legs Diagnosis ICD-10-CM 170.229 Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity Diagnosis ICD-10-CM 170.231 Atherosclerosis of native arteries of right leg with ulceration of thigh Diagnosis ICD-10-CM 170.233 Atherosclerosis of native arteries of right leg with ulceration of alf Diagnosis ICD-10-CM 170.233 Atherosclerosis of native arteries of right leg with ulceration of help Diagnosis ICD-10-CM 170.234 Atherosclerosis of native arteries of right leg with ulceration of help and midfoot Diagnosis ICD-10-CM 170.235 Atherosclerosis of native arteries of right leg with ulceration of other part of foot Diagnosis ICD-10-CM 170.236 Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.237 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.238 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.241 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.244 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.246 Atherosclerosis of native arteries of left leg with ul	170.213		Diagnosis	ICD-10-CM
unspecified extremity 170.221 Atherosclerosis of native arteries of extremities with rest pain, right leg 170.222 Atherosclerosis of native arteries of extremities with rest pain, left leg 170.223 Atherosclerosis of native arteries of extremities with rest pain, bilateral legs 170.228 Atherosclerosis of native arteries of extremities with rest pain, other extremity 170.229 Atherosclerosis of native arteries of extremities with rest pain, other extremity 170.229 Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity 170.231 Atherosclerosis of native arteries of right leg with ulceration of thigh 170.232 Atherosclerosis of native arteries of right leg with ulceration of calf 170.233 Atherosclerosis of native arteries of right leg with ulceration of ankle 170.234 Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot 170.235 Atherosclerosis of native arteries of right leg with ulceration of ther part of foot 170.236 Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg 170.237 Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg 170.238 Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg 170.241 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.242 Atherosclerosis of native arteries of left leg with ulceration of thigh 170.243 Atherosclerosis of native arteries of left leg with ulceration of thigh 170.244 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.246 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.247 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.248 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.249 Atherosclerosis of native arteries	170.218		Diagnosis	ICD-10-CM
170.222	170.219		Diagnosis	ICD-10-CM
170.223	170.221	Atherosclerosis of native arteries of extremities with rest pain, right leg	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of extremities with rest pain, other extremity Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity Diagnosis ICD-10-CM Atherosclerosis of native arteries of right leg with ulceration of thigh Diagnosis ICD-10-CM Atherosclerosis of native arteries of right leg with ulceration of calf Diagnosis ICD-10-CM Atherosclerosis of native arteries of right leg with ulceration of ankle Diagnosis ICD-10-CM Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot Diagnosis ICD-10-CM Atherosclerosis of native arteries of right leg with ulceration of other part of foot Diagnosis ICD-10-CM Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of the Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of the Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of the Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of the Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of the Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of the Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, pilpt leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, pilpt leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremiti	170.222	Atherosclerosis of native arteries of extremities with rest pain, left leg	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity Diagnosis ICD-10-CM 170.232 Atherosclerosis of native arteries of right leg with ulceration of thigh Diagnosis ICD-10-CM 170.232 Atherosclerosis of native arteries of right leg with ulceration of calf Diagnosis ICD-10-CM 170.233 Atherosclerosis of native arteries of right leg with ulceration of ankle Diagnosis ICD-10-CM 170.234 Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot Diagnosis ICD-10-CM 170.235 Atherosclerosis of native arteries of right leg with ulceration of other part of foot Diagnosis ICD-10-CM 170.238 Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.239 Atherosclerosis of native arteries of left leg with ulceration of unspecified site Diagnosis ICD-10-CM 170.241 Atherosclerosis of native arteries of left leg with ulceration of calf Diagnosis ICD-10-CM 170.242 Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM 170.243 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot Diagnosis ICD-10-CM 170.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot Diagnosis ICD-10-CM 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot Diagnosis ICD-10-CM 170.246 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.249 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.250 Atherosclerosis of native arteries of extremities with gangrene, right leg Diagnosis ICD-10-CM 170.261 Atherosclerosis of native arteries of extremities with gangrene, left leg Diagnosis ICD-10-CM 170.262 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs Diagnosis ICD-10-CM 170.263 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity Di	170.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of right leg with ulceration of thigh Diagnosis ICD-10-CM	170.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of right leg with ulceration of calf Diagnosis ICD-10-CM 170.233	170.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.233	170.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot Diagnosis ICD-10-CM 170.238	170.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg Atherosclerosis of native arteries of right leg with ulceration of unspecified site Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of calf Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of other part of foot Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of unspecified site Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with ulceration Atherosclerosis of native arteries of extremities with gangrene, right leg Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, left leg Diagnosis ICD-10-CM	170.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg Atherosclerosis of native arteries of right leg with ulceration of unspecified site Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of calf Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM D	170.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	
Atherosclerosis of native arteries of left leg with ulceration of unspecified site Diagnosis ICD-10-CM 170.241 Atherosclerosis of native arteries of left leg with ulceration of thigh Diagnosis ICD-10-CM 170.242 Atherosclerosis of native arteries of left leg with ulceration of calf Diagnosis ICD-10-CM 170.243 Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM 170.244 Atherosclerosis of native arteries of left leg with ulceration of ankle Diagnosis ICD-10-CM 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot Diagnosis ICD-10-CM 170.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg Diagnosis ICD-10-CM 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site Diagnosis ICD-10-CM 170.25 Atherosclerosis of native arteries of other extremities with ulceration Diagnosis ICD-10-CM 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg Diagnosis ICD-10-CM 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg Diagnosis ICD-10-CM 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs Diagnosis ICD-10-CM 170.269 Atherosclerosis of native arteries of extremities with gangrene, other extremity Diagnosis ICD-10-CM 170.269 Other atherosclerosis of native arteries of extremities, right leg Diagnosis ICD-10-CM 170.291 Other atherosclerosis of native arteries of extremities, left leg Diagnosis ICD-10-CM 170.292 Other atherosclerosis of native arteries of extremities, bilateral legs Diagnosis ICD-10-CM 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs Diagnosis ICD-10-CM 170.298 Other atherosclerosis of native arteries of extremities, other extremity Diagnosis ICD-10-CM			Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of left leg with ulceration of thigh 170.242 Atherosclerosis of native arteries of left leg with ulceration of calf 170.243 Atherosclerosis of native arteries of left leg with ulceration of ankle 170.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot 170.246 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.247 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.25 Atherosclerosis of native arteries of other extremities with ulceration 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.268 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.269 Atherosclerosis of native arteries of extremities, right leg 170.290 Other atherosclerosis of native arteries of extremities, left leg 170.291 Other atherosclerosis of native arteries of extremities, left leg 170.292 Other atherosclerosis of native arteries of extremities, bilateral legs 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.294 Other atherosclerosis of native arteries of extremities, bilateral legs 170.295 Other atherosclerosis of native arteries of extremities, other extremity 170.296 Other atherosclerosis of native arteries of extremities, other extremity 170.297 Other atherosclerosis of native arteries of extremities, other extremity	170.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of left leg with ulceration of thigh 170.242 Atherosclerosis of native arteries of left leg with ulceration of calf 170.243 Atherosclerosis of native arteries of left leg with ulceration of ankle 170.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot 170.246 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.247 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.25 Atherosclerosis of native arteries of other extremities with ulceration 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.268 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.269 Atherosclerosis of native arteries of extremities, right leg 170.290 Other atherosclerosis of native arteries of extremities, left leg 170.291 Other atherosclerosis of native arteries of extremities, left leg 170.292 Other atherosclerosis of native arteries of extremities, bilateral legs 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.294 Other atherosclerosis of native arteries of extremities, bilateral legs 170.295 Other atherosclerosis of native arteries of extremities, other extremity 170.296 Other atherosclerosis of native arteries of extremities, other extremity 170.297 Other atherosclerosis of native arteries of extremities, other extremity				
Atherosclerosis of native arteries of left leg with ulceration of calf 170.243 Atherosclerosis of native arteries of left leg with ulceration of ankle 170.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot 170.246 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.247 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.248 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.249 Atherosclerosis of native arteries of extremities with ulceration 170.25 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.261 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs 170.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.269 Atherosclerosis of native arteries of extremities, right leg 170.290 Other atherosclerosis of native arteries of extremities, left leg 170.291 Other atherosclerosis of native arteries of extremities, left leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.296 Other atherosclerosis of native arteries of extremities, bilateral legs 170.297 Other atherosclerosis of native arteries of extremities, bilateral legs 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity	170.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of left leg with ulceration of ankle 170.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot 170.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.25 Atherosclerosis of native arteries of other extremities with ulceration 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs 170.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.290 Other atherosclerosis of native arteries of extremities, right leg 170.291 Other atherosclerosis of native arteries of extremities, left leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, left leg 170.294 Other atherosclerosis of native arteries of extremities, left leg 170.295 Other atherosclerosis of native arteries of extremities, left leg 170.296 Diagnosis ICD-10-CM 170.297 Other atherosclerosis of native arteries of extremities, left leg 170.298 Other atherosclerosis of native arteries of extremities, bilateral legs 170.298 Diagnosis ICD-10-CM	170.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot 170.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot 170.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.25 Atherosclerosis of native arteries of other extremities with ulceration 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs 170.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.260 Other atherosclerosis of native arteries of extremities, right leg 170.291 Other atherosclerosis of native arteries of extremities, left leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.294 Other atherosclerosis of native arteries of extremities, bilateral legs 170.295 Other atherosclerosis of native arteries of extremities, bilateral legs 170.296 Other atherosclerosis of native arteries of extremities, other extremity 170.297 Other atherosclerosis of native arteries of extremities, bilateral legs 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity	170.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of left leg with ulceration of other part of foot 170.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.25 Atherosclerosis of native arteries of other extremities with ulceration 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs 170.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.291 Other atherosclerosis of native arteries of extremities, right leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Diagnosis ICD-10-CM	170.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg 170.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site 170.25 Atherosclerosis of native arteries of other extremities with ulceration 170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs 170.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.291 Other atherosclerosis of native arteries of extremities, right leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity	170.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of left leg with ulceration of unspecified site Diagnosis ICD-10-CM Atherosclerosis of native arteries of other extremities with ulceration Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, right leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, left leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, bilateral legs Diagnosis ICD-10-CM Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, other extremity Diagnosis ICD-10-CM	170.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of other extremities with ulceration Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, right leg Diagnosis ICD-10-CM Atherosclerosis of native arteries of extremities with gangrene, left leg Diagnosis ICD-10-CM	170.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.261 Atherosclerosis of native arteries of extremities with gangrene, right leg 170.262 Atherosclerosis of native arteries of extremities with gangrene, left leg 170.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs 170.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity 170.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity 170.291 Other atherosclerosis of native arteries of extremities, right leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.294 Other atherosclerosis of native arteries of extremities, bilateral legs 170.295 Other atherosclerosis of native arteries of extremities, bilateral legs 170.296 Other atherosclerosis of native arteries of extremities, bilateral legs 170.297 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.299 Diagnosis ICD-10-CM 170.299 Other atherosclerosis of native arteries of extremities, other extremity 170.290 Diagnosis ICD-10-CM	170.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.262Atherosclerosis of native arteries of extremities with gangrene, left legDiagnosisICD-10-CM170.263Atherosclerosis of native arteries of extremities with gangrene, bilateral legsDiagnosisICD-10-CM170.268Atherosclerosis of native arteries of extremities with gangrene, other extremityDiagnosisICD-10-CM170.269Atherosclerosis of native arteries of extremities with gangrene, unspecified extremityDiagnosisICD-10-CM170.291Other atherosclerosis of native arteries of extremities, right legDiagnosisICD-10-CM170.292Other atherosclerosis of native arteries of extremities, left legDiagnosisICD-10-CM170.293Other atherosclerosis of native arteries of extremities, bilateral legsDiagnosisICD-10-CM170.298Other atherosclerosis of native arteries of extremities, other extremityDiagnosisICD-10-CM	170.25	Atherosclerosis of native arteries of other extremities with ulceration	Diagnosis	ICD-10-CM
170.263Atherosclerosis of native arteries of extremities with gangrene, bilateral legsDiagnosisICD-10-CM170.268Atherosclerosis of native arteries of extremities with gangrene, other extremityDiagnosisICD-10-CM170.269Atherosclerosis of native arteries of extremities with gangrene, unspecified extremityDiagnosisICD-10-CM170.291Other atherosclerosis of native arteries of extremities, right legDiagnosisICD-10-CM170.292Other atherosclerosis of native arteries of extremities, left legDiagnosisICD-10-CM170.293Other atherosclerosis of native arteries of extremities, bilateral legsDiagnosisICD-10-CM170.298Other atherosclerosis of native arteries of extremities, other extremityDiagnosisICD-10-CM	170.261	Atherosclerosis of native arteries of extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.268Atherosclerosis of native arteries of extremities with gangrene, other extremityDiagnosisICD-10-CM170.269Atherosclerosis of native arteries of extremities with gangrene, unspecified extremityDiagnosisICD-10-CM170.291Other atherosclerosis of native arteries of extremities, right legDiagnosisICD-10-CM170.292Other atherosclerosis of native arteries of extremities, left legDiagnosisICD-10-CM170.293Other atherosclerosis of native arteries of extremities, bilateral legsDiagnosisICD-10-CM170.298Other atherosclerosis of native arteries of extremities, other extremityDiagnosisICD-10-CM	170.262	Atherosclerosis of native arteries of extremities with gangrene, left leg	Diagnosis	ICD-10-CM
Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity Diagnosis ICD-10-CM Other atherosclerosis of native arteries of extremities, right leg Other atherosclerosis of native arteries of extremities, left leg Diagnosis ICD-10-CM Diagnosis ICD-10-CM Other atherosclerosis of native arteries of extremities, bilateral legs Other atherosclerosis of native arteries of extremities, other extremity Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM	170.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.291 Other atherosclerosis of native arteries of extremities, right leg 170.292 Other atherosclerosis of native arteries of extremities, left leg 170.293 Other atherosclerosis of native arteries of extremities, bilateral legs 170.298 Other atherosclerosis of native arteries of extremities, other extremity 170.298 Diagnosis	170.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.292Other atherosclerosis of native arteries of extremities, left legDiagnosisICD-10-CM170.293Other atherosclerosis of native arteries of extremities, bilateral legsDiagnosisICD-10-CM170.298Other atherosclerosis of native arteries of extremities, other extremityDiagnosisICD-10-CM	170.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.292Other atherosclerosis of native arteries of extremities, left legDiagnosisICD-10-CM170.293Other atherosclerosis of native arteries of extremities, bilateral legsDiagnosisICD-10-CM170.298Other atherosclerosis of native arteries of extremities, other extremityDiagnosisICD-10-CM				
170.293 Other atherosclerosis of native arteries of extremities, bilateral legs Diagnosis ICD-10-CM 170.298 Other atherosclerosis of native arteries of extremities, other extremity Diagnosis ICD-10-CM	170.291	Other atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
170.298 Other atherosclerosis of native arteries of extremities, other extremity Diagnosis ICD-10-CM			Diagnosis	ICD-10-CM
			-	
170.299 Other atherosclerosis of native arteries of extremities, unspecified extremity Diagnosis ICD-10-CM				
	170.299	Other atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 758 of 990



Fiocedure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
170.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right	Diagnosis	ICD-10-CM
170.302	leg Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 759 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.35	Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
170.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.391	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.392	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.393	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.398	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.399	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.501	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.502	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 760 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.503	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.508	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.509	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.511	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.512	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.513	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.518	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.519	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.521	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.522	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.523	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.528	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.529	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 761 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.55	Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
170.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.591	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.592	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.593	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.598	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.599	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.601	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.602	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.603	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.608	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 762 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.609	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.611	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.612	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.613	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.618	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.619	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.621	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.622	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.623	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.628	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.629	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.642 170.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 763 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.65 170.661	Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
170.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.691	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.692	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.693	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.698	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.699	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.701	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.702	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.703	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.708	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.709	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.711	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.712	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 764 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Codo	
Code	Description	Code	Code Type
170.713	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent	Category Diagnosis	ICD-10-CM
170.713	claudication, bilateral legs	Diagnosis	ICD-10-CIVI
170.718	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.719	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.721	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.722	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.723	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.732 170.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
170.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 765 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Codo Typo
			Code Type
170.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral	Diagnosis	ICD-10-CM
	legs		
170.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other	Diagnosis	ICD-10-CM
1701700	extremity	2146110313	100 10 0.11
170.760	·	Diagrasia	ICD 10 CM
170.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene,	Diagnosis	ICD-10-CM
	unspecified extremity		
170.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
		J	
170.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified	Diagnosis	ICD-10-CM
170.755	extremity	Diagnosis	TED TO CIVI
170.0	•	. .	100 10 011
170.8	Atherosclerosis of other arteries	Diagnosis	ICD-10-CM
170.90	Unspecified atherosclerosis	Diagnosis	ICD-10-CM
170.91	Generalized atherosclerosis	Diagnosis	ICD-10-CM
170.92	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-10-CM
172.0 172.1	Aneurysm of carotid artery Aneurysm of artery of upper extremity	Diagnosis	ICD-10-CM
172.1	Aneurysm of renal artery	Diagnosis	ICD-10-CM
172.2	Aneurysm of iliac artery	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
172.3	Aneurysm of artery of lower extremity	Diagnosis	ICD-10-CM
172.4	Aneurysm of other specified arteries	Diagnosis	ICD-10-CM
172.8	Aneurysm of unspecified site	Diagnosis	ICD-10-CM
172.3	Other specified peripheral vascular diseases	Diagnosis	ICD-10-CM
173.9	Peripheral vascular disease, unspecified	Diagnosis	ICD-10-CM
177.71	Dissection of carotid artery	Diagnosis	ICD-10-CM
177.72	Dissection of iliac artery	Diagnosis	ICD-10-CM
177.73	Dissection of renal artery	Diagnosis	ICD-10-CM
177.74	Dissection of vertebral artery	Diagnosis	ICD-10-CM
177.79	Dissection of other specified artery	Diagnosis	ICD-10-CM
179.8	Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere	Diagnosis	ICD-10-CM
	,	J	
Z95.820	Peripheral vascular angioplasty status with implants and grafts	Diagnosis	ICD-10-CM
Z95.828	Presence of other vascular implants and grafts	Diagnosis	ICD-10-CM
0312090	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-CW
3312030	Open Approach	. roccaure	.55 10 1 65
0212001		Drocodura	ICD 10 DCs
0312091	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 766 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0312092	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312093	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312094	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312095	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312096	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312097	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312098	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312099	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313090	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313091	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313092	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313093	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313094	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313095	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313096	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313097	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313098	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313099	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314090	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314091	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314092	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 767 of 990



. roccaare	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0314093	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314094	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314095	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314096	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314097	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314098	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314099	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315090	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315091	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315092	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315093	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315094	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315095	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315096	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315097	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315098	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315099	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316090	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316091	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316092	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316093	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 768 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0316094	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
0316095	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316096	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0310030	Open Approach	Trocedure	ICD-10-I C5
0316097	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
0316098	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0316099	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0217000	Open Approach	Dunnadii	ICD 10 DCC
0317090	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317093	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0027000	Open Approach		.02 20 . 00
0318091	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0318094	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0319093	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0373046	Open Approach Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0373040	Open Approach	riocedule	ICD-10-FC3
0373056	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0373066	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0373076	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0272246	Intraluminal Devices, Open Approach		160 40 066
0373346	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0373356	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0373330	Devices, Percutaneous Approach	Troccaure	100 101 05
0373366	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0373376	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0373446	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0272456	Percutaneous Endoscopic Approach	Drocado	ICD 40 DCC
0373456	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	Devices, i eleutalieuus Eliuuscopic Appivacii		

cder_mpl1p_wp077 Page 769 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0373466	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0373476	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0374046	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0274056	Open Approach		160 40 066
0374056	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374066	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0374000	Devices, Open Approach	Trocedure	1CD-10-1 C3
0374076	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0374346	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0374356	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0374366	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0074076	Devices, Percutaneous Approach		100 10 000
0374376	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374446	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0374440	Percutaneous Endoscopic Approach	Troccaure	100 101 05
0374456	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0374466	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0374476	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0075046	Intraluminal Devices, Percutaneous Endoscopic Approach		100 10 000
0375046	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
0375056	Approach Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0373030	Open Approach	riocedure	ICD-10-FC3
0375066	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0375076	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0375346	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0375356	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0275266	Percutaneous Approach	Dun - I	100 40 500
0375366	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 770 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	_Code Type
0375376	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0375446	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0275456	Percutaneous Endoscopic Approach	Dunnadii	ICD 10 DCC
0375456	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375466	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0375476	Percutaneous Endoscopic Approach Dilation of Right Avillagy Astony Bifurcation with Four or Mara Drug cluting Introluminal	Dragodura	ICD 10 DCS
03/54/6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376046	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
0376056	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0376066	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0076076	Open Approach		100 40 000
0376076	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376346	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0376356	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376366	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0376376	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0376446	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376456	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0370430	Percutaneous Endoscopic Approach	Troccaure	100 101 05
0376466	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0376476	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0377046	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
0377056	Approach Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0377030	Open Approach	riocedure	ICD-10-LC3
0377066	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0377076	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		

cder_mpl1p_wp077 Page 771 of 990



Trocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0377346	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0377356	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0377366	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0377376	Devices, Percutaneous Approach Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/73/0	Devices, Percutaneous Approach	riocedule	ICD-10-PC3
0377446	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		.02 20 . 00
0377456	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0377466	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0377476	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0070046	Devices, Percutaneous Endoscopic Approach		100 40 000
0378046	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0378056	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0370030	Open Approach	Troccaure	101 101 05
0378066	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0378076	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0378346	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0070056	Percutaneous Approach		100 40 000
0378356	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378366	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0370300	Percutaneous Approach	Troccaure	101 101 05
0378376	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0378446	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0378456	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0378466	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0270476	Percutaneous Endoscopic Approach Dilation of Loft Prophial Artony Diffusion with Four or Mars Drug cluting Introluminal	Dragadura	ICD 10 DCS
0378476	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379046	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
23, 30-10	Approach	. roccuure	.02 10 100
	••		

cder_mpl1p_wp077 Page 772 of 990



Trocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0379056	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
227225	Open Approach		100 40 000
0379066	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379076	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0375070	Devices, Open Approach	Troccaure	100 10 1 05
0379346	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0379356	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0379366	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379376	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/33/0	Devices, Percutaneous Approach	Troccaure	101 101 05
0379446	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0379456	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0379466	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379476	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/3//0	Devices, Percutaneous Endoscopic Approach	rioccaare	105 10 1 00
0410096	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0410097	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0440000	Open Approach	Dunandous	ICD 40 DCC
0410098	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410099	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0410496	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0410497	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0410400	Percutaneous Endoscopic Approach	Dunnadium	ICD 10 DCC
0410498	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410499	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.120.33	Percutaneous Endoscopic Approach	rioccaare	105 10 1 00
0470046	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
0470056	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 773 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0470066	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0470076	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0470346	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0470356	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0470366	Percutaneous Approach Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD 10 DCS
0470300	Percutaneous Approach	Procedure	ICD-10-PCS
0470376	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0470370	Devices, Percutaneous Approach	rroccaarc	100 10 1 05
0470446	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0470456	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0470466	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0470476	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
03730E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
0272256	Approach	Dunnadiina	ICD 10 DCS
03733E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03734E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0373420	Percutaneous Endoscopic Approach	rroccaare	100 10 1 03
03740E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03743E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03744E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03750E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
0275256	Approach	Dan en el con	ICD 10 DCC
03753E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
03754E6	Approach Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Drocadura	ICD-10-PCS
03734L0	Endoscopic Approach	riocedure	ICD-10-FC3
03760E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
,	,		
03763E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 774 of 990



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03764E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03770E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03773E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03774E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03780E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03783E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03784E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03790E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03793E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03794E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04703E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04704E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E041	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E046	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E056	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E066	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E076	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
031209B	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031209C	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
03120A0	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 775 of 990



TTOCCUUTC	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03120A1	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A3	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A4	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A6	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A7	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A9	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AB	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120J0	Bypass Innominate Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J1	Bypass Innominate Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J3	Bypass Innominate Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J4	Bypass Innominate Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J6	Bypass Innominate Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J7	Bypass Innominate Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J9	Bypass Innominate Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 776 of 990



Code Type
ICD-10-PCS
ICD-10-PCS
,
ICD-10-PCS

cder_mpl1p_wp077 Page 777 of 990



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03130A0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue,		ICD-10-PCS
	Open Approach		
03130A1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
03130A3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
03130A6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0242040	Open Approach		100 40 000
03130A8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
0212040	Tissue, Open Approach Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Drocoduro	ICD 10 DCS
03130A9	Open Approach	Procedure	ICD-10-PCS
03130AB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03130AD	Open Approach	riocedure	ICD-10-FC3
03130AC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
03130AC	Tissue, Open Approach	rroccaare	100 10 1 05
03130J0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
001000	Approach	rroccaare	100 10 1 00
03130J1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03130J3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03130J6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0242010	Approach	Dunna !	100 40 500
03130J8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0212010	Open Approach Pyross Right Subclavian Artery to Right Lower Log Artery with Synthetic Subctitute, Open	Drocodura	ICD 10 DCS
03130J9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 778 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03130JB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130JC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03130K0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130KB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130KC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0040070	Substitute, Open Approach		100 10 000
03130Z0	Bypass Right Subclavian Artery to Right Upper Arm Artery, Open Approach Bypass Right Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure Procedure	ICD-10-PCS
03130Z1 03130Z2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS ICD-10-PCS
03130Z2 03130Z3	Bypass Right Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z4	Bypass Right Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z6	Bypass Right Subclavian Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z7	Bypass Right Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z9	Bypass Right Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZB 03130ZC	Bypass Right Subclavian Artery to Left Lower Leg Artery, Open Approach Bypass Right Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
031302C 031409B	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery, Open Approach Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		102 20 1 00
031409C	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		20.00
	errory a first ordinary and the second		

cder_mpl1p_wp077 Page 779 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03140A0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
024 40 4 2	Tissue, Open Approach	Donordono	ICD 40 DCC
03140A3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03140/4	Open Approach	rroccaare	100 10 1 05
03140A5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
03140A6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
024.40.40	Tissue, Open Approach	Donosalous	ICD 40 DCC
03140A9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03140AB	Open Approach Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03140AB	Open Approach	riocedure	ICD-10-FC3
03140AC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
03140J0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140J1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140J2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
024 4012	Open Approach		ICD 40 DCC
03140J3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
03140J4	Approach Bypass Left Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0314014	Approach	rrocedure	10-10-1 03
03140J5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03140J6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140J7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140J8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
00445:5	Open Approach		100 15 555
03140J9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 780 of 990



riocedure	e Codes Used to Define Baseline Characteristics in this Request		Code	
Code	Description	Category	Code Type	
03140JB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS	
	Approach			
03140JC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS	
	Open Approach			
03140K0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
	Substitute, Open Approach			
03140K1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
	Substitute, Open Approach			
03140K2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
	Substitute, Open Approach			
03140K3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
	Substitute, Open Approach			
03140K4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
	Substitute, Open Approach			
03140K5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
	Substitute, Open Approach			
03140K6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
0044047	Substitute, Open Approach		100 10 000	
03140K7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
024 401/0	Substitute, Open Approach		100 40 000	
03140K8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
0244000	Substitute, Open Approach	Duagadiina	ICD 10 DCC	
03140K9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
03140KB	Substitute, Open Approach Punass Left Substantian Artery to Left Lower Leg Artery with Nepautologous Tissue	Procedure	ICD-10-PCS	
U314UKB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PC3	
03140KC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS	
03140KC	Substitute, Open Approach	riocedure	1CD-10-1 C3	
03140Z0	Bypass Left Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z1	Bypass Left Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z3	Bypass Left Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z4	Bypass Left Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z6	Bypass Left Subclavian Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z7	Bypass Left Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS	
03140Z9	Bypass Left Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS	
03140ZB	Bypass Left Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS	
03140ZC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS	
031509B	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS	
0215000	Open Approach Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue,	Drocodura	ICD 10 DCs	
031509C		Procedure	ICD-10-PCS	
	Open Approach			

cder_mpl1p_wp077 Page 781 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03150A0	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A1	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0215042	Open Approach	Dunnandii	ICD 10 DCC
03150A3	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A4	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03130/4	Open Approach	Troccaure	100 101 05
03150A5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A6	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A7	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0215040	Open Approach Dispess Dight Avillage Astory to Dight Lower Log Astory with Autologous Astorial Tissue	Dragodura	ICD 10 DCS
03150A9	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150AB	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03130/18	Open Approach	rroccaure	100 101 05
03150AC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150J0	Bypass Right Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J1	Bypass Right Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0045010	Approach		100 40 000
03150J2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
03150J3	Approach Bypass Right Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0313013	Approach	Trocedure	1CD-10-1 C3
03150J4	Bypass Right Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J6	Bypass Right Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J7	Bypass Right Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0215010	Approach Pypage Bight Avillary Artery to Bilateral Hanor Log Artery with Synthetic Substitute, Open	Drocodure	ICD 10 DCC
03150J8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J9	Bypass Right Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
3313013	Approach	Toccuure	100 10100
	· it it		

cder_mpl1p_wp077 Page 782 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03150JB	Bypass Right Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150JC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150K0	Bypass Right Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K1	Bypass Right Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K3	Bypass Right Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
J0 _ 0 0 .	Substitute, Open Approach		.02 20 . 00
03150K4	Bypass Right Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
00100111	Substitute, Open Approach		100 10 1 00
03150K5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
00100110	Substitute, Open Approach	rioccaare	100 10 1 05
03150K6	Bypass Right Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0313010	Substitute, Open Approach	Troccaure	100 10 1 03
03150K7	Bypass Right Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
031301(7	Substitute, Open Approach	Troccaure	100 10 1 03
03150K8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
)3130KO	Substitute, Open Approach	Troccaure	100 10 1 05
03150K9	Bypass Right Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
)3130K3	Substitute, Open Approach	riocedure	1CD-10-1 C3
03150KB	Bypass Right Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
J3130KD	Substitute, Open Approach	riocedure	1CD-10-1 C3
03150KC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
33130KC	Substitute, Open Approach	Troccaure	100 10 1 03
03150Z0	Bypass Right Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z0 03150Z1	Bypass Right Axillary Artery to Right Opper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z3	Bypass Right Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z4	Bypass Right Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z6	Bypass Right Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z7	Bypass Right Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z9	Bypass Right Axillary Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150ZB	Bypass Right Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150ZB 03150ZC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031502C 031609B	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
,510000	Approach	occuure	.02 10 1 05
031609C	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
721003C		riocedule	10-10-403
	Open Approach		

cder_mpl1p_wp077 Page 783 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03160A0	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160A1	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
0216042	Approach Proposed off Avillany Artemyte Biletoral Happer Arm Artemywith Autologous Arterial Tissue	Dragodura	ICD 10 DCS
03160A2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A3	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160A4	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
03160A5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0216046	Open Approach	Dunnanduun	ICD 10 DCC
03160A6	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A7	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
03160A8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160A9	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03160AB	Open Approach Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
03100AB	Approach	riocedure	ICD-10-PC3
03160AC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160J0	Bypass Left Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J1	Bypass Left Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0310072	Approach	rroccaare	100 10 1 05
03160J3	Bypass Left Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J4	Bypass Left Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
024 0015	Approach	Dunnanduun	ICD 10 DCC
03160J5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J6	Bypass Left Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J7	Bypass Left Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
03160J9	Approach Bypass Left Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0310013	Approach	rrocedure	1CD-10-LC3

cder_mpl1p_wp077 Page 784 of 990



Troccaare	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03160JB	Bypass Left Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160JC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160K0	Bypass Left Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K1	Bypass Left Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K3	Bypass Left Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K4	Bypass Left Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
00200	Substitute, Open Approach		.02 20 . 00
03160K5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
00100113	Substitute, Open Approach		102 10 1 03
03160K6	Bypass Left Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
03100N0	Substitute, Open Approach	rroccaare	100 10 1 05
03160K7	Bypass Left Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
03100117	Open Approach	rroccaare	100 10 1 05
03160K8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
03100110	Substitute, Open Approach	rroccaare	100 10 1 05
03160K9	Bypass Left Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
03100113	Substitute, Open Approach	rroccaare	100 10 1 05
03160KB	Bypass Left Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
03100KB	Open Approach	Troccaure	100 10 1 05
03160KC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
03100KC	Substitute, Open Approach	Troccaure	100 10 1 05
03160Z0	Bypass Left Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z1	Bypass Left Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z3	Bypass Left Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z4	Bypass Left Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z6	Bypass Left Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z7	Bypass Left Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z9	Bypass Left Axillary Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZB	Bypass Left Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03170A0	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03170A3	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 785 of 990



		Code	
Code	Description	Category	Code Type
03170J0	Bypass Right Brachial Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03170J3	Bypass Right Brachial Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03170K0	Bypass Right Brachial Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03170K3	Bypass Right Brachial Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03170Z0	Bypass Right Brachial Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03170Z3	Bypass Right Brachial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180A1	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03180A4	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03180J1	Bypass Left Brachial Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03180J4	Bypass Left Brachial Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03180K1	Bypass Left Brachial Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03180K4	Bypass Left Brachial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03180Z1	Bypass Left Brachial Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180Z4	Bypass Left Brachial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03190A3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03190J3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03190K3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03190Z3	Bypass Right Ulnar Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031A094	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031A0A4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
031A0J4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031A0K4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031A0Z4	Bypass Left Ulnar Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031B093	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031B0A3	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 786 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
031B0J3	Bypass Right Radial Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
031B0K3	Bypass Right Radial Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
031B0Z3	Bypass Right Radial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031C094	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
031C0A4	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
031C0J4	Bypass Left Radial Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
031C0K4	Bypass Left Radial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
031C0Z4	Bypass Left Radial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
037304Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037305Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open	Dracadura	ICD-10-PCS
03/3032	Approach	Procedure	ICD-10-PC3
037306Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373002	Approach	riocedure	ICD-10-FC3
037307Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0373072	Open Approach	rroccaure	100 10 1 05
03730D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0070020	2. a.		.02 20 . 00
03730DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03730EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03730FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03730GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
0272076	Approach	5 1	100 40 000
03730Z6 03730ZZ	Dilation of Right Subclavian Artery, Bifurcation, Open Approach Dilation of Right Subclavian Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0373022 037334Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0070012	Approach		102 10 1 00
037335Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037336Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037337Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 787 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03733D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03733DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03733FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03733G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03733GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03733Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03733ZZ	Dilation of Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037344Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037345Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0373432	Percutaneous Endoscopic Approach	riocedure	ICD-10-PC3
037346Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0373402	Percutaneous Endoscopic Approach	rroccuare	100 101 05
037347Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0070172	Percutaneous Endoscopic Approach		.02 20 . 00
03734D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03734DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03734EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03734F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03734FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03734G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03734GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03734Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734ZZ 037404Z	Dilation of Right Subclavian Artery, Percutaneous Endoscopic Approach Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
U3/4U4Z	Disaction of Left Subclavian Aftery with Drug-eluting intratuminal Device, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 788 of 990



	·	Code	
Code	Description	Category	Code Type
037405Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037406Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037407Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740EZ 03740F6	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Open Approach Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03740FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740Z6	Dilation of Left Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03740ZZ	Dilation of Left Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037434Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037435Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037436Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037437Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03743DZ 03743EZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Approach Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03743F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03743ZZ	Dilation of Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037444Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 789 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	_Code Type
037445Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037446Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037447Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03744D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03744DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03744EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03744F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03744FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		100 10 000
03744G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0274467	Percutaneous Endoscopic Approach	Dunandous	ICD 40 DCC
03744GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0274476	Endoscopic Approach Dilation of Loft Subdayion Artery, Diffuseation, Description and Approach	Dragodura	ICD 10 DCS
03744Z6 03744ZZ	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach Dilation of Left Subclavian Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
037504Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037505Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037506Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037507Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03750D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750DZ	Dilation of Right Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		100 10 000
03750FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Open Approach Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
03750G6	Approach	Procedure	ICD-10-PCS
03750GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03/3002	Dilation of hight Axillary Artery with Four of More Intraluminal Devices, Open Approach	Procedure	1CD-10-4C2
03750Z6	Dilation of Right Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03750Z6 03750ZZ	Dilation of Right Axillary Artery, Open Approach	Procedure	ICD-10-PCS
0375022 037534Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 790 of 990



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037535Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous		ICD-10-PCS
	Approach		
037536Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037537Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03753D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03753DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03753EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03753FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03753GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03753Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03753ZZ	Dilation of Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037544Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037545Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0075467	Endoscopic Approach		100 10 000
037546Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0075477	Percutaneous Endoscopic Approach		100 10 000
037547Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0275406	Percutaneous Endoscopic Approach	Dunnandous	ICD 40 DCC
03754D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0275407	Endoscopic Approach	Dunnadii	ICD 10 DCC
03754DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0275457	Approach Pilation of Right Avillany Artery with Two Introluminal Povices, Persutaneous Endescenis	Dracadura	ICD 10 DCS
03754EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0275456		Procedure	ICD-10-PCS
03754F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
0275457	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD 10 BCS
03754FZ	Approach	i iocedule	ICD-10-PCS
0275466	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD 10 DCS
03754G6	Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754GZ	· ··	Procedure	ICD-10-PCS
03/3402	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	FIOCEGUIE	ICD-10-4C3
03754Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03/34/0	Direction of Night Ashiaty Artery, Directation, Percutaneous Effuoscopic Approach	riocedule	100-10-703

cder_mpl1p_wp077 Page 791 of 990



Troccuare	Codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03754ZZ	Dilation of Right Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037604Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037605Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037606Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037607Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760DZ	Dilation of Left Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760Z6	Dilation of Left Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03760ZZ	Dilation of Left Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037634Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037635Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037636Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037637Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763Z6 03763ZZ 037644Z	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Approach Dilation of Left Axillary Artery, Percutaneous Approach Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 792 of 990



	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037645Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037646Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Drocadura	ICD-10-PCS
0370402	Endoscopic Approach	rrocedure	ICD-10-I C3
037647Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03764D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03764DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03764EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03764F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0276457	Endoscopic Approach		100 40 000
03764FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
03764G6	Approach Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0370400	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
03764GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070102	Endoscopic Approach	rioccaare	102 10 1 03
03764Z6	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764ZZ	Dilation of Left Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037704Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037705Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037706Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037707Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03770D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770DZ	Dilation of Right Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03770FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0277067	Open Approach	Dunnadium	ICD 10 DCC
03770GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770Z6	Dilation of Right Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03770ZZ	Dilation of Right Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037734Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 793 of 990



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037735Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037736Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037737Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03773D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03773DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03773EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03773FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03773GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03773Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03773ZZ	Dilation of Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037744Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0277457	Endoscopic Approach Dilation of Right Brechiel Arten with Two Drug electing Introluminal Devices	Dracadura	ICD 10 DCC
037745Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
037746Z	Percutaneous Endoscopic Approach Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0377402	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
037747Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
03//4/2	Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
03774D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0377400	Endoscopic Approach	rroccuare	100 101 05
03774DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0077.52	Approach		.02 20 . 00
03774EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03774F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03774FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03774G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03774GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03774Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 794 of 990



	·	Code	
Code	Description	Category	Code Type
03774ZZ	Dilation of Right Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037804Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037805Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037806Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037807Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780DZ	Dilation of Left Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780Z6	Dilation of Left Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03780ZZ	Dilation of Left Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037834Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037835Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037836Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037837Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03783ZZ	Dilation of Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 795 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037844Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037845Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037846Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037847Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03784D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03784DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03784EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03784F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03784FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03784G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03784GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03784Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784ZZ	Dilation of Left Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037904Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037905Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037906Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373002	Approach	rroccaure	100 10 1 05
037907Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
00,30,2	Approach	rroccaare	102 10 1 03
03790D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03790DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03790EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03790FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03790GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790Z6	Dilation of Right Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03790ZZ	Dilation of Right Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
037934Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 796 of 990



riocedure	Codes osed to Define basefine Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037935Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037936Z		Procedure	ICD-10-PCS
	Approach		
037937Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03793D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03793DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03793EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03793FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03793GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03793Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03793ZZ	Dilation of Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037944Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach	_	
037945Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach	_	
037946Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037947Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03794D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03794DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0070457	Approach	5 .	100 40 000
03794EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0270456	Approach	5 .	100 40 000
03794F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0270457	Endoscopic Approach Dilation of Right I lang Arten with Three Introluminal Devices Percutanceus Endoscopie	Dragoduro	ICD 10 DCC
03794FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0270466	Approach	Dunnadii	ICD 10 DCC
03794G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0270467	Percutaneous Endoscopic Approach Dilation of Bight I llags Astony with Four or Mare Introluminal Devices Percutaneous	Drooseline	ICD 10 DCC
03794GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0270476	Endoscopic Approach	Drooseline	ICD 10 DCC
03794Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 797 of 990



Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1	
Dilation of Right Ulnar Artery, Percutaneous Endoscopic Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, With Drug-e	Type
Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, De	
Approach Dilation of Left Ulnar Artery, Bifurcation, with Tree Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation of L	
Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach Open Approach Open Approach Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Open Approach Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Open Approach Open Approach Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Open Approach Open Approach Open Approach Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach O37A0FZ Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach O37A0GZ Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Di	
Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Depart Approach	O-DCS
Open Approach Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach Open Approach Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Open Approach Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach Oilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilati	
Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open A	J-1 C3
037A066 Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach 037A06Z Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach Procedure ICD-1 037A076 Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach 037A07Z Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach 037A07Z Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach 037A0D6 Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach 037A0D7 Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach 037A0E6 Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach 037A0E7 Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, 03F0E0E0E0E0E0E0E0E0E0E0E0E0E0E0E0E0E0E0	0 DCC
Open Approach Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach Procedure ICD-1 Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Procedure ICD-1 Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of	J-PCS
Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1	0-PCS
Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1	
Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach	0-PCS
Devices, Open Approach 037A07Z Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach 037A0D6 Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach 037A0D7 Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach 037A0E6 Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach 037A0E7 Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach 037A0F6 Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach 037A0F7 Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach 037A0F8 Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach 037A0F9 Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach 037A0F0 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F0 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F2 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F0 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, 037A0F1 Procedure ICD-1 037A0F2 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0F2 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0F2 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0F1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	
Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, With Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Den Approach Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, Procedure ICD-1	0-PCS
Approach 037A0D6 Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach 037A0D7 Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach 037A0E6 Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach 037A0E7 Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach 037A0E8 Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach 037A0E9 Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach 037A0E9 Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach 037A0E9 Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach 037A0E0 Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach 037A0E0 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0E1 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0E1 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0E2 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0E1 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0E1 Dilation of Left Ulnar Artery, Deen Approach 037A0E2 Dilation of Left Ulnar Artery, Bifurcation, With Drug-eluting Intraluminal Device, 037A0E2 Procedure ICD-1 037A0E2 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 037A0E2 Procedure ICD-1 037A0E2 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, 03FOPEN Approach	
037A0D6Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open ApproachProcedureICD-1037A0D2Dilation of Left Ulnar Artery with Intraluminal Device, Open ApproachProcedureICD-1037A0E6Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open ApproachProcedureICD-1037A0EZDilation of Left Ulnar Artery with Two Intraluminal Devices, Open ApproachProcedureICD-1037A0F6Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open ApproachProcedureICD-1037A0F7Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open ApproachProcedureICD-1037A0G6Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open ApproachProcedureICD-1037A0G7Dilation of Left Ulnar Artery, Bifurcation, Open ApproachProcedureICD-1037A0Z6Dilation of Left Ulnar Artery, Bifurcation, Open ApproachProcedureICD-1037A0Z7Dilation of Left Ulnar Artery, Open ApproachProcedureICD-1037A0346Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous ApproachProcedureICD-1	0-PCS
037A0D6Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open ApproachProcedureICD-1037A0D2Dilation of Left Ulnar Artery with Intraluminal Device, Open ApproachProcedureICD-1037A0E6Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open ApproachProcedureICD-1037A0EZDilation of Left Ulnar Artery with Two Intraluminal Devices, Open ApproachProcedureICD-1037A0F6Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open ApproachProcedureICD-1037A0F7Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open ApproachProcedureICD-1037A0G6Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open ApproachProcedureICD-1037A0G7Dilation of Left Ulnar Artery, Bifurcation, Open ApproachProcedureICD-1037A0Z6Dilation of Left Ulnar Artery, Bifurcation, Open ApproachProcedureICD-1037A0Z7Dilation of Left Ulnar Artery, Open ApproachProcedureICD-1037A0346Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous ApproachProcedureICD-1	
Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1	0-PCS
Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Deen Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Dilation Of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	
Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	0-PCS
Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	
Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	0-PCS
037A0FZ Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	0-PCS
Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Deen Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Deen Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	
Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach Dilation of Left Ulnar Artery, Bifurcation, Open Approach Dilation of Left Ulnar Artery, Deen Approach Dilation of Left Ulnar Artery, Open Approach Dilation of Left Ulnar Artery, Deen Approach Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	0-PCS
Approach 037A0GZ Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach 037A0Z6 Dilation of Left Ulnar Artery, Bifurcation, Open Approach 037A0ZZ Dilation of Left Ulnar Artery, Open Approach 037A346 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 037A346 Percutaneous Approach	0-PCS
037A0GZDilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open ApproachProcedureICD-1037A0Z6Dilation of Left Ulnar Artery, Bifurcation, Open ApproachProcedureICD-1037A0ZZDilation of Left Ulnar Artery, Open ApproachProcedureICD-1037A346Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous ApproachProcedureICD-1	
037A0Z6Dilation of Left Ulnar Artery, Bifurcation, Open ApproachProcedureICD-1037A0ZZDilation of Left Ulnar Artery, Open ApproachProcedureICD-1037A346Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous ApproachProcedureICD-1	0-PCS
037A0ZZ Dilation of Left Ulnar Artery, Open Approach 037A346 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach Procedure ICD-1 ICD-1	
037A346 Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Procedure ICD-1 Percutaneous Approach	
	0-PCS
037A34Z Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Procedure ICD-1	0-PCS
Approach	
037A356 Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Procedure ICD-1	0-PCS
Percutaneous Approach	J . CS
	0-PCS
	J-PC3
Approach	0 DCC
037A366 Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Procedure ICD-1	J-PCS
Percutaneous Approach	
037A36Z Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Procedure ICD-1	J-PCS
Approach	
037A376 Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Procedure ICD-1	0-PCS
Devices, Percutaneous Approach	
037A37Z Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Procedure ICD-1	J-PCS
Percutaneous Approach	

cder_mpl1p_wp077 Page 798 of 990



Trocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037A3D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037A3DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A3E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0074057	Approach		ICD 40 DCC
037A3EZ 037A3F6	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS ICD-10-PCS
USTASFO	Approach	Procedure	ICD-10-PC3
037A3FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037A3GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037A3Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037A3ZZ	Dilation of Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037A446	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A44Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0377442	Endoscopic Approach	Trocedure	10-10-1 03
037A456	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A45Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A466	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A46Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A476	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
037A47Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0274406	Percutaneous Endoscopic Approach Dilation of Left Ulary Artery, Diffusion, with Introluminal Device, Percutaneous	Dragodura	ICD 10 DCS
037A4D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377402	bilation of Left offiar Artery with intratumnal bevice, refeatalleous Endoscopic Approach	Trocedure	10-10-1 03
037A4E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
00////20	Endoscopic Approach		.02 20 . 00
037A4EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
037A4F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A4FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 799 of 990



		Code	
Code	Description	Category	Code Type
037A4G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A4GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A4Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4ZZ	Dilation of Left Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B046	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
037B04Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B056	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
037B05Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037B066	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
037B06Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037B076	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
037B07Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037B0D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0DZ	Dilation of Right Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037B0FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037B0GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0Z6	Dilation of Right Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037B0ZZ	Dilation of Right Radial Artery, Open Approach	Procedure	ICD-10-PCS
037B346	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037B34Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037B356	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037B35Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 800 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037B366	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B36Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B376	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B37Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B3DZ 037B3E6	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
037B3EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037B3ZZ	Dilation of Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037B446	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B44Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B456	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B45Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B466	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B46Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B476	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B47Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 801 of 990



		Code	
Code	Description	Category	Code Type
037B4DZ	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4ZZ	Dilation of Right Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C046	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C04Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C056	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C05Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C066	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C06Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C076	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C07Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0DZ	Dilation of Left Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0Z6	Dilation of Left Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037C0ZZ	Dilation of Left Radial Artery, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 802 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037C346	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C34Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C356	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C35Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C366	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C36Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C376	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
037C37Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C3D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0276207	Approach	Dun and	ICD 40 DCC
037C3DZ 037C3E6	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Approach Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03/03E0	Approach	Procedure	ICD-10-PC3
037C3EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3E2	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C3FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
	,		
037C3G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C3GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C3Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037C3ZZ	Dilation of Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037C446	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037C44Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0070456	Endoscopic Approach		100 40 000
037C456	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0276457	Percutaneous Endoscopic Approach	Duagadiina	ICD 10 DCC
037C45Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0270466	Endoscopic Approach Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Drocedure	ICD-10-PCS
037C466	Percutaneous Endoscopic Approach	Procedure	ICD-10-5C3
037C46Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0370402	Endoscopic Approach	rioccuure	100 10-1 03
	Zinacocci, i ppi oddii		

cder_mpl1p_wp077 Page 803 of 990



riocedure	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037C476	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
037C47Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037C4D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0070407	Endoscopic Approach		ICD 40 DCC
037C4DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
037 C4E0	Endoscopic Approach	Trocedure	10-10-1 03
037C4EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
037C4F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037C4FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
037C4G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0276467	Percutaneous Endoscopic Approach	Dunnadiina	ICD 10 DCC
037C4GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4ZZ	Dilation of Left Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D046	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
037D04Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D056	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
037D05Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D066	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0370000	Open Approach	Procedure	ICD-10-PC3
037D06Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
007,0002	Approach	1100004110	105 10 1 05
037D076	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
037D07Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037D0D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0DZ	Dilation of Right Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0EZ 037D0F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 804 of 990



		Code	
Code	Description	Category	Code Type
037D0FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037D0GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0Z6	Dilation of Right Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037D0ZZ	Dilation of Right Hand Artery, Open Approach	Procedure	ICD-10-PCS
037D346	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037D34Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D356	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037D35Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D366	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037D36Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037D376	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
037D37Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037D3D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037D3DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D3E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070057	Approach	5 1	100 40 000
037D3EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037D3FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037D3GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0072002	Approach		.02 20 . 00
037D3Z6	Dilation of Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037D3ZZ	Dilation of Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037D446	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037D44Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 805 of 990



riocedure	Codes Osed to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037D456	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D45Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D466	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D46Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D476	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D47Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4Z6 037D4ZZ 037F046	Dilation of Right Hand Artery, Bifurcation, Percutaneous Endoscopic Approach Dilation of Right Hand Artery, Percutaneous Endoscopic Approach Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
037F04Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F056	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F05Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F066	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F06Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 806 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037F076	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F07Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0DZ	Dilation of Left Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0Z6	Dilation of Left Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037F0ZZ	Dilation of Left Hand Artery, Open Approach	Procedure	ICD-10-PCS
037F346	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F34Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F356	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F35Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F366	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F36Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F376	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F37Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 807 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037F3GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037F3Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037F3ZZ	Dilation of Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037F446	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037F44Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037F456	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F45Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F466	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F46Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F476	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F47Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4ZZ	Dilation of Left Hand Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03C33Z6	Extirpation of Matter from Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C33ZZ	Extirpation of Matter from Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C43Z6	Extirpation of Matter from Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C43ZZ	Extirpation of Matter from Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 808 of 990



Procedure	Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03C53Z6	Extirpation of Matter from Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C53ZZ	Extirpation of Matter from Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C63Z6	Extirpation of Matter from Left Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C63ZZ	Extirpation of Matter from Left Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C73Z6	Extirpation of Matter from Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
	γ,		
03C73ZZ	Extirpation of Matter from Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C83Z6	Extirpation of Matter from Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C83ZZ	Extirpation of Matter from Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C93Z6	Extirpation of Matter from Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C93ZZ	Extirpation of Matter from Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3Z6	Extirpation of Matter from Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3ZZ	Extirpation of Matter from Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3Z6	Extirpation of Matter from Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3ZZ	Extirpation of Matter from Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3Z6	Extirpation of Matter from Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3ZZ	Extirpation of Matter from Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3Z6	Extirpation of Matter from Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3ZZ	Extirpation of Matter from Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3Z6	Extirpation of Matter from Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3ZZ	Extirpation of Matter from Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
041009B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041009C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041009D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041009F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
0.12000.	Approach		.02 20 . 00
041009G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0120050	Open Approach	110000010	100 10 1 00
041009H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
04100311	Approach	Troccaure	100 101 05
0410001		Dracadura	ICD 10 DCC
041009J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
0.44.0001/	Approach		100 10 000
041009K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041009Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
5.200/1/	Open Approach		.02 10 1 00
0410049		Drocodura	ICD 10 DCs
04100A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		

cder_mpl1p_wp077 Page 809 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04100A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
0440046	Approach	5 1	100 40 000
04100AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04100AH	Open Approach Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
04100AH	Approach	Procedure	ICD-10-PC3
04100AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
04100/0	Approach	rroccaare	100 101 05
04100AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100AR	Bypass Abdominal Aorta to Lower Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
0410010	Open Approach	Duagadiina	ICD 10 DCC
04100J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0410010	Approach	riocedure	ICD-10-FC3
04100JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0.12000	Approach		.02 20 . 00
04100JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 810 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04100JK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0.1200	Approach		.02 20 . 00
04100JQ	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
04100KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
04100KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
04100KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
04100KR	Bypass Abdominal Aorta to Lower Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
0440070			100 10 000
04100Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
0410070	Dunges Abdominal Aarta to Loft Internal Ilias Artany, Oraci Amarasah	Droopaliina	ICD 10 DCC
04100ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
0/10070	Punace Abdominal Aorta to Bilatoral Internal Iliae Arterios Open Approach	Drocodura	ICD 10 DCS
04100ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 811 of 990



Procedure (Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04100ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZH	Bypass Abdominal Aorta to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100211	bypass Abdominal Act to Right Femoral Artery, Open Approach	Trocedure	1CD-10-1 C3
04100ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
0440070			100 10 000
04100ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041049B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0 120 135	Percutaneous Endoscopic Approach	Troccaure	102 10 1 00
041049C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041049D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041049F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
041049G	Percutaneous Endoscopic Approach Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue,	Dracadura	ICD-10-PCS
0410490	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
041049H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041049J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041049K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0440400	Percutaneous Endoscopic Approach		100 40 000
041049Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04104710	Percutaneous Endoscopic Approach	Troccaure	100 10 1 03
04104A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
04104A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0410440	Percutaneous Endoscopic Approach Punass Andominal Aceta to Loft Internal Ilias Arteny with Autologous Arterial Tissue	Dracadura	ICD 10 DCS
04104AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
-	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 812 of 990



Trocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04104AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach	_	
04104JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
0440410	Percutaneous Endoscopic Approach		100 10 000
04104JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0440415	Percutaneous Endoscopic Approach	Dualandona	ICD 40 DCC
04104JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0440416	Percutaneous Endoscopic Approach	Dun and duna	ICD 40 DCC
04104JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
04404111	Percutaneous Endoscopic Approach	Duesedine	ICD 10 DCC
04104JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
0410411	Endoscopic Approach Propose Abdominal Agesta to Left Formaral Astory with Synthetic Sylbatitute, Persyltaneous	Drocoduro	ICD 10 DCC
04104JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
0410416	Endoscopic Approach Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute,	Drocoduro	ICD 10 DCC
04104JK	Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410410	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD 10 DCS
04104JQ	Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0410410	Substitute, Percutaneous Endoscopic Approach	TOCCUUIC	1CD-10-FC3
04104K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0710 7 1(/	Substitute, Percutaneous Endoscopic Approach	Toccuure	100 10-1 03
	Substitute, i creaturicous Enaoscopie Approach		

cder_mpl1p_wp077 Page 813 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04104K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0440440	Substitute, Percutaneous Endoscopic Approach		100 10 000
04104KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
04104KC	Substitute, Percutaneous Endoscopic Approach Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
04104KC	Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
04104KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0410410	Substitute, Percutaneous Endoscopic Approach	rroccaarc	100 10 1 05
04104KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
0410460	Substitute, Percutaneous Endoscopic Approach Diverses Abdominal Agesta to Louver Extremity Actor with Nangutalagous Tissue Substitute	Dragodura	ICD 10 DCS
04104KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0410420	Approach	rroccaare	100 10 1 03
04104Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04104Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410476	Dunass Abdaminal Aarta to Bilatoral Internal Ilias Artarias Dargutanagus Endasgania	Dragodura	ICD 10 DCS
04104ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410425	bypass / Isaa / Imar / Isaa la Ingine External mae / Itery, i ereataneous Enaoscopie / Ippi ouen	rroccaare	100 10 1 05
04104ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04104ZH	Bypass Abdominal Aorta to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 814 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04104ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04104ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C09H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041C09J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041C09K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041C0AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041C0AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041C0AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041C0JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041C0JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041C0JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041C0KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041C0KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041C0KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041C0ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041C49H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0446401	Percutaneous Endoscopic Approach	5 1	100 40 000
041C49J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0446401/	Percutaneous Endoscopic Approach	5 1	100 40 000
041C49K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
04464411	Tissue, Percutaneous Endoscopic Approach	Dunanalisa	ICD 40 DCC
041C4AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0446441	Percutaneous Endoscopic Approach	Dunanalisa	ICD 40 DCC
041C4AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0416441	Percutaneous Endoscopic Approach	Dragodii	ICD 10 DCC
041C4AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 815 of 990



		Code	
Code	Description	Category	Code Type
041C4JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D09H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D09J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D09K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0ZH 041D0ZJ	Bypass Left Common Iliac Artery to Right Femoral Artery, Open Approach Bypass Left Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 816 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041D0ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041D49H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041D49J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041D49K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041D4AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0445441	Percutaneous Endoscopic Approach		160 40 066
041D4AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0410441	Percutaneous Endoscopic Approach	Duanadiina	ICD 10 DCC
041D4AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
041D4JH	Tissue, Percutaneous Endoscopic Approach Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
04104111	Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
041D4JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0410433	Percutaneous Endoscopic Approach	rroccaare	100 10 1 05
041D4JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
0.120.0.0	Percutaneous Endoscopic Approach		.02 20 : 00
041D4KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041D4KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041D4KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041D4ZH	Bypass Left Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041D4ZJ	Bypass Left Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041D4ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041E09H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0445001	Open Approach		100 10 000
041E09J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0445001/	Open Approach	Dunnalium	ICD 10 DCC
041E09K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
04150411	Tissue, Open Approach Propose Right Internal High Arter to Right Femoral Arter with Autologous Arterial Tissue.	Dracadura	ICD 10 DCS
041E0AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
OTILUMI	Open Approach	Trocedure	1CD-10-LC3
041E0AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
O-TILUMN	Tissue, Open Approach	rioccuure	1CD 10-1 C3
	11334C) Open Approach		

cder_mpl1p_wp077 Page 817 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041E0JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041E0JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041E0JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041E0KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041E0KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.44.501/1/	Substitute, Open Approach	5 .	100 40 000
041E0KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
041E0ZH	Substitute, Open Approach Bypass Right Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD 10 DCS
041E0ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS ICD-10-PCS
041E0ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041E49H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E49J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E49K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041E4AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041E4JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041E4KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041E4KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
04454711	Substitute, Percutaneous Endoscopic Approach		105 10 500
041E4ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0445471	Approach	Dun I	100 40 500
041E4ZJ	Bypass Right Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 818 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041E4ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F09H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F09J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F09K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0ZH 041F0ZJ 041F0ZK 041F49H	Bypass Left Internal Iliac Artery to Right Femoral Artery, Open Approach Bypass Left Internal Iliac Artery to Left Femoral Artery, Open Approach Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
041F49J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F49K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 819 of 990



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041F4JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F4JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F4KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041F4KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H09H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041H0ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041H0ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 820 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041H49H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H49J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H49K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
D41H4JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J09H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J09J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J09K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 821 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041J0JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041J0JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041J0JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041J0KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.4.4.1.01.4.1	Substitute, Open Approach		100 10 000
041J0KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.44.101/1/	Substitute, Open Approach	Dan and an	ICD 40 DCC
041J0KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZH 041J0ZJ	Bypass Left External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041J49H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J49J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J49K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041J4AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041J4JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		100 10 000
041J4KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
044141414	Substitute, Percutaneous Endoscopic Approach	Dun on de con	ICD 40 DCC
041J4KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
04414711	Substitute, Percutaneous Endoscopic Approach	Dragodura	ICD 10 DCC
041J4ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Drocodure	ICD-10 PCS
J+1J4∠J	Approach	Procedure	ICD-10-PCS
	Αμφισακίι		

cder_mpl1p_wp077 Page 822 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041J4ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K09H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 823 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	C- d-	
C- d-	Description	Code	Code Tune
Code	Description	Category	Code Type
041K0JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041KOJN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0ZH	Bypass Right Femoral Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041K0ZL	Bypass Right Femoral Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZM	Bypass Right Femoral Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZN	Bypass Right Femoral Artery to Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZP	Bypass Right Femoral Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZQ	Bypass Right Femoral Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041K49H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 824 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	_Code Type
041K49K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 825 of 990



Tocedure	Codes Osed to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041K4JN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZH	Bypass Right Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZL 041K4ZM 041K4ZN	Bypass Right Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach Bypass Right Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach Bypass Right Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
041K4ZP 041K4ZQ	Bypass Right Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach Bypass Right Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041K4ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 826 of 990



Frocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041L09H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041LOJJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 827 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041L0JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JP 041L0JQ	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041L0JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
041L0ZH	Substitute, Open Approach Bypass Left Femoral Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZJ 041L0ZK	Bypass Left Femoral Artery to Left Femoral Artery, Open Approach Bypass Left Femoral Artery to Bilateral Femoral Arteries, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041L0ZL	Bypass Left Femoral Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZM	Bypass Left Femoral Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZP	Bypass Left Femoral Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041L49H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 828 of 990



Fiocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041L49L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L49M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L49N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L49P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041L49Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04414444	Percutaneous Endoscopic Approach	5 .	ICD 40 DCC
041L4AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0411400	Percutaneous Endoscopic Approach Disposal off Formaral Astory to Postarior Tibial Astory with Autologous Astorial Tissue	Dragodura	ICD 10 DCS
041L4AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
041L4AF	Endoscopic Approach	riocedule	ICD-10-FC3
041L4AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
01121710	Percutaneous Endoscopic Approach	rroccaare	105 10 1 05
041L4AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041L4JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041L4JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041L4JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JP	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 829 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041L4JQ	Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
•	Percutaneous Endoscopic Approach		
041L4JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041L4KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041L4KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041L4KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041L4ZH	Bypass Left Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZJ	Bypass Left Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0441.471/	Described Francisco Antonio de Dileteral Francisco Described and Francisco	Dunnali	ICD 10 DCC
041L4ZK	Bypass Left Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
041L4ZL	Approach Bypass Left Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZL 041L4ZM	Bypass Left Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
041L4ZP	Bypass Left Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041L4ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M09L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041M09M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041M09P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 830 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041M09Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041M09S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041M0AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041M0AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041M0AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
04414040	Approach	Dunanda	ICD 40 DCC
041M0AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
041IVIOA3	Open Approach	riocedule	ICD-10-FC3
041M0JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0 .2002	Approach		.02 20 . 00
041M0JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041M0JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041M0JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0.44.8.401/1	Approach	Dunanda	ICD 40 DCC
041M0KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
041M0KM	Open Approach Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
OTIVIORIVI	Open Approach	Troccaure	100 101 05
041M0KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041M0KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041M0KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041M0ZL	Bypass Right Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZM	Bypass Right Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZP 041M0ZQ	Bypass Right Popliteal Artery to Foot Artery, Open Approach Bypass Right Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041M0ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041M49L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M49M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 831 of 990



		Code	
Code	Description	Category	Code Type
041M49P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041M49Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M49S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M4AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M4AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0448448	Percutaneous Endoscopic Approach		100 40 000
041M4AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
04114440	Endoscopic Approach Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Dragodura	ICD 10 DCS
041M4AQ	Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
U4IIVI4A3	Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
041M4JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
0 12111 132	Endoscopic Approach	110000010	100 101 00
041M4JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041M4JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041M4JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M4JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M4KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M4KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041M4KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		100 10 000
041M4KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
04414446	Substitute, Percutaneous Endoscopic Approach	Dunnadiiina	ICD 10 DCC
041M4KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
04114471	Substitute, Percutaneous Endoscopic Approach Bypass Right Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD 10 DCS
041M4ZL	bypass Right Pophiteal Artery to Pophiteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZM	Bypass Right Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZP	Bypass Right Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZQ	Bypass Right Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041M4ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 832 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041N09L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041N09M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JP 041N0JQ	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041N0JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0ZL	Bypass Left Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZM	Bypass Left Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZP	Bypass Left Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 833 of 990



	Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041N49L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N49M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N49P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
04444400	Percutaneous Endoscopic Approach		100 10 000
041N49S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
044N4AD	Percutaneous Endoscopic Approach	Duanadiina	ICD 10 DCC
041N4AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		100 10 000
041N4AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
J41N4JL	Endoscopic Approach	riocedule	ICD-10-PC3
041N4JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
5-111-13111	Endoscopic Approach	Troccaure	100 101 05
041N4JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041N4JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041N4KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
244 NI 471	Substitute, Percutaneous Endoscopic Approach	D !	100 40 500
041N4ZL	Bypass Left Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach Bypass Left Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041N4ZM 041N4ZP	Bypass Left Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach Bypass Left Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
O 1111-761	Sypuss Lett : Spirited in the year of the factory, it creatained as Emasteopic Approach	. roccaure	.05 10 1 05

cder_mpl1p_wp077 Page 834 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041N4ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041N4ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T09P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
0447000	Approach	Dunnadiiina	ICD 10 DCC
041T09Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T09S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0447010	Open Approach	Dunandous	ICD 40 DCC
041T0JP 041T0JQ	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041103Q	Approach	rroccuure	100-10-1 03
041T0JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041T0KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0ZP	Bypass Right Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041T49P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041T4AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 835 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041T4JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041T4JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
0447440	Percutaneous Endoscopic Approach		100 10 000
041T4KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041T4KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041T4ZP	Bypass Right Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0.1	Approach		.02 20 . 00
041U09P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041U09Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.4411000	Open Approach	5 1	ICD 40 DCC
041U09S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041U0AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041U0AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
041U0JP	Open Approach Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0JP 041U0JQ	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Open Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041U0JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041U0KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
041U0KQ	Approach Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
04100KQ	Substitute, Open Approach	Troccaure	100 101 05
041U0KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041U0ZP	Bypass Left Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZS 041U49P	Bypass Left Peroneal Artery to Lower Extremity Vein, Open Approach Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous	Procedure Procedure	ICD-10-PCS ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 836 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041U49Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U49S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U4AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0.200	Percutaneous Endoscopic Approach		.02 20 . 00
041U4JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041U4JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U4JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U4KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U4KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041U4KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
04411470	Substitute, Percutaneous Endoscopic Approach	Duanadiina	ICD 10 DCC
041U4ZP 041U4ZQ	Bypass Left Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach Bypass Left Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0410420	Approach	Troccaure	100 101 05
041U4ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V09P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V09Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041V09S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041V0AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041V0AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open	Procedure	ICD-10-PCS
505	Approach		

cder_mpl1p_wp077 Page 837 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041V0KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041V0KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0ZP	Bypass Right Foot Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZS	Bypass Right Foot Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041V49P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZP 041V4ZQ	Bypass Right Foot Artery to Foot Artery, Percutaneous Endoscopic Approach Bypass Right Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
3-1 V-72Q	Sypossing Oot fittery to Lower Extremity Artery, refeatureous Emoscopic Approach	. roccaure	10 103
041V4ZS	Bypass Right Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W09P	Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W09Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 838 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Codo	
Code	Description	Code Category	Code Type
041W09S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
04111033	Approach	rrocedure	1CD-10-1 C3
041W0AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0JP 041W0JQ	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041W0JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0ZP 041W0ZQ 041W0ZS 041W49P	Bypass Left Foot Artery to Foot Artery, Open Approach Bypass Left Foot Artery to Lower Extremity Artery, Open Approach Bypass Left Foot Artery to Lower Extremity Vein, Open Approach Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
041W49Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W49S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JP	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JQ	Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 839 of 990



Procedure	Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041W4KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041W4KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZP	Bypass Left Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZQ	Bypass Left Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZS	Bypass Left Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
04700F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700Z6	Dilation of Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04703D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04703F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04703G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04704D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0.470.456	Endoscopic Approach		105 10 500
04704F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C041	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Open Approach		
047C046	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C04Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C056	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C05Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C066	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C06Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 840 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Codo	
Codo	Description	Code	Codo Tuno
Code 047C076	Description Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	Code Type ICD-10-PCS
0470076	Intraluminal Devices, Open Approach	Procedure	ICD-10-PC3
047C07Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C0D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C0DZ 047C0E6	Dilation of Right Common Iliac Artery with Intraluminal Device, Open Approach Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047C0EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0Z1 047C0Z6 047C0ZZ 047C341	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Open Approach Dilation of Right Common Iliac Artery, Bifurcation, Open Approach Dilation of Right Common Iliac Artery, Open Approach Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
047C346	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C34Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C356	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C35Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C366	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C36Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C376	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C37Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 841 of 990



rocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047C3D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
0476206	Balloon, Percutaneous Approach	Dunandana	ICD 40 DCC
047C3D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C3Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047C3ZZ 047C441	Dilation of Right Common Iliac Artery, Percutaneous Approach Dilation of Right Common Iliac Artery with Drug eluting Introducing Davise, using Drug	Procedure	ICD-10-PCS ICD-10-PCS
047C441	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
047C446	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C44Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C456	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C45Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C466	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C46Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C476	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C47Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 842 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047C4D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4ZZ 047D041	Dilation of Right Common Iliac Artery, Percutaneous Endoscopic Approach Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047D046	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D04Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D056	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D05Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D066	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D06Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D076	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D07Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 843 of 990



	·	Code	
Code	Description	Category	Code Type
047D0D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047D0Z6	Dilation of Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047D0ZZ	Dilation of Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047D341	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D346	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D34Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D356	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D35Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D366	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D36Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D376	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D37Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 844 of 990



Toccaute	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047D3EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z6 047D3ZZ 047D441	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Approach Dilation of Left Common Iliac Artery, Percutaneous Approach Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
047D446	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D44Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D456	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D45Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D466	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D46Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D476	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D47Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 845 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Codo	
Code	Description	Code	Codo Typo
047D4F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Category Procedure	_Code Type ICD-10-PCS
04704F0	Percutaneous Endoscopic Approach	riocedure	ICD-10-PC3
047D4FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z6	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4ZZ 047E04Z	Dilation of Left Common Iliac Artery, Percutaneous Endoscopic Approach Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047E05Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E06Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E07Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E0D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E0DZ 047E0E6	Dilation of Right Internal Iliac Artery with Intraluminal Device, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047E0EZ 047E0F6	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047E0FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0Z1 047E0Z6 047E0ZZ 047E341	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, Open Approach Dilation of Right Internal Iliac Artery, Open Approach Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 846 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047E346	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047E34Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E356	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E35Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E366	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E36Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E376	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E37Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047E3ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047E441	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E446	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 847 of 990



riocedure	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047E44Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047E456	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047E45Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047E466	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0.475.467	Devices, Percutaneous Endoscopic Approach		100 40 000
047E46Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0475476	Percutaneous Endoscopic Approach	Dracadura	ICD 10 DCS
047E476	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E47Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0471472	Percutaneous Endoscopic Approach	Trocedure	1CD-10-1 C3
047E4D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
•	Percutaneous Endoscopic Approach		
047E4D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047E4DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047E4E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047E4EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047E4F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0.475.457	Percutaneous Endoscopic Approach	Danasakaa	ICD 40 DCC
047E4FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0471400	Percutaneous Endoscopic Approach	Trocedure	1CD-10-1 C3
047E4GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0.72.02	Percutaneous Endoscopic Approach		.02 20 . 00
047E4Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047E4Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F041	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Open Approach		
047F046	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0475047	Open Approach Pilotion of Left Internal Ilian Actors with Drug cluting Introluminal Davise, Open Approach	Droopaliina	ICD 10 DCC
047F04Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 848 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047F056	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047F05Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F066	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047F06Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F076	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
047F07Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047F0D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Open Approach		
047F0D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F0EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
0475057	Approach	Duanadiina	ICD 10 DCC
047F0FZ 047F0G6	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Open Approach Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0471000	Open Approach	Troccaure	100 10 1 05
047F0GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
0471002	Approach	Troccaure	100 10 1 05
047F0Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F0Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047F0ZZ	Dilation of Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047F341	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047F346	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F34Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047F356	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047F35Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F366	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047F36Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 849 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047F376	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
047F37Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F3D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F3D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047F3DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F3EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047F3F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F3FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0.4750.00	Approach		100 10 000
047F3G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0475267	Percutaneous Approach	Dun du	ICD 40 DCC
047F3GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0475271	Approach Dilation of Loft Internal Ilias Artery using Drug Coated Balloon, Bergytoneous Approach	Dracadura	ICD 10 DCS
047F3Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047F3ZZ	Dilation of Left Internal Iliac Artery, Bridication, Fercutaneous Approach	Procedure	ICD-10-PCS
047F441	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Endoscopic Approach		
047F446	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F44Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047F456	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047F45Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F466	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047F46Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F476	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 850 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047F47Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F4D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F4D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047F4DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
047F4E6	Approach Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
04/F4E0	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
047F4EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
04714LZ	Endoscopic Approach	riocedure	ICD-10-FC3
047F4F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		.02 20 . 00
047F4FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047F4G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F4GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047F4Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0.175.176	Approach		100 10 000
047F4Z6 047F4ZZ	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach Dilation of Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0471422 047H041	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Open Approach		
047H046	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
047H04Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047H056	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047H05Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0.4711066	Approach	5 1	10D 40 D66
047H066	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
047H06Z	Devices, Open Approach Dilation of Right External Ilias Artery with Three Drug cluting Intraluminal Devices. Open	Dracadura	ICD 10 DCS
04711002	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H076	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
34711070	Intraluminal Devices, Open Approach	. roccaure	.00 10103
047H07Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
- '	Open Approach		
U4/NU/Z		rrocedure	ICD-10-PC2

cder_mpl1p_wp077 Page 851 of 990



Tocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047H0D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0Z6	Dilation of Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047H0ZZ 047H341	Dilation of Right External Iliac Artery, Open Approach Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure Procedure	ICD-10-PCS ICD-10-PCS
04/11341	Coated Balloon, Percutaneous Approach	riocedure	ICD-10-PC3
047H346	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H34Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H356	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H35Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H366	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H36Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H376	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H37Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H3DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 852 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047H3E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047H3EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047H3F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047H3FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047H3G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047H3GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047H3Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047H3ZZ	Dilation of Right External Iliac Artery, Percutaneous Approach	Procedure Procedure	ICD-10-PCS
047H441	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H446	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
04711440	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
047H44Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
04711442	Endoscopic Approach	riocedure	ICD-10-FC3
047H456	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
04711450	Devices, Percutaneous Endoscopic Approach	rroccaare	100 10 1 03
047H45Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0 1711.102	Percutaneous Endoscopic Approach		.02 20 . 00
047H466	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047H46Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047H476	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
047H47Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047H4D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047H4D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047H4DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047H4E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 853 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047H4EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0.4711.456	Endoscopic Approach		105 40 500
047H4F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4ZZ	Dilation of Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J041	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J046	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J04Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J056	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J05Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J066	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J06Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J076	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J07Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J0DZ 047J0E6	Dilation of Left External Iliac Artery with Intraluminal Device, Open Approach Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047J0EZ 047J0F6	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Open Approach Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 854 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047J0FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047J0GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047J0Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0Z6	Dilation of Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047J0ZZ	Dilation of Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047J341	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J346	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J34Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047J356	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047J35Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J366	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047J36Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J376	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
047J37Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J3D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J3D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047J3DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0173352	Diation of Left External macriticity with metalanimal before, reformations reproduct		105 10 1 05
047J3E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0173320	Percutaneous Approach		102 10 1 00
047J3EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
04735LZ	Approach	rroccaare	100 101 05
047J3F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
04/13/10	Percutaneous Approach	riocedure	1CD-10-1C3
047J3FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
U4/J3fZ	Approach	FIOCEGUIE	10-10-403
0471266	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Drocodura	ICD. 10 PCS
047J3G6	•	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 855 of 990



Tocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047J3GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047J3Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J3Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047J3ZZ	Dilation of Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047J441	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J446	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J44Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J456	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J45Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J466	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J46Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J476	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J47Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 856 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047J4Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4ZZ	Dilation of Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K041	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K046	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K04Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K056	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K05Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K066	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K06Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K076	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K07Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0DZ	Dilation of Right Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0Z6	Dilation of Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047K0ZZ	Dilation of Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047K341	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 857 of 990



Troccaure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047K346	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K34Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K356	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K35Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K366	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047K36Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K376	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047K37Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K3DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K3E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K3EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K3Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047K3Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
)47K3ZZ	Dilation of Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047K441	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047K446	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
)47K44Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 858 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047K456	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K45Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K466	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K46Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K476	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K47Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4ZZ	Dilation of Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L041	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L046	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L04Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L056	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 859 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047L05Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L066	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L06Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L076	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L07Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0DZ	Dilation of Left Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0Z6	Dilation of Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047L0ZZ 047L341	Dilation of Left Femoral Artery, Open Approach Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0 . 7 . 20 2	Balloon, Percutaneous Approach		.02 20 . 00
047L346	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0471247	Percutaneous Approach	Dunnadium	ICD 10 DCC
047L34Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L356	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L35Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L366	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L36Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 860 of 990



Toccuule	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047L376	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047L37Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047L3D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047L3FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047L3GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047L3ZZ	Dilation of Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047L441	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L446	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L44Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047L456	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L45Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L466	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L46Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L476	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L47Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 861 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047L4D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4ZZ 047M041	Dilation of Left Femoral Artery, Percutaneous Endoscopic Approach Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M046	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M04Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M056	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M05Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M066	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M06Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M076	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M07Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 862 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047M0D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0DZ 047M0E6	Dilation of Right Popliteal Artery with Intraluminal Device, Open Approach Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M0EZ 047M0F6	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Open Approach Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M0FZ 047M0G6	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Open Approach Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M0GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0Z1 047M0Z6 047M0ZZ 047M341	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Open Approach Dilation of Right Popliteal Artery, Bifurcation, Open Approach Dilation of Right Popliteal Artery, Open Approach Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
047M346	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M34Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M356	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M35Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M366	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M36Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M376	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M37Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M3DZ 047M3E6	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M3EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 863 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047M3F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047M3FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047M3GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047M3ZZ	Dilation of Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047M441	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M446	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M44Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M456	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M45Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M466	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M46Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M476	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M47Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 864 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047M4FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047M4G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4ZZ	Dilation of Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N041	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047N046	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N04Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N056	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N05Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N066	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N06Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N076	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N07Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 865 of 990



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047N0Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0Z6	Dilation of Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047N0ZZ	Dilation of Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
047N341	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047N346	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N34Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N356	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
04711330	Percutaneous Approach	rroccaare	100 101 05
047N35Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
04/11332	Approach	Procedure	100-10-703
04701266	• •	Dun and dun	ICD 40 DCC
047N366	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N36Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N376	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047N37Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N3D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N3D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N3DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N3E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous		ICD-10-PCS
	Approach		
047N3EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047NSLZ	bilation of Lett ropincal Artery with two intralaminal bevices, refeatanceds Approach	rroccaure	100 101 05
047N2F6	Dilation of Loft Doubleton Artony Differentian with Three Introduminal Devices	Dracadura	ICD 10 DCS
047N3F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0.4741057			100 10 000
047N3FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N3GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N3Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N3Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047N3ZZ	Dilation of Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047N441	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 866 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047N446	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N44Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N456	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N45Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N466	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N46Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N476	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N47Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4ZZ 047P041	Dilation of Left Popliteal Artery, Percutaneous Endoscopic Approach Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 867 of 990



Toccaute	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047P046	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0470047	Open Approach Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open	Dragodura	ICD 10 DCS
047P04Z	Approach	Procedure	ICD-10-PCS
047P056	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047P05Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P066	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047P06Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047P076	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
047P07Z	Intraluminal Devices, Open Approach Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0477072	Devices, Open Approach	riocedure	ICD-10-PC3
047P0D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047P0D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047P0DZ 047P0E6	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Open Approach Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0471 020	Approach	rrocedure	ICD-10-I C3
047P0EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0.470056	Dilation of Dialet Autorian Tibial Autora Differentian with Three lates being Decision Const	Donasadona	ICD 40 DCC
047P0F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0 17 1 01 =			.02 20 . 00
047P0G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047P0GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
047P0Z1	Approach	Dunnadii	ICD 10 DCC
047P0Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Open Approach Dilation of Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047P0ZZ	Dilation of Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047P341	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047P346	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047P34Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 868 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047P356	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047P35Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P366	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P36Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P376	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P37Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047P3ZZ 047P441	Dilation of Right Anterior Tibial Artery, Percutaneous Approach Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0471 441	Coated Balloon, Percutaneous Endoscopic Approach	rroccaare	100 101 05
047P446	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P44Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P456	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 869 of 990



riocedure	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047P45Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P466	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047P46Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0.470.476	Percutaneous Endoscopic Approach		100 10 000
047P476	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0470477	Intraluminal Devices, Percutaneous Endoscopic Approach	Dragadura	ICD 10 DCC
047P47Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
0471401	Balloon, Percutaneous Endoscopic Approach	Trocedure	1CD-10-1 C3
047P4D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P4DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047P4E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P4EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047P4F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
047P4FZ	Percutaneous Endoscopic Approach Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0477472	Endoscopic Approach	riocedule	ICD-10-PC3
047P4G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
0 .700	Devices, Percutaneous Endoscopic Approach		.02 20 . 00
047P4GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P4Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047P4Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0.430.433			100 10 000
047P4ZZ 047Q041	Dilation of Right Anterior Tibial Artery, Percutaneous Endoscopic Approach Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047Q041	Coated Balloon, Open Approach	Procedure	ICD-10-PC3
047Q046	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
017 0010	Open Approach	rroccaare	105 10 1 05
047Q04Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047Q056	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047Q05Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 870 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047Q066	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
017 4000	Devices, Open Approach		.02 20 . 00
047Q06Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0 ./ 000_	Approach		.02 20 . 00
047Q076	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
047Q07Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047Q0D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
017 Q051	Open Approach	rroccaare	100 10 1 00
047Q0D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
047 Q000	Approach	rroccaure	100 10 1 05
047Q0DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047Q0EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047Q0FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047Q0GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047Q0Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047Q0ZZ	Dilation of Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047Q341	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047Q346	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q34Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047Q356	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047Q35Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q366	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047Q36Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q376	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		

cder_mpl1p_wp077 Page 871 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047Q37Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0470207	Approach		100 40 000
047Q3DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047Q3F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047Q3G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0470267	Percutaneous Approach	5 .	100 40 000
047Q3GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
047Q3Z1	Percutaneous Approach Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Drocoduro	ICD 10 DCS
047Q3Z1	Dilation of Left Africator Tibial Aftery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047Q441	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Endoscopic Approach		
047Q446	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0.170.1.17	Percutaneous Endoscopic Approach		100 10 000
047Q44Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0470456	Endoscopic Approach Dilation of Loft Approach Tibial Artony Bifurgation, with Two Drug cluting Introluminal	Dracadura	ICD 10 DCS
047Q456	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q45Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047 Q432	Percutaneous Endoscopic Approach	riocedure	ICD-10-I C3
047Q466	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
017 Q100	Devices, Percutaneous Endoscopic Approach		.02 20 . 00
047Q46Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q476	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
047Q47Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q4D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 872 of 990



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047Q4D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4ZZ 047R041	Dilation of Left Anterior Tibial Artery, Percutaneous Endoscopic Approach Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047R046	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R04Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R056	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R05Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R066	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R06Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R076	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R07Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R0DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 873 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047R0E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047R0EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047R0FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047R0GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047R0Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047R0ZZ	Dilation of Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047R341	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047R346	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R34Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R356	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047R35Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R366	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047R36Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R376	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
047R37Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047R3D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047R3D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R3DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R3E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R3EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 874 of 990



		Code	
Code	Description	Category	Code Type
047R3F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R3FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047R3G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047R3GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R3Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047R3Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047R3ZZ 047R441	Dilation of Right Posterior Tibial Artery, Percutaneous Approach Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure Procedure	ICD-10-PCS ICD-10-PCS
U4/N441	Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
047R446	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
04711440	Percutaneous Endoscopic Approach	riocedule	ICD-10-FC3
047R44Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
04711442	Percutaneous Endoscopic Approach	Troccaure	100 101 05
047R456	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
01711130	Devices, Percutaneous Endoscopic Approach		100 10 1 00
047R45Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0 17 11 10 2	Percutaneous Endoscopic Approach		.02 20 . 00
047R466	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R46Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R476	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
047R47Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R4D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047R4D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047R4E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047R4F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 875 of 990



		Code	
Code	Description	Category	Code Type
047R4G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R4GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047R4Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S041	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Open Approach		
047S046	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
047S04Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047S056	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0.476057	Devices, Open Approach	5 .	ICD 40 DCC
047S05Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
047S066	Approach Pilotion of Loft Postorior Tibial Artony, Bifurestian, with Three Drug sluting Introluminal	Dragadura	ICD 10 DCS
0473000	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S06Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0473002	Approach	riocedure	ICD-10-PC3
047S076	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0175070	Intraluminal Devices, Open Approach	1100000010	105 10 1 05
047S07Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0 17 00 7 =	Devices, Open Approach		.02 20 . 00
047S0D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047S0D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047S0DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S0E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047S0EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
0473010	Approach	Troccaure	100 101 05
047S0FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
5 17 551 E	22.5 5. 2516.1 Section 1	. 10000010	.05 10 100
047S0G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047S0GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 876 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047S0Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S0Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047S0ZZ	Dilation of Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047S341	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047S346	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S34Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S356	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S35Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S366	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S36Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S376	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S37Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z6 047S3ZZ	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Approach Dilation of Left Posterior Tibial Artery, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 877 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047S441	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Endoscopic Approach		
047S446	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047S44Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047S456	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047S45Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047S466	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0.476.467	Devices, Percutaneous Endoscopic Approach		10D 40 D00
047S46Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0475476	Percutaneous Endoscopic Approach Dilation of Loft Postorior Tibiol Artony Diffusertion, with Four or More Drug eluting	Dragodura	ICD 10 DCS
047S476	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
047S47Z	Intraluminal Devices, Percutaneous Endoscopic Approach Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
04/34/2	Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
047S4D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
0473401	Balloon, Percutaneous Endoscopic Approach	riocedure	100-10-1 03
047S4D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0 17 0 100	Endoscopic Approach		100 10 1 00
047S4DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		.02 20 . 00
047S4E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047S4EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047S4F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047S4FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047S4G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047S4GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047S4Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047S4Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4ZZ	Dilation of Left Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T041	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated		ICD-10-PCS
	Balloon, Open Approach		

cder_mpl1p_wp077 Page 878 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047T046	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open		ICD-10-PCS
	Approach		
047T04Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0.47705.6		5 1	100 40 000
047T056	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T05Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0471032	Approach	Troccaure	100 101 05
047T066	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047T06Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047T076	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047T07Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047T0D1	Open Approach Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Drocoduro	ICD 10 DCS
04/1001	Open Approach	Procedure	ICD-10-PCS
047T0D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0020			.02 20 . 00
047T0DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T0E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047T0EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047T0GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047T0Z6	Dilation of Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047T0ZZ	Dilation of Right Peroneal Artery, Open Approach Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
047T341	Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T346	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0471340	Percutaneous Approach	Troccaure	100 101 05
047T34Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047T356	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T35Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 879 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047T366	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047T36Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T376	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047T37Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0.4772.07	Approach		10D 40 D66
047T3DZ 047T3E6	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices,	Procedure Procedure	ICD-10-PCS ICD-10-PCS
04713L0	Percutaneous Approach	riocedule	ICD-10-FC3
047T3EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0171011			.02 20 . 00
047T3F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047T3Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T3Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047T3ZZ 047T441	Dilation of Right Peroneal Artery, Percutaneous Approach Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS ICD-10-PCS
04/1441	Balloon, Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
047T446	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0471440	Percutaneous Endoscopic Approach	rroccaure	100 101 05
047T44Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0171112	Endoscopic Approach	rioccaare	102 10 1 03
047T456	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T45Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T466	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047T46Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 880 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047T476	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047T47Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T4D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T4D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047T4DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047T4E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T4EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047T4F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0477457	Percutaneous Endoscopic Approach	5 .	100 40 000
047T4FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0477466	Endoscopic Approach	Dunnadiina	ICD 10 DCC
047T4G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0477467	Percutaneous Endoscopic Approach Dilation of Right Percusal Artery with Four or More Introlyminal Povices, Percutaneous	Dragodura	ICD 10 DCS
047T4GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0471421	Approach	riocedule	ICD-10-PC3
047T4Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4ZZ	Dilation of Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U041	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047U046	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047U04Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U056	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047U05Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047U066	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047U06Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047U076	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047U07Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 881 of 990



Tocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047U0D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Open Approach		
047U0D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U0Z6	Dilation of Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047U0ZZ	Dilation of Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
047U341	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U346	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U34Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U356	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U35Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U366	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U36Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U376	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U37Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 882 of 990



Procedure (Codes Used to Define Baseline Characteristics in this Request		
		Code	
Code	Description	Category	_Code Type
047U3F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047U3ZZ	Dilation of Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047U441	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U446	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U44Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U456	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U45Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U466	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U46Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U476	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U47Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 883 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047U4G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U4GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047U4Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047U4Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4ZZ	Dilation of Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V041	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047V046	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047V04Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V056	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047V05Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V066	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047V06Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047V076	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047V07Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0	Approach		.02 20 . 00
047V0D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open	Procedure	ICD-10-PCS
0171001	Approach	rioccaare	102 10 1 03
047V0D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0DZ	Dilation of Right Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , , ,		
047V0EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach		ICD-10-PCS
	, , , , , , , , , , , , , , , , , , , ,		
047V0FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047V0GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V0Z6	Dilation of Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047V0ZZ	Dilation of Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
047V341	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047V346	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 884 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047V34Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V356	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V35Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
047V366	Approach Dilation of Bight Foot Artony Bifurcation, with Three Drug cluting Introluminal Devices	Dracadura	ICD 10 DCS
U47V300	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V36Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
047 1302	Approach	rioccaure	100 10 1 05
047V376	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047V37Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V3D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V3D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0.471/207	Approach	Donasalous	ICD 40 DCC
047V3DZ 047V3E6	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047 V3L0	Approach	rroccaure	100 101 05
047V3EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V3FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
047 7300	Percutaneous Approach	rioccaure	100 101 05
047V3GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V3Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V3Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047V3ZZ	Dilation of Right Foot Artery, Percutaneous Approach	Procedure Procedure	ICD-10-PCS
047V441	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V446	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
047 (440	Percutaneous Endoscopic Approach	rroccaare	100 10 1 05
047V44Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V456	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V45Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 885 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047V466	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V46Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V476	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V47Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4ZZ	Dilation of Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W041	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W046	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W04Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W056	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W05Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W066	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W06Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 886 of 990



. roccaure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047W076	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047W07Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047W0D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open	Procedure	ICD-10-PCS
	Approach		
047W0D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0DZ	Dilation of Left Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047W0GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W0Z6	Dilation of Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047W0ZZ	Dilation of Left Foot Artery with Drug cluting Introluminal Device, using Drug Coated	Procedure	ICD-10-PCS
047W341	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W346	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047W34Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W356	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047W35Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047W366	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047W36Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0.4714.07.6	Approach	Dunandana	ICD 40 DCC
047W376	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
04714/277	Devices, Percutaneous Approach Dilation of Left Foot Attany with Four or More Prug cluting Introluminal Devices	Dracadura	ICD 10 DCS
047W37Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
047 W3D1	Percutaneous Approach	riocedule	ICD-10-PC3
047W3D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
			.02 20 1 00
047W3DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W3E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 887 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Codo	
Codo	Description	Code	Codo Tuno
Code 047W3EZ	Description Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Category Procedure	Code Type ICD-10-PCS
047W3E2	Dilation of Left Foot Artery with Two intradminal Devices, Fercutaneous Approach	Procedure	ICD-10-PCS
047 1131 0	Approach	Troccaure	100 101 05
0.4714/257		Duagadiina	ICD 10 DCC
047W3FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047W3GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047W3Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W3Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047W3ZZ	Dilation of Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047W441	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047W446	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W44Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W456	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W45Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
01711132	Endoscopic Approach	rroccaare	102 10 1 00
047W466	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047 00400	Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
04714467		Drocoduro	ICD 10 DCC
047W46Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0.4711.476	Endoscopic Approach		100 10 000
047W476	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047W47Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W4D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W4D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W4DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , , ,		
047W4E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0 17 11 120	Endoscopic Approach	rroccaare	105 10 1 05
047W4EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
047 VV4LZ	·	riocedure	ICD-10-FC3
0.47114456	Approach	5 1	160 40 066
047W4F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W4FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 888 of 990



1100001010	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	_Code Type
047W4G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W4GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W4Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047W4Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4ZZ	Dilation of Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04C00Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04C03Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04C04Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CC0Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CC0ZZ	Extirpation of Matter from Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CC3Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CC3ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CC4Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CC4ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CD0Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CD0ZZ	Extirpation of Matter from Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CD3Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CD3ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CD4Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CD4ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CE0Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CE0ZZ	Extirpation of Matter from Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CE3Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CE3ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CE4Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CE4ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CF0Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CF0ZZ	Extirpation of Matter from Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CF3Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CF3ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CF4Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic		ICD-10-PCS
	Approach		
	• •		

cder_mpl1p_wp077 Page 889 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	0 1	
		Code	
Code	Description	Category	_Code Type
04CF4ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH0Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CH0ZZ	Extirpation of Matter from Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CH3Z6	Extirpation of Matter from Right External Iliac Artery, Open Approach Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Approach		ICD-10-PCS
0401320	Extil pation of Matter from Night External mac Artery, Bildication, Percutaneous Approach	riocedure	ICD-10-FC3
04CH3ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CH4Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CH4ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04011422	Extripation of Matter from Night External filac Artery, Fercutarieous Emoscopic Approach	riocedure	ICD-10-1 C3
04CJ0Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CJ0ZZ	Extirpation of Matter from Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CJ3Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ3ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ4Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CJ4ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK0Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CK0ZZ	Extirpation of Matter from Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CK3Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CK3ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CK4Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
04611420	Approach	Troccaure	100 10 1 05
04CK4ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL0Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CL0ZZ	Extirpation of Matter from Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CL3Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CL3ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CL4Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0401420	Approach	riocedure	ICD-10-1 C3
04CL4ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM0Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CM0ZZ	Extirpation of Matter from Right Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CM3Z6	Extirpation of Matter from Right Popliceal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CIVI3Z0	Extil pation of Matter from Night Populear Artery, Bild Cation, Percutaneous Approach	riocedure	ICD-10-FC3
04CM3ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CM4Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CM4ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
U4CIVI4ZZ	Extinpation of Matter from Right Populear Artery, Percutaneous Endoscopic Approach	FIOCEGUIE	ICD-10-4C3
04CN0Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CN0ZZ	Extirpation of Matter from Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CN3Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
5 . 5. 1520	pulletine in the control of the		.02 20 100

cder_mpl1p_wp077 Page 890 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Codo	
Code	Description	Code Category	Code Type
04CN3ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CN4Z6	Extirpation of Matter from Left Popliteal Artery, Percutaneous Approach Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0.000.00	Approach	rroccaare	100 10 1 00
04CN4ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CN4ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CF0ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CP3Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
0.101.020	Approach	110000010	105 10 1 05
04CP3ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CP4Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CP4ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CQ0Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CQ0ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CQ3Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach		ICD-10-PCS
04CQ3ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CQ4Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CQ4ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	, p		
04CR0Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CR0ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CR3Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04CR3ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CR4Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CR4ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CS0Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CS0ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CS3Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04CS3ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CS4Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CS4ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CT0Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CT0ZZ	Extirpation of Matter from Right Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CT3Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CT3ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
	**		

cder_mpl1p_wp077 Page 891 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04CT4Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CT4ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CU0Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CU0ZZ	Extirpation of Matter from Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CU3Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CU3ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CU4Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CU4ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CV0Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CV0ZZ	Extirpation of Matter from Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CV3Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CV3ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CV4Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CV4ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CW0Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CW0ZZ	Extirpation of Matter from Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CW3Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CW3ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CW4Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CW4ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Y6C0Z1	Detachment at Right Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z2	Detachment at Right Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z3	Detachment at Right Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z1	Detachment at Left Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z2	Detachment at Left Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z3	Detachment at Left Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6F0ZZ	Detachment at Right Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6G0ZZ	Detachment at Left Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z1	Detachment at Right Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z2	Detachment at Right Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z3	Detachment at Right Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z1	Detachment at Left Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z2	Detachment at Left Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z3	Detachment at Left Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z0	Detachment at Right Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z4	Detachment at Right Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z5	Detachment at Right Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z6	Detachment at Right Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z7	Detachment at Right Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z8	Detachment at Right Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z9	Detachment at Right Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZB	Detachment at Right Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZC	Detachment at Right Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 892 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0Y6M0ZD	Detachment at Right Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
OY6MOZF	Detachment at Right Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z0	Detachment at Left Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z4	Detachment at Left Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z5	Detachment at Left Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z6	Detachment at Left Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z7	Detachment at Left Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z8	Detachment at Left Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z9	Detachment at Left Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZB	Detachment at Left Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZC	Detachment at Left Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZD	Detachment at Left Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZF	Detachment at Left Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z0	Detachment at Right 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z1	Detachment at Right 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z2	Detachment at Right 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z3	Detachment at Right 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z0	Detachment at Left 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z1	Detachment at Left 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z2	Detachment at Left 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z3	Detachment at Left 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z0	Detachment at Right 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z1	Detachment at Right 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z2	Detachment at Right 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z3	Detachment at Right 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z0	Detachment at Left 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z1	Detachment at Left 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z2	Detachment at Left 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z3	Detachment at Left 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z0	Detachment at Right 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z1	Detachment at Right 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z2	Detachment at Right 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z3	Detachment at Right 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z0	Detachment at Left 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z1	Detachment at Left 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z2	Detachment at Left 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z3	Detachment at Left 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z0	Detachment at Right 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z1	Detachment at Right 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z2	Detachment at Right 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z3	Detachment at Right 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z0	Detachment at Left 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z1	Detachment at Left 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z2	Detachment at Left 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z3	Detachment at Left 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z0	Detachment at Right 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z1	Detachment at Right 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z2	Detachment at Right 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z3	Detachment at Right 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z0	Detachment at Left 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 893 of 990



Fiocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0Y6Y0Z1	Detachment at Left 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z2	Detachment at Left 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z3	Detachment at Left 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
33877	Repair of thoracoabdominal aortic aneurysm with graft, with or without cardiopulmonary bypass	Procedure	CPT-4
24454			CDT 4
34151	Embolectomy or thrombectomy, with or without catheter; renal, celiac, mesentery, aortoiliac artery, by abdominal incision	Procedure	CPT-4
34201	Embolectomy or thrombectomy, with or without catheter; femoropopliteal, aortoiliac artery, by leg incision	Procedure	CPT-4
34808	Endovascular placement of iliac artery occlusion device (List separately in addition to code for primary procedure)	Procedure	CPT-4
34820	Open iliac artery exposure for delivery of endovascular prosthesis or iliac occlusion during endovascular therapy, by abdominal or retroperitoneal incision, unilateral (List separately in addition to code for primary procedure)	Procedure	CPT-4
34825	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; initial vessel	Procedure	CPT-4
34826	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
35081	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta	Procedure	CPT-4
35102	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta involving iliac vessels (common, hypogastric, external)	Procedure	CPT-4
35131	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35132	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35141	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35142	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35450	Transluminal balloon angioplasty, open; renal or other visceral artery	Procedure	CPT-4
35452	Transluminal balloon angioplasty, open; aortic	Procedure	CPT-4
35454	Transluminal balloon angioplasty, open; iliac	Procedure	CPT-4

cder_mpl1p_wp077 Page 894 of 990



		Code	
Code	Description	Category	Code Type
35471	Transluminal balloon angioplasty, percutaneous; renal or visceral artery	Procedure	CPT-4
35472	Transluminal balloon angioplasty, percutaneous; aortic	Procedure	CPT-4
35473	Transluminal balloon angioplasty, percutaneous; iliac	Procedure	CPT-4
35480	Transluminal peripheral atherectomy, open; renal or other visceral artery	Procedure	CPT-4
35490	Transluminal peripheral atherectomy, percutaneous; renal or other visceral artery	Procedure	CPT-4
35537	Bypass graft, with vein; aortoiliac	Procedure	CPT-4
35538	Bypass graft, with vein; aortobi-iliac	Procedure	CPT-4
35540	Bypass graft, with vein; aortobifemoral	Procedure	CPT-4
35548	Bypass graft, with vein; aortoiliofemoral, unilateral	Procedure	CPT-4
35549	Bypass graft, with vein; aortoiliofemoral, bilateral	Procedure	CPT-4
35563	Bypass graft, with vein; ilioiliac	Procedure	CPT-4
35566	Bypass graft, with vein; femoral-anterior tibial, posterior tibial, peroneal artery or other	Procedure	CPT-4
	distal vessels		
35621	Bypass graft, with other than vein; axillary-femoral	Procedure	CPT-4
35637	Bypass graft, with other than vein; aortoiliac	Procedure	CPT-4
35638	Bypass graft, with other than vein; aortobi-iliac	Procedure	CPT-4
35646	Bypass graft, with other than vein; aortobifemoral	Procedure	CPT-4
35647	Bypass graft, with other than vein; aortofemoral	Procedure	CPT-4
35651	Bypass graft, with other than vein; aortofemoral-popliteal	Procedure	CPT-4
35654	Bypass graft, with other than vein; axillary-femoral-femoral	Procedure	CPT-4
35656	Bypass graft, with other than vein; femoral-popliteal	Procedure	CPT-4
35661	Bypass graft, with other than vein; femoral-femoral	Procedure	CPT-4
35663	Bypass graft, with other than vein; ilioiliac	Procedure	CPT-4
35665	Bypass graft, with other than vein; iliofemoral	Procedure	CPT-4
35666	Bypass graft, with other than vein; femoral-anterior tibial, posterior tibial, or peroneal	Procedure	CPT-4
	artery Valuated (Active I Valua Bianasa		
105.0	Valvular/Mitral Valve Disease Rheumatic mitral stenosis	Diagnosis	ICD-10-CM
105.0	Rheumatic mitral insufficiency	Diagnosis	ICD-10-CM
105.2	Rheumatic mitral stenosis with insufficiency	Diagnosis	ICD-10-CM
105.2	Other rheumatic mitral valve diseases	Diagnosis	ICD-10-CM
105.8	Rheumatic mitral valve diseases Rheumatic mitral valve disease, unspecified	Diagnosis	ICD-10-CM
106.0	Rheumatic aortic stenosis	Diagnosis	ICD-10-CM
106.0	Rheumatic aortic steriosis		ICD-10-CM
106.1	•	Diagnosis	
	Rheumatic aortic stenosis with insufficiency	Diagnosis	ICD-10-CM
106.8	Other rheumatic aortic valve diseases	Diagnosis	ICD-10-CM
106.9	Rheumatic aortic valve disease, unspecified	Diagnosis	ICD-10-CM
107.0	Rheumatic tricuspid stenosis	Diagnosis	ICD-10-CM
107.1	Rheumatic tricuspid insufficiency	Diagnosis	ICD-10-CM
107.2	Rheumatic tricuspid stenosis and insufficiency	Diagnosis	ICD-10-CM
107.8	Other rheumatic tricuspid valve diseases	Diagnosis	ICD-10-CM
107.9	Rheumatic tricuspid valve disease, unspecified	Diagnosis	ICD-10-CM
108.0	Rheumatic disorders of both mitral and aortic valves	Diagnosis	ICD-10-CM
108.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	ICD-10-CM
108.2	Rheumatic disorders of both aortic and tricuspid valves	Diagnosis	ICD-10-CM
108.3	Combined rheumatic disorders of mitral, aortic and tricuspid valves	Diagnosis	ICD-10-CM
108.8	Other rheumatic multiple valve diseases	Diagnosis	ICD-10-CM
108.9	Rheumatic multiple valve disease, unspecified	Diagnosis	ICD-10-CM
109.1	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 895 of 990



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
109.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
109.89	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
109.9	Rheumatic heart disease, unspecified	Diagnosis	ICD-10-CM
Z95.2	Presence of prosthetic heart valve	Diagnosis	ICD-10-CM
Z95.3	Presence of xenogenic heart valve	Diagnosis	ICD-10-CM
Z95.4	Presence of other heart-valve replacement	Diagnosis	ICD-10-CM
027F04Z	Dilation of Aortic Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0DZ	Dilation of Aortic Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0ZZ	Dilation of Aortic Valve, Open Approach	Procedure	ICD-10-PCS
027G04Z	Dilation of Mitral Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0DZ	Dilation of Mitral Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0ZZ	Dilation of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
027H04Z	Dilation of Pulmonary Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0DZ	Dilation of Pulmonary Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0ZZ	Dilation of Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
027J04Z	Dilation of Tricuspid Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0DZ	Dilation of Tricuspid Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0ZZ	Dilation of Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02NF0ZZ	Release Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02NG0ZZ	Release Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02NH0ZZ	Release Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02NJ0ZZ	Release Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02QF0ZZ	Repair Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02QG0ZZ	Repair Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02QH0ZZ	Repair Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02QJ0ZZ	Repair Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02RF07Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF08Z	Replacement of Aortic Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RF0JZ	Replacement of Aortic Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RF0KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF47Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02RF48Z	Replacement of Aortic Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF4JZ	Replacement of Aortic Valve with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02RF4KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
02N14N2	· -	riocedure	ICD-10-FC3
	Endoscopic Approach		
02RG07Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG08Z	Replacement of Mitral Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RG0JZ	Replacement of Mitral Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RG0KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG37Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG38Z	Replacement of Mitral Valve with Zooplastic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 896 of 990



riocedure	Codes osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02RG47Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Endoscopic		ICD-10-PCS
	Approach		
02RG48Z	Replacement of Mitral Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02RG4KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH07Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH08Z	Replacement of Pulmonary Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RH0JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RH0KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH47Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH48Z	Replacement of Pulmonary Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ07Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ08Z	Replacement of Tricuspid Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RJ0JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ0KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ37Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ38Z	Replacement of Tricuspid Valve with Zooplastic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ47Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ48Z	Replacement of Tricuspid Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02VG0ZZ	Restriction of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
X2RF032	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Open Approach, New Technology Group 2	Procedure	ICD-10-PCS
X2RF432	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Percutaneous Endoscopic Approach, New Technology Group 2	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 897 of 990



		Code	
Code	Description	Category	_Code Type
0257T	Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic approach	Procedure	CPT-4,
	(eg, transapical, transventricular)		Category III
0258T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-	Procedure	CPT-4,
	delivered aortic valve replacement; without cardiopulmonary bypass		Category III
0259T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-	Procedure	CPT-4,
	delivered aortic valve replacement; with cardiopulmonary bypass		Category III
0262T	Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach	Procedure	CPT-4,
32021	implantation of catheter-delivered prostnetic pulmonary valve, endovascular approach	rrocedure	Category III
33400	Valvuloplasty, aortic valve; open, with cardiopulmonary bypass	Procedure	CPT-4
33400 33401	Valvuloplasty, aortic valve, open, with cardiopullionary bypass Valvuloplasty, aortic valve; open, with inflow occlusion	Procedure	CPT-4
33403	Valvuloplasty, aortic valve; open, with innow occasion Valvuloplasty, aortic valve; using transventricular dilation, with cardiopulmonary bypass	Procedure	CPT-4
,5405	valvulopiasty, aortic valve, using transventricular unation, with cardiopulinonary bypass	riocedure	CI I-4
33420	Valvotomy, mitral valve; closed heart	Procedure	CPT-4
33422	Valvotomy, mitral valve; open heart, with cardiopulmonary bypass	Procedure	CPT-4
33425	Valvuloplasty, mitral valve, with cardiopulmonary bypass;	Procedure	CPT-4
33426	Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring	Procedure	CPT-4
33427	Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction, with or	Procedure	CPT-4
	without ring		
33430	Replacement, mitral valve, with cardiopulmonary bypass	Procedure	CPT-4
3460	Valvectomy, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
33463	Valvuloplasty, tricuspid valve; without ring insertion	Procedure	CPT-4
33464	Valvuloplasty, tricuspid valve; with ring insertion	Procedure	CPT-4
33465	Replacement, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
33468	Tricuspid valve repositioning and plication for Ebstein anomaly	Procedure	CPT-4
33475	Replacement, pulmonary valve	Procedure	CPT-4
33496	Repair of non-structural prosthetic valve dysfunction with cardiopulmonary bypass	Procedure	CPT-4
	(separate procedure)		
33660	Repair of incomplete or partial atrioventricular canal (ostium primum atrial septal defect),	Procedure	CPT-4
	with or without atrioventricular valve repair		
33665	Repair of intermediate or transitional atrioventricular canal, with or without	Procedure	CPT-4
	atrioventricular valve repair		
	Diseases of Veins and Lymphatics and Other Diseases of the Circulatory Syst	em	
80	Phlebitis and thrombophlebitis	Diagnosis	ICD-10-CM
180.0	Phlebitis and thrombophlebitis of superficial vessels of lower extremities	Diagnosis	ICD-10-CM
80.00	Phlebitis and thrombophlebitis of superficial vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
80.01	Phlebitis and thrombophlebitis of superficial vessels of right lower extremity	Diagnosis	ICD-10-CM
80.02	Phlebitis and thrombophlebitis of superficial vessels of left lower extremity	Diagnosis	ICD-10-CM
180.03	Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
80.1	Phlebitis and thrombophlebitis of femoral vein	Diagnosis	ICD-10-CM
80.10	Phlebitis and thrombophlebitis of unspecified femoral vein	Diagnosis	ICD-10-CM
80.11	Phlebitis and thrombophlebitis of right femoral vein	Diagnosis	ICD-10-CM
80.12 80.13	Phlebitis and thrombophlebitis of left femoral vein	Diagnosis Diagnosis	ICD-10-CM
80.13	Phlebitis and thrombophlebitis of femoral vein, bilateral Phlebitis and thrombophlebitis of other and unspecified deep vessels of lower extremities	_	ICD-10-CM
ο υ .Ζ	Finebitis and thrombophiebitis of other and unspectified deep vessels of lower extremities	niagi10212	ICD-10-CM
180.20	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CM
180.201	Phlebitis and thrombophlebitis of unspecified deep vessels of right lower extremity	Diagnosis	ICD-10-CM
	and the state of t		

cder_mpl1p_wp077 Page 898 of 990



	·	Cl -	
		Code	
Code	Description	Category	Code Type
180.202	Phlebitis and thrombophlebitis of unspecified deep vessels of left lower extremity	Diagnosis	ICD-10-CM
180.203	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
180.209	Phlebitis and thrombophlebitis of unspecified deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
180.21	Phlebitis and thrombophlebitis of iliac vein	Diagnosis	ICD-10-CM
180.211	Phlebitis and thrombophlebitis of right iliac vein	Diagnosis	ICD-10-CM
180.212	Phlebitis and thrombophlebitis of left iliac vein	Diagnosis	ICD-10-CM
180.213	Phlebitis and thrombophlebitis of iliac vein, bilateral	Diagnosis	ICD-10-CM
180.219	Phlebitis and thrombophlebitis of unspecified iliac vein	Diagnosis	ICD-10-CM
180.22	Phlebitis and thrombophlebitis of popliteal vein	Diagnosis	ICD-10-CM
180.221	Phlebitis and thrombophlebitis of right popliteal vein	Diagnosis	ICD-10-CM
180.222	Phlebitis and thrombophlebitis of left popliteal vein	Diagnosis	ICD-10-CM
180.223	Phlebitis and thrombophlebitis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
180.223	Phlebitis and thrombophlebitis of unspecified popliteal vein	Diagnosis	ICD-10-CIVI
180.223	Phlebitis and thrombophlebitis of tibial vein	Diagnosis	ICD-10-CM
180.23	Phlebitis and thrombophlebitis of right tibial vein	Diagnosis	ICD-10-CIVI
180.231	Phlebitis and thrombophlebitis of left tibial vein	Diagnosis	ICD-10-CIVI
180.232	Phlebitis and thrombophlebitis of tibial vein, bilateral	Diagnosis	ICD-10-CIVI
180.233	Phlebitis and thrombophlebitis of unspecified tibial vein	Diagnosis	ICD-10-CM
180.239	Phlebitis and thrombophlebitis of peroneal vein	Diagnosis	ICD-10-CIVI
180.24			ICD-10-CIVI
	Phlebitis and thrombophlebitis of left peroneal vein	Diagnosis	
180.242	Phlebitis and thrombophlebitis of left peroneal vein	Diagnosis	ICD-10-CM
180.243	Phlebitis and thrombophlebitis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
180.249	Phlebitis and thrombophlebitis of unspecified peroneal vein	Diagnosis	ICD-10-CM
180.25	Phlebitis and thrombophlebitis of calf muscular vein	Diagnosis	ICD-10-CM
180.251	Phlebitis and thrombophlebitis of right calf muscular vein	Diagnosis	ICD-10-CM
180.252	Phlebitis and thrombophlebitis of left calf muscular vein	Diagnosis	ICD-10-CM
180.253	Phlebitis and thrombophlebitis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
180.259	Phlebitis and thrombophlebitis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
180.29	Phlebitis and thrombophlebitis of other deep vessels of lower extremities	Diagnosis	ICD-10-CM
180.291	Phlebitis and thrombophlebitis of other deep vessels of right lower extremity	Diagnosis	ICD-10-CM
180.292	Phlebitis and thrombophlebitis of other deep vessels of left lower extremity	Diagnosis	ICD-10-CM
180.293	Phlebitis and thrombophlebitis of other deep vessels of lower extremity, bilateral	Diagnosis	ICD-10-CM
180.299	Phlebitis and thrombophlebitis of other deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
180.3	Phlebitis and thrombophlebitis of lower extremities, unspecified	Diagnosis	ICD-10-CM
180.8	Phlebitis and thrombophlebitis of other sites	Diagnosis	ICD-10-CM
180.9	Phlebitis and thrombophlebitis of unspecified site	Diagnosis	ICD-10-CM
181	Portal vein thrombosis	Diagnosis	ICD-10-CM
182	Other venous embolism and thrombosis	Diagnosis	ICD-10-CM
182.0	Budd-Chiari syndrome	Diagnosis	ICD-10-CM
182.1	Thrombophlebitis migrans	Diagnosis	ICD-10-CM
182.2	Embolism and thrombosis of vena cava and other thoracic veins	Diagnosis	ICD-10-CM
182.21	Embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
182.210	Acute embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
182.211	Chronic embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
182.22	Embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
182.220	Acute embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
182.221	Chronic embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 899 of 990



riocedure	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
182.29	Embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
182.290	Acute embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
182.291	Chronic embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
182.3	Embolism and thrombosis of renal vein	Diagnosis	ICD-10-CM
182.4	Acute embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
182.40	Acute embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
182.401	Acute embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
182.402	Acute embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
182.403	Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
.0200		2108.100.0	.02 20 0
182.409	Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
182.41	Acute embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
182.411	Acute embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
182.412	Acute embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
182.413	Acute embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
182.419	Acute embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
182.42	Acute embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
182.421	Acute embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
182.422	Acute embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
182.423	Acute embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
182.429	Acute embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
182.43	Acute embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
182.431	Acute embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
182.432	Acute embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
182.433	Acute embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
182.439	Acute embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
182.44	Acute embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
182.441	Acute embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
182.442	Acute embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
182.443	Acute embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM
182.449	Acute embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM
182.45	Acute embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
182.451	Acute embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
182.452	Acute embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
182.453	Acute embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
182.459	Acute embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
182.46	Acute embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
182.461	Acute embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
182.462	Acute embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
182.463	Acute embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
182.469	Acute embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
182.49	Acute embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
182.491	Acute embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
182.492	Acute embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
182.493	Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.499	Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 900 of 990



	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
182.4Y	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y1	Acute embolism and thrombosis of unspecified deep veins of right proximal lower	Diagnosis	ICD-10-CM
182.4Y2	extremity Acute embolism and thrombosis of unspecified deep veins of left proximal lower	Diagnosis	ICD-10-CM
	extremity	J	
182.4Y3	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.4Y9	Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
182.4Z	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z1	Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
182.4Z2	Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
182.4Z3	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
182.4Z9	Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
182.5	Chronic embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
182.50	Chronic embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
182.501	Chronic embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
182.502	Chronic embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
182.503	Chronic embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.509	Chronic embolism and thrombosis of unspecified deep veins of unspecified lower	Diagnosis	ICD-10-CM
	extremity		
182.51	Chronic embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
182.511	Chronic embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
182.512	Chronic embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
182.513	Chronic embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
182.519	Chronic embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
182.52	Chronic embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
182.521	Chronic embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
182.522	Chronic embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
182.523	Chronic embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
182.529 182.53	Chronic embolism and thrombosis of unspecified iliac vein Chronic embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
		Diagnosis	ICD-10-CM
182.531 182.532	Chronic embolism and thrombosis of right popliteal vein Chronic embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
	· ·	Diagnosis	ICD-10-CM
182.533 182.539	Chronic embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
182.539 182.54	Chronic embolism and thrombosis of unspecified popliteal vein Chronic embolism and thrombosis of tibial vein	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
182.54 182.541	Chronic embolism and thrombosis of tibial vein Chronic embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
	Chronic embolism and thrombosis of light tibial vein		
182.542 182.543	Chronic embolism and thrombosis of left tibial vein.	Diagnosis	ICD-10-CM ICD-10-CM
182.543	Chronic embolism and thrombosis of tibial vein, bilateral Chronic embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM
102.349	Chronic emponsin and thrombosis of unspectied tibial vein	Diagnosis	ICD-TO-CIAI

cder_mpl1p_wp077 Page 901 of 990



riocedure	Codes osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
182.55	Chronic embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
182.551	Chronic embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
182.552	Chronic embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
182.553	Chronic embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
182.559	Chronic embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
182.56	Chronic embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
182.561	Chronic embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
182.562	Chronic embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
182.563	Chronic embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
182.569	Chronic embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
182.59	Chronic embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
182.591	Chronic embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
182.592	Chronic embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
182.593	Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.599	Chronic embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM
182.5Y	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y1	Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity	Diagnosis	ICD-10-CM
182.5Y2	Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity	Diagnosis	ICD-10-CM
182.5Y3	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Y9	Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
182.5Z	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z1	Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
182.5Z2	Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
182.5Z3	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Z9	Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
182.6	Acute embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
182.60	Acute embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
182.601	Acute embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
182.602	Acute embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
182.603	Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.609	Acute embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.61	Acute embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 902 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
182.611	Acute embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
182.612	Acute embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
182.613	Acute embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.619	Acute embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.62	Acute embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
182.621	Acute embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
182.622	Acute embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
182.623	Acute embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.629	Acute embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.7	Chronic embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
182.70	Chronic embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
182.701	Chronic embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
182.702	Chronic embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
182.703	Chronic embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.709	Chronic embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.71	Chronic embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM
182.711	Chronic embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
182.712	Chronic embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
182.713	Chronic embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.719	Chronic embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.72	Chronic embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
182.721	Chronic embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
182.722	Chronic embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
182.723	Chronic embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.729	Chronic embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.8	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.81	Embolism and thrombosis of superficial veins of lower extremities	Diagnosis	ICD-10-CM
182.811	Embolism and thrombosis of superficial veins of right lower extremity	Diagnosis	ICD-10-CM
182.812	Embolism and thrombosis of superficial veins of left lower extremity	Diagnosis	ICD-10-CM
182.813	Embolism and thrombosis of superficial veins of lower extremities, bilateral	Diagnosis	ICD-10-CM
182.819	Embolism and thrombosis of superficial veins of unspecified lower extremity	Diagnosis	ICD-10-CM
182.89	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.890	Acute embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.891	Chronic embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.9	Embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
182.90	Acute embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
182.91 182.A	Chronic embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
182.A 182.A1	Embolism and thrombosis of axillary vein Acute embolism and thrombosis of axillary vein	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
182.A1	Acute embolism and thrombosis of axillary vein Acute embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
182.A11	Acute embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
182.A12	Acute embolism and thrombosis of left axillary vein. Acute embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM
182.A13	Acute embolism and thrombosis of axillary vein, bliateral	Diagnosis	ICD-10-CM
182.A13	Chronic embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
182.A21	Chronic embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
182.A21	Chronic embolism and thrombosis of light axillary vein	Diagnosis	ICD-10-CM
182.A23	Chronic embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM
		U 74.4	

cder_mpl1p_wp077 Page 903 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
182.A29	Chronic embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
182.B	Embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
182.B1	Acute embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
182.B11	Acute embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
182.B12	Acute embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
182.B13	Acute embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
182.B19	Acute embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
182.B2	Chronic embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
182.B21	Chronic embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
182.B22	Chronic embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
182.B23	Chronic embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
182.B29	Chronic embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
182.C	Embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
182.C1	Acute embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
182.C11	Acute embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
182.C12	Acute embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
182.C13	Acute embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
182.C19	Acute embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
182.C2	Chronic embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
182.C21	Chronic embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
182.C22	Chronic embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
182.C23	Chronic embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
182.C29	Chronic embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
183	Varicose veins of lower extremities	Diagnosis	ICD-10-CM
183.0	Varicose veins of lower extremities with ulcer	Diagnosis	ICD-10-CM
183.00	Varicose veins of unspecified lower extremity with ulcer	Diagnosis	ICD-10-CM
183.001	Varicose veins of unspecified lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
183.002	Varicose veins of unspecified lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
183.003	Varicose veins of unspecified lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
183.004	Varicose veins of unspecified lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
183.005	Varicose veins of unspecified lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
183.008	Varicose veins of unspecified lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
183.009	Varicose veins of unspecified lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
183.01	Varicose veins of right lower extremity with ulcer	Diagnosis	ICD-10-CM
183.011	Varicose veins of right lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
183.012	Varicose veins of right lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
183.013	Varicose veins of right lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
183.014	Varicose veins of right lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
183.015	Varicose veins of right lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
183.018	Varicose veins of right lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
183.019	Varicose veins of right lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
183.02	Varicose veins of left lower extremity with ulcer	Diagnosis	ICD-10-CM
183.021	Varicose veins of left lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
183.022	Varicose veins of left lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
183.023	Varicose veins of left lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
183.024	Varicose veins of left lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
183.025	Varicose veins of left lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
183.028	Varicose veins of left lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
183.029	Varicose veins of left lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
183.1	Varicose veins of lower extremities with inflammation	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 904 of 990



Procedure	Code		
Code	Description	Category	Code Type
183.10	Varicose veins of unspecified lower extremity with inflammation	Diagnosis	ICD-10-CM
183.11	Varicose veins of right lower extremity with inflammation	Diagnosis	ICD-10-CM
183.12	Varicose veins of left lower extremity with inflammation	Diagnosis	ICD-10-CM
183.2	Varicose veins of lower extremities with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.20	Varicose veins of unspecified lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.201	Varicose veins of unspecified lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
183.202	Varicose veins of unspecified lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
183.203	Varicose veins of unspecified lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
183.204	Varicose veins of unspecified lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
183.205	Varicose veins of unspecified lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
183.208	Varicose veins of unspecified lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
183.209	Varicose veins of unspecified lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
183.21	Varicose veins of right lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.211	Varicose veins of right lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
183.212	Varicose veins of right lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
183.213	Varicose veins of right lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.214	Varicose veins of right lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.215	Varicose veins of right lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.218	Varicose veins of right lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.219	Varicose veins of right lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
183.22	Varicose veins of left lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.221	Varicose veins of left lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
183.222	Varicose veins of left lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
183.223	Varicose veins of left lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
183.224	Varicose veins of left lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
183.225	Varicose veins of left lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
183.228	Varicose veins of left lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
183.229	Varicose veins of left lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
183.8	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
183.81	Varicose veins of lower extremities with pain	Diagnosis	ICD-10-CM
183.811	Varicose veins of right lower extremity with pain	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 905 of 990



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
183.812	Varicose veins of left lower extremity with pain	Diagnosis	ICD-10-CM
183.813	Varicose veins of helt lower extremities with pain	Diagnosis	ICD-10-CM
183.819	Varicose veins of unspecified lower extremity with pain	Diagnosis	ICD-10-CM
183.89	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
183.891	Varicose veins of right lower extremity with other complications	Diagnosis	ICD-10-CM
183.892	Varicose veins of left lower extremity with other complications	Diagnosis	ICD-10-CM
183.893	Varicose veins of bilateral lower extremities with other complications	Diagnosis	ICD-10-CM
183.899	Varicose veins of unspecified lower extremity with other complications	Diagnosis	ICD-10-CM
183.9	Asymptomatic varicose veins of lower extremities	Diagnosis	ICD-10-CM
183.90	Asymptomatic varicose veins of unspecified lower extremity	Diagnosis	ICD-10-CM
183.91	Asymptomatic varicose veins of right lower extremity	Diagnosis	ICD-10-CM
183.92	Asymptomatic varicose veins of left lower extremity	Diagnosis	ICD-10-CM
183.93	Asymptomatic varicose veins of left lower extremity Asymptomatic varicose veins of bilateral lower extremities	Diagnosis	ICD-10-CM
185. <i>9</i> 5	Esophageal varices	Diagnosis	ICD-10-CM
185.0	Esophageal varices	Diagnosis	ICD-10-CM
185.00	Esophageal varices Esophageal varices without bleeding		ICD-10-CM
185.00	Esophageal varices without bleeding Esophageal varices with bleeding	Diagnosis	ICD-10-CM
185.01 185.1		Diagnosis	
185.10	Secondary esophageal variess without blooding	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
185.10 185.11	Secondary ecophageal varies with blooding	-	
185.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
	Varicose veins of other sites	Diagnosis	ICD-10-CM
186.0	Sublingual varices	Diagnosis	ICD-10-CM
186.1	Scrotal varices	Diagnosis	ICD-10-CM
186.2	Pelvic varices	Diagnosis	ICD-10-CM
186.3	Vulval varices	Diagnosis	ICD-10-CM
186.4	Gastric varices	Diagnosis	ICD-10-CM
186.8	Varicose veins of other specified sites	Diagnosis	ICD-10-CM
187	Other disorders of veins	Diagnosis	ICD-10-CM
187.0	Postthrombotic syndrome	Diagnosis	ICD-10-CM
187.00	Postthrombotic syndrome without complications	Diagnosis	ICD-10-CM
187.001	Postthrombotic syndrome without complications of right lower extremity	Diagnosis	ICD-10-CM
187.002	Postthrombotic syndrome without complications of left lower extremity	Diagnosis	ICD-10-CM
187.003	Postthrombotic syndrome without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
187.009	Postthrombotic syndrome without complications of unspecified extremity	Diagnosis	ICD-10-CM
187.01	Postthrombotic syndrome with ulcer	Diagnosis	ICD-10-CM
187.011	Postthrombotic syndrome with ulcer of right lower extremity	Diagnosis	ICD-10-CM
187.012	Postthrombotic syndrome with ulcer of left lower extremity	Diagnosis	ICD-10-CM
187.013	Postthrombotic syndrome with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
187.019	Postthrombotic syndrome with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
187.02	Postthrombotic syndrome with inflammation	Diagnosis	ICD-10-CM
187.021	Postthrombotic syndrome with inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.022	Postthrombotic syndrome with inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.023	Postthrombotic syndrome with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
187.029	Postthrombotic syndrome with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.03	Postthrombotic syndrome with ulcer and inflammation	Diagnosis	ICD-10-CM
187.031	Postthrombotic syndrome with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.032	Postthrombotic syndrome with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.033	Postthrombotic syndrome with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 906 of 990



Code	Description	Category	Code Type
187.039	Postthrombotic syndrome with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.09	Postthrombotic syndrome with other complications	Diagnosis	ICD-10-CM
187.091	Postthrombotic syndrome with other complications of right lower extremity	Diagnosis	ICD-10-CM
187.092	Postthrombotic syndrome with other complications of left lower extremity	Diagnosis	ICD-10-CM
187.093	Postthrombotic syndrome with other complications of bilateral lower extremity	Diagnosis	ICD-10-CM
187.099	Postthrombotic syndrome with other complications of unspecified lower extremity	Diagnosis	ICD-10-CM
187.1	Compression of vein	Diagnosis	ICD-10-CM
187.2	Venous insufficiency (chronic) (peripheral)	Diagnosis	ICD-10-CM
187.3	Chronic venous hypertension (idiopathic)	Diagnosis	ICD-10-CM
187.30	Chronic venous hypertension (idiopathic) without complications	Diagnosis	ICD-10-CM
187.301	Chronic venous hypertension (idiopathic) without complications of right lower extremity	Diagnosis	ICD-10-CM
187.302	Chronic venous hypertension (idiopathic) without complications of left lower extremity	Diagnosis	ICD-10-CM
187.303	Chronic venous hypertension (idiopathic) without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
187.309	Chronic venous hypertension (idiopathic) without complications of unspecified lower extremity	Diagnosis	ICD-10-CM
187.31	Chronic venous hypertension (idiopathic) with ulcer	Diagnosis	ICD-10-CM
187.311	Chronic venous hypertension (idiopathic) with ulcer of right lower extremity	Diagnosis	ICD-10-CM
187.312	Chronic venous hypertension (idiopathic) with ulcer of left lower extremity	Diagnosis	ICD-10-CM
187.313	Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
187.319	Chronic venous hypertension (idiopathic) with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
187.32	Chronic venous hypertension (idiopathic) with inflammation	Diagnosis	ICD-10-CM
187.321	Chronic venous hypertension (idiopathic) with inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.322	Chronic venous hypertension (idiopathic) with inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.323	Chronic venous hypertension (idiopathic) with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
187.329	Chronic venous hypertension (idiopathic) with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.33	Chronic venous hypertension (idiopathic) with ulcer and inflammation	Diagnosis	ICD-10-CM
187.331	Chronic venous hypertension (idiopathic) with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.332	Chronic venous hypertension (idiopathic) with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.333	Chronic venous hypertension (idiopathic) with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
187.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.39 187.391	Chronic venous hypertension (idiopathic) with other complications Chronic venous hypertension (idiopathic) with other complications of right lower extremity	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
187.392	Chronic venous hypertension (idiopathic) with other complications of left lower extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 907 of 990



	Code			
Code	Description	Category	Code Type	
187.393	Chronic venous hypertension (idiopathic) with other complications of bilateral lower	Diagnosis	ICD-10-CM	
	extremity			
187.399	Chronic venous hypertension (idiopathic) with other complications of unspecified lower	Diagnosis	ICD-10-CM	
	extremity			
187.8	Other specified disorders of veins	Diagnosis	ICD-10-CM	
187.9	Disorder of vein, unspecified	Diagnosis	ICD-10-CM	
188	Nonspecific lymphadenitis	Diagnosis	ICD-10-CM	
188.0	Nonspecific mesenteric lymphadenitis	Diagnosis	ICD-10-CM	
188.1	Chronic lymphadenitis, except mesenteric	Diagnosis	ICD-10-CM	
188.8	Other nonspecific lymphadenitis	Diagnosis	ICD-10-CM	
188.9	Nonspecific lymphadenitis, unspecified	Diagnosis	ICD-10-CM	
189	Other noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM	
189.0	Lymphedema, not elsewhere classified	Diagnosis	ICD-10-CM	
189.1	Lymphangitis	Diagnosis	ICD-10-CM	
189.8	Other specified noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM	
189.9	Noninfective disorder of lymphatic vessels and lymph nodes, unspecified	Diagnosis	ICD-10-CM	
195	Hypotension	Diagnosis	ICD-10-CM	
195.0	Idiopathic hypotension	Diagnosis	ICD-10-CM	
195.1	Orthostatic hypotension	Diagnosis	ICD-10-CM	
195.2	Hypotension due to drugs	Diagnosis	ICD-10-CM	
195.3	Hypotension of hemodialysis	Diagnosis	ICD-10-CM	
195.8	Other hypotension	Diagnosis	ICD-10-CM	
195.81	Postprocedural hypotension	Diagnosis	ICD-10-CM	
195.89	Other hypotension	Diagnosis	ICD-10-CM	
195.9	Hypotension, unspecified	Diagnosis	ICD-10-CM	
196	Gangrene, not elsewhere classified	Diagnosis	ICD-10-CM	
197	Intraoperative and postprocedural complications and disorders of circulatory system, not	Diagnosis	ICD-10-CM	
	elsewhere classified			
197.0	Postcardiotomy syndrome	Diagnosis	ICD-10-CM	
197.1	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM	
197.11	Postprocedural cardiac insufficiency	Diagnosis	ICD-10-CM	
197.110	Postprocedural cardiac insufficiency following cardiac surgery	Diagnosis	ICD-10-CM	
197.111	Postprocedural cardiac insufficiency following other surgery	Diagnosis	ICD-10-CM	
197.12	Postprocedural cardiac arrest	Diagnosis	ICD-10-CM	
197.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM	
197.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM	
197.13	Postprocedural heart failure	Diagnosis	ICD-10-CM	
197.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM	
197.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM	
197.19	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM	
197.190	Other postprocedural cardiac functional disturbances following cardiac surgery	Diagnosis	ICD-10-CM	
197.191	Other postprocedural cardiac functional disturbances following other surgery	Diagnosis	ICD-10-CM	
197.2	Postmastectomy lymphedema syndrome	Diagnosis	ICD-10-CM	
197.3	Postprocedural hypertension	Diagnosis	ICD-10-CM	
197.4	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure	Diagnosis	ICD-10-CM	
	complicating a procedure			
197.41	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure	Diagnosis	ICD-10-CM	
	complicating a circulatory system procedure			

cder_mpl1p_wp077 Page 908 of 990



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
197.410	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac catheterization	Diagnosis	ICD-10-CM
197.411	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac bypass	Diagnosis	ICD-10-CM
197.418	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other circulatory system procedure	Diagnosis	ICD-10-CM
197.42	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
197.5	Accidental puncture and laceration of a circulatory system organ or structure during a procedure	Diagnosis	ICD-10-CM
197.51	Accidental puncture and laceration of a circulatory system organ or structure during a circulatory system procedure	Diagnosis	ICD-10-CM
197.52	Accidental puncture and laceration of a circulatory system organ or structure during other procedure	Diagnosis	ICD-10-CM
197.6	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following a procedure	Diagnosis	ICD-10-CM
197.61	Postprocedural hemorrhage of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
197.610	Postprocedural hemorrhage of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
197.611	Postprocedural hemorrhage of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
197.618	Postprocedural hemorrhage of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
197.62	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.620	Postprocedural hemorrhage of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.621	Postprocedural hematoma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.622	Postprocedural seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.63	Postprocedural hematoma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
197.630	Postprocedural hematoma of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
197.631	Postprocedural hematoma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
197.638	Postprocedural hematoma of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
197.64	Postprocedural seroma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 909 of 990



	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
197.640	Postprocedural seroma of a circulatory system organ or structure following a cardiac	Diagnosis	ICD-10-CM
	catheterization		
197.641	Postprocedural seroma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
	, , , , , , , , , , , , , , , , , , , ,	J	
197.648	Postprocedural seroma of a circulatory system organ or structure following other	Diagnosis	ICD-10-CM
	circulatory system procedure	•	
197.7	Intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
197.71	Intraoperative cardiac arrest	Diagnosis	ICD-10-CM
197.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
197.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
197.79	Other intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
197.790	Other intraoperative cardiac functional disturbances during cardiac surgery	Diagnosis	ICD-10-CM
197.791	Other intraoperative cardiac functional disturbances during other surgery	Diagnosis	ICD-10-CM
197.8	Other intraoperative and postprocedural complications and disorders of the circulatory	Diagnosis	ICD-10-CM
	system, not elsewhere classified		
197.81	Intraoperative cerebrovascular infarction	Diagnosis	ICD-10-CM
197.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
197.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
197.82	Postprocedural cerebrovascular infarction	Diagnosis	ICD-10-CM
197.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
197.88	Other intraoperative complications of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
		Ü	
197.89	Other postprocedural complications and disorders of the circulatory system, not	Diagnosis	ICD-10-CM
	elsewhere classified	2.0000.0	.02 20 0
199	Other and unspecified disorders of circulatory system	Diagnosis	ICD-10-CM
199.8	Other disorder of circulatory system	Diagnosis	ICD-10-CM
199.9	Unspecified disorder of circulatory system	Diagnosis	ICD-10-CM
133.3	Obstructive Sleep Apnea	Blagilosis	TEB 10 CIVI
G47.3	Sleep apnea	Diagnosis	ICD-10-CM
G47.30	Sleep apnea, unspecified	Diagnosis	ICD-10-CM
G47.31	Primary central sleep apnea	Diagnosis	ICD-10-CM
G47.33	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-10-CM
G47.37	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
R06.81	Apnea, not elsewhere classified	Diagnosis	ICD-10-CM
	Hypertrophic Cardiomyopathy		
142.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
142.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
142.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
142.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
142.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
142.9	Cardiomyopathy, unspecified	Diagnosis	ICD-10-CM
143	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
090.3	Peripartum cardiomyopathy	Diagnosis	ICD-10-CM
142	Cardiomyopathy	Diagnosis	ICD-10-CM
142.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
A36.81	Diphtheritic cardiomyopathy	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 910 of 990



		Code	
Code	Description	Category	Code Type
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
142.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
B33.24	Viral cardiomyopathy	Diagnosis	ICD-10-CM
142.3	Endomyocardial (eosinophilic) disease	Diagnosis	ICD-10-CM
142.4	Endocardial fibroelastosis	Diagnosis	ICD-10-CM
	Tachyarrhythmia		
146	Cardiac arrest	Diagnosis	ICD-10-CM
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
147	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
147.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
148	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
148.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
148.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
148.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
148.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
148.3	Typical atrial flutter	Diagnosis	ICD-10-CM
148.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
148.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
148.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
148.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
149	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
149.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
149.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
149.02	Ventricular flutter	Diagnosis	ICD-10-CM
149.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
149.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
149.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
149.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
149.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
149.49	Other premature depolarization	Diagnosis	ICD-10-CM
149.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
149.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
	History of Serious Hypoglycemia		
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.64	Drug or chemical induced diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 911 of 990



		Code	
Code	Description	Category	Code Type
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.0	Drug-induced hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.1	Other hypoglycemia	Diagnosis	ICD-10-CM
E16.2	Hypoglycemia, unspecified	Diagnosis	ICD-10-CM
P70.3	latrogenic neonatal hypoglycemia	Diagnosis	ICD-10-CM
P70.4	Other neonatal hypoglycemia	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 912 of 990



	Appendix G. Generic and Brand Names of	f Medical Products Used to Define	Baseline Characteristics in this Request
--	--	-----------------------------------	--

Generic Name	Brand Name
Alpha-Gluco	sidase Inhibitor
acarbose	acarbose
acarbose	Precose
miglitol	miglitol
Amyli	n Analogs
oramlintide acetate	SymlinPen 60
pramlintide acetate	SymlinPen 120
Dipeptidyl Peptida	se 4 (DPP-4) Inhibitors
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin/linagliptin	Glyxambi
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
linagliptin	Tradjenta
saxagliptin HCl	Onglyza
sitagliptin phosphate	Januvia
	n Mimetics
dulaglutide	Trulicity
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
insulin degludec/liraglutide	Xultophy 100/3.6
insulin glargine, human recombinant analog/lixisenatide	Soliqua 100/33
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
tirzepatide	Mounjaro
	litinides
nateglinide	nateglinide
repaglinide	repaglinide
repaglinide/metformin HCl	repaglinide-metformin
· -	nsulin
insulin aspart	insulin aspart U-100
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart (macmamae) insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin degludec	insulin degludec
insulin degludec insulin degludec	Tresiba FlexTouch U-100
insulin degludec insulin degludec	Tresiba FlexTouch U-200
insulin degludec insulin degludec	Tresiba U-100 Insulin
insulin degludec insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U-100 Insuln
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin

cder_mpl1p_wp077 Page 913 of 990



Generic Name	Brand Name
nsulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)InsIn
nsulin glargine,human recombinant analog	insulin glargine
nsulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
nsulin glargine,human recombinant analog	Lantus U-100 Insulin
nsulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
nsulin glargine,human recombinant analog	Semglee U-100 Insulin
nsulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
nsulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
nsulin glargine-yfgn	insulin glargine-yfgn
nsulin glargine-yfgn	Semglee(insulin glargine-yfgn)
nsulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
nsulin glulisine	Apidra SoloStar U-100 Insulin
nsulin glulisine	Apidra U-100 Insulin
nsulin lispro	Admelog SoloStar U-100 Insulin
nsulin lispro	Admelog U-100 Insulin lispro
nsulin lispro	Humalog Junior KwikPen U-100
nsulin lispro	Humalog KwikPen Insulin
nsulin lispro	Humalog Tempo Pen(U-100)Insuln
nsulin lispro	Humalog U-100 Insulin
nsulin lispro	insulin lispro
nsulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
nsulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
nsulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
nsulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
nsulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
nsulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
nsulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
nsulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
nsulin lispro-aabc	Lyumjev U-100 Insulin
nsulin NPH human isophane	Humulin N NPH Insulin KwikPen
nsulin NPH human isophane	Humulin N NPH U-100 Insulin
nsulin NPH human isophane	Novolin N FlexPen
nsulin NPH human isophane	Novolin N NPH U-100 Insulin
nsulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
nsulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
nsulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
nsulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
nsulin regular, human	Afrezza
nsulin regular, human	Humulin R Regular U-100 Insuln
nsulin regular, human	Humulin R U-500 (Conc) Insulin
nsulin regular, human	Humulin R U-500 (Conc) Kwikpen
nsulin regular, human	Novolin R FlexPen
nsulin regular, human	Novolin R Regular U-100 Insuln
U /	Myxredlin

alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet

cder_mpl1p_wp077 Page 914 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix G. Generic and Brand Names of Medical Products U Generic Name	Brand Name		
glipizide/metformin HCl	glipizide-metformin		
glyburide/metformin HCl	glyburide-metformin		
linagliptin/metformin HCl	Jentadueto		
linagliptin/metformin HCl	Jentadueto XR		
metformin HCl	Fortamet		
metformin HCl	Glumetza		
metformin HCl	metformin		
metformin HCl	Riomet		
metformin HCl	Riomet ER		
pioglitazone HCI/metformin HCI	Actoplus MET		
pioglitazone HCI/metformin HCI	pioglitazone-metformin		
repaglinide/metformin HCl	repaglinide-metformin		
saxagliptin HCI/metformin HCI	Kombiglyze XR		
sitagliptin phosphate/metformin HCl	Janumet		
sitagliptin phosphate/metformin HCl	Janumet XR		
Sodium-Glucose Cotranspo			
canagliflozin	Invokana		
dapagliflozin propanediol	Farxiga		
dapagliflozin propanediol/saxagliptin HCl	Qtern		
empagliflozin	Jardiance		
empagliflozin/linagliptin	Glyxambi		
ertugliflozin pidolate	Steglatro		
ertugliflozin pidolate/sitagliptin phosphate	Steglujan		
Sulfon			
glimepiride	Amaryl		
glimepiride	glimepiride		
glipizide	glipizide		
glipizide	Glucotrol		
glipizide	Glucotrol XL		
glipizide/metformin HCl	glipizide-metformin		
glyburide	glyburide		
glyburide,micronized	glyburide micronized		
glyburide,micronized	Glynase		
glyburide/metformin HCl	glyburide-metformin		
pioglitazone HCl/glimepiride	DUETACT		
pioglitazone HCl/glimepiride	pioglitazone-glimepiride		
Thiazolidi			
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone		
alogliptin benzoate/pioglitazone HCl	Oseni		
pioglitazone HCl	Actos		
pioglitazone HCl	pioglitazone		
pioglitazone HCl/glimepiride	DUETACT		
pioglitazone HCI/glimepiride	pioglitazone-glimepiride		
pioglitazone HCI/metformin HCI	Actoplus MET		
pioglitazone HCI/metformin HCI	pioglitazone-metformin		
Other Antidiabetic Drugs (Bromocriptine, Mifepristone)			
	omocriptine, Mifepristone)		
bromocriptine mesylate	omocriptine, Mifepristone) Cycloset		
bromocriptine mesylate mifepristone	omocriptine, Mifepristone) Cycloset Korlym		
bromocriptine mesylate mifepristone Sodium Char	omocriptine, Mifepristone) Cycloset Korlym nnel Blocker		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate Norpace		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate disopyramide phosphate disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate Norpace Norpace CR		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate Norpace		

cder_mpl1p_wp077 Page 915 of 990



Generic Name	Brand Name
lidocaine HCl in sodium chloride, iso-osmotic/PF	lidocaine in NaCl,iso-osmo(PF)
lidocaine HCI/PF	lidocaine (PF)
lidocaine HCI/PF	Xylocaine (Cardiac) (PF)
mexiletine HCl	mexiletine
phenytoin sodium	phenytoin sodium
procainamide HCl	procainamide
propafenone HCl	propafenone
propaterione HCl	Rythmol SR
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate Beta Blocker
acebutolol HCl	acebutolol
atenolol	atenolol
atenolol	Tenormin
atenolol/chlorthalidone	atenolol-chlorthalidone
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
betaxolol HCl	betaxolol
bisoprolol fumarate	bisoprolol fumarate
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
canakinumab/PF	Ilaris (PF)
carvedilol	carvedilol
carvedilol	Coreg
carvedilol phosphate	carvedilol phosphate
carvedilol phosphate	Coreg CR
esmolol HCl	Brevibloc
esmolol HCl	esmolol
esmolol HCl in sodium chloride, iso-osmotic	Brevibloc in NaCl (iso-osm)
esmolol HCl in sodium chloride, iso-osmotic	esmolol in NaCl (iso-osm)
esmolol HCl in sterile water	esmolol in sterile water
	labetalol
labetalol HCl	
labetalol HCl in dextrose, iso-osmotic	labetalol in dextrose,iso-osm
labetalol HCl in sodium chloride, iso-osmotic	labetalol in NaCl (iso-osmot)
metoprolol succinate	Kapspargo Sprinkle
metoprolol succinate	metoprolol succinate
metoprolol succinate	Toprol XL
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate	Lopressor
metoprolol tartrate	metoprolol tartrate
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
nadolol	Corgard
nadolol	nadolol
nebivolol HCl	Bystolic
nebivolol HCl	nebivolol
pindolol	pindolol
propranolol HCl	Hemangeol
propranolol HCl	Inderal LA
propranolol HCl	Inderal XL
propranolol HCl	InnoPran XL

Page 916 of 990 $cder_mpl1p_wp077$

propranolol

Betapace AF

Betapace

propranolol-hydrochlorothiazid

propranolol HCl

sotalol HCl

sotalol HCl

propranolol HCl/hydrochlorothiazide



	Appendix G. Generic and Brand Names of	f Medical Products Used to Define	Baseline Characteristics in this Request
--	--	-----------------------------------	--

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request			
Generic Name	Brand Name		
sotalol HCl	Sorine		
sotalol HCl	sotalol		
sotalol HCl	Sotalol AF		
sotalol HCl	Sotylize		
timolol maleate	timolol maleate		
Potassium Channe	l Blocker/Openers		
amiodarone HCl	amiodarone		
amiodarone HCl	Pacerone		
amiodarone HCI/dextrose 5 % in water	amiodarone in dextrose 5 %		
amiodarone in dextrose, iso-osmotic	Nexterone		
bretylium tosylate	bretylium tosylate		
dofetilide	dofetilide		
dofetilide	Tikosyn		
dronedarone HCl	Multag		
ibutilide fumarate	Corvert		
ibutilide fumarate	ibutilide fumarate		
	alcium Channel Blockers		
diltiazem HCl	diltiazem HCl		
verapamil HCl	verapamil		
Digo			
digoxin	Digitek		
digoxin	Digox		
digoxin	digoxin		
digoxin	Lanoxin		
digoxin	Lanoxin Pediatric		
Other Antiarrh	ythmic Agents		
adenosine	adenosine		
Angiotensin-Converting	Enzyme (ACE) Inhibitors		
Angiotensin-Converting amlodipine besylate/benazepril HCl	Enzyme (ACE) Inhibitors amlodipine-benazepril		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril captopril maleate Epaned Vasotec enalapril-hydrochlorothiazide		
Angiotensin-Converting amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalaprilat dihydrate	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium/fosinopril sodium/hydrochlorothiazide lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium/hydrochlorothiazide lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil Qbrelis		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril dihydrate fosinopril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil Qbrelis		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril dihydrate fosinopril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril prinivil Qbrelis Zestril		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil Qbrelis Zestril lisinopril-hydrochlorothiazide		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalaprils odium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide moexipril HCl	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril-hydrochlorothiazide lisinopril Prinivil Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic moexipril		
amlodipine besylate/benazepril HCl amlodipine besylate/benazepril HCl benazepril HCl benazepril HCl benazepril HCl/hydrochlorothiazide benazepril HCl/hydrochlorothiazide captopril captopril/hydrochlorothiazide enalapril maleate enalapril maleate enalapril maleate enalapril maleate/hydrochlorothiazide enalapril maleate/hydrochlorothiazide enalapril sodium fosinopril sodium fosinopril sodium/hydrochlorothiazide lisinopril lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide moexipril HCl perindopril arginine/amlodipine besylate	Enzyme (ACE) Inhibitors amlodipine-benazepril Lotrel benazepril Lotensin benazepril-hydrochlorothiazide Lotensin HCT captopril captopril-hydrochlorothiazide enalapril maleate Epaned Vasotec enalapril-hydrochlorothiazide Vaseretic enalaprilat fosinopril fosinopril Prinivil Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic moexipril Prestalia		

cder_mpl1p_wp077 Page 917 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil

Angiotensin II Receptor Blockers (ARBs)

amlodipine besylate/olmesartan medoxomil amlodipine-olmesartan

amlodipine besylate/olmesartan medoxomil Azor

amlodipine besylate/valsartan amlodipine-valsartan

amlodipine besylate/valsartan Exforge

amlodipine besylate/valsartan/hydrochlorothiazide amlodipine-valsartan-hcthiazid

amlodipine besylate/valsartan/hydrochlorothiazide
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
candesartan cilexetil
candesartan cilexetil
candesartan cilexetil/hydrochlorothiazide

Exforge HCT
Edarbi
Edarbi
Edarbyclor
Atacand
candesartan cilexetil
candesartan
Candesartan cilexetil/hydrochlorothiazide

candesartan cilexetil/hydrochlorothiazide candesartan-hydrochlorothiazid

eprosartan mesylate eprosartan irbesartan Avapro irbesartan irbesartan irbesartan Avalide Avalide

irbesartan/hydrochlorothiazide irbesartan-hydrochlorothiazide

Iosartan potassiumCozaarIosartan potassiumIosartanIosartan potassium/hydrochlorothiazideHyzaar

losartan potassium/hydrochlorothiazide losartan-hydrochlorothiazide

olmesartan medoxomil Benicar olmesartan medoxomil olmesartan

olmesartan medoxomil/amlodipine

besylate/hydrochlorothiazide olmesartan-amlodipin-hcthiazid

olmesartan medoxomil/amlodipine

besylate/hydrochlorothiazide Tribenzor olmesartan medoxomil/hydrochlorothiazide Benicar HCT

olmesartan medoxomil/hydrochlorothiazide olmesartan-hydrochlorothiazide

sacubitril/valsartan Entresto
telmisartan Micardis
telmisartan telmisartan

telmisartan/amlodipine besylate telmisartan-amlodipine

telmisartan/amlodipine besylate Twynsta telmisartan/hydrochlorothiazide Micardis HCT

telmisartan/hydrochlorothiazide telmisartan-hydrochlorothiazid

valsartanDiovanvalsartanvalsartanvalsartan/hydrochlorothiazideDiovan HCT

valsartan/hydrochlorothiazide valsartan-hydrochlorothiazide

Dihydropyridines

amlodipine benzoate Katerzia
amlodipine besylate amlodipine besylate Norliqva
amlodipine besylate Norvasc

cder_mpl1p_wp077 Page 918 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
amlodipine besylate/celecoxib	Consensi
clevidipine butyrate	Cleviprex
felodipine	felodipine
isradipine	isradipine
levamlodipine maleate	Conjupri
levamlodipine maleate	levamlodipine
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nifedipine	nifedipine
nifedipine	Procardia
nifedipine	Procardia XL
nimodipine	nimodipine
nimodipine	Nymalize
nisoldipine	nisoldipine
nisoldipine	Sular
	Diurotics

_					
- h	ш	11	0	П	CS

acetazolamide acetazolamide acetazolamide sodium acetazolamide sodium

amiloride HCl amiloride

amiloride HCl/hydrochlorothiazide amiloride-hydrochlorothiazide

bumetanide bumetanide chlorothiazide Diuril

chlorothiazide sodium chlorothiazide sodium

chlorothiazide sodiumDiuril IVchlorthalidonechlorthalidonechlorthalidoneThalitone

conivaptan HCI/dextrose 5 % in water Vaprisol in 5 % dextrose

eplerenone eplerenone lnspra

ethacrynate sodium
ethacrynate sodium
Sodium Edecrin

ethacrynic acid Edecrin
ethacrynic acid ethacrynic acid
furosemide Furoscix
furosemide furosemide
furosemide Lasix

furosemide in 0.9 % sodium chloride furosemide in 0.9 % NaCl hydrochlorothiazide hydrochlorothiazide

indapamideindapamidemethazolamidemethazolamidemetolazonemetolazonespironolactoneAldactonespironolactoneCaroSpirspironolactonespironolactonespironolactone/hydrochlorothiazideAldactazide

spironolactone/hydrochlorothiazide spironolacton-hydrochlorothiaz

tolvaptan Samsca tolvaptan torsemide Soaanz torsemide torsemide

cder_mpl1p_wp077 Page 919 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
triamterene	Dyrenium
triamterene	triamterene
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid

triamterene/hydrochlorothiazide triamterene-hydrochlorothiazid

Other Antihypertensives

hydralazine

aliskiren hemifumarate aliskiren hemifumarate Tekturna aliskiren hemifumarate/hydrochlorothiazide Tekturna HCT

atenolol/chlorthalidone atenolol-chlorthalidone

atenolol/chlorthalidone Tenoretic 100 atenolol/chlorthalidone Tenoretic 50

bisoprolol fumarate/hydrochlorothiazide bisoprolol-hydrochlorothiazide

bisoprolol fumarate/hydrochlorothiazide Ziac

clonidine Catapres-TTS-1 clonidine Catapres-TTS-2 clonidine Catapres-TTS-3 clonidine clonidine clonidine HCl clonidine HCl Nexiclon XR clonidine HCl doxazosin mesylate Cardura doxazosin mesylate Cardura XL doxazosin mesylate doxazosin fenoldopam mesylate Corlopam finerenone Kerendia guanfacine HCl guanfacine

isosorbide dinitrate/hydralazine HCl BiDil

hydralazine HCl

isosorbide dinitrate/hydralazine HCl isosorbide-hydralazine

isoxsuprine HCl isoxsuprine mecamylamine HCl Vecamyl methyldopa methyldopa

methyldopa/hydrochlorothiazide methyldopa-hydrochlorothiazide

methyldopate HCl methyldopate metoprolol succinate/hydrochlorothiazide Dutoprol

metoprolol tartrate/hydrochlorothiazide metoprolol ta-hydrochlorothiaz

metyrosineDemsermetyrosinemetyrosineminoxidilminoxidilnitroprusside sodiumNitropress

nitroprusside sodium sodium nitroprusside

nitroprusside sodium in 0.9 % sodium chloride
papaverine HCl
phenoxybenzamine HCl
phenoxybenzamine HCl
phenoxybenzamine HCl
phenoxybenzamine HCl
phenoxybenzamine
phentolamine mesylate
phentolamine
prazosin HCl
Minipress
prazosin

propranolol HCI/hydrochlorothiazide propranolol-hydrochlorothiazid

terazosin HCl terazosin

Oral Anticoagulants

apixaban Eliquis

apixaban Eliquis DVT-PE Treat 30D Start

dabigatran etexilate dabigatran etexilate dabigatran etexilate

cder_mpl1p_wp077 Page 920 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dabigatran etexilate mesylate	Pradaxa
edoxaban tosylate	Savaysa
rivaroxaban	Xarelto
rivaroxaban	Xarelto DVT-PE Treat 30d Start

Warfarin sodium Jantoven warfarin sodium warfarin

Other Cardiac Medications (Not Including Oral Anticoagulants or Vitamin K Antagonists)

ambrisentanambrisentanambrisentanLetairisamyl nitriteamyl nitritebosentanbosentanbosentanTracleerepoprostenol sodiumepoprostenolepoprostenol sodiumVeletri

epoprostenol sodium (glycine) epoprostenol (glycine)

epoprostenol sodium (glycine) Flolan iloprost tromethamine Ventavis isosorbide dinitrate Dilatrate-SR isosorbide dinitrate Isordil

isosorbide dinitrate Isordil Titradose isosorbide dinitrate isosorbide mononitrate isosorbide mononitrate

ivabradine HCl Corlanor Opsumit macitentan GoNitro nitroglycerin nitroglycerin Minitran nitroglycerin Nitro-Bid nitroglycerin Nitro-Dur nitroglycerin nitroglycerin nitroglycerin Nitrolingual nitroglycerin **Nitromist** nitroglycerin **Nitrostat** nitroglycerin Nitro-Time

nitroglycerin in 5 % dextrose in water nitroglycerin in 5 % dextrose

ranolazine Aspruzyo Sprinkle

ranolazine Ranexa ranolazine ranolazine ranolazine ranolazine Adempas selexipag Uptravi sildenafil citrate Revatio

sildenafil citrate sildenafil (pulm.hypertension)

tadalafil Adcirca tadalafil Alyq

tadalafil tadalafil (pulm. hypertension)

tadalafil Tadliq
treprostinil Tyvaso
treprostinil treprostinil diolamine Orenitram
treprostinil sodium Remodulin
treprostinil sodium treprostinil/nebulizer accessories Tyvaso Refill Kit

treprostinil/nebulizer and accessories Tyvaso Institutional Start Kit

treprostinil/nebulizer and accessories Tyvaso Starter Kit

cder_mpl1p_wp077 Page 921 of 990



Generic Name	Brand Name
vericiguat	Verquvo
Lip	id Lowering Therapy
alirocumab	Praluent Pen
ımlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin
ımlodipine besylate/atorvastatin calcium	Caduet
torvastatin calcium	atorvastatin
torvastatin calcium	Lipitor
empedoic acid	Nexletol
empedoic acid/ezetimibe	Nexlizet
holestyramine (with sugar)	cholestyramine (with sugar)
holestyramine (with sugar)	Questran
holestyramine/aspartame	Cholestyramine Light
holestyramine/aspartame	cholestyramine-aspartame
holestyramine/aspartame	Prevalite
holestyramine/aspartame	Questran Light
olesevelam HCl	colesevelam
olesevelam HCl	WelChol
olestipol HCl	Colestid
olestipol HCl	Colestid Flavored
olestipol HCl	colestipol
vinacumab-dgnb	Evkeeza
volocumab	Repatha Pushtronex
volocumab	Repatha SureClick
volocumab	Repatha Syringe
zetimibe	ezetimibe
zetimibe	Zetia
zetimibe/atorvastatin calcium	ezetimibe-atorvastatin
zetimibe/rosuvastatin calcium	ezetimibe-rosuvastatin
zetimibe/rosuvastatin calcium	Roszet
zetimibe/simvastatin	ezetimibe-simvastatin
zetimibe/simvastatin	Vytorin 10-10
zetimibe/simvastatin	Vytorin 10-20
zetimibe/simvastatin	Vytorin 10-40
zetimibe/simvastatin	Vytorin 10-80
enofibrate	fenofibrate
enofibrate	Fenoglide
enofibrate	Lipofen
enofibrate nanocrystallized	fenofibrate nanocrystallized
enofibrate nanocrystallized	Tricor
enofibrate, micronized	Antara
enofibrate,micronized	fenofibrate micronized
enofibric acid	fenofibric acid
enofibric acid	Fibricor
enofibric acid (choline)	fenofibric acid (choline)
enofibric acid (choline)	Trilipix
uvastatin sodium	fluvastatin
uvastatin sodium	Lescol XL
emfibrozil	gemfibrozil
emfibrozil	Lopid
cosapent ethyl	icosapent ethyl
cosapent ethyl	Vascepa
nclisiran sodium	Leqvio
omitapide mesylate	Juxtapid
ovastatin	Altoprov

cder_mpl1p_wp077 Page 922 of 990

lovastatin

Altoprev



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lovastatin	lovastatin
niacin	niacin
niacin	Niacor
niacin	Niaspan Extended-Release
omega-3 acid ethyl esters	Lovaza
omega-3 acid ethyl esters	omega-3 acid ethyl esters
pitavastatin calcium	Livalo
pitavastatin magnesium	Zypitamag
pravastatin sodium	pravastatin
rosuvastatin calcium	Crestor
rosuvastatin calcium	Ezallor Sprinkle
rosuvastatin calcium	rosuvastatin
simvastatin	FloLipid
simvastatin	simvastatin
simvastatin	Zocor
D	Disk of Dusky and OT and Tours does do Deinter

Drugs with a Known Risk of Prolonged QT and Torsades de Pointes

amiodarone HCl	amiodarone
amiodarone HCl	Pacerone

amiodarone HCl/dextrose 5 % in water amiodarone in dextrose 5 %

amiodarone in dextrose, iso-osmotic Nexterone anagrelide HCl Agrylin anagrelide HCl anagrelide arsenic trioxide arsenic trioxide arsenic trioxide Trisenox azithromycin AzaSite azithromycin azithromycin azithromycin Zithromax azithromycin Zithromax TRI-PAK azithromycin Zithromax Z-Pak

azithromycin/chondroitin sulfate A sodium/PF Klarity-A (azithro-chondr)(PF) chloroquine phosphate chloroquine phosphate chlorpromazine HCl chlorpromazine cilostazol cilostazol ciprofloxacin Cipro ciprofloxacin ciprofloxacin ciprofloxacin Otiprio Cetraxal ciprofloxacin HCl

ciprofloxacin HClCiloxanciprofloxacin HClCiprociprofloxacin HClciprofloxacin HClciprofloxacin HCl/dexamethasoneCiprodex

ciprofloxacin HCl/dexamethasone ciprofloxacin HCl/fluocinolone acetonide ciprofloxacin-fluocinolone

ciprofloxacin HCI/fluocinolone acetonide Otovel ciprofloxacin HCI/hydrocortisone Cipro HC

ciprofloxacin lactate/dextrose 5 % in water ciprofloxacin in 5 % dextrose

citalopram hydrobromideCelexacitalopram hydrobromidecitalopramclarithromycinclarithromycincocaine HClcocainecocaine HClGopreltococaine HClNumbrino

dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF dexameth-moxiflox(PF)-NaCl,iso

cder_mpl1p_wp077 Page 923 of 990



Generic Name Brand Name

dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF dexamet-moxifl-ketoro-NaCl(PF)

dextromethorphan Hbr/quinidine sulfate Nuedexta

disopyramide phosphate disopyramide phosphate

disopyramide phosphate **Norpace** disopyramide phosphate Norpace CR dofetilide dofetilide dofetilide Tikosvn donepezil HCl Adlarity donepezil HCl Aricept donepezil HCl donepezil dronedarone HCl Multag droperidol droperidol erythromycin base Ery-Tab

erythromycin base erythromycin erythromycin ethylsuccinate E.E.S. 400 erythromycin ethylsuccinate E.E.S. Granules erythromycin ethylsuccinate EryPed 200 erythromycin ethylsuccinate EryPed 400

erythromycin ethylsuccinate erythromycin ethylsuccinate

erythromycin lactobionate Erythrocin

erythromycin lactobionate erythromycin stearate Erythrocin (as stearate) erythromycin stearate escitalopram oxalate escitalopram oxalate

escitalopram oxalate Lexapro flecainide acetate fluconazole Diflucan fluconazole fluconazole

fluconazole in sodium chloride, iso-osmotic fluconazole in NaCl (iso-osm)

gatifloxacingatifloxacingatifloxacinZymaxidhaloperidolhaloperidolhaloperidol decanoateHaldol Decanoatehaloperidol decanoatehaloperidol decanoate

haloperidol lactate Haldol

haloperidol lactate
hydroxychloroquine sulfate
hydroxychloroquine

hydroxychloroquine sulfate Plaquenil ibutilide fumarate Corvert

ibutilide fumarate ibutilide fumarate

lansoprazole/amoxicillin trihydrate/clarithromycin amoxicil-clarithromy-lansopraz

levofloxacin levofloxacin

levofloxacin/dextrose 5 % in water levofloxacin in D5W

memantine HCI/donepezil HCI Namzaric
methadone HCI Diskets
methadone HCI methadone

methadone HCl Methadone Intensol

methadone HCl Methadose

methadone hydrochloride in 0.9 % sodium chloride methadone in 0.9 % sod.chlorid midazolam/ketamine HCl/ondansetron HCl MKO (Midazolam-Ketamine-Ondan)

mobocertinib succinate Exkivity
moxifloxacin HCl Moxeza
moxifloxacin HCl moxifloxacin

cder mpl1p wp077 Page 924 of 990



Generic Name	Brand Name
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate, water, iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCI/PF	ondansetron HCl (PF)
oxaliplatin	oxaliplatin
papaverine HCl	papaverine
papaverine HCI/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCI/phentolamine mesylate/alprostadil	Tri-Mix (papavrn-phntlmn-PGE1)
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
pimozide	pimozide
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCI/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac	
sod	prednisoln sp-moxiflox-bromfen
procainamide HCl	procainamide
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
sevoflurane	sevoflurane
sevoflurane	Ultane
	Betapace
sotalol HCl	Betapace
sotalol HCl	Betapace AF
	•
sotalol HCl sotalol HCl	Betapace AF
sotalol HCl	Betapace AF Sorine sotalol
sotalol HCl sotalol HCl sotalol HCl sotalol HCl	Betapace AF Sorine sotalol Sotalol AF
sotalol HCl sotalol HCl sotalol HCl sotalol HCl	Betapace AF Sorine sotalol Sotalol AF Sotylize
sotalol HCl sotalol HCl sotalol HCl sotalol HCl	Betapace AF Sorine sotalol Sotalol AF

cder_mpl1p_wp077 Page 925 of 990



Generic Name	Brand Name
vandetanib	Caprelsa

vonoprazan fumarate/amoxicillin trihydrate/clarithromycin Voquezna Triple Pak

Drugs with a Known/Possible/Conditional Risk of Prolonged QT and Torsades de Pointes

abiraterone acetate abiraterone Zytiga abiraterone acetate, submicronized Yonsa acetaminophen/diphenhydramine citrate Goody's PM acetaminophen/diphenhydramine citrate Headache Relief PM

acetaminophen/diphenhydramine citrate Midol PM acetaminophen/diphenhydramine HCl Acetadryl

acetaminophen/diphenhydramine HCl Acetaminophen PM

acetaminophen/diphenhydramine HCl Acetaminophen PM Extra Str

acetaminophen/diphenhydramine HCl EaZZZe The Pain acetaminophen/diphenhydramine HCl Headache PM

acetaminophen/diphenhydramine HCl Night Time Pain Medicine

acetaminophen/diphenhydramine HCl Non-Aspirin PM acetaminophen/diphenhydramine HCl Pain and Sleep acetaminophen/diphenhydramine HCl Pain Relief PM

acetaminophen/diphenhydramine HCl Pain Relief PM Rapid Release acetaminophen/diphenhydramine HCl Pain Reliever PM Ex-Strength

acetaminophen/diphenhydramine HCl Percogesic

acetaminophen/diphenhydramine HCl Percogesic Extra Strength

acetaminophen/diphenhydramine HCl Severe Allergy

acetaminophen/diphenhydramine HCl Tylenol PM Extra Strength

acetaminophen/diphenhydramine HCl Unisom PM Pain acetaminophen/diphenhydramine HCl Wal-Nadol PM adagrasib Krazati

alfuzosin HCl alfuzosin
alfuzosin HCl Uroxatral
aliskiren hemifumarate/hydrochlorothiazide Tekturna HCT
amantadine HCl amantadine HCl

amantadine HCl amantadine II Gocovri amantadine HCl Osmolex ER

amiloride HCl/hydrochlorothiazide amiloride-hydrochlorothiazide

amiodarone HCl amiodarone amiodarone HCl Pacerone

amiodarone HCl/dextrose 5 % in water amiodarone in dextrose 5 %

amiodarone in dextrose, iso-osmotic

amisulpride

amitriptyline HCl

amitriptyline

amitriptyline HCl/chlordiazepoxide amlodipine besylate/valsartan/hydrochlorothiazide amlodipine-valsartan-hcthiazid

amlodipine besylate/valsartan/hydrochlorothiazide Exforge HCT
amphetamine Adzenys ER
amphetamine Adzenys XR-ODT
amphetamine amphetamine Dyanavel XR

amphetamine sulfate amphetamine sulfate

amphetamine sulfateEvekeoamphetamine sulfateEvekeo ODTamphotericin Bamphotericin B

amphotericin B lipid complex Abelcet amphotericin B liposome AmBisome

amphotericin B liposome amphotericin B liposome

cder mpl1p wp077 Page 926 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
apalutamide	Erleada
apomorphine HCl	APOKYN
apomorphine HCl	apomorphine
apomorphine HCl	Kynmobi
aripiprazole	Abilify
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
arsenic trioxide	arsenic trioxide
arsenic trioxide	Trisenox
artemether/lumefantrine	Coartem
asenapine	Secuado
asenapine maleate	asenapine maleate
asenapine maleate	Saphris
aspirin/acetaminophen/diphenhydramine citrate	Pain Relief PM (w-aspirin)
aspirin/diphenhydramine citrate	Bayer PM
aspirin/omeprazole	aspirin-omeprazole
aspirin/omeprazole	Yosprala
atazanavir sulfate	atazanavir
atazanavir sulfate	Reyataz
atazanavir sulfate/cobicistat	Evotaz
atomoxetine HCl	atomoxetine
atomoxetine HCl	Strattera
azithromycin	AzaSite
azithromycin	azithromycin
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin/chondroitin sulfate A sodium/PF	Klarity-A (azithro-chondr)(PF)
bedaquiline fumarate	Sirturo
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
bendamustine HCl	Belrapzo
bendamustine HCl	bendamustine
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	Vivimusta
benzhydrocodone HCI/acetaminophen	Apadaz
benzhydrocodone HCI/acetaminophen	benzhydrocodone-acetaminophen
bicalutamide	bicalutamide
bicalutamide	Casodex
bismuth subsalicylate/metronidazole/tetracycline HCl	Helidac
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol furnarate/hydrochlorothiazide	Ziac
bortezomib	bortezomib
bortezomib	Velcade
bosutinib	Bosulif
buprenorphine	buprenorphine
pupi choi pinnic	Supremorphine

cder_mpl1p_wp077 Page 927 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
buprenorphine	Butrans
puprenorphine	Sublocade
ouprenorphine HCl	Belbuca
ouprenorphine HCl	Buprenex
ouprenorphine HCl	buprenorphine HCl
ouprenorphine HCl	Probuphine
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
buprenorphine HCI/naloxone HCI	Suboxone
buprenorphine HCI/naloxone HCI	Zubsolv
cabotegravir/rilpivirine	Cabenuva
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
capecitabine	capecitabine
capecitabine	Xeloda
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
ceritinib	Zykadia
chloroquine phosphate	chloroquine phosphate
chlorpromazine HCl	chlorpromazine
cilostazol	cilostazol
cimetidine	Acid Reducer (cimetidine)
cimetidine	cimetidine
cimetidine	Heartburn Relief (cimetidine)
cimetidine	Tagamet HB
cimetidine HCl	cimetidine HCl
ciprofloxacin	Cipro
ciprofloxacin	ciprofloxacin
ciprofloxacin	Otiprio
ciprofloxacin HCl	Cetraxal
ciprofloxacin HCl	Ciloxan
ciprofloxacin HCl	Cipro
ciprofloxacin HCl	ciprofloxacin HCl
ciprofloxacin HCI/dexamethasone	Ciprodex
ciprofloxacin HCI/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/hydrocortisone	Cipro HC
ciprofloxacin factate/dextrose 5 % in water	ciprofloxacin in 5 % dextrose
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clarithromycin	clarithromycin
clantinomycin clomipramine HCl	Anafranil
clomipramine HCl	
	clomipramine
clozapine	clozapine Clozaril
clozapine	
clozapine	Versacloz
cobimetinib fumarate	Cotellic
cocaine HCl	cocaine
cocaine HCl	Goprelto
cocaine HCl	Numbrino
colloidal bismuth subcitrate/metronidazole/tetracycline HCl	Pylera
crizotinib	Xalkori

cder_mpl1p_wp077 Page 928 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Congris Name	•
Generic Name	Brand Name Toficles
dabrafenib mesylate	Tafinlar
dasatinib	Sprycel
degarelix acetate	Firmagon Firmagon kit w diluont suringo
degarelix acetate	Firmagon kit w diluent syringe
desipramine HCl	desipramine
desipramine HCl	Norpramin
desvenlafaxine	desvenlafaxine
desvenlafaxine succinate	desvenlafaxine succinate
desvenlafaxine succinate	Pristiq
deutetrabenazine	Austedo
deutetrabenazine	Austedo 12mg Start Titr(Wk1-4)
deutetrabenazine	Austedo TD Titratn Pk (Wk 1-2)
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	
dexlansoprazole	Dexilant
dexlansoprazole	dexlansoprazole
dexmedetomidine HCl	dexmedetomidine
dexmedetomidine HCl	Igalmi
dexmedetomidine HCl	Precedex
dexmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
dexmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor
dexmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
dextroamphetamine	Xelstrym
dextroamphetamine sulfate	Dexedrine Spansule
dextroamphetamine sulfate	dextroamphetamine sulfate
dextroamphetamine sulfate	ProCentra
dextroamphetamine sulfate dextroamphetamine sulf-saccharate/amphetamine sulf-	Zenzedi
aspartate dextroamphetamine sulf-saccharate/amphetamine sulf-	Adderall
aspartate	Adderall XR
dextroamphetamine sulf-saccharate/amphetamine sulf-	
aspartate	dextroamphetamine-amphetamine
dextroamphetamine sulf-saccharate/amphetamine sulf-	p p
aspartate	Mydayis
dextromethorphan HBr/acetaminophen/diphenhydramine HCl	Diabetic Tussin Night Time
dextromethorphan Hbr/quinidine sulfate	Nuedexta
dextromethorphan/phenylephrine/acetaminophen/diphenhydra	
mine	Day-Night Severe Cold-Flu
dextromethorphan/phenylephrine/acetaminophen/diphenhydra	, 0
mine	HerbioMed Deep Cold-Flu Night
dextromethorphan/phenylephrine/acetaminophen/diphenhydra	
mine	Multi-Symptom Severe Cold-Nt
dextromethor phan/phenyle phrine/acetamin ophen/diphen hydra	
mine	Wal-Flu Day-Night Cold-Cough
diltiazem HCl	Cardizem
diltiazem HCl	Cardizem CD
diltiazem HCl	Cardizem LA
diltiazem HCl	Cartia XT
diltiazem HCl	diltiazem HCl
diltiazem HCl	DILT-XR
diltiazem HCl	Matzim LA
diltiazem HCl	Taztia XT

cder_mpl1p_wp077 Page 929 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diltiazem HCl	Tiadylt ER
diltiazem HCl	Tiazac
diltiazem HCl in 0.9 % sodium chloride	diltiazem HCl in 0.9% NaCl
diltiazem HCI/dextrose 5 % in water	diltiazem in dextrose 5 %
diluent for lefamulin(10mM citrate buffered 0.9 % sod chlor)	Diluent for lefamulin(Xenleta)
diluent for leuprolide (polyglactin)	Diluent for Eligard
diluent for romidepsin (propylene glycol)	Diluent For Istodax
diluent for romidepsin (propylene glycol)	diluent, romidepsin (prop gly)
diphenhydramine HCl	Aler-Cap
diphenhydramine HCl	Alka-Seltzer Plus Allergy
diphenhydramine HCl	Aller-G-Time
diphenhydramine HCl	Allergy
diphenhydramine HCl	Allergy (diphenhydramine)
diphenhydramine HCl	Allergy Medication
diphenhydramine HCl	Allergy Medicine
diphenhydramine HCl	Allergy Relief(diphenhydramin)
diphenhydramine HCl	Banophen
diphenhydramine HCl	Benadryl
diphenhydramine HCl	Benadryl Allergy
diphenhydramine HCl	Child Allergy Relief (diphen)
diphenhydramine HCl	Children's Allergy (diphenhyd)
diphenhydramine HCl	Children's Benadryl Allergy
diphenhydramine HCl	Children's Diphenhydramine
diphenhydramine HCl	Children's Wal-Dryl Allergy
diphenhydramine HCl	Complete Allergy
diphenhydramine HCl	Complete Allergy Medicine
DIPHENHYDRAMINE HCL	Dicopanol
diphenhydramine HCl	Diphedryl
diphenhydramine HCl	Diphedryl Allergy
diphenhydramine HCl	Diphen
diphenhydramine HCl	Diphenhist
diphenhydramine HCl	diphenhydramine HCl
diphenhydramine HCl	EZ Nite Sleep
diphenhydramine HCl	Geri-Dryl
diphenhydramine HCl	M-Dryl
diphenhydramine HCl	Naramin
diphenhydramine HCl	Nightime Sleep
diphenhydramine HCl	Nighttime Allergy Relief
diphenhydramine HCl	NightTime Sleep Aid (diphen)
diphenhydramine HCl	Nytol
diphenhydramine HCl	PediaClear Cough
diphenhydramine HCl	Pharbedryl
diphenhydramine HCl	Siladryl SA
diphenhydramine HCl	Simply Sleep
diphenhydramine HCl	Sleep Aid (diphenhydramine)
	Sleep Aid Max Str (diphenhydr)
diphenhydramine HCl	
diphenhydramine HCl	Sleep II
diphenhydramine HCl	Sleep Tablet (diphenhydramine)
diphenhydramine HCl	Sleep Time
diphenhydramine HCl	Sleeping
diphenhydramine HCl	Sleep-Tabs
diphenhydramine HCl	Sominex
diphenhydramine HCl	Sominex Maximum Strength
diphenhydramine HCl	Total Allergy Medicine

cder_mpl1p_wp077 Page 930 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix G. Generic and Brand Names of Medical Products Use	·
Generic Name	Brand Name
diphenhydramine HCl	Unisom (diphenhydramine)
diphenhydramine HCl	Unisom SleepGels
diphenhydramine HCl	Unisom SleepMelts
diphenhydramine HCl	Unisom SleepMinis
diphenhydramine HCl	Wal-Dryl Allergy
diphenhydramine HCl	Wal-Sleep Z
diphenhydramine HCl	Wal-Som (diphenhydramine)
diphenhydramine HCl	Z-Sleep
diphenhydramine HCl	ZzzQuil
diphenhydramine HCl in 0.9 % sodium chloride	diphenhydramine-0.9 % sod.chlr
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Sinus Headache (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Delsym Cough-Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Mucinex M-S Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children Dimetapp M-S Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children's Mucinex Night Time
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cold and Flu Relief(diphen-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cough and Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Delsym Cough-Cold NightTime
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu Severe Cold-Night(diph-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu-Severe Cold-Cough Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Herbiomed Allergy Cold-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Nite Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Nite Congest
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Robitussin Cold-Flu Night (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Allergy-Sinus Headache
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold Cough-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold PE
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu ExpressMax Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Night Severe Cold-Cgh
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Nighttime PowerPod
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Dryl Severe Allergy-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Night Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Severe Cold and Cough
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Phed PE Nighttime Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-phed PE Severe Cold
diphenhydramine HCI/phenylephrine HCI/dextromethorphan	Child Cold-Cough Day-Night
diphenhydramine	
HCI/phenylephrine/acetaminophen/guaifenesin	Mucinex Sinus-Max D-N (diphen)
diphenhydramine	
HCI/phenylephrine/acetaminophen/guaifenesin	Sinus Relief Max Str Day-Night
diphenhydramine/brompheniramine/phenyleph/dextromethorp	
han	Children's Dimetapp Day Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Child Delsym Cough Plus Dy-Nt
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	, ,
n/GG	Child Mucinex M-S Cold Day-Nte
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Children's M-S Cold Day-Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	,
n/GG	Daytime-Cold Nighttime-Cld-Flu
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Delsym Cough Plus Day-Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	, , , , ,
n/GG	Mucinex Fast-Max Day-Nite Cold
•	,

cder_mpl1p_wp077 Page 931 of 990



Generic Name	Brand Name
liphenhydramine/phenylephrin/dextromethorph/acetaminoph	e
n/GG	Mucinex Fast-Max Day-Nite Cong
liphenhydramine/phenylephrin/dextromethorph/acetaminoph	e
n/GG	Mucinex Fst-Mx Dy-Nt Cold(dph)
liphenhydramine/phenylephrin/dextromethorph/acetaminoph	e
n/GG	Wal-Phed PE Day-Night
lisopyramide phosphate	disopyramide phosphate
lisopyramide phosphate	Norpace
lisopyramide phosphate	Norpace CR
lofetilide	dofetilide
lofetilide	Tikosyn
olasetron mesylate	Anzemet
lolutegravir sodium/rilpivirine HCl	Juluca
lonepezil HCl	Adlarity
lonepezil HCl	Aricept
onepezil HCl	donepezil
oxepin HCl	doxepin
oxepin HCl	Silenor
ronedarone HCl	Multaq
roperidol	droperidol
favirenz	efavirenz
favirenz	Sustiva
favirenz/emtricitabine/tenofovir disoproxil fumarate	Atripla
favirenz/emtricitabine/tenofovir disoproxil fumarate	efavirenz-emtricitabin-tenofov
favirenz/lamivudine/tenofovir disoproxil fumarate	efavirenz-lamivu-tenofov disop
favirenz/lamivudine/tenofovir disoproxil fumarate	Symfi
favirenz/lamivudine/tenofovir disoproxil fumarate	Symfi Lo
liglustat tartrate	Cerdelga
mtricitabine/rilpivirine HCl/tenofovir alafenamide fumarate	Odefsey
mtricitabine/rilpivirine HCl/tenofovir disoproxil fumarate	Complera
nalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
nalapril maleate/hydrochlorothiazide	Vaseretic
ncorafenib	Braftovi
ntrectinib	Rozlytrek
pirubicin HCl	Ellence
pirubicin HCl	epirubicin
ribulin mesylate	Halaven
rythromycin base	Ery-Tab
rythromycin base	erythromycin
rythromycin ethylsuccinate	E.E.S. 400
rythromycin ethylsuccinate	E.E.S. Granules
rythromycin ethylsuccinate	EryPed 200
rythromycin ethylsuccinate	EryPed 400
rythromycin ethylsuccinate	erythromycin ethylsuccinate
rythromycin lactobionate	Erythrocin
rythromycin lactobionate	erythromycin lactobionate
rythromycin stearate	Erythrocin (as stearate)
rythromycin stearate	erythromycin stearate
escitalopram oxalate	escitalopram oxalate
scitalopram oxalate	Lexapro
	•
	esomeprazoie magnesium
someprazole magnesium	esomeprazole magnesium Nexium
someprazole magnesium someprazole magnesium someprazole magnesium	

cder_mpl1p_wp077 Page 932 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
esomeprazole magnesium/glycerin	Esomep-EZS
esomeprazole sodium	esomeprazole sodium
esomeprazole sodium	Nexium IV
esomeprazole strontium	esomeprazole strontium
amotidine	Acid Controller
amotidine	Acid Reducer (famotidine)
amotidine	Acid-Pep
amotidine	famotidine
amotidine	Heartburn Prevention
amotidine	Heartburn Relief (famotidine)
amotidine	Pepcid
amotidine	Pepcid AC
amotidine	Pepcid AC Maximum Strength
amotidine	Zantac-360 (famotidine)
amotidine in sodium chloride, iso-osmotic/PF	famotidine (PF)-NaCl (iso-os)
amotidine/calcium carbonate/magnesium hydroxide	Acid Controller Complete
amotidine/calcium carbonate/magnesium hydroxide	Acid Reducer Complete (famot)
amotidine/calcium carbonate/magnesium hydroxide	Complete
amotidine/calcium carbonate/magnesium hydroxide	Dual Action Complete
amotidine/calcium carbonate/magnesium hydroxide	Pepcid Complete
amotidine/calcium carbonate/magnesium hydroxide	Tums Dual Action (famotidine)
amotidine/PF	famotidine (PF)
elbamate	felbamate
elbamate	Felbatol
ingolimod HCl	fingolimod
ingolimod HCl	Gilenya
ingolimod lauryl sulfate	Tascenso ODT
lecainide acetate	flecainide
luconazole	Diflucan
luconazole	fluconazole
luconazole in sodium chloride, iso-osmotic	fluconazole in NaCl (iso-osm)
luorouracil	Adrucil
luorouracil	fluorouracil
luoxetine HCl	fluoxetine
luoxetine HCl	Prozac
luvoxamine maleate	fluvoxamine
osinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
osnetupitant chloride HCl/palonosetron HCl	Akynzeo (fosnetupitant)
urosemide	Furoscix
rurosemide	furosemide
urosemide	Lasix
urosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
galantamine HBr	galantamine
galantamine HBr	Razadyne ER
gatifloxacin	gatifloxacin
gatifloxacin	Zymaxid
gemifloxacin mesylate	Factive
gilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
granisetron	Sancuso
granisetron	Sustol
	granisetron HCl
tranicatron Hi I	41.01113E1111111111
granisetron HCl granisetron HCl/PF	granisetron (PF)

cder_mpl1p_wp077 Page 933 of 990



Generic Name	Brand Name
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
hydrochlorothiazide	hydrochlorothiazide
hydrocodone bitartrate	hydrocodone bitartrate
hydrocodone bitartrate	Hysingla ER
hydrocodone bitartrate	Zohydro ER
hydrocodone bitartrate/acetaminophen	hydrocodone-acetaminophen
hydrocodone bitartrate/acetaminophen	Lortab Elixir
hydrocodone bitartrate/guaifenesin	Obredon
hydrocodone bitartrate/homatropine methylbromide	Hycodan
hydrocodone bitartrate/homatropine methylbromide	Hycodan (with homatropine)
hydrocodone bitartrate/homatropine methylbromide	Hydrocodone Compound
hydrocodone bitartrate/homatropine methylbromide	hydrocodone-homatropine
hydrocodone bitartrate/homatropine methylbromide	Hydromet
hydrocodone polistirex/chlorpheniramine polistirex	hydrocodone-chlorpheniramine
hydrocodone polistirex/chlorpheniramine polistirex	TussiCaps
hydrocodone/ibuprofen	hydrocodone-ibuprofen
hydroxyamphetamine hbr/tropicamide	Paremyd
hydroxychloroquine sulfate	hydroxychloroquine
hydroxychloroquine sulfate	Plaquenil
hydroxyzine HCl	hydroxyzine HCl
hydroxyzine pamoate	hydroxyzine pamoate
hydroxyzine pamoate	Vistaril
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
iloperidone	Fanapt
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
imipramine HCl	imipramine HCl
imipramine pamoate	imipramine ner
indapamide	indapamide
inotuzumab ozogamicin	Besponsa
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
isradipine	isradipine
itraconazole	itraconazole
itraconazole	Sporanox
itraconazole	Sporanox Sporanox Pulsepak
itraconazole	Tolsura
	Corlanor
ivabradine HCl	Corianor Tibsovo
ivosidenib	
ketoconazole	ketoconazole
LANSOPRAZOLE	FIRST-Lansoprazole
lansoprazole	lansoprazole
lansoprazole	Prevacid

cder_mpl1p_wp077 Page 934 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Insoprazole Insoprazole Insoprazole Insoprazole/Insopr	Generic Name	Brand Name
Insoprazole/amoxiciliu trihydrate/clarithromycin Iapatrini ditosylate Iapatrini ditosylate Iapatrini ditosylate Iefamulin acetate Iefamulin acetate Ieurorilide acetate/norethindrone Ieurorilide acetate	lansoprazole	Prevacid 24Hr
lapatinib ditosylate lapatinib ditosylate lapatinib ditosylate lefamulin acetate lefamulin acetate lematinib mesylate leuprolide acetate leuprolide acetate/norethindrone acetate levertiracetam levertira	lansoprazole	Prevacid SoluTab
Ispatnib ditosylate Tykerb Enfantlin acctate Enfantlin acctate Envarinib mesylate Envarinib messlate	lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
lefamulin acetate lewatinib mesylate leuprolide acetate leuprolide acetate/norethindrone leup	lapatinib ditosylate	lapatinib
lewatnib mesylate Lenvima leuprolide acetate leuprolide acetate/norethindrone leuprolide acetate/norethindro	lapatinib ditosylate	Tykerb
leuprolide acetate Eligard (3 month) Leuprolide acetate Eligard (4 month) Leuprolide acetate Eligard (6 month) Leuprolide acetate Eligard (6 month) Leuprolide acetate Eligard (6 month) Leuprolide acetate Leuprolide Leuprolide acetate Leuprolide Leuprolide Leuprolide acetate Leuprolide Leuprolide Leuprolide acetate Lupron Depot (7 month) Leuprolide acetate Lupron Depot (8 month) Leuprolide acetate Lupron Depot (6 month) Leuprolide acetate/norethindrone acetate Lupron Depot-Ped (3 month) Leuprolide acetate/norethindrone acetate Lupron Depot-Ped (3 month) Leuprolide acetate/norethindrone acetate Lupron Depot-Ped (8 month) Leuprolide acetate/norethindrone acetate Lupron Depot-Ped (9 month) Leuprolide acetate/norethindrone acetate Lupron Depot-Ped (9 month) Leuprolide acetate/norethindrone acetate Lupron Depot-Ped (9 month) Leuprolide acetate/norethindrone acetate Lupron Depot Ped (9 month) Leuprolide acetate/norethindrone acetate Lupron Depot Ped (9 month) Leuprolide acetate/norethindrone acetate Lupron Depot Ped (9 month) Leuprolide acetate/norethindrone Leuprolide	lefamulin acetate	Xenleta
leuprolide acetate Eligard (4 month) Leuprolide acetate Eligard (5 month) Leuprolide acetate Eligard (6 month) Leuprolide acetate Eligard (6 month) Leuprolide acetate Leuprolide Le	lenvatinib mesylate	Lenvima
leuprolide acetate Eligard (4 month)	leuprolide acetate	Eligard
leuprolide acetate leuprolide acetate/lorethindrone acetate leuprolide acetate/norethindrone levetiracetam levetirace	leuprolide acetate	Eligard (3 month)
leuprolide acetate leuprolide acetate/norethindrone leuprolide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl/simethicone loperamide	leuprolide acetate	Eligard (4 month)
leuprolide acetate leuprolide acetate/norethindrone leupr	leuprolide acetate	Eligard (6 month)
leuprolide acetate leuprol	leuprolide acetate	Fensolvi
leuprolide acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide mesylate leuprolide mesylate leuprolide mesylate levetiracetam in sodium chloride, iso-osmotic levofloxacin levofloxacin/dextrose 5 % in water levofloxacin levofloxacin in D5W levofloxacin levofloxacin dextrose 5 % in water levofloxacin in D5W levofloxacin levoflox	leuprolide acetate	leuprolide
leuprolide acetate leuprolide acetate/norethindrone acetate leuprolide mesylate levetiracetam leuprolide mesylate levetiracetam in sodium chloride, iso-osmotic levefloxacin levofloxacin levoflox	leuprolide acetate	leuprolide (3 month)
leuprolide acetate leuprolide acetate/norethindrone acetate leuprolide mesylate leuprolide mesylate levetiracetam in Sodium chloride, iso-osmotic levofloxacin levetiracetam levet	leuprolide acetate	Lupron Depot
leuprolide acetate leuprolide acetate leuprolide acetate leuprolide acetate leuprolide acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide mesylate leuprolide mesylate levetiracetam levetiracet	leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate leuprolide acetate leuprolide acetate leuprolide acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide mesylate levetiracetam ni sodium chloride, iso-osmotic levefloxacin levefloxacin levofloxacin/dextrose 5 % in water levofloxacin/lextrose 5 % in water levofloxacin levofloxacin lo D5W levofloxacin/lextrose 5 % in water levofloxacin levofloxacin lo D5W levofloxacin lo D5	leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide mesylate leuprolide mesylate levetiracetam in sodium chloride, iso-osmotic levofloxacin levofloxacin in DSW levofloxacin levofloxacin/dextrose 5 % in water levofloxacin/dextrose 5 % in water levofloxacin/dextrose 5 % in water levofloxacin/levofloxorthiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium carbonate lithofexidine HCI loperamide HCI/simethicone loperamide-	leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate/norethindrone acetate leuprolide acetate/norethindrone acetate leuprolide mesylate levetiracetam in sodium chloride, iso-osmotic levefloxacin levofloxacin levofloxacin levofloxacin levofloxacin in DSW levoketoconazole levofloxacin/dextrose 5 % in water levofloxacin/dextrose 5 % in water levofloxacin/dextrose 5 % in water levofloxacin in DSW levoketoconazole lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium carbonate lithoperamide HCI loperamide HCI/simethicone loperamide-	leuprolide acetate	Lupron Depot-Ped
leuprolide acetate/norethindrone acetate leuprolide mesylate camcevi (6 month) leuvetiracetam levetiracetam in sodium chloride, iso-osmotic levofloxacin levofloxacin levofloxacin levofloxacin/dextrose 5 % in water levofloxacin in D5W levoloxacin levofloxacin levofl	leuprolide acetate	Lupron Depot-Ped (3 month)
leuprolide mesylate levetiracetam in sodium chloride, iso-osmotic levefloxacin levofloxacin levetiracetam l	leuprolide acetate/norethindrone acetate	Lupaneta Pack (1 month)
levetiracetam Elepsia XR Reppra Revetiracetam Revetiracetam in sodium chloride, iso-osmotic Revetiracetam in NaCl (iso-os) Revofloxacin Revoflox	leuprolide acetate/norethindrone acetate	Lupaneta Pack (3 month)
levetiracetam Keppra XR levetiracetam Repra XR levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam Roweepra levetiracetam Roweepra XR levetiracetam Spritam levetiracetam levetiracetam levetiracetam Spritam levetiracetam in sodium chloride, iso-osmotic levofloxacin in D5W levoketoconazole Recorlev lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide Zestoretic lithium aspartate Lithate lithium carbonate lithium carbonat	leuprolide mesylate	Camcevi (6 month)
levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam Roweepra XR levetiracetam Roweepra XR levetiracetam Roweepra XR levetiracetam in sodium chloride, iso-osmotic levefloxacin levefloxacin in levefloxacin levofloxacin levofloxacin levofloxacin levofloxacin in D5W levoketoconazole Recorlev lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium aspartate Lithate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lithobid lofexidine HCl Lucemyra loperamide HCl Diamode loperamide HCl Inperamide HCl/simethicone Inperamide-simethicone Inperami	levetiracetam	Elepsia XR
levetiracetam levetiracetam Roweepra Roweepra levetiracetam Roweepra Roweepra Roweepra XR levetiracetam Spritam Spritam levetiracetam in sodium chloride, iso-osmotic levofloxacin levofloxonece Recorlev lisinopril/hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril-hydrochlorothiazide lithium carbonate Lithate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lithopid lofexidine HCl Lucemyra loperamide HCl Lucemyra loperamide HCl Imodium A-D loperamide HCl Imodium A-D loperamide HCl Imodium A-D loperamide HCl simethicone Imodium Multi-Symptom Relief loperamide HCl/simethicone loperamide HC	levetiracetam	Keppra
levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam levetiracetam in sodium chloride, iso-osmotic levefloxacin levofloxacin levofloxacin levofloxacin levofloxacin in D5W levoketoconazole levofloxacin in D5W levoketoconazole lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium aspartate lithium carbonate lithium c	levetiracetam	Keppra XR
levetiracetam levetiracetam levetiracetam in sodium chloride, iso-osmotic levefiracetam in sodium chloride, iso-osmotic levofloxacin levofloxacin levofloxacin levofloxacin/dextrose 5 % in water levofloxacin/dextrose 5 % in water levofloxacin/dextrose 5 % in water levofloxacin in D5W levoketoconazole lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium aspartate lithium carbonate l	levetiracetam	levetiracetam
levetiracetam levetiracetam in sodium chloride, iso-osmotic levefiracetam in NaCl (iso-os) levofloxacin levofloxacin levofloxacin levofloxacin levofloxacin levofloxacin in D5W levoketoconazole Recorlev lisinopril/hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril-hydrochlorothiazide lithium aspartate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lithoud lofexidine HCl Lucemyra loperamide HCl Diamode loperamide HCl Diamode loperamide HCl loperamide HCl/simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir/ritonavir lopinavir-ritonavir lopinavir-ritonavir lopinavisimphydrochlorothiazide losartan potassium/hydrochlorothiazide losartan-hydrochlorothiazide lumateperone tosylate	levetiracetam	Roweepra
levetiracetam in sodium chloride, iso-osmotic levofloxacin levofloxacin levofloxacin levofloxacin levofloxacin levofloxacin levofloxacin levofloxacin in D5W levoketoconazole Recorlev lisinopril/hydrochlorothiazide lisinopril-hydrochlorothiazide lisinopril/hydrochlorothiazide Zestoretic lithium aspartate Lithate lithium carbonate lithium carbonate lithium carbonate Lithobid lofexidine HCl Lucemyra loperamide HCl Diamode loperamide HCl Imodium A-D loperamide HCl Imodium A-D loperamide HCl Ioperamide loperamide HCl/simethicone Imodium Multi-Symptom Relief loperamide HCl/simethicone loperamide-simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir/ritonavir lopinavir-ritonavir losartan potassium/hydrochlorothiazide lumateperone tosylate Levetiracetam in NaCl (iso-os) levofloxacin in D5W Recorlev Recorlev Recorlev Recorlev Recorlev Recorlev Recorlev Lithate lisinopril-hydrochlorothiazide levofloxacin in D5W Recorlev Recorlev Recorlev Recorlev Recorlev Recorlev Lithate lisinopril-hydrochlorothiazide losartan-hydrochlorothiazide levofloxacin in D5W Recorlev Levofloxacin in D5W Recorlev Levofloxacin in D5W Recorlev Lithate lisinopril-hydrochlorothiazide losartan-hydrochlorothiazide	levetiracetam	Roweepra XR
levofloxacin levofloxacin/dextrose 5 % in water levofloxacin in D5W levoketoconazole Recorlev lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide Zestoretic lithium aspartate Lithate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lithium carbonate lofexidine HCl Lucemyra loperamide HCl Diamode loperamide HCl Diamode loperamide HCl Imodium A-D loperamide HCl loperamide HCl/simethicone Anti-Diarrheal (lope)-Anti-Gas loperamide HCl/simethicone loperamide-simethicone loperamide-simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir-ritonavir lopinavir-ritonav	levetiracetam	·
levofloxacin/dextrose 5 % in water levoketoconazole lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium aspartate lithium carbonate lithobid lofexidine HCl loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir/ritonavir losartan potassium/hydrochlorothiazide lumateperone tosylate		
levoketoconazole lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium aspartate lithium carbonate lofexidine HCl loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir/ritonavir losartan potassium/hydrochlorothiazide lumateperone tosylate Recorlev lisinopril-hydrochlorothiazide lithate Lith		levofloxacin
lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide lithium aspartate lithium carbonate lithium carbon		
lisinopril/hydrochlorothiazide lithium aspartate lithium carbonate		
lithium aspartate lithium carbonate lithium A-D loperamide (loperamide) loperamide lithium carbonate l		lisinopril-hydrochlorothiazide
lithium carbonate lithobid lofexidine HCl lucemyra loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide loperamide HCl loperamide HCl loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone loperamide HCl/simethicone lopinavir/ritonavir lopinavir/ritonavir losartan potassium/hydrochlorothiazide losartan potassium/hydrochlorothiazide lumateperone tosylate lithium carbonate lithobid lucemyra lopiamora loperamide loperamide) loperamide lithium carbonate lithobid lucemyra loperamide) loperamide loperamide) loperamide loperamide-loperamide-simethicone lopinavir-ritonavir lopinavir-ritonavir losartan potassium/hydrochlorothiazide lumateperone tosylate	lisinopril/hydrochlorothiazide	
lithium carbonate lofexidine HCl Lucemyra loperamide HCl Loperamide HCl Diamode loperamide HCl Imodium A-D loperamide HCl Ioperamide HCl Ioperamide HCl Ioperamide HCl Ioperamide HCl Ioperamide Ioperamide Ioperamide Ioperamide Ioperamide Ioperamide HCl/simethicone Iopinavir/ritonavir Iopinavir/ritonavir Iopinavir/ritonavir Iosartan potassium/hydrochlorothiazide Iosartan potassium/hydrochlorothiazide Iosartan-hydrochlorothiazide Iosartan-hydrochlorothiazide Iosartan-hydrochlorothiazide Iosartan-hydrochlorothiazide Iosartan-hydrochlorothiazide Iosartan-hydrochlorothiazide		Lithate
lofexidine HClLucemyraloperamide HClAnti-Diarrheal (loperamide)loperamide HClDiamodeloperamide HClImodium A-Dloperamide HClloperamideloperamide HClUltra A-Dloperamide HCl/simethiconeAnti-Diarrheal (lope)-Anti-Gasloperamide HCl/simethiconeImodium Multi-Symptom Reliefloperamide HCl/simethiconeloperamide-simethiconelopinavir/ritonavirKaletralopinavir/ritonavirlopinavir-ritonavirlosartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta		
loperamide HCl Diamode loperamide HCl Imodium A-D loperamide HCl Ioperamide HCl Ioperamide loperamide HCl/simethicone Imodium Multi-Symptom Relief loperamide HCl/simethicone Ioperamide-simethicone loperamide HCl/simethicone Ioperamide-simethicone lopinavir/ritonavir Kaletra lopinavir/ritonavir Iopinavir-ritonavir losartan potassium/hydrochlorothiazide lumateperone tosylate Caplyta		Lithobid
loperamide HCl Imodium A-D loperamide HCl loperamide HCl loperamide loperamide HCl loperamide loperamide HCl Ultra A-D loperamide HCl/simethicone Imodium Multi-Symptom Relief loperamide HCl/simethicone loperamide-simethicone lopinavir/ritonavir lopinavir/ritonavir losartan potassium/hydrochlorothiazide losartan potassium/hydrochlorothiazide lumateperone tosylate Diamode Imodium A-D Imodium A-D Ioperamide loperamide loperamide loperamide loperamide lope)-Anti-Gas Imodium Multi-Symptom Relief loperamide+simethicone loperamide-simethicone loperamide-simethicone loperamide HCl/simethicone loperamide HCl/simethi		•
loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl loperamide HCl/simethicone Ultra A-D loperamide HCl/simethicone Imodium Multi-Symptom Relief loperamide HCl/simethicone loperamide HCl/simethicone loperamide-simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir/ritonavir losartan potassium/hydrochlorothiazide Hyzaar losartan potassium/hydrochlorothiazide losartan-hydrochlorothiazide lumateperone tosylate Imodium A-D loperamide loperamide (loperamide) loperamide lop		
loperamide HCl loperamide HCl loperamide HCl/simethicone lopinavir/ritonavir lopinavir/ritonavir lopinavir/ritonavir losartan potassium/hydrochlorothiazide losartan potassium/hydrochlorothiazide lumateperone tosylate losartan botassium/hydrochlorothiazide		
loperamide HCl Ultra A-D loperamide HCl/simethicone Anti-Diarrheal (lope)-Anti-Gas loperamide HCl/simethicone Imodium Multi-Symptom Relief loperamide HCl/simethicone loperamide-simethicone lopinavir/ritonavir Kaletra lopinavir/ritonavir lopinavir-ritonavir losartan potassium/hydrochlorothiazide Hyzaar losartan potassium/hydrochlorothiazide losartan-hydrochlorothiazide lumateperone tosylate Caplyta	•	
loperamide HCl/simethiconeAnti-Diarrheal (lope)-Anti-Gasloperamide HCl/simethiconeImodium Multi-Symptom Reliefloperamide HCl/simethiconeloperamide-simethiconelopinavir/ritonavirKaletralopinavir/ritonavirlopinavir-ritonavirlosartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta	•	•
loperamide HCl/simethiconeImodium Multi-Symptom Reliefloperamide HCl/simethiconeloperamide-simethiconelopinavir/ritonavirKaletralopinavir/ritonavirlopinavir-ritonavirlosartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta		
loperamide HCl/simethiconeloperamide-simethiconelopinavir/ritonavirKaletralopinavir/ritonavirlopinavir-ritonavirlosartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta		
lopinavir/ritonavirKaletralopinavir/ritonavirlopinavir-ritonavirlosartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta		
lopinavir/ritonavirlopinavir-ritonavirlosartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta	·	·
losartan potassium/hydrochlorothiazideHyzaarlosartan potassium/hydrochlorothiazidelosartan-hydrochlorothiazidelumateperone tosylateCaplyta		
losartan potassium/hydrochlorothiazide losartan-hydrochlorothiazide Caplyta		•
lumateperone tosylate Caplyta		
		·
lurasidone HCl Latuda		
	lurasidone HCl	Latuda

cder_mpl1p_wp077 Page 935 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
macimorelin acetate MAG HYDROXIDE/AL	Macrilen
HYDROXIDE/SIMETH/DIPHENHYDRAMINE/LIDOCAINE	FIRST-Mouthwash BLM
memantine HCI/donepezil HCl	Namzaric
methadone HCl	Diskets
methadone HCl	methadone
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
methamphetamine HCl	Desoxyn
methamphetamine HCl	methamphetamine
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
metoclopramide HCl	Gimoti
metoclopramide HCl	metoclopramide HCl
metoclopramide HCl	Reglan
metolazone	metolazone
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metronidazole	Flagyl
metronidazole	Metrogel Vaginal
metronidazole	metronidazole
metronidazole	Nuvessa
metronidazole	Vandazole
metronidazole in sodium chloride	Metro I.V.
metronidazole in sodium chloride	metronidazole in NaCl (iso-os)
midazolam/ketamine HCl/ondansetron HCl	MKO (Midazolam-Ketamine-Ondan)
midostaurin	Rydapt
mifepristone	Korlym
mifepristone	Mifeprex
mifepristone	mifepristone
mirabegron	Myrbetriq
mirtazapine	mirtazapine
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mobocertinib succinate	Exkivity
moxifloxacin HCl	Moxeza
moxifloxacin HCl	moxifloxacin
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate, water, iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/esomeprazole magnesium	Vimovo
necitumumab	Portrazza
nelfinavir mesylate	Viracept
netupitant/palonosetron HCl	Akynzeo (netupitant)
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose Cardene IV in sodium chloride
meararpine in socialit cilionae, 150-031110tic	caractic iv in socialii cilionae

cder_mpl1p_wp077 Page 936 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nilotinib HCl	Tasigna
nortriptyline HCl	nortriptyline
nortriptyline HCl	Pamelor
nusinersen sodium/PF	Spinraza (PF)
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/LIDOCAINE HCL/DIPHENHYDRAMINE HCL NYSTATIN/TETRACYCLINE	First-BXN
HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
ofloxacin	Ocuflox
ofloxacin	ofloxacin
olanzapine	olanzapine
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
planzapine pamoate	Zyprexa Relprevv
planzapine/fluoxetine HCl	olanzapine-fluoxetine
planzapine/fluoxetine HCl	Symbyax
olanzapine/samidorphan malate	Lybalvi
oliceridine fumarate	Olinvyk
olmesartan medoxomil/amlodipine	·
oesylate/hydrochlorothiazide olmesartan medoxomil/amlodipine	olmesartan-amlodipin-hcthiazid
pesylate/hydrochlorothiazide	Tribenzor
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
OMEPRAZOLE	FIRST-Omeprazole
omeprazole	omeprazole
OMEPRAZOLE	Omeprazole+SyrSpend SF Alka
omeprazole magnesium	Acid Reducer (omeprazole)
omeprazole magnesium	omeprazole magnesium
omeprazole magnesium	Prilosec
omeprazole magnesium	Prilosec OTC
omeprazole magnesium/amoxicillin trihydrate/rifabutin	Talicia
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
omeprazole/sodium bicarbonate	omeprazole-sodium bicarbonate
omeprazole/sodium bicarbonate	Zegerid
omeprazole/sodium bicarbonate	Zegerid OTC
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCI/PF	ondansetron HCl (PF)
osilodrostat phosphate	Isturisa
osimertinib mesylate	Tagrisso
oxaliplatin	oxaliplatin
oxytocin	oxytocin
pxytocin	Pitocin
oxytocini oxytocin in 0.9 % sodium chloride	oxytocin in 0.9 % sod chloride
	oxytocin in dextrose 5 % in LR
oxytocin in dextrose 5 %-lactated ringers	5.7, 13011 III GEAG 330 3 70 III EN
- · · · · · · · · · · · · · · · · · · ·	oxytocin in lactated ringers
oxytocin/Ringer's solution,lactated	oxytocin in lactated ringers Zenosia
oxytocin in dextrose 5 %-lactated ringers oxytocin/Ringer's solution,lactated ozanimod hydrochloride ozanimod hydrochloride	oxytocin in lactated ringers Zeposia Zeposia Starter Kit

cder_mpl1p_wp077 Page 937 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name		
paliperidone	Invega		
paliperidone	paliperidone		
paliperidone palmitate	Invega Hafyera		
paliperidone palmitate	Invega Sustenna		
paliperidone palmitate	Invega Trinza		
palonosetron HCl	palonosetron		
panobinostat lactate	Farydak		
pantoprazole sodium	pantoprazole		
pantoprazole sodium	Protonix		
papaverine HCl	papaverine		
papaverine HCI/phentolamine mesylate in water	IFE-BiMix 30/1		
papaverine HCI/phentolamine mesylate/alprostadil	Tri-Mix (papavrn-phntlmn-PGE1)		
paroxetine HCl	paroxetine HCl		
paroxetine HCl	Paxil		
paroxetine HCl	Paxil CR		
paroxetine mesylate	Brisdelle		
paroxetine mesylate	paroxetine mesylate(menop.sym)		
paroxetine mesylate	Pexeva		
pasireotide diaspartate	Signifor		
pasireotide pamoate	Signifor LAR		
pazopanib HCl	Votrient		
pentamidine isethionate	Nebupent		
pentamidine isethionate	Pentam		
pentamidine isethionate	pentamidine		
perphenazine	perphenazine		
perphenazine/amitriptyline HCl	perphenazine-amitriptyline		
phenylephrine HCl/diphenhydramine HCl	Allergy and Sinus Relief		
phenylephrine HCl/diphenhydramine HCl	Benadryl Allergy Plus Congest		
phenylephrine HCl/diphenhydramine HCl	Child Allergy Plus Congestion		
phenylephrine HCl/diphenhydramine HCl	Child Benadryl Plus Congestion		
phenylephrine HCl/diphenhydramine HCl	Children Night Time Cold-Cough		
phenylephrine HCl/diphenhydramine HCl	Childs Triacting Cold-Cough		
phenylephrine HCl/diphenhydramine HCl	Dimetapp Cold-Congestion		
phenylephrine HCl/diphenhydramine HCl	Dr Manzanilla Cough-Cold		
phenylephrine HCl/diphenhydramine HCl	KinderMed Kid Night Cold-Cough		
phenylephrine HCI/diphenhydramine HCI	Sudafed PE Day and Night		
phenylephrine HCl/diphenhydramine HCl	Triaminic Cold and CoughNT(PE)		
phenylephrine HCl/diphenhydramine HCl	Wal-Dryl-D Allergy and Sinus		
phenylephrine HCl/promethazine HCl	Promethazine VC		
phenylephrine HCl/promethazine HCl	promethazine-phenylephrine		
pimavanserin tartrate	Nuplazid		
pimozide	pimozide		
piperacillin and tazobactam in dextrose, iso-osmotic	Zosyn in dextrose (iso-osm)		
piperacillin sodium/tazobactam sodium	piperacillin-tazobactam		
pitolisant HCl	Wakix		
ponesimod	Ponvory		
ponesimod	Ponvory 14-Day Starter Pack		
posaconazole	Noxafil		
posaconazole	posaconazole		
pralsetinib	Gavreto		
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin		
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen		
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl		
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen		

cder_mpl1p_wp077 Page 938 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
prednisolone acetate/moxifloxacin HCI/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/gatinoxacin/brofineriac sodium prednisolone sodium phosphate/moxifloxacin HCl	prednisolne sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac	prednisolone sod pri-moxinox
sod	prednisoln sp-moxiflox-bromfen
pretomanid	pretomanid
primaquine phosphate	primaquine
procainamide HCl	procainamide
promethazine HCl	Phenergan
promethazine HCl	promethazine
promethazine HCl	Promethegan
promethazine HCl in 0.9 % sodium chloride	promethazine in 0.9 % NaCl
promethazine HCI/codeine	promethazine-codeine
promethazine HCl/dextromethorphan HBr	promethazine-DM
promethazine/phenylephrine HCl/codeine	Promethazine VC-Codeine
promethazine/phenylephrine HCl/codeine	promethazine-phenyleph-codeine
propafenone HCl	propafenone
propafenone HCl	Rythmol SR
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
quetiapine fumarate	quetiapine
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
quinine sulfate	Qualaquin
quinine sulfate	quinine sulfate
ranolazine	Aspruzyo Sprinkle
ranolazine	Ranexa
ranolazine	ranolazine
relugolix	Orgovyx
relugolix/estradiol/norethindrone acetate	Myfembree
remdesivir	remdesivir
remdesivir	Veklury
remimazolam besylate	Byfavo
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
rilpivirine	rilpivirine
rilpivirine HCl	Edurant
risperidone	Perseris
risperidone	Risperdal
risperidone	risperidone
risperidone microspheres	Risperdal Consta
•	•

cder_mpl1p_wp077 Page 939 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
romidepsin	Istodax
romidepsin	romidepsin
rucaparib camsylate	Rubraca
saquinavir mesylate	Invirase
selpercatinib	Reteymo
sertraline HCl	sertraline
sertraline HCl	Zoloft
sevoflurane	sevoflurane
sevoflurane	Ultane
siponimod	Mayzent
siponimod	Mayzent Starter(for 1mg maint)
siponimod	Mayzent Starter(for 2mg maint)
solifenacin succinate	solifenacin
solifenacin succinate	Vesicare
solifenacin succinate	Vesicare LS
sorafenib tosylate	Nexavar
sorafenib tosylate	sorafenib
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
sunitinib malate	sunitinib
sunitinib malate	Sutent
tacrolimus	Astagraf XL
tacrolimus	Envarsus XR
tacrolimus	Prograf
tacrolimus	tacrolimus
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tazemetostat hydrobromide	Tazverik
tebentafusp-tebn	Kimmtrak
telavancin HCl	Vibativ
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
terlipressin acetate	Terlivaz
tetrabenazine	tetrabenazine
tetrabenazine	Xenazine
thioridazine HCl	thioridazine
tizanidine HCl	tizanidine
tizanidine HCl	Zanaflex
tizanidine HCl/irritant counter-irritants combination no.2	Comfort Pac-tizanidine
tolterodine tartrate	Detrol
tolterodine tartrate	Detrol LA
tolterodine tartrate	tolterodine
toremifene citrate	Fareston
toremifene citrate	toremifene
torsemide	Soaanz
torsemide	torsemide
tramadol HCl	ConZip
tramadol HCl	Qdolo

cder_mpl1p_wp077 Page 940 of 990



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name		
tramadol HCl	tramadol		
tramadol HCl	Ultram		
tramadol HCI/acetaminophen	tramadol-acetaminophen		
tramadol HCI/acetaminophen	Ultracet		
tramadol HCI/celecoxib	Seglentis		
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn		
trazodone HCl	trazodone		
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)		
triamterene/hydrochlorothiazide	Maxzide		
triamterene/hydrochlorothiazide	Maxzide-25mg		
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid		
trifluridine/tipiracil HCl	Lonsurf		
trimipramine maleate	trimipramine		
valbenazine tosylate	Ingrezza		
valbenazine tosylate	Ingrezza Initiation Pack		
valsartan/hydrochlorothiazide	Diovan HCT		
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide		
vandetanib	Caprelsa		
vardenafil HCl	vardenafil		
vemurafenib	Zelboraf		
venlafaxine besylate	venlafaxine besylate		
venlafaxine HCl	Effexor XR		
venlafaxine HCl	venlafaxine		
voclosporin	Lupkynis		
vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak		
voriconazole	Vfend		
voriconazole	Vfend IV		
voriconazole	voriconazole		
vorinostat	Zolinza		
ziprasidone HCl	Geodon		
ziprasidone HCl	ziprasidone HCl		
ziprasidone mesylate	Geodon		
ziprasidone mesylate	ziprasidone mesylate		

cder_mpl1p_wp077 Page 941 of 990



Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for 183 Days Lookback, Cohorts 1-3)

To describe the incidence rate of hospitalized arrhythmia, defined as principal diagnosis of arrhythmia in the emergency department visit or inpatient hospital setting, overall and by subtype, that occurred between May 13, 2022 (the approval date of Mounjaro in the U.S.) to June 30, 2023 (the end date of the latest available data), in adult T2DM patients who newly initiated tirzepatide or other long-acting GLP-1 receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

- report 02 has a preindex enrollment requirement of 183 days (sensitivity analysis)

Query period start date (binds Index Date): May 13, 2022 (tirzepatide approval date in U.S.)

Query period end date (binds Index Date): June 30, 2023

Coverage requirement: Medical & Drug Coverage

Pre-index enrollment requirement: 183 days (sensitivity analyses)

Post-index enrollment requirement: $_{\text{N/A}}$

Enrollment gap: 45 days

Age groups: 0-40, 41-64, 65-74, 75-84, 85+ years old

Sex groups: Male, Female

Race groups: White, Black or African American, Asian, American Indian or Alaska Native, Native

Hawaiian or Other Pacific Islander, Unknown, Multi-Racial

Stratifications: Age group (0-40, 41-64, 65-74, 75-84, ≥85)

Sex (M F) Calendar Year

Race (White, Black or African American, Asian, American Indian or Alaska Native,

Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)

Calendar Year * Race Age group * Race Arrhythmia at baseline

Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive

sleep apnea, and hypertrophic cardiomyopathy)

Censor output stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+); Continuous **Follow-up time stratifications:** Categorical (0-30 31-60 61-90 91-183 184-365 366-455+); Continuous

Envelope macro: No reclassification

Features: Censoring table, follow-up time table, exposure/HOI code distribution tables

Plus programming:

- Disease severity risk score and comorbidity score categorical bins

- Report baseline characteristics, effect estimates by race

- Truncation code distribution

Freeze data: No Notes: N/A

cder mpl1p wp077 Page 942 of 990



	Cohort Group 1	for 183 Days Lookback, Cohorts 1-3) Cohort Group 2	Cohort Group 3
-	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Exposure	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Code Details (type, days supply,	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Incident with respect to:	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,
	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,
	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Code Details (type, days supply,	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Washout (days)	183 days	183 days	183 days
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Exposure Episode Truncation	*Death	*Death	*Death
Criteria	*Disenrollment	*Disenrollment	*Disenrollment
	*DP end date	*DP end date	*DP end date
	*Study period end date	*Study period end date	*Study period end date
	*Pregnancy	*Pregnancy	*Pregnancy
	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-
	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)
	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA
	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on
	implementation)	implementation)	implementation)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
(This does not apply to index-			
defining criteria)			
Forced supply to attach to codes	N/A	N/A	N/A



Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for 183 Days Lookback, Cohorts 1-3) **Cohort Group 1 Cohort Group 2 Cohort Group 3 Exenatide synthetic** Semaglutide **Tirzepatide** (Mounjaro) (Bydureon, Bydureon BCISE) (Ozempic) **Cohort Definition** Only the first valid treatment episode Only the first valid treatment episode Only the first valid treatment episode during the query period (01) during the query period (01) during the query period (01) **Prevalent Cohort creation?** No No No **Exposure Episode Gap** 5 days 5 days 5 days **Exposure Extension Period** 5 days 5 days 5 days **Minimum Episode Duration** 1 day 1 dav 1 day Minimum Days Supplied 1 day 1 day 1 day Point Exposure? No No No **Maximum Episode Duration** N/A N/A N/A Event/Outcome Hospitalized tachyarrhythmia Hospitalized tachyarrhythmia Hospitalized tachyarrhythmia

a
Ĕ
ţ
2
ort
ě
e C
3as
ш

Code Details (type, days supply,	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
etc.)			
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day



		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide	Exenatide synthetic	Semaglutide
		(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar
	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
		event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
	when considering washout, i.e. ignore days supply (after stockpiling)?			
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
_	5 ./0 :	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Event/Outcome	•	·	•
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar
	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
		event characteristics (0)	event characteristics (0)	event characteristics (0)



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Only consider dispensing date when considering washout, i.e. ignore days supply (after	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during a exposure episode are counted for event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
Code Details (type, days supply,	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
etc.)			
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
·	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Page 947 of 990



		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide	Exenatide synthetic	Semaglutide
		(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for al event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
L	Blackout Period	1 day	1 day	1 day
	T/	V		
	Event/Outcome Code Details (type, days supply, etc.)	Ventricular tachycardia Diagnosis (DX) codes	Ventricular tachycardia Diagnosis (DX) codes	Ventricular tachycardia Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
I	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for al event characteristics (0)



,	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Only consider dispensing date when considering washout, i.e. ignore days supply (after	No	No	No
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Include or Exclude	Inclusion	Inclusion	Inclusion
Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	AND	AND	AND
Include or Exclude	Inclusion	Inclusion	Inclusion
Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			



Cohort Group 1	Cohort Group 2	Cohort Group 3
Tirzepatide	Exenatide synthetic	Semaglutide
(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
N/A	N/A	N/A
1x	1x	1x
AND (AND (AND (
Exclusion	Exclusion	Exclusion
Insulin	Insulin	Insulin
Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Any	Any	Any
		(-183, -1)
		(-183, -1) No
NO	NO	NO
·	· · · · · · · · · · · · · · · · · · ·	N/A
1x		1x
AND NOT	AND NOT	AND NOT
Exclusion	Exclusion	Exclusion
Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
,	,	Any
		(-183, -1)
No	No	No
N/A	N/A	N/A
1x	1x	1x
	Tirzepatide (Mounjaro) N/A 1x AND (Exclusion Insulin Dispensing (RX) codes Any (-183, -1) No N/A 1x AND NOT Exclusion Any anti-diabetic drug other than insulin Dispensing (RX) codes Any (-183, -1) No	Tirzepatide (Mounjaro) N/A N/A N/A 1x AND (Exclusion Insulin Dispensing (RX) codes Any (-183, -1) NAD NOT Exclusion Any AND NOT Exclusion Any AND NOT Exclusion Any AND NOT AND NOT Exclusion Any Any Any (-183, -1) No No No No No No No No Any Any Any Any Any Any Any An



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
<u> </u>	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illnes
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Short-acting GLP-1 RA	Short-acting GLP-1 RA	Short-acting GLP-1 RA
Contactions	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua
Code Details (type, days supply,	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
<u> </u>	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Pregnancy	Pregnancy	Pregnancy
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x



		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide	Exenatide synthetic	Semaglutide
		(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
	Include or Exclude	Exclusion	Exclusion	Exclusion
		Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	o 111.	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro
	Conditions	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,
		Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
ı	Code Details (type, days supply,	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	etc.)			
	Care Setting/PDX	Any	Any	Any
ı	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	Group(s) Affected by Custom	Long or Chart acting CLD 1 DAs by brand	Long or Short acting CLD 1 DAs by brand	Long or Chart acting CLD 1 DAs by bran
		Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by bran
	Stockpiling Rules	name	name	name
		(for Victoza, both brand names	(for Victoza, both brand names	(for Victoza, both brand names
		consolidated to one stockgroup)	consolidated to one stockgroup)	consolidated to one stockgroup)
		(Other RXs by generic name, default	(Other RXs by generic name, default	(Other RXs by generic name, default
		stockpiling rules)	stockpiling rules)	stockpiling rules)
ı	Same Day Processing (days	Max	Max	Max
	supply)			
	Same Day Processing (amount	Max	Max	Max
	supply)			
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of	0%	0%	0%
	Percentage Overlap Allowed	(No shifting of index date;	(No shifting of index date;	(No shifting of index date;
	Prior to Shifting Dispensing Date	truncate previous dispensing at any	truncate previous dispensing at any	truncate previous dispensing at any
		overlap with next dispensing)	overlap with next dispensing)	overlap with next dispensing)



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
© Code Details (type, days supply,	(See Appendix I)	(See Appendix I)	(See Appendix I)
etc.)			
Code Details (type, days supply, etc.) Care Setting/PDX Covariate evaluation window	N/A	N/A	N/A
Covariate evaluation window	(See Appendix I)	(See Appendix I)	(See Appendix I)
(days)			
© Comorbidity Score evaluation window (days)	(-183, -1)	(-183, -1)	(-183, -1)
Medical Utilization Evaluation Window Medical Utilization Care setting Drug Utilization Evaluation	(-183, -1)	(-183, -1)	(-183, -1)
Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
E Drug Utilization Evaluation	(-183, -1)	(-183, -1)	(-183, -1)
O Diag Camzation Transaction	(=00) =/	(, -,	(, -,

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable



	. Specifications Defining Parameters for this Request (Sensitivity Analysis for 183 Days Lookback, Cohorts 4-6)		
	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Exposure	Semaglutide	Semaglutide	Liraglutide
	(Rvbelsus)	(Wegovv)	(Saxenda)
Code Details (type, days	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
supply, etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Incident with respect to:	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,
	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,
	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Code Details (type, days	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
supply, etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Washout (days)	183 days	183 days	183 days
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Exposure Episode Truncation	*Death	*Death	*Death
Criteria	*Disenrollment	*Disenrollment	*Disenrollment
	*DP end date	*DP end date	*DP end date
	*Study period end date	*Study period end date	*Study period end date
	*Pregnancy	*Pregnancy	*Pregnancy
	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-
	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)
	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA
	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on
	implementation)	implementation)	implementation)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
(This does not apply to index-			
defining criteria)			
Forced supply to attach to	N/A	N/A	N/A



	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Cohort Definition	Only the first valid treatment episode	Only the first valid treatment episode	Only the first valid treatment epis
	during the query period (01)	during the query period (01)	during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A
Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
supply, etc.)			
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect	N/A	N/A	N/A
to			
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted fo
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes			
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day



ppendix	(H. Specifications Defining Parame	ters for this Request (Sensitivity Analysis	for 183 Days Lookback, Cohorts 4-6)	
		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)			
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	to			
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX		·	·
a)	Event washout (days)	0 days	0 days	0 days
Outcome	` ' '	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
rtcc	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
õ	·	event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes	,	.,,	,,,
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
-				
	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)			
пе	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
200	Event Incidence with Respect	N/A	N/A	N/A
Outcome	to			
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX		·	·
1	Event washout (days)	0 days	0 days	0 days



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
-		(Rybelsus)	(Wegovy)	(Saxenda)
		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
		event characteristics (0)	event characteristics (0)	event characteristics (0)
ĺ	Only consider dispensing date	No	No	No
ı	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
ľ	Forced supply to attach to	N/A	N/A	N/A
	codes			
ľ	Start of at-risk period	N/A	N/A	N/A
I	Blackout Period	1 day	1 day	1 day
	_			
I	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
ı	supply, etc.)			
I	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
l	to			
ĺ	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
ľ	Event washout (days)	0 days	0 days	0 days
		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar
	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
		event characteristics (0)	event characteristics (0)	event characteristics (0)
ľ	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes	•	,	·
ŀ	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
_		= +1	=,	=,

Page 958 of 990



···		ters for this Request (Sensitivity Analysis		Cohout Corres C
	ŀ	Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
_		(Rybelsus)	(Wegovy)	(Saxenda)
Г	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	to			
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
a	Event washout (days)	0 days	0 days	0 days
Outcome		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during a
ntc	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
ō	,	event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)	Diagnosis (DN) codes	Biaginosis (BN) codes	Biaginosis (BN) codes
ne	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
S	Event Incidence with Respect	N/A	N/A	N/A
Outcome	to			
-	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
Г		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
		event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
ω	when considering washout, i.e.			
Ē	ignore days supply (after			
Jutcome	stockpiling)?			
٥	Forced supply to attach to	N/A	N/A	N/A
	codes		.,	.,,
	Start of at-risk period	N/A	N/A	N/A
L	Blackout Period	1 day	1 day	1 day
ı	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)	ζ , ,	5 (,	
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	to			
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
a)	Event washout (days)	0 days	0 days	0 days
Outcome		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
ntc	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for al
ō		event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day



JIX	n. Specifications Defining Parame	ters for this Request (Sensitivity Analysis		
		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during a exposure episode are counted for a event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
L	Blackout Period	1 day	1 day	1 day
_		<u> </u>		
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions Code Details (type, days supply, etc.)	Type 2 Diabetes Diagnosis (DX) codes	Type 2 Diabetes Diagnosis (DX) codes	Type 2 Diabetes Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
ווכומאוסוו/ באכומאוסוו כו ונכוומ	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A

Page 961 of 990



dix	H. Specifications Defining Parameter	rs for this Request (Sensitivity Analysis	for 183 Days Lookback, Cohorts 4-6)	
		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	Number of Code Occurrences	1x	1x	1x
	-	AND	AND	AND
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
5	Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
2	supply, etc.)			
5	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
í	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
2	Forced supply to attach to	N/A	N/A	N/A
	codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND (AND (AND (
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
5	supply, etc.)			
	Care Setting/PDX	Any	Any	Any
5	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
9	ignore days supply (after			
5	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes	, ·	,	- 77
	Number of Code Occurrences	1x	1x	1x



		Cohort Group 4	for 183 Days Lookback, Cohorts 4-6) Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	-	AND NOT	AND NOT	AND NOT
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions		Any anti-diabetic drug other than insulin	
0	Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
ב ע	supply, etc.)			
5	Care Setting/PDX	Any	Any	Any
5	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
2	Only consider dispensing date	No	No	No
Z	when considering washout, i.e.			
2	ignore days supply (after			
inciusiori/ Exclusiori Criteria	stockpiling)?			
2	Forced supply to attach to	N/A	N/A	N/A
	codes	,	·	·
	Number of Code Occurrences	1x	1x	1x
) OR) OR) OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
σ	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
<u> </u>	supply, etc.)			
5	Care Setting/PDX	Any	Any	Any
5	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
2	Only consider dispensing date	No	No	No
ž	when considering washout, i.e.			
	ignore days supply (after			
inciusion/exclusion criteria	stockpiling)?			
2	Forced supply to attach to	N/A	N/A	N/A
	codes	,	,	,
	Number of Code Occurrences	1x	1x	1x



	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
code Details (type, days supply, etc.) Care Setting/PDX Lookback Period Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illnes
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Code Details (type, days supply, etc.) Care Setting/PDX Lookback Period Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	0 100	Short-acting GLP-1 RA	Short-acting GLP-1 RA	Short-acting GLP-1 RA
	Conditions	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
<u> </u>	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	_	OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	-	OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
		Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
inclusion) Exclusion (washour) of items		(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjard
	Conditions	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity
		Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
	Code Details (type, days	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	supply, etc.)			
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Number of Code Occurrences	1x	1x	1x
	Group(s) Affected by Custom	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by bra
	Stockpiling Rules	name	name	name
		(for Victoza, both brand names	(for Victoza, both brand names	(for Victoza, both brand names
		consolidated to one stockgroup)	consolidated to one stockgroup)	consolidated to one stockgroup)
		(Other RXs by generic name, default	(Other RXs by generic name, default	(Other RXs by generic name, default
		stockpiling rules)	stockpiling rules)	stockpiling rules)
	Same Day Processing (days	Max	Max	Max
Ī	supply)			
	Same Day Processing (amount	Max	Max	Max
	supply)			
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount	Greater than 0	Greater than 0	Greater than 0
	Allowable Kalige (allioulit	Greater than o	Greater than 0	Greater triair o



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	Maximum Amount of	0%	0%	0%
	Percentage Overlap Allowed	(No shifting of index date;	(No shifting of index date;	(No shifting of index date;
	Prior to Shifting Dispensing	truncate previous dispensing at any	truncate previous dispensing at any	truncate previous dispensing at an
	Date	overlap with next dispensing)	overlap with next dispensing)	overlap with next dispensing)
-	,			
	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
es	Code Details (type, days	(See Appendix I)	(See Appendix I)	(See Appendix I)
Covariates	supply, etc.)			
ovariate	Care Setting/PDX	N/A	N/A	N/A
S	Covariate evaluation window	(See Appendix I)	(See Appendix I)	(See Appendix I)
	(days)			
	Comorbidity Score evaluation	(-183, -1)	(-183, -1)	(-183, -1)
core	window (days)	(103,-1)	(-165, -1)	(-105, -1)
ty So	Medical Utilization Evaluation	(-183, -1)	(-183, -1)	(-183, -1)
Comorbidity Score	Window			
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
Com	Drug Utilization Evaluation	(-183, -1)	(-183, -1)	(-183, -1)
_	Window			

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable



H. Specifications Defining Parameters for this Request (Sensitivity Analysis for 183 Days Lookback, Cohorts 7-9)			
	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
7_	(Victoza)	(Trulicity)	(Xultophy)
Exposure	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Code Details (type, days	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
supply, etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Incident with respect to:	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,
	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,
	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Code Details (type, days	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
supply, etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Washout (days)	183 days	183 days	183 days
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Exposure Episode Truncation	*Death	*Death	*Death
Criteria	*Disenrollment	*Disenrollment	*Disenrollment
	*DP end date	*DP end date	*DP end date
	*Study period end date	*Study period end date	*Study period end date
	*Pregnancy	*Pregnancy	*Pregnancy
	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-
	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)
	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA
	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on
	implementation)	implementation)	implementation)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
(This does not apply to index-			
defining criteria)			



	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Forced supply to attach to	N/A	N/A	N/A
codes			
Cohort Definition	Only the first valid treatment episode	Only the first valid treatment episode	Only the first valid treatment episod
	during the query period (01)	during the query period (01)	during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A
Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
supply, etc.)	Diagnosis (DA) codes	Diagnosis (DA) codes	Diagnosis (DA) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect	N/A	N/A	N/A
to			
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during a
	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes			
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day



		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
			21	
	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
Outcome	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar
100		exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
3		event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
L	Blackout Period	1 day	1 day	1 day
г	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)	Diagnosis (DA) codes	Diagnosis (DA) codes	Diagnosis (DA) codes
ne	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Outcome	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days



		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
		exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
		event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
3	ignore days supply (after			
5	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Start of at-risk period	N/A	N/A	N/A
L	Blackout Period	1 day	1 day	1 day
	_			
	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	supply, etc.)			
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	to			
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
,	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during a
		exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
ľ		event characteristics (0)	event characteristics (0)	event characteristics (0)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
I	Forced supply to attach to	N/A	N/A	N/A
I	codes			
I	Start of at-risk period	N/A	N/A	N/A
ı	Blackout Period	1 day	1 day	1 day

Page 971 of 990



<u>ndix</u>	H. Specifications Defining Parame	ters for this Request (Sensitivity Analysis			
		Cohort Group 7	Cohort Group 8	Cohort Group 9	
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide	
		(Victoza)	(Trulicity)	(Xultophy)	
	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia	
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes	
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*	
	Event Incidence with Respect to	N/A	N/A	N/A	
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A	
1)	Event washout (days)	0 days	0 days	0 days	
Outcome	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar	
2	·	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a	
5		event characteristics (0)	event characteristics (0)	event characteristics (0)	
	Only consider dispensing date	No	No	No	
	when considering washout, i.e.				
	ignore days supply (after				
	stockpiling)?				
	Forced supply to attach to	N/A	N/A	N/A	
	codes	ŕ	·	,	
	Start of at-risk period	N/A	N/A	N/A	
L	Blackout Period	1 day	1 day	1 day	
Г	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest	
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes	
	supply, etc.)	5 (,			
иe	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*	
Jutcome	Event Incidence with Respect	N/A	N/A	N/A	
	to				
	Event Incidence Criteria	N/A	N/A	N/A	
	Care Setting / PDX				
1	Event washout (days)	0 days	0 days	0 days	



		Cohort Group 7	Cohort Group 8	Cohort Group 9				
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide				
		(Victoza)	(Trulicity)	(Xultophy)				
	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an				
		exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for al				
		event characteristics (0)	event characteristics (0)	event characteristics (0)				
	Only consider dispensing date	No	No	No				
	when considering washout, i.e.							
	ignore days supply (after							
	stockpiling)?							
	Forced supply to attach to	N/A	N/A	N/A				
	codes							
	Start of at-risk period	N/A	N/A	N/A				
L	Blackout Period	1 day	1 day	1 day				
	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter				
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes				
	supply, etc.)							
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*				
	Event Incidence with Respect	N/A	N/A	N/A				
	to							
	Event Incidence Criteria	N/A	N/A	N/A				
	Care Setting / PDX							
	Event washout (days)	0 days	0 days	0 days				
	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar				
		exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a				
1		event characteristics (0)	event characteristics (0)	event characteristics (0)				
	Only consider dispensing date	No	No	No				
	when considering washout, i.e.							
	ignore days supply (after							
	stockpiling)?							
	Forced supply to attach to	N/A	N/A	N/A				
	codes			·				
	Start of at-risk period	N/A	N/A	N/A				
	Blackout Period	1 day	1 day	1 day				



pendix	H. Specifications Defining Parame	ters for this Request (Sensitivity Analysis	for 183 Days Lookback, Cohorts 7-9)		
		Cohort Group 7	Cohort Group 8	Cohort Group 9	
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide	
		(Victoza)	(Trulicity)	(Xultophy)	
_					
	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia	
	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes	
	supply, etc.)				
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*	
	Event Incidence with Respect	N/A	N/A	N/A	
	to				
	Event Incidence Criteria	N/A	N/A	N/A	
	Care Setting / PDX				
a)	Event washout (days)	0 days	0 days	0 days	
Outcome	Event de-duplication	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an	
rtc		exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for al	
õ		event characteristics (0)	event characteristics (0)	event characteristics (0)	
	Only consider dispensing date	No	No	No	
	when considering washout, i.e.				
	ignore days supply (after				
	stockpiling)?				
	Forced supply to attach to	N/A	N/A	N/A	
	codes			.,,	
	Start of at-risk period	N/A	N/A	N/A	
	Blackout Period	1 day	1 day	1 day	
<u> </u>	Siderical Cited	Tudy	1 day	1 44,	
σ.	Include or Exclude	Inclusion	Inclusion	Inclusion	
eri	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes	
ij	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes	
, L	supply, etc.)				
usic	Care Setting/PDX	Any	Any	Any	
Inclusion/Exclusion Criteria	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)	
n/E	Only consider dispensing date	No	No	No	
Sio	when considering washout, i.e.				
n	ignore days supply (after				
=	stockpiling)?				



	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Forced supply to attach to	N/A	N/A	N/A
codes			
Number of Code Occurrences	1x	1x	1x
_	AND	AND	AND
Include or Exclude	Inclusion	Inclusion	Inclusion
Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
supply, etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes	·	,	,
Number of Code Occurrences	1x	1x	1x
<u> </u>	AND (AND (AND (
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Insulin	Insulin	Insulin
Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
supply, etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes			
 	1x	1x	1x

Page 975 of 990



	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
	AND NOT	AND NOT	AND NOT
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insul
Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
supply, etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes			
Number of Code Occurrences	1x	1x	1x
) OR) OR) OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
supply. etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes			
Number of Code Occurrences	1x	1x	1x



ndix l	H. Specifications Defining Paramet	ters for this Request (Sensitivity Analysis	for 183 Days Lookback, Cohorts 7-9)	
		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
	_	OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
<u> </u>	Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
<u>:</u> te	supply, etc.)			
בֿ	Care Setting/PDX	Any	Any	Any
<u> </u>	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
Ĕ	when considering washout, i.e.			
on/	ignore days supply (after			
inciusion/exclusion Criteria	stockpiling)?			
≦	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illnes
<u>a</u>	Code Details (type, days	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
ite	supply, etc.)			
בֿן	Care Setting/PDX	Any	Any	Any
<u> </u>	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
Ĭ	when considering washout, i.e.			
on,	ignore days supply (after			
inciusion/Exciusion Criteria	stockpiling)?			
u L	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Number of Code Occurrences	1x	1x	1x



	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Short-acting GLP-1 RA	Short-acting GLP-1 RA	Short-acting GLP-1 RA
	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua)
Code Details (type, days	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
supply, etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes			
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Pregnancy	Pregnancy	Pregnancy
Code Details (type, days	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
supply, etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to	N/A	N/A	N/A
codes	•		
Number of Code Occurrences	1x	1x	1x



1111	n. Specifications Defining Parame	ters for this Request (Sensitivity Analysis		Calland C
		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
	=	OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
		(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjard
		Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity
		Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
	Code Details (type, days	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	supply, etc.)			
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-183, -1)	(-183, -1)	(-183, -1)
	Only consider dispensing date	No	No	No
	when considering washout, i.e.			
	ignore days supply (after			
	stockpiling)?			
	Forced supply to attach to	N/A	N/A	N/A
	codes			
	Number of Code Occurrences	1x	1x	1x
	Group(s) Affected by Custom	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by bra
	Stockpiling Rules	name	name	name
		(for Victoza, both brand names	(for Victoza, both brand names	(for Victoza, both brand names
		consolidated to one stockgroup)	consolidated to one stockgroup)	consolidated to one stockgroup)
		(Other RXs by generic name, default	(Other RXs by generic name, default	(Other RXs by generic name, default
		stockpiling rules)	stockpiling rules)	stockpiling rules)
	Same Day Processing (days	Max	Max	Max
	supply)			
	Same Day Processing (amount	Max	Max	Max
	supply)			
l	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount	Greater than 0	Greater than 0	Greater than 0
ĺ	supply)			



		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
	Maximum Amount of	0%	0%	0%
	Percentage Overlap Allowed	(No shifting of index date;	(No shifting of index date;	(No shifting of index date;
	Prior to Shifting Dispensing	truncate previous dispensing at any	truncate previous dispensing at any	truncate previous dispensing at an
	Date	overlap with next dispensing)	overlap with next dispensing)	overlap with next dispensing)
-	_			
	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
es	Code Details (type, days	(See Appendix I)	(See Appendix I)	(See Appendix I)
Covariates	supply, etc.)			
val	Care Setting/PDX	N/A	N/A	N/A
ပိ	Covariate evaluation window	(See Appendix I)	(See Appendix I)	(See Appendix I)
	(days)			
_				
Score	Comorbidity Score evaluation window (days)	(-183, -1)	(-183, -1)	(-183, -1)
orbidity So	Medical Utilization Evaluation	(-183, -1)	(-183, -1)	(-183, -1)
Comorbidity	Window			
orb	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
E O	Drug Utilization Evaluation	(-183, -1)	(-183, -1)	(-183, -1)
O	Window			

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable



Only consider dispensing date when considering baseline characteristics, i.e.

			Care	Covariate		Minimum # of	ignore days supply	Forced supply to
Group	No.	Covariate	Setting	Window	Code Type	Instances	(after stockpiling)?	attach to codes
Demographic	N/A	Continuous age	N/A	Index Day	N/A	N/A	N/A	N/A
Characteristics	N/A	Age groups (0-40, 41-64, 65-74, 75-84, 85+)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Race (White, Black or African American,	N/A	Index Day	N/A	N/A	N/A	N/A
		Asian, American Indian or Alaska Native,						
		Native Hawaiian or Other Pacific Islander,						
		Unknown, Multi-Racial)						
	N/A	Sex (M F)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Calendar year	N/A	Index Day	N/A	N/A	N/A	N/A
ifestyle Risk	1	Alcohol use or abuse	Any	(-183, -1)	Diagnosis	1x	No	N/A
Factor	2	Obesity	Any		Diagnosis	1x	N/A	N/A
	3	Tobacco Use	Any		Diagnosis	1x	No	N/A
∕ledical	4	Arrhythmia	Any	(-183, -1)	Diagnosis	1x	No	N/A
listory	5	Cerebrovascular disease/stroke/transient	Any	(-183, -1)	Diagnosis	1x	No	N/A
		ischemic attack						
	6	Chronic kidney disease	Any	(-183, -1)	Diagnosis	1x	No	N/A
	7	Chronic obstructive pulmonary disease	Any	(-183, -1)	Diagnosis	1x	No	N/A
	8	Congenital heart disease	Any	(-183, -1)	Diagnosis	1x	No	N/A
	9	Heart failure	Any	(-183, -1)	Diagnosis	1x	No	N/A
	10	Hyperlipidemia	Any	(-183, -1)	Diagnosis	1x	No	N/A
	11	Hypertensive disease	Any		Diagnosis	1x	No	N/A
	12	Thyroid disease	Any	(-183, -1)	Diagnosis	1x	No	N/A
	13	Ischemic heart disease/coronary artery	Any	(-183, -1)	Diagnosis	1x	No	N/A
		disease/myocardial infarction						
	14	Left ventricular hypertrophy	Any	(-183, -1)	Diagnosis	1x	No	N/A
	15	Peripheral artery disease	Any		Diagnosis	1x	No	N/A
	16	Valvular/mitral valve disease	Any	1	Diagnosis	1x	No	N/A
	17	Diseases of veins and lymphatics, and other	Any	(-183, -1)	Diagnosis	1x	No	N/A
		diseases of circulatory systemstem						
	18	Obstructive sleep apnea	Any	(-183, -1)	Diagnosis	1x	No	N/A
	19	Hypertrophic cardiomyopathy	Any		Diagnosis	1x	No	N/A



			Care	Covariate		Minimum # of	ignore days supply	Forced supply to
Group	No.	Covariate	Setting	Window	Code Type	Instances	(after stockpiling)?	attach to codes
	20	Other cardiac disease (heart failure,	N/A	N/A	Complex	N/A	N/A	N/A
		ischemic heart disease/coronary artery			Covariate			
		disease/myocardial infarction, hypertension,						
		valvular disease, obstructive sleep apnea,						
		and hypertrophic cardiomyopathy)						
	21	Tachyarrhythmia Day 0	Any	(0, 0)	Diagnosis	1x	No	N/A
	22	Hospitalized Tachyarrhythmia Day 0	ED*, IP*	(0, 0)		1x	No	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index	N/A	(-183, -1)	N/A	N/A	N/A	N/A
	Risk score	Charlson/Elixhauser combined comorbidity	N/A	(-183, -1)	Custom Coding	N/A	N/A	N/A
	(custom)	index (0)						
	Risk score	Charlson/Elixhauser combined comorbidity	N/A	(-183, -1)	Custom Coding	N/A	N/A	N/A
	(custom)	index (1 or 2)						
	Risk score	Charlson/Elixhauser combined comorbidity	N/A	(-183, -1)	Custom Coding	N/A	N/A	N/A
	(custom)	index (3 or 4)						
	Risk score	Charlson/Elixhauser combined comorbidity	N/A	(-183, -1)	Custom Coding	N/A	N/A	N/A
	(custom)	index (5 or greater)						
Severity of	Risk score	Diabetes complications severity index	Any	(-183, -1)	Risk Score	1x	No	N/A
Diabetes	Risk score	Diabetes complications severity index (0)	Any	(-183, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (1)	Any	(-183, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (2)	Any	(-183, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (3)	Any	(-183, -1)	Custom Coding	1x	No	N/A
	(custom)							
	Risk score	Diabetes complications severity index (4)	Any	(-183, -1)	Custom Coding	1x	No	N/A
	(custom)							



			Care	Covariate		Minimum # of	ignore days supply	Forced supply to
Group	No.	Covariate	Setting	Window	Code Type	Instances	(after stockpiling)?	attach to codes
	Risk score	Diabetes complications severity index (5 or	Any	(-183, -1)	Custom Coding	1x	No	N/A
	(custom)	greater)						
	25	History of serious hypoglycemia (emergency	ED*, IP*	(-183, -1)	Diagnosis	1x	No	N/A
		department visit and/or inpatient care)						
Baseline Use	26	Alpha-glucosidase inhibitors	N/A	(-183, -1)	Dispensings	1x	No	N/A
of Antidiabetic					(Dispensings			
rug					Table)			
	27	Amylin analogs (Pramlintide)	N/A	(-183, -1)	Dispensings	1x	No	N/A
					(Dispensings			
					Table)			
	28	Dipeptidyl peptidase 4 (DPP-4) inhibitors	N/A	(-183, -1)	Dispensings	1x	No	N/A
			`		(Dispensings			
					Table)			
	29	Incretin mimetics (Dipeptidyl peptidase 4	N/A	(-183, -1)	Dispensings	1x	No	N/A
		(DPP-4) inhibitors, Victoza, Byetta,	'		(Dispensings			'
		Bydureon, Bydureon BCISE)			Table)			
	30	Meglitinides	N/A	(-183, -1)	Dispensings	1x	No	N/A
			'	,	(Dispensings			'
					Table)			
	31	Insulin	N/A	(-183, -1)	Dispensings	1x	No	N/A
			'	,	(Dispensings			'
					Table)			
	32	Biguanides (metformin)	N/A	(-183, -1)		1x	No	N/A
	[-		'''	100, 1	(Dispensings	<u> </u>	"	
					Table)			
	33	SGLT2 Inhibitors	N/A	(-183, -1)		1x	No	N/A
	33	JOE12 IIIIIDILOIS	11/7	(-105, -1)	(Dispensings	<u></u>	INO	N/A
					Table)			
				I	Table)			



Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances	ignore days supply (after stockpiling)?	Forced supply to attach to codes
·	34	Sulfonylurea	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	35 36	Thiazolidinedione No baseline use of any of the above antidiabetic drugs	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	37	Other antidiabetic drugs (bromocriptine, mifepristone)	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
Baseline Use of Other Medications	38	Sodium channel blockers	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	39	Beta blockers	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	40	Potassium channel blockers/openers	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	41	Non-dihydropyridine calcium channel blockers	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	42	Digoxin	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	43	Other antiarrhythmic agents	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A



			Care	Covariate		Minimum # of	ignore days supply	Forced supply to
Group	No.	Covariate	Setting	Window	Code Type	Instances	(after stockpiling)?	attach to codes
	44	Antiarrhythmic agents (any of the above antiarrhythmic agents)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	45	Angiotensin-converting-enzyme (ACE) inhibitors	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	46	Angiotensin II receptor blockers (ARB)	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	47	Dihydropyridines	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	48	Diuretics	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	49	Other antihypertensives	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	50	Antihypertensives (any of the above antihypertensives)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	51	Oral anticoagulants	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	52	Vitamin K antagonists	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A



Only consider dispensing date when considering baseline characteristics, i.e.

Group	oup No. Covariate		Care Setting	Covariate Window	Code Type	Minimum # of Instances	ignore days supply (after stockpiling)?	Forced supply to attach to codes	
	53	Other cardiac medications (not including oral anticoagulants or vitamin K antagonists)	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A	
	54	Other cardiac medications (any of above "other" medications")	N/A	N/A	Complex Covariate	N/A	N/A	N/A	
	55	Lipid lowering therapy	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A	
	56	Drugs with a known risk of prolonged QT and torsades de pointes	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A	
	57	Drugs with a known/possible/conditional risk of prolonged QT and torsades de pointes	N/A	(-183, -1)	Dispensings (Dispensings Table)	1x	No	N/A	
Concomitant use of drugs with a risk of prolonged QT and torsades de pointes	58 59	Drugs with a known risk of prolonged QT and torsades de pointes Drugs with a known/possible/conditional risk of prolonged QT and torsades de pointes	N/A N/A	(0, 0)	Dispensings (Dispensings Table) Dispensings (Dispensings Table)	1x 1x	No No	N/A N/A	
Intensity of Health Care Utilization		Number of inpatient hospital stays Number of non-acute institutional stays Number of emergency department visits Number of ambulatory visits	IP* IS* ED* AV*	' '	N/A N/A N/A N/A	N/A N/A N/A N/A	N/A N/A N/A N/A	N/A N/A N/A N/A	



Only consider dispensing date when considering baseline characteristics, i.e.

			Care	Covariate		Minimum # of	ignore days supply	Forced supply to
Group	No.	Covariate	Setting	Window	Code Type	Instances	(after stockpiling)?	attach to codes
		Number of other ambulatory visits (includes other non overnight ambulatory encounters such as home health visits, telemedicine, telephone and email consultations)		(-183, -1)	N/A	N/A	N/A	N/A
Intensity of		Number of dispensings	N/A	(-183, -1)	N/A	N/A	N/A	N/A
Drug		Number of unique generics dispensed	N/A	(-183, -1)	N/A	N/A	N/A	N/A
Utilization		Number of unique drug classes dispensed	N/A	(-183, -1)	N/A	N/A	N/A	N/A

^{*}N/A: Not Applicable



Appendix J. Specifications Defining Combination Code Parameters Used in this Request

						Time					
				Order		window	AND/		New	New	
	Combo			within	Base	between	AND	Combined-to	Anchor	Episode	
Order	description	Purpose	Final Combo	Combo	component	components	NOT?	component	Date	Length	Details
1	IP encounter	Truncation	RX	1	IP or ED	(0, 0)	AND	Pregnancy (any)	Start date	Start date	- This will prevent IP/ED
	Other than Non-		(IPENCOUNTER)		encounter		NOT	or	of base	of IP	encounters from reporting
	HOI Hospitalized				(EN01)			Tachyarrhythmia	component	encounter	IP/ED pregnancy codes in the
	Tachyarrhythmia							(any)			code distribution for
											truncation codes.
											'- All tachyarrhythmia codes in
											all care settings are excluded
											in this combo so that
											hospitalized tachyarrhythmia
											(IPP, ED*) will be used as
											truncation criteria for cohorts
											where the hospitalized
											tachyarrhythmia code is not
											used in the HOI definition.
2	ED encounter	Truncation	RX	1	IP or ED	(0, 0)	AND	Pregnancy (any)	Start date	Start date	Ditto above
	Other than Non-		(EDENCOUNTER)		encounter		NOT	or	of base	of ED	
	HOI Hospitalized				(EN01)			Tachyarrhythmia	component	encounter	
	Tachyarrhythmia							(any)			


Abbreviations:

IP: Inpatient

ED: Emergency Department



Type 2 design diagram: Sensitivity analysis (183 days lookback)



Abbreviations:

DP: Data Partner ER: Emergency Room

HOI: Health Outcome of Interest

GLP-1 RA: Glucagon-like Peptide 1 Receptor Agonist



Appendix K. Design Diagram Detailing this Request

*Exclusion Criteria

Window 1: use of insulin without other antidiabetic drugs, type 1 diabetes, gestational diabetes, other secondary diabetes illnesses, short-acting GLP-1 RAs, pregnancy, long-acting GLP-1 RAs

**Inclusion Criteria

Window A: type 2 diabetes, any oral anti- Window I: Age, year, race, sex diabetic drug

***Covariates:

Window II: Charlson/Elixhauser combined comorbidity index, adapted Diabetes Complications Severity Index (ADCSI), alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease/stroke/transient ischemic attack, chronic kidney disease, COPD, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease/coronary artery disease/myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular/mitral valve disease, diseases of veins and lymphatics and other diseases of circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac diseases, history of serious hypoglycemia, alphaglucosidase inhibitor, amylin analogs (pramlintide), DPP-4 inhibitors, incretin mimetics, meglitinides, insulin, biguanides, SGLT-2 inhibitors, sulfonylurea, thiazolidinedione, no baseline use of above mentioned antidiabetic drugs, sodium channel blocker, beta blocker, potassium channel blockers/openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents, any of the above mentioned antiarrhythmic agents, ACE inhibitor, ARBs, dihydropyridines, diuretic, other antihypertensives, any of the above mentioned antihypertensives, oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists), any of the above mentioned "other" medications, lipid lowering therapy, drugs with a known risk of Prolong QT and Torsades de Pointes, drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes, healthcare and utilization metrics

Window III: tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of Prolong QT and Torsades de Pointes, drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes

Page 990 of 990 cder_mpl1p_wp077